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Summary	  	  This	  study	  describes	  the	  translation	  of	  an	  assay	  developed	  for	  use	  in	  cell	  culture	   models	   to	   into	   a	   method	   of	   measuring	   patterns	   of	   DNA	   damage	   from	  platinum	   agents	   in	   human	   blood	   samples.	   	   These	   adduct	   patterns	   could	  potentially	  be	  used	  in	  future	  studies	  for	  the	  stratification	  of	  patients	  for	  response	  and	  toxicity	  to	  oxaliplatin	  chemotherapy.	  Chapters	  3	  and	  4	  of	   this	   thesis	  describe	   the	  steps	   taken	   to	   translate	  our	  DIP-­‐chip	   assay,	   a	   tool	   previously	   used	   in	   the	   study	   of	   DNA	   repair	   capacity	   in	  yeast	  and	  to	  measure	  induction	  of	  platinum-­‐DNA	  adducts	  in	  cell	  culture	  models,	  into	  an	  assay	  capable	  of	  reproducibly	  analysing	  chemotherapy	  damage	  in	  human	  clinical	   samples.	   	   These	   results	   clearly	   demonstrate	   the	   protocol	  modifications	  required	  to	  use	  the	  assay	  on	  human	  blood	  samples,	  and	  show	  the	  reproducibly	  of	  the	   assay	   in	   detecting	   patterns	   of	   oxaliplatin	   induced	   DNA-­‐adducts	   in	   clinical	  material.	  	  Chapter	   5	   describes	   the	   development	   of	   novel	   bioinformatic	   tools	   and	  analysis	  methods	  for	  interpreting	  DIP-­‐chip	  DNA-­‐adduct	  microarray	  outputs.	  	  The	  translation	   of	   a	   genomic-­‐scale	   laboratory	   technology	   into	   a	   tool	   for	   patient	  stratification	  is	  a	  technical	  and	  bioinformatic	  challenge.	  	  The	  tools	  developed	  are	  a	   significant	   advance	   on	   previously	   available	   bioinformatic	   functions,	   and	   are	  essential	  for	  the	  application	  of	  this	  technique	  as	  a	  clinically	  useful	  assay.	  	  	  The	   final	   results	   section,	   chapter	   6,	   documents	   the	   successful	  development	   of	   functional	   models	   to	   experimentally	   confirm	   links	   between	  single	   nucleotide	   polymorphisms	   in	   nucleotide	   excision	   repair	   genes	   with	   the	  development	  of	  oxaliplatin	   induced	  peripheral	  neuropathy	  (OIPN).	   	  This	  aspect	  of	   the	  study	  utilises	  new	   information,	   recently	  derived	   from	  experiments	  DNA-­‐sequencing	  colorectal	  cancer	  patients,	  to	  develop	  a	  functional	  model	  of	  OIPN	  in	  
Saccharomyces	  cerevisiae.	  	  This	  model	  is	  then	  used	  to	  demonstrate	  the	  impact	  of	  variations	  in	  DNA	  repair	  genes	  on	  the	  development	  of	  OIPN	  -­‐	  a	  relationship	  that	  highlights	   the	   significance	   of	   DNA	   repair	   to	   the	   development	   of	   oxaliplatin	  toxicity.	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Chapter	  1 Introduction	  
1.1.1 Platinum	  chemotherapy	  	   The	  first	  platinum	  compound	  to	  find	  clinical	  use	  as	  an	  anti-­‐cancer	  agent,	  cisplatin	   (cis-­‐platinum(II)-­‐diamine-­‐chloride),	   was	   first	   synthesised	   by	   Michele	  Peyrone	   in	   1844	   (Kauffman	   et	   al.	   2010;	   Peyrone	   1844).	   The	   anti-­‐proliferative	  effect	  of	  cisplatin	  was	  not	  recognised	  until	  1965	  when,	  during	  an	  experiment	  to	  investigate	  the	  effect	  of	  an	  electric	  field	  on	  the	  growth	  of	  bacteria	  in	  liquid	  media,	  it	   was	   serendipitously	   discovered	   that	   the	   platinum	   salts	   generated	   from	   the	  electrodes	   in	   the	   experimental	   chamber	   inhibited	   bacterial	   cell	   growth	  (Rosenberg	  et	  al.	  1965).	   	  The	  primary	  platinum	  compound	  responsible	   for	   this	  effect	  was	  identified	  as	  ‘Peyrone’s	  platinum’	  -­‐	  cisplatin.	  	  Over	   the	   following	   decades	   these	   properties	   have	   been	   thoroughly	  investigated	  and	  exploited;	  cisplatin	  has	  become	  one	  of	  the	  most	  frequently	  used	  antineoplastic	   agents	   in	   clinical	   use	   and	   is	   an	   essential	   component	   of	   many	  widely	  used	  combination	  chemotherapy	  regimes	  (Bowden	  2014).	   	  Despite	   this,	  the	  response	  of	  an	  individual	  patient	  to	  cisplatin	  is	  unpredictable,	  and	  cisplatin	  is	  ineffective	   against	   several	   important	   malignancies,	   notably	   colorectal	   cancer.	  	  Even	  in	  patients	  who	  respond	  well	  to	  treatment,	  at	  therapeutic	  doses	  there	  is	  a	  significantly	   elevated	   risk	   of	   severe	   ototoxicity,	   nephrotoxicity	   and	   myelo-­‐suppression	  that	  limits	  the	  use	  of	  this	  agent	  (Hartmann	  and	  Lipp	  2003).	  	  	  Several	   derivatives	   of	   cisplatin	   have	   been	   synthesised	   in	   an	   attempt	   to	  improve	   the	   therapeutic	  profile;	   increasing	   the	   clinical	   efficacy	  or	   reducing	   the	  risk	  of	  dose-­‐limiting	  toxicities.	  Two	  agents	  have	  made	  a	  significant	  impact	  in	  the	  clinical	   setting;	   carboplatin	   (cis-­‐diamine(cyclobutane-­‐dicarboxylato-­‐1,1(2-­‐0)-­‐0.0)	   platinum),	   which	   has	   a	   similar	   spectrum	   of	   activity	   as	   cisplatin,	   is	   less	  nephrotoxic	   but	   more	   myelo-­‐suppressive,	   and	   oxaliplatin	   (oxalato(trans-­‐L-­‐1,2-­‐diaminocyclohexane)platinum)	  which	   is	   less	   ototoxic	   and	   nephrotoxic	   and	   has	  demonstrable	  activity	  against	  colorectal	  malignancies	  (Figure	  1.1).	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Figure	  1.1:	  The	  structure	  of	  the	  platinum	  drugs.	  The	   structure	   of	   cisplatin	   (cis-­‐platinum(II)-­‐diamine-­‐chloride),	   carboplatin	   (cis-­‐diamine(cyclobutane-­‐dicarboxylato-­‐1,1(2-­‐0)-­‐0.0)	  platinum),	  and	  oxaliplatin	  (oxalato(trans-­‐L-­‐1,2-­‐diaminocyclohexane)platinum)	  	  (Adapted	  from	  (O'Dwyer	  et	  al.	  2000))	  
	  	  Following	   FDA	   approval	   in	   2004	   oxaliplatin	   has	   become	  widely	   used	   in	  the	  treatment	  of	  colorectal	  cancers,	  a	  group	  of	  malignancies	  that	  remains	  one	  of	  the	  most	  common	  cancers	  worldwide	  and	  are	  notable	  for	  resistance	  to	  cisplatin	  and	  carboplatin	  (Di	  Francesco	  et	  al.	  2002;	  Rabik	  and	  Dolan	  2007).	  One	  of	  the	  key	  dose-­‐limiting	  toxicities	  of	  oxaliplatin	  is	  ‘oxaliplatin	  induced	  peripheral	   neuropathy’	   (OIPN);	   damage	   to	   peripheral	   nerves	   resulting	   in	  numbness	   and	   painful	   paresthesia	   in	   the	   distal	   extremities,	   which	   may	   be	  permanent	   following	   treatment	   (Andre	   et	   al.	   2009;	   Argyriou	   et	   al.	   2014).	  	  Methods	   to	  predict	  which	  patients	  are	  at	  higher	  risk	  of	   this	  common	  and	   long-­‐term	  toxicity	  are	  urgently	  needed,	  and	  would	  allow	  the	  use	  of	  alternative	  agents	  in	  patients	  at	  high	  risk,	  or	  could	  potentially	  improve	  efficacy	  by	  allowing	  higher	  doses	  to	  be	  used	  in	  patients	  at	  a	  lower	  risk	  of	  OIPN.	  Central	   to	   developing	   tools	   to	   predict	   for	   the	   response	   and	   toxicity	   to	  platinum	  agents	  in	  general,	  and	  oxaliplatin	  on	  colorectal	  cancer	  in	  particular,	  is	  a	  detailed	   understanding	   of	   the	   mechanism	   of	   action	   of	   these	   agents	   from	   the	  initial	   drug	   administration	   through	   to	   drug	   metabolism	   and	   excretion,	   with	   a	  
less toxic analogues.[5] It was found that modifica-
tion of cisplatin to contain less labile leaving
groups alters both the pharmacokinetics and the
toxicity profile of the drug. In a murine screen for
nephrotoxicity, replacement of the chloride leaving
groups with a cyclobutanodicarboxylato ligand,
forming carboplatin (fig. 1), diminished renal ef-
fects, while antitumour activity was retained.[6] At
effective doses, carboplatin produced substantially
less nausea, vomiting, nephrotoxicity and neuro-
toxicity than cisplatin, and bone marrow suppres-
sion was its predominant toxicity.[7] Phase III trials
have demonstrated the equivalence of carboplatin
and cisplatin in the treatment of ovarian cancer,[8]
but in testicular and head and neck cancers, cis-
platin appears to be superior.[9,10] Therefore, on the
basis of superior therapeutic index, together with
greater ease of administration and more predict-
able individualised dosing (see sections 2 to 4),
carboplatin has largely replaced cisplatin in the
treatment of many but not all platinum-sensitive
tumours.
Altering the structure of the leaving group influ-
ences tissue and intracellular distribution of the
platinum coordination complex; however, the sta-
ble (carrier) amine group determines the structure
of the adduct when bound to DNA. The adducts
produced by cisplatin and carboplatin are largely
identical, which explains their very similar patterns
of tumour sensitivity. To find novel platinum
agents with activity in cisplatin-resistant disease, a
variety of carrier ligands were investigated.
Compounds containing the 1,2-diammino-
cyclohexane (DACH) ligand as a stable carrier
group were first synthesised by Connors et al.,[5]
and Burchenal et al.[11] first demonstrated their ac-
tivity in murine models. Based on these studies (re-
viewed by Chaney[12]), a number of compounds
were developed, but clinical application was lim-
ited by toxicity. However, Kidani synthesised oxali-
platin [DACH-oxalato platinum (II)], which has
been successfully developed as an agent with ac-
tivity in colorectal cancer.[13-15] Oxaliplatin ad-
ducts form more rapidly (15 minutes vs 12 hours)
and are more toxic than those of cisplatin.[16,17]
Oxaliplatin is active in several cisplatin-resistant
tumour cell lines; moreover, comparative analysis
of the results from the National Cancer Institute
human tumour screen suggests that oxaliplatin and
other DACH ligand-containing platinum drugs
represent a distinct family of agents with a pattern
of tumour sensitivity that differs from that of cis-
platin.[18-20] The most important evidence support-
ing this concept is the activity of oxaliplatin in
colorectal cancer, a disease in which cisplatin and
carboplatin have no significant clinical activity.[21]
2. Clinical Pharmacokinetics
This section provides a comparison of the
pharmacokinetic properties of the 3 established
platinum drugs cisplatin, carboplatin and oxali-




As noted in section 1, the pharmacokinetic dif-
ferences observed between platinum drugs may be



























Fig. 1. Structures of platinum complexes.
20 O’Dwyer et al. 
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focus	  on	  the	  effect	  of	  platinum	  agents	  on	  the	  cellular	  machinery	  at	  the	  molecular	  level.	  	  The	  majority	  of	  the	  studies	  to	  elucidate	  the	  mechanisms	  of	  action	  of	  these	  agents	   at	   the	  molecular	   level	   have	   been	   conducted	   with	   cisplatin,	   but	   equally	  apply	   to	   oxaliplatin.	   	   Several	   key	   differences	   in	   action	   between	   cisplatin	   and	  oxaliplatin	   have	   been	   demonstrated	   and	   will	   be	   highlighted	   in	   the	   following	  discussion.	  
	  
1.1.2 Colorectal	  cancer	  	  	   Adenocarcinomas	   of	   the	   lower	   gastrointestinal	   tract	   (the	   colon	   and	  rectum	  –	   grouped	   as	   ‘colorectal’	   cancer)	   are	   the	   third	  most	   common	   cancer	   in	  the	  U.K.	  with	  over	  40,000	  new	  cases	  registered	  annually	  (CRUK	  2014a),	  and	  are	  the	  second	  most	  common	  cause	  of	  cancer	  death	  in	  the	  U.K.,	  despite	  the	  fact	  that	  more	   than	   half	   of	   people	   with	   colorectal	   cancer	   survive	   for	   10	   years	   after	  diagnosis	  (CRUK	  2014b).	  	  The	  number	  of	  people	  in	  the	  U.K.	  alive	  with	  colorectal	  cancer	   or	   having	   previously	   been	   treated	   for	   the	   disease	   was	   approximately	  250,000	   in	   2008	   and	   is	   increasing	   (NICE	   2011).	   	   Globally,	   new	   colorectal	  malignancies	  are	  recorded	  in	  over	  1,200,000	  people	  annually	  and	  over	  600,000	  deaths	  from	  this	  disease	  are	  estimated	  to	  occur	  each	  year	  (Jemal	  et	  al.	  2011).	  	  In	  developed	  countries	  between	  70%	  and	  80%	  of	  new	  patients	  undergo	  attempts	  at	  curative	  surgery,	  usually	  by	  removing	  the	  primary	  tumour	  and	  local	  lymphatic	  nodes	  (NICE	  2011).	  	  Without	  further	  treatment	  over	  the	  following	  five	  years	   approximately	   40%	   of	   patients	   develop	   metastatic	   disease,	   almost	  invariably	   due	   to	   the	   subsequent	   growth	   of	   micro-­‐metastatic	   disease	   present,	  but	  undetectable,	  at	   the	   time	  of	   initial	  diagnosis.	   	  As	  a	  consequence,	  and	   in	   the	  absence	  of	  further	  adjuvant	  therapy,	  the	  subsequent	  five-­‐year	  survival	  rates	  are	  principally	   determined	   by	   the	   risk	   of	  micro-­‐metastatic	   disease	   undetectable	   at	  presentation.	   	   The	   risk	   can	   be	   estimated	   by	   a	   combination	   of	   clinical	   and	  pathological	  factors;	  a	  histological	  assessment	  of	  the	  degree	  of	  de-­‐differentiation	  of	   the	  tumour	  (the	  grade)	  and	  the	  pathological	  stage	  of	   the	  disease	  (figure	  1.2)	  derived	  from	  an	  assessment	  of	  the	  depth	  of	  the	  primary	  tumour	  penetration	  into	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the	  intestinal	  wall	  and	  the	  extent	  of	   local	   lymph	  node	  involvement	  (NICE	  2011;	  Walker	  et	  al.	  2014).	  	  
	  
Figure	  1.2:	  An	  overview	  of	  the	  staging	  of	  colorectal	  cancer.	  	  http://alamocitycancercouncil.org/cancer/colorectal-­‐cancer/diagnosis/staging/)	  	   	  In	  stage	  II	  disease,	  approximately	  25%	  of	  patients	  at	  the	  time	  of	  diagnosis,	  the	  primary	  tumour	  has	  locally	  invaded	  through	  the	  bowel	  wall	  and	  beyond	  the	  sub-­‐mucosa,	  but	   there	   is	  no	  detectible	   involvement	  of	  regional	   lymph	  nodes	  or	  distant	   metastasis.	   	   After	   treatment	   with	   surgery	   alone	   over	   the	   following	   5	  years	   25%	   of	   patients	   with	   stage	   II	   disease	   die	   from	   recurrent	   or	   metastatic	  disease	  (Cunningham	  and	  Starling	  2007).	  However,	  this	  group	  is	  heterogeneous,	  and	  some	  patients	  have	  a	  significantly	  worse	  outcome,	  similar	  to	  more	  advanced	  stage	  III	  patients	  (O'Connell	  et	  al.	  2004).	  	  	  In	   stage	   III	   disease,	   again	   approximately	   25%	   of	   patients	   at	   initial	  diagnosis,	   there	   is	   tumour	   invading	   through	   the	   bowel	   wall	   and,	   in	   addition,	  involvement	   of	   regional	   lymph	   nodes,	   but	   again	   without	   detectable	   distant	  metastasis.	   	   Without	   further	   treatment	   the	   chances	   of	   developing	   distant	  metastasis	   and	   death	   over	   the	   subsequent	   5	   years	   for	   a	   patient	  with	   stage	   III	  disease	  are	   in	  the	  order	  of	  50%	  (Andre	  et	  al.	  2009).	   	   	   In	  both	  high-­‐risk	  stage	  II	  disease	   and	   stage	   III	   disease	   the	   addition	   of	   6	   months	   of	   oxaliplatin	   and	  fluoropyrimidine	  based	  adjuvant	  chemotherapy,	  given	  to	  treat	  any	  occult	  micro-­‐
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metastatic	   disease	   if	   present,	   can	   significantly	   reduce	   the	   risk	   of	   recurrence	  (Andre	  et	  al.	  2009).	  	  Patients	   with	   stage	   IV	   disease,	   with	   distant	   metastasis	   at	   the	   time	   of	  presentation,	   are	   typically	   offered	   palliative	   treatment	   with	   a	   combination	   of	  surgery,	   radiotherapy,	   biological	   agents	   and	   chemotherapy	   (usually	  fluoropyrimidine	  and	  oxaliplatin	  based),	  resulting	  in	  a	  median	  survival	  of	  18-­‐24	  months	  (Seymour	  et	  al.	  2007).	  	  	  
1.1.3 The	  development	  of	  oxaliplatin	  for	  use	  in	  colorectal	  cancer	  
1.1.3.1 Pre-­‐clinical	  evidence	  of	  efficacy	  	   Although	  the	  discovery	  of	  cisplatin	  and	  its	  introduction	  into	  clinical	  use	  in	  1971	  showed	  great	  promise	   (Hill	   et	   al.	  1975)	  even	  at	  an	  early	   stage	   there	  was	  awareness	  of	   its	   limitations,	  particularly	  the	  significant	  toxicity	  profile	  and	  lack	  of	  efficacy	  against	  colorectal	  malignancies	  (Alcindor	  and	  Beauger	  2011).	  	  Efforts	  to	   develop	   platinum	   compounds	   with	   improved	   efficacy	   or	   reduced	   adverse	  effects	   (a	   better	   ‘therapeutic	   profile’)	   resulted	   in	   the	   synthesis	   of	   several	  derivative	   compounds.	   	   Of	   particular	   interest	   were	   platinum	   compounds	   with	  1,2-­‐diaminocyclohexane	  (DACH)	  carrier	  ligands,	  first	  successfully	  synthesised	  in	  the	  early	  1970s	   (Connors	  et	   al.	   1972),	   and	  of	  which	  oxaliplatin	   is	   included.	   	   In	  initial	   studies	   involving	   oxaliplatin,	   and	   similar	   DACH-­‐platinum	   based	   agents,	  were	   shown	   to	  be	   effective	   against	   cisplatin	   resistant	  mouse	  L1210	  and	  p-­‐388	  leukaemia	  cell	   lines	  (Burchenal	  et	  al.	  1979;	  Gale	  et	  al.	  1974),	  and	  oxaliplatin	   in	  particular	   was	   demonstrated	   to	   be	   effective	   against	   a	   variety	   of	   cisplatin	   and	  carboplatin	  resistant	  human	  cancer	  cell	  lines	  and	  xenografts	  (Mathe	  et	  al.	  1989).	  	  In	  view	  of	  the	  lack	  of	  activity	  of	  cisplatin	  against	  colorectal	  cancer	  considerable	  interest	  was	  generated	  by	  the	  demonstration	  that	  oxaliplatin	  was	  effective	  as	  a	  single	   agent	   against	   5-­‐FU	   resistant	  HT29	   colorectal	   cancer	   cell	   lines,	   and	   after	  supra-­‐additive	  effects	  were	  noted	  in	  combination	  with	  5-­‐FU	  in	  cisplatin	  resistant	  colon	  cancer	  cell	  lines	  (Raymond	  et	  al.	  1998a).	  	  
	   6	  
1.1.3.2 Phase	  I	  clinical	  trials	  
	   In	   an	   initial	   phase	   I	   trial	   44	   patients	   with	   a	   variety	   of	   advanced	  malignancies	  received	  a	  combined	  total	  of	  116	  courses	  of	  oxaliplatin,	  with	  doses	  escalating	   from	   45mg/m2	   to	   200mg/m2.	   	   Neither	   haematological	   nor	   renal	  toxicities	  were	  observed	  at	  doses	  up	  to	  200mg/m2,	  although	  at	  doses	  exceeding	  135mg/m2	   the	   investigators	  noted	  a	   ‘’peculiar	   toxicity”	  of	  a	  peripheral	   sensory	  neuropathy	   which	   developed	   in	   some	   individuals	   and	   was	   associated	   with	  cumulative	  dose.	  The	  development	  of	  a	  clinically	  severe	  peripheral	  neurotoxicity	  was	   noted	   in	   6	   of	   44	   patients	   treated	   at	   cumulative	   doses	   above	   500mg/m2.	  	  These	   patients	   were	   investigated	   with	   nerve	   conduction	   studies,	   revealing	   a	  sensory	  neuropathy	  characterised	  by	  axonal	  degeneration.	  	  The	  development	  of	  acute	   and	   transient	   peripheral	   paraesthesia	   was	   also	   noted,	   particularly	  triggered	  when	  patients	  touched	  cold	  surfaces.	  	  As	  a	  result	  of	  this	  trial	  a	  dose	  of	  130mg/m2	  given	  every	  3	  weeks	  by	  IV	  infusion	  over	  2	  hours	  was	  recommended	  for	  future	  clinical	  studies	  (Extra	  et	  al.	  1990).	  	  
1.1.3.3 Phase	  II	  clinical	  trials	  	  	   The	  first	  clinical	  trials	  with	  oxaliplatin	  as	  a	  single	  agent	  in	  patients	  with	  5-­‐flourouracil	   (5-­‐FU)	   resistant	   colorectal	   cancer	  demonstrated	  modest	  activity	  of	  10%	  (Levi	  et	  al.	  1993;	  Machover	  et	  al.	  1996).	  	  An	  improved	  activity	  rate	  of	  up	  to	  20%	   was	   noted	   using	   oxaliplatin	   as	   a	   single	   agent	   in	   previously	   untreated	  patients	  (Diaz-­‐Rubio	  et	  al.	  1998).	  	  In	  combination	  with	  5-­‐FU	  response	  rates	  as	  high	  as	  58%	  were	  achieved,	  as	   shown	   in	   a	   heterogeneous	   cohort	   of	   both	   previously	   treated	   and	   untreated	  patients	  with	  metastatic	  colorectal	  cancer	  conducted	  by	  Levi	  in	  1993	  (Levi	  et	  al.	  1993).	   	   In	   the	   period	   following	   these	   initial	   studies	   the	   addition	   of	   folinic	   acid	  (leucovorin	  in	  the	  USA)	  to	  the	  then	  standard	  treatment	  of	  5-­‐FU	  was	  shown	  to	  be	  of	  benefit,	  and	  the	  activity	  of	  a	  combination	  of	  oxaliplatin,	  5-­‐FU	  and	   leucovorin	  was	   confirmed	   in	   subsequent	   phase	   II	   trials	   and	   given	   the	   commonly	   used	  acronym	  FOLFOX	  (de	  Gramont	  et	  al.	  1997).	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1.1.3.4 Phase	  III	  clinical	  trials	  	  Initial	   phase	   3	   trials	   comparing	   FOLFOX	   to	   5-­‐FU	   and	   leucovorin,	   the	  previous	  standard	  of	  care,	   in	  untreated	  patients	  with	  stage	  IV	  colorectal	  cancer	  resulted	  in	  an	  improvement	  in	  response	  rate	  (50.7%	  vs.	  22.3%)	  and	  progression	  free	  survival	  (9.0	  months	  vs.	  6.2	  months)	  in	  favour	  of	  FOLFOX	  (de	  Gramont	  et	  al.	  2000).	   	   The	   oral	   5-­‐FU	   pro-­‐drug	   capecitabine	   (Xeloda,	   Roche)	   has	   been	  successfully	  substituted	  with	  5-­‐FU	  and	   leucovorin	   in	  the	  regime	   ‘CAPOX’	  and	   is	  equally	   efficacious,	   indicating	   the	   choice	   between	   either	   intravenous	   or	   oral	  fluoropyrimidine	  is	  not	  clinically	  significant	  (Cassidy	  et	  al.	  2004).	  Given	   the	  beneficial	   response	   to	   treatment	   in	   the	  palliation	  of	   advanced	  disease	   the	   FOLFOX	   combination	   was	   subsequently	   tested	   as	   an	   adjuvant	  treatment	   following	   surgery	   in	   early	   stage	   patients.	   	   Previous	   studies	  with	   six	  months	   of	   adjuvant	   chemotherapy	   using	   5-­‐FU	   and	   leucovorin	   in	   patients	   who	  had	   undergone	   surgical	   resection	   for	   stage	   II	   and	   III	   colorectal	   cancer,	   when	  compared	   to	   observation	  only,	   reduced	   the	   relative	   risk	   of	   recurrence	  by	  22%	  and	   death	   by	   18%	   during	   a	   median	   follow-­‐up	   of	   five	   and	   a	   half	   years	  (Cunningham	  and	  Starling	  2007).	  	  The	  MOSAIC	  trial,	  a	  large	  international	  trial	  of	  2,246	   patients	   with	   stage	   II	   or	   III	   colorectal	   cancer	   compared	   the	   addition	   of	  oxaliplatin	   to	   six	   months	   adjuvant	   chemotherapy	   with	   5-­‐FU	   and	   leucovorin	  following	   primary	   surgical	   resection.	   	   The	   study	   demonstrated	   a	   relative	   risk	  reduction	  of	  death	  in	  six	  years	  following	  treatment	  of	  20%	  in	  stage	  III	  disease	  in	  favour	   of	   the	   addition	   of	   oxaliplatin,	   although	   no	   benefit	   from	   the	   addition	   of	  oxaliplatin	  was	  demonstrated	  in	  stage	  II	  disease	  (Andre	  et	  al.	  2009).	  	  These	   trials,	   and	  confirmatory	  studies	   including	  NSABP	  C-­‐07,	  a	   large	  US	  trial	   similar	   to	   MOSAIC	   (Kuebler	   et	   al.	   2007),	   have	   resulted	   in	   the	   use	   of	   the	  FOLFOX	  combination	  chemotherapy	  regimen	  throughout	  the	  developed	  world	  as	  the	   standard	   adjuvant	   treatment	   for	   stage	   III	   disease	   and	   as	   a	   key	   palliative	  treatment	  in	  advanced	  disease	  (Attard	  et	  al.	  2010;	  NCCN	  2012;	  NICE	  2011).	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1.1.3.5 Clinical	  toxicity	  of	  oxaliplatin	  
	   The	   addition	   of	   oxaliplatin	   to	   fluoropyrimidine	   based	   chemotherapy	   in	  colorectal	   cancer	  has	  undoubtedly	   improved	   the	  response	  rate,	   time	   to	  disease	  progression,	   and	   increased	   the	   duration	   of	   survival	   in	   patients	  with	   advanced	  disease,	   and	   in	   those	   treated	   with	   curative	   intent	   when	   used	   as	   an	   adjuvant	  treatment.	  	  However,	  the	  addition	  of	  oxaliplatin	  undoubtedly	  results	  in	  a	  higher	  rate	  of	  side	  effects	  compared	  to	  fluoropyrimidine-­‐based	  treatments	  (Andre	  et	  al.	  2009;	   Ibrahim	   et	   al.	   2004).	   	   Of	   particular	   importance	   is	   the	   trade-­‐off	   between	  side	   effects	   and	   clinical	   efficacy	   in	   both	   patients	  with	   incurable	   disease	   and	   in	  patients	  who	  are	  treated	  with	  curative	  intent,	  the	  majority	  of	  whom	  are	  expected	  to	  have	  a	  normal	  life	  expectancy	  following	  treatment.	  	  Patients	  with	  advanced	  or	  terminal	   disease	   are	   prepared	   to	   accept	   higher	   rates	   of	   side	   effects	   whereas	  those	   treated	   for	   lower	   risk	   disease,	   who	   only	   gain	   small	   absolute	   benefit	   in	  terms	  of	  reduced	  risk	  of	  recurrence,	  and	  who	  have	  a	  normal	  life	  expectancy	  the	  adverse	  consequences	  of	  chronic	  side	  effects	  can	  be	  more	  problematic	  (Balmer	  et	  al.	  2001;	  Matsuyama	  et	  al.	  2006;	  Mende	  et	  al.	  2013).	  	   The	  2004	  FDA	  approval	  documentation	  for	  oxaliplatin,	  based	  on	  the	  early	  trials	   of	   patients	  with	   stage	   IV	  disease	   treated	  with	  palliative	   intent,	   compares	  the	  rates	  of	  toxicity	  from	  5-­‐FU/LV,	  single	  agent	  oxaliplatin,	  and	  from	  the	  addition	  of	  oxaliplatin	  to	  5-­‐FU/LV.	  	  The	  rate	  of	  any	  severe	  or	  life-­‐threatening	  toxicity	  (NCI	  CTC	   toxicity	   grading	   3	   or	   4(NCI	   2009))	   increases	   from	   41%	   to	   73%	  with	   the	  combination	   of	   agents,	   mainly	   from	   the	   increase	   in	   gastrointestinal,	  haematological	   and	   neuropathic	   side	   effects.	   The	   rate	   of	   transient	   and	   chronic	  OIPN	  is	  similar	   for	  single	  agent	  oxaliplatin	  and	  the	  combination	  treatment,	  and	  both	  are	   significantly	  higher	   than	   the	  minimal	   rate	  of	  neuropathy	  seen	  with	  5-­‐FU/LV,	  indicating	  that	  neuropathy	  is	  a	  consequence	  mainly	  of	  oxaliplatin,	  rather	  than	  the	  combination	  with	  5-­‐FU	  (figure	  1.3)	  (Ibrahim	  et	  al.	  2004).	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rates	  of	  residual	  OIPN	  of	  any	  grade	  in	  the	  FOLFOX	  group	  was	  still	  17.1%	  	  (Figure	  1.4)	  (Andre	  et	  al.	  2009).	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1.1.3.6 Conclusions	  from	  oxaliplatin	  clinical	  data	  
	   Whilst	   oxaliplatin	   is	   unquestionably	   of	   benefit	   to	   many	   patients	   with	  colorectal	   cancer,	   a	   significant	   proportion	   of	   patients	   are	   developing	   toxicity	  from	   treatment	   with	   significant	   long	   term	   economic,	   social	   and	   health	  consequences	  in	  a	  cohort	  of	  patients	  with	  a	  10-­‐year	  survival	  of	  over	  55%	  (Berger	  et	  al.	  2004;	  CRUK	  2014b;	  Kautio	  et	  al.	  2011;	  O'Connor	  2009;	  Pike	  et	  al.	  2012).	  The	  development	  of	  tools	  to	  predict	  who	  will	  benefit	  from	  treatment	  and	  who	  is	  at	  greater	  risk	  of	  toxicity	  are	  urgently	  needed,	  and	  would	  allow	  rational	  investigation	  and	  modification	  of	  treatment	  schedules.	  	  These	  tools	  are	  needed	  to	  improve	  the	  cure	  rates,	  by	  increasing	  treatment	  intensity	  in	  patients	  unlikely	  to	  develop	  toxicity,	  and	  to	  reduce	  the	  burden	  of	  long-­‐term	  toxicity	  in	  patients	  who	  are	  more	  sensitive	  to	  these	  agents.	  	  With	  this	  in	  mind,	  the	  next	  section	  will	  focus	  on	  the	  mechanism	  of	  action	  of	  oxaliplatin,	  with	  a	  view	  to	  understanding	  how,	  at	  the	  molecular	  level,	  methods	  to	  stratify	  patients	  for	  response	  and	  toxicity	  could	  be	  developed.	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 The	  molecular	  mechanism	  of	  action	  of	  oxaliplatin	  1.2	   Knowledge	  of	  the	  molecular	  mechanism	  of	  action	  of	  these	  drugs	  is	  crucial	  to	   predicting	   the	   spectrum	   of	   clinical	   effects	   of	   the	   platinum	   agents,	   and	   in	  understanding	   the	   similarities	   and	   differences	   between	   these	   agents.	  	  Particularly	  important	  in	  the	  context	  of	  this	  thesis	  is	  the	  effect	  of	  oxaliplatin	  on	  the	  neurones	  of	  the	  dorsal	  root	  ganglia,	  and	  the	  idiosyncratic	  response	  of	  these	  cells	  to	  DNA	  damage	  through	  the	  nucleotide	  excision	  repair	  (NER)	  pathway	  –	  a	  mechanism	  that	  may	  be	  responsible	  for	  the	  risk	  of	  the	  development	  of	  neuronal	  toxicity	  and	  could	  potentially	  be	  used	  as	  a	  predictive	  marker	  for	  OIPN.	  The	   majority	   of	   studies	   investigating	   the	   mechanism	   of	   action	   of	   the	  platinum	  drugs	   at	   the	  molecular	   level	   are	  based	  on	   cisplatin,	   but	   apply	   also	   to	  oxaliplatin.	   Differences	   exist	   in	   molecular	   interactions	   between	   cisplatin	   and	  oxaliplatin	   and	   explain	   the	   differences	   in	   efficacy	   and	   toxicity	   of	   these	   agents.	  	  Several	  have	  been	  elucidated	  and	  will	  be	  highlighted	  in	  the	  following	  discussion.	  	  	  
1.2.1 Oxaliplatin	  pharmacokinetics	  
	   Pharmacokinetics	   studies	   analyse	   how	   the	   body	   affects	   a	   drug	   after	  administration,	  through	  the	  mechanisms	  of	  absorption,	  distribution,	  metabolism	  and	  the	  through	  the	  effects	  of	  excretion	  of	  the	  drug	  and	  of	  drug	  metabolites.	  	  The	  pharmacokinetics	  of	  oxaliplatin	  and	  cisplatin	  have	  been	  extensively	  studied.	  	  The	  central	   platinum	   ion	   of	   oxaliplatin	   is	   bound	   to	   an	   oxalate	   leaving	   group	   and	   a	  diaminocyclohexane	  (DACH)	  carrier	  ligand	  (figure	  1.5).	  	  In	  comparison,	  cisplatin,	  a	  neutral	   inorganic	  compound,	  consists	  of	  a	  central	  platinum	  ion	  bound	  to	   two	  labile	  chloride	  ligand	  leaving	  groups	  in	  a	  square	  planar	  cis-­‐	  configuration,	  and	  to	  two	  non-­‐labile	  ammine	  carrier	  ligands	  (figure	  1.5)	  (Arnesano	  et	  al.	  2013).	  	  	  Both	  compounds	  shed	  their	  leaving	  groups	  before	  entering	  the	  cell.	  	  As	  a	  result,	  it	  is	  primarily	  the	  differential	  cellular	  response	  to	  the	  DACH	  carrier	  ligand	  of	  oxaliplatin	   compared	   to	   the	  amine	  carrier	   ligands	  of	   cisplatin	   that	   results	   in	  the	  different	  spectrum	  of	  clinical	  activity	  and	  toxicity	  of	  these	  agents	  (Raymond	  et	  al.	  1998b).	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Figure	  1.5:	  The	  chemical	  structure	  of	  cisplatin	  and	  oxaliplatin.	  The	   structure	   of	   cisplatin	   (cis-­‐platinum(II)-­‐diamine-­‐chloride)	   and	   oxaliplatin	  (oxalato(trans-­‐L-­‐1,2-­‐diaminocyclohexane)platinum).	   	  The	  leaving	  groups	  are	  to	  the	  right	  of	  the	   central	   platinum	   ion	   and	   the	   carrier	   ligands	   to	   the	   left	   	   (Adapted	   from(O'Dwyer	   et	   al.	  2000))	   	  After	   intravenous	  administration	  the	  platinum	  agents	  undergo	  a	  process	  of	   rapid	   stepwise	   biotransformation	   –	   the	   process	   of	   modification	   of	   the	  chemical	   compound	   by	   the	   organism.	   Unlike	   most	   chemotherapy	  pharmacokinetic	   studies,	   investigation	   of	   the	   transformation	   of	   the	   platinum	  agents	  is	  limited	  by	  technological	  constraints:	  it	  is	  possible	  only	  to	  measure	  total	  platinum,	  rather	  than	  the	  specific	  biotransformation	  products	  of	  the	  drugs	  using	  the	  available	  techniques	  of	  atomic	  absorption	  spectroscopy	  (AAS)	  or	  inductively	  coupled	   mass	   spectrometry	   (Jerremalm	   et	   al.	   2009).	   	   The	   lack	   of	   ability	   to	  differentiate	   between	   bio-­‐transformants	   (the	   products	   of	   biotransformation)	  results	   in	   co-­‐determination	   of	   the	   initial	   platinum	   agent	   and	   the	   short-­‐lived	  platinum	   containing	   intermediate	   complexes,	   hence	   monitoring	   of	   platinum	  rather	   than	   specifically	   for	   cisplatin	   or	   oxaliplatin	   for	   pharmacokinetic	  assessment	  is	  generally	  conducted	  and	  accepted	  (Graham	  et	  al.	  2000).	  Oxaliplatin	   is	   administered	   usually	   as	   an	   intravenous	   infusion	   over	   two	  hours	   at	   a	   dose	   of	   130mg/m2	   -­‐	   the	   dose	   recommended	   in	   initial	   phase	   I	   trials	  (Extra	  et	  al.	  1990).	  	  Subsequently,	  plasma	  levels	  rapidly	  decrease,	  with	  a	  half-­‐life	  of	  15	  minutes.	  	  This	  occurs	  primarily	  a	  result	  of	  non-­‐enzymatic	  transformation	  to	  reactive	   compounds	   through	   the	   displacement	   of	   the	   oxalate	   leaving	   group,	  forming	   a	   variety	   of	   reactive	   intermediates	   in	   both	   the	   blood	   and	   plasma,	  including	   monochloro-­‐,	   dichloro-­‐,	   and	   diaquo-­‐platinum	   species	   (figure	   1.6)	  
less toxic analogues.[5] It was found that modifica-
tion of cisplatin to contain less labile leaving
groups alters both the pharmacokinetics and the
toxicity profile of the drug. In a murine screen for
nephrotoxicity, replacement of the chloride leaving
groups with a cyclobutanodicarboxylato ligand,
forming carboplatin (fig. 1), diminished renal ef-
fects, while antitumour activity was retained.[6] At
effective doses, carboplatin produced substantially
less nausea, vomiting, nephrotoxicity and neuro-
toxicity than cisplatin, and bone marrow suppres-
sion was its predominant toxicity.[7] Phase III trials
have demonstrated the equivalence of carboplatin
and cisplatin in the treatment of ovarian cancer,[8]
but in testicular and head and neck cancers, cis-
platin appears to be superior.[9,10] Therefore, on the
basis of superior therapeutic index, together with
greater ease of administration and more predict-
able individualised dosing (see sections 2 to 4),
carboplatin has largely replaced cisplatin in the
treatment of many but not all platinum-sensitive
tumours.
Altering the structure of the leaving group influ-
ences tissue and intracellular distribution of the
platinum coordination complex; however, the sta-
ble (carrier) amine group determines the structure
of the adduct when bound to DNA. The adducts
produced by cisplatin and carboplatin are largely
identical, which explains their very similar patterns
of tumour sensitivity. To find novel platinum
agents with activity in cisplatin-resistant disease, a
variety of carrier ligands were investigated.
Compounds containing the 1,2-diammino-
cyclohexane (DACH) ligand as a stable carrier
group were first synthesised by Connors et al.,[5]
and Burchenal et al.[11] first demonstrated their ac-
tivity in murine models. Based on these studies (re-
viewed by Chaney[12]), a number of compounds
were developed, but clinical application was lim-
ited by toxicity. However, Kidani synthesised oxali-
platin [DACH-oxalato platinum (II)], which has
been successfully developed as an agent with ac-
tivity in colorectal cancer.[13-15] Oxaliplatin ad-
ducts form more rapidly (15 minutes vs 12 hours)
and are more toxic than those of cisplatin.[16,17]
Oxaliplatin is active in several cisplatin-resistant
tumour cell lines; moreover, comparative analysis
of the results from the National Cancer Institute
human tumour screen suggests that oxaliplatin and
other DACH ligand-containing platinum drugs
represent a distinct family of agents with a pattern
of tumour sensitivity that differs from that of cis-
platin.[18-20] The most important evidence support-
ing this concept is the activity of oxaliplatin in
colorectal cancer, a disease in which cisplatin and
carboplatin have no significant clinical activity.[21]
2. Clinical Pharmacokinetics
This section provides a comparison of the
pharmacokinetic properties of the 3 established
platinum drugs cisplatin, carboplatin and oxali-
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less toxic analogues.[5] It was found that modifica-
tion of cisplatin to contain less labile leaving
groups alters both the pharmacokinetics and the
toxicity profile of the drug. In a murine screen for
nephrotoxicity, replacement of the chloride leaving
groups with a cyclobutanodicarboxylato ligand,
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fects, while antitumour activity was retained.[6] At
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have demonstrated the equivalence of carboplatin
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but in testicular and head and neck cancers, cis-
platin appears to be superior.[9,10] Therefore, on the
basis of superior therapeutic index, together with
greater ease of administration and more predict-
able individualised dosing (see sections 2 to 4),
carboplatin has largely replaced cisplatin in the
treatment of many but not all platinum-sensitive
tumours.
Altering the structure of the leaving group influ-
ences tissue and intracellular distribution of the
platinum coordination complex; however, the sta-
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of the adduct when bound to DNA. The adducts
produced by cisplatin and carboplatin are largely
identical, which explains their very similar patterns
of tumour sensitivity. To find novel platinum
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variety of carrier ligands were investigated.
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pharmacokinetic properties of the 3 established
platinum drugs cisplatin, carboplatin and oxali-




As noted in section 1, the pharmacokinetic dif-
ferences observed between platinum drugs may be



























Fig. 1. Structures of platinum complexes.
20 O’Dwyer et al. 
 Adis International Limited. All rights reserved. Drugs 2000; 59 Suppl. 4
	   14	  
(Jerremalm	   et	   al.	   2009).	   	   Oxaliplatin	   and	   the	   immediate	   derivatives	   undergo	  rapid	   distribution	   -­‐	   by	   the	   end	   of	   the	   two-­‐hour	   administration	   only	   15%	   of	  detectible	   platinum	   remains	   in	   the	   blood;	   85%	  has	   been	  distributed	   to	   tissues	  and	  a	  small	  fraction	  has	  been	  eliminated	  by	  urinary	  excretion.	  	  	  	  
	  
Figure	  1.6:	  The	  biotransformation	  of	  oxaliplatin.	  The	   biotransformation	   of	   oxaliplatin	   to	   monchloro,	   dichloro	   and	   diaquo	   compounds	  (Jerremalm	  et	  al.	  2009).	  	  A	   three-­‐compartment	   model	   for	   the	   distribution	   of	   oxaliplatin	   in	  circulating	  blood	  has	  been	  proposed;	  total	  plasma	  platinum,	  ultra-­‐filterable	  ‘free’	  platinum	  and	  erythrocyte	  sequestered	  platinum	  (Extra	  et	  al.	  1998;	  Graham	  et	  al.	  2000).	   	   Of	   the	   15%	   remaining	   in	   the	   systemic	   circulation	   after	   administration,	  40%	  has	  been	  irreversibly	  sequestered	  in	  circulating	  erythrocytes	  and	  30%	  has	  irreversibly	   bound	   to	   plasma	   proteins	   (Mani	   et	   al.	   2002),	   including	   plasma	  gamma-­‐globulins,	   albumin	   and	   haemoglobin	   (Allain	   et	   al.	   2000)	   forming	   non-­‐cytotoxic	  products	  (Luo	  et	  al.	  1999).	  	  Only	  the	  unbound	  fraction,	  detectible	  after	  plasma	  ultra-­‐filtration	  to	  remove	  the	  inert	  platinum	  bound	  to	  plasma	  proteins,	  is	  
and time dependent. Equilibrium was attained after 6 h for
serum and after 24 h for albumin. Most of platinum was found
to be covalently bound. There was no evidence of saturable
binding over the concentration range 0.3–20 !g/ml (44).
The main serum binding proteins were found to be albumin
and gamma-globulins (44). Similar in vitro binding studies were
performed by Pendyala and Creaven (7), except that plasma,
rather than serum protein, was used. The binding of oxaliplatin
derived platinum to plasma protein was found to be moderate,
with 85–88% of the total platinum bound within 5 h.
The plasma protein binding of platinum has also been
investigated in patients receiving 130 mg/m2 oxaliplatin by 2-h
infusion every 3 weeks for five cycles (n " 6 patients; Refs. 19
and 20). At the end of infusion at 2 h on cycle 5, the mean
percentage of platinum bound to plasma protein was 65.5 #
4.89%, which progressively increased to 90.3 # 1.75% at 6 h
and to 98.0 # 0.42% by 3 weeks.
Similar in vivo protein binding results have also been
reported by Misset and Allain (30). On day 1 at 2 h posttreat-
ment, plasma protein binding was estimated at 70%. Five days
posttreatment, with oxaliplatin at 130 mg/m2, plasma protein
binding was estimated to be $95%.
Binding of Platinum to Erythrocytes. Platinum has
been shown to irreversibly bind to and accumulate in erythro-
cytes (7). The half-life of erythrocytic bound platinum is there-
fore likely to be determined by the rate of erythrocyte turnover
(19, 20). Blood cell associated platinum is not considered to be
a reservoir of pharmacologically active platinum due to the
irreversible nature of the binding and the lack of platinum efflux
in in vitro experiments (7, 19, 20).
Although platinum binds to blood cells, the blood cells
only represent a minor compartment for drug distribution in
patients (19, 20). At the end of infusion (2 h), approximately
15% of the administered platinum is present in the blood. The
remaining 85% has undergone distribution from the plasma into
tissues or has been subjected to urinary elimination. Therefore,
platinum distribution to blood cells represents a relatively small
component when consideration is given to the total body dis-
position of platinum.
Binding of Platinum to Lymphocytes. The uptake of
platinum into peripheral lymphocytes of patients has been in-
vestigated after multiple doses of oxaliplatin at 130 mg/m2 (45).
Platinum was found in DNA extracts from all oxaliplatin tre ted
patients 1 h after the end of infusion on cycles 1 and 3. The
removal of platinum adducts was rapid. In four of six patients,
no platinum was detected 24 h posttreatment on cycle 1, and
platinum levels could only be detected in one of six patients on
day 5.
Biotransformation and Metabolic Fate of Oxaliplatin
Metabolism and Biotransformation Overview. Oxali-
platin undergoes a series of spontaneous, nonenzymatic conver-
sions in biological fluids, a process referred to as drug biotrans-
formation. These reactions are mediated primarily through the
displacement of the oxalate group by H2O and endogenous
nucleophiles, such as Cl% and HCO3% ions. Several transient
reactive species are formed, including dichloro-, monochloro-,
and diaquo-DACH platin, which can complex with amino acids,
proteins, DNA, and other macromolecules in plasma and tissues
(Fig. 6; Refs. 21 and 22).
Studies to investigate the met bolism of oxaliplatin by
human liver microsome extracts indicated that oxaliplatin was
not a substrate for CYP450 in vitro (32).
Drug Metabolism Studies. The biotransformation of
[3H]oxaliplatin was investigated using human liver microsomal
fractions in vitro (31). H man liver mi rosomes were prepared
from three human livers with high CYP450 activity.
After a 30-min incubation of [3H]oxaliplatin with human
hepatic microso es in the presence of NADPH, most of the
radioactivity (67%) was associated with unchanged drug. An-
other major component, which comprised 17% of the total
radioactivity, co-eluted with the diaquo-DACH platin standard.
Several other minor products were also detected, each repre-
senting less than 1–3% of the radioactivity. Similar results were
obtained in the absence of NADPH (71% co-eluting as un-
changed drug and 17% as diaquo-DACH platin) and using
heat-denatured microsomes, indicating that the biotransforma-
tion of oxaliplatin was nonenzymatic and occurred by chemical
degradation.
In summary, no oxidative metabolism of the DACH group
was detected in vitro. [3H]Oxaliplatin was stable to oxidative
CYP450-mediated metabolism and degraded nonenzymatically
to a single major product, tentatively identified as diaquo-
DACH platin (31, 32).
Biotransformation Studies in Vitro. The in vitro bio-
transformation and distribution of [3H]oxaliplatin has been in-
vestigated in plasma ultrafiltrate, urine, and whole blood sam-
ples (33, 34).
Fig. 6 Biotransformation of oxaliplatin and pharmacological activity
of the major products (IC50 values in HT-29 human colon carcinoma
cells in vitro; Refs. 21, 22, and 42).
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the	   residual	   biologically	   active	   fraction,	   and	   is	   termed	   the	   ultra-­‐filterable	  fraction.	  	  	  The	  maximum	   plasma	   ultra-­‐filtrate	   concentration	   of	   oxaliplatin	   (i.e.	   the	  maximum	   biologically	   active	   concentration)	   after	   a	   2-­‐hour	   infusion	   is	  approximately	  1.21	  +/-­‐	  0.1	  µg/ml	  of	  plasma	  (a	  concentration	  of	  approximately	  3µM).	  	  As	  a	  consequence	  of	  the	  rapid	  clearance	  of	  intact	  oxaliplatin	  and	  reactive	  dichloro-­‐	  monochloro	  and	  diaquo-­‐DACH	  platinum	  intermediates	  into	  tissues,	  or	  removal	  by	  renal	  filtration,	  the	  half-­‐life	  of	  platinum	  in	  ultra-­‐filtrate	  follows	  a	  tri-­‐exponential	  pattern;	  a	  rapid	  alpha	  phase	  with	  a	  T1/2	  of	  0.28	  hours,	  a	  beta	  T1/2	  of	  16.3	  hours,	   and	  a	   long	   terminal	  gamma	  phase	  T1/2	  of	  273	  hours	   (figure	  1.7	  A).	  	  This	  pattern	  reflects	  the	  slow	  release	  of	  platinum	  amino-­‐acid	  conjugates	  after	  the	  degradation	  of	  cellular	  macromolecules	  (Di	  Francesco	  et	  al.	  2002;	  Graham	  et	  al.	  2000).	   	   Notably,	   longer	   time-­‐course	   experiments	   show	   that	   no	   significant	  accumulation	  occurs	   in	  plasma	  ultra-­‐filtrate	  after	  multiple	  dosing	  at	  130mg/m2	  every	  3	  weeks	  (figure	  1.7C)	  (Graham	  et	  al.	  2000).	  	   The	   circulating	   ultra-­‐filterable	   and	   biologically	   active	   fraction	   continues	  to	  be	  distributed	   to	   the	   tissues	   and	  enters	   the	   extra-­‐cellular	   fluid	   for	  24	  hours	  after	   infusion,	  where	   it	   is	   available	   for	  uptake	   into	  both	  malignant	   and	  normal	  cells	  (Figure	  1.7B)	  (Burz	  et	  al.	  2009).	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Figure	  1.7:	  The	  pharmacokinetics	  of	  oxaliplatin.	  	  	  Panel	   A	   shows	   the	   blood	   concentration	   of	   oxaliplatin	   during	   a	   2-­‐hour	   infusion	   and	   in	   the	  first	  hour	  afterwards	   (figure	  adapted	   from(Ehrsson	  et	  al.	  2002)).	  Panel	  B	   shows	   the	  ultra-­‐filterable	   compartment	   platinum	   concentration	   over	   24	  hours	   following	   infusion	   (adapted	  from	  (Burz	  et	  al.	  2009)).	  	  Figure	  C	  shows	  no	  significant	  oxaliplatin	  accumulation	  when	  given	  3	  weekly	  for	  5	  cycles	  (Graham	  et	  al.	  2000).	  	  
1.2.2 Cellular	  uptake	  of	  platinum	  -­‐	  Influx	  vs.	  Efflux	  
	   Initially,	   experimental	   studies	   of	   the	   uptake	   of	   cisplatin	   suggested	   this	  class	   of	   drug	   is	   taken	   into	   the	   cell	   through	   passive	   diffusion.	   	   	   In	   these	   initial	  experiments	   demonstrated	   that	   uptake	   into	   the	   cell	   occurs	   in	   a	   concentration	  dependent	  linear	  manner	  over	  60	  minutes,	  the	  concentration	  dependent	  uptake	  of	  platinum	  could	  not	  be	  saturated,	  and	  was	  not	  inhibited	  by	  analogues,	  and	  that	  there	   was	   no	   optimum	   pH	   for	   entry;	   all	   suggesting	   that	   no	   significant	   active	  transport	   mechanism	   was	   operating	   (Binks	   and	   Dobrota	   1990;	   Gately	   and	  Howell	  1993;	  Hromas	  et	  al.	  1987).	  	  	  The	   evidence	   for	   an	   active	   component	   to	   drug	   influx	   came	   with	   the	  discovery	  that	  reactive	  aldehydes	  inhibit	  cisplatin	  entry	  into	  the	  cell.	  	  A	  putative	  mechanism	   involving	   a	   modification	   of	   membrane	   transporter	   proteins	   was	  proposed	  (Dornish	  and	  Pettersen	  1990).	  	  The	  suggestion	  that	  the	  involvement	  of	  copper	  transporter	  mechanisms	  are	  involved	  in	  the	  influx	  and	  efflux	  of	  cisplatin	  









































between FAAS and ICPMS (approximately 50 and 1 ng/ml,
respectively). For example, the terminal half-life of platinum
estimated by Kern et al. (23) was approximately 27.3 ! 10.6 h
in plasma ultrafiltrate. However, blood sampling was only con-
ducted over a 24-h period, which results in an imprecise esti-
mate of the terminal elimination phase. In contrast, in studies in
which complete PK monitoring was conducted 2–3 weeks post-
treatment and using a more sensitive ICPMS method, the ter-
minal half-life of platinum in ultrafiltrate was estimated to be
273 ! 19.0 h (19, 20).
The latter half-life estimate of 273 h represents a more
rigorous and precise evaluation of the terminal half-life of
platinum after oxaliplatin administration. However, the half-
lives of the shorter " and # phases (0.28 and 16.3 h, respec-
tively) probably represent the more clinically relevant t1/2 values
of pharmacologically active platinum, given that the platinum in
Fig. 4 Multiple dose PKs of plati-
num in plasma ultrafiltrate showing
lack of accumulation after a 2-h infu-
sion of oxaliplatin at 130 mg/m2 every
3 weeks (n $ 6 patients). Line repre-
sents mean platinum concentration; E,
individual platinum concentrations;
f, trough platinum concentrations
(19, 20).
Fig. 5 Platinum AUC0–48 accumula-
tion ratios in blood cells, plasma, and
ultrafiltrate, after multiple doses of
oxaliplatin at 85 m /m2 (cycle 3/cycle
1; E) and 130 mg/m2 (cycle 5/cycle 1;
F; Refs. 19 and 20). Data points,
mean; bars, SD.
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came	   with	   the	   observation	   that	   transfection	   of	   DNA	   coding	   for	   copper-­‐transporting	   ATP7B	   efflux	   pumps	   into	   cell	   line	   models	   increased	   the	   cellular	  resistance	  to	  cisplatin	  as	  a	  direct	  result	  of	  enhanced	  cellular	  efflux	  (Komatsu	  et	  al.	   2000).	   	   Several	   key	   copper	   transporting	   proteins	   have	   now	   been	  demonstrated	   to	   be	   involved	   in	   the	   active	   influx	   and	   efflux	   of	   cisplatin	   and	   its	  analogues.	   	   The	   principle	   influx	   transport	   channels	   are	   copper	   transporter	   1	  (CTR1)	  and	  organic	  cation	  transporter	  3	  (OCT3),	  with	  the	  efflux	  channels	  ATP7A	  and	  B	  primarily	  responsible	  for	  drug	  efflux,	  as	  will	  be	  discussed	  below.	  	  
1.2.2.1 Copper	  transporter	  1	  (CTR1)	  
	   CTR1,	  a	  190	  amino	  acid	  protein	  with	  three	  trans-­‐membrane	  domains,	  is	  a	  high	   affinity	   copper	   transporter	   protein	   that	   mediates	   the	   influx	   of	   cellular	  copper	   (Safaei	   and	  Howell	  2005).	   	   It	   is	  highly	   conserved	  during	  evolution,	   and	  orthologs	   from	   mammalian	   cells	   complements	   copper	   transport	   deficits	   in	   a	  yeast	   S.	   cerevisiae	  model	   (Howell	   et	   al.	   2010).	   	   The	   yeast	   protein	   Ctrl1,	   a	   high	  affinity	   copper	   transporter,	   when	   absent	   results	   in	   decreased	   intra-­‐cellular	  cisplatin	  accumulation	  and	  enhanced	  resistance	  to	  cisplatin	  (Ishida	  et	  al.	  2002).	  	  A	   similar	   effect	   with	   other	   platinum	   agents,	   including	   oxaliplatin,	   has	   been	  described	   (Lin	   et	   al.	   2002).	   	   	   In	   murine	   embryological	   fibroblasts	   (MEFs)	   the	  accumulation	   of	   platinum	   drugs	   into	   the	   cell	   is	   partially	   depended	   on	   CTR1,	  especially	  at	  physiologically	  achievable	  doses	  of	  platinum	  drugs.	   	  MEFs	  that	  are	  CTR1-­‐/-­‐	   accumulate	   one	   third	   of	   the	   amount	   of	   cisplatin	   and	   oxaliplatin	   that	  accumulates	  in	  CTR1+/+	  MEFs	  after	  1	  hour	  of	  incubation	  at	  physiological	  doses	  of	   2uM.	   	   At	   higher	   doses	   (of	   over	   10uM)	   the	   difference	   in	   uptake	   of	   cisplatin	  between	   wildtype	   and	   CTR1-­‐/-­‐	   cells	   remains	   similar,	   whereas	   there	   is	   no	  differential	   uptake	   with	   oxaliplatin,	   suggesting	   a	   differential	   mechanism	   of	  uptake	  between	  these	  drugs	  at	  supra-­‐physiological	  doses	  (Holzer	  et	  al.	  2006).	  The	   over-­‐expression	   of	   hCTR1	   in	   ovarian	   cancer	   cell	   lines	   results	   in	   a	  significant	   increase	   in	   the	   accumulation	   of	   intra-­‐cellular	   cisplatin,	   although,	   of	  note,	   the	   amount	   of	   platinum-­‐DNA	   adducts	   generated	   was	   not	   increased	   and	  there	  is	  only	  a	  marginal	  increase	  in	  resulting	  cytotoxicity	  (Holzer	  et	  al.	  2004).	  	  	  
	   18	  
The	   association	   of	   platinum	   drug	   uptake	   and	   physiological	   copper	  transport	  may	  be	   a	  mutually	   exclusive	   effect.	   	   Copper	   and	   cisplatin	   reduce	   the	  uptake	  of	  one	  another,	  trigger	  degradation	  and	  delocalisation	  of	  CTR1	  (Ishida	  et	  al.	   2002)	   and	   show	   bi-­‐directional	   cross-­‐resistance	   (Katano	   et	   al.	   2002;	   Safaei	  2006).	  
	  
1.2.2.2 Organic	  cation	  transporters	  (OCT1-­‐3)	  	   The	   organic	   cation	   transporters	   1	   to	   3	   (OCT1-­‐3)	   are	   a	   subgroup	   of	   the	  SLC2	  family	  of	  solute	  transporters.	  	  Facilitated	  delivery	  of	  platinum	  drugs	  by	  the	  organic	  cation	  transporters	  has	  been	  demonstrated,	  and	  this	  may	  correspond	  to	  a	   mechanism	   for	   cisplatin	   nephrotoxicity,	   as	   OCT2	   has	   been	   shown	   to	   be	  important	  in	  mediating	  cisplatin	  uptake	  in	  renal	  proximal	  tubule	  cells.	   	  In	  these	  models	  an	  OCT2	  substrate	  can	  be	  used,	  and	  inhibits	  cisplatin-­‐induced	  renal	  cell	  apoptosis	  (Ciarimboli	  et	  al.	  2005).	  In	   human	   colorectal	   cancer	   cell	   lines	   OCT1	   and	   OCT2	   overexpression	  increases	   the	   accumulation	   of	   oxaliplatin,	   but	   not	   cisplatin	   or	   carboplatin,	   and	  may	  account	  for	  some	  of	  the	  spectrum	  of	  tumour	  specific	  cytotoxicity	  (Burger	  et	  al.	   2010;	  Zhang	  et	   al.	   2006).	   	  This	   is	   explained	  by	   the	  nature	  of	   the	  oxaliplatin	  leaving	  group,	  which	  has	  been	  found	  to	  give	  a	  degree	  of	  specificity	   for	   the	  OCT	  transporters	   with	   a	   differential	   uptake	   between	   the	   DACH	   leaving	   group	  compared	  to	  cisplatin	  and	  carboplatin	  (Burger	  et	  al.	  2010;	  Zhang	  et	  al.	  2006).	  
	  
1.2.2.3 Efflux	  	  	   After	  drug	   influx	   further	  biotransformation	  occurs	   in	   the	  cytoplasm	  as	  a	  consequence	   of	   the	   low	   intra-­‐cellular	   chloride	   concentration,	   resulting	   in	   the	  formation	  of	  aquated	  species	  (figure	  1.6)	  (Jerremalm	  et	  al.	  2009).	  	  	  The	  resulting	  cationic	   molecules	   are	   unable	   to	   diffuse	   through	   the	   lipid	   bilayer,	   remaining	  trapped	  in	  the	  cell	  as	  a	  consequence	  of	  this	  biotransformation	  and	  the	  resulting	  gain	  of	  electrostatic	  charge	  (Jung	  and	  Lippard	  2007).	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Active	  drug	  efflux	  occurs	  via	  copper	  homeostasis	  mechanisms.	  	  The	  efflux	  pump	   copper	   transporting	   P	   type	   adenosine	   triphosphate	   (ATP7B)	   has	   an	  important	   role	   in	   regulating	   copper	   levels	   and	   is	   associated	   with	   cisplatin	  resistance	  in	  vitro	  (Komatsu	  et	  al.	  2000)	  and	  in	  various	  cancers	  (Miyashita	  et	  al.	  2003;	  Nakayama	  et	  al.	  2002;	  Nakayama	  et	  al.	  2004).	  	  Copper	  transporters	  ATP7A	  and	  ATP7B	  may	  have	  a	  roll	   specifically	   in	  oxaliplatin	  efflux,	  as	  over	  expression	  results	   in	   resistance,	   although	   the	   mechanism	   is	   unclear	   and	   may	   occur	   as	   a	  result	   of	   enhanced	   cytoplasmic	   sequestration	   rather	   than	   through	   increased	  efflux	  (Samimi	  et	  al.	  2004).	  	  The	  levels	  of	  ATP7A	  have	  been	  shown	  to	  increase	  in	  response	   to	   oxaliplatin	   (Plasencia	   et	   al.	   2006)	   and	   have	   been	   correlated	   with	  longer	   time	   to	   progression	   in	   some	   clinical	   samples	   (Martinez-­‐Balibrea	   et	   al.	  2009).	   	   Additionally,	   the	   expression	   of	   ATP7B	   in	   human	   carcinoma	   cells	  modulates	  sensitivity	  to	  cisplatin	  and	  copper	  by	  increasing	  efflux	  (Komatsu	  et	  al.	  2000).	  	  
1.2.3 Intra-­‐cellular	  biotransformation	  	   In	   the	   chloride-­‐rich	   environment	   outside	   of	   the	   cell	   (principally	   ultra-­‐filterable	  plasma	  and	  extracellular	  fluid)	  the	  oxalate	  leaving-­‐group	  of	  oxaliplatin	  is	  replaced	  by	  chloride	  ions	  to	  form	  dichloro-­‐	  intermediates	  (figure	  1.6)	  (Luo	  et	  al.	   1998).	   	   Under	   these	   conditions,	   typically	   with	   a	   chloride	   concentration	   of	  100mM,	   hydrolysis	   of	   the	   dichloro-­‐platinum	   compounds	   is	   unfavourable	  (Kartalou	  and	  Essigmann	  2001a).	   	  Following	  diffusion	  and	  active	  uptake	   to	   the	  cytoplasm	  the	   low	   intra-­‐cellular	  chloride	  concentration	  (typically	  4mM)	  results	  in	  aquation,	   replacing	  one	  of	   the	   chloride	   ions	  with	  water,	   to	   form	  a	  positively	  charged	  electrophilic	  aquo-­‐chlorido	  species.	  	  The	  aquated	  species	  are	  much	  more	  biologically	   active,	   and	  have	  a	  high	  affinity	   for	  N7	  of	   guanine	  or	  adenine	  bases	  (Kozelka	  2009).	  	  	  	  The	  interaction	  of	  platinum	  agents	  with	  DNA	  occurs	  only	  after	  aquation.	  	  Experimentally	   increasing	   chloride	   concentrations	   to	   reduce	   aquation	  proportionally	  slows	  the	  rate	  of	  adduct	  formation	  (Horacek	  and	  Drobnik	  1971),	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and	   the	   rate	   of	   reaction	   between	   salmon	   sperm	   DNA	   and	   cisplatin	   is	   almost	  identical	  to	  the	  rate	  of	  cisplatin	  hydrolysis	  (Bodenner	  et	  al.	  1986).	  	  
1.2.4 Intracellular	  interactions	  	  Following	  aquation,	  and	   the	  resulting	  accumulation	  of	  a	  positive	  charge,	  reactions	  with	  cellular	  components	  occurs	  rapidly	  and	  frequently.	  	  Over	  90%	  of	  all	  platinum	  ions	  entering	  the	  cell	  are	  sequestered	  in	  the	  cytoplasm	  (Akaboshi	  et	  al.	  1992;	  Akaboshi	  et	  al.	  1994;	  Raymond	  et	  al.	  2002)	  and	  there	  are	  a	  multitude	  of	  intra-­‐cellular	   components	   that	   platinum	   agents	   can	   interact	   with,	   including	  proteins,	   membrane	   phospholipids,	   microfilaments,	   thio-­‐	   containing	  molecules	  such	   as	   glutathione,	   DNA	   and	   RNA.	   	   The	   detailed	   nature	   of	   these	   reactions	   is	  uncertain	   because	   of	   the	   complexity	   of	   the	   intracellular	   environment	   and	   the	  lack	   of	   techniques	   available	   to	   investigate	   the	   subtleties	   of	   these	   interactions,	  although	  some	  information	  can	  be	  inferred	  from	  studies	  of	  platinum	  complexes	  with	  aqueous	  buffers	  and	  with	  growth	  medium	  components	  in	  vitro	  (Bancroft	  et	  al.	  1990;	  Luo	  et	  al.	  1999).	  	  	  Although	  the	  weight	  of	  evidence	  suggests	  that	  DNA	  is	  the	  lethal	  target	  of	  platinum	  agents	  (as	  will	  be	  discussed	  in	  detail	  in	  the	  next	  section)	  it	  is	  possible	  that	  targets	  other	  than	  DNA	  may	  contribute	  to	  cytotoxic	  effect,	  however	  evidence	  to	  support	  this	  hypothesis	  is	  limited.	  	  Only	  5-­‐10%	  of	  covalently	  bound	  cisplatin	  is	  found	   in	   DNA	   whereas	   the	   rest	   is	   bound	   to	   protein	   (Akaboshi	   et	   al.	   1992;	  Raymond	  et	  al.	  2002).	  	  Cellular	  protein	  binding	  via	  sulphur	  atoms	  in	  cysteine	  and	  methionine	   residues	   may	   affect	   enzymatic	   functions,	   other	   proteins	   and	   the	  activity	   of	   cellular	   receptors,	  with	   the	  damage	   resulting	   in	   apoptosis	   induction	  (Woynarowski	   et	   al.	   2000).	   	   Platinum-­‐protein	   binding	   in	   A2780	   cells	   is	   high	  (Pendyala	  and	  Creaven	  1993)	  and	  the	  DACH	  moiety	  of	  oxaliplatin	  may	  direct	  the	  drug	   towards	   hydrophobic	   pockets,	   as	   opposed	   to	   polarised	   cisplatin	  (Woynarowski	   et	   al.	   2000),	   and	   this	   effect	   may	   account	   for	   some	   of	   the	  differences	  seen	  between	  cisplatin	  and	  oxaliplatin	  adduct	   levels	  and	  equivalent	  cytotoxicity	  (Chaney	  and	  Sancar	  1996).	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1.2.5 Interaction	  of	  platinum	  agents	  with	  DNA	  	  Having	   traversed	   the	   cytosolic	   compartments,	   platinum	  drugs	   enter	   the	  nucleus.	   	   Following	   entry	   to	   the	   nucleus	   the	   high	   concentration	   of	   nucleotides	  results	   in	   substantial	   interactions	  with	   nuclear	   DNA	   (Jung	   and	   Lippard	   2007).	  	  There	  is	  extensive	  evidence	  that	  a	  defined	  family	  of	  platinum-­‐DNA	  adducts	  form	  between	  the	  platinum	  atom	  and	  cis-­‐N-­‐donor	   ligands,	  resulting	   in	  the	   formation	  of	  cross-­‐links	  with	  the	  nucleobases	  of	  DNA	  (Jamieson	  and	  Lippard	  1999).	  The	   evidence	   that	   DNA	   is	   the	   primary	   target	   of	   platinum	   drugs,	   among	  many	   potential	   cellular	   possibilities,	   has	   been	   extensively	   reviewed	   (Jamieson	  and	   Lippard	   1999).	   	   Initial	   evidence	   came	   from	   the	   observation	   that	   cisplatin	  treated	   bacteria	   show	   phenotypes	   characteristic	   of	   those	   evoked	   by	   DNA	  damaging	  agents	  (Reslova	  1971).	   	  More	  convincing	  evidence	  was	  demonstrated	  by	   experiments	   revealing	   that	  DNA	   repair-­‐deficient	   cells	   are	  more	   sensitive	   to	  cisplatin	   (Brouwer	   et	   al.	   1981;	   Popoff	   et	   al.	   1987).	   	   Levels	   of	   platinum	   atoms	  bound	   to	   RNA	   and	   protein	   are	   too	   low	   to	   have	   significant	   targeted	   inhibitory	  effects,	  and	  hence	  are	  thought	  to	  be	  less	  likely	  to	  be	  significant	  (Blommaert	  et	  al.	  1998).	   	   Cisplatin	  modification	   of	   cellular	   DNA	   can	   be	  measured	   using	   specific	  cisplatin-­‐DNA	  adduct	  antibodies,	  and	  these	  can	  also	  be	  used	  to	  define	  the	  nature	  of	   crosslinks	   (Blommaert	   et	   al.	   1998;	   Fichtinger-­‐Schepman	   et	   al.	   1990;	  Fichtinger-­‐Schepman	   et	   al.	   1987).	   	   A	   significant	   correlation	   typically	   occurs	  between	  platinum-­‐DNA	  adduct	   levels	   and	   the	   sensitivity	   of	   treated	   cells	   to	   the	  drug	  (Boffetta	  et	  al.	  1998;	  Welters	  et	  al.	  1999a).	  	  	  	  
1.2.6 Adduct	  formation	  and	  base	  specificity	  	   The	   formation	   of	   platinum	   adducts	   with	   DNA	   has	   been	   extensively	  reviewed	   (Kozelka	  2009).	   	   Platinum	  agents	   initially	   bind	   a	   guanine	  nucleotide,	  resulting	   in	   the	   formation	   of	   a	  mono-­‐adduct.	   Chemical	  manipulation	   of	  mono-­‐adducts	   by	   trapping	   the	   platinum	   ion	   at	   the	   mono-­‐adduct	   stage	   and	   allowing	  investigation	  of	  initial	  single	  intercalation	  is	  possible	  with	  the	  use	  of	  NH4HC03	  or	  with	  thiourea	  (Eastman	  1986).	   	  These	  trapping	  experiments	  confirm	  that	  initial	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mono-­‐adducts	   form	   exclusively	   at	   guanine	   bases.	   	   Guanine	   bases	   are	   the	  preferred	  targets	  of	  cisplatin	  as	  the	  N7	  position	  is	  the	  most	  reactive	  position	  in	  double	   stranded	   DNA	   -­‐	   it	   combines	   a	   high	   electronic	   density	   and	   enhanced	  accessibility	  through	  its	  localisation	  in	  the	  major	  grove	  of	  the	  DNA	  helix.	  	  Mono-­‐intercalated	  platinum	  agents	  retain	  a	  single	  labile	  chloride	  or	  aqua	  ligand	   capable	   of	   di-­‐adduct	   formation.	   	   The	   free	   second	   arm	   forms	   covalent	  bonds	   to	   the	   N7	   positions	   of	   closely	   situated	   purine	   bases	   to	   form	   1,2	   or	   1,3	  intrastrand	  crosslinks.	  	  The	  negative	  electrostatic	  potential	  of	  the	  N7	  position	  of	  guanine	   is	   increased	   when	   flanked	   by	   other	   guanine	   residues,	   resulting	   in	   an	  increased	  specificity	   for	  GG	  di-­‐nucleotides	  (Gillet	  and	  Scharer	  2006).	   	  A	  similar	  interaction	  with	  juxtaposed	  purines	  on	  the	  opposite	  strand	  results	  in	  intrastrand	  cross-­‐links	   (ICLs),	   although	  at	   a	  much	   lower	   frequency	   (figure	  1.8)	   (Wang	  and	  Lippard	  2005).	  	  	  
	  
Figure	  1.8:	  The	  platinum-­‐DNA	  adducts.	  Cisplatin-­‐DNA	   monoadducts,	   intrastrand,	   interstrand	   and	   DNA-­‐protein	   crosslinks.	  	  (Adapted	  from	  (Rabik	  and	  Dolan	  2007))	  	  The	  rate	  of	  formation	  of	  diadducts	  from	  monoadducts	  has	  been	  calculated	  using	   thio-­‐urea	   trapping	   experiments	   (Eastman	   1986;	   Kozelka	   2009).	   	   After	   a	  short	   incubation	   of	   15	   minutes	   the	   majority	   of	   adducts	   are	   guanine	  monoadducts,	   although	   significant	   amounts	   of	   GG	   diadducts	   have	   already	  formed.	  	  Over	  the	  following	  60	  minutes	  incubation	  and	  after	  a	  16-­‐hour	  follow-­‐up	  period	   all	  monoadducts	   are	   converted,	   principally	   to	   GG	   intrastrand	   diadducts	  (figure	  1.8).	  
Background
Cisplatin [cis-diammine-dichloroplatinum(II)]4 (Fig. 1) is a
commonly used chemotherapeutic agent that was discov-
ered in 1970 as an inhibitor of growth in Eschericia coli.1
The clinical benefits of cisplatin as an anti-cancer agent
have been recognized for over 30years. Cisplatin is consid-
ered to be curative treatment for testicular cancer, when
combined with bleomycin and etoposide. It is closely re-
lated to its second generation analog carboplatin; the two
compounds share a mechanism of action, are fully crossre-
sistant, and form identical lesions on DNA. Both ag nts are
used for many other types of cancer, including ovarian, cer-
vical, head and neck, non-small cell lung, an lymphoma.
However, for many, particularly head and neck, lung, and
relapsed lymphomas, cisplatin treatment is plagued by
problems – including toxicities and resistance, both intrin-
sic and acquired.2 Oxalate (trans-l-1,2-diamminocyclohex-
ane) platinum(II) (oxaliplatin) is an analog which does not
share the same mechanism as cisplatin, and likewise does
not share in crossresistance (reviewed in Ref. 3).
In this review, we will focus on the most commonly used
platinating agents – cisplatin, carboplatin, and oxaliplatin.
It is worth mentioning, however, that a fourth platinating
agent, satraplatin (bis(aceto)amminedichloro(cyclohexyl-
amine) platinum(IV)), is available, and is currently the only
orally available platinating agent. Satraplatin does not share
crossresistance with cisplatin, which is thought to be due to
a different detoxification mechanism, and it shows activity
in advanced hormone-refractory prostate cancer.4,5
Mechanism of action
DNA Lesions
Upon entering a cell, all platinating agents become aqua-
ted, losing chloride or oxalate ions, and gaining two water
molecules. This positively charged molecule is then able
to interact with nucleophilic molecules within the cell,
including DNA, RNA, and proteins. It is generally agreed that
DNA is the preferential and cytotoxic target for cisplatin and
other platinating agents (reviewed in Ref. 6). When binding
to DNA, platinating agents favor the N7 atoms of the imidaz-
ole rings of guanosine and adenosine. Three different types
of lesions can form on purine bases of DNA: monoadducts,
intrastrand crosslinks, and interstrand crosslinks (Fig. 2).
Monoadducts are first formed as one molecule of water is
lost from aquated platinating agents; however, greater than
90% of monoadducts then react to form crosslinks. Almost
all of these crosslinks are intrastrand, with the majority
being 1,2-d(GpG) crosslinks. Additional DNA lesions include
interstrand crosslinks. Oxaliplatin forms fewer crosslinks
than cisplatin at equimolar concentrations; however, it is
equally as potent at these concentrations7,8 and is able to
induce similar numbers of single-strand and double-strand
breaks on DNA.9
All crosslinks result in contortion of the DNA (reviewed in
Ref. 10). Cisplatin and c rb platin intrastrand crosslinks
bend the double helix by 32–35! toward the major groove,
whereas oxaliplatin treatment bends the helix even fur-
ther.11 Both 1,2-d(GpG) and 1,2-d(ApG) intrastrand cross-
links unwind DNA by 13!, while he 1,3-d(GpXpG)
intrastrand lesion unwinds DNA by 34!. Interstrand lesions
induce even more steric changes in DNA, with extrusion of
the cytosines at the crosslinked d(GpC)d(GpC) sites, bend-
ing of the double helix toward the minor groove by 20–
40!, and extensive DNA unwinding of up to 80!. Oxaliplatin
adducts are bulkier and more hydrophobic than those
formed from cisplatin or carboplatin, leading to different
effects in the cell (reviewed in Ref. 12).
HMG involvement
There are different theories as to which lesion is responsible
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Figure 2 Platinating agent adducts on DNA. Platinating
agents are able to react with DNA to form monoadducts,
intrastr nd crossl ks (1,2- (GpG), 1,2-d(ApG), 1,3-
d(GpXpGp)), interstrand crosslinks (G-G), and DNA–protein
crosslinks.
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The	  effect	  of	  specific	  adducts	  on	  DNA	  have	  been	  elucidated	  (Chaney	  et	  al.	  2005;	   Jamieson	  and	  Lippard	  1999).	   	  The	  major	  1,2	   intrastrand	  adduct	  unwinds	  the	   DNA	   in	   the	   vicinity,	   bending	   towards	   the	   major	   groove	   and	   generating	   a	  widened	   and	   shallow	   minor	   groove	   (Coste	   et	   al.	   1999;	   Gelasco	   and	   Lippard	  1998).	   	   The	   cisplatin	   inter-­‐strand	   DNA	   cross-­‐link	   bends	   the	   helix	   towards	   the	  minor	   groove	   (Coste	   et	   al.	   1999).	   	   There	   is	   a	   subtle	   variation	   in	   adduct-­‐DNA	  distortion	   with	   different	   types	   of	   platinum	   drugs	   that	   may	   account	   for	   some	  spectrum	  of	  activity	  and	  toxicity	  differences	  between	  platinum	  agents,	  although	  no	  gross	  difference	  between	  oxaliplatin	  and	  cisplatin	  induced	  DNA	  distortion	  has	  been	  demonstrated	  (Wong	  and	  Giandomenico	  1999).	  	  	  	  
1.2.7 The	  biological	  relevance	  of	  specific	  platinum-­‐DNA	  adducts	  	   The	   relevance	   of	   the	   different	   platinum-­‐DNA	   adducts	   in	   respect	   of	  cytotoxicity	   is	   important.	   	   The	   key	   distinction	   is	   between	   the	   1,2-­‐d(GpG)	  intrastrand	   crosslink	   and	   the	   ICLs.	   	   Evidence	   for	   a	   difference	   in	   cytotoxicity	  comes	  from	  comparing	  the	  cytotoxicity	  of	  cisplatin	  to	  transplatin,	  trans-­‐diamine-­‐dichloroplatinum(II)	   (Figure	  1.10).	   	  Transplatin	   is	  not	   cytotoxic,	  despite	  a	  very	  similar	  structure.	  	  	  It	  forms	  a	  different	  profile	  of	  adducts	  due	  to	  steric	  restriction	  resulting	  in	  inability	  to	  form	  1,2-­‐intrastrand	  crosslinks,	  but	  retains	  the	  ability	  to	  form	   1,3-­‐intrastrand	   crosslinks	   and	   interstrand	   crosslinks	   (Eastman	   1987;	  Eastman	  et	  al.	  1988).	  	  This	  is	  a	  strong	  indication	  that	  the	  primary	  cytotoxic	  lesion	  is	  the	  most	  prevalent	  1,2	  intrastrand	  crosslink.	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Figure	  1.10:	  The	  structure	  of	  Cisplatin	  and	  transplatin.	  
	  
	  	   Another	  indication	  of	  the	  relative	  cytotoxicity	  of	  the	  most	  common	  lesions	  is	   that	   oxaliplatin	   forms	   significantly	   fewer	   ICLs	   than	   cisplatin	   at	   equimolar	  doses,	   but	   is	   more	   potent.	   	   Additionally,	   the	   1,3	   intrastrand	   crosslink	   is	  more	  readily	  repaired	  than	  1,2	  intrastrand	  crosslink	  by	  NER,	  due	  to	  increased	  helical	  distortion	   and	   easier	   accessibility	   of	   the	   1,3	   lesion	   to	   damage	   recognition	  proteins	  (Wang	  and	  Lippard	  2005).	  	   	  
Background
Cisplatin [cis-diammine-dichloroplatinum(II)]4 (Fig. 1) is a
commonly used chemotherapeutic agent that was discov-
ered in 1970 as an inhibitor of growth in Eschericia coli.1
The clinical benefits of cisplatin as an anti-cancer agent
have been recognized for over 30years. Cisplatin is consid-
ered to be curative treatment for testicular cancer, when
combined with bleomycin and etoposide. It is closely re-
lated to its second generation analog carboplatin; the two
compounds share a mechanism of action, are fully crossre-
sistant, and form identical lesions on DNA. Both agents are
used for many other types of cancer, including ovarian, cer-
vical, head and neck, non-small cell lung, and lymphoma.
However, for many, particularly head and neck, lung, and
relapsed lymphomas, cisplatin treatment is plagued by
problems – including toxicities and resistance, both intrin-
sic and acquired.2 Oxalate (trans-l-1,2-diamminocyclohex-
ane) platinum(II) (oxaliplatin) is an analog which does not
share the same mechanism as cisplatin, and likewise does
not share in crossresistance (reviewed in Ref. 3).
In this review, we will focus on the most commonly used
platinating agents – cisplatin, carboplatin, and oxaliplatin.
It is worth mentioning, however, that a fourth platinating
agent, satraplatin (bis(aceto)amminedichloro(cyclohexyl-
amine) platinum(IV)), is available, and is currently the only
orally available platinating agent. Satraplatin does not share
crossresistance with cisplatin, which is thought to be due to
a different detoxification mechanism, and it shows activity
in advanced hormone-refractory prostate cancer.4,5
Mechanism of action
DNA Lesions
Upon entering a cell, all platinating agents become aqua-
ted, losing chloride or oxalate ions, and gaining two water
molecules. This positively charged molecule is then able
to interact with nucleophilic molecules within the cell,
including DNA, RNA, and proteins. It is generally agreed that
DNA is the preferential and cytotoxic target for cisplatin and
other platinating agents (reviewed in Ref. 6). When binding
to DNA, platinating agents favor the N7 atoms of the imidaz-
ole rings of guanosine and adenosine. Three different types
of lesions can form on purine bases of DNA: monoadducts,
intrastrand crosslinks, and interstrand crosslinks (Fig. 2).
Monoadducts are first formed as one molecule of water is
lost from aquated platinating agents; however, greater than
90% of monoadducts then react to form crosslinks. Almost
all of these crosslinks are intrastrand, with the majority
being 1,2-d(GpG) crosslinks. Additional DNA lesions include
interstrand crosslinks. Oxaliplatin forms fewer crosslinks
than cisplatin at equimolar concentrations; however, it is
equally as potent at these concentrations7,8 and is able to
induce similar numbers of single-strand and double-strand
breaks on DNA.9
All crosslinks result in contortion of the DNA (reviewed in
Ref. 10). Cisplatin and carboplatin intrastrand crosslinks
bend the double helix by 32–35! toward the major groove,
whereas oxaliplatin treatment bends the helix even fur-
ther.11 Both 1,2-d(GpG) and 1,2-d(ApG) intrastrand cross-
links unwind DNA by 13!, while the 1,3-d(GpXpG)
intrastrand lesion unwinds DNA by 34!. Interstrand lesions
induce even more steric changes in DNA, with extrusion of
the cytosines at the crosslinked d(GpC)d(GpC) sites, bend-
ing of the double helix toward the minor groove by 20–
40!, and extensive DNA unwinding of up to 80!. Oxaliplatin
adducts are bulkier and more hydrophobic than those
formed from cisplatin or carboplatin, leading to different
effects in the cell (reviewed in Ref. 12).
HMG involvement
There are different theories as to which lesion is responsible




























Figure 1 The chemical structures of cisplatin, transplatin,
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Figure 2 Platinating agent adducts on DNA. Platinating
agents are able to react with DNA to form monoadducts,
intrastrand crosslinks (1,2-d(GpG), 1,2-d(ApG), 1,3-
d(GpXpGp)), interstrand crosslinks (G-G), and DNA–protein
crosslinks.
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1.2.8 Platinum	  DNA	  adducts	  in	  the	  context	  of	  chromatin	  structure	  	  	   In	   the	   eukaryotic	   nucleus	   DNA	   is	   wound	   around	   positively	   charged	  histone	  proteins	  forming	  the	  nucleosome.	  	  These	  are	  further	  compacted	  to	  form	  the	  higher	  order	  chromatin	  structure	  (Figure	  1.11).	  	  	  	  
	  
Figure	  1.11:	  The	  organisation	  of	  DNA	  packaged	  in	  the	  chromatin	  structure.	  	  	  	  DNA	  is	  wound	  around	  histone	  proteins	  to	  form	  the	  nucleosome.	   	  Stings	  of	  nucleosomes	  are	  folded	   to	   form	   the	   chromatin	   fibre,	   which	   is	   folded	   further	   into	   higher	   order	   structures	  (reproduced	  from(Felsenfeld	  and	  Groudine	  2003))	  	  Binding	   of	   platinum	   compounds	   to	   chromosomal	   DNA	   is	   different	  compared	   to	   platinum-­‐DNA	   binding	   in	   naked	   DNA	   (Wang	   and	   Lippard	   2005).	  	  Experiments	   reveal	   that	   linker	   DNA	   is	   a	   preferred	   target	   for	   platinum	  compounds	   (Foka	   and	  Paoletti	   1986;	  Galea	   and	  Murray	  2002)	  with	   a	   linker	   to	  nucleosome	   core	   ratio	   of	   1:1.3	   in	   reconstituted	   histone	   models	   treated	   with	  cisplatin	  and	  assessed	  using	  a	   stop-­‐PCR	  based	  assay	   (Galea	  and	  Murray	  2002).	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Evidence	   also	   exists	   for	   increased	   adduct	   formation	   every	   10bp	   over	   a	  nucleosome,	  a	  relationship	  that	  corresponds	  to	  the	  site	  of	  major	  groove	  exposure	  around	   the	   nucleosome	   core	   and	   coincides	   with	   the	   preferential	   nature	   of	  cisplatin	  to	  form	  adducts	  in	  the	  major	  groove	  (Galea	  and	  Murray	  2002),	  although	  this	   is	   less	  pronounced	  at	  higher	  drug	  concentrations	  (Foka	  and	  Paoletti	  1986;	  Galea	   and	   Murray	   2002).	   	   Other	   studies	   have	   support	   the	   evidence	   for	  preferential	   targeting	   of	   linker	   regions	   (Foka	   and	   Paoletti	   1986;	   Hayes	   and	  Scovell	  1991).	  	  	  	  	   The	   formation	   of	   platinum-­‐DNA	   adducts	   on	   chromosomal	   DNA	   also	  depends	   on	   the	   level	   and	   nature	   of	   post-­‐translational	   modifications	   of	   the	  associated	  histones	   (Bubley	  et	   al.	   1996).	   	   	   Levels	  of	  platinum-­‐DNA	  adducts	  are	  higher	   in	   human	   cancer	   cell	   lines	   following	   treatment	   with	   HDAC	   inhibitor	  agents,	  drugs	  that	  result	  in	  chromatin	  unfolding	  (Bubley	  et	  al.	  1996).	  	  Structural	  changes	  in	  chromatin	  by	  transcriptional	  activation	  or	  protein	  binding	  have	  also	  been	  demonstrated	   to	  modulate	   cisplatin	  binding	   to	  DNA	   in	  human	   cells	   (Jung	  and	  Lippard	  2007).	  The	   structure	   of	   chromatin	   has	   significant	   impact	   on	   DNA	   replication,	  transcription	  and	  on	  rates	  of	  DNA	  repair.	   	  For	  example,	  NER	  in	  DNA	  containing	  site	   specific	   platinum	   adducts	   is	   less	   efficient	   in	   cell	   extracts	   than	   free	   DNA	  containing	  the	  same	  DNA	  (Reed	  2005;	  Wang	  et	  al.	  2003).	  	  The	   influence	   of	   cisplatin	   on	   chromatin	   structure	   has	   been	   investigated	  both	   in	   vivo	   and	   in	   vitro	   (Hayes	   and	   Scovell	   1991;	   Jung	   and	   Lippard	   2007).	  	  Cisplatin	   binding	   has	   an	   effect	   on	   the	   higher	   order	   chromatin	   structure	   rather	  than	  that	  of	  the	  core	  nucleosome	  structure	  (Millard	  and	  Wilkes	  2000).	  	  Cisplatin	  treatment	   of	   HeLa	   cells	   induces	   histone	   H3	   phosphorylation	   and	   histone	   H4	  hyperacetlyation	  (Wang	  and	  Lippard	  2005),	  although	  whether	  this	  is	  a	  response	  to	  cisplatin	  binding	  on	  chromatin,	  or	  the	  effect	  of	  a	  downstream	  cellular	  pathway	  is	  uncertain	  (Jung	  and	  Lippard	  2007).	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1.2.9 Differences	  in	  DNA	  interaction	  between	  cisplatin	  and	  oxaliplatin	  	  	   Oxaliplatin	  forms	  fewer	  DNA	  adducts	  than	  cisplatin,	  although	  oxaliplatin	  is	  at	  least	  equally	  as	  cytotoxic	  as	  cisplatin	  in	  cell	  models,	  indicating	  that,	  on	  a	  per-­‐adduct	   basis,	   oxaliplatin-­‐induced	  DNA	  damage	   is	  more	   cytotoxic	   than	   cisplatin	  damage	  (Saris	  et	  al.	  1996).	  	  The	  lower	  adduct	  levels	  could	  result	  from	  oxaliplatin	  being	  less	  reactive	  than	  cisplatin	  with	  naked	  DNA,	  demonstrated	   in	  vitro	  and	  in	  A2780	   cells	  with	   3-­‐fold	   less	   adducts	   formed	   in	   naked	  DNA	   than	  with	   cisplatin	  (Saris	  et	  al.	  1996)	  detected	  using	  an	  antibody	  raised	  against	   cisplatin	  modified	  DNA.	   	  In	   agreement,	  Woynarowski	  used	  a	  PCR-­‐stop	  assay	   to	  demonstrate	   that	  oxaliplatin	  and	  cisplatin	  form	  lesions	  at	  the	  same	  sequence	  specificity	  and	  with	  a	  similar	   profile	   of	   adducts	   in	   naked	   SV40	   DNA	   (Woynarowski	   et	   al.	   1998).	  	  However	  the	  frequency	  of	  lesions	  in	  intracellular	  DNA	  in	  A2780	  cells	  was	  2	  to	  4	  times	   lower	   with	   oxaliplatin,	   although	   oxaliplatin	   IC50	   in	   A2780	   cells	   was	  0.56µM	  compared	  to	  2.3µM	  for	  cisplatin,	  approximately	  a	  four	  fold	  difference.	  	  	  The	  rate	  of	  formation	  of	  adducts	  may	  be	  different	  between	  these	  agents.	  	  Di-­‐adduct	  formation	  occurs	  more	  slowly	  with	  oxaliplatin	  than	  with	  cisplatin,	  yet	  as	  overall	  oxaliplatin	  is	  more	  cytotoxic	  this	  suggests	  that	  the	  therapeutic	  effects	  do	  not	  depend	  solely	  on	  the	  rate	  of	  the	  intercalating	  effect	  of	  the	  platinum	  moiety	  (Di	   Francesco	   et	   al.	   2002).	   	   Inter-­‐strand	   cross	   links	   are	   also	   believed	   to	  contribute	   to	   toxicity,	   more	   so	   in	   cisplatin	   than	   in	   oxaliplatin	   treated	   cells	  (Zwelling	  et	  al.	  1978).	  The	   downstream	   response	   to	   oxaliplatin	   adducts,	   although	   similar	   in	  terms	  of	  NER	  -­‐	  the	  predominant	  adduct	  repair	  pathway	  (Raymond	  et	  al.	  2002),	  differs	  compared	  to	  cisplatin	  and	  carboplatin	  adducts,	  particularly	  as	  oxaliplatin	  fails	   to	   generate	   a	   mismatch	   repair	   (MMR)	   response.	   	   DNA	   synthesis	   is	   also	  inhibited	  to	  a	  greater	  extent	  with	  oxaliplatin	  adducts	  compared	  to	  cisplatin-­‐DNA	  adducts	  because	  of	  the	  steric	  affect	  of	  the	  DACH	  moiety	  (Raymond	  et	  al.	  1998b).	  	  The	   downstream	   processing	   of	   platinum	   adducts,	   and	   specific	   differences	  between	  cisplatin	  and	  oxaliplatin,	  will	  be	  discussed	  in	  the	  next	  section.	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 The	  cellular	  processing	  of	  platinum-­‐DNA	  adducts	  1.3	  	   Once	   platinum-­‐DNA	   adducts	   have	   formed,	   and	   have	   been	   recognised,	  several	  pathways	  in	  the	  cell	  are	  activated.	  	  Adducts	  are	  recognised	  by	  the	  binding	  to	  adduct-­‐distorted	  DNA	  by	  wide	  variety	  of	  proteins,	  leading	  to	  the	  activation	  of	  cellular	  signalling	  cascades,	  and	  resulting	  in	  cell	  cycle	  arrest	  and	  the	  activation	  of	  mechanisms	  to	  attempt	  to	  repair	  the	  damaged	  DNA.	  	  During	  cell	  cycle	  arrest	  and	  the	  cessation	  of	  DNA	  replication,	  the	  inhibition	  of	  mRNA	  synthesis	  by	  platinum-­‐DNA	   adducts	   additionally	   results	   in	   significant	   stresses	   to	   the	   cell.	   	   Unless	  platinum	   DNA	   adducts	   are	   repaired	   (by	   the	   mechanisms	   discussed	   later	   in	  section	  1.4)	  the	  continued	  activation	  of	  DNA	  damage	  signal	  cascades,	  combined	  with	   the	   cellular	   response	   to	   failed	   replication	   and	   impaired	   transcription,	  results	  in	  cell	  death	  via	  apoptosis	  or	  necrosis	  (Figure	  1.12),	  as	  will	  be	  discussed	  in	  this	  section	  (Jung	  and	  Lippard	  2007;	  Wang	  and	  Lippard	  2005).	  	  	   	  
	  
Figure	  1.12:	  Overview	  of	  the	  cellular	  response	  to	  the	  presence	  of	  platinum-­‐DNA	  adducts.	  Following	   the	   formation	   of	   platinum-­‐DNA	   adducts,	   distortion	   in	   DNA	   structure	   results	   in	  protein-­‐DNA	   binding,	   triggering	  multiple	   signalling	   cascades,	   resulting	   in	   cell	   cycle	   arrest	  and	  attempted	  DNA	  repair,	  and	  leading	  to	  either	  cell	  survival	  or	  cell	  death	  via	  apoptosis	  or	  necrosis	  (Adapted	  from	  (Wang	  and	  Lippard	  2005))	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Cisplatin and nucleosomes. In eukaryotic cells, DNA is
packaged as chromatin. The basic structural unit of chro-
matin is the nucleosome, which comprises 146 bp of
DNA wrapped around a histone octamer. Incorporation
into chromatin alters the dynamic and structural proper-
ties of DNA and consequently modulates various bio-
logical processes, such as replication, transcription and
repair. Therefore, the nucleosome context must be con-
sidered to fully understand the mechanism of cisplatin
cytotoxicity in vivo.
The influence of chromatin structure on cisplatin–
DNA adduct formation has been investigated both 
in vitro and in vivo. Studies have shown that DNA in the
linker region of polynucleosomes is a preferred site of
cisplatin DNA binding192,193, but this apparent preference
is not observed at higher drug levels193,194. Moreover,
cisplatin and trans-DDP show different nucleosome-
binding preferences193,195,196. Cisplatin modification
influences inter-nucleosomal DNA–protein interactions,
but does not significantly disrupt the structure within
the core particle197,198. Recently, hydroxyl-radical foot-
printing work revealed that the cisplatin modification
changes the rotational setting of nucleosomes (D.W., A.
Danford, Q. Wang, T. D. Tullius and S.J.L., unpublished
observations).
Cisplatin, but not trans-DDP (FIG. 1), significantly
inhibits chromatin remodelling and transcription-factor
binding, as well as transcription from mouse mammary
tumour virus promoter in vivo199. In addition, com-
parison of DNA alone, nucleosomes prepared with
native histones and nucleosomes prepared with recom-
binant, unmodified histones, each containing the same
site-specific platinum–DNA adduct, revealed that the
nucleosome significantly inhibits NER. Moreover, post-
translational modification of histones can modulate
NER from damaged chromatin in vitro158.
Development of new platinum-based drugs
The major cellular processes by which cisplatin enters
and attacks cancer cells include uptake and transport,
formation of DNA adducts and their recognition by
damage-response proteins, and signal transduction
leading to cell-cycle arrest, repair and/or death. Any
factors that interfere with these pathways can lead to
drug resistance. Several studies have revealed that the
major resistance mechanisms fall into the following
four categories: limitation of drug levels by reduced
uptake and/or increased efflux; increased cellular thiol
levels; enhanced DNA repair and/or increased damage
tolerance; and failure of cell-death pathways (TABLE 1).
Thousands of platinum compounds have been
screened for antitumour activity. Most of the com-
pounds are straightforward analogues of the parent
compounds cisplatin, carboplatin or oxaliplatin. With
the use of robotic combinatorial methods, more than
3,000 new combinations were prepared over the course
of several weeks and screened for their ability to inhibit
transcription in a reporter-gene fluorescence assay200.
Four hits were obtained, three of which had been pre-
viously evaluated. The fourth was a close analogue of
ZD0473, discussed below, which was already in clinical
such as CASP3 and CASP7. These caspases are largely
responsible for the cleavage of many other cellular
proteins, leading to apoptosis180.
Two major distinct apoptotic pathways have been
described for mammalian cells. One involves CASP8,
which is recruited by the adapter molecule Fas/APO1-
associated death domain protein to death receptors on
extracellular ligand binding184. The other involves
activation of CASP9 through APAF1 that is dependent
on cytochrome c release185. Increased levels of cyto-
chrome c are observed in the cytoplasm of cisplatin-
treated cells, indicating that cytochrome c release is
required for cisplatin-induced apoptosis186.
CASP3 has an essential role for procaspase 9 process-
ing and cisplatin-induced apoptosis. Cytochrome c- and
CASP8-mediated procaspase 9 processing are highly
dependent on CASP3 (REFS 187–189). CASP3-deficient
MCF7 breast cancer cells are unable to induce apoptosis
in response to cisplatin treatment. Stable transfection of
CASP3 cDNA into MCF-7 cells results in increased
apoptosis after cisplatin treatment189. Some studies also
reported that cisplatin-induced apoptosis involves
CASP3-independent pathways in cisplatin-resistant and
-sensitive human ovarian cancer cell lines190. Another
study showed that at least 50% of cisplatin-induced renal
proximal tubular cell (RPTC) apoptosis is independent
of p53 and CASP 3, 8 and 9 (REF. 191). Moreover, cisplatin
can also upregulate Fas and Fas ligand (FasL) proteins184.















Figure 7 | Cisplatin and cell-death pathways. Cisplatin
induces necrosis and a opto is — two different modes of cell
death. DNA damage arrests the cell cycle, inhibits transcription
and initiates apoptosis. Excessive DNA damage induces hyper-
activation of poly(ADP-ribose)polymerase (PARP). PARP cleaves
NAD+ and transfers ADP-ribose moieties (ADPR) to carboxyl
groups of nuclear roteins. It thereby causes NAD+/ATP
depletion, resulting in necrotic cell death if ATP depletion reaches
lethal-inducing levels. TCR, transcription-coupled repair.
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1.3.1 Recognition	  of	  DNA	  platinum	  adducts	  
	   Many	  proteins	   that	   bind	  DNA	   in	   the	   presence	   of	   platinum-­‐DNA	  adducts	  have	   been	   described	   and,	   in	   general,	   are	   proteins	   that	   bind	   primarily	   to	  structurally	   distorted	   DNA.	   	   They	   typically	   play	   important	   roles	   in	   chromatin	  structure	   modulation,	   transcription,	   DNA	   repair,	   DNA	   recombination,	   or	   DNA	  damage	  recognition	  (Chaney	  et	  al.	  2005;	  Raymond	  et	  al.	  2002).	   	  The	  number	  of	  interacting	  proteins	  is	  large,	  and	  includes	  HMG	  domain	  proteins	  (HMG1,	  HMG2,	  Ixr1,	  tsHMG,	  SRY,	  LEF-­‐1	  and	  hUBF)	  or	  non-­‐HMG	  proteins	  (including	  TBP,	  histone	  H1,	  p53,	  XPE,	  Ku,	  XPA	  and	  RPA)	  (Chaney	  et	  al.	  2005).	  	  	  Platinum-­‐DNA	   adduct-­‐induced	   DNA	   distortion	   is	   central	   to	   protein	  binding	   in	   this	   context	   (Kartalou	   and	   Essigmann	   2001b).	   	   The	   formation	   of	  platinum-­‐DNA	  adducts	  results	  in	  distortion	  of	  the	  DNA	  duplex,	  and	  the	  degree	  of	  distortion	  is	  differs	  slightly	  between	  cisplatin	  and	  oxaliplatin.	   	  DNA	  is	  distorted	  towards	   the	  major	   groove	   by	   the	  most	   prevalent	   1,2	   diadducts,	   resulting	   in	   a	  wide	  and	  shallow	  minor	  groove	  surface	  to	  which	  several	  classes	  of	  proteins	  can	  bind,	   especially	   the	   high	   mobility	   group	   box	   proteins	   (HMG),	   DNA	   repair	  proteins,	   transcription	   factors	   and	   histone	   H1	   (Jamieson	   and	   Lippard	   1999;	  Kartalou	  and	  Essigmann	  2001b;	  Vaisman	  et	  al.	  1999).	  	  The	   functional	   effects	   of	   the	   interaction	   of	   DNA-­‐binding	   proteins	   with	  adduct	   distorted	   DNA	   are	   diverse,	   and	   include	   NER,	   replicative	   bypass,	  utilisation	   of	   transcription	   factors	   and/or	   action	   as	   damage	   sensors	   initiating	  signal	   cascades,	   and	   resulting	   in	   cell	   cycle	  arrest	  and	  apoptosis	   (Vaisman	  et	  al.	  1999).	   	   Although	   many	   similarities	   occur,	   differences	   in	   the	   platinum-­‐DNA	  adducts	   formed	   by	   oxaliplatin	   and	   cisplatin	   result	   in	   a	   different	   spectrum	   of	  protein	  binding,	  notably	   resulting	   in	  differences	   in	   the	   interaction	  of	  platinum-­‐DNA	   adducts	   with	   the	   MMR	   pathway,	   as	   discussed	   in	   later	   section	   1.4.2.2	  (Vaisman	  et	  al.	  1999).	  Especially	   important	   is	   the	   interaction	  of	  platinated-­‐DNA	  with	  HMG	  box	  protein	   1	   (HMGB1)	   which	   has	   been	   shown	   to	   interact	   with	   mismatch	   repair	  (MMR)	  protein	  MutSα	  (Yuan	  et	  al.	  2004)	  and	  with	  p53	  in	  vitro	  and	  enhances	  p53	  DNA	  binding	   activity	   (Wang	   and	   Lippard	   2005)	   providing	   a	   possible	   link	  with	  p53	  mediated	  DNA	  repair	  (Imamura	  et	  al.	  2001).	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HMGB1	  has	  been	  shown	  to	  interact	  with	  the	  nucleosome	  and	  facilitate	  the	  binding	   of	   ATP-­‐utilising	   chromatin	   assembly	   and	   remodelling	   factor	   (ACF)	   to	  nucleosomal	  DNA,	  accelerating	  chromatin	  structural	  changes	  and	  demonstrated	  to	   bind	   irreversibly	   to	   chromatin	   in	   apoptotic	   cells	   putatively	   representing	  acetylation	   changes	   and	   HMGB1	   may	   also	   act	   as	   a	   cytokine	   to	   signal	   tissue	  damage	  (Wang	  and	  Lippard	  2005).	  Some	  of	   the	  binding	  proteins,	  especially	  HMG-­‐domain	   family,	  bind	  more	  tightly	   to	   cisplatin	   adducts	   compared	   to	   oxaliplatin	   adducts.	   	   This	   ability	   to	  discriminate	   between	   adducts	   has	   been	   shown	   with	   HMG1,	   TBP,	   and	   hUBF,	  although	   has	   not	   been	   looked	   at	   in	   several	   other	   damage	   recognition	   proteins	  (Chaney	  et	  al.	  2005).	   	  The	  biological	  consequences	  are	  unclear,	  although	  HMG1	  inhibits	   translesion	   synthesis	   (TLS)	   past	   cisplatin	   adducts	   in	   vitro	   more	   than	  oxaliplatin	  adducts	  (Vaisman	  et	  al.	  1999).	  	  
1.3.2 Transduction	  of	  DNA	  damage	  signals	  
	   In	   addition	   to	   the	   interaction	   of	   HMGB1	   proteins	   with	   the	   pathways	  discussed	   above,	   another	   important	   interaction	   with	   DNA	   distorted	   by	   the	  presence	  of	  platinum-­‐DNA	  adducts	   is	  by	  c-­‐ABL,	  a	  member	  of	   the	  SRC	   family	  of	  non-­‐receptor	   tyrosine	  kinases.	   	  This	  occurs	   through	   the	   interaction	  c-­‐ABL	  with	  adduct	  distorted	  DNA	  via	  a	  HMG-­‐like	  domain,	  and	  results	  in	  initiation	  of	  several	  DNA	  damage	  signalling	  cascades,	   including	  activation	  of	  p53.	   	  Activation	  of	  p53	  results	  in	  the	  subsequent	  initiation	  of	  the	  cell	  cycle	  arrest	  response	  or	  leads	  to	  a	  pro-­‐apoptotic	   response,	   depending	   on	   the	   level	   of	   DNA	   damage	   detected	   and	  underlying	   levels	   of	   cellular	   stress	   (Wang	   and	   Lippard	   2005).	   	   Several	   NER	  proteins,	  including	  XPC,	  TFIIH	  and	  RPA	  (see	  section	  1.4	  for	  details)	  interact	  with	  activated	   p53,	   enhancing	   the	   DNA	   repair	   response	   to	   platinum-­‐DNA	   adducts	  (Wang	  and	  Lippard	  2005).	  Activated	   c-­‐ABL	   additionally	   activates	   other	   protein	   kinase	   cascades,	  including	   the	   p38-­‐MAPK	   pathway,	   activated	   via	   the	   activation	   of	   mitogen	  activated	  protein	  kinase	  kinases	  MKK3	  and	  MKK6,	  resulting	   in	  changes	  to	  gene	  expression	   and	   chromatin	   state.	   	   Extracellular	   signal	   regulated	   kinase	   (ERK)	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activation	   follows	  phosphorylation	   of	  MEK1	   and	  MEK2,	   also	  mitogen	   activated	  protein	   kinases.	   	   The	   c-­‐Jun	   N	   terminal	   kinase	   (JNK)	   signalling	   cascade	   is	   also	  activated,	   and	  has	  been	  proposed	  as	  a	   further	  mechanism	  of	  platinum	   induced	  cell	  death	  (Pandey	  et	  al.	  1996)	  	  
1.3.3 Cell	  cycle	  arrest	  	  Following	  DNA	  damage	  response	  activation,	  phosphorylation	  of	  ATM	  and	  ATR	   result	   in	   activation	   of	   CHK1	   and	   CHK2	   through	   phosphorylation,	  subsequently	   phosphorylating	   CDC25C,	   leading	   to	   CDC2	   phosphorylation	   and	  ultimately	   to	   cell	   cycle	   arrest	   in	   G2	   (Wang	   and	   Lippard	   2005).	   	   As	   mitosis	  involving	  unrepaired	  DNA	  can	  pass	  DNA	  damage	  and	  mutation	  to	  daughter	  cells,	  or	  result	  in	  catastrophic	  mitosis	  through	  replication	  fork	  collapse,	  G2	  arrest	  is	  a	  crucial	   component	   of	   the	   cellular	   response	   to	   cisplatin	   (Siddik	  2003;	   Sorenson	  and	  Eastman	  1988).	  	  	  
	  
1.3.4 Inhibition	  of	  mRNA	  synthesis	  	   Following	   platinum-­‐DNA	   damage	   cell	   cycle	   arrest	   and	   DNA	   replication	  inhibition	  occurs,	  preventing	  mitosis	  whilst	   significant	  DNA	  damage	   is	  present.	  	  During	  cell	  cycle	  arrest,	  transcription	  is	  on-­‐going.	  	  Inhibition	  of	  transcription	  by	  platinum-­‐DNA	  adducts	  is	  an	  additional	  cellular	  stress	  that	  can	  have	  a	  bearing	  on	  whether	  the	  cell	  survives,	  or	  undergoes	  cell	  death	  through	  apoptosis	  or	  necrosis	  (Wang	   and	   Lippard	   2005),	   although	   the	   magnitude	   of	   this	   contribution	   is	  debated	  (Roos	  and	  Kaina	  2013).	  	  	  Three	  main	  mechanisms	  of	  DNA-­‐damage	  induced	  transcription	  inhibition	  that	   have	   been	   proposed	   (Todd	   and	   Lippard	   2009).	   	   Firstly,	   binding	   of	  transcription	  factors	  occurs.	  	  Platinum-­‐DNA	  adducts	  can	  serve	  as	  binding	  sites	  of	  transcription	  factors,	  especially	  those	  which	  have	  a	  strong	  affinity	  for	  platinum,	  preventing	   binding	   of	   transcription	   factors	   at	   promoter	   sites.	   	   Secondly,	  inhibition	  of	  RNA	  polymerases	  occurs.	  	  This	  has	  been	  demonstrated	  for	  cisplatin	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and	   probably	   occurs	   with	   oxaliplatin,	   and	   occurs	   because	   distorted	   bases	   of	  platinum-­‐DNA	  adducts	  are	  unable	  to	  enter	  the	  binding	  site	  of	  Pol	  II.	  	  Additionally,	  nucleosome-­‐DNA	  adducts	  have	  the	  potential	  to	  block	  access	  by	  RNA	  polymerase	  to	  the	  DNA	  template	  (Todd	  and	  Lippard	  2009).	  
	  
1.3.5 Cell	  death:	  via	  apoptosis	  and	  necrosis	  	  	   Exposure	  to	  cisplatin	  results	  in	  cell	  death	  through	  necrosis	  and	  apoptosis.	  	  The	  pathway	  activated	  is	  partly	  concentration	  dependent	  (Gonzalez	  et	  al.	  2001).	  	  Higher	  concentrations	  of	  cisplatin	  results	  in	  necrosis	  in	  mouse	  renal	  cell	  models	  at	  800uM,	  where	  as	  concentrations	  of	  10uM	  over	  several	  days	  result	  in	  apoptosis	  (Lieberthal	  et	  al.	  1996).	  	  One	  proposed	  mechanism	  for	  concentration	  dependent	  necrosis	   is	   through	   the	  hyper-­‐activation	  of	  PARP	  at	  higher	  does	  with	  excessive	  DNA	  damage,	  resulting	  in	  NAD+/ATP	  depletion	  and	  ultimately	  in	  necrosis	  (Wang	  and	  Lippard	  2005).	  	  	  The	   most	   common	   cell	   death	   response	   to	   cytotoxic	   agents	   is	   through	  apoptosis,	  resulting	  from	  activation	  of	  the	  apoptosis-­‐caspase-­‐cascade.	   	  Cisplatin	  treated	   cells	   have	   been	   shown	   to	   increase	   cytochrome	   C	   in	   the	   cytoplasm,	   an	  indicator	   of	   activation	   of	   the	   extrinsic	   apoptotic	   cascade	   (Kojima	   et	   al.	   1998).	  	  The	   importance	   of	   apoptotic	   pathways	   to	   platinum	   agents	   is	   demonstrated	   by	  the	   inability	   of	   caspase	   3	   deficient	   MCF7	   breast	   cancer	   cell	   lines	   to	   undergo	  apoptosis	   in	   response	   to	   platinum	   treatment,	   which	   can	   be	   revered	   by	   stable	  transfection	  of	  CAP3	  cDNA	  into	  MCF-­‐7	  cells	  (Blanc	  et	  al.	  2000).	  	  Cisplatin	  can	  also	  up	  regulate	  Fas	  and	  Fas	  Ligand	  (FasL)	  proteins	  (Fulda	  et	  al.	  1998).	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 Platinum-­‐DNA	  adduct	  repair	  	  1.4
	   As	  outlined	  above,	   the	  continuing	  presence	  of	  unrepaired	  platinum-­‐DNA	  adducts	   triggers	   cell	   death	   through	   activation	   of	   the	   DNA	   damage	   response,	  leading	  to	  apoptosis	  or	  necrosis,	  especially	   if	  DNA	  replication	  and	  transcription	  is	   inhibited	  and	  if	  high	   levels	  of	  cellular	  stress	  persist.	   	  During	  cell	  cycle	  arrest,	  DNA	   repair	   is	   initiated.	   	   The	   repair	   of	   platinum-­‐DNA	   damage	   has	   a	   significant	  impact	  on	  whether	  a	  cell	  enters	  apoptosis	  or	  survives	  (Wang	  and	  Lippard	  2005),	  with	  corresponding	  pre-­‐clinical	  and	  clinical	  correlations	  (see	  section	  1.4.1.6).	  Studies	  in	  yeast	  and	  mammalian	  cell	  lines	  have	  shown	  that	  platinum-­‐DNA	  adducts	   are	   processed	   by	   a	   combination	   of	   nucleotide	   excision	   repair	   (NER),	  recombination	  repair	  (RR)	  and	  trans-­‐lesion	  synthesis	  (TLS).	  	  The	  primary	  repair	  mechanism,	   responsible	   for	   repair	   of	   the	   predominant	   1,2	   intrastrand	  conformation	  of	  platinum-­‐DNA	  adducts,	  is	  the	  NER	  pathway.	  	  The	  combination	  of	  the	   NER,	   RR	   and	   TLS	   pathways	   is	   involved	   in	   the	   repair	   of	   interstrand	   DNA	  damage	  (Chaney	  et	  al.	  2005).	  	  	  	  
	  
1.4.1 Nucleotide	  excision	  repair	  (NER)	  
	   The	   nucleotide	   excision	   repair	   (NER)	   pathway	   removes	   many	   different	  DNA	   lesions	   and	   specifically	   the	   predominant	   1,2	   and	   1,3	   intrastrand	   adducts	  formed	  by	  the	  interaction	  of	  platinum	  with	  DNA.	  	  For	  a	  recent	  review	  of	  NER	  see	  (Marteijn	  et	  al.	  2014).	  	  NER	   is	   highly	   conserved,	   comprising	   in	   eukaryotes	   a	   pathway	   of	  approximately	   30	   interacting	   proteins,	   and	   is	   a	  multi-­‐step	   process	   that	   can	   be	  conceptualised	  in	  five	  distinct	  sub-­‐processes:	  DNA	  damage	  detection,	  open	  DNA	  complex	   formation	   (separation	  of	   the	  double	   strand	  DNA	  via	  unwinding	  of	   the	  DNA	  helix),	  incision	  of	  the	  single	  stranded	  DNA	  5’	  and	  3’	  of	  the	  lesion,	  extrusion	  of	  the	  damage,	  and	  finally	  strand	  re-­‐synthesis	  and	  ligation	  (figure	  1.12)	  (Marteijn	  et	  al.	  2014).	  	  Two	   sub-­‐pathways	   of	   NER	   operate	   with	   distinct	   mechanisms	   of	   DNA	  damage	   detection;	   global	   genome	   repair	   (GG-­‐NER)	   and	   transcription-­‐coupled	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repair	   (TC-­‐NER).	   	  These	  pathways	  differ	   in	   the	   initial	  DNA	  damage	  recognition	  phase,	   allowing	  NER	   to	   respond	   to	   a	  wide	   spectrum	  of	   damaging	   lesions.	   	   GG-­‐NER	   removes	   lesions	   from	   all	   non-­‐transcribed	   DNA	   and	   the	   non-­‐transcribed	  stands	  of	  active	  genes,	  resulting	  in	  a	  genome	  wide	  DNA	  repair	  capability,	  whilst	  TC-­‐NER	  occurs	   in	  actively	   transcribed	  genes,	   regions	  at	  which	  unresolved	  DNA	  damage	   is	   particularly	   problematic	   for	   the	   cell	   (Hanawalt	   and	   Spivak	   2008;	  Tornaletti	  and	  Hanawalt	  1999).	  
	  
1.4.1.1 Stage	  I	  -­‐	  DNA	  damage	  recognition	  	  
	   DNA	   lesions	   block	   the	   action	   of	   DNA	   and	   RNA	   polymerases,	   interfering	  with	   the	  critical	   cellular	   functions	  of	   replication	  and	   transcription.	  Appropriate	  recognition	  of	  these	  lesions	  is	  the	  first	  step	  to	  successful	  NER.	  	  Importantly,	  the	  initial	  damage	  recognition	  step	  in	  NER	  is	  the	  stage	  at	  which	  GG-­‐NER	  and	  TC-­‐NER	  differ,	  with	  different	  protein	  complexes	  involved	  in	  both	  sub-­‐pathways.	  	  
1.4.1.1.1 Stage	  I	  –	  Global	  genome	  NER	  damage	  recognition	  	   Global	  genome	  NER	  proteins	  continuously	  examine	  the	  genome	  for	  helical	  distortion	  resulting	  from	  DNA	  damage.	  	  Damage	  recognition	  occurs	  through	  the	  interaction	  of	  damaged	  and	  distorted	  DNA	  with	  a	  complex	  of	  XPC,	  RAD23B	  and	  centrin	  2	  (CETN2)	  proteins,	  with	  the	  assistance	  of	  the	  UV-­‐DDB	  protein	  complex	  in	   specific	   circumstances	   (Friedberg	   2005;	   Marteijn	   et	   al.	   2014).	   The	   three-­‐subunit	   complex	   of	   XPC,	   RAD23B	   and	   CETN2	   recognises	   DNA	   structural	  distortion	   (Araki	   et	   al.	   2001),	   with	   XPC	   binding	   to	   small	   single	   stranded	   DNA	  gaps	  that	  result	  from	  disruptions	  in	  base	  pairing	  (Maillard	  et	  al.	  2007;	  Marteijn	  et	   al.	   2014).	   	   NER	   is	   functional	   in	   the	   presence	   of	   XPC	   alone,	   however	   the	  addition	  of	  RAD23B	  and	  CETN2	  enhances	  the	  reaction,	  with	  the	  56	  amino	  acids	  of	  RAD23B	  being	  particularly	  important	  (Gillet	  and	  Scharer	  2006).	  	  The	  binding	  to	   damaged	   DNA	   of	   the	   XPC-­‐RAD23B-­‐CETN2	   complex	   results	   in	   further	  distortion	   of	   the	   DNA	   helix	   allowing	   the	   recruitment	   and	   participation	   other	  necessary	  repair	  factors	  (Janicijevic	  et	  al.	  2003).	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After	   DNA	   damage	   the	   affinity	   of	   XPC	   for	   DNA	   is	   enhanced	   by	   poly-­‐ubiquitinylation,	   without	   triggering	   an	   increase	   in	   protein	   degradation	  (Sugasawa	  et	  al.	  2005).	  	  	  
	  







































































DNA damage verification. Binding of XPC to lesions 
provides a substrate for the association of the TFIIH 
(transcription initiation factor IIH) complex18–20, which 
is a transcription initiation and repair factor consisting 
of ten protein subunits. Its two DNA helicases, the two 
TFIIH basal transcription factor complex helicase sub-
units XPB and XPD (encoded by ERCC3 and ERCC2, 
respectively), have opposite polarities and extend 
the open DNA configuration around the lesion21,22, 
which probably verifies the presence of a lesion (FIG. 1). 
Whereas the ATPase activity of XPB, rather than its heli-
case activity, is implicated in recruiting TFIIH to DNA 
damage23,24, the 5ʹ–3ʹ unwinding activity of XPD seems 
to be indispensable for NER25. In vitro experiments 
clearly showed that TFIIH itself (assisted by XPA; see 
below), when loaded by XPC onto a bubble DNA sub-
strate, scans the DNA in a 5ʹ–3ʹ direction for helicase-
blocking lesions26, suggesting that the XPD helicase 
is mainly required for damage verification. Structural 
analysis of archaeal XPD orthologues further suggests 
that the Arch and Fe-S cluster domains of XPD form 
an internal channel through which undamaged ssDNA 
can probably pass but damaged DNA cannot27–31. 
When the XPD helicase does not detect any damage, 
the repair reaction may be aborted27–31. Damage veri-
fication also probably involves the XPA protein, which 
detects nucleotides with altered chemical structures in 
ssDNA32. TFIIH was originally identified as an essential 
transcription initiation factor, but it can switch between 
functions in transcription and in NER22,33. The trimeric 
CAK subcomplex (CDK-activating kinase subcomplex) 
of TFIIH is essential for transcription initiation, but it 
is not required for its repair function. Upon binding 
of TFIIH to DNA-bound XPC, the CAK subcomplex 
dissociates34. Conversely, the 8 kD TFIIH basal trans-
cription factor complex TTDA subunit (also known 
as GTF2H5) seems to be important for the role of 
TFIIH in NER, but it is dispensable for its t ranscription 
activity35,36.
Dual incision and gap filling. The highly dynamic multi-
step strategy of lesion detection and verification contains 
several reversible steps before the actual removal of 
lesions by dual (5ʹ and 3ʹ) incision, presumably to pre-
vent the formation of undesirable and irreversible DNA 
modifications37,38. However, the next step is strand inci-
sion, after which a ‘point of no return’ is reached (FIG. 1) 
and the reaction must be efficiently concluded to avoid 
leaving potentially dangerous intermediates. Lesion exci-
sion is catalysed by the structure-specific endo nucleases 
XPF–ERCC1 and XPG (encoded by ERCC5), which 
incise the damaged strand at short distances 5ʹ and 3ʹ 
from the lesion, respectively39 (FIG. 1). The excision leaves 
a single-strand gap of 22–30 nucleotides, which prob-
ably triggers a DNA-damage-signalling reaction (BOX 2). 
Increased damage signalling and genomic instability 
are indeed observed if the dual incision is improp-
erly co ordinated40. Accurate co ordination of incision 
involves the assembly of XPA, XPG and replication pro-
tein A (RPA) at NER lesions that are marked by XPC and 
verified by TFIIH.
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The	  concept	  of	  a	  bipartite	  system	  of	  damage	  recognition	  and	  confirmation	  of	  damage	  has	  been	  developed;	  a	   lesion	  has	   to	  both	  distort	  DNA	  and	   to	  have	  a	  chemical	  modification	  for	  NER	  to	  occur	  (Friedberg	  2005;	  Hess	  et	  al.	  1997).	  	  The	  distortion	  induced	  by	  XPC-­‐RAD23B-­‐CETN2	  allows	  the	  entry	  of	  XPA,	  RPA	  and	  the	  TFIIH	   complex,	   necessary	   for	   the	   subsequent	   phases	   of	   NER.	   	   Entry	   of	   these	  proteins	   allows	   scanning	   in	   an	   5’	   to	   3’	   ATP-­‐dependent	   fashion	   to	   identify	  chemically	   modified	   bases,	   arresting	   translocation	   at	   sites	   of	   damage	   and	  allowing	  NER	  to	  proceed.	  	  If	  chemically	  modified	  bases	  are	  not	  detected	  a	  stable	  open	   complex	   cannot	   form	   and	   NER	   does	   not	   proceed	   (Friedberg	   2005;	  Sugasawa	  et	  al.	  2001).	  	   Damage	   recognition	  by	   the	  XPC-­‐RAD23B-­‐CETN2	  complex	   is	  poor	   in	  UV-­‐radiation	  induced	  damage	  (primarily	  UV	  induced	  cyclobutane-­‐pyrimidine	  dimers	  (CPDs)),	  as	  these	  lesions	  result	  in	  only	  minor	  helical	  distortion.	  	  Instead,	  the	  UV	  DNA	  Damage	  Binding	  Protein	  complex	  (UV-­‐DDB),	  a	  complex	  of	  DDB1	  and	  DDB2,	  binds	   to	  UV	   induced	   lesions,	   increasing	   the	   degree	   of	   helical	   distortion,	   and	   in	  turn	  stimulating	  XPC-­‐RAD23B-­‐CENT2	  binding	   (Chu	  and	  Chang	  1988;	  Wakasugi	  et	   al.	   2002).	   	   This	   mechanism	   increases	   the	   spectrum	   of	   lesions	   that	   can	   be	  identified	  by	  GG-­‐NER.	  	  
	  
1.4.1.1.2 Stage	  I	  –	  Transcription	  coupled	  NER	  -­‐	  damage	  recognition	  
	   DNA	   damage	   in	   actively	   transcribed	   genes	   results	   in	   significant	  impairment	  of	  cellular	  function,	  particularly	  through	  impaired	  transcription;	  no	  RNA	  polymerases	  are	  known	  that	  can	  bypass	  lesions	  that	  distort	  the	  DNA	  helix.	  	  In	   addition,	   although	   the	   crucial	   process	   of	   DNA	   replication	   may	   continue	  through	  the	  function	  of	  alternative	  DNA	  polymerases	  (although	  this	  may	  induce	  mutations	   (Hendriks	   et	   al.	   2010;	   Marietta	   and	   Brooks	   2007))	   or	   through	  homologous	   recombination-­‐dependent	   template	   switching,	   impaired	   DNA	  replication	  activates	  cell	  cycle	  checkpoints,	  can	  result	  in	  the	  generation	  of	  lethal	  double	   strand	   breaks,	   and	   failure	   to	   resolve	   transcription	   arrest	   can	   trigger	  apoptosis	  (Ljungman	  and	  Zhang	  1996).	  	  As	  cells	  are	  particularly	  sensitive	  to	  DNA	  damage	   in	   these	   regions,	   lesions	   in	   actively	   transcribed	   genes	   trigger	   NER	  through	  an	  additional	  pathway	  –	  transcription	  coupled	  NER	  (TC-­‐NER).	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TC-­‐NER	   is	   initiated	   by	   the	   detection	   of	   stalled	   RNA	   polymerase	   II	  (RNAPII).	  	  Several	  lines	  of	  experimental	  evidence	  support	  this	  assertion.	  	  Lesions	  that	  induce	  the	  inhibition	  of	  transcription	  elongation	  by	  RNAPII	  such	  as	  CPDs	  or	  cisplatin	   adducts	   are	   repaired	   by	   TC-­‐NER	   (Laine	   and	   Egly	   2006;	   Sarker	   et	   al.	  2005)	   whilst	   lesions	   that	   do	   not	   inhibit	   RNAPII	   elongation,	   such	   as	   an	   N-­‐2-­‐aminoflourine	   adduct,	   are	   not	   preferentially	   repaired	   within	   the	   transcribed	  strand	  (Donahue	  et	  al.	  1996;	  Tang	  et	  al.	  1989).	  	  The	  inhibition	  of	  RNAPII	  through	  chemical	  means	  or	  via	  temperature	  sensitive	  mutants	  prevents	  the	  preferential	  repair	   of	   lesions	  on	   the	   transcribed	   strand	  of	   a	   gene	   (Christians	   and	  Hanawalt	  1992;	  Sweder	  and	  Hanawalt	  1992).	   	  Additionally,	   the	   incision	  phase	  of	  TC-­‐NER	  can	   be	   reconstituted	   in	   vitro	   at	   a	   lesion	   containing	   arrested	   RNAPII	   with	  recombinant	  NER	  proteins	  excluding	  XPC,	  indicating	  a	  the	  role	  of	  RNAPII	  stalling	  as	   a	   different	   mechanism	   for	   damage	   recognition	   to	   GG-­‐NER	   (Laine	   and	   Egly	  2006;	  Mu	  et	  al.	  1996;	  Rademakers	  et	  al.	  2003;	  Volker	  et	  al.	  2001).	  Defects	   in	   TC-­‐NER	   result	   in	   Cockayne	   syndrome	   (CS);	   a	   condition	  characterised	   by	   UV-­‐sensitivity,	   accelerated	   aging	   and	   neurological	  abnormalities	   (Nouspikel	   2009).	   	   The	   majority	   of	   these	   patients	   have	   been	  shown	  to	  have	  a	  defect	  in	  one	  of	  two	  proteins,	  CSA	  and	  CSB	  (Licht	  et	  al.	  2003).	  	  	  CSA	  is	  a	  component	  of	  a	  ubiquitin	  ligase	  complex,	  along	  with	  the	  proteins	  cullin4A,	  Roc1	  and	  the	  COP9	  signalosome	  (CSN),	  which	  associates	  with	  RNAPII	  in	  a	  UV	  dependent	  fashion	  (Groisman	  et	  al.	  2003).	  	  CSB	  is	  a	  DNA	  dependent	  ATPase	  of	   the	   SNF2	   protein	   family	   (Eisen	   et	   al.	   1995)	   and	   has	   a	   putative	   role	   in	   the	  modification	  of	  the	  interface	  between	  RNAPII	  and	  DNA.	  	  CSB	  has	  been	  identified	  as	   a	   target	   for	   the	   CSA-­‐containing	   ubiquitin-­‐ligase	   complex	   (Groisman	   et	   al.	  2006).	   	   Ubiquitination	   of	   CSB	   leads	   to	   UV	   dependent	   degradation	   by	   the	  proteasome	   at	   late	   repair	   times	   and	   is	   important	   for	   the	   recovery	   of	   RNA	  synthesis	   after	  TC-­‐NER.	   	   The	  ubiquitin-­‐binding	  domain	  of	   CSB	   is	   essential	   also	  for	  damage	  incision	  during	  TC-­‐NER	  (Anindya	  et	  al.	  2010).	  	  The	   presence	   of	   stalled	   RNAPII	   recruits	   CSA	   and	   CSB,	   resulting	   in	   the	  recruitment	   and	   assembly	   of	   several	   proteins	   specific	   to	   TC-­‐NER,	   including	  UVSSA,	   USP7,	   XPAB2	   and	   HMGN1,	   and	   recruitment	   of	   the	   core	   NER	   factors	  (excepting	  GG-­‐NER	  specific	  XPC	  and	  UV-­‐DDB	  GG-­‐NER	  proteins)	  and	  progress	  to	  the	  second	  stage	  of	  NER	  (Marteijn	  et	  al.	  2014;	  Vermeulen	  and	  Fousteri	  2013).	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1.4.1.2 Stage	  II	  -­‐	  Open	  complex	  formation	  	   Following	  the	  recognition	  of	  DNA	  damage	  recognition	  through	  GG-­‐NER	  or	  TC-­‐NER,	   a	   multi-­‐protein	   ‘pre-­‐incision	   complex’	   (the	   PIC)	   is	   recruited	   and	  assembled	  at	  the	  site	  of	  damage,	  resulting	  in	  the	  separation	  of	  double	  stranded	  DNA	   around	   lesion	   (Mu	   et	   al.	   1996;	   Wakasugi	   and	   Sancar	   1998).	   	   The	   PIC	  structure	   allows	  dual	   incision	  5’	   and	  3’	   of	   the	   lesion,	  with	   extrusion	  of	   a	   short	  oligonucleotide	  containing	   the	  damage.	   	  Excepting	  GG-­‐NER	  damage	  recognition	  specific	   XPC-­‐RAD23B	   and	   TC-­‐NER	   specific	   RNAPII,	   CSA	   and	   CSB,	   the	   proteins	  required	   for	  oligonucleotide	  extrusion	   to	  occur	   in	  vitro	   are	   identical,	   indicating	  that	  after	  damage	  recognition	  the	  same	  pathway	  operates	   for	   the	  remainder	  of	  NER	  (Laine	  and	  Egly	  2006;	  Riedl	  et	  al.	  2003).	  	  	  The	   key	   components	   of	   the	   PIC	   are	   the	   human	   basal	   transcription	  initiation	  factor	  IIH	  (TFIIH),	  a	  ten-­‐subunit	  protein	  complex,	  and	  the	  proteins	  XPA	  and	   RPA.	   	   Evidence	   suggests	   that	   TFIIH	   is	   the	   initial	   protein	   complex	   to	   join	  damage	  sites	  after	  detection	  has	  occurred	  (Riedl	  et	  al.	  2003;	  Tapias	  et	  al.	  2004;	  Volker	  et	  al.	  2001).	  	  The	  TFIIH	  complex	  consists	  of	  XPB,	  XPD,	  GTF2H	  (aka	  p62),	  GTF2H4	  (p52),	  GTF2H2	  (p44),	  GTF2h3	  (p34),	  GTF2H5	  (TTDA).	  XPD	  and	  XPB	  are	  the	  key	  functional	  subunits	  of	  TFIIH,	  and	  both	  have	  DNA	  helicase	   activity	   (Friedberg	   2005).	   	   DNA	   unwinding	   is	   catalysed	   by	   these	  helicases,	  each	  with	  opposite	  polarity.	  	  	  The	  result	  of	  TFIIH	  activity,	  and	  XPD	  and	  XPB	   function,	   is	   the	   formation	   of	   an	   open	   DNA	   structure,	   allowing	   the	  recruitment	  of	  XPA,	  RPA	  and	  XPG	  (Tapias	  et	  al.	  2004),	  the	  recruitment	  of	  which	  leads	  to	  stabilisation	  of	  the	  PIC.	   	  XPA	  has	  a	  high	  affinity	  for	  kinked	  DNA,	  rather	  than	  specifically	   for	  damaged	  DNA,	  and	  can	  sense	   the	   loss	  of	  normal	  hydrogen	  bonding	   as	   a	   consequence	   of	   the	   exposure	   of	   hydrophobic	   bases	   that	   are	  normally	   inaccessible	   (Friedberg	  2005)	   and	   the	  DNA	  binding	   affinity	  of	  XPA	   is	  enhanced	   by	   the	   presence	   of	   RPA.	   	   The	   interaction	   of	   XPA,	   RPA	   and	   TFIIH	  ensures	  the	  correct	  siting	  of	  the	  PIC,	  and	  the	  correct	  placement	  on	  the	  damaged	  strand	   of	   the	   subsequently	   recruited	   XPF-­‐ERCC1	   and	   XPG	   endonucleases	   near	  each	  single	  strand-­‐double	  strand	  junction	  (Fagbemi	  et	  al.	  2011;	  Friedberg	  2005).	  RPA	  is	  a	  trimeric	  protein	  with	  a	  role	  in	  repair	  and	  recombination,	  and	  can	  bind	   to	   a	   single	   stranded	   region	  of	  unwound	  DNA	   (de	  Laat	   et	   al.	   1998)	  with	   a	  
	   40	  
distinct	  polarity	  -­‐	  with	  the	  RPA-­‐1	  subunit	  directed	  to	  the	  5’	  end.	  	  RPA	  appears	  to	  bind	  the	  undamaged	  strand	  and	  can	  enhance	  the	  activity	  of	  the	  structure-­‐specific	  endonuclease	   ERCC1-­‐XPF	   on	   the	   opposite	   strand	   (de	   Laat	   et	   al.	   1998).	   	   XPG	  interacts	  with	  TFIIH	   in	  manner	  dependent	  on	  RPA	  and	  XPA	  and	   this	   results	   in	  the	   formation	   of	   the	   pre-­‐incision	   complex	   at	   the	   correct	   site,	   strand	   and	  orientation.	   	   The	   two	   endonucleases	   XPF	   and	   XPG	   can	   then	   perform	   dual	  incisions	  5’	  and	  3’	  of	  the	  lesion	  during	  the	  next	  stage	  of	  NER.	  
	  
1.4.1.3 Stage	  III	  –	  Dual	  incision	  and	  oligonucleotide	  excision	  	   XPF-­‐ERCC1	  forms	  a	  mutually	  supportive	  heterodimeric	  complex;	  if	  one	  of	  the	  two	  proteins	  is	  absent	  the	  other	  is	  unstable	  (Sijbers	  et	  al.	  1996;	  van	  Vuuren	  et	  al.	  1993).	   	  XPF	  is	  a	  nuclease,	  with	  the	  active	  nuclease	  domain	  at	  amino	  acids	  670	  to	  740	  (Friedberg	  2005).	  	  As	  well	  as	  interaction	  with	  ERCC1,	  the	  function	  of	  the	  endonuclease	  also	  requires	  interaction	  with	  XPA	  (Friedberg	  2005).	  	  The	  XPF-­‐ERRCC1	  heterodimer	  incises	  at	  the	  5’	  side	  of	  the	  lesion.	  XPG	  is	  also	  a	  structure	  specific	  endonuclease	  and	  has	  a	  preference	  for	  the	  single	  to	  double	  strand	  junction	  at	  the	  3’	  end	  of	  the	  unwound	  DNA	  bubble	  (Mu	  et	  al.	   1996).	   	   In	   the	   absence	   of	   XPG	   the	  TFIIH	   complex	   is	   unstable	   and	   results	   in	  dissociation,	  indicating	  a	  structural	  role	  in	  addition	  to	  the	  endonuclease	  function	  (Friedberg	  2005).	  	  The	  presence,	  but	  not	  the	  function,	  of	  XPG	  is	  also	  required	  for	  the	   function	   of	   XPF-­‐ERCC1,	   which	   indicates	   it	   may	   have	   role	   in	   the	   correct	  positioning	  of	  the	  opposite	  endonuclease	  (Mu	  et	  al.	  1996;	  Wakasugi	  and	  Sancar	  1998).	  The	  exact	  order	  of	  incisions	  with	  XPF	  and	  XPG	  is	  uncertain	  and	  an	  area	  of	  current	   research,	   although	   evidence	   suggests	   these	   are	   ordered	   and	   not	  independent	  or	  simultaneous	  events,	  allowing	  better	  coordination	  of	  the	  repair	  and	  synthesis	   stages	   (Fagbemi	  et	   al.	  2011)	  and	  preventing	   site	   single	   stranded	  gap	   occurring	   in	   the	   non-­‐damaged	   strand	   which	   could	   potential	   trigger	   the	  activation	  of	  a	  further	  DNA	  damage	  response	  (Marteijn	  et	  al.	  2014).	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1.4.1.4 Stage	  IV	  –	  DNA	  synthesis	  and	  ligation	  After	   oligonucleotide	   extrusion,	   gap	   filling	   occurs	   by	   DNA	   synthesis,	  followed	   by	   ligation	   of	   the	   synthesised	   DNA	   and	   the	   restoration	   of	   chromatin	  structure.	  	  After	  excision	  a	  22	  -­‐	  30	  nucleotide	  gap	  needs	  to	  be	  filled,	  as	  the	  build-­‐up	   of	   single	   stranded	   gaps	   may	   trigger	   a	   DNA	   damage	   signalling	   response	  (Marteijn	  et	  al.	  2014).	   	  The	  5’	  incision	  is	  enough	  to	  initiate	  DNA	  synthesis,	  even	  before	   XPG	   mediated	   3’	   incision	   has	   completed.	   	   The	   DNA	   polymerases	  responsible	  are	  the	  replicate	  DNA	  polymerases	  Polδ	  or	  Polε	  that	  are	  associated	  with	   the	   activity	   of	   the	   protein	   PCNA.	   	   PCNA	   loads	   onto	   the	   3’	   dsDNA-­‐ssDNA	  junction	  and	  works	  to	  facilitate	  gap	  filling	  by	  recruiting	  polδ	  or	  polε	  to	  the	  site.	  	  Polδ	   also	   recruits	   polΚ	   -­‐	   aiding	   efficient	   synthesis.	   Polδ	   and	   polΚ	   are	   typically	  active	  in	  non-­‐replicating	  cells	  and	  Polε	  in	  replicating	  cells	  (Marteijn	  et	  al.	  2014).	  The	   ligase	   responsible	   for	   sealing	   the	   nick	   is	   ligase	   III	   with	   the	   XRCC1	  partner	   in	   non-­‐cycling	   cells,	   or	   both	   DNA	   ligase	   II/XRCC1	   and	   DNA	   ligase	   I	   in	  dividing	  cells	  (Friedberg	  2005;	  Nouspikel	  2009;	  Wang	  and	  Lippard	  2005).	  	  
1.4.1.5 Regulation	  of	  NER	  by	  post-­‐translational	  modification	  and	  
chromatin	  modification	  
	  
	   The	  pathway	  discussed	  above	  describes	  how	  platinum-­‐DNA	  adducts	  are	  removed	   throughout	   the	   genome,	   or	   specifically	   in	   the	   transcribed	   strand	   of	  active	  genes.	  	  The	  complex	  multistage	  process	  requires	  coordination	  and	  occurs	  in	   the	   context	   of	   the	   chromatin	   structure.	   	   There	   are	   several	   regulatory	  modifications	   necessary	   to	   optimise	   access	   to	   damaged	   DNA	   for	   the	   repair	  machinery.	   This	   thesis	   concerns	   the	   removal	   of	   platinum	   adducts,	   rather	   than	  the	   complex	   regulatory	   pathways	   and	   chromatin	   environment,	   and	   for	   this	  reason	   these	   pathways	   will	   not	   be	   discussed	   further.	   	   A	   recent	   review	   by	  Marteijn	  (Marteijn	  et	  al.	  2014)	  includes	  a	  thorough	  review	  of	  this	  topic.	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1.4.1.6 NER	  in	  the	  context	  of	  cisplatin	  and	  oxaliplatin	  response	  and	  toxicity	  
	   There	  are	   several	   lines	  of	  evidence	   to	   support	   the	  assertion	   that	  NER	   is	  the	   principle	   pathway	   for	   the	   repair	   of	   platinum-­‐DNA	   adducts,	   with	  correspondingly	  important	  clinical	  correlations.	  	  	  Evidence	   includes	   the	   observation	   that	   bacterial	   and	   mammalian	   cells	  deficient	   in	   NER	   are	   more	   sensitive	   to	   platinum	   compounds	   (Jamieson	   and	  Lippard	  1999;	  Wozniak	  and	  Blasiak	  2002),	  and	  in	  the	  human	  context,	  XP	  protein	  deficient	  cell	  lines	  are	  5	  to	  10	  times	  more	  sensitive	  to	  platinum	  drugs	  (Furuta	  et	  al.	  2002).	  	  Extracts	  from	  XP	  cell	  lines	  fail	  to	  repair	  cisplatin	  modified	  DNA	  when	  compared	  to	  control	  cell	  extracts	  (Dijt	  et	  al.	  1988;	  Hansson	  et	  al.	  1991).	  	  NER	  is	  the	   primary	   process	   for	   the	   removal	   of	   platinum	   damaged	   DNA,	   specifically	  intrastrand	  1,2	  and	  1,3	  crosslinks,	  and	  cisplatin	  is	  removed	  by	  NER	  in	  vivo	  and	  in	  
vitro	   (Furuta	  et	  al.	  2002;	  Wang	  et	  al.	  2003;	  Wang	  et	  al.	  1993).	   	  XPC	  and	  ERCC1	  mRNA	   is	   over	   expressed	   in	   ovarian	   cancer	   tissues	   resistant	   to	   cisplatin	   and	  carboplatin	   (Dabholkar	  et	   al.	   1994),	   and	  enhanced	   sensitivity	  of	  human	  cancer	  cells	  to	  cisplatin	  has	  been	  demonstrated	  when	  ERCC1	  was	  suppressed	  by	  siRNA	  (Selvakumaran	  et	  al.	  2003).	  Several	  clinical	  studies	  demonstrate	  a	  relationship	  between	  NER	  factors,	  through	   assessment	   of	   mRNA	   or	   protein	   expression,	   and	   the	   response	   to	  platinum	   agents	   in	   various	   cancers.	   	   The	   high	   rate	   of	   response	   of	   testicular	  cancer	   to	   cisplatin	   has	   been	   correlated	   with	   low	   tissue	   levels	   of	   several	   NER	  proteins,	   particularly	   XPA,	   ERCC1	   and	   XPF	   (Koberle	   et	   al.	   1999;	   Welsh	   et	   al.	  2004).	   NER	   factors	   have	   been	   assessed	   especially	  when	   compared	   to	   cisplatin	  sensitivity	   and	   resistance,	   including	   XPC,	   CSB,	   XPA,	   XPB,	   XPD,	   XPF,	   XPG	   and	  ERCC1	   levels,	   and	   many	   clinical	   studies	   are	   underway,	   especially	   to	   assess	  ERCC1	  as	  a	  predictor	  of	  platinum	  response	  in	  lung	  cancer	  (Reviewed	  in	  (Bowden	  2014)).	  This	   discussion	   of	   NER,	   and	   the	   above	   clinical	   and	   preclinical	  observations	  indicate	  the	  importance	  of	  platinum	  DNA-­‐adduct	  formation	  and	  the	  importance	  of	  NER	  repair	   in	   the	  response	  of	  patients	   to	   these	  agents.	   	  To-­‐date,	  however,	   there	   are	   no	   proven	  methods	   to	   stratify	   patients	   for	   platinum	  based	  chemotherapy	   despite	   the	   considerable	   efforts	   and	   interest	   in	   the	   use	   of	   NER	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factors	  as	  predictive	  biomarkers,	  primarily	  because	  of	  the	  contradictory	  results	  from	  measurements	  of	   a	   single	  NER	   factor.	   	   It	   has	  been	  hypothesised	   that	   this	  reflects	   NER	   action	   as	   a	   complex	   system	   of	   several	   interacting	   proteins,	   and	  measurements	  of	  a	  single	  factor	  will	  always	  have	  poor	  sensitivity	  and	  specificity	  with	   many	   potentially	   confounding	   variables	   (Bowden	   2014).	   A	   functional	  measurement	   of	   total	   NER	   capacity	   would	   obviate	   these	   issues,	   and	   this	  approach	  will	  be	  discussed	  in	  the	  final	  section	  of	  this	  introduction.	  	  	  
	  
1.4.2 Platinum-­‐DNA	  adducts	  and	  interaction	  with	  alternative	  DNA	  repair	  
pathways.	  	  For	  completeness	  when	  discussing	  the	  molecular	  mechanism	  and	  effects	  of	  the	  platinum	  agents	  the	  effect	  of	  the	  interstrand	  crosslink	  (ICL)	  and	  ICL	  repair	  on	   platinum	   toxicity	   needs	   to	   be	   addressed,	   as	   does	   the	   effect	   of	   platinum	  adducts	  on	  the	  other	  key	  DNA	  repair	  pathways,	  notably	  mismatch	  repair.	  
	  
1.4.2.1 Platinum-­‐induced	  ICL	  damage	  and	  repair	  	   After	   platinum	   adducts	   initially	   form	   as	   a	  monoadduct,	   the	   free	   second	  arm	   forms	  covalent	  bonds	   to	   the	  N7	  positions	  of	   closely	   situated	  purine	  bases,	  with	   5-­‐10%	   forming	   with	   juxtaposed	   purines	   on	   the	   opposite	   DNA	   strand	  resulting	  in	  cross-­‐links	  between	  DNA	  strands	  (an	  interstrand	  crosslink	  –	  (ICL)),	  preventing	   essential	   cellular	   processes	   of	   transcription	   and	   replication	   by	  preventing	   the	   separation	   of	   complementary	   DNA	   strands	   (Spanswick	   et	   al.	  2012).	  Unlike	   NER,	   with	   its	   specific	   and	   highly	   evolutionary	   conserved	   repair	  process,	   ICL	   repair	   is	   achieved	   by	   the	   interaction	   of	   several	   repair	   pathways,	  hypothesised	  to	  be	  a	  result	  of	  ICLs	  not	  representing	  a	  major	  evolutionary	  threat	  to	   cells	   (Vasquez	   and	   Legerski	   2010).	   	   Two	   main	   sub-­‐pathways	   result	   in	   ICL	  repair;	  the	  process	  is	  either	  recombination	  independent	  (repair	  occurs	  in	  G1/G0	  and	   relies	   primarily	   on	   NER	   and	   translesion-­‐synthesis	   (TLS)),	   or	   is	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recombination	   dependent,	   referred	   to	   as	   a	   ‘S	   phase	   pathway’,	   and	   utilises	   the	  homologous	   recombination	   (HR)	   repair	  machinery	   (Huang	   and	   Li	   2013).	   	   The	  precise	  mechanistic	  detail	   of	   the	   complex	   interplay	  of	  DNA	   repair	  pathways	   to	  repair	  ICLs	  is	  an	  area	  of	  considerable	  research,	  and	  the	  full	  details	  are	  not	  fully	  elucidated.	   	   The	   current	   knowledge	   of	   the	   ICL	   repair	   pathways	   is	   extensively	  reviewed	  by	  Deans	  (Deans	  and	  West	  2011)	  and	  will	  be	  briefly	  discussed	  here.	  The	   recombination-­‐independent	   ICL	   mechanism,	   also	   described	   as	  ‘mutagenic’	   ICL	   repair,	   requires	   XPC	   to	   recognise	   lesions	   followed	   by	   dual	  incision	  through	  the	  action	  of	  XPF-­‐ERCC1	  and	  XPG.	  	  Repair	  synthesis	  past	  the	  gap	  is	   performed	   by	   TLS	   polymerase	  ζ;	   a	   process	   recognised	   to	   result	   in	   potential	  mutation	  via	  this	  pathway	  (Huang	  and	  Li	  2013).	  Recombination-­‐dependent	   ICL	   repair	   occurs	   during	   DNA	   replication.	  	  Repair	   is	   triggered	  when	  a	   replication	   fork	   is	   stalled	  by	   the	   lesion,	   resulting	   in	  initiation	  of	  the	  coordinated	  action	  of	  the	  NER,	  TLS	  and	  HR	  pathways.	  	  The	  NER	  factor	  XPF-­‐ERCC1	  makes	  dual	  incisions	  across	  the	  lesion	  on	  the	  same	  strand	  and	  TLS	  polymerases	  fill	  the	  resulting	  gap.	   	  The	  restored	  duplex	  is	  then	  repaired	  by	  NER.	  	  The	  remaining	  double	  strand	  break	  in	  the	  sister	  chromatid	  is	  repaired	  by	  classical	   homologous	   recombination	   using	   the	   repaired	   chromatid	   as	   the	  template	  (Huang	  and	  Li	  2013).	  	  	  	   The	   majority	   of	   evidence	   points	   to	   the	   intrastrand	   crosslink	   being	   the	  principle	  cytotoxic	  platinum-­‐DNA	  adduct,	  as	  discussed	  above	  (section	  1.4.1.6).	  	  A	  recent	  study	  has	  shown	  a	  correlation	  between	   ICL	  repair	  and	   the	  sensitivity	  of	  cell	   lines	   to	   cisplatin	   (Wynne	   et	   al.	   2007)	   and	   the	   need	   to	   reassess	   the	  contribution	  of	  ICLs	  to	  platinum	  toxicity	  with	  further	  studies	  has	  been	  suggested	  (Enoiu	  et	  al.	  2012).	  	  
1.4.2.2 Mismatch	  repair	  pathway	  (MMR)	  	   Mismatch	   repair	   (MMR)	   corrects	   single	   base	   mismatches	   and	   repairs	  insertion/deletion	   loops	   (IDLs)	   which	   can	   arise	   as	   a	   consequence	   of	   base	  mismatches	  (Sameer	  et	  al.	  2014).	   	  The	  MMR	  apparatus	  is	  highly	  conserved	  and	  operates	   specific	   to	   the	   damaged	   strand	   (Martin	   et	   al.	   2008).	   	   A	   differential	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response	   of	   the	   MMR	   pathway	   to	   platinum-­‐DNA	   adducts	   is	   an	   important	  difference	   between	   the	   cellular	   responses	   to	   cisplatin	   adducts	   compared	   to	  oxaliplatin.	  	  	  	   The	  details	  of	  the	  MMR	  pathway	  were	  initially	  elucidated	  in	  prokaryotes.	  	  	  The	   homologous	   system	   subsequently	   identified	   in	   eukaryotes	   requires	   the	  stepwise	   action	   of	   at	   least	   6	   Mut	   proteins.	   	   After	   detection	   of	   a	   nucleotide	  mismatch	   single	   strand	   incision	   occurs.	   Following	   this,	   recruitment	   of	   MMR	  proteins	   is	   triggered	   leading	   to	   strand	   incision,	   nucleotide	   excision,	   and	   the	  action	  of	  DNA	  polymerases	  to	  repair	  the	  defect	  (Martin	  et	  al.	  2008).	  In	   the	   prokaryotic	   MMR	   pathway	   the	   MutS	   protein	   acts	   as	   a	   sensor	   of	  mismatched	   DNA	   and	   triggers	   the	   MMR	   response.	   	   The	   eukaryotic	   system	   is	  more	   complex	   and	   five	   human	  MutS	   homologues	   (termed	  MSH	  proteins)	   have	  been	   identified.	   	   The	   functional	   unit	   of	   MSH	   proteins	   are	   heterodimeric,	   as	  combinations	   of	   MSH2,	   MSH3	   and	   MSH6.	   	   The	   combination	   of	   MSH	   proteins	  depends	   on	   the	   specific	   mismatch	   to	   be	   repaired.	   	   	   MSH2	   is	   required	   for	   the	  correct	  of	   the	  majority	  of	  mismatches	   in	  nuclear	  DNA,	  whilst	  MSH3	  and	  MSH6	  are	  required	  for	  distinct	  lesions	  (Marsischky	  et	  al.	  1996).	  	  Specifically,	  the	  MSH2-­‐MSH6	   heterodimer,	   MutSα,	   recognises	   base-­‐base	   mismatches	   and	   small	  insertion/deletion	   loops,	   whilst	   larger	   insertion/deletion	   loops	   are	   recognised	  by	  the	  MSH2-­‐MSH3	  heterodimer	  (MutSβ)	  (Jun	  et	  al.	  2006).	  	   Following	   mismatch	   or	   IDL	   recognition,	   human	   homologs	   of	   the	  
Escherichia	  coli	  MutL	  protein	  (named	  MLH)	  are	  recruited	  to	  co-­‐ordinate	  repair,	  again	   through	   formation	   of	   functional	   heterodimers.	   	   Four	  MLH	   proteins	   have	  been	  identified	  in	  humans:	  MLH1,	  MLH3,	  PMS1	  and	  PMS2	  (Jun	  et	  al.	  2006).	  The	  assembly	   of	   the	   mismatch	   recognition	   complex	   with	   other	   MMR	   proteins	  required	   for	   repair	  are	  coordinated	  primarily	  by	   the	  MLH1-­‐PMS2	  heterodimer,	  MutLα.	   	   The	   other	   MLH	   heterodimers	   participate	   in	   a	   subset	   of	   IDL	   repair	  (Sameer	  et	  al.	  2014).	  	  The	  interaction	  between	  MutSα	  and	  MutLα,	  PCNA	  and	  RPA	  leads	   to	   recruitment	   of	   EXO1	   (Li	   2014).	   	   Recruitment	   of	   EXO1	   occurs	   to	   pre-­‐existing	   or	   MutLα	   generated	   nicks	   5’	   to	   the	   mismatch.	   	   EXO1	   excises	   the	  mismatched	  base	  and	  creates	  a	  single	  strand	  gap	   that	   is	   filled	  by	  polymerase	  δ	  using	  the	  parental	  strand	  as	  the	  template.	  	  The	  nick	  is	  ligated	  by	  DNA	  ligase	  I	  (Li	  2014).	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   Activation	  of	   the	  MMR	  pathway	  results	   in	  downstream	  activation	  of	   cell	  cycle	   regulators,	   including	   p53	   and	   c-­‐ABL,	   resulting	   in	   cell	   cycle	   arrest	   and/or	  apoptosis	  (Jun	  et	  al.	  2006).	  	  	  Cisplatin-­‐DNA	  adducts	   can	   trigger	   the	  MMR	  pathway,	   unlike	  oxaliplatin,	  and	  in	  several	  studies	  deficiencies	  in	  the	  MMR	  pathway	  has	  been	  correlated	  with	  resistance	   to	   cisplatin	   (Jung	   and	   Lippard	   2007).	   	   Cisplatin	   activation	   of	  downstream	   signalling	   requires	   functional	   MMR	   pathways,	   specifically	   the	  activity	  of	  the	  proteins	  MSH2	  and	  MLH	  (Nehme	  et	  al.	  1997).	   	  Two	  models	  have	  been	  proposed	  as	  to	  how	  MMR	  activation	  by	  cisplatin-­‐DNA	  adducts	  induces	  cell	  death.	   	  One	  proposed	  mechanism	   is	   futile	  cycling.	   	  MMR	  may	  be	   triggered	  by	  a	  perceived	   mismatch	   between	   the	   cisplatin-­‐guanine	   adduct	   and	   the	   opposing	  cytosine	  base.	   	  MMR	  proteins	  become	  engaged	   in	  cycles	  of	  attempted	  repair	  of	  the	  cytosine,	  without	  resolution	  of	   the	   initiating	   lesion,	  which	  can	   lead	  to	   futile	  cycles	  of	  repair,	  and	  ultimately	  to	  cell	  death	  (Kartalou	  and	  Essigmann	  2001a).	  	  In	  the	   second	   proposed	   mechanism	   non-­‐repairable	   lesions	   result	   in	   continuous	  DNA	  damage	   recognition	   through	   the	  MMR	  pathway	   acting	   as	   a	   sensor	   lesion,	  signalling	  through	  ATM/ATR	  to	  activate	  cell	  cycle	  arrest	  and	  apoptotic	  pathways	  (Bellacosa	  2001).	  A	  deficiency	  in	  MMR	  confers	  resistance	  to	  cisplatin	  but	  not	  to	  oxaliplatin	  (Fink	  et	  al.	  1996).	  	  Defects	  in	  MMR	  diminish	  the	  cisplatin-­‐induced	  expression	  of	  several	   damage	   response	   genes	   including	   c-­‐jun	   and	   c-­‐abl	   (Nehme	   et	   al.	   1997).	  	  The	  same	  defects	  have	  little	  effect	  on	  the	  expression	  of	  the	  same	  genes	  following	  oxaliplatin	   treatment	   (Nehme	   et	   al.	   1999).	   	   The	   DACH	   ligand	   of	   oxaliplatin	  decreases	  the	  affinity	  of	  MMR	  proteins	  for	  oxaliplatin-­‐DNA	  adducts	  (Chaney	  et	  al.	  2005;	  Di	  Francesco	  et	  al.	  2002;	  Raymond	  et	  al.	  2002)	  and	  MMR	  fails	  to	  recognise	  oxaliplatin	  adducts	  and	  trigger	  the	  repair	  pathway.	   	  This	  could	  explain	  some	  of	  the	   different	   therapeutic	   profile	   of	   these	   agents	   (Raymond	   et	   al.	   1998b).	   The	  effectiveness	  of	  oxaliplatin	  in	  cisplatin	  resistant	  cell	  lines	  may	  be	  between	  due	  to	  repair	  or	  damage	  recognition	  established	  in	  the	  context	  of	  mismatch	  repair.	  	  	  Defects	   in	   MMR	   also	   increase	   TLS	   past	   cisplatin	   adducts	   but	   not	  oxaliplatin	   (Vaisman	   et	   al.	   1998),	   and	   cisplatin	   induced	   secondary	   mutations	  occur	  much	  more	  readily	  in	  MMR	  deficient	  cell	  lines	  (Chaney	  et	  al.	  2005).	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1.4.2.3 Trans-­‐lesion	  synthesis	  (TLS)	  	  	   Several	   DNA	   polymerases	   are	   able	   to	   synthesise	   DNA	   on	   the	  complementary	   strand	   to	  platinum-­‐DNA	  adducts,	   a	  process	   termed	   translesion	  synthesis	  (TLS),	  albeit	  with	  reduced	  fidelity	  (Chijiwa	  et	  al.	  2010).	  	  	  As	  discussed	  in	  section	  1.4.2.1	  TLS	  is	  a	  component	  of	  the	  repair	  of	  ICL,	  although	  the	  details	  of	  the	   interactions	   of	   the	   DNA	   repair	   pathway	   required	   for	   the	   repair	   of	   these	  lesions	   has	   not	   yet	   been	   fully	   elucidated	   (Huang	   and	   Li	   2013).	   	   It	   has	   been	  demonstrated	   that	   XP-­‐V	   cell	   lines	   proficient	   in	   NER	   but	   deficient	   in	   TLS	   are	  hypersensitive	  to	  cisplatin,	  indicating	  the	  importance	  of	  this	  DNA	  repair	  process	  in	  the	  repair	  of	  platinum–induced	  ICL	  (Chijiwa	  et	  al.	  2010).	  	  	  
1.4.2.4 The	  Interaction	  of	  DNA	  repair	  pathways	  	   In	  the	  discussion	  above	  the	  DNA	  repair	  pathways	  have	  been	  presented	  as	  independent	  pathways	  with	  separate	  roles	   in	   the	   identification,	  processing	  and	  repair	   of	   specific	   types	   of	   DNA	   damage.	   	   This	   reflects	   the	   development	   of	   the	  field,	   primarily	   through	   the	   use	   of	   experimental	   methods	   and	   techniques	  isolating	  and	  elucidating	  the	  specific	  details	  of	  individual	  pathways,	  initially	  in	  in	  model	   organism	   systems	   and	   using	   ex	   vivo	   models	   (Friedberg	   2005).	   	   Recent	  evidence	   suggests,	   however,	   that	   complex	   interaction	  may	  occur	  between	  DNA	  repair	   pathways,	   particularly	   at	   the	   level	   of	   DNA	   damage	   detection	   and	   in	   the	  initiation	  of	  the	  DNA	  damage	  response	  (for	  an	  example	  see	  (Peng	  et	  al.	  2014)).	  	  	  Whilst	   the	   mechanics	   of	   the	   majority	   of	   DNA	   repair	   pathways	   are	   reasonably	  well	  understood,	  this	  recent	  evidence,	  in	  combination	  with	  emerging	  evidence	  of	  the	  effect	  of	   chromatin	  structure	  on	  DNA	  repair	   (section	  1.4.1.5),	   suggests	   that	  DNA	   repair	   in	   vivo	  will	   ultimately	   turn	   out	   to	   be	   more	   complex	   than	   initially	  envisaged	  (Friedberg	  2005;	  Marteijn	  et	  al.	  2014;	  Peng	  et	  al.	  2014).	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1.4.3 Summary:	  cisplatin-­‐DNA	  adducts	  compared	  to	  oxaliplatin-­‐DNA	  
adducts	  
	  In	  general,	  the	  mechanism	  of	  action	  with	  respect	  to	  the	  profile	  of	  adducts	  formed	   by	   cisplatin	   and	   oxaliplatin	   is	   similar.	   	   At	   equimolar	   doses	   oxaliplatin	  forms	   fewer	   adducts	   than	   cisplatin	   but	   is	   equally	   potent	   (Chaney	   et	   al.	   2005),	  indicating	   that	   oxaliplatin	   requires	   fewer	   inter	   and	   intrastrand	   cross	   links	   to	  achieve	  equivalent	  cytotoxicity	  to	  cisplatin	  (Luo	  et	  al.	  1998;	  Raymond	  et	  al.	  2002;	  Raymond	  et	  al.	  1998b).	  	  	  Studies	   indicate	   that	   once	   adducts	   have	   formed,	   the	   principle	   repair	  process,	  NER,	  does	  not	  discriminate	  between	  cisplatin	  and	  oxaliplatin	  adducts	  in	  
vitro	   (Page	   et	   al.	   1990;	   Reardon	   et	   al.	   1999)	   and	   differences	   in	   nucleotide	  excision	   repair	   activity	   have	   an	   equal	   effect	   on	   cisplatin	   and	   oxaliplatin	  cytotoxicity	  in	  vivo	  (Petersen	  et	  al.	  1996;	  Schmidt	  and	  Chaney	  1993).	  The	   bulky	   DACH	   carrier	   ligand	   of	   oxaliplatin	   results	   in	   differing	  interaction	   with	   damage	   recognition	   proteins,	   conferring	   less	   cross-­‐resistance	  and	   enhanced	   activity	   compared	   to	   cisplatin	   (Raymond	   et	   al.	   2002).	   	   The	  difference	   between	   cisplatin	   and	   oxaliplatin	   may	   be	   result	   of	   differential	  recognition	   damage	   recognition	   proteins	   such	   as	   high-­‐mobility	   group	   box	   1	  (HMGB1),	  TATA	  box	  binding	  protein	  (TBP)	  and	  human	  upstream	  binding	  factor	  (UBF)	   and	   particularly	   of	   recognition	   and	   activation	   of	   the	   mismatch	   repair	  pathway,	  resulting	  in	  activity	  in	  cells	  which	  are	  resistant	  to	  cisplatin	  (Raymond	  et	  al.	  1998a;	  Raymond	  et	  al.	  1998b;	  Wang	  and	  Lippard	  2005).	  	  	  
1.4.4 Oxaliplatin	  Induced	  Peripheral	  Neuropathy	  	   One	   of	   the	   most	   devastating	   and	   long-­‐term	   side	   effects	   from	  chemotherapy	  with	  platinum	  agents,	  and	  of	  oxaliplatin	   in	  particular,	   is	  damage	  to	   peripheral	   nerves	   resulting	   in	   permanent	   numbness	   and	   paresthesia	   in	   the	  distal	   extremities.	   	   For	   a	   detailed	   understanding	   of	   the	   potential	   role	   of	  predictive	  biomarkers	  in	  this	  condition	  it	  is	  important	  to	  understand	  the	  natural	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history	  and	  molecular	  mechanisms	  of	  OIPN,	  as	  will	  be	  outlined	  in	  the	  following	  discussion.	  
	  
1.4.4.1 Chemotherapy	  Induced	  Peripheral	  Nerve	  Damage	  	   Neuronal	  tissue	  in	  the	  peripheral	  nervous	  system	  is	  especially	  vulnerable	  to	  the	  effects	  of	  cytotoxic	  agents;	   it	   is	  not	  protected	  by	  the	  blood-­‐brain	  barrier,	  unlike	  the	  central	  nervous	  system.	  	  Drug-­‐induced	  neurotoxicity	  can	  affect	  either	  the	  nerve	  fibres	  or	  neuronal	  bodies,	  although	  the	  typical	  effect	  is	  at	  the	  cell	  body	  in	  the	  dorsal	  root	  ganglia	  (DRG)	  of	  the	  primary	  sensory	  neurone.	  	  The	  neurotoxic	  effects	   of	  many	   of	   the	   commonly	   used	   chemotherapy	   drugs	   on	   the	   peripheral	  nervous	   system	   are	   a	  major	   clinical	   problem,	   given	   their	  widespread	   use,	   and	  peripheral	  neuropathy	  (PN)	  remains	  one	  of	   the	  main	  dose-­‐limiting	   toxicities	  of	  several	   chemotherapy	   agents	   (for	   a	   review	   see	   (Argyriou	   et	   al.	   2012a)).	   	   Even	  when	  PN	  is	  not	  dose	  limiting,	  the	  severity	  and	  duration	  of	  PN	  may	  significantly	  affect	  the	  quality	  of	  life	  of	  cancer	  patients	  and	  cause	  chronic	  discomfort	  (Kautio	  et	  al.	  2011).	  
1.4.4.2 Natural	  history	  of	  OIPN	  	   Peripheral	   neuropathy	   in	   oxaliplatin	   treated	   patients	   is	   common	   and	  occurs	   in	   two	   distinct	   forms	   –	   an	   acute,	   transient	   PN,	   and	   a	   chronic	   PN.	  	  Henceforth	  the	  chronic	  PN	  will	  be	  referred	  to	  as	  OIPN.	  	  The	  exact	  cause	  of	  each	  is	  not	   fully	  understood,	   although	  distinct	  but	  overlapping	  mechanisms	  have	  been	  proposed	  (Alcindor	  and	  Beauger	  2011).	  Acute	   neuropathy	   typically	   manifests	   as	   transient	   paraesthesia	   and	  dysaethesias	   of	   the	   distal	   extremities	   and	   perioral	   region.	   	   It	   typically	   occurs	  during	  and	  for	  a	  few	  hours	  following	  treatment,	  although	  occasionally	  symptoms	  can	  persist	  for	  one	  or	  two	  days.	  	  Symptoms	  are	  often	  precipitated	  by	  exposure	  to	  cold,	   and	   when	   occur	   are	   associated	   with	   symptoms	   of	   neuromuscular	  hyperactivity	   including	   jaw	   tightness,	   cramps	   and	   muscle	   fasciculations	  (Argyriou	  et	  al.	  2013).	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Chronic	  OIPN	  occurs	  frequently,	  with	  more	  lasting	  significance	  for	  many	  patients.	   	   It	   usually	  manifests	  during	   the	   several-­‐month	   schedule	  of	   treatment,	  and,	   in	   some	   instances,	   can	   continue	   to	  worsen	   for	  many	  months	  after	   the	   full	  course	  of	  chemotherapy	   is	  complete.	   	  Approximately	  50%	  of	  patients	  receiving	  oxaliplatin	   chemotherapy	   develop	   CTC	   grade	   2	   or	  more	   neuropathy,	  with	   CTC	  grade	  3	  (see	  figure	  1.14)	  occurring	  in	  10-­‐20%	  (de	  Gramont	  et	  al.	  2000).	  	  	  
	  
Figure	  1.14:	  NCI	  Common	  Toxicity	  Criteria	  for	  Adverse	  Advents	  Version	  3	  Sensory	  Neuropathy	  Criteria	  (http://ctep.cancer.gov)	  	  
	   The	  earliest	  clinical	  signs	  of	  OIPN	  are	  a	  decreased	  vibratory	  sensitivity	  in	  the	   toes	   and	   subtle	   reduction	   of	   ankle	   reflexes,	   associated	   with	   numbness,	  tingling	   or	   paraesthesia	   in	   the	   fingers	   and	   toes.	   	   Prolonged	   treatment	   may	  worsen	   symptoms	   and	   signs,	   resulting	   in	   the	   loss	   of	   deep	   tendon	   reflexes	   and	  gradual	   proximal	   spread	   of	   vibratory	   sensitivity	   impairment.	   	   Pin	   and	  temperature	  sensation,	  joint	  position	  and	  light	  touch	  perception	  are	  less	  severely	  affected	  (Alejandro	  et	  al.	  2013;	  Argyriou	  et	  al.	  2014).	  Nerve	   conduction	   studies	   in	   the	   acute	   PN	   setting,	   24-­‐48	   hours	   after	  oxaliplatin	   treatment,	   show	   neuro-­‐myotonic	   discharges	   and	   repetitive	  compound	   muscle	   action	   potentials	   that	   fully	   resolve	   within	   3	   weeks	   of	  treatment	   (Lehky	   et	   al.	   2004).	   	   In	   chronic	   OIPN	   nerve	   conduction	   studies	  consistently	   demonstrate	   sensory	   axonal	   damage	   with	   reduced	   sensory	   nerve	  action	   potentials	   (Argyriou	   et	   al.	   2007;	   Krishnan	   et	   al.	   2006).	   	   Motor	   nerve	  conduction	  velocities,	  compound	  muscle	  action	  potentials	  and	  F	  wave	   latencies	  remain	  unchanged,	  highlighting	  the	  specific	  sensory	  nature	  of	  this	  phenomenon	  (Cavaletti	  et	  al.	  2001).	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Neuropathy: cranial  
– Select 
Asymptomatic, detected 
on exam/testing only 
– CN I  Smell 
– CN II  Vision 
– CN III  Pupil, upper eyelid, extra ocular movements 
– CN IV  Downward, inward movement of eye 
– CN V  Motor-jaw muscles; Sensory-facial 
– CN VI  Lateral deviation of eye 
– CN VII Motor-face; Sensory-taste 
– CN VIII Hearing and balance 
– CN IX Motor-pharynx; Sensory-ear, pharynx, tongue 
– CN X Motor-palate; pharynx, larynx 
– CN XI Motor-sternomastoid and trapezius 
– CN XII Motor-tongue 
Symptomatic, not 
interfering with ADL 
Symptomatic, interfering 
with ADL 
Life-threatening; disabling Death 
Neuropathy: 
motor  
Neuropathy-motor Asymptomatic, weakness 
on exam/testing only 
Symptomatic weakness 
interfering with function, 
but not interfering with 
ADL 
Weakness interfering with 
ADL; bracing or 
assistance to walk (e.g., 
cane or walker) indicated 
Life-threatening; disabling 
(e.g., paralysis)  
Death 
REMARK: Cranial nerve motor neuropathy is graded as Neuropathy: cranial – Select. 
ALSO CONSIDER: Laryngeal nerve dysfunction; Phrenic nerve dysfunction.  
Neuropathy: 
sensory 
Neuropathy-sensory Asymptomatic; loss of 
deep tendon reflexes or 
paresthesia (including 
tingling) but not 
interfering with function 
Sensory alteration or 
paresthesia (including 
tingling), interfering with 
function, but not 
interfering with ADL 
Sensory alteration or 
paresthesia interfering 
with ADL  
Disabling  Death 
REMARK: Cranial nerve sensory neuropathy is graded as Neuropathy: cranial – Select. 
Personality/behavioral Personality Change, but not 
adversely affecting 
patient or family 
Change, adversely 
affecting patient or family  
Mental health intervention 
indicated 
Change harmful to others 
or self; hospitalization 
indicated 
Death 
Phrenic nerve dysfunction  Phrenic nerve Asymptomatic weakness 
on exam/testing only 
Symptomatic but not 
interfering with ADL; 












Psychosis — Transient episode Interfering with ADL; 
medication, supervision 
Harmful to others or self; 
life-threatening 
Death 
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Symptomatic but not 
interfering with ADL; 
intervention not indicated 
Significant dysfunction; 
intervention indicated 









Psychosis — Transient episode Interfering with ADL; 
medication, supervision 
Harmful to others or self; 
life-threatening 
Death 
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In	   general,	   there	   is	   no	   clinically	   validated	   tool	   for	   diagnosis	   or	  investigation	   of	   OIPN	   during	   treatment,	   and	   the	   chemotherapy	   schedule	   is	  modified	  according	  to	  self	  reported	  symptoms	  and	  clinician	  preferences,	  rather	  than	   an	   objective	  measure	   of	   neuropathy	   or	   risk	   of	   progression	  with	   on-­‐going	  treatment.	   	   The	   management	   of	   OIPN	   is	   complicated	   by	   the	   fact	   that	   no	  treatment	   is	  available	   that	  has	  been	  shown	  to	  be	  effective	   in	  high	  quality	   large	  clinical	   trials	   (Ali	   2010).	   	   High	   doses	   of	   analgesia	   may	   mask	   some	   of	   the	  symptoms	  of	  pain,	  but	  are	  of	  no	  benefit	  for	  numbness	  and	  have	  considerable	  risk	  of	  adverse	  effects	  (Ali	  2010;	  O'Connor	  2009).	  Recovery	   from	   OIPN	   is	   frequently	   incomplete,	   even	   several	   years	   after	  treatment	   (Mangiameli	   et	   al.	   2002).	   	  The	   condition	   is	   reversible	   to	   a	  degree	   in	  approximately	  80%	  of	  patients,	  and	  it	  fully	  resolves	  in	  about	  40%	  of	  sufferers	  six	  to	  eight	  months	  after	  treatment	  has	  completed	  (Argyriou	  et	  al.	  2008).	  	  However,	  a	   significant	   proportion	   of	   patients	   are	   left	  with	   symptoms	  more	   than	   2	   years	  after	   treatment.	   	   In	   a	   large	   UK	   based	   trial	   of	   oxaliplatin	   and	   5-­‐FU/LV	   44%	   of	  patients	  had	  CTC	  grade	  2	  or	  3	  OIPN	  at	  the	  end	  of	  treatment,	  6%	  after	  1	  year	  and	  4	  %	  after	  18	  months	  (Andre	  et	  al.	  2009)	  and	  in	  a	  large	  US	  trial	  of	  oxaliplatin	  as	  adjuvant	  therapy	  for	  colorectal	  cancer,	  NSABP	  C-­‐07,	  more	  than	  10%	  of	  patients	  still	   had	   persistent	   neurological	   symptoms	   2	   years	   after	   chemotherapy	   was	  complete	  (Land	  et	  al.	  2007).	  Long-­‐term	  symptoms	  tend	  to	  occur	  in	  those	  with	  more	  severe	  symptoms	  at	   the	   time	   of	   chemotherapy.	   	   In	   a	   European	   trial	   of	   oxaliplatin	   treatment	   for	  colorectal	   cancer	   26%	   of	   patients	   with	   CTC	   grade	   3	   OIPN	   still	   had	   persistent	  symptoms	  at	  a	  median	  follow	  up	  of	  28	  months	  (de	  Gramont	  et	  al.	  2000).	  	  These	   studies	   highlight	   that	   for	   patients	  with	   OIPN	   that	   fails	   to	   resolve	  after	   treatment	   it	   can	   remain	   long-­‐term.	   	   In	   a	   cross-­‐sectional	   study	  of	   patients	  treated	  with	  cisplatin	  for	  testicular	  cancer	  between	  22	  and	  33	  years	  previously,	  platinum-­‐induced	  peripheral	  neuropathy	  was	  clinically	  detectable	  in	  up	  to	  20%	  of	   patients,	   and	   10%	   were	   still	   symptomatic	   (Glendenning	   et	   al.	   2010).	   	   In	  agreement,	  in	  another	  study	  of	  cisplatin	  treated	  patients	  after	  a	  mean	  follow-­‐up	  of	   15	   years:	   38%	   and	   28%	   had	   asymptomatic	   and	   symptomatic	   neuropathy	  respectively	   and	   PN	   was	   disabling	   in	   6%	   (Strumberg	   et	   al.	   2002).	   	   Although	  oxaliplatin	   has	   been	   used	   in	   the	   clinic	   over	   a	   much	   shorter	   timescale,	   so	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comparable	   long	   duration	   studies	   of	   trends	   over	   decades	   are	   unavailable	  compared	  to	  cisplatin,	  similar	  rates	  appear	  to	  occur	  over	  the	  period	  oxaliplatin	  has	  been	  clinically	  available.	  	  For	  example,	  studies	  have	  documented	  long	  lasting	  OIPN	   in	   35%	   of	   patients	   exposed	   to	   the	   drug	   5-­‐6	   years	   after	   chemotherapy	  (Brouwers	  et	  al.	  2009).	  	  In	   general,	   patients	   with	   pre-­‐existent	   or	   significant	   risk	   factors	   for	  neuropathy	  are	  excluded	  from	  clinical	  trials	  of	  oxaliplatin	  therapy	  (Adelsberger	  et	   al.	   2000).	   	   However,	   common	   causes	   of	   peripheral	   neuropathy,	   such	   as	  diabetes	  mellitus,	  do	  not	  appear	  to	  be	  associated	  with	  an	  increased	  risk	  of	  OIPN	  (Ramanathan	  et	  al.	  2010),	  nor	  does	  age	  (Goldberg	  et	  al.	  2006).	  	  The	  principle	  risk	  factor	  appears	  to	  be	  the	  cumulative	  dose	  of	  chemotherapy	  drug	  (Glendenning	  et	  al.	  2010).	  	  Chronic	  OIPN	  develops	  with	  increasing	  dose,	  and	  has	  been	  observed	  in	  the	   dose	   range	   510-­‐765	  mg/m2	   in	   up	   to	   10%	   of	   patients,	   but	   typically	   effects	  50%	   in	  patients	   receiving	  >1000mg/m2	   (Argyriou	  et	   al.	   2012b;	  Goekkurt	   et	   al.	  2009a;	  Goekkurt	  et	  al.	  2009b;	  Park	  et	  al.	  2009).	  	  	  It	  is	  the	  idiosyncratic	  response	  to	  oxaliplatin	  at	  moderate	  doses	  that	  may	  be	   most	   amenable	   to	   patient	   stratification	   approaches,	   allowing	   dose	  modifications	   in	   those	   at	   high	   risk	   and	   continuation	   of	   treatment	   in	   those	  unlikely	  to	  develop	  OIPN.	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1.4.4.3 Molecular	  mechanism	  of	  OIPN	  	  	   The	   specific	  molecular	   cause	   of	   OIPN	   appears	   to	   be	   through	   damage	   to	  peripheral	   nerves	   at	   the	   dorsal	   root	   ganglia	   (DRG)	   resulting	   in	  morphological	  and	  functional	  changes	  to	  DRG	  neural	  cells	  (Argyriou	  et	  al.	  2014;	  Cavaletti	  et	  al.	  2011;	  Meijer	  et	  al.	  1999).	   	   	   In	  animal	  and	  in	  in	  vitro	  models,	  DRG	  cell	  apoptosis	  and	  neuronal	  atrophy	  are	  a	  common	  finding	  following	  oxaliplatin	  therapy	  (Ta	  et	  al.	   2006),	   and	   the	   development	   of	   these	   changes	   is	   associated	   with	   impaired	  electrophysiological	   conduction,	   similar	   to	   that	   seen	   in	   patients	   with	   OIPN	  (Jamieson	  et	  al.	  2005;	  Park	  et	  al.	  2009;	  Renn	  et	  al.	  2011).	  There	   is	   a	   strong	   correlation	   between	   platinum-­‐DNA	   adduct	   levels	   in	  DRG,	   induced	  neuronal	   changes	   and	   the	   severity	  of	   symptoms	  of	  OIPN	   in	  both	  animal	  models	  and	  human	  post-­‐mortem	  studies	  (Dzagnidze	  et	  al.	  2007;	  Gregg	  et	  al.	  1992).	   	  Platinum-­‐DNA	  adducts	  also	  appear	  disproportionately	  to	  accumulate	  in	  DRG	  cells	   compared	   to	  other	   tissues,	   indicating	  perhaps	  why	  OIPN	   is	   such	  a	  common	   toxicity	   experienced	   in	   patients	   treated	   with	   platinum	   agents	  	  (McDonald	  et	  al.	  2005).	  	   There	   is	   some	   debate	   about	   the	   exact	   mechanism	   through	   which	  increased	   levels	  of	  DRG	  platinum-­‐DNA	  accumulation	   triggers	  neuronal	   changes	  of	   apoptosis,	   neuronal	   atrophy	   and	   the	   corresponding	   electrophysiological	  phenomena	  that	  give	  rise	  to	  the	  symptoms	  of	  OIPN.	  	  
1.4.4.4 NER	  in	  terminally	  differentiated	  cells	  	   One	   theory,	   of	   particular	   interest	   to	   explain	   OIPN,	   is	   the	   idiosyncratic	  response	   of	   terminally	   differentiated	   cells	   to	   DNA	   damage,	   which	   may	   be	   a	  specific	   reason	   why	   peripheral	   nerves	   are	   particularly	   sensitive	   to	   oxaliplatin	  and	  platinum-­‐DNA	  damage	  (Nouspikel	  2007,	  2011).	  The	  functional	  capacity	  of	  NER	  is	  variable	  in	  different	  tissues,	  and	  aspects	  of	   the	  NER	   pathway,	   particularly	   GG-­‐NER,	   are	   notably	   decreased	   in	   terminally	  differentiated	  cells,	   including	  neurones	  and	  peripheral	  blood	  mononuclear	  cells	  (PBMC)	  (Nouspikel	  2007).	  	  As	  outlined	  in	  chapter	  1	  (section	  1.4),	  the	  persistence	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of	   unrepaired	  platinum-­‐DNA	  adducts	   impairs	   two	  major	  molecular	  processes	   -­‐	  transcription	  and	  DNA	  replication.	   	  TC-­‐NER	  is	  maintained	  in	  post-­‐differentiated	  cells	   as	   these	   continue	   to	   actively	   transcribe	   genes	   necessary	   for	   their	   specific	  cellular	  functions.	  	  Hence	  stalling	  of	  RNA	  polymerase	  II	  by	  DNA	  adducts	  and	  the	  failure	  of	  accurate	  transcription	  remains	  a	  significant	  problem.	  	  The	  fundamental	  importance	  of	  TC-­‐NER	  for	  post-­‐differentiated	  neuronal	  tissue	  is	  demonstrated	  by	  Cockayne	   syndrome,	   a	   failure	   of	   TC-­‐NER,	   associated	   with	   developmental	   and	  neurodegenerative	   symptoms	   but	   without	   an	   increased	   risk	   of	   malignancy	  (Nance	  and	  Berry	  1992).	  	  Neurones,	   as	   an	   example	   of	   a	   post-­‐differentiated	   cell,	   do	  not	   proliferate	  and	   are	   not	   replaced	   if	   lost.	   	   In	   terminally	   differentiated	   cells,	   including	  peripheral	  nerves,	  it	  has	  been	  demonstrated	  that	  NER	  is	  heavily	  down-­‐regulated	  in	   the	   GG-­‐NER	   sub-­‐pathway	   (Nouspikel	   and	   Hanawalt	   2000).	   	   As	   there	   is	   no	  requirement	   to	   repair	   non-­‐transcribed	   regions	   of	   the	   genome	   in	   order	   to	  maintain	  the	  fidelity	  of	  DNA	  during	  replication,	  it	  has	  been	  hypothesised	  that	  the	  lack	   of	   evolutionary	   pressure	   to	   develop	   and	   maintain	   NER	   capacity	   in	   non-­‐transcribed	   regions	   has	   resulted	   in	   the	   attenuation	   of	   the	   GG-­‐NER	   pathway	   in	  comparison	  to	  TC-­‐NER	  (Nouspikel	  and	  Hanawalt	  2002).	  	  	  	  	  Over	   time,	   an	   accumulation	   of	   DNA	   lesions	   in	   non-­‐transcribed	   regions	  occurs	   in	   the	   context	   of	   attenuated	   GG-­‐NER.	   	   This	   phenomenon	   has	   been	  demonstrated	   in	   post-­‐mitotic	   human	   B-­‐lymphocytes,	   which	   have	   also	   been	  shown	   to	   similarly	  down-­‐regulate	  GG-­‐NER.	   	   If	  B-­‐lymphocytes	  are	   subsequently	  forced	  to	  re-­‐enter	   the	  cell	  cycle	  and	  replicate	  high	  rates	  of	  mutation	  occur	  as	  a	  consequence	   of	   accumulated	   DNA	   damage	   in	   previously	   inactive	   genes	   (Hyka-­‐Nouspikel	  et	  al.	  2011).	  An	  obvious	  hypothesis	  to	  explain	  the	  sensitivity	  of	  DRG	  cells	  for	  platinum	  adducts	  emerges	  from	  this	  body	  of	  work.	  	  If	  the	  neuronal	  cell	  is	  forced	  to	  re-­‐enter	  the	  cell	  cycle	  the	  level	  of	  long-­‐term	  accumulated	  damage	  (and	  additional	  burden	  of	  unrepaired	  platinum-­‐DNA	  adducts	  accrued	  during	  months	  of	  chemotherapy)	  may	   be	   catastrophic,	   drug	   implications	   and	   the	   cellular	   resources	   available	   to	  repair	   the	   accumulated	   damage	   would	   be	   limited.	   	   This	   mechanism	   has	   been	  proposed	   to	   be	   a	   cause	   of	   Alzheimer’s	   and	   other	   neurodegenerative	   diseases	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(Nouspikel	   2009),	   and	   could	   play	   a	   role	   in	   the	   exquisite	   sensitivity	   of	   DRG	  neurones	  for	  platinum-­‐DNA	  damage.	  Biopsies	  to	  obtain	  neuronal	  tissue	  for	  research	  and	  clinical	   investigation	  of	   peripheral	   neuropathies	   are	   rarely	   conducted	   and	   have	   a	   significant	  complication	   rate,	   including	   high	   rates	   of	   post-­‐biopsy	   sensory	   loss,	   pain	   and	  paraesthesia	  in	  the	  distribution	  of	  the	  nerve	  from	  which	  material	  is	  taken	  (Hilton	  et	   al.	   2007).	   	   This	   evidence	   suggests	   that	   other	   post-­‐differentiated	   cells	   types	  may	  be	  a	  useful	  surrogate	  tissue	  for	  the	  investigation	  of	  OIPN,	  particularly	  PBMC,	  a	  cell	  type	  that	  is	  easily	  obtained	  by	  venesection.	  	  
1.4.4.5 Summary	  	  	   The	   balance	   of	   evidence,	   and	   the	   widely	   accepted	   paradigm,	   is	   that	  chronic	   OIPN	   is	   a	   result	   of	   an	   idiosyncratic	   response	   to	   dose-­‐dependent	  accumulation	   of	   platinum-­‐DNA	   adducts	   in	   the	   dorsal	   root	   ganglia	   cell	   body.	  	  Adducts	   interfere	  with	  normal	  cellular	   function	  and	  trigger	  apoptosis,	  resulting	  in	   neuronal	   atrophy,	   although	   the	   exact	   mechanism	   by	   which	   apoptosis	   is	  induced	  is	  still	  a	  subject	  of	  considerable	  research	  (Sereno	  et	  al.	  2014;	  Velasco	  et	  al.	  2014).	  	  	  The	   accumulation	   of	   platinum-­‐DNA	   adducts	   also	   is	   a	   function	   of	   DNA	  repair,	   particularly	   NER.	   	   In	   NER	   deficient	  mouse	  models	   the	   accumulation	   of	  platinum-­‐adducts	  at	   the	  DRG	  is	   increased,	  and	  the	  electrophysiological	  changes	  corresponding	   to	   clinical	   outcomes	   in	   humans	   are	   worse	   in	   these	   animals	  (Dzagnidze	  et	  al.	  2007).	  	  Further	  evidence	  for	  this	  relationship	  is	  the	  correlation	  between	  polymorphisms	  in	  DNA	  repair	  genes	  and	  OIPN	  demonstrated	  in	  several	  genetic	   studies	   (Cavaletti	   et	   al.	  2011).	   	  This	  area	   is	  discussed	   in	  more	  detail	   in	  chapter	   6,	   section	   6.1.3.	   	   Additional	   evidence	   supporting	   this	   link	   has	   been	  developed	   in	   a	   study	   by	   Professor	   J.	   Cheadle	   at	   Cardiff	   University,	   identifying	  several	  novel	  single	  nucleotide	  polymorphisms	  (SNPs)	   in	  NER	  genes	  associated	  with	   the	   development	   of	   OIPN	   in	   colorectal	   cancer	   patients	   treated	   with	  oxaliplatin-­‐based	   chemotherapy	   (West	   2013).	   	   These	   candidate	   OIPN	  biomarkers	  will	  be	  the	  focus	  of	  chapter	  6	  of	  this	  thesis,	  in	  which	  evidence	  will	  be	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presented	  to	  demonstrate	  a	  functional	   link	  between	  DNA	  repair	  and	  oxaliplatin	  toxicity,	   confirming	   the	   importance	   of	   DNA	   repair	   as	   a	   critical	   factor	   in	   the	  development	  of	  OIPN.	  The	   hypothesis	   surrounding	   the	   down-­‐regulation	   of	   GG-­‐NER	   and	   the	  accumulation	  of	  DNA	  damage	  is	  interesting,	  and,	  if	  correct,	  may	  be	  an	  area	  where	  our	   DIP-­‐chip	   genome	   scale	   stratification	   technology	   could	   be	   applied.	   	   Our	  technique,	  capable	  of	  detecting	  accumulated	  DNA	  damage	  at	  high	  resolution	  on	  a	  genomic	   scale,	   could	   be	   used	   to	   identify	   patients	   with	   genomic	   DNA	   damage	  profiles	   (particularly	   in	   regions	   of	   attenuated	   GG-­‐NER)	   that	   may	   be	   potential	  biomarkers	  of	  the	  risk	  of	  developing	  OIPN.	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 The	  measurement	  of	  platinum-­‐DNA	  adducts	  and	  adduct	  DNA	  repair	  1.5
capacity	  as	  a	  biomarker	  for	  platinum	  response	  and	  toxicity	  
	   The	   discussion	   of	   NER	   and	   the	   above	   clinical,	   and	   preclinical,	  observations	   highlight	   the	   importance	   of	   platinum	   DNA-­‐adducts	   and	   the	  importance	  of	  NER	  repair	  in	  the	  response	  seen	  in	  patients	  to	  these	  agents.	  	  	  To-­‐date,	   however,	   there	   are	   no	   proven	  methods	   to	   stratify	   patients	   for	  platinum	   based	   chemotherapy	   despite	   the	   considerable	   efforts	   and	   interest	   in	  the	   use	   of	   NER	   factors	   as	   predictive	   biomarkers,	   primarily	   because	   of	   the	  contradictory	   results	   from	  measurements	   of	   a	   single	   NER	   factor.	   	   It	   has	   been	  hypothesised	  that	   this	  reflects	   the	  role	  of	  NER	  as	  a	  complex	  system	  of	  multiple	  interacting	  proteins,	  and	  measurements	  of	  a	  single	  factor	  will	  always	  have	  poor	  sensitivity	   and	   specificity	   with	   many	   confounding	   variables	   (Bowden	   2014).	  Potentially	   a	   functional	  measurement	   of	   adduct	   levels	   rather	   than	   the	   level	   of	  factors	   involved,	   which	   could	   be	   used	   to	   measure	   the	   changes	   in	   adduct	  frequency	  over	  time	  after	  drug	  exposure	  to	  measure	  NER	  capacity,	  could	  obviate	  these	  issues.	  	  This	  possible	  approach	  -­‐	  measuring	  adduct	  levels	  rather	  than	  NER	  factor	  levels	  -­‐	  will	  be	  discussed	  in	  the	  final	  section	  of	  this	  introductory	  chapter.	  	  	  
	  
1.5.1 Methods	  of	  measuring	  platinum-­‐adducts	  and	  DNA	  damage	  
	   Until	  recently,	  the	  determination	  of	  DNA	  damage	  has	  required	  the	  use	  of	  techniques	   that	   could	   be	   considered	   as	   either	   low	   or	   high	   resolution.	   	   The	  techniques	   classed	   as	   low	   resolution	   allow	   total	   genomic	   damage	   to	   be	  measured,	  but	  are	  unable	  to	  be	  used	  to	  determine	  DNA	  damage	  and	  repair	  at	  the	  level	   of	   the	   genome	   or	   over	   small	   ranges	   of	   nucleotides.	   	   High	   resolution	  techniques	  can	  be	  used	  to	  measure	  DNA	  repair	  at	  the	  single	  nucleotide	  or	  short	  oligonucleotide	  levels,	  but	  typically	  can	  only	  be	  used	  over	  a	  very	  small	  range	  of	  the	  genome,	  and	  so	  do	  not	  allow	  genome	  scale	  hypotheses	  or	  conclusions	  to	  be	  generated.	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1.5.2 Low-­‐resolution	  DNA	  damage	  detection	  techniques.	  
	   Initial	   techniques	   to	   determine	   and	   detect	   DNA	   damage	   used	  radioactively	   labelled	   DNA	   to	   assess	   for	   the	   activity	   of	   DNA	   damaging	   agents.	  	  Alkaline	  sucrose	  gradient	   techniques	  were	  used	   to	  separate	   labelled	  strands	  of	  genomic	  DNA	  by	  length	  to	  determine	  the	  presence	  of	  different	  length	  fragments	  after	   damage	   with	   x-­‐radiation	   and	   alkylating	   agents	   (McGrath	   and	   Williams	  1966).	  	  The	  incorporation	  of	  labelled	  thymine	  bases	  into	  damaged	  cells	  can	  also	  be	  used	  as	   a	   gross	  marker	  of	  damage	   (Setlow	  and	  Carrier	  1964).	   	  This	   type	  of	  assay	   was	   first	   used	   to	   demonstrate	   the	   activity	   of	   NER	   in	   mammalian	   cells	  (Rasmussen	   and	   Painter	   1964).	   	   Typically	   only	   cells	   in	   S-­‐phase	   accumulate	  radiolabelled	   nucleotides,	   indicating	   on-­‐going	   DNA	   replication.	   	   After	   DNA	  damage	  with	  UV	   radiation	   short	   patches	  of	   incorporated	   labelled	  bases	   can	  be	  detected	  by	  autoradiography,	  first	  evidence	  of	  new	  sequence	  synthesis	  following	  DNA	  damage	  and	  evidence	  of	  NER.	  	   Several	   gel-­‐based	   assays	   have	   been	   used	   to	   detect	   and	   measure	   DNA	  damage,	  again	  all	  at	  low	  resolution.	  	  Pulsed	  Field	  Gel	  Electrophoresis	  (PFGE)	  can	  be	  used	  to	  detect	  double	  strand	  breaks,	  with	  the	  identification	  of	  chromosomes	  as	  bands	  on	  a	  gel	  (Contopoulou	  et	  al.	  1987)	  and	  a	  modification,	   the	  Fraction	  of	  Activity	  Released	   (FAR	  assay)	   (Rydberg	  et	  al.	  1994)	  has	  been	  used	   to	  measure	  the	   amount	   of	   DNA	   released	   from	   a	   plug	   of	   gel	   containing	   DNA	   samples	   with	  separation	  of	  fragments	  by	  PFGE.	  	   Chemical	  modifications	   to	   separate	   single	   strand	   DNA	   (for	   example	   the	  alkaline	  unwinding	  assay,	  (Elkind	  and	  Chang-­‐Liu	  1972))	  can	  be	  used	  to	  measure	  single	   strand	   breaks	   following	   lesion	   excision	   in	   NER	   (Erixon	   and	   Ahnstrom	  1979).	  	  	  	   One	   commonly	   used	   assay	   operating	   at	   low	   resolution	   to	   detect	   DNA	  damage	  is	  the	  comet	  assay	  (Collins	  2004).	  	  Electrophoresis	  of	  DNA	  products	  from	  a	  single	  cell	  separates	  DNA	  by	  the	  length	  of	  fragment.	   	  Damaged	  DNA	  results	  in	  either	  short	  or	  long	  fragments,	  with	  more	  heavily	  damaged	  DNA	  forming	  a	  smear	  or	   ‘comet’	   tail.	   	  This	  assay	  can	  be	  adapted	  to	  measure	  single	  and	  double	  strand	  breaks,	  crosslinks	  and	  base	  damage,	  and	  has	  been	  adapted	  for	  high	  throughput	  screening	  in	  96	  well	  plates	  (Wood	  et	  al.	  2010).	   	  In	  a	  similar	  type	  of	  assay	  using	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circumferential	  separation	  of	  DNA	  fragments	  is	  the	  HALO	  assay,	  using	  diffusion	  to	  determine	  short	  and	  long	  DNA	  fragments	  (Sestili	  et	  al.	  2006).	  The	  TUNEL	  assay	  (terminal	  deoxynuleotidyl	  transferase	  mediated	  dUTP-­‐biotin	  nick	  end	  labelling)	  uses	  a	  similar	  system	  but	  with	  fluorescence	  rather	  than	  radiolabelling	  to	  determine	  the	  proportion	  of	  DNA	  fragments	  present	  (Gavrieli	  et	  al.	  1992).	  Other	   commonly	   used	   low	   resolution	   techniques	   include	   mass	  spectrometry,	  which	   although	   highly	   sensitive	   is	   expensive	   and	   limited	   by	   the	  amount	  of	  material	  that	  is	  needed	  for	  detection,	  and	  immunological	  methods	  of	  DNA	   damage	   detection	   using	   antibodies	   against	   the	   damage	   of	   interest.	   	   This	  includes	   immuno-­‐slotblot,	   where	   damaged	   DNA	   is	   transferred	   to	   a	  membrane	  and	   probed	   with	   a	   primary	   antibody	   to	   the	   damage	   and	   identified	   with	   an	  appropriate	   secondary	   antibody	   and	   has	   been	   used	   for	   UV	   damage	   detection	  (Perdiz	  et	  al.	  2000).	  	  
	  
1.5.3 High-­‐resolution	  DNA	  damage	  analysis	  techniques	  
	   DNA	   damaging	   agents	   block	   the	   action	   of	   many	   DNA	   polymerases,	  allowing	  modifications	  of	   the	  polymerase	  chain	  reaction	  (PCR)	  to	  be	  utilised	  as	  an	  assay	  to	  detect	  DNA	  damage,	  demonstrated	  initially	  in	  a	  study	  by	  Govan	  III	  in	  1990	  (Govan	  et	  al.	  1990).	  	  Analysis	  of	  the	  relative	  reduction	  in	  PCR	  yield	  between	  undamaged	  and	  damaged	  DNA	  regions	  can	  give	  high-­‐resolution	   information	  on	  relative	  DNA	  damage	  at	  a	  limited	  number	  of	  sites.	  	  	  An	   assay	   utilising	   enzymes	   to	   cut	   DNA	   adjacent	   to	   sites	   of	   damage	   and	  subsequently	  separation	  of	  resulting	  fragments	  by	  electrophoresis	  can	  also	  give	  a	   high-­‐resolution	   view	   of	   damage	   and	   repair.	   	   A	   method	   developed	   in	   our	  laboratory	  by	  Teng	  (Teng	  et	  al.	  1997)	  uses	  a	  T4	  phage	  endonuclease	  to	  cut	  at	  UV	  radiation	  induced	  CPD	  damage	  sites	  and	  specific	  end-­‐damage	  probes	  to	  pick	  out	  areas	   for	   investigation.	   	   Radiolabelling	   of	   the	   longer	   undamaged	   and	   shorter	  damaged	  fragments,	  again	  by	  gel	  electrophoresis,	  allows	  identification	  of	  areas	  of	  damage	   and	   repair	   at	   high	   resolution	   but	   at	   only	   a	   short	   100-­‐200	   nucleotide	  range.	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1.5.4 The	  use	  of	  functional	  measures	  of	  DNA	  damage	  as	  clinical	  tools	  
	  
	   The	  discussion	  above	  highlights	   the	  role	  of	  adduct	   formation	  and	  repair	  via	  NER	  as	  the	  main	  mechanism	  of	  action	  of	   the	  platinum	  agents,	   through	  DNA	  damage	  in	  tumour	  tissue	  to	  give	  response,	  and	  through	  DNA	  damage	  in	  normal	  tissues	   to	   cause	   toxicity.	   	   The	   benefits	   of	   a	   tool	   for	   stratifying	   patients	   for	  treatment	  are	  evident.	  	  However,	  so	  far,	  no	  DNA	  repair	  assay	  has	  been	  developed	  into	  a	  clinically	  useful	  tool,	  despite	  the	  use	  of	  the	  platinum	  agents	  in	  the	  clinic	  for	  over	  40	  years.	  	  	  	   The	   clinical	   application	   of	   DNA	   repair	   and	   NER	   factor	   assays	   will	   be	  discussed	   in	  more	   detail	   in	   chapter	   4,	   and,	   to	   summarise,	   the	   failure	   of	   these	  tools	   is	   due	   to	   a	   lack	   of	   specificity,	   sensitivity	   and	   predicative	   power.	   	   The	  currently	  available	  assays	  measure	  either	  the	  level	  of	  a	  single	  NER	  repair	  factor,	  at	  risk	  of	   low	  specificity	  by	  confounding	   from	  the	  effects	  of	  unmeasured	  repair	  factors,	  or	  use	  a	  low	  resolution	  approach	  to	  measure	  platinum	  DNA	  adducts	  with	  a	  lack	  of	  sophistication	  and	  sensitivity.	  	   	  A	   novel	   DNA	   damage	   and	   repair	   analysis	   technique	   developed	   in	   our	  laboratory	   combines	   the	  measurement	   of	  DNA	  adducts	   through	   comparison	  of	  treated	  and	  untreated	  samples	  by	  DNA-­‐immunoprecipitation	   (DIP)	  of	  platinum	  damaged	  DNA.	   	  When	   combined	  with	  microarray	   analysis	   (chip)	   this	   DIP-­‐chip	  technique	  give	  high-­‐resolution	  measurement	  of	  levels	  and	  patterns	  of	  platinum-­‐DNA	  adducts	  throughout	  the	  genome.	  	  	  	   The	   technique	  will	  be	  described	   in	  detail	   in	   this	   thesis;	   the	  DIP	  assay	   in	  chapter	  3	  and	  the	  chip	  aspect	   in	  chapter	  4.	   	   It	  may	  be	  possible	  to	  translate	  this	  assay	  for	  use	  on	  clinical	  samples	  to	  improve	  on	  the	  sensitivity	  and	  specificity	  of	  currently	   available	   DNA	   analysis	   tools,	   and	   to	   develop	   an	   assay	   capable	   of	  predicting	  response	  and	  toxicity	  from	  platinum	  based	  chemotherapy	  treatment.	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1.5.5 Potential	  applications	  of	  human	  DIP-­‐chip	  platinum-­‐DNA	  adduct	  
patterns	  
	  
	   The	   ability	   to	  measure	   and	  map	   the	   genomic	   location	   of	   platinum-­‐DNA	  adducts	  at	  high-­‐resolution	  with	  the	  DIP-­‐chip	  assay	  offers	  a	  potential	  mechanism	  to	   improve	   the	   sensitivity	   and	   specificity	   of	   currently	   available	   platinum-­‐DNA	  adduct	   based	   methods	   of	   patient	   stratification	   for	   response	   and	   toxicity	   to	  platinum	   chemotherapy.	   	   This	   theme	   will	   be	   discussed	   in	   more	   detail	   in	   the	  introductory	  sections	  of	  chapters	  3	  and	  4.	  	   The	   ability	   to	   map	   the	   genomic	   location	   of	   platinum-­‐DNA	   adducts	   in	  human	   samples	   has	   other	   potential	   research	   applications.	   	   For	   instance,	   the	  rapid	  development	  of	  DNA	  sequencing	  technology	  has	  allowed	  the	  sequencing	  of	  thousands	   of	   paired	   tumour	   and	   normal	   tissue	   samples,	   resulting	   in	   the	  identification	  of	  thousands	  of	  somatic	  mutations	  present	  throughout	  the	  genome	  of	  germline	  DNA	  and	  cancer	  tissues	  (Alexandrov	  et	  al.	  2013a;	  Alexandrov	  et	  al.	  2013b).	   	   Analysis	   of	   patterns	   of	   mutation	   has	   revealed	   the	   presence	   of	  characteristic	   mutational	   signatures,	   associated	   with	   particular	   mutagenic	  processes.	   	  For	  example,	  characteristic	  patterns	  of	  mutation	  associated	  with	  UV	  radiation	   exposure	   can	   be	   determined	   in	   the	   genome	   of	   cells	   from	  melanoma	  samples,	   and	   patterns	   of	   mutation	   following	   treatment	   with	   the	   alkylating	  chemotherapy	  agent	  temozolomide	  in	  melanoma	  patients	  treated	  with	  this	  agent	  can	  also	  be	  identified.	  	  Of	  the	  21	  mutational	  signatures	  identified	  so	  far	  over	  half	  do	  not	  have	  an	  obvious	  underlying	  mutagenic	  cause.	  	  	  	   The	   presence	   of	   mutational	   signatures	   reflects	   previous	   carcinogen	  exposure,	  and	  have	  been	  proposed	  as	  a	  method	  for	  identifying	  patients	  at	  risk	  of	  developing	   malignancies	   associated	   with	   these	   particular	   mutational	   patterns,	  allowing	  closer	  monitoring	  and	  screening	  for	  these	  cancers.	  	  The	  DIP-­‐chip	  assay	  generated	   patterns	   of	   platinum-­‐DNA	   adducts	   could	   potentially	   be	   applied	   in	  several	  ways.	   	  For	  example,	  in	  the	  context	  of	  chemotherapy	  induced	  mutational	  signatures,	   the	   ability	   to	  map	   the	   location	   of	   platinum-­‐DNA	   adducts	   (or	   other	  DNA	   adducts	   depending	   on	   DIP-­‐chip	   assay	   modifications)	   and	   correlate	   these	  patterns	  with	  resulting	  mutational	  signatures	  could	  provide	  further	  evidence	  to	  support	  this	  area	  of	  research.	  	  Additionally,	  as	  a	  research	  tool	  it	  may	  be	  possible	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to	  compare	  DIP-­‐chip	  adduct	  patterns	  with	  mutational	  signatures	  which	  have	  no	  currently	   identified	  mutagenic	   process,	   as	   a	  method	   to	   determine	   the	   cause	   of	  this	  phenomenon.	   	  Finally,	  as	   the	  DIP-­‐chip	  adduct	  pattern	   is	  a	  precursor	   to	   the	  development	  of	  mutated	  DNA	  sequence,	  in	  the	  same	  way	  mutational	  signatures	  offer	   an	   potential	   avenue	   for	   early	   identification	   of	   malignancy	   risk	   the	  precursor,	   DIP-­‐chip	   signatures	   are	   an	   even	   earlier	   identification	   step	   in	   this	  process.	  	  
 Aims	  and	  objectives	  of	  the	  current	  study	  1.6	   This	  thesis	  focuses	  on	  the	  relationship	  between	  oxaliplatin-­‐DNA	  adducts,	  DNA	   repair	   capacity	   and	   the	   response	   and	   toxicity	   to	   oxaliplatin	   based	  chemotherapy	  treatment.	  The	  first	  three	  results	  chapters	  of	  this	  thesis	  will	  describe	  the	  translation	  of	   the	   DIP-­‐chip	   DNA	   damage	   and	   repair	   assay	   into	   a	   clinical	   tool	   capable	   of	  investigating,	   in	  high	  resolution	  and	  at	  genomic	  scale,	   the	  relationship	  between	  oxaliplatin-­‐DNA	   adducts	   and	   clinical	   outcome	   in	   clinical	   samples.	   	   This	   will	  involve	   the	   modification	   and	   validation	   of	   the	   DNA-­‐immunoprecipitation	  technology	  for	  use	  on	  clinical	  samples	  in	  chapter	  3.	  	  Chapter	  4	  will	  focus	  on	  the	  translation	  and	  optimisation	  of	  the	  microarray	  technique	  to	  producing	  accurate	  patterns	  at	   genomic	   resolution	  of	  platinum-­‐DNA	  adducts	   that	   could	  potentially	  be	  used	  to	  stratify	  patients	  for	  treatment.	  The	   development	   and	   translation	   of	   genomic-­‐scale	   technologies	   into	   a	  tool	   for	   patient	   stratification	   is	   a	   significant	   challenge,	   and	   especially	   requires	  detailed	   bioinformatic	   analysis	   to	   allow	   appropriate	   and	   accurate	   data	  interpretation.	   Chapter	   5	   describes	   the	   development	   of	   new	   bioinformatic	  techniques	  for	  interpreting	  DIP-­‐chip	  microarray	  outputs.	  	  These	  techniques	  are	  a	  significant	  advance	  on	  previously	  available	  bioinformatic	  tools	  and,	  when	  used	  in	  this	  chapter,	  shed	  new	  light	  on	  the	  interpretation	  and	  understanding	  of	  platinum	  DNA	   adduct	   patterns	   in	   this	   context,	   and	   are	   essential	   for	   the	   further	  development	  of	  this	  technique	  into	  a	  clinically	  applicable	  tool.	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In	  the	  second	  section	  of	   this	  work,	  presented	   in	  chapter	  6,	  evidence	  will	  be	   described	   linking	   single	   nucleotide	   polymorphisms	   in	   the	   human	  NER	   gene	  
XPF	  with	  the	  development	  of	  oxaliplatin	  induced	  peripheral	  neuropathy	  (OIPN).	  	  This	  phase	  of	  the	  study	  will	  use	  new	  information,	  derived	  from	  DNA	  sequencing	  of	   colorectal	   cancer	   patients,	   and	   develop	   a	   functional	   model	   of	   OIPN	   in	   S.	  
cerevisiae,	   a	   model	   organism	   ideally	   suited	   for	   genetic	   manipulation.	   	   This	  experimental	   system	  will	   allow	   the	   functional	   impact	   of	   NER	   gene	   SNPs	   to	   be	  studied	   in	   simplified	   and	   controlled	   conditions.	   	   The	   results	   described	   in	   this	  phase	  of	   the	  study	  will	  demonstrate	  a	   functional	   link	  between	  newly	   identified	  single	  nucleotide	  polymorphisms	  in	  NER	  genes	  on	  the	  development	  of	  oxaliplatin	  toxicity.	   	   This	   evidence	   is	   important	   functional	   evidence	   to	   support	   the	  statistically	   significant	   findings	   of	   the	   genetic	   study	   that	   discovered	   the	   SNPs	  modelled,	  as	  well	  as	  providing	  support	  to	  the	  underlying	  hypothesis	  of	  this	  thesis	  -­‐	  that	  measuring	  differences	  between	  individuals	  in	  their	  chemotherapy-­‐induced	  platinum-­‐DNA	  adduct	   levels	  and	  NER	  capacity	  are	  an	   important	   route	   towards	  the	  goal	  of	  patient	  stratification	  for	  the	  platinum	  chemotherapy	  agents.	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Chapter	  2 Materials	  and	  Methods	  	   The	  materials	  and	  methods	  used	  to	  conduct	  the	  experiments	  discussed	  in	  this	  thesis	  are	  described	  in	  this	  chapter.	  	  Where	  possible,	  the	  supplying	  company	  and	  catalogue	  number	  of	  items	  sourced	  for	  use	  in	  the	  experiments	  described	  in	  this	   thesis	   is	   indicated	   by	   the	   abbreviation	   CN.	   	   The	  majority	   of	   the	   solutions	  used	  in	  this	  study	  are	  described	  in	  the	  relevant	  text,	  but	  occasionally	  some	  of	  the	  solutions	   are	   named	   but	   the	   details	   of	   the	   contents	   are	   not	   fully	   described.	  	  Further	  information	  about	  these	  solutions	  can	  be	  found	  in	  appendix	  1.	  	  	  	  
 The	  human	  PBMC	  DIP-­‐chip	  assay	  protocol	  2.1 	  The	   protocol	   for	   the	   DIP-­‐chip	   assay	   extensively	   used	   in	   this	   thesis	   is	  described	  below.	  The	   version	  described	  here	   is	   the	   final	   version	  of	   the	  human	  PBCM	  DIP-­‐chip	  assay;	  it	  has	  been	  modified	  following	  the	  experiments	  described	  in	   chapters	   3	   to	   5,	   and	   is	   the	   protocol	   that	   was	   used	   to	   generate	   the	   data	  presented	  in	  these	  chapters.	  
	  
2.1.1 Preparation	  of	  oxaliplatin	  and	  cisplatin	  	   	  Oxaliplatin	   and	   cisplatin	   was	   obtained	   from	   the	   chemotherapeutics	  pharmacy	   at	   Velindre	   Cancer	   Centre,	   Cardiff,	   and	  was	   stored	   at	   4°C	   at	   a	   stock	  concentration	  of	  12.6mM	  for	  oxaliplatin	  and	  3.3mM	  for	  cisplatin.	  	  Commercially	  obtained	  oxaliplatin	  was	  obtained	  from	  Abcam	  (CN:ab141054)	  as	  a	  powder	  and	  stored	  at	  4°C	   for	  up	   to	  6	  months.	   	  The	  powder	  was	  dissolved	   in	  DMSO	   (Sigma	  CN:D2650)	  to	  a	  concentration	  of	  12.6mM	  immediately	  before	  use.	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2.1.2 Blood	  samples,	  PBMC	  isolation	  and	  platinum	  drug	  treatment	  
protocol	  
	   The	  peripheral	  blood	  mononuclear	  cells	  (PBMC)	  used	  in	  the	  experiments	  in	   chapters	   3	   to	   5	   were	   harvested	   from	   whole	   blood	   samples	   using	   density	  gradient	   centrifugation.	   	   Samples	   were	   obtained	   from	   two	   healthy	   volunteers	  (labelled	   throughout	   as	  patient	  A	  or	  B)	  or	  were	  obtained	   from	  donations	   from	  the	  Welsh	  Blood	  Service	   following	  ethical	   approval	   for	   the	  use	  of	   these	   tissues	  for	  research	  purposes	  (application	  number	  WBS	  Ad-­‐hoc	  008-­‐12).	  	  Samples	  from	  the	  Welsh	  Blood	  Service	  consisted	  of	  a	  single	  donor	  unit	  of	  450ml	  whole	  blood,	  following	   the	   removal	   for	   clinical	   purposes	  prior	   to	  delivery	  of	   the	  majority	   of	  erythrocytes,	  plasma	  and	  platelets.	  	  These	  samples	  were	  diluted	  50:50	  with	  PBS	  prior	  to	  use.	  	  All	  samples	  were	  processed	  using	  the	  following	  protocol:	  	  1. Whole	  blood	  samples	  were	  divided	  into	  equal	  aliquots	  of	  a	  maximum	  of	   30ml	   and	   gently	   overlaid	   onto	   15mls	   of	   room	   temperature	  Histopaque-­‐1077	  (Sigma-­‐Aldrich)	  in	  50ml	  sterile	  tubes.	  	  	  2. Samples	   were	   centrifuged	   at	   500g	   for	   20	   minutes	   at	   room	  temperature	  in	  a	  Heraeus	  Megafuge	  1.0	  swinging-­‐head	  centrifuge	  with	  the	  brake	  in	  the	  off	  setting.	  	  	  3. Plasma	   was	   carefully	   removed	   to	   within	   5mls	   of	   the	   buffy	   coat	  interface	   and	   discarded.	   	   The	   buffy	   coat	   layer	  was	   aspirated	   using	   a	  3ml	  Pasteur	  pipette	   (Fisherbrand	  CN:FB55349)	   and	   transferred	   to	   a	  15ml	  sterile	  tube,	  before	  dilution	  to	  15mls	  final	  volume	  in	  warm	  PBS	  (pre-­‐heated	  to	  37°C).	  	  Samples	  were	  centrifuged	  at	  300g	  for	  5	  minutes	  at	   room	   temperature	   and	   resuspended	   in	   15mls	   PBS.	   	   The	   samples	  were	   centrifuged	   for	   a	   second	   time	   with	   the	   same	   parameters	   and	  again	  the	  supernatant	  was	  removed	  and	  discarded.	  	  	  4. To	   remove	   erythrocyte	   contamination	   the	   pellet	   was	   briefly	  resuspended	  in	  5	  ml	  of	  sterile	  H2O	  for	  a	  total	  of	  5	  to	  10	  seconds	  before	  being	  diluted	  to	  15ml	  with	  PBS.	  	  	  5. All	   samples	   were	   centrifuged	   at	   300g	   for	   5	   minutes	   at	   room	  temperature	   before	   the	   supernatant	   was	   removed	   and	   the	   sample	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resuspended	   in	   1	   ml	   of	   RPMI-­‐1640	   supplemented	   with	   1%	   L-­‐Glutamine	  and	  HEPES	  (Life-­‐Technologies	  CN:52400-­‐025),	  10%	  foetal	  calf	   serum	   (Invitrogen	   CN:10106-­‐169)	   and	   1%	   penicillin	   and	  streptomycin	  (Sigma	  CN:P0781),	  pre-­‐warmed	  to	  37°C.	  6. The	  total	  number	  of	  cells	  were	  counted	  using	  a	  KOVA	  Glasstic	  slide	  10	  haemocytometer	   (Fisher	   CN:22-­‐270-­‐141)	   and	   the	   final	   cell	  concentration	  in	  the	  sample	  was	  adjusted	  to	  5*106	  cells	  per	  200µL	  of	  media.	   	   Subsequently,	   200µL	   of	   media	   containing	   5*106	   cells	   were	  added	   4.8ml	   of	   media	   per	   well	   in	   a	   6	   well	   plate	   (Thermo	   Scientific	  CN:130184)	   and	   incubated	   in	   a	   Heraeus	   HERA	   cell	   incubator	   or	   30	  minutes	  at	  37°C	  and	  5%	  CO2.	  7. After	  30	  minutes,	  oxaliplatin	  or	  cisplatin	  was	  added	  to	  a	  final	  desired	  concentration	   and	   cells	   were	   incubated	   in	   a	   Heraeus	   HERA	   cell	  incubator	  for	  24	  hours	  at	  37°C	  and	  5%	  CO2.	  8. Following	  incubation,	  media	  was	  aspirated	  and	  transferred	  to	  a	  15	  ml	  sterile	  tube.	  	  All	  plates	  were	  washed	  twice	  with	  2mls	  of	  warm	  PBS	  and	  the	  surface	  was	  gently	  scraped	  during	  each	  wash	  using	  a	  cell	  scraper	  (BD	  Falcon	  CN:353085).	   	  The	  PBS	   from	  each	  wash	  was	  added	   to	   the	  collected	  media	  and	  plates	  were	  checked	  to	  ensure	  cell	  removal	  using	  a	  Leica	  DMIL	  microscope.	  	  If	  large	  numbers	  of	  cells	  remained	  a	  further	  2ml	  PBS	  wash	  and	  repeat	  scraping	  step	  was	  employed.	  9. All	   samples	   were	   centrifuged	   at	   300g	   for	   5	   minutes	   at	   room	  temperature	  and	  the	  supernatant	  was	  removed	  and	  disposed	  of	  using	  appropriate	   protocols	   for	   the	   disposal	   of	   waste	   contaminated	   with	  cytotoxic	   agents.	   	   The	   cell	   pellet	   was	   resuspended	   in	   200µL	   room	  temperature	   PBS	   before	   re-­‐centrifugation	   at	   300g	   for	   5	   minutes	   at	  room	  temperature.	  	  The	  supernatant	  was	  removed	  and	  appropriately	  disposed	  of.	  	  Cells	  were	  re-­‐suspended	  in	  200µL	  room	  temperature	  PBS	  prior	  immediate	  DNA	  extraction,	  or	  stored	  overnight	  at	  -­‐20°C.	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2.1.3 DNA	  extraction	  
	  	   DNA	  was	  extracted	  using	  the	  Qiagen	  DNeasy	  blood	  and	  tissue	  Kit	  (Qiagen	  CN:69506)	   following	   the	  manufacturers	   protocol	   for	   DNA	   extraction	   from	   cell	  culture	   material	   with	   the	   following	   amendments	   at	   the	   start	   and	   end	   of	   the	  protocol.	  	   1. Prior	   to	   commencing	   DNA	   extraction:	   	   PBMC	   pellets	   are	   split	   into	   two	  equal	  samples	  in	  a	  final	  volume	  of	  200µL	  PBS	  prior	  to	  DNA	  extraction.	  2. At	  the	  end	  of	  the	  protocol:	   	  DNA	  extraction	  columns	  are	  eluted	  a	  second	  time	   in	   a	   volume	   of	   100µL	   buffer	   AE.	   	   Both	   the	   initial	   200µL	   and	   the	  second	  100µL	  elution	  buffer	  volumes	  were	  combined	  prior	  to	  sonication.	  	  
2.1.4 DNA	  Sonication	  	  	   A	  Bioruptor	   Sonicator	   (Diagenode)	  was	   used	   to	   fragment	   the	  DNA	  with	  the	  following	  steps:	  	   1. Samples	  of	  genomic	  DNA	  in	  300µL	  volume	  of	  buffer	  AE	  from	  the	  Qiagen	  DNeasy	  Blood	  and	  Tissue	  Kit	  were	  transferred	  to	  1.5ml	  micro-­‐centrifuge	  tubes.	  	  2. Tubes	  were	  placed	   in	  a	  cooling	  water	  bath	  at	  4°C	  before	  sonication	  was	  conducted	  on	   the	  high	  setting,	  with	  cycles	  of	  30	  seconds	  on/30	  seconds	  off	  for	  a	  total	  of	  30	  cycles.	  	  	  3. After	   15	   cycles	  were	   complete	   the	   samples	  were	   removed,	   kept	   on	   ice,	  and	   centrifuged	   briefly	   to	   ensure	   all	   DNA	  was	   in	   the	  maintained	   in	   the	  lower	   section	   of	   the	   tube.	   	   The	   final	   15	   cycles	  were	   continued	  with	   the	  same	  settings.	  4. Equal	   sonication	  between	  samples	  was	   confirmed	  using	  a	  1.2%	  TAE	  gel	  and	  a	  GeneRule	  100bp	  ladder	  for	  reference,	  with	  a	  desired	  mean	  fragment	  length	  of	  400	  nucleotides.	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2.1.5 DNA	  purification	  
	   Sonicated	   DNA	  was	   purified	  with	   PureLink	   PCR	   Kit	   (Invitrogen	   CN:K3100-­‐01)	   following	   the	  manufacturers	   standard	  protocol.	   	   Elutions	   volumes	   of	   50µL	  from	  the	  paired	  samples	  that	  were	  previously	  split	  into	  two	  volumes	  at	  the	  stage	  of	  DNA	  extraction	  were	  recombined	  following	  elution.	  
	  
2.1.6 DNA	  immunoprecipitation	  
	  
	   Sonicated	   DNA	   was	   used	   as	   the	   starting	   material	   for	   the	  immunoprecipitation	   of	   oxaliplatin-­‐DNA	   adducts	   with	   CP9/19	   anti	   cisplatin-­‐modified	  DNA	  antibody	  (Abcam	  CN:ab103261)	  with	  the	  following	  protocol:	  	   1. A	  well-­‐mixed	  aliquot	  of	  40µL	  per	  experimental	  condition	  of	  sheep	  anti-­‐rat	  Dynabeads	  (Invitrogen	  CN:11035)	  was	  washed	  three	  times	  in	  500µL	  of	  cold	  (4°C)	   PBS-­‐BSA	   solution	   (0.1%)	   and	   resuspended	   in	   a	   final	   volume	   of	   50µl	  PBS-­‐BSA	  (0.1%)	  per	  sample	  to	  a	  maximum	  volume	  of	  500µL.	  	  To	  this,	  1.5	  µg	  of	  CP9/19	  antibody	  per	  sample	  was	  added	  before	  incubation	  at	  30°C	  for	  30	  minutes	  at	  1300	  rpm	  in	  a	   thermomixer	  (Eppendorf).	   	  Following	   incubation	  the	  Dynabead/antibody	  mix	  was	  washed	   three	   times	   in	   chilled	   (4°C)	   PBS-­‐BSA	  (0.1%)	  and	  resuspended	  in	  50µl	  chilled	  PBS	  per	  sample.	  2. PBS-­‐BSA	  (1%)	  of	  30µl	  and	  6µg	  of	  sonicated	  DNA	  solution	  were	  added	  to	  each	  50µl	  aliquot	  of	  Dynabead/antibody	  mix	  and	  made	  up	  with	  PBS	  to	  a	  final	  volume	  of	  300µl.	  	  	  3. The	  samples	  were	  incubated	  in	  a	  thermomixer	  for	  3	  hours	  at	  21°C	  at	  1300	  rpm.	  	  	  4. Following	   incubation,	   a	   series	   of	   wash	   steps	   were	   conducted	   in	   the	  following	  order,	  with	  all	  reagents	  chilled	  at	  4°C:	  1x	  500µL	  FA/SDS	  buffer,	  3	  washes	  in	  500µL	  FA/SDS+1mM	  NaCl,	  1	  wash	  in	  500µl	  LiCl	  solution,	  1	  wash	  with	  500µL	  1X	  TE.	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5. After	  complete	  aspiration	  and	  removal	  of	  all	   residual	  TE,	  DNA	  was	  eluted	  by	  the	  addition	  of	  125µL	  1X	  pronase	  buffer	  and	  incubation	  at	  65°C	  for	  30	  minutes	  at	  900	  rpm	  in	  a	  thermomixer.	  6. All	  samples	  were	  then	   incubated	  overnight	  at	  65°C	  following	  the	  addition	  of	  6.25µl	  1X	  pronase	  (20mg/ml).	  7. Control	   IN	   samples	   were	   produced	   using	   600ng	   of	   the	   pre-­‐immunoprecipitation	  DNA	  (a	  10th	  of	   the	   IP	  starting	  quantity),	  made	  up	   to	  100µl	  in	  1X	  TE	  and	  then	  by	  the	  addition	  of	  25µl	  5X	  pronase	  buffer.	  	  The	  IN	  samples	   were	   incubated	   alongside	   the	   IP	   sample	   overnight	   at	   65°C	  following	  the	  addition	  of	  6.25µL	  pronase.	  	  	  8. The	  next	  day	  5µl	  RNase	  A	  (10mg/ml)	  was	  added	  to	  all	   IP	  and	  IN	  samples	  and	  incubated	  at	  37°C	  for	  1	  hour.	  	  
2.1.7 Reversal	  of	  platinum-­‐DNA	  adducts	  	   	  To	   remove	   platinum	   adducts	   from	   the	   DNA,	   IP	   and	   IN	   sample	   were	  incubated	   at	   65°C	   for	   2	   hours	   following	   the	   addition	   of	   32.5µL	   of	   1M	   NaCN,	  following	  appropriate	  precautions	  for	  the	  use	  and	  disposal	  of	  sodium	  cyanide.	  	  
2.1.8 Phenol/chloroform	  purification	  and	  ethanol	  precipitation	  
	  
	   Following	   cyanide	   treatment	   samples	   were	   purified	   using	  phenol/chloroform	  and	  precipitated	  under	  the	  following	  conditions:	  	  	  	   1. 1	   mL	   of	   25:24:1	   phenol/chloroform/isoamyl-­‐alcohol	   mix	   was	   added	   to	  each	  sample.	  	  	  2. Samples	   were	   vortexed	   vigorously	   and	   centrifuged	   at	   15,000g	   for	   20	  minutes.	  	  	  3. The	  upper	  aqueous	  phase	  was	  carefully	  removed	  and	  retained.	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4. An	   additional	   phenol:chlorophorm:isoamyl-­‐alcohol	   purification	   and	   a	  subsequent	   chloroform	   only	   purification	   were	   used	   following	   the	   same	  procedure	  (repeat	  steps	  1-­‐3).	  5. Glycogen	   0.5µl	   (20mg/ml),	   18ul	   of	   3M	   NaAC	   and	   180µl	   100%	   ethanol	  chilled	  to	  -­‐20°C	  was	  added	  to	  the	  final	  aqueous	  phase.	  	  6. Samples	  were	   chilled	   at	   -­‐80°C	   for	   45	  minutes	   followed	   by	   -­‐20°C	   for	   45	  minutes.	  7. All	  samples	  were	  centrifuged	  at	  4°C,	  20,000	  rpm	  for	  20	  minutes.	  	  	  8. The	   supernatant	   was	   removed	   and	   discarded	   before	   the	   pellet	   was	  washed	  in	  200µl	  75%	  ethanol	  at	  -­‐20°C	  and	  re-­‐centrifuged	  at	  20,000	  rpm	  10	  minutes	  at	  4°C.	  	  	  9. The	   supernatant	   was	   removed	   and	   the	   pellet	   was	   dried	   for	   5	   minutes	  using	   an	   ISS110	   SpeedVac	   system	   (ThermoSavant)	   and	   resuspended	   in	  13.5µl	  PCR	  grade	  H2O.	  	  
2.1.9 Quantitative	  PCR	  (qPCR)	  
	   The	   DNA	   content	   of	   the	   post-­‐immunoprecipitation	   samples	   was	  quantified	  by	  qPCR.	   	   Samples	  were	  amplified	  using	   the	  CFX-­‐connect	  Real-­‐Time	  PCR	  Detection	  System	  (Bio-­‐Rad)	  equipment	  using	  the	  iTAQ	  universal	  SYBRgreen	  supermix,	   and	   primers	   to	   the	   28S	   genetic	   loci,	   with	   the	   following	   parameters	  used:	  	   1. The	   qPCR	   standards	   used	   were	   ‘master’	   standards,	   pre-­‐diluted	   in	   5	  sequential	  10-­‐fold	  dilutions	   from	  as	  mixed	  sample	  of	  untreated	   IN	  DNA.	  	  Identical	  standards	  are	  used	  as	  a	  quality	  control	  measure,	  to	  quantify	  the	  relative	   amount	   of	   DNA	   per	   experimental	   sample	   (with	   respect	   to	   the	  amount	   in	   the	   standards),	   and	   to	   allow	   accurate	   comparison	   between	  plates.	  	  	  2. 2.5µl	  of	  IP	  sample	  was	  diluted	  with14µl	  H2O	  	  3. IN	  samples	  were	  diluted	  500	  fold.	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4. 5µl	  of	  either	  standards,	  or	  diluted	  IN	  and	  IP	  sample,	  was	  mixed	  with	  5µl	  of	  SYBRgreen/1%	   28S	   primer	   mix	   (10mM	   concentration)	   for	   the	   PCR	  reaction,	   giving	   a	   final	   primer	   concentration	   of	   500nM	   in	   a	   final	   well	  volume	  of	  10µL	  5. All	   qPCR	   experiments	   were	   processed	   in	   96-­‐well	   plates	   (Hard-­‐Shell	   96	  well	   plates,	   Bio-­‐Rad)	   and	   each	   sample	   was	   processed	   in	   triplicate,	  including	   for	   the	   standard	   samples.	   	   After	   sealing	   the	   plates,	   each	   plate	  was	  vortexed	  briefly	  and	  centrifuged	  at	  2000	  rpm	  for	  2	  minutes	  at	  room	  temperature.	  	  
2.1.9.1 qPCR	  programme	  settings	  	  1.	  95°C	  for	  3	  minutes	  2.	  95°C	  for	  10	  seconds	  3.	  60°C	  for	  20	  seconds	  –	  followed	  by	  optical	  image	  4.	  Go	  to	  step	  2	  x	  44	  times	  5.	  95°C	  for	  10	  seconds	  6.	  65°C	  for	  5	  seconds	  7.	  Melt	  curve	  from	  65°C	  	  
2.1.9.2 The	  28S	  primer	  sequence	  
	  	   The	  sequence	  of	  the	  28S	  primers	  used	  in	  this	  study	  were: 
 	   28S:	   Forward:	  	   5′	  -­‐	  CGCAATACGAATGCCCCCG	  	   	   Tm	  61.0	  °C	  	   28S	   Reverse:	  	   5′	  -­‐	  AGCCGCCTGGATACCGC	  	   	   Tm	  60.5	  °C	  
	  
2.1.9.3 Data	  analysis	  and	  calculation	  of	  IP/IN	  ratio	  
	   All	   data	   was	   analysed	   using	   Bio-­‐Rad	   CFX	   Manager	   (Version	   3.1)	   and	  Microsoft	  Excel	  in	  the	  following	  process:	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1. Prior	   to	   analysis,	   the	   threshold	   for	   CT	   calculation	   was	   adjusted	   to	   500	  RFU,	   ensuring	   that	   each	   sample	   crosses	   the	   threshold	   during	   the	  logarithmic	  phase	  of	  fluorescence	  increase.	  2. Standards	   were	   checked	   to	   ensure	   quantification	   was	   consistent	   with	  previous	  experiments	  (depending	  on	  the	  batch	  of	  master	  standards	  used)	  and	  that	  PCR	  efficiency	  was	  between	  80%	  and	  110%	  3. Any	   unknown	   sample	   replicate	   results	   outside	   the	   linear	   range	   of	   the	  standards	   or	   with	   a	   threshold	   cycle	   value	   difference	   greater	   than	   0.5	  cycles	  from	  the	  other	  two	  replicates	  were	  discarded.	  4. The	  DNA	  quantity	  relative	  to	  the	  standards	  was	  calculated,	  and	  exported	  to	  Excel.	  5. The	  mean	  starting	  quantity	  from	  triplicate	  wells	  for	  each	  of	  the	  IP	  and	  IN	  samples	   was	   used	   to	   calculate	   an	   IP/IN	   ratio	   for	   each	   experimental	  condition.	  6. This	  value	  was	  normalised	  to	  the	  IP/IN	  ratio	  from	  an	  untreated	  sample.	  	   	  
 Microarray	  Work	  2.2
	  	   To	   process	   the	   immunoprecipitated	   DNA	   for	   genome	   scale	   microarray	  analysis	  (the	  ‘chip’	  aspect	  of	  the	  assay)	  the	  following	  protocols	  were	  used:	  
	  
2.2.1 DNA	  amplification	  
	   For	  the	  amplification	  of	  IP	  and	  IN	  samples	  prior	  to	  labelling	  and	  hybridisation	  the	  GenomePlex	  WGA2	  kit	  (Sigma	  CN:WGA2-­‐50RXN)	  was	  used	  according	  to	  the	  manufacturers	  standard	  protocol,	  but	  with	  the	  following	  amendments:	  	   1. As	  the	  DNA	  is	  pre-­‐fragmented,	  the	  WGA2	  fragmentation	  step	  is	  omitted	  2. A	  volume	  of	  10µl	  from	  the	  post	  immunoprecipitation	  IP	  sample	  is	  used	  3. A	  volume	  of	  10µL	  of	  a	  1:10	  dilution	  from	  the	  IN	  sample	  is	  used	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4. The	  amplification	   is	  conducted	  according	  to	   the	  manufacturers	  protocol,	  except	  a	  total	  of	  15	  cycles	  of	  PCR	  is	  used.	  5. During	   the	   post-­‐amplification	   purification	   stage,	   DNA	   samples	   were	  eluted	   in	  50µl	  H2O	  and	  concentrated	   to	  a	   final	  volume	  of	  15µL	  using	  an	  ISS110	  SpeedVac	  system	  (ThermoSavant)	  6. The	   DNA	   in	   each	   sample	   was	   quantified	   using	   the	   Nanodrop-­‐1000	  spectrophotometer	  and	  adjusted	   to	  an	  equal	   concentration	   (which	  must	  be	   >50ng/µL	   to	   allow	   adequate	   DNA	   from	   later	   microarray	  hybridisation).	  
	  
2.2.2 Labelling	  	  	   The	   IP	  and	   IN	  samples	  were	  differentially	   fluorescently	   labelled	  with	  Cy5	  and	   Cy3	   fluorophore	   respectively	   using	   the	   BioPrime	  Total	   Genomic	   Labelling	  Module	  (Invitrogen)	  using	  the	  following	  protocol:	  	   1. The	   IP	   and	   IN	   sample	   were,	   pre-­‐adjusted	   to	   identical	   DNA	   amounts	  >50ng/µl	  and	  in	  a	  volume	  of	  10.5µL.	  2.5µL	  of	  5mM	  EDTA	  and	  15µl	  Cy3	  (to	  the	  IN	  sample)	  or	  Cy5	  (to	  the	  IP	  sample)	  was	  added	  and	  mixed	  with	  pipette	  before	  incubation	  at	  95°C	  for	  5	  minutes	  in	  the	  dark.	  	  2. Each	  sample	  was	  chilled	  on	  ice	  for	  a	  5	  minutes,	   following	  which	  2μl	  of	  Exo-­‐Klenow	  fragment	  was	  added.	  	  Samples	  were	  incubated	  for	  2	  hours	  at	  37°C.	  	  3. The	   labelled	  DNA	  samples	  were	  purified	  using	  the	   Invitrogen	  columns	  provided	  with	  the	  BioPrime	  Labelling	  Module	  and	  eluted	  in	  a	  volume	  of	  52µL	  of	  elution	  buffer	  4. The	   efficiency	   of	   labelling	   was	   assessed	   using	   the	   NanoDrop-­‐1000	  Spectrophotometer	  Microarray	  Measurement	  setting.	  5. 50μl	  of	  paired	  IP	  and	  IN	  samples	  were	  combined	  together	  and	  12μl	  of	  NaAc	   (3M)	   and	   5μl	   polyacrylamide	   (2.5μg/ml)	   were	   added	   to	   each	  combined	  sample.	  	  6. The	  DNA	  was	  precipitated	  with	  the	  addition	  of	  290μl	  of	  100%	  ethanol	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and	  cooling	  the	  samples	  at	  -­‐80°C	  for	  10	  minutes	  or	  -­‐20°C	  overnight.	  	  7. Each	  sample	  was	  centrifuged	  at	  13000	  rpm	  for	  20	  minutes	  at	  4°C.	  	  The	  supernatant	   was	   removed	   from	   each	   sample	   and	   the	   DNA	   pellet	   was	  washed	  with	  200µl	  of	  cold	  75%	  ethanol	  and	  centrifuged	  again	  at	  13000	  rpm	  for	  10	  minutes	  at	  4°C.	  	  8. The	   supernatant	   was	   removed	   and	   the	   DNA	   pellet	   was	   dried	   for	   5	  minutes	   using	   the	   SpeedVac	  system	   (Thermo	   Savant).	   	   Dried	   DNA	  pellets	  were	  stored	  at	  -­‐20°C	  overnight.	  	  
2.2.3 Hybridisation	  and	  washing	  	  	   1. Pellets	  were	  resuspended	  in	  39μl	  of	  water.	  	  	  2. The	  following	  reagents	  were	  added	  to	  each	  sample	  in	  the	  following	  order;	  5μl	   of	   human	   Cot-­‐1	  DNA	   (1.0mg/ml)	   (Invitrogen	   CN:15279-­‐011),	   11μl	   of	  Agilent	   10x	   blocking	   agent	   and	   55μl	   of	   Agilent	   2	   x	   hybridisation	   buffer	  (Agilent	  CN:5188-­‐5220).	  	  3. The	  hybridisation	  mix	  was	  incubated	  at	  95°C	  for	  3	  minutes	  then	  at	  37°C	  for	  30	  minutes.	  	  4. 	  The	   total	   volume	   of	   110μl	   of	   each	   sample	   was	   applied	   to	   the	   desired	  microarray	  on	  the	  glass	  slide,	  and	  firmly	  sealed	  with	  the	  appropriate	  cover	  slip	   and	   metal	   gasket	   (Agilent	   CN:G2534-­‐60011),	   before	   transfer	   to	   a	  rotating	   hybridization	   oven	   pre-­‐heated	   to	   65°C.	   	   Microarrays	   were	  incubated	  for	  24	  hours.	  5. Following	   hybridisation,	   slides	   were	   removed	   from	   the	   apparatus	   and	  washed	   for	   5	   minutes	   in	   room	   temperature	   wash	   buffer	   I	   (consisting	   of	  300ml	  of	  20	  x	  SSPE,	  250μl	  of	  20%	  sarcosine	  and	  700ml	  of	  H2O),	  followed	  by	   a	   second	  wash	   for	   a	   further	   5	  minutes	   in	  wash	   buffer	   II	   (3ml	   of	   20	   x	  SSPE,	  997ml	  of	  H2O).	  	  Wash	  buffer	  II	  was	  warmed	  to	  31°C	  before	  use.	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2.2.4 Microarray	  scanning	  and	  data	  processing	  	  	   1. All	  microarrays	   were	   scanned	  with	   an	   Agilent	   G2565BA	  microarray	  scanner	  using	  the	  following	  settings:	  	  




 The	  materials	  and	  methods	  for	  S.	  cerevisiae	  experiments	  described	  in	  2.3
chapter	  6	  
	  
2.3.1 Yeast	  media	  
	  	   	   	  
	   The	  recipes	  for	  growth	  media	  used	  in	  this	  study	  are	  listed	  in	  appendix	  1.	  	  All	  growth	  media	  was	  made	  up	  before	  use	  and	  autoclaved	  on	  a	  liquid	  cycle.	   	  To	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produce	  plates,	  2%	  agar	  was	  added	  prior	  to	  autoclaving,	  and	  25ml	  was	  poured	  into	  sterile	  petri	  dish	  whilst	  in	  liquid	  form	  and	  allowed	  to	  set.	  
	  
2.3.2 Storage	  and	  growth	  conditions	  	   The	  strain,	  genotype	  and	  the	  origin	  of	  the	  yeast	  strains	  used	  in	  this	  thesis	  are	   described	   in	   chapter	   6.	   	   The	   yeast	  manipulations	   discussed	   in	   this	   section	  were	   conducted	   in	   sterile	   conditions	   using	   growth	   media	   and	   equipment	  sterilised	  by	  autoclaving	  before	  use.	  	  For	   the	   long-­‐term	   storage	   of	   yeast	   strains,	   cells	   were	   grown	   to	   the	  exponential	   phase	   and	   suspended	   in	   a	   30%	   glycerol	   solution	   prior	   to	   freezing	  with	  liquid	  nitrogen.	  	  In	  this	  way,	  all	  strains	  were	  kept	  in	  long-­‐term	  storage	  at	  -­‐80°C.	   	   Before	   use,	   frozen	   cultures	   were	   streaked	   onto	   solid	   media	   plates	   and	  incubated	  at	  30°C	  in	  a	  LEEC	  compact	  incubator	  until	  grown	  to	  stationary	  phase,	  typically	  after	  2	  days.	  	  These	  plates	  were	  then	  stored	  at	  4°C	  for	  short-­‐term	  use.	  For	   each	   experiment,	   single	   colonies	   from	   short-­‐term	   plates	   were	  inoculated	  in	  fresh	  liquid	  media	  and	  maintained	  in	  exponential	  phase.	  	  This	  pre-­‐culture	   was	   used	   to	   inoculate	   liquid	   media,	   as	   required,	   with	   the	   necessary	  dilution	   calculated	   to	   achieve	   the	   required	   cell	   density	   for	   the	   experiments	  conducted	   on	   the	   following	   day.	   	   After	   inoculation	   all	   liquid	   cultures	   were	  incubated	  at	  30°C	  in	  an	  Infors	  HT	  multitron	  standard	  incubator	  at	  180	  rpm.	  	  	  Cell	   cultures	   were	   grown	   to	   a	   density	   of	   2*107	   cells/ml	   before	   use,	  calculated	   using	   an	   Improved	   Neubauer	   BS7482	   cell	   counting	   chamber	  (Hawksley).	   	  When	  an	  OD600	  measurement	  of	   cell	  density	  was	  required,	  1ml	  of	  cell	  culture	  was	  used	  for	  assessment	  of	  optical	  density	  at	  600nm	  using	  a	  UV-­‐Vis	  Spectrophotometer	  (Thermo	  Scientific)	  
	  
2.3.3 Gel	  electrophoresis	  
	   Gel	  electrophoresis	  was	  used	  routinely	  during	  this	  study.	   	  Depending	  on	  the	  application,	  different	   agarose	  gel	   concentrations	  were	  prepared.	   	  Typically,	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1.0%	  agarose	   gel	  was	  used,	  whilst	   a	   lower	   concentration	  of	   0.8%	  agarose	  was	  used	   for	   isolation	   of	   DNA	   during	   cloning.	   	   Agarose	   was	   added	   to	   TAE	   buffer	  (40mM	  Tris-­‐Acetate,	  1mM	  ethylenediamine	  tetraacetic	  acid	  (EDTA),	  pH8.0)	  and	  heated	  until	  dissolved.	  	  	  The	  solution	  was	  cooled	  to	  approximately	  50°C	  and,	  for	  every	  100ml	  of	  solution,	  5µl	  of	  10mg/ml	  ethidium	  bromide	  was	  added.	  	  TAE	  gels	  were	  cast	  in	  either	  a	  Horizon	  58	  (Life	  Technologies)	  or	  a	  Mini-­‐Sub	  cell	  GT	  (Bio-­‐Rad).	  	  DNA	  was	  added	  to	  sterile	  water	  up	  to	  a	  final	  volume	  of	  10µl,	  to	  which	  2µl	  of	  6x	  MassRuler	   loading	  dye	  (Fermentas)	  was	  added.	   	  The	  gel	  tanks	  were	  filled	  with	  TAE	  buffer	  and	  samples	  were	  loaded	  into	  each	  well,	  with	  either	  GeneRuler	  1kb	  DNA	   ladder	  or	  FastRuler	   low	   range	  DNA	   ladder	   (Fermentas)	   added	   to	   the	  first	   lane.	  Gels	  were	   run	   at	   10V	  per	   cm	  on	   a	  power-­‐pac	  200	   (BioRad)	   at	   room	  temperature.	   	   After	   electrophoresis,	   the	   gel	   was	   examined	   using	   a	   BioDoc-­‐It	  imaging	  system	  (UVP)	  at	  a	  wavelength	  302nm.	  	  	  If,	   following	   electrophoresis,	   isolation	   and	   purification	   of	   specific	   DNA	  bands	  was	  required	  the	  gel	  was	  visualised	  at	  a	  wavelength	  of	  365nm	  to	  minimise	  UV	  damage	   to	   the	  DNA,	   and	   the	  desired	  band	  was	   excised	   from	   the	   gel	  with	   a	  scalpel.	  	  The	  extracted	  DNA	  was	  purified	  using	  a	  PureLink	  quick	  gel	  extraction	  kit	  (Invitrogen)	  according	  to	  the	  manufacturer’s	  instructions.	  
	  
2.3.4 Polymerase	  chain	  reaction	  (PCR)	  	   All	   PCR	  was	   performed	   in	   a	   total	   reaction	   volume	   of	   50µl,	   using	   either	  GoTaq	  Flexi	  DNA	  Polymerase	  (Promega),	  Phusion	  High	  Fidelity	  DNA	  polymerase	  (NEB)	   or	   Q5	  Hot	   Start	   High	   Fidelity	   DNA	   Polymerase	   (NEB),	   and	   all	   reactions	  were	   run	   on	   a	   PTC-­‐200	   PCR	   machine	   (MJ	   Research)	   using	   the	   conditions	  described	  in	  the	  text	  and	  according	  to	  the	  standard	  protocol	  for	  each	  enzyme,	  as	  documented	  in	  the	  manufacturers	  datasheet.	  The	  annealing	  temperature	  of	  each	  primer	   was	   calculated	   as	   5°C	   lower	   than	   the	   lowest	   primer	   ‘Tm’	   and	   the	  extension	   time	  was	   calculated	   according	   to	   the	   respective	   enzyme	   data	   sheet.	  	  	  All	   PCR	   products	   were	   purified	   using	   the	   PureLink	   PCR	   Purification	   Kit	  (Invitrogen)	  according	  to	  the	  manufacturer’s	  instructions	  and	  eluted	  into	  either	  water	  at	  pH	  8.5	  or	  1X	  TE	  buffer.	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2.3.5 DNA	  sequencing	  	  	   Sequencing	   reactions	  were	  performed	  using	   the	  BigDye	   terminator	  v3.1	  cycle	  sequencing	  kit	  (Applied	  Biosystems)	  using	  the	  manufacturers	  protocol.	  	  	  	  Briefly:	  1. A	   PCR	   reaction	   was	   prepared	   in	   a	   0.5ml	   polypropylene	   tube	   on	   ice	  with	  the	  following	  constituents:	  	  
	  2. A	   PCR	   reaction	   was	   performed	   using	   a	   PTC-­‐200	   PCR	   machine	   (MJ	  Research)	  and	  the	  following	  programme:	  	  1.	  96.0°C	  for	  1:00	  minutes	  	  2.	  96.0°C	  for	  0:10	  minutes	  3.	  50°C	  for	  0:05	  minutes	  4.	  60.0°C	  for	  4:00	  minutes	  5.	  Go	  to	  2,	  25	  times	  6.	  End	  	   3. 5μl	  of	  EDTA	  and	  60μl	  of	  100%	  ethanol	  were	  added	  to	  each	  reaction.	  	  Samples	  were	  centrifuged	  at	  13000	  rpm	  for	  20	  minutes	  in	  a	  Beckman	  Coulter	  Microfuge	  22R	  centrifuge	  at	  4°C.	  	  	  4. After	  aspirating	   the	  supernatant,	   the	  pellet	  was	  washed	  with	  60μl	  of	  70%	   ethanol	   and	   subsequent	   centrifugation	   was	   performed	   for	   5	  minutes	  with	  the	  conditions	  as	  described	  above.	  5. The	  supernatant	  was	  removed	  and	  pellets	  were	  dried	  for	  15	  minutes.	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6. All	   samples	   were	   analysed	   by	   Central	   Biotechnology	   Services	   at	  Cardiff	  University.	  	  	  	  
2.3.6 Cloning	  	   DNA	  manipulation	  was	   performed	   for	   cloning	   purposes	   as	   described	   in	  chapter	  6.	  	  The	  manipulations	  involved	  included	  DNA	  restriction	  digestions	  and	  DNA	   ligation.	   	   All	   enzymes	   and	   buffers	   required	   were	   obtained	   from	   New	  England	  Biolabs	  (NEB).	  	   1. All	  DNA	  used	  was	  purified	  into	  either	  water	  or	  10mM	  Tris-­‐HCl	  pH	  8.0,	  and	  quantified	   using	   a	   Nanodrop	   1000	   spectrophotometer	   (Thermo	  Scientific)	  according	  to	  manufacturer’s	  instructions.	  	  2. All	   restriction	   digestions	  were	   conducted	   in	   a	   volume	   of	   40µl.	   	   DNA	   of	  1500ng	  was	  combined	  with	  water	  to	  a	  volume	  of	  34	  µl	  for	  single	  enzyme	  digests,	  or	  32	  µl	  for	  double	  enzyme	  digests.	  	  4	  µl	  of	  enzyme	  buffer	  and	  1	  µl	  of	  each	  enzyme	  (at	  a	  starting	  concentration	  of	  10,000	  or	  20,000	  units/ml)	  was	  added	  and	  the	  reaction	  was	  incubated	  at	  37°C	  for	  90	  minutes.	   	  DNA	  was	   either	   directly	   purified	   with	   the	   QIAquick	   PCR	   purification	   kit	  (Qiagen)	   to	   30µl	   water	   or	   purified	   following	   gel	   electrophoresis	   as	  described	  in	  section	  2.3.3.	  	  3. For	  DNA	  ligation	  and	  cloning,	  DNA	  samples	  were	  combined	  with	  water	  to	  a	  volume	  of	  18µl,	  consisting	  of	  approximately	  200ng	  of	  DNA.	   	  An	   insert:	  vector	  ratio	  of	  3:1	  was	  used.	  	  2µl	  of	  10x	  T4	  DNA	  ligase	  reaction	  buffer	  and	  1µl	   of	   T4	  DNA	   ligase	   (400,000	   cohesive	   end	   units/ml;	  NEB)	  was	   added	  and	  reactions	  were	  incubated	  at	  4°C	  overnight	  or	  at	  16°C	  for	  2-­‐3	  hours.	  	  	  	  
2.3.7 Site	  directed	  mutagenesis	  	  	   Site	   directed	   mutagenesis	   was	   conducted	   using	   the	   Quick-­‐change	  Lightening	   SDM	   kit	   (Agilent)	   according	   to	   the	   manufacturers	   instructions.	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Primers	  used	  for	  SDM	  were	  as	  described	  in	  the	  relevant	  text.	  	  Briefly,	  10ng	  of	  the	  plasmid	   template	   was	   added	   to	   a	   PCR	   reaction	   mixture	   containing	   2x	  QuikChange	   Buffer,	   1.25	   pmol	   of	   each	   primer,	   10mM	   dNTP,	   6%	   QuikChange	  reagent,	   and	  2.5U	  of	  PfuUltra	  HF	  DNA	  polymerase.	   	   Each	   sample	  was	  made	  up	  with	  H2O	  to	  a	  final	  volume	  of	  50µL.	  	   Samples	   were	   cycled	   under	   the	   following	   conditions	   using	   a	   PTC-­‐200	   PCR	  machine	  (MJ	  Research):	  	   1. 95°C	  for	  1	  minute	  2. 95°C	  for	  50	  seconds	  3. 60°C	  for	  50	  seconds	  4. 68°C	  for	  1	  minute	  per	  template	  Kb	  	  5. Go	  to	  2,	  18	  times	  6. 68°C	  for	  7	  minutes	  7. Cool	  to	  37°C	  8. End	  	   The	   paternal	   plasmid	   strand	   does	   not	   contain	   the	   mutation	   and	   is	   dam	  methylated,	   rendering	   it	   vulnerable	   to	   digestion	   by	   DpnI	   endonuclease	   that	  digests	  methylated	  DNA.	   	  Digestion	  of	   the	  paternal	   strand	  was	  achieved	  by	   the	  addition	  of	  1µL	  DpnI	   to	  the	  post-­‐PCR	  reaction	  mix	  and	  incubation	  at	  37°C	  for	  1	  hour.	  	  	  
2.3.8 E.	  coli	  transformation	  
	   100µl	   of	   Library	   efficient	  DH5α	   chemically	   competent	   cells	   (Invitrogen)	  were	   transformed	   with	   10µl	   of	   plasmid	   according	   to	   the	   manufacturer’s	  protocol.	   	   As	   the	   plasmids	   used	   in	   this	   study	   all	   contained	   ampicillin	   as	   a	  selection	   marker	   transformed	   cells	   were	   plated	   onto	   LB	   plates	   supplemented	  with	   100µg/ml	   ampicillin	   and	  were	   grown	   overnight	   at	   37°C.	   	  E.	   coli	   colonies	  were	  tested	  for	  the	  transformation	  of	   the	  correct	  plasmid	  by	  colony	  PCR,	  using	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the	   technique	   discussed	   in	   section	   2.3.10.	   	   Positive	   colonies	   were	   grown	  overnight	  in	  LB	  media	  supplemented	  with	  100µg/ml	  ampicillin	  at	  37°C	  and	  225	  rpm	  in	  a	  Multitron	  standard	  incubation	  shaker	  (Infors	  AG).	  	  Following	  overnight	  incubation	   5ml	   of	   culture	   was	   purified	   to	   50µl	   of	   EB	   buffer	   with	   the	   Plasmid	  miniprep	  kit	  (Qiagen).	  	  When	  plasmid	  preparations	  were	  analysed	  by	  restriction	  digestion,	  half	  of	  the	  reaction	  volume	  to	  that	  stated	  above	  was	  used	  (20µl	  in	  total)	  and	  incubated	  at	   37°C	   for	   one	   hour.	   	   Following	   this,	   3µl	   of	   6x	   MassRuler	   loading	   dye	  (Fermentas)	  was	  added	  and	  the	  samples	  were	  run	  on	  a	  1%	  agarose	  TAE	  gel.	  	  	  
2.3.9 Yeast	  transformation	  	  	   This	   protocol	   was	   used	   for	   the	   transformation	   of	   plasmids	   into	   S.	  
cerevisiae.	  	  	   1. 50ml	   of	   cell	   culture	   was	   grown	   overnight	   to	   a	   density	   of	   2*107	  cells/ml.	  	  2. Cells	   were	   centrifuged	   at	   3000	   rpm	   for	   5	   minutes	   at	   room	  temperature	   in	   an	   Eppendorf	   centrifuge	   5810R.	   	   Cell	   pellets	   were	  washed	   once	   in	   20ml	   of	   sterile	   water	   and	   collected	   again	   by	  centrifugation.	  	  3. Cell	   pellets	   were	   resuspended	   in	   15ml	   of	   lithium	   acetate	   solution	  (100mM	  lithium	  acetate,	  10mM	  Tris	  base,	  1mM	  EDTA,	  pH7.5)	  and	  left	  for	  one	  hour	  at	  room	  temperature.	  	  4. Cells	  were	  collected	  again	  by	  centrifugation	  and	  resuspended	  in	  500µl	  lithium	  acetate	  solution.	  	  5. For	   each	   transformation	   the	   following	  was	   added	   to	   a	   1.5ml	  micro-­‐centrifuge	  tube:	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   6. The	  solutions	  were	  incubated	  on	  a	  Mini	  Labroller	  rotator	  (Labnet)	  at	  room	   temperature	   for	  30	  minutes	  and	   then	   transferred	   into	  a	  water	  bath	  at	  42°C	  for	  15	  minutes.	  7. After	   the	  15-­‐minute	   incubation	  was	   completed	   the	   cells	  were	  placed	  on	  ice	  for	  3	  minutes.	  	  	  8. 1ml	  of	  water	  was	  added	  to	  each	  tube,	   the	  solution	  was	  spun	  at	  3000	  rpm	   for	   5	   minutes	   in	   an	   Eppendorf	   centrifuge	   5414D	   and	   the	  supernatant	  was	  subsequently	  discarded.	  	  9. Cells	   were	   resuspended	   in	   100µl	   of	   sterile	   water	   and	   plated	   on	  selective	   media	   plates	   in	   either	   undiluted,	   1:10	   diluted	   and	   1:100	  diluted	  solutions.	  10. These	  plates	  were	  incubated	  at	  a	  30°C	  for	  72	  hours.	   	  Visible	  colonies	  were	   identified	   and	   transformation	   was	   confirmed	   by	   colony	   PCR,	  DNA	  sequencing	  and	  qPCR	  	  	  	  
2.3.10 Colony	  PCR	  
	  	   Colony	  PCR	  was	  performed	  in	  both	  E.	  coli	  and	  S.	  cerevisiae	  to	  check	  for	  the	  presence	  of	  DNA.	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1. Selected	  cell	   colonies	  were	  numbered	  on	   the	  plate	   for	   later	   reference.	  A	  sterile	  pipette	   tip	  was	  used	  to	   touch	  numbered	  colonies	  and	  the	  tip	  was	  placed	  into	  11.5µl	  of	  water	  within	  a	  0.2ml	  PCR	  tube.	  	  Tips	  were	  left	  for	  5	  minutes	  to	  allow	  cells	  to	  transit	  into	  solution,	  removed	  and	  the	  PCR	  tubes	  were	  closed	  and	  micro-­‐waved	  at	  full	  power	  in	  a	  800W	  power	  microwave	  for	   2	  minutes.	   	   In	   each	   tube	   0.5µl	   of	   forward	   and	   reverse	   primer	   at	   an	  initial	   concentration	   of	   10µM	   were	   added,	   followed	   by	   12.5µl	   of	   2x	  ReddyMix	  PCR	  master	  Mix	  (Thermo	  Scientific).	  2. All	  reactions	  were	  vortex	  mixed,	  spun	  down,	  and	  run	  on	  a	  PTC-­‐200	  PCR	  machine	  (MJ	  Research)	  with	  the	  following	  programme:	  	  1.	  95.0°C	  for	  4:00	  minutes	  	  2.	  94.0°C	  for	  0:40	  minutes	  3.	  55.0°C	  for	  0:50	  minutes	  4.	  72.0°C	  for	  1:00	  minutes	  5.	  Go	  to	  2.	  +3	  sec/cycle	  x30	  times	  6.	  72.0°C	  for	  10:00	  minutes	  7.	  End	  	   3. To	  check	  for	  the	  presence	  of	  the	  correct	  PCR	  product	  7µl	  of	  the	  PCR	  mix	  was	   loaded	   onto	   a	   1%	   agarose	   TAE	   gel,	   run	   under	   the	   conditions	  discussed	  above.	  	  
2.3.11 The	  preparation	  of	  yeast	  genomic	  DNA	  	   To	   obtain	   large	   amounts	   of	   high	   quality	   genomic	   DNA	   for	   sequencing,	  qPCR	   and	   immuno-­‐slot	   blot	   experiments	   the	   following	   protocol	   was	   used.	   	   A	  maximum	  of	   1010	   cells	   can	   be	   used	   and	   yield	   typically	   300-­‐500	  μg	   of	   genomic	  DNA	  from	  haploid	  yeast	  strains.	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1. Cells	   were	   collected	   by	   centrifugation	   at	   5000	   rpm	   for	   5	   min	   and	   the	  supernatant	  was	  discarded.	  	  Cells	  were	  washed	  once	  with	  a	  5ml	  Sorbitol-­‐TE	   solution	   (comprising	   0.9M	   sorbitol,	   0.1M	   Tris-­‐HCL,	   pH	   8.0,	   0.1M	  EDTA).	  2. Cells	  were	  centrifuged	  again	  and	  re-­‐suspended	  in	  5ml	  of	  Sorbitol	  with	  the	  addition	   of	   1mg/ml	   zymolyase	   20T	   and	   0.28M	   β-­‐mercaptoethanol	  (Sigma).	   	   Cells	   were	   incubated	   for	   either	   1	   hour	   at	   37°C	   in	   a	   shaking	  incubator,	  or	  incubated	  overnight	  at	  4°C	  in	  the	  dark.	  3. Samples	  were	   centrifuged	  at	  2000	   rpm	   for	  5	  minutes.	   	  The	   supernatant	  was	   discarded	   and	   the	   cell	   pellet	   was	   re-­‐	   suspended	   in	   5ml	   of	   lysis	  buffer/PBS	  1:1(v/v)	  solution	  (see	  appendix	  1).	  	  To	  each	  0.3	  ml	  of	  RNase	  A	  (10mg/ml	  in	  TE	  buffer,	  incubated	  at	  95°C	  for	  10	  min,	  Sigma)	  was	  added.	  	  Samples	   were	   incubated	   at	   37°C	   for	   1	   hour	   with	   occasional	   shaking	  before	   0.2ml	   of	   Pronase	   (20mg/ml	   in	   TE	   buffer)	   was	   added	   to	   each	  sample	  and	  incubated	  at	  37°C	  for	  1	  hour	  and	  then	  at	  65°C	  for	  1	  hour,	  with	  occasional	  shaking.	  4. An	   equal	   volume	   of	   phenol/chloroform	   1:1	   (v/v)	   was	   added	   to	   each	  sample.	   	   Tubes	   were	   shaken	   vigorously	   before	   being	   centrifuged	   at	  10,000	   rpm	   for	  10	  min	  with	  a	   JA-­‐20	   rotor.	  Nucleic	  acids	   in	   the	  aqueous	  upper	  phase	  were	   transferred	   to	  a	  new	  polypropylene	   tube	  with	  a	  3	  ml	  plastic	  Pasteur	  pipette.	  	  5. To	   ensure	   complete	   deproteinisation	   a	   second	   extraction	   with	  phenol/chloroform	   and	   a	   third	   with	   chloroform/isoamyl	   alcohol	   (24:1)	  were	   performed	   under	   the	   same	   conditions	   as	   the	   first	   extraction.	   The	  absence	   of	   protein	   precipitate	   at	   the	   interphase	   was	   indicative	   of	  complete	  deproteinisation.	  	  	  6. The	  aqueous	  phase	  was	  transferred	  to	  a	  new	  tube.	  7. To	   each	   sample	   2	   volumes	   of	   chilled	   100%	   ethanol	   (-­‐20°C)	  was	   added.	  	  Samples	  were	  cooled	  at	  -­‐80°C	  for	  1	  hour	  or	  overnight	  at	  –	  20°C.	  8. Precipitated	   DNA	  was	   collected	   by	   centrifugation	   at	   10,000	   rpm	   for	   15	  min	  at	  4°C.	  	  DNA	  pellets	  were	  air	  dried	  before	  re-­‐suspension	  in	  1ml	  of	  1x	  TE.	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9. DNA	   was	   precipitated	   again	   by	   the	   addition	   of	   1	   volume	   chilled	  isopropanol	   (1	   ml).	   The	   samples	   were	   gently	   shaken	   until	   the	   DNA	  became	   visible	   in	   the	   solution.	   The	   DNA	   precipitate	   was	   collected	   by	  centrifugation	  at	  12000	  rpm	  for	  10	  minutes	  at	  room	  temperature	  and	  re-­‐	  suspended	  in	  500μl	  1x	  TE.	  10. The	   concentration	   of	   the	   DNA	   was	   measured	   using	   a	   Nanodrop	   1000	  Spectrophotometer	  (ThermoScientific).	  11. The	   DNA	   was	   stored	   at	   4°C	   short-­‐term	   or	   at	   -­‐20°C	   for	   longer-­‐term	  storage.	  	  
2.3.12 Quantitative	  PCR	  	  
	  
RAD1	  gene	  DNA	  content	  was	  assessed	  by	  qPCR,	  and	  compared	  to	  RAD16	  as	  a	  control	  gene.	  	  Samples	  were	  amplified	  using	  the	  CFX-­‐connect	  Real-­‐Time	  PCR	  Detection	   System	   (Bio-­‐Rad)	   equipment	   using	   the	   iTAQ	   universal	   SYBRgreen	  supermix,	   and	   primers	   to	   the	   both	   genetic	   loci	   as	   discussed	   in	   the	   relevant	  results	  chapter,	  with	  the	  following	  parameters	  used:	  	   1. qPCR	  standards	  were	  obtained	  by	  5	  sequential	  10-­‐fold	  dilutions	  of	  RAD16	  DNA	  from	  the	  wild-­‐type	  SX46a	  strain.	  	  2. 5µl	  of	  each	  DNA	  sample	  was	  diluted	  with	  95µl	  H2O	  	  3. 5µl	   of	   either	   standard	   or	   experimental	   sample,	   was	   mixed	   with	   5µl	   of	  SYBRgreen/1%	  primer	  mix	   (10mM	  concentration)	   for	   the	  PCR	   reaction,	  giving	  a	   final	  primer	  concentration	  of	  500nM	  and	  a	   final	  well	  volume	  of	  10µL	  4. All	   qPCR	   experiments	   were	   processed	   in	   96-­‐well	   plates	   (Hard-­‐Shell	   96	  well	   plates,	   Bio-­‐Rad)	   and	   each	   sample	   was	   processed	   in	   triplicate,	  including	   for	   the	   standards.	   	   After	   sealing	   the	   plates,	   each	   plate	   was	  vortexed	   briefly	   and	   centrifuged	   at	   2000	   rpm	   for	   2	   minutes	   at	   room	  temperature.	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2.3.12.1 qPCR	  programme	  settings	  	  1.	  95°C	  for	  3	  minutes	  2.	  95°C	  for	  10	  seconds	  3.	  55°C	  for	  20	  seconds	  –	  followed	  by	  optical	  image	  4.	  Go	  to	  step	  2	  x	  44	  times	  5.	  95°C	  for	  10	  seconds	  6.	  65°C	  for	  5	  seconds	  7.	  Melt	  curve	  from	  65°C	  
	  
	  
2.3.12.2 Data	  analysis	  and	  calculation	  of	  IP/IN	  ratio	  
	   All	   data	   was	   analysed	   using	   Bio-­‐Rad	   CFX	   Manager	   (Version	   3.1)	   and	  Microsoft	  Excel	  by	  the	  following	  process:	  
	   1. Standards	   were	   checked	   to	   ensure	   quantification	   was	   appropriate,	   and	  that	  the	  qPCR	  reaction	  efficiency	  was	  between	  80%	  and	  110%.	  2. Any	   unknown	   sample	   replicates	   results	   outside	   the	   linear	   range	   of	   the	  standards	  or	  with	  a	  threshold	  cycle	  value	  greater	  than	  0.5	  cycles	  from	  the	  remaining	  two	  replicates	  was	  discarded.	  3. The	  DNA	  quantity	  relative	  to	  the	  standards	  was	  calculated,	  and	  exported	  to	  Excel.	  4. The	  mean	  starting	  quantity	  from	  triplicate	  wells	  for	  each	  sample	  was	  used	  as	  the	  initial	  DNA	  quantity	  5. This	  RAD1	  DNA	  quantity	  was	  normalised	  to	  the	  RAD16	  DNA	  quantity	  for	  each	  experimental	  sample.	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 Yeast	  survival	  and	  DNA	  damage	  assays	  2.4	  
2.4.1 UV	  survival	  analysis	  	   Cells	   were	   grown	   to	   log-­‐phase	   in	   appropriate	  media,	   then	   counted	   and	  adjusted	   to	  a	  concentration	  of	  107	  cells/ml.	   	   Samples	  were	  serially	  diluted	   to	  a	  concentration	  of	  2,000	  cells/ml.	   	  To	  each	  2%	  agar	  plate	  containing	  appropriate	  growth	  media,	   200	   cells	   (100µl	   volume	   of	   cell	   suspension)	  was	   plated	   for	   UV	  treatments	  of	  <40	  J/m2.	  	  For	  40-­‐80	  J/m2	  doses	  a	  total	  of	  2000	  cells	  per	  plate	  were	  used	  and	  20,000	  cells	  per	  plate	  were	  used	  for	  UV	  doses	  above	  80	  J/m2.	   	  For	  all	  UV	  doses	  plates	  were	  produced	  in	  triplicate.	  Each	   plate	  was	   irradiated	   by	   exposure	   of	   between	   1	   to	   160	   J/m2	   of	   UV	  light	   at	  254nm	   from	  a	   germicidal	   lamp	  at	   a	   fluence	  of	  10W/m2.	   	   Following	  UV	  irradiation,	   plates	   were	   incubated	   at	   37°C	   for	   48	   hours.	   	   After	   this	   interval	  colonies	   were	   counted,	   and	   the	   mean	   percentage	   of	   surviving	   cells	   was	  calculated	   for	   each	   triplicate	   set	   of	   plates,	   and	   adjusted	   to	   an	   untreated	   plate	  average	  as	  the	  100%.	  	  
2.4.2 UV	  damage	  and	  repair	  assay	  protocol	  	  	   Yeast	   cells	   were	   collected	   by	   centrifugation	   and	   resuspended	   in	   chilled	  PBS	   (at	  4°C)	   to	  a	   cell	  density	  of	  2*107	  cells/ml.	   	   	   For	  UV	   treatment	  aliquots	  of	  50ml	  of	  resuspended	  culture	  was	  poured	  into	  a	  15cm	  diameter	  clear	  glass	  Pyrex	  dish	  and	  exposed	  to	  varying	  dose	  of	  UV	  light	  at	  254nm	  from	  a	  germicidal	  lamp	  at	  a	  fluence	  of	  10W/m2.	  	  This	  procedure	  was	  repeated	  until	  the	  total	  volume	  of	  all	  samples	  had	  been	   treated.	   	   Yeast	   cells	  were	   subsequently	   centrifuged,	   the	  PBS	  was	  removed,	  and	  the	  cells	  were	  resuspended	  in	  liquid	  media.	  	  Cells	  were	  either	  used	  for	  immediate	  DNA	  extraction	  or	  allowed	  to	  repair	  for	  varying	  amounts	  of	  time	  before	  DNA	  was	  extracted.	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2.4.3 Immuno-­‐slotblot	  assay	  
	  	   For	   the	  detection	  of	  DNA	  adducts	   (either	  CPDs	   following	  UV	   irradiation	  and	  oxaliplatin-­‐DNA	  adducts	  following	  oxaliplatin	  exposure),	  DNA	  was	  obtained	  following	  treatment	  using	  the	  protocol	  described	  in	  section	  2.3.11.	  	  	  
	  	   Samples	   of	   DNA	  were	   assessed	   for	   the	   presence	   of	   DNA	   adducts	   using	  Bio-­‐Dot	  SF	  Microfiltration	  equipment	  and	  antibody	  detection,	  using	  the	  protocol	  as	  follows:	  	   1. A	   double	   layer	   of	   Bio-­‐DOT	   SF	   (Bio-­‐Rad)	   paper	   was	   placed	   on	   the	  equipment	   and	   overlaid	   by	   a	   layer	   of	   Gene	   Screen	   Plus	   Hybridisation	  transfer	  membrane,	  pre-­‐soaked	  in	  0.4M	  NaOH	  for	  2	  minutes.	  	  2. The	   lid	  was	   secured	   tightly	   and	   the	   outlet	  was	   attached	   to	   a	   VacuGene	  pump	  (Pharmacia	  Biotech,	  UK).	  	  A	  pressure	  of	  60	  mbar	  was	  applied.	  	  	  3. 200µL	  of	  DNA	  solution	  (comprising	  200ng	  DNA,	  1X	  TE	  buffer	  and	  NaOH	  at	  a	  final	  concentration	  of	  0.4M)	  was	  pipetted	  into	  each	  well.	  	  	  4. Following	   complete	   aspiration	   through	   to	   the	   membrane	   of	   the	   DNA	  solution,	  a	  further	  200µL	  of	  NaOH	  was	  applied	  to	  each	  well	  and	  aspirated	  again	  to	  the	  membrane.	  5. The	   membrane	   was	   removed	   from	   the	   equipment	   and	   blocked	   by	  overnight	   immersion	   in	   a	  3%	  non-­‐fat	  milk	  powder/1X	  TBST	   solution	  at	  4°C	  overnight	  or	  room	  temperature	  for	  2	  hours.	  6. The	  membrane	  was	   placed	   in	   a	   shallow	   tray	   and	   immersed	   in	   3%	  milk	  powder/1X	   TBST	   solution,	   with	   the	   addition	   of	   either	   1uL	   CP9/19	  antibody	   for	   the	   detection	   of	   platinum	   adducts	   or	   2uL	   CPD	   antibody	  (Kamiya	   Biomedical	   Company,	   Seattle	   Anti-­‐Thymine	   Dimer	   Clone	  KTM53),	   used	   for	   the	   detection	   of	   UV	   damage.	   	   The	   membrane	   was	  immersed	   for	   2	   hours	   at	   room	   temperature	   on	   a	   platform	   shaker	   with	  gentle	  agitation.	  7. The	  membrane	  was	  washed	  3	  times	  in	  1X	  TBST	  for	  a	  total	  of	  10	  minutes	  each	  wash,	   before	   immersion	   for	   1	   hour	   at	   room	   temperature	   in	   10mls	  3%	  milk/1X	  TBST	  with	   the	   addition	  of	   5uL	   alkaline-­‐phosphatase	   linked	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Goat	   anti-­‐rat	   IgG	   secondary	   antibody	   (Sigma-­‐Aldrich	  A8439)	   (1:10,000)	  on	  a	  platform	  shaker.	  	  	  8. Following	   secondary	   antibody	   exposure,	   a	   further	   3	   washes	  with	   TBST	  were	  conducted	  as	  described	  previously.	  9. 2mls	  of	  enhanced	  Chemo-­‐Florescence	  (ECF)	  solution	  (GE	  Healthcare)	  was	  applied	   to	   the	   membrane	   at	   room	   temperature	   for	   2	   minutes.	   The	  emission	   of	   fluorescence	  was	   detected	  with	   the	  Typhoon	  TRIO	  Variable	  Mode	  imager	  (Amersham	  Biosciences).	  	  	  10. Bands	  were	  quantified	  using	  ImageJ	  software	  (http://imagej.nih.gov/ij/)	  	  
2.4.4 Oxaliplatin	  treatment	  of	  yeast	  strains	  	  
2.4.5 Yeast	  growth	  analysis	  following	  oxaliplatin	  exposure	  
	  	   Growth	  curves	  were	  assessed	  with	  each	  yeast	  strain	  to	  determine	  the	  rate	  and	   manner	   in	   which	   the	   culture	   grows	   with	   or	   without	   the	   addition	   of	  oxaliplatin.	   	  Yeast	  cultures	  of	  5ml	  volume	  were	  grown	  overnight	   to	  reach	  early	  stationary	  phase.	  	  The	  cultures	  were	  then	  diluted	  to	  OD600	  of	  0.5,	  and	  exact	  OD600	  values	  were	  recorded	  at	  hourly	   intervals.	   	  Once	  cells	  were	  growing	  at	  a	  rate	  of	  increase	   in	   OD600	   of	   0.28	   per-­‐hour,	   for	   two	   successive	   hours,	   oxaliplatin	   was	  added	  to	  the	  media	  to	  the	  desired	  final	  concentration.	  	  The	  sequential	  change	  in	  OD600	  was	  measured	  over	  the	  next	  6	  hours.	  	  	  	  
2.4.6 Oxaliplatin	  treatment	  in	  PBS	  solution	  	   10mls	   of	   yeast	   culture	   were	   grown	   overnight	   to	   reach	   early	   stationary	  phase.	  	  The	  cultures	  were	  then	  diluted	  to	  OD600	  0.5,	  and	  exact	  OD600	  value	  were	  recorded	   at	   hourly	   intervals.	   	   Once	   cells	  were	   growing	   at	   a	   rate	   of	   increase	   of	  0.28	  OD	  per-­‐hour	  for	  two	  successive	  hours	  cells	  were	  collected	  by	  centrifugation	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and	   resuspended	   in	   room	   temperature	   PBS,	   with	   or	   without	   the	   addition	   of	  oxaliplatin	   to	   the	   desired	   final	   concentration.	   	   Cells	   were	   incubated	   for	   three	  hours	   at	   30°C	   at	   180	   rpm.	   	   Following	   the	   three-­‐hour	   incubation,	   cells	   were	  collected	  by	  centrifugation,	  washed	  twice	  with	  growth	  media,	  and	  resuspended	  in	  appropriate	  media.	  	  	  	  The	  samples	  were	  assessed	  for	  the	  effect	  of	  oxaliplatin	  in	  two	  ways:	  	   1. To	   measure	   the	   effect	   of	   treatment	   on	   growth	   rate	   of	   cells,	   the	  OD600	  was	  adjusted	   to	  0.8	  and	  measured	  hourly	   for	   the	   following	  12	  hours.	   	  At	  OD600	  of	  2	  cells	  were	  diluted	  to	  an	  OD600	  of	  1	  and	  all	  subsequent	   values	   were	   adjusted	   to	   take	   into	   account	   of	   this	  dilution.	  	   2. To	   determine	   survival	   by	   the	   effect	   on	   colony	   formation	   after	  oxaliplatin	   exposure,	   samples	  were	   diluted	   to	   a	   concentration	   of	  200	  cells	  per	  100µl	  and	  plated	  in	  triplicate.	  	  Plates	  were	  incubated	  at	   37°C	   for	   48	   hours.	   	   Colonies	   were	   counted,	   and	   the	   mean	  percentage	  of	  surviving	  cells	  was	  calculated	  for	  each	  triplicate	  set	  of	  plates	  was	  used,	  and	  adjusted	  to	  the	  untreated	  average	  as	  100%.	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Chapter	  3 The	  translation	  of	  a	  ‘DIP-­‐chip’	  assay,	  capable	  of	  measuring	  
genome	  wide	  DNA	  repair,	  into	  a	  clinical	  tool	  to	  measure	  oxaliplatin-­‐
DNA	  adducts	  in	  patient	  blood	  samples	  
	  
 Introduction	  3.1
	  	   Many	   studies	   have	   demonstrated	   that	   the	   measurement	   of	   DNA	   repair	  capacity,	   and	   in	   particular	   the	   measurement	   of	   platinum-­‐DNA	   adduct	   levels,	  could	   potentially	   be	   used	   to	   predict	   response	   and	   toxicity	   from	   chemotherapy	  (for	   examples	   see	   section	   3.1.1).	   	   The	   findings	   of	   these	   studies	   are	   consistent	  with	   the	   central	   hypothesis	   of	   this	   thesis	   -­‐	   that	   as	   DNA	   repair	   pathways	   are	  responsible	   for	   the	   removal	   of	   adducts	   formed	   by	   the	   interaction	   of	   platinum	  agents	  with	  DNA,	   through	  understanding	  variations	   in	   the	   functioning	  of	   these	  pathways	   in	   individual	   patients	   it	   may	   be	   possible	   to	   stratify	   patients	   for	  response	  and	   toxicity	   from	  these	  agents,	  and	   for	   the	  risk	  of	  OIPN	   in	  particular.	  	  However,	   the	   currently	   available	   methods	   of	   NER	   analysis	   or	   platinum-­‐DNA	  adduct	   measurements	   give	   an	   average	   measure	   of	   the	   level	   of	   platinum-­‐DNA	  adducts	  across	   the	  whole	  genome,	  and,	  as	  a	   result,	  have	   limited	  predictive	  and	  prognostic	  power,	  as	  will	  be	  outlined	  in	  the	  following	  discussion	  (Bowden	  2014).	  	   Our	   laboratory	   has	   made	   several	   advances	   in	   DNA	   repair	   assay	  technology	   that	   have	   resulted	   in	   the	   development	   of	   an	   assay	   capable	   of	  measuring	  DNA	  damage	  and	  DNA	  repair	  capacity	  at	  high	  resolution	  at	  a	  genomic	  scale	   (Teng	   et	   al.	   2010).	   	   This	  DIP-­‐chip	   technology,	   based	   an	   a	   combination	   of	  DNA	   immunoprecipitation	   (DIP)	   and	   microarray	   analysis	   (chip),	   has	   more	  recently	  been	  translated	   for	  use	   in	  human	  tissue	   for	   the	  detection	  of	  platinum-­‐DNA	   adducts	   in	   cultured	   cells	   previously	   exposed	   to	   cisplatin	   or	   oxaliplatin	  (Powell	  2014).	  	   It	  may	   be	   possible	   to	   use	   this	   technique	   in	   patient	   samples	   to	   produce	  high-­‐resolution,	  genomic	  scale	  patterns	  of	  DNA	  damage	  and	  repair,	  in	  the	  context	  of	  oxaliplatin-­‐induced	  DNA	  damage.	  	  This	  approach	  has	  the	  potential	  to	  improve	  the	   sensitivity	   and	   specificity	   of	  DNA	  damage	   and	   repair	   analysis	   compared	   to	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currently	  available	  methods,	  with	  the	  novel	  ability	  to	  detect	  subtle	  differences	  in	  platinum-­‐DNA	  adduct	  patterns	  at	  key	  regions	  of	  the	  genome.	  	  It	  has	  the	  potential	  to	  be	  a	  potent	  tool	  for	  patient	  stratification.	  	   Several	  challenges	  need	  to	  be	  overcome	  in	  the	  translation	  of	  this	  research	  tool	   into	   a	   clinically	   usable	   assay,	   including	   adapting	   the	   method	   for	   use	   on	  appropriate	   clinical	   samples,	   ensuring	   the	   reliability	   and	   reproducibility	   of	   the	  assay,	   the	   development	   of	   bioinformatic	   tools	   and	   robust	   pipelines	   for	   data	  analysis,	  and	  clinical	  validation.	  	  These	  steps	  must	  be	  addressed	  before	  the	  assay	  can	  be	  confidently	  used	  on	  precious	  and	  limited	  clinical	  samples	  obtained	  from	  patients.	   	   It	   is	   these	  challenges	   that	  will	  be	  addressed	   in	   this	  and	   the	   following	  chapters.	  Following	   a	   discussion	   of	   the	   previous	   technologies	   available,	   the	  evidence	  supporting	  the	  use	  of	  this	  type	  of	  approach	  to	  patient	  stratification	  and	  a	  discussion	  of	  the	  development	  of	  the	  DIP-­‐chip	  technique,	  the	  main	  focus	  of	  this	  chapter	   will	   be	   on	   the	   translation	   and	   validation	   of	   the	   DNA	  immunoprecipitation	   (DIP)	   stage	   of	   the	   assay	   into	   a	   tool	   for	   reliably	   and	  reproducibly	   measuring	   levels	   of	   platinum-­‐DNA	   adducts	   in	   ex	   vivo	   oxaliplatin	  treated	  human	  blood	  samples.	  
	  
3.1.1 An	  overview	  of	  platinum-­‐DNA	  adduct	  studies	  
	  	   Since	   the	   introduction	   into	   routine	   clinical	   practice	   of	   cisplatin	   in	   the	  1970s,	   and	   of	   oxaliplatin	   in	   the	   last	   decade,	   the	   potential	   benefits	   of	   accurate	  patient	   stratification	   for	   response	   and	   toxicity	   to	   these	   agents	   has	   been	  recognised	   and	   studied.	   	   As	   early	   as	   the	   1980s	   attempts	   to	   predict	   clinical	  outcome	   by	   measuring	   platinum-­‐DNA	   adduct	   levels	   commenced	   (Fichtinger-­‐Schepman	  et	  al.	  1987;	  Poirier	  et	  al.	  1982).	  	  Initial	  evidence	  from	  these	  studies	  is	  contradictory	  with	  conflicting	  outcomes	  (Ma	  et	  al.	  1995),	  but	  as	  the	  technology	  available	   to	   measure	   adducts	   has	   developed	   these	   assays	   have	   become	   more	  sophisticated	  and	  more	  accurate	  (Nel	  et	  al.	  2013;	  Wang	  et	  al.	  2011).	  	  Broadly,	  the	  methods	  used	  can	  be	  classified	  as	  antibody	  based,	  radio-­‐nucleotide	  approaches,	  analytical	  chemistry	  techniques,	  or	  can	  be	  grouped	  as	  functional	  studies.	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  Of	  note,	  all	  of	  the	  technologies	  available	  measure	  a	  broad	  output	  of	  total	  platinum-­‐DNA	  adducts	  per	  unit	   of	  DNA,	   or	   result	   in	   a	   crude	  measure	  of	   global	  DNA	   adduct	   repair.	   	   Until	   the	   development	   of	   our	   DIP-­‐chip	   approach,	   these	  techniques	   have	   been	   unable	   to	   investigate	   the	   subtleties	   of	   platinum-­‐DNA	  adduct	  patterns	  at	  high	  resolution	  throughout	  the	  genome,	  with	  a	  resulting	  lack	  of	  sensitivity	  that	  has	  hindered	  progression	  to	  a	  workable	  clinical	  assay.	  	  It	  is	  this	  key	  difference	  that	  we	  aim	  to	  exploit	  with	  our	  technique.	  
	  
3.1.2 Antibody	  based	  assays	  	  Several	   antibodies	   have	   been	   raised	   against	   platinum-­‐DNA	   adducts	   and	  have	   been	   applied	   in	   a	   variety	   of	   studies.	   	   These	   typically	   use	   enzyme-­‐linked	  immunosorbent	  assays	  (ELISA)	  and	  immunohistochemical	  based	  techniques.	  Examples	   include	   a	   study	   by	   Poirier,	  with	   the	   development	   rabbit	   anti-­‐serum	  raised	  against	  cisplatin	  treated	  calf	  thymus	  DNA	  (Poirier	  et	  al.	  1982).	  	  The	  resulting	   antibody	   was	   capable	   of	   detecting	   platinum-­‐DNA	   adducts	   with	   high	  specificity	   for	   platinum	   modified	   DNA	   in	   ELISA	   assays	   (Poirier	   1982).	   	   In	   a	  similar	   study	   by	   Fischtinger-­‐Schepman,	   the	   group	   immunised	   rabbits	  with	   cis-­‐Pt(pGpG)	  or	  cis-­‐Pt(ApG)	  to	  produce	  an	  antibody	  against	   these	  specific	  epitopes	  (Fichtinger-­‐Schepman	  et	  al.	  1987).	  	  The	  resulting	  antibody	  was	  able	  to	  recognise	  adducts	   after	   ELISA,	   nuclease	   digestion	   of	   isolated	   DNA	   and	   chromatographic	  isolation	  of	  platinum-­‐dinucleotides,	  and	  was	  tested	  and	  able	  to	  detect	  platinum	  DNA-­‐adducts	  in	  DNA	  extracted	  from	  blood	  samples	  from	  7	  patients	  undergoing	  cisplatin	  chemotherapy	  (Fichtinger-­‐Schepman	  et	  al.	  1987).	  	  There	  are	  several	  other	  examples	  of	  antibodies	  raised	  to	  platinum	  treated	  DNA,	  including	  platinum-­‐DNA	  adduct	  antibodies	  developed	  by	  Tilby	  (Tilby	  et	  al.	  1991),	   Chao	   (Chao	   et	   al.	   1994)	   and	   Sundquist	   (Sundquist	   et	   al.	   1987).	   Other	  examples	   of	   anti-­‐platinum	   antibodies	   developed	   for	   the	   measurement	   of	  platinum-­‐GG	   adducts	   are	   the	   antibodies	   Mab	   R-­‐C18	   and	   Pt-­‐(ApG)	   R-­‐B3	  developed	  by	  Liedert	  (Liedert	  et	  al.	  2006).	  Only	   one	   antibody	   is	   commercially	   available	   and	   is	   the	   antibody	   used	  throughout	  this	  study,	  CP	  9/19.	  	  This	  antibody	  was	  developed	  by	  Tilby	  and	  used	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initially	   for	   ELISA	   studies	   (Tilby	   1999).	   The	   epitope	   was	   elucidated	   and	  confirmed	   to	   be	   the	   predominant	   intrastrand	   platinum-­‐GG	   adduct	   by	  demonstrating	   the	   preference	   for	   binding	   of	   the	   antibody	   CP9/19	   to	   guanine-­‐guanine	  intrastrand	  crosslinks	  (Meczes	  et	  al.	  2005).	  	  Platinum-­‐antibody	  ELISA	  based	  assays	  have	  been	  used	  in	  several	  clinical	  studies.	   Examples	   include	   an	   ELISA	   assay	   used	   on	   samples	   from	   55	   ovarian	  cancer	  patients	  undergoing	  platinum	  chemotherapy.	  	  This	  study	  demonstrated	  a	  positive	  correlation	  between	  treatment	  response	  and	  adduct	  levels	  in	  leukocyte	  DNA	  (Reed	  et	  al.	  1987).	  	  Another	  early	  example	  of	  a	  similar	  clinical	  study	  used	  an	  ELISA	  based	  on	  an	  antibody	  raised	  to	  platinum	  drugs	  to	  measure	  platinum-­‐DNA	  adducts	  in	  peripheral	  blood	  leukocytes	  in	  several	  patients	  with	  either	  testicular	  or	  ovarian	  cancer	  undergoing	  chemotherapy	  with	  carboplatin	  or	  cisplatin.	   	  This	  study	  demonstrated	  a	  positive	  correlation	  between	  adduct	   levels	  and	  response	  to	  the	  treatment	  (Reed	  et	  al.	  1987,	  1988).	  	  Several	  studies	  have	  been	  conducted	  using	   a	   similar	   approach	   in	   a	   wide	   variety	   of	   clinical	   samples	   also	   showed	   a	  positive	   correlation,	   including	   germ	   cell	   tumours	   (Motzer	   et	   al.	   1994),	   ovarian	  cancer	  (Reed	  et	  al.	  1990),	  breast	  cancers	  (Gupta-­‐Burt	  et	  al.	  1993)	  and	  a	  study	  an	  unselected	  wide	  variety	  of	   cancers	   (Reed	  et	   al.	   1993).	   	  However,	   other	   studies	  using	  ELISA	  based	  techniques	  failed	  to	  show	  any	  significant	  correlation	  between	  platinum-­‐DNA	   adduct	   levels	   and	   response	   to	   treatment	   (e.g.	   (Fichtinger-­‐Schepman	  et	  al.	  1987)).	  When	  these	  early	  studies	  were	  reviewed	  (Ma	  et	  al.	  1995)	  the	  variable	  and	  contradictory	   outcomes	   were	   attributed	   to	   differences	   in	   sample	   preparation	  technique	   and	   analysis	  methods,	   occasionally	   resulting	   in	   greater	   than	   10	   fold	  differences	  in	  adduct	  levels	  recorded	  between	  similarly	  treated	  patients.	  
	   Immunohistochemical	   assays	   are	   an	   alternative	   antibody-­‐based	   assay	  approach,	  and	  can	  be	  used	  to	  directly	  visualise	  cellular	  and	  nuclear	  adduct	  levels.	  	  In	   one	   example,	   using	   antibodies	   developed	   by	   Terheggen	   ((Terheggen	   et	   al.	  1991)),	   buccal	   cells	   from	   patients	   undergoing	   platinum	   chemotherapy	   for	   a	  variety	   of	   tumour	   types	   were	   assessed.	   	   This	   study	   described	   a	   positive	  correlation	  between	  adduct	   levels	   and	   response	   to	   treatment	  with	   carboplatin,	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but	  not	  with	  cisplatin	  (Blommaert	  et	  al.	  1993).	   	  Similar	  experiments	  have	  been	  conducted	  in	  patients	  with	  non-­‐small	  cell	  lung	  cancer	  (NSCLC)	  receiving	  cisplatin	  and	   carboplatin,	   suggesting	   adduct	   levels	  may	   be	   prognostic	   in	   these	   patients	  (van	  de	  Vaart	  et	  al.	  2000).	  In	   a	   contemporary	   example	   of	   the	   approach,	   levels	   of	   cisplatin	   adducts	  were	  measured	  by	  an	  immunocytochemistry	  assay	  of	  platinum-­‐(GpG)	  adducts	  in	  nuclear	  DNA	  of	  circulating	  tumour	  cells	  treated	  ex	  vivo,	  and	  compared	  to	  ERCC1	  mRNA	  expression	  profiles	  (Nel	  et	  al.	  2013).	  	  The	  formation	  and	  repair	  of	  adducts	  was	  assessed	  over	  a	  24-­‐hour	  period	   in	  a	   small	  number	  of	  patients	  with	  NSCLC	  undergoing	   cisplatin	   chemotherapy.	   	   Using	   multivariate	   regression	   analysis	  cisplatin	  AUC	  and	  maximum	  detectible	  adduct	   levels	   correlated	  with	  a	  positive	  response	   to	   treatment	  when	   compared	   to	   patients	  with	   stable	   disease.	   	   There	  was	  no	  significant	  correlation	  of	  with	  ERCC1	  expression.	  	  
	  
3.1.3 Radio-­‐nucleotide	  assays	  
	   The	   32P-­‐post-­‐labelling	   assay	   (PLA)	   was	   developed	   by	   Blommaert	  (Blommaert	  and	  Saris	  1995)	  and	  subsequently	  modified	  by	  Welters	  (Welters	  et	  al.	  1997)	  and	  Pluim	  (Pluim	  et	  al.	  1999).	  	  This	  assay	  has	  been	  shown	  to	  be	  up	  to	  10	   fold	  more	   sensitive	   than	  ELISA	  based	  DNA-­‐adduct	   assays,	   and	   is	   capable	  of	  detecting	   in	   the	   range	  of	   one	   adduct	  per	  107	   to	  108	  nucleotides	   (Welters	   et	   al.	  1997).	  	  Advantageously,	  the	  PLA	  requires	  sample	  processing	  steps	  that	  render	  it	  incompatible	  with	   the	  measurement	   of	   platinum-­‐DNA	  mono-­‐adducts,	   reducing	  the	  risk	  of	  cross-­‐specificity.	  	  Briefly,	  DNA	  is	  digested	  and	  platinum-­‐DNA	  adducts	  are	  separated	  by	  cation	  exchange	  chromatography,	  due	  to	  positive	  charge	  of	  the	  platinum	   ion.	   	   After	   removal	   of	   platinum,	   remaining	   dinucleotides	   are	   labelled	  with	   32P	   and	   separated	   by	   chromatography,	   before	   scintillation	   counting	   for	  quantification	  (Pluim	  et	  al.	  1999).	  Three	  clinical	  studies	  have	  used	  the	  PLA	  to	  analyse	  platinum-­‐DNA	  adduct	  levels	   and	   relationship	   between	   adducts	   and	   the	   patient	   response	   to	  chemotherapy.	   	   In	   one	   example,	   fresh	   samples	   from	   eight	   testicular	   cancer	  patients	  and	  head	  and	  neck	  patients	  were	  treated	  ex	  vivo	  with	  cisplatin.	  Higher	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adduct	   levels	   in	   ex	   vivo	   treated	   biopsy	   specimens	   detected	   by	   PLA	   correlated	  with	   better	   clinical	   response	   (Welters	   et	   al.	   1999b).	   	   Hoebers	   (Hoebers	   et	   al.	  2008;	  Hoebers	  et	   al.	   2006)	  examined	  adduct	   levels	   in	  35	  patients	   treated	  with	  cisplatin	   as	   part	   of	   chemo-­‐radiotherapy	   treatment	   for	   head	   an	   neck	   squamous	  cell	  cancer,	  finding	  a	  correlation	  between	  disease	  free	  survival	  and	  the	  platinum-­‐GG	   adduct	   levels	   in	   the	   primary	   tumour	   and	   a	   trend,	   but	   no	   statistical	  significance,	   for	   overall	   survival.	   	   In	   a	   further	   study	   using	   PLA,	   adducts	   were	  determined	  in	  63	  patient	  from	  normal	  tissue	  (peripheral	  blood	  mononuclear	  cell	  (PBMC)	   and	   buccal	   cells)	   and	   from	   23	   biopsies	   in	   cisplatin	   treated	   patients	  undergoing	  chemo-­‐radiation.	  	  No	  correlation	  was	  demonstrable	  between	  tumour	  biopsies	  and	  normal	  tissues	  (Hoebers	  et	  al.	  2008).	  The	   advantage	  of	   PLA	   is	   a	   high	   sensitivity	   for	  detecting	   the	  presence	  of	  adducts,	   and	   that	   it	   requires	   only	   minimal	   DNA	   samples	   for	   processing.	  	  However,	   it	   is	   labour	   intensive	   and	   requires	   radioactive	   reagents,	   making	   it	  somewhat	   impractical	   to	   develop	   for	   routine	   clinical	   use	   (Phillips	   et	   al.	   2000;	  Zayed	  et	  al.	  2011).	  
	  
3.1.4 Gel	  based	  platinum-­‐DNA	  adduct	  assays	  	  A	   gel-­‐based	   assay	   for	   the	   detection	   of	   platinum-­‐DNA	   adducts	   has	   been	  developed,	   described	   as	   the	   TARDIS	   assay,	   an	   acronym	   for	   trapped	   in	   agarose	  DNA	   immunostaining	  assay	   (Cowell	   et	   al.	   2011).	   	  This	   technique	   traps	  a	   single	  cell	  in	  agarose,	  then	  detects	  adducts	  using	  a	  primary	  anti-­‐platinum	  antibody.	  	  So	  far	  no	  clinical	  studies	  have	  used	  this	  research	  technique.	  	   	  A	  modification	  of	  the	  comet	  assay	  (discussed	  in	  chapter	  1	  section	  1.5.2)	  has	  been	  used	  on	  peripheral	  blood	   lymphocytes	   samples	   from	   colorectal	   cancer	   patients	   treated	   with	  oxaliplatin	   to	   measure	   oxaliplatin-­‐DNA	   adducts,	   and	   some	   evidence	   of	   inter-­‐individual	   variability	   could	   be	   determined	   with	   this	   approach	   (Almeida	   et	   al.	  2006).	   	   However,	   this	   assay	   is	   generally	   considered	   qualitative	   as	   it	   does	   not	  directly	  provide	  information	  on	  adduct	  number	  (Zayed	  et	  al.	  2011).	  	  It	  is	  possible	  that	   further	  modifications	  of	   this	  approach	  may	  result	   in	  a	  clinically	  useful	   tool	  (McKenna	  et	  al.	  2008).	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3.1.5 Analytical-­‐chemistry	  based	  assays	  
	   Broadly,	   several	   methods	   can	   be	   considered	   as	   a	   group	   of	   analytical	  chemistry	  based	  approaches	  to	  determine	  platinum-­‐DNA	  adduct	  levels.	  	  Methods	  include	  mass	   spectrometry,	  which	   can	  be	  used	   to	  measure	  platinum	   levels	  per	  unit	   of	   DNA.	   	   These	   approaches	   are	   highly	   sensitive,	   however	   they	   require	  expensive	   and	   specialised	   equipment	   limiting	   the	   potential	   clinical	   utility	  (Phillips	   et	   al.	   2000).	   	   Variations	   on	   this	   technique	   include	   Atomic	   Absorption	  Spectroscopy	  (AAS)	  (Kloft	  et	  al.	  1999),	  LC-­‐ion	  trap	  Mass	  Spectroscopy	  (Le	  Pla	  et	  al.	   2007),	   Accelerator	   mass	   spectrometry	   (AMS)	   combined	   with	   HPLC	  purification	  (Hah	  et	  al.	  2007)	  and	  ICP-­‐MC	  (Bonetti	  et	  al.	  1996;	  Zayed	  et	  al.	  2011).	  	  Atomic	   absorption	   spectroscopy	  measures	   total	   platinum,	   but	   lacks	   specificity	  for	   routine	   clinical	   applications	   (Henderson	   et	   al.	   2011).	   	   Inductively	   coupled	  mass	   spectrometry	   has	   higher	   sensitivity	   that	   could	   be	   useful	   for	   clinical	  applications,	  although	  results	  in	  a	  general	  measure	  of	  total	  platinum,	  not	  the	  type	  or	  location	  of	  adducts	  (Henderson	  et	  al.	  2011).	  Several	  clinical	  studies	  have	  used	  these	  approaches.	  	  The	  earliest	  example	  used	  AAS	  to	  measure	  platinum	  ions	  per	  unit	  of	  DNA	  extracted	  from	  PBMC,	  with	  no	   clinical	   correlation	   evident	   in	   this	   study	   (Bonetti	   et	   al.	   1996).	   	   The	  measurement	  of	  adduct	  levels	  using	  these	  types	  of	  analysis	  techniques	  has	  been	  proposed	  as	  a	  method	  of	  adjusting	  treatment	  in	  several	  tumour	  types,	  including	  head	  and	  neck	  cancer	  (Schellens	  et	  al.	  1996)	  and	  non-­‐small	  cell	   lung	  cancer.	   	  A	  study	   of	   oxaliplatin	   response	   and	   toxicity	   used	   adsorptive	   stripping	  voltammetry,	  a	  variant	  of	  mass	  spectrometry,	  to	  measure	  oxaliplatin	  adducts	  per	  unit	  of	  extracted	  DNA	  in	  a	  cohort	  of	  27	  patients	  with	  a	  variety	  of	  solid	  tumours	  all	   treated	  with	  oxaliplatin.	   	  With	   increasing	  adduct	   levels	  there	  was	  a	  positive,	  but	   not	   statistically	   significant,	   increase	   in	   tumour	   response	   and	   toxicity	   (an	  OIPN	   based	   neuropathy	   score).	   	   Given	   the	   low	   number	   of	   patients	   and	  heterogeneous	  tumour	  types	  studied,	  the	  lack	  of	  statistical	  power	  is	  unsurprising	  (Pieck	  et	  al.	  2008).	  Again	   the	   clinical	   results	   of	   analytic	   chemistry	   based	   techniques	   have	  been	  contradictory,	   especially	  when	  measuring	  adducts	  generated	   in	   surrogate	  tissues	  of	  peripheral	  blood	  cells,	   in	  germ	  cell	   tumours	  and	  ovarian	  cancer.	   	  The	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differences	   in	   outcome	   reported	   have	   been	   explained	   by	   the	   wide	   variety	   of	  tumour	  types,	  clinical	  samples,	  investigative	  tools	  and	  preparation	  methods	  used	  in	   these	   studies	   (Bonetti	   et	   al.	   1996;	   Motzer	   et	   al.	   1994;	   Pieck	   et	   al.	   2008;	  Schellens	  et	  al.	  1996).	  	  	  
	  
3.1.6 Recent	  functional	  studies	  showing	  a	  relationship	  between	  	  DNA	  
repair	  capacity	  and	  clinical	  response	  to	  platinum	  chemotherapy	  	   	  Rather	   than	   measure	   total	   adduct	   levels	   an	   alternative	   approach	   is	   to	  measure	   functional	   DNA	   repair	   capacity	   for	   platinum	   adducts.	   	   Wang	   used	   a	  functional	  assay	  in	  an	  example	  of	  this	  approach	  (Wang	  et	  al.	  2011).	  	  PBMC	  from	  591	   patients	   with	   NSCLC	   were	   stored	   pre-­‐cisplatin	   chemotherapy.	   	   The	   cells	  were	  subsequently	  cultured	  and	  assessed	  for	  DNA	  repair	  characteristics	  using	  a	  host	  reactivation	  assay	  with	  benzo[a]pyrine	  diol	  epoxide	  (BPDE)	  damaged	  non-­‐replicating	  recombinant	  plasmid	  with	  a	  chloramphenicol	  acetyltransferase	  (CAT)	  reporter	  gene.	  	  Higher	  DNA	  repair	  capacity	  resulted	  in	  higher	  expression	  of	  CAT,	  detected	   by	   the	   radioactivity	   of	   products	   produced	   from	   the	   addition	   of	   3H-­‐radiolabelled	   acetyl	   coenzyme	   A	   and	   chloramphenicol.	   	   Lower	   germline	   DNA	  repair	  capacity	  measured	  with	  this	  assay	  was	  associated	  with	  improved	  survival	  following	  cisplatin	  treatment,	  indicating	  that	  DNA	  repair	  capacity	  of	  peripherally	  harvested	  PBMC	  may	  be	  used	  as	  a	  surrogate	  biomarker	  for	  platinum	  response	  in	  tumours.	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3.1.7 Surrogate	  tissue	  versus	  tumour	  tissue	  for	  clinical	  sample	  analysis	  	   	  Measuring	   platinum-­‐DNA	   levels	   in	   tumour	   tissue	   is	   technically	   difficult	  and,	   for	  a	   true	   reflection	  of	   treatment	  effect,	   requires	   the	  extraction	  of	   tumour	  after	   treatment	  with	   inherent	   risks	   of	   additional	   tumour	   sampling	   in	   the	  post-­‐chemotherapy	   period.	   An	   alternative	   would	   be	   an	   additional	   biopsy	   pre-­‐treatment	  to	  allow	  adequate	  cellular	  material	  to	  be	  gathered	  and	  treated	  ex	  vivo,	  although	   the	   link	   with	   the	   specific	   tumour	   microenvironment	   and	   treatment	  conditions	   is	   then	   disturbed.	   	   As	   an	   indication	   of	   the	   risk	   of	   repeat	   patient	  sampling	   in	   a	   recent	   study	   of	   image-­‐guided	   biopsies	   conducted	   for	   research	  purposes	   in	   clinical	   studies	   the	   rate	   of	   complications	  was	   5.2%	   generally,	   and	  17.1%	   in	   intra-­‐thoracic	   and	  abdomino-­‐pelvic	   solid	  organ	  biopsies	   (Overman	  et	  al.	  2013).	   	  Particularly	  during	  assay	  development	  projects	   these	  concerns	   limit	  the	  available	  material	  for	  research	  purposes	  and	  the	  limit	  the	  practicality	  of	  this	  approach.	  	  Surrogate	   tissue,	   such	   as	   blood	   cells,	   have	   significant	   advantages	   in	  reducing	   these	   risks.	   However,	   there	   are	   obvious	   concerns	   with	   using	   tissue	  other	   than	   the	   tumour,	   including	   that	   platinum	   uptake	   and	   DNA	   adduct	  processing	  may	  be	  different	  among	  the	  different	  haematopoietic	  cells	  commonly	  used	   as	   surrogate	   tissue	   (Bracker	   et	   al.	   2006)	   and	   that	   platinum-­‐DNA	   adduct	  levels	  may	   be	   lower	   at	   physiological	   doses	   in	   normal	   tissues	   than	   in	   tumours	  (Liedert	  et	  al.	  2006).	  	  When	  using	  normal	  tissues	  as	  a	  marker	  of	  germline	  repair	  capacity	  or	  to	  examine	  the	  response	  of	  normal	  tissues,	  for	  example	  in	  a	  study	  of	  toxicity,	  these	  issues	  are	  less	  of	  a	  concern.	  	  	  One	  promising	  contemporary	  approach	   is	  using	  circulating	   tumour	  cells	  (CTC)	   as	   a	  more	   accurate	   surrogate	   of	   tumour	   characteristics.	   	   A	   recent	   study	  used	  circulating	  tumour	  cells	  treated	  ex	  vivo	  with	  cisplatin	  to	  compare	  platinum-­‐DNA	   adduct	   levels	   detected	  with	   immunocytochemistry	  with	   tumour	   response	  (Nel	  et	  al.	  2013).	   	  This	  approach	  obviates	  the	  need	  for	  collecting	  tumour	  tissue	  and	  may	  be	  a	  more	  reliable	  surrogate	  marker.	  	  However,	  in	  about	  1/3	  of	  patients	  with	  metastatic	  cancer	  CTC	  are	  undetectable,	  most	  patients	  have	  small	  numbers	  of	  CTC,	  and	  a	  count	  of	  >100	  per	  7.5ml	  of	  blood	   is	   considered	  extreme	  and	   is	  a	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very	  poor	  prognostic	  marker	  (Alemar	  and	  Schuur	  2013).	   	  Evidently	  the	  yield	  of	  CTC	  from	  a	  clinical	  blood	  sample,	  and	  hence	  usable	  DNA,	  is	  very	  low.	  	  	  In	   many	   of	   the	   currently	   available	   assay	   techniques	   and	   in	   the	   clinical	  studies	  discussed	  above	  the	  use	  of	  blood	  samples	  and	  PBMC	  as	  a	  surrogate	  tissue	  attests	   to	   fact	   that	   this	   is	   the	   best	   and	  most	   practical	   surrogate	   patient	   tissue	  available.	  	  	  
3.1.8 Potential	  improvements	  using	  a	  high-­‐resolution	  genome-­‐wide	  
approach	  	  Compared	  to	  markers	  of	  DNA	  repair	  or	  NER	  protein	  levels,	  in	  the	  context	  of	   platinum-­‐DNA	   adduct	   clinical	   studies	   the	   measurement	   of	   total	   platinum	  content	  of	  cells	  has	  been	  suggested	  as	  a	  more	  relevant,	  and	  hence	  more	  reliable,	  marker	  of	  platinum	  effectiveness	  and	  toxicity	  (Henderson	  et	  al.	  2011;	  Kim	  et	  al.	  2012),	   since	   primarily	   the	   level	   of	   platinum	   damage	   represents	   the	   effective	  stimulus	  leading	  to	  downstream	  effects	  of	  apoptosis	  and	  cell	  death.	  	  The	   studies	   discussed	   in	   this	   section	   demonstrate	   that	   the	   approach	   of	  measuring	  platinum-­‐DNA	  adduct	   levels,	  of	  studying	  DNA	  repair	   in	  the	  germline	  of	   patients	   treated	   with	   platinum-­‐based	   chemotherapy,	   and	   the	   issues	  surrounding	  the	  use	  of	  tumour,	  surrogate	  or	  CTC	  tissues	  are	  an	  active	  area	  of	  on-­‐going	   research,	   driven	   by	   the	   need	   to	   improve	   the	   therapeutic	   profile	   of	   the	  platinum	  agents.	  	  Unfortunately,	  the	  results	  so	  far	  are	  conflicting,	  and	  lack	  robust	  predictive	  power	   for	  response	  or	  toxicity.	   	  To-­‐date	  these	  remain	  research	  tools	  and	  no	  technique	  or	  assay	  has	  made	  an	  impact	  in	  the	  clinic	  (Bowden	  2014).	  There	  is	  a	  wealth	  of	  genetic	  data	  such	  as	  genome	  wide	  association	  studies	  (GWAS)	  for	  platinum	  response	  and	  toxicity,	  as	  extensively	  discussed	  in	  chapter	  6,	   that	   suggest	   that	   small	   changes	   in	   DNA	   damage	   levels	   or	   repair	   capacity	   at	  different	   genes	   and	   sections	   of	   the	   genome	   could	   be	   important	   predictors	   of	  response	   and	   toxicity.	   	   Tools	   to	   capture	   the	   intricacies	   of	   genome-­‐wide	   DNA	  damage	  and	  repair	  are	  potentially	  more	  sophisticated	  ways	  of	  characterising	  the	  effects	  of	  platinum-­‐DNA	  adducts,	  and	  may	  be	  more	  sensitive	  and	  specific	  than	  a	  global	   measures	   of	   ‘whole	   genome	   platinum	   per	   unit	   of	   DNA’	   available	   in	   the	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studies	   outlined	   in	   this	   chapter.	   	   Differential	   damage	   and	   repair	   in	   varied	  sections	   of	   the	   genome,	   particularly	   evident	   in	   post-­‐mitotic	   tissues	  where	   GG-­‐NER	   is	   down	   regulated	   whilst	   TC-­‐NER	   is	   not	   (Nouspikel	   2009),	   are	   potential	  mechanisms	  through	  which	   idiosyncratic	  patient	  responses	   to	   treatment	  occur,	  and	   are	   not	   detectable	   with	   currently	   available	   approaches	   to	   DNA	   adduct	  measurement.	  	  High	  resolution	  genome-­‐wide	  platinum-­‐DNA	  adduct	  patterns	  are	  detectable	   in	   cell	   culture	   models	   with	   DIP-­‐chip	   assay	   technology	   recently	  developed	   in	   our	   laboratory	   (Powell	   2014;	   Teng	   et	   al.	   2010)	   and	  may	   offer	   a	  method	  to	  resolve	  some	  of	  these	  issues.	  	  
3.1.9 The	  development	  of	  the	  DIP-­‐chip	  assay	  
	  
	   The	   DIP-­‐chip	   assay	   used	   in	   the	   experiments	   discussed	   in	   this,	   and	  following,	  chapters	  involve	  two	  main	  steps,	  DNA	  immunoprecipitation	  (DIP)	  and	  microarray	  (chip)	  analysis	  to	  obtain	  high-­‐resolution	  genome	  scale	  platinum-­‐DNA	  adduct	  profiles.	   	  The	  assay	  is	  a	  development	  of	  chromatin	  immunoprecipitation	  and	  microarray	  (ChIP-­‐chip),	  a	  technique	  that	  first	  gained	  common	  acceptance	  as	  a	  research	  tool	  almost	  15	  years	  ago	  (Iyer	  et	  al.	  2001;	  Ren	  et	  al.	  2000).	  	  The	  ChIP-­‐chip	   experimental	   approach	   has	   proved	   useful	   primarily	   for	   deciphering	   the	  complexities	  of	  transcriptional	  regulation	  in	  the	  context	  of	  chromatin	  (Lee	  et	  al.	  2002)	  and	  epigenetic	  regulation	  through	  the	  modification	  of	  histones	  (Pokholok	  et	  al.	  2005).	  	  The	  technique	  has	  been	  extensively	  used	  with	  S.	  cerevisiae	  to	  study	  the	  genome-­‐wide	  location	  of	  transcription	  factor	  binding	  sites	  (Iyer	  et	  al.	  2001;	  Lee	   et	   al.	   2002;	   Ren	   et	   al.	   2000)	   and	   histone	   modifications	   (Kurdistani	   et	   al.	  2002;	  Robyr	  et	  al.	  2002),	  and	  in	  human	  cells	  for	  similar	  types	  of	  studies	  (Kim	  et	  al.	  2005;	  Weinmann	  et	  al.	  2002;	  Wells	  et	  al.	  2003).	  	  In	  the	  clinical	  context,	  ChIP-­‐chip	  has	  been	  used	  to	   identify	  novel	  disease	  markers	  and	  potential	   targets	   in	  a	  number	   of	   conditions,	   including	   cancer	   (Ordway	   et	   al.	   2006),	   cardiac	   disease	  (Movassagh	  et	  al.	  2010)	  and	  psychiatric	  disorders	  (Tsankova	  et	  al.	  2007).	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3.1.9.1 An	  overview	  of	  ChIP-­‐chip	  experimental	  design	  	   The	  basic	  design	  of	  a	  ChIP-­‐chip	  experiment	  is	  maintained	  throughout	  the	  applications	   discussed	   above.	   	   Broadly,	   cells	   cultured	   under	   experimental	  conditions	  are	  exposed	  to	  formaldehyde	  to	  fix	  the	  amino	  groups	  of	  proteins	  with	  the	   nitrogen	   atoms	   of	   DNA	   (or	   other	   proteins)	   by	   crosslinking.	   	   Chromatin	   is	  extracted	   and	   fragmented	   through	   sonication	   or	   enzymatic	  means,	   typically	   to	  between	  200	  to	  1000	  nucleotides	  in	  length.	  	  Fragments	  of	  chromatin	  containing	  the	   cross-­‐linked	   protein,	   or	   target	   of	   interest,	   are	   immunoprecipitated	   by	  incubation	  with	   an	   antibody	   to	   the	   target	   (usually	   a	   protein	   or	   experimentally	  designed	   epitope-­‐tagged	   protein	   if	   no	   appropriate	   primary	   antibody	   is	  available),	   and	   antibody	   bound	   fragments	   are	   separated	   from	   the	   undesired	  fraction	   with	   an	   appropriate	   secondary	   antibody	   (e.g.	   Invitrogen	   Dynabead	  system).	  	  	   To	  improve	  the	  accuracy	  of	  the	  assay	  results,	  several	  methods	  of	  internal	  control	  and	  data	  normalisation	  have	  been	  used	  (Adriaens	  et	  al.	  2012).	  	  In	  many	  experiments,	   and	   in	   our	   assay	   DIP-­‐chip,	   an	   input	   (IN)	   sample	   is	   processed	  alongside	  each	   immunoprecipitated	  (IP)	  sample.	   	  An	   IN	  sample	   is	  an	  aliquot	  of	  the	  purified,	  treated	  genomic	  DNA	  that	  has	  been	  taken	  from	  the	  starting	  material	  prior	  immunoprecipitation.	  	  It	  is	  subject	  to	  all	  of	  the	  steps	  in	  the	  assay	  except	  the	  immunoprecipitation	   reaction.	   	   As	   such,	   it	   represents	   both	   the	   background	  variation	   in	  DNA	  quantity	  and	   initial	   fragment	   frequency,	  and	  acts	  as	  a	   control	  for	   non-­‐biological	   variability	   in	   the	   assay	   technique,	   including	   in	   sample	  handling	  and	  differential	  labelling	  and	  PCR	  amplification	  efficiency	  (Adriaens	  et	  al.	  2012).	  	  During	  quantification	  of	  fragments,	  either	  by	  qPCR	  or	  microarray,	  the	  amount	   of	   fragments	   at	   each	   analysed	   locus	   in	   the	   immunoprecipitated	   (IP)	  sample	  is	  divided	  by	  the	  number	  of	  fragments	  at	  that	  locus	  in	  the	  paired	  control	  IN	  sample,	  to	  account	  for	  these	  potential	  sources	  of	  sample	  variability.	  Following	  reversal	  of	  crosslinking,	  proteinase	  treatment	  and	  purification	  (resulting	  in	  naked	  DNA),	  the	  relative	  proportion	  of	  DNA	  fragments	  in	  the	  IP	  and	  IN	   samples	   can	  be	   calculated	  by	  quantitative	  PCR	   (qPCR).	   	  This	   gives	   an	   IP/IN	  ratio	   -­‐	   the	   relative	   amount	   of	   DNA	   in	   both	   samples	   at	   the	   genetic	   region	  immunoprecipitated	   as	   determined	   by	   the	   qPCR	   primers	   used	   in	   the	   reaction.	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By	   comparing	   the	   efficiency	   of	   immunoprecipitation,	   using	   the	   IP/IN	   ratio,	  between	  different	  conditions,	  the	  relative	  effect	  of	  each	  condition	  compared	  to	  a	  reference	  sample	  (typically	  an	  untreated	  sample)	  can	  be	  observed.	  	   This	   phase	   of	   the	   assay	   is	   useful	   in	   its	   own	   right,	   and	  has	   been	  used	   in	  experiments	   as	   a	   ChIP-­‐qPCR	   assay	   (e.g.	   (Hecht	   et	   al.	   1996)).	   	   It	   is,	   however,	  limited	   in	  power	  by	   the	   requirement	   to	  use	  one	  or	   a	   small	   number	  of	   pairs	   of	  PCR	   primers	   to	   generate	   information	   at	   a	   limited	   number	   of	   genetic	   loci.	   	   By	  combining	   ChIP	   experiments	   with	   microarrays	   (and	   more	   recently	   with	   next	  generation	   sequencing	   technology	   (Marinov	   et	   al.	   2014;	   Park	   2009))	   it	   is	  possible	  to	  analyse	  the	  relationship	  between	  IP	  and	  IN	  samples	  at	  thousands,	  or	  millions,	  of	  genetic	  loci	  simultaneously.	  	  DNA	   microarrays	   consist	   of	   short	   oligonucleotide	   fragments	   (probes)	  printed	  onto	  a	  glass	  slide,	  grouped	  into	  ‘features’	  –lithographically	  printed	  spots	  of	   DNA	   on	   the	   slide	   of	   identical	   oligonucleotide	   probes.	   	   The	   application	   of	  differentially	  fluorescently	  labelled	  DNA	  (typically	  the	  IP	  and	  IN	  samples)	  results	  in	   competitive	   hybridisation	   of	   these	   to	   complementary	   probes	   on	   the	   array.	  	  The	  relative	  quantity	  of	  IP	  and	  IN	  samples	  at	  each	  probe	  can	  be	  calculated	  by	  the	  relative	  fluorescence	  at	  each	  feature.	  With	  appropriate	  bioinformatic	  processing	  it	   is	   then	   possible	   to	   produce	   an	   overview	   of	   the	   relative	   levels	   of	  immunoprecipitation	  efficiency,	  which	  is	  a	  reflection	  of	  the	  condition	  of	  interest,	  along	  the	  genome	  at	  high-­‐resolution	  (Figure	  3.1).	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Figure	   3.1:	   An	   overview	   of	   DNA	   microarray	   approach	   to	   immunoprecipitation	   coupled	  
with	  genome-­‐wide	  analysis.	  Hybridisation	   of	   fluorescently	   labelled	  DNA	   fragments	   containing	   the	   immunoprecipitated	  target	   of	   interest	   to	   oligonucleotide	   probes	   on	   a	  microarray	   results	   in	   relative	   changes	   in	  fluorescence	   detected	   on	   the	   microarray	   surface.	   	   After	   bioinformatic	   processing	   the	  changes	  in	  fluorescence	  can	  be	  converted	  to	  calculate	  the	  location	  of	  the	  site	  of	   interest,	  at	  high	  resolution	  and	  on	  a	  genomic	  scale	  (adapted	  from	  (Adriaens	  et	  al.	  2012)).	  	  
3.1.9.2 Modifications	  to	  ChIP-­‐chip	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   The	  advent	  of	  improved	  sequencing	  technology	  over	  the	  past	  decade	  has	  lead	   to	   the	   adoption	   of	   DNA	   sequencing	   as	   a	   viable	   alternative	   method	   for	  genome-­‐wide	  analysis,	   in	  comparison	  to	  microarrays	  (Johnson	  et	  al.	  2007;	  Park	  2009).	   	  ChIP	   followed	  by	  sequencing	   (ChIP-­‐seq)	  offers	   certain	  advantages	  over	  ChIP-­‐chip,	  including	  having	  no	  requirement	  to	  use	  organism	  specific	  microarrays	  with	   a	   spatially	   limited	   number	   of	   potential	   probes,	   and	   a	   reduction	   in	   the	  amount	  of	   starting	  material	   required	   following	   immunoprecipitation.	   	  ChIP-­‐seq	  also	  has	  the	  potential	  advantage	  of	  improved	  resolution	  and	  dynamic	  range,	  and	  an	  improved	  signal-­‐to	  noise	  ratio	  compared	  to	  ChIP-­‐chip,	  resulting	  in	  increased	  sensitivity	   and	   specificity	   for	   binding-­‐site	   detection.	   	   As	   DNA	   sequencing	  technology	   evolves	   these	   advantages	   are	   leading	   to	   rapid	   adoption	   of	   this	  technology	  as	  an	  alternative	  to	  ChIP-­‐chip	  (Ho	  et	  al.	  2011).	  	  	  	  Given	   the	   advantages	   of	   sequencing	   techniques,	   the	   continued	   use	   of	  microarrays	   for	   the	   genomic	   component	   of	   our	   DIP-­‐chip	   assay	   could	   be	  questioned.	   	   However,	   there	   are	   significant	   advantages	   to	   working	   with	  microarrays,	  particularly	  in	  assay	  development	  work.	  	  These	  advantages	  include	  that	   the	   technique	   is	   less	   expensive,	   is	   widely	   available,	   is	   robust,	   is	   well	  established	   with	   a	   clear	   experimental	   workflow,	   and	   the	   bioinformatic	  methodologies	  used	  when	  interpreting	  the	  large	  datasets	  generated	  have	  been	  a	  studied	  for	  over	  a	  decade.	  	  Whilst	  sequencing	  is	  becoming	  the	  optimal	  technique	  to	   analyse	   ChIP	   samples,	   the	   current	   experimental	   and	   discovery	   phase	   of	   the	  platform,	   and	   the	  experience	  our	  group	  has	   in	   the	  microarray	   field,	  make	  DIP-­‐chip	  a	  more	  attractive	  platform	  for	  the	  development	  of	  this	  assay	  at	  the	  current	  time.	  
	  
	  
3.1.9.3 The	  DIP-­‐chip	  assay	  	  	   The	  DIP-­‐chip	  assay	  used	  in	  this	  thesis	  was	  developed	  in	  our	  laboratory	  as	  a	  modification	  of	  ChIP-­‐chip	  technology,	  initially	  through	  adjustment	  to	  detect	  UV	  radiation	   induced	   CPDs	   in	   S.	   cerevisiae	  with	   the	   use	   of	   an	   anti-­‐CPD	   antibody	  (Teng	  et	  al.	  2010).	  	  Recently,	  we	  have	  made	  a	  further	  modification	  to	  use	  an	  anti-­‐
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platinum	   modified	   DNA	   antibody	   to	   immunoprecipitate	   cisplatin-­‐induced	  damage,	   first	   in	   yeast	   and	   then	   in	   human	   cell	   cultures	   (Powell	   2014).	   	   	   An	  overview	  of	  the	  technique	  is	  shown	  in	  figure	  3.2.	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3.1.9.4 The	  development	  of	  the	  DIP-­‐chip	  assay	  for	  the	  detection	  of	  
platinum-­‐DNA	  adducts	  	  
	   When	   a	   novel	   DNA	   adduct	   is	   detected	   using	   an	   alternative	   antibody	  several	   adjustments	   to	   the	   experimental	   pathway	   are	   required	   to	   generate	  reliable	   results.	   	   The	   formation	   of	   platinum-­‐induced	   DNA	   adducts	   results	   in	  conformational	  changes	  to	  the	  DNA.	  	  In	  this	  context,	  compared	  to	  protein	  binding	  experiments,	   the	   requirement	   for	   crosslinking	   of	   chromatin	   is	   removed,	   and	  naked	  DNA	  can	  be	  used	  during	  the	  immunoprecipitation	  –	  hence	  DIP-­‐chip	  rather	  than	  ChIP-­‐chip.	  	  Additionally,	  the	  presence	  of	  platinum-­‐DNA	  adducts	  impairs	  the	  function	   of	   DNA	   polymerases,	   and	   this	   must	   be	   accounted	   for	   in	   the	   assay	  protocol.	  	  For	  example,	  modifications	  to	  remove	  platinum	  adducts	  prior	  to	  qPCR	  are	  required,	  otherwise	  a	  range	  of	  PCR	  efficiency	  between	  fragments	  may	  occur	  dependent	  on	   the	   levels	  of	  DNA	  adducts	  present	  on	  each	   fragment.	   	  This	  could	  result	   in	  different	  amplification	  rates	  during	  PCR,	  and	  as	  a	  consequence	  lead	  to	  inaccurate	   quantification	   of	   the	   DNA	   concentration	   of	   differentially	   treated	  samples.	   	   The	   amplification	   process	   prior	   to	  microarrays	   is	   also	  modified,	   and	  will	  be	  discussed	  in	  detail	  in	  the	  next	  two	  chapters.	  	   	  In	   this	   chapter	   the	   translation	   of	   the	   DIP	   phase	   of	   the	   assay	   from	   a	  research	   tool	   used	   in	   cell	   cultures	   into	   a	   reliable	   technique	   for	   use	   in	   human	  clinical	  samples	  will	  be	  discussed.	  	  The	  samples	  used	  in	  the	  experiments	  outlined	  in	   this	  chapter	  will	  be	  analysed	  by	  qPCR.	   	  The	   following	  chapters,	  4	  and	  5,	  will	  discuss	   the	  microarray	   ‘chip’	  phase	  of	   the	   translation	  of	   this	   tool.	   	  With	   this	   in	  mind,	   two	   other	   pieces	   of	   information	   are	   essential	   for	   consideration	   in	   this	  chapter;	   what	   is	   the	   exact	   target	   of	   the	   immunoprecipitation	   reaction,	   and	   at	  which	   genetic	   locus	   is	   the	   IP/IN	   ratio	   to	   be	   calculated	   by	   qPCR.	   	   In	   the	  experiments	  presented	   in	   this	   thesis	   the	  anti-­‐platinum	  antibody	   is	  CP9/19	  and	  the	  qPCR	  primers	  used	  are	  from	  the	  28S	  genetic	  loci.	  	  The	  details	  of	  both	  will	  be	  discussed	  below.	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3.1.9.5 The	  CP9/19	  Antibody	  	   	  The	   CP9/19	   antibody,	   initially	   developed	   by	   Tilby	   has	   been	   used	   to	  reliably	   detect	   adducts	   from	   cisplatin	   and	   carboplatin	  modified	  DNA	   by	   ELISA	  (Tilby	  et	   al.	   1991).	   	  The	  antibody	   is	   sensitive,	   regardless	  of	  whether	   treatment	  was	  in	  vivo	  or	  in	  vitro,	  with	  low	  background	  binding	  to	  untreated	  DNA,	  and	  with	  demonstrated	   specificity	   for	   carboplatin	   induced	   DNA	   adducts	   in	   addition	   to	  cisplatin	  adducts	  to	  which	  it	  was	  raised.	  	  Further	  experiments	  in	  our	  laboratory	  have	   demonstrated	   that	   the	   antibody	   also	   detects	   oxaliplatin	   induced	   DNA	  damage	  (Powell	  2014).	  	   The	   exact	   epitope	   recognised	   was	   initially	   uncertain	   and	   was	   not	  addressed	  in	  the	  original	  publication,	  although	  the	  poor	  antibody	  recognition	  to	  platinum-­‐DNA	  adducts	  formed	  by	  transplatin	  (which	  fails	  to	  form	  the	  1,2-­‐d(GpG)	  intrastrand	   crosslink)	   indicated	   that	   this	   lesion	   is	   probably	   a	   major	   target.	  	  Further	   evidence	   to	   support	   this	   was	   elucidated	   using	   a	   set	   of	   restricted	  oligonucleotide	  fragments	  as	  targets	  in	  a	  competitive	  ELISA	  (Meczes	  et	  al.	  2005).	  	  These	   results	  demonstrated	   that	   the	  antibody	  acts	  by	   recognition	  of	   crosslinks	  between	  adjacent	  guanines.	  	   Employed	  for	  ELISA	  based	  assays	  predominantly,	  CP9/19	  has	  been	  used	  to	  detect	  platinum-­‐DNA	  adducts	  in	  ovarian	  cancer	  cell	  lines	  (Mellish	  et	  al.	  1995),	  rat	  thymocyte	  (Evans	  et	  al.	  1994),	  Chinese	  Hamster	  Ovary	  cell	  lines	  (De	  Silva	  et	  al.	  2002)	  and	  in	  clinical	  samples	  of	  peripheral	  blood	  mononuclear	  cells	  (Ghazal-­‐Aswad	  et	  al.	  1999;	  Peng	  et	  al.	  1997;	  Veal	  et	  al.	  2001).	   	  All	  of	  these	  experiments	  were	   conducted	   prior	   to	   the	   development	   and	   clinical	   use	   of	   oxaliplatin.	   	   As	  adducts	   formed	  by	  cisplatin	  and	  oxaliplatin	  are	  the	  very	  similar	  (chapter	  1.2.9)	  the	  antibody	  should	  be	  applicable	   for	   the	  detection	  of	  oxaliplatin	  DNA	  damage.	  	  This	   has	   been	   confirmed	   by	   experiments	   conducted	   in	   our	   laboratory	   (Powell	  2014).	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3.1.9.6 The	  28S	  locus	  	   	  Platinum-­‐induced	   DNA	   damage	   is	   predominantly	   specific	   for	   small	  dinucleotide	  sequences,	  but	   there	   is	  no	  evidence	  of	  a	  bias	   for	  different	  parts	  of	  the	  genome	  (see	  chapter	  1	  section	  1.2.5	  -­‐	  1.2.6).	  	  With	  this	  in	  mind,	  the	  selection	  of	  the	  locus	  for	  qPCR	  assessment	  of	  fragments	  enriched	  by	  immunoprecipitation	  is	   to	   some	  extent	   arbitrary,	   although	   the	  genome-­‐wide	  approaches	  used	   in	   the	  subsequent	   chapters	   may	   provide	   greater	   information	   on	   optimum	   sites	   for	  qPCR	  fragment	  quantification.	  	  The	  qPCR	  locus	  chosen	  in	  this	  study	  is	  that	  used	  in	  the	  initial	  development	  work	  in	  our	  laboratory	  (Powell	  2014)	  and	  is	  the	  28S	  locus,	  the	  ribosomal	  28s	  gene,	  present	  in	  5	  regions	  on	  chromosome	  13,	  14,	  15,	  21	  and	  22.	  	  	  There	   are	   advantages	   to	   using	   qPCR	   primers	   to	   a	   gene	   with	   multiple	  genetic	   loci,	   as	   opposed	   to	   primers	   at	   a	   single	   site.	   	   There	   is	   the	   potential	   for	  confounding	   if	   analysing	   at	   a	   single	   qPCR	   locus,	   from	   large-­‐scale	   structural	  variants,	   such	   as	  deletions,	   translocation	   and	   chromosomal	  breakages,	   or	   from	  the	   millions	   of	   insertions	   and	   deletions	   ranging	   from	   1	   to	   10,000	   nucleotides	  occur	   throughout	   the	   human	   genome	   (Mills	   et	   al.	   2011)	   that	   could	   affect	   the	  ability	  of	  the	  assay	  to	  detect	  platinum-­‐DNA	  adducts	  in	  different	  individuals.	  	  The	  absence,	   or	   low	   concentration,	   of	   DNA	   in	   a	   DIP-­‐chip	   sample	  with	   the	   use	   of	   a	  single	   unique	   PCR	   locus	   may	   reflect	   natural	   genetic	   variability,	   rather	   than	  differences	  in	  platinum-­‐DNA	  adduct	  levels	  between	  individuals.	   	  The	  multi-­‐locus	  nature	  of	  the	  ribosomal	  28S	  gene	  offers	  a	  degree	  of	  redundancy	  to	  counter	  this,	  whilst	   retaining	   the	   same	   sequence	   characteristics,	   and	   hence	   likely	   platinum-­‐DNA	  adduct	  levels,	  in	  the	  same	  individual	  at	  each	  specific	  28S	  locus.	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 Aims	  of	  this	  chapter	  3.2
	   The	  DIP-­‐chip	  assay	  developed	   in	  our	   laboratory	  has	  been	  used	  to	  detect	  patterns	   of	   platinum-­‐DNA	   adduct	   formation	   in	   human	   cell	   culture	   conditions.	  	  The	  assay	  may	  be	  of	  benefit	  as	  a	  predictive	  tool	  for	  the	  response	  and	  toxicity	  of	  platinum	  agents,	  as	  discussed	  above.	  	  	  For	  use	  in	  human	  clinical	  samples	  the	  assay	  has	  to	  be	  translated	  to	  detect	  adducts	   on	   patient	   samples.	   	   It	   can	   be	   used	   initially	   as	   a	   DIP-­‐qPCR	   assay	   to	  measure	   adduct	   levels	   at	   the	   28S	   genetic	   locus,	   analogous	   to	   a	   functional	  approach	  to	  platinum-­‐DNA	  adduct	  measurements	  similar	  to	  the	  study	  on	  NSCLC	  patients	  conducted	  by	  Wang	  (Wang	  et	  al.	  2011),	  as	  discussed	  in	  section	  3.1.6.	  	  If	  a	  consistent	   DIP-­‐qPCR	   assay	   output	   can	   be	   obtained	   showing	   reproducible	  measurement	   of	   induced	   platinum-­‐DNA	   adducts	   using	   qPCR,	   then	   this	   would	  provide	   confidence	   that	   these	   samples	   might	   be	   used	   reliably	   for	   patient	  stratification	  and	  downstream	  genomic	  approaches	   to	  measure	  damage	  at	  high	  resolution	   in	  multiple	   loci	   using	  DIP-­‐chip	   approaches,	  where	   the	   signatures	   of	  the	  response	  to	  the	  drug	  may	  be	  detected.	  	   The	  experiments	  described	   in	   this	   chapter	  will	  outline	   the	  experimental	  approaches	  and	  evidence	  obtained	  to	  translate	  the	  methods	  used	  in	  yeast	  and	  in	  human	  cell	   cultures	   into	  a	  method	  applicable	   to	  clinical	  samples	   in	   the	   form	  of	  human	  fresh	  blood	  samples,	  using	  PBMC	  as	  a	  surrogate	  tissue	  to	  measure	  ex	  vivo	  generated	  adducts	  to	  oxaliplatin.	  	   The	  experiments	  outlined	  below	  are	  used	  to	  generate	  consistent	  samples	  to	   use	   in	   a	   DIP-­‐qPCR	   assay	   and	   allow	   further	   development	   using	   genomic	  technologies	  outlined	  in	  the	  following	  chapters.	   	  The	  first	  stage	  of	  this	  aspect	  of	  the	   project	   is	   to	   demonstrate	   the	   ability	   to	   affinity-­‐capture	   oxaliplatin-­‐DNA	  adducts	   in	  ex	  vivo	   treated	  PBMC,	   as	   confirmed	  by	  demonstrating	   an	   increasing	  ratio	  of	  DNA	  fragments	  between	  untreated	  and	  treated	  samples	  using	  qPCR.	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3.2.1 Methods	  
	  
	   The	  methods	  used	  in	  the	  experiments	  in	  this	  chapter	  are	  briefly	  discussed	  in	  each	  section.	  	  For	  full	  details	  of	  the	  methods	  used	  see	  chapter	  2.	  	  Note	  that	  the	  DIP-­‐chip	   protocol	   in	   chapter	   2	   is	   the	   final	   version,	   incorporating	   the	   protocol	  modifications	  and	  amendments	  discussed	  in	  this	  chapter.	  	  
3.2.2 An	  overview	  of	  the	  initial	  DIP-­‐chip	  workflow	  	  	  	   For	   context,	  when	   considering	   the	   protocol	   amendments	   examined	   and	  described	   in	   this	   chapter,	   the	   initial	   DIP-­‐chip	   workflow	   developed	   to	   detect	  platinum-­‐DNA	  adduct	  patterns	  in	  human	  cell	  cultures	  will	  be	  described	  here.	  	  It	  is	  this	  protocol	  that	  is	  modified	  in	  the	  experiments	  described	  below.	  	  The	   cells	   used	   for	   DIP-­‐chip	   human	   cell	   culture	   experiments	   were	  AG16409	  human	  dermal	  fibroblast	  cells,	  grown	  in	  DMEM	  media	  containing	  10%	  foetal	  calf	  serum,	  L-­‐glutamine	  and	  1%	  penicillin	  and	  streptomycin	  and	  incubated	  at	  37°C	  and	  5%	  CO2.	  	  Prior	  to	  treatment,	  cells	  were	  grown	  to	  80%	  confluence	  on	  tissue	  culture	  plates,	  media	  was	  removed	  and	  DMEM	  was	  added	  (without	  foetal	  calf	   serum,	   l-­‐glutamine	   or	   penicillin/streptomycin).	   	   Oxaliplatin	   and	   cisplatin	  were	  added	   to	   these	  cultures	   to	  a	   final	   concentration	  of	  2.5mM.	   	  After	  4	  hours	  incubation,	   cells	   were	   treated	   with	   trypsin	   for	   30	   minutes	   before	   the	   media	  (containing	   all	   cellular	   material)	   was	   transferred	   to	   a	   15ml	   sterile	   tube	   and	  centrifuged.	   	   The	   media,	   containing	   cytotoxic	   waste,	   was	   removed	   and	   safely	  disposed	  of.	  	  The	  cell	  pellet	  was	  washed	  twice	  in	  PBS	  before	  a	  final	  re-­‐suspension	  in	  200µL	  PBS	  prior	  to	  DNA	  extraction.	  	   DNA	  was	  extracted	  using	   the	  Qiagen	  DNeasy	  Blood	  and	  Tissue	  Kit	  using	  the	  manufacturers	  standard	  protocol,	  into	  a	  final	  elution	  volume	  of	  200µL	  buffer.	  	  Samples	  were	  sonicated	  at	  4°C	  using	  a	  Bioruptor	  Sonicator	   (Diagenode)	   for	  24	  cycles	   of	   30	   seconds	   off/30	   seconds	   on	   high	   power	   setting,	   resulting	   in	   an	  average	  fragment	  length	  of	  200bp.	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A	  total	  of	  6µg	  sonicated	  DNA	  was	  used	  as	  the	  starting	  material	  for	  the	  DIP	  phase	   of	   the	   assay.	   	   	   A	   mixture	   of	   1.5µg	   CP9/19	   (Abcam)	   antibody	   and	   40µl	  sheep	   anti-­‐rat	   Dynabeads	   (Invitrogen)	   per	   experimental	   sample	   were	   pre-­‐incubated	  for	  30	  minutes,	  before	  combining	  with	  the	  6µg	  sonicated	  of	  DNA	  per	  sample.	   	  After	  a	  3-­‐hour	  incubation,	  the	  bead	  mixture	  was	  washed	  several	  times	  to	   remove	   unbound,	   or	   weakly	   bound,	   DNA	   fragments.	   	   The	   final	   pool	   of	  immunoprecipitated	  DNA	   fragments	  were	   eluted	   from	   the	   antibody/Dynabead	  sample	   and	   treated	   overnight	   with	   pronase,	   and	   subsequently	   with	   RNase,	   to	  remove	   any	   residual	   protein	   or	  RNA	   contamination.	   	   This	   immunoprecipitated	  sample	  is	  the	  IP	  sample.	  An	  internal	  control	  input	  (‘IN’)	  sample	  containing	  600ng	  of	   sonicated	   DNA	   is	   treated	   overnight	   with	   pronase,	   then	   RNase	   A,	   and	   is	  processed	  in	  parallel	  during	  the	  remainder	  of	  the	  DIP-­‐chip	  assay	  	   To	   remove	   platinum	   adducts	   from	   the	   DNA	   fragments,	   the	   IP	   and	   IN	  sample	  were	   incubated	   at	   65°C	   for	   2	   hours	   in	   a	   final	   concentration	   of	   0.2mM	  NaCN.	   	  The	  DNA	  samples	  were	  purified	  by	  phenol/chloroform	  purification	  and	  ethanol	  precipitation	  before	  a	  final	  suspension	  of	  the	  IP	  and	  IN	  fragment	  pools	  of	  DNA	  fragments	  in	  15µl	  PCR	  grade	  H2O.	  	  DNA	  in	  the	  post	  immunoprecipitation	  sample	  was	  quantified	  by	  qPCR	  to	  determine	   the	   DNA	   concentration	   in	   paired	   IP	   and	   IN	   samples	   between	  experimental	   conditions,	  using	  a	  CFX-­‐connect	  Real-­‐Time	  PCR	  Detection	  System	  (Bio-­‐Rad),	  iTAQ	  universal	  SYBRgreen	  supermix,	  and	  primers	  for	  the	  28S	  genetic	  locus.	  	  The	  DNA	  amount	  in	  the	  paired	  IP	  and	  IN	  samples	  are	  used	  to	  calculate	  the	  IP/IN	  ratio	  for	  each	  pair	  of	  samples	  -­‐	  the	  proportion	  of	  DNA	  fragments	  that	  have	  been	  immunoprecipitated	  in	  each	  experimental	  condition,	  as	  an	  indication	  of	  the	  relative	  adduct	  levels	  generated	  in	  the	  DNA	  for	  each	  treatment	  level.	   	  The	  qPCR	  result	  is	  primarily	  used	  as	  a	  quality	  control	  step	  for	  the	  DIP	  stage	  of	  the	  assay.	  	  It	  can	   be	   used	   to	   demonstrate	   successful	   immunoprecipitation	   by	   comparing	   the	  IP/IN	   ratio	   in	   treated	   and	   untreated	   samples,	   and	   the	   IP/IN	   ratio	   can	   be	  compared	   between	   identical	   samples	   to	   give	   an	   indication	   of	   the	   assay	  reproducibility.	  	  
	   113	  
	   Following	  quantification	  of	  DNA	  amounts	  in	  the	  IP	  and	  IN	  samples	  at	  the	  28S	  loci,	   the	  samples	  are	  prepared	  for	  microarray	  analysis	  –	  the	   ‘chip’	  phase	  of	  the	  assay.	  	  The	  paired	  IP	  and	  IN	  samples	  are	  amplified	  to	  generate	  adequate	  DNA	  for	  microarray	   hybridisation	   (a	  minimum	   of	   500ng).	   	   This	   is	   performed	   using	  whole	  genome	  PCR-­‐based	  amplification	  (WGA-­‐PCR)	  using	  the	  WGA2	  kit	  (Sigma)	  using	  16	  cycles	  of	  PCR,	  and	  otherwise	  conducted	  according	  to	  the	  manufacturers	  protocol.	   	   The	   amplified	   fragments	   are	   labelled	  with	   a	  different	   fluorophore	   in	  the	  IN	  and	  IP	  DNA	  fragments	  using	  the	  BioPrime	  Total	  Genomic	  Labelling	  System	  (Invitrogen)	  following	  the	  manufacturers	  standard	  protocol.	  	  Following	  this,	  the	  labelled	   DNA	   fragments	   are	   hybridised	   to	   a	   custom	   DNA	   microarray	   (Agilent	  Technologies	  G4497A)	  using	  the	  Agilent	  Technologies	  aGCH	  protocol.	   	  The	  DNA	  fragments	   hybridise	   to	   complementary	   DNA	   probes	   on	   the	   microarray	   slide	  surface.	  	   Following	  hybridisation	   the	  microarray	   slides	   are	   scanned	   to	   reveal	   the	  relative	   proportion	   of	   fragments	   from	   the	   IP	   and	   IN	   sample	   at	   each	   cluster	   of	  probes.	   	   The	   scanner	   uses	   a	   laser	   of	   appropriate	   wavelength	   to	   excite	   the	  fluorophore	  labelled	  DNA	  and	  detect	  emitted	  light,	  in	  this	  way	  it	  can	  measure	  the	  relative	   intensity	   of	   fluorescence	   at	   each	   probe	   cluster	   between	   the	   IP	   and	   IN	  samples.	   	  The	  data	   is	  processed	  to	  generate	  a	  plot	  of	   the	  relative	   IP/IN	  ratio	  at	  each	   probe	   position	   along	   the	   section	   of	   the	   genome	   represented	   on	   the	  microarray	   slide.	   	   This	   is	   a	   measure	   at	   each	   probe	   position	   of	   the	   relative	  immunoprecipitation	  efficacy	  as	  the	  result	  of	  the	  adduct	  levels	  at	  that	  region	  of	  the	   genome.	   	   A	   typical	   output	   from	   the	   DIP-­‐chip	   assay	   for	   the	   detection	   of	  cisplatin-­‐DNA	   adducts	   in	   fibroblast	   cell	   cultures	   after	   treatment	   with	   2500µM	  cisplatin	  is	  shown	  as	  an	  example	  below	  (figure	  3.3).	  	  The	  IP/IN	  ratio	  is	  plotted	  on	  the	   y-­‐axis,	   typically	   as	   the	   log2	   of	   the	   value	   to	   compress	   the	   extremes	   of	   the	  possible	  range	  of	  data.	  	  In	  this	  plot	  scale,	  a	  value	  of	  1	  represents	  equal	  fragment	  numbers	  in	  the	  IP	  and	  IN	  samples.	  	  On	  the	  x-­‐axis	  the	  probe	  position	  is	  plotted	  as	  a	  grey	  dot	  in	  the	  lower	  axis	  and	  the	  genomic	  location	  is	  plotted	  on	  the	  upper	  x-­‐axis.	   	  This	  builds	  up	   to	   represent	   the	  pattern	  of	   adducts	  present	   in	   the	   sample	  along	  the	  genome.	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Figure	  3.3:	  A	  cisplatin-­‐DNA	  adduct	  DIP-­‐chip	  assay	  output	  A	  DIP-­‐chip	  assay	  output	  from	  two	  cisplatin	  treated	  dermal	  fibroblast	  samples	  in	  cell	  culture.	  	  Probes	   over	   a	   5Mb	   region	   of	   chromosome	   17	   are	   present	   on	   the	   custom	   microarray.	  	  Hybridisation	   of	   differentially	   labelled	   IP	   and	   IN	   DNA	   samples	   results	   changes	   to	   the	  relative	   fluorescence	   at	   each	   probe	   detected	   during	   scanning,	   reflecting	   the	   relative	  immunoprecipitation	   efficacy	   as	   a	   consequence	   of	   platinum-­‐DNA	   adduct	   levels	   at	   each	  probe	   site.	   The	   IP/IN	   ratio	   value	   at	   each	   probe	   is	   calculated	   and	   plotted	   at	   all	   the	   probe	  regions	   in	   a	   circos	   plot	   (A),	   with	   the	   genomic	   position	   along	   chromosome	   17	   as	   labelled,	  giving	   an	   indication	   of	   the	   adduct	   pattern	   along	   the	   whole	   dataset.	   	   (B)	   shows	   a	   short	  section.	  The	   log2	  IP/IN	  is	  plotted	  on	  the	  y-­‐axis	  as	  the	  damage	   level	  at	  each	  probe	  position,	  shown	  by	  the	  grey	  dot	  in	  the	  lower	  x-­‐axis.	   	  The	  upper	  x-­‐axis	  shows	  the	  genomic	  location	  of	  the	  probes.	   	  Two	  biological	  repeat	  samples	  are	  shown	  in	  B,	  with	  a	  close	  match	  between	  the	  adduct	  patterns	  over	  this	  section	  of	  the	  genome	  (Powell	  2014).	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3.2.3 Sources	  of	  clinical	  samples	  used	  in	  these	  studies	  
	  
	   For	  the	  assay	  development	  work	  presented	  in	  this	  chapter	  blood	  samples	  will	  be	  the	  clinical	  material	  used.	  	  This	  reflects	  the	  common	  use	  of	  blood	  samples	  in	   platinum-­‐DNA	   adduct	   studies,	   and	   the	   ease	   of	   obtaining	   and	   using	   these	  samples.	   	   Specifically,	   blood	   cells	   with	   nuclear	   DNA	   are	   required	   for	   adduct	  analysis	   -­‐	   the	   fraction	  containing	  peripheral	  blood	  mononuclear	  cells	   (PBMC)	  –	  which	   can	   be	   separated	   from	   the	   whole	   blood	   sample	   by	   density	   gradient	  centrifugation.	   	  The	  blood	  samples	   in	   this	  study	  are	  obtained	   from	  two	  healthy	  volunteers	   in	   the	   laboratory	   (labelled	   patients	   A,	   B)	   or	   are	   obtained	   from	  donations	  from	  the	  Welsh	  Blood	  Service	  following	  ethical	  approval	  for	  the	  use	  of	  these	  tissues	  for	  research	  purposes	  (application	  WBS	  Ad-­‐hoc	  008-­‐12).	   	  Samples	  from	   the	   Welsh	   Blood	   Service	   consist	   of	   a	   single	   donor	   unit	   of	   450ml	   whole	  blood	   with	   the	   majority	   of	   erythrocytes,	   plasma	   and	   platelets	   removed	   for	  clinical	   purposes	  prior	   to	  delivery.	   	  As	   such,	   they	   are	   a	   concentrated	   source	  of	  PBMC	  cells	  and	  once	  diluted	   in	  phosphate	  buffered	  saline	  can	  be	  subject	   to	  the	  same	   density	   gradient	   centrifugation	   procedure	   as	   whole	   blood	   samples	   (see	  chapter	  2,	  section	  2.1).	  	  	  	  
 Results	  3.3
	  
3.3.1 Confirmation	  of	  successful	  sample	  processing	  and	  DNA	  extraction
	   	  
	   To	   confirm	   successful	   sample	   preparation	   and	   handling	   using	   the	  protocol	  for	  PBMC	  separation,	  extraction	  and	  treatment	  in	  cell	  culture	  conditions	  using	  the	  protocol	  described	   in	  chapter	  2	  section	  2.1,	   five	  repeat	  samples	  were	  taken	  from	  one	  individual	  of	  20ml	  blood	  and	  PBMC	  were	  harvested.	  	  The	  amount	  collected	  is	  shown	  in	  figure	  3.4	  (panel	  A),	  and	  is	  in	  the	  range	  expected	  for	  these	  types	  of	  procedures	  of	  0.8	  to	  3	  million	  PBMC	  per	  ml	  of	  whole	  blood	  (Njai	  et	  al.	  2011),	   confirming	   the	   protocol	   is	   appropriate	   for	   PBMC	   harvest	   from	   these	  clinical	  samples.	  	  Following	  separation,	  these	  PBMC	  were	  cultured	  in	  RPMI-­‐1640	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without	   the	   addition	   of	   serum	   or	   antibiotics,	   with	   or	   without	   the	   addition	   of	  oxaliplatin.	   	   These	   conditions	  were	   chosen	   as	   they	   are	   the	   treatment	   protocol	  used	   for	   cell	   culture	   experiments	   on	   human	   dermal	   fibroblasts	   in	   the	  development	  work	  of	  the	  DIP-­‐chip	  assay	  (Powell	  2014).	  	  	  Following	   treatment	   with	   oxaliplatin	   (at	   variable	   doses)	   DNA	   was	  extracted	   using	   the	   DNeasy	   Blood	   and	   Tissue	   Kit	   (Qiagen)	   following	   the	  manufacturers	   protocol	   and	   quantified	   using	   a	   Nanodrop-­‐1000	  spectrophotometer.	   	  The	  results,	   figure	  3.4(B)	  are	  the	  average	  of	  untreated	  and	  treated	  samples	  for	  each	  of	  the	  5	  independent	  experiments.	  	  The	  average	  of	  these	  two	   conditions	   is	   used	   as	   there	   is	   no	   significant	   difference	   in	   untreated	   and	  treated	  sample	  yield	  in	  these	  experiments.	  
	  
	  
Figure	  3.4:	  Successful	  PBMC	  sample	  processing	  and	  DNA	  extraction.	  (A)	   Following	   the	   protocol	   outlined	   in	   chapter	   2,	   section	   2.1,	   PBMC	  were	   harvested	   from	  20ml	  whole	  blood	  samples	  and	  5	  sequential	  occasions	  from	  the	  same	  individual.	   	  The	  yield	  of	   PBMC	   in	   each	   of	   5	   independent	   experiments	   is	   shown.	   	   The	   normal	   range	   is	  demonstrated	  by	  the	  grey	  dotted	  lines	  (Njai	  et	  al.	  2011).	  (B)	   Following	   culture	   with,	   or	   without,	   the	   addition	   of	   oxaliplatin	   and	   a	   variable	   time	   to	  recover	   after	   treatment,	   DNA	   was	   extracted	   using	   Qiagen	   DNeasy	   Blood	   and	   tissue	   kit	  following	  the	  manufacturers	  protocol.	  	  DNA	  quantity	  was	  calculated	  using	  a	  Nanodrop-­‐1000	  spectrophotometer.	   	   The	   mean	   and	   SEM	   of	   4-­‐6	   samples	   from	   each	   of	   5	   sequential	  independent	  experiments	  is	  shown.	  
	   The	  PBMC	  yield	  per	  20mls	  of	   fresh	  blood	   is	  within	   the	  normal	   range	   in	  each	   of	   5	   sequential	   experiments,	   indicated	   by	   the	   grey	   dashed	   lines,	   and	  evidence	   that	   the	   PBMC	   isolation	   protocol	   is	   suitable	   (Figure	   3.4	   A).	   	   In	   a	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standard	   fibroblast	   cell	   culture	   DIP	   experiment	   6.6µg	   of	   DNA	   per	   sample	   is	  required	  and	  the	  average	  yield	  of	  DNA	  per	  ml	  of	  blood	  is	  in	  the	  range	  of	  0.47	  to	  1.27µg	   over	   5	   sequential	   independent	   experiments.	   	   This	   translates	   to	   a	  minimum	  blood	  volume	  to	  obtain	  adequate	  DNA	  for	  immunoprecipitation	  of	  14.4	  ml	  per	   experimental	   condition.	   	   In	   view	  of	   this,	   the	  DIP-­‐chip	  protocol	   requires	  modification	   to	   ensure	   enough	   DNA	   is	   available	   for	   downstream	   processing	  during	   the	  assay	  and	   to	  maximise	   the	  DNA	  yield	  per	  ml	  of	  blood	  sample.	   	  This	  would	   give	   the	   greatest	   scope	   for	   development	   experiments,	   to	   maximise	   the	  number	  of	  experimental	   conditions	   that	  can	  be	  studied	   in	  each	  clinical	   sample,	  and	   minimise	   the	   volume	   of	   blood	   required	   from	   patients	   when	   the	   DIP-­‐chip	  assay	  is	  used	  in	  the	  clinical	  setting.	  	   Nevertheless,	  these	  results	  indicate	  that	  the	  first	  step	  in	  the	  translation	  of	  the	   DIP-­‐chip	   assay	   is	   working,	   and	   that	   PBMC	   can	   be	   successfully	   harvested,	  treated	  and	  DNA	  extracted	  for	  use	  in	  the	  immunoprecipitation	  reaction.	  
	  
3.3.2 Analysis	  of	  initial	  DIP	  protocol	  for	  variability	  	  For	  use	  as	  a	  clinical	  assay	  to	  stratify	  patients	  prior	  to	  chemotherapy,	  and	  for	  use	  in	  complex	  treatment	  decisions	  with	  significant	  consequences,	  the	  assay	  must	  be	  reliable	  and	  reproducible.	   	  Consistent	   results	  and	   low	  variability	  must	  be	   demonstrated	   before	   for	   it	   to	   be	   validated	   for	   clinical	   use,	   and	  would	   give	  confidence	  for	  the	  sample	  to	  be	  taken	  on	  for	  genome-­‐wide	  microarray	  analysis.	  	  A	  commonly	  used	  measure	  of	  laboratory	  assay	  variability	  for	  the	  assessment	  of	  quantitative	  assays	  is	  the	  coefficient	  of	  variance	  (CV),	  calculated	  by	  dividing	  the	  standard	  deviation	  by	  the	  mean	  of	  a	  number	  of	  repeat	  experiments,	  expressed	  as	  a	   percentage	   (Reed	   et	   al.	   2002).	   	   This	   has	   the	   advantage	   of	   normalising	   the	  standard	  deviation	   for	   the	  magnitude	  of	   the	  mean	   and	   allows	   a	   comparison	  of	  variability	  between	  assays.	  	  For	  a	  typical	  laboratory	  assay	  the	  standard	  deviation	  of	  repeat	  measurements	  on	  the	  same	  sample	  should	  be	  less	  than	  5%	  of	  the	  mean	  of	   an	   assay	   result,	   giving	   a	   CV	   of	   <5%.	   	   A	   CV	   of	   10%	   or	   more	   is	   considered	  variable	  and	  over	  20%	  is	  a	  clinically	  unreliable	  assay	  (Burd	  2010).	   	  In	  our	  case,	  the	  DIP-­‐qPCR	  result	  is	  not	  the	  final	  assay	  output,	  as	  the	  sample	  will	  be	  applied	  to	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microarrays	   for	   genome-­‐scale	   platinum-­‐DNA	   adduct	   analysis,	   rather	   than	  used	  as	  an	  assay	  of	   the	   level	  of	  adducts	  at	  a	   single	   locus.	   	  This	  affords	  an	  additional	  opportunity	  beyond	  the	  qPCR	  stage	  for	  further	  data	  processing,	  using	  the	  greater	  scale	   of	   genomic	   data	   to	   reduce	   the	   variability	   in	   the	   final	   result	   (as	   will	   be	  demonstrated	  in	  chapter	  5,	  section	  5.6).	  	  In	  this	  context,	  a	  high	  CV	  result	  for	  qPCR	  from	  DIP	  samples	  does	  not	  render	  the	  DIP-­‐chip	  assay	  non-­‐viable.	  	  Nevertheless,	  the	   DIP-­‐qPCR	   output	   is	   an	   important	   measure	   of	   the	   consistency	   of	   the	  immunoprecipitation	   ‘DIP’	   step	  of	   the	  assay,	   and	   the	  CV	  provides	  a	   robust	   and	  widely	   used	   metric	   to	   quantify	   improvements	   in	   assay	   variability	   that	   can	   be	  potentially	  be	  made	  through	  modifications	  to	  the	  experimental	  protocol.	  	  	  	  	  To	   calculate	   the	   CV	   of	   the	   DIP	   assay	   a	   series	   of	   independent	  experiments	  using	  blood	   samples	   from	  patient	  A	  and	  B	  were	   treated	   following	  the	  protocol	  and	  by	  the	  method	  outlined	  -­‐	  directly	  adapted	  from	  the	  human	  cell	  culture	   development	   experiments.	   	   Briefly,	   following	   harvesting	   and	   washing,	  cultured	   PBMC	   were	   incubated	   for	   4	   hours	   in	   serum	   free	   media	   containing	  oxaliplatin	  at	  1mM,	  before	  either	  immediate	  DNA	  extraction	  or	  culture	  in	  media	  containing	   10%	   foetal	   calf	   serum,	   penicillin/streptomycin	   and	   L-­‐glutamine	   at	  37°C	   and	   5%	  CO2	   for	   either	   24	   or	   48	   hours	   before	  DNA	   extraction.	   	   DNA	  was	  sonicated,	  immunoprecipitated	  and	  purified	  and	  analysed	  following	  the	  standard	  fibroblast	   DIP-­‐chip	   method	   outlined	   above.	   	   The	   results	   of	   several	   repeat	  experiments	  are	  shown	  in	  figure	  3.5	  and	  the	  CV	  is	  calculated	  for	  5	  repeats	  from	  patient	   B	   in	   table	   3.1.	   	   Due	   to	   technical	   failure	   of	   the	   assay	   with	   two	   of	   the	  exponential	  conditions	  for	  patient	  A,	  insufficient	  data	  is	  available	  to	  calculate	  the	  CV	  for	  this	  individual,	  except	  for	  at	  the	  24-­‐hour	  time	  point.	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Figure	  3.5:	  Analysis	  of	  initial	  DIP	  protocol	  for	  variability.	  Several	   independent	   repeat	   DIP	   experiments	   were	   conducted	   according	   to	   the	   standard	  protocol	  and	  treated	  with	  1mM	  oxaliplatin	  for	  4	  hours	  following	  PBMC	  harvest	  and	  culture	  (section	  4.3.1).	  	  The	  result	  of	  the	  DIP	  assay	  is	  displayed	  as	  the	  relative	  change	  in	  IP/IN	  ratio	  calculated	  by	  qPCR	  with	  primers	  for	  28S	  loci.	  	  The	  results	  are	  normalised	  to	  the	  IP/IN	  ratio	  in	   the	  untreated	  sample.	   	  3	   independent	   consecutive	   repeats	   from	  patient	  A	  and	  5	   repeats	  from	  patient	  B	  are	  displayed.	  	  Due	  to	  experimental	  failure	  two	  samples	  from	  patient	  A	  were	  not	  processed	  (indicated	  by	  N/P).	  	  
	  
Table	  3.1:	  PBMC	  DIP	  result	  variability	  calculation	  The	  IP/IN	  ratio	  normalised	  to	  the	  untreated	  sample	  for	  5	   independent	  consecutive	  repeats	  of	   the	   DIP	   assay	   for	   patient	   B	   is	   used	   for	   this	   table.	   	   The	   mean,	   standard	   deviation	   and	  coefficient	  of	  variance	  (CV)	  are	  calculated	  for	  each	  time-­‐point.	  	  
	   These	   results	   highlight	   two	   main	   features	   of	   the	   use	   of	   PBMC	   samples	  with	  this	  experimental	  protocol.	   	  Firstly,	  the	  level	  of	  induced	  damage	  detectible	  


















































Repeat 1: Patient A 1mM 4 hrs
Repeat 2: Patient A 1mM 4 hrs
Repeat 3: Patient A 1mM 4 hrs




































































































Repeat 1: Patient B 1mM 2hrs
Repeat 2: Patient B 1mM 4hrs
Repeat 3: Patient B 1mM 4hrs
Repeat 4: Patient B 1mM 4hrs
Repeat 5: Patient B 1mM 4hrs



















































































































































































Time%post%exposure% Mean% Standard%Devia4on% Coeﬃcient%of%Variance%
Untreated% 1% <% <%
0%hours% 12.6% 9.9% 78.4%%
24%hours% 25.6% 36.7% 143.5%%
48%hours% 26.7% 22.9% 85.1%%
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by	   DIP-­‐qPCR	   when	   these	   cells	   are	   treated	   at	   1mM	   oxaliplatin	   for	   4	   hours	   in	  serum	  free	  media	  is	  relatively	  low	  -­‐	  the	  relative	  enrichment	  in	  all	  but	  one	  of	  the	  results	  obtained	  at	  time	  0	  (directly	  after	  treatment)	  is	  in	  the	  order	  of	  5-­‐10	  times	  the	   amount	   of	   DNA	   immunoprecipitated	   in	   the	   untreated	   sample.	   	   This	  demonstrates	  poor	  discrimination	  between	  treated	  and	  untreated	  samples	  when	  using	  this	  schedule	  of	  oxaliplatin	  treatment.	  	  In	  comparable	  studies	  with	  dermal	  fibroblasts	   cultures	   in	   the	   development	   stages	   of	   this	   work	   the	   enrichment	  immediately	  after	  treatment	  is	  in	  the	  order	  of	  50-­‐100	  fold	  (Powell	  2014).	  	   This	   difference	   could	   reflect	   a	   relative	   platinum	   resistance	   of	   PBMC	  compared	   to	   dermal	   fibroblasts.	   	   The	   dose	   used	   in	   the	   fibroblast	   experiments	  was	  in	  the	  order	  of	  2.5mM,	  so	  is	  significantly	  higher,	  although	  the	  effect	  on	  cell	  function	  and	  cell	   survival	  was	  not	  assessed.	   	  The	   time	  scale	  of	  exposure	   is	  also	  relatively	   short,	   given	   that	   the	   platinum	   agents	   initially	   form	   mono-­‐adducts,	  before	  forming	  di-­‐adducts	  over	  several	  hours	  (Chapter	  1,	  section	  1.2.6)	  the	  true	  value	  of	  an	  immediate	  time	  point	  post	  exposure	  is	  questionable.	  	  It	  is	  notable	  24	  hours	  after	   exposure	   in	  all	   experiments	  a	   significantly	   increased	  enrichment	   is	  demonstrated	   compared	   to	   immediately	   post	   exposure,	   although	   this	   too	   is	  highly	  variable.	  	   Another	   obvious	   finding	   is	   that	   there	   is	   significant	   variability	   in	   results	  generated	  using	   this	  protocol,	  with	   the	  5	   repeats	  of	   individual	  B	  having	  a	  high	  degree	  of	  variation	  in	  the	  outcome,	  which	  is	  also	  shown	  in	  the	  three	  repeats	  with	  individual	  A.	  	  The	  calculated	  CV	  from	  the	  5	  independent	  repeats	  from	  patient	  B	  is	  between	  80-­‐140%,	  indicating	  that	  the	  standard	  deviation	  similar	  in	  magnitude	  to	  the	  mean,	  and	  that	  the	  results	  are	  highly	  variable.	  	  A	  typical	  laboratory	  assay	  has	  a	   CV	   of	   <5%,	   and	   10%	   is	   considered	   a	   high	   degree	   of	   assay	   variation	   (Burd	  2010).	   	   Although	   this	   could	   be	   explained	   by	   the	   outlying	   abnormal	   result	   in	  Patient	  B	  repeat	  3	  (Figure	  3.4),	  Patient	  A	  has	  a	  CV	  of	  60%	  on	  the	  24	  hour	  sample	  (calculation	   not	   shown)	   confirming	   high	   assay	   variability	   between	   the	   same	  patient	  repeat	  samples.	  	   As	  discussed	  above,	  the	  qPCR	  quantification	  of	  the	  DIP	  stage	  of	  the	  assay	  is	   intended	   as	   a	   confirmation	   of	   the	   success	   of	   immunoprecipitation	   and	   as	   a	  quality	   control	   step,	   rather	   than	   as	   an	   output	   for	   patient	   stratification,	   so	   a	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proportion	  of	   the	  variability	  seen	  here	  will	  be	  reduced	   through	   the	  microarray	  processing	  and	  by	  using	  properties	  of	  the	  genomic	  scale	  of	  the	  resulting	  data	  to	  identify	  and	  remove	  experimental	  noise	  from	  the	  system,	  as	  will	  be	  discussed	  in	  chapter	  5.	  	  The	  use	  of	  CV,	  in	  this	  context,	  is	  to	  quantify	  the	  variability	  at	  this	  stage	  of	   the	   assay	   and	   when	   the	   assay	   is	   conducted	   using	   the	   assay	   protocol	   as	  developed	   in	  cell	  culture	  system,	  notably	  with	  standardised	  conditions	  that	  are	  inherently	   less	   achievable	  with	   clinical	   samples.	   	   Even	  with	   these	   caveats,	   it	   is	  clear	   that	   the	  DIP	  stage	  of	   the	  assay	   requires	   further	   study	   to	   identify	  areas	  of	  high	  variability	  and	  to	  improve	  the	  protocol	  to	  reduce	  variability	  demonstrated	  here,	  and	  quantified	  using	  the	  assay	  CV	  metric.	  	  	  
	  
3.3.3 Identification	  of	  assay	  stages	  with	  high	  variability	  
	   	  The	   variability	   seen	   in	   the	   previous	   experiment	   could	   have	   a	   biological	  component	   –	   for	   example	   due	   to	   variability	   in	   PBMC	   responses	   to	   oxaliplatin	  during	  the	  several	  weeks	  over	  which	  the	  experiment	  was	  conducted.	   	  However,	  there	   is	   also	   likely	   to	   be	   a	   component	   of	   technical	   variation	   in	   the	   assay.	   	   To	  investigate	   the	   relative	   contributions	   of	   biological	   and	   technical	   variability	   on	  the	   DIP	   assay,	   a	   single	   large	   pooled	   sample	   of	   DNA	   extracted	   from	   oxaliplatin	  treated	   PBMC	   was	   used	   for	   multiple	   repeat	   experiments.	   	   DNA	   was	   obtained	  from	  several	  identical	  aliquots	  of	  PBMC	  harvested	  from	  a	  single	  blood	  donation.	  	  The	   PBMC	   were	   treated	   in	   identical	   conditions	   with	   three	   dose	   levels	   of	  oxaliplatin	  for	  a	  24	  hour	  incubation	  to	  increase	  the	  generated	  levels	  of	  adducts.	  	  Once	  extracted,	  DNA	  from	  replicates	  at	  the	  same	  dose	  level	  was	  combined	  to	  give	  a	  large	  pool	  of	  identical	  DNA	  for	  each	  dose	  point.	  	  	  DNA	  samples	  from	  each	  oxaliplatin	  dose	  (Untreated,	  100µM,	  500µM	  and	  1mM)	  was	   then	   immunoprecipitated	  on	   three	   separate	  occasions	   to	  determine	  technical	  variability,	  as	  opposed	  to	  biological	  differences	  in	  the	  starting	  material.	  	  Each	  replicate	  was	  then	  analysed	  by	  qPCR	  in	  triplicate,	  to	  give	  nine	  assay	  outputs	  for	   each	   dose	   level.	   	   Any	   variability	   demonstrated	   should	   be	   due	   to	   technical	  variation	   in	   the	   immunoprecipitation	   reaction	   and	   from	   the	   qPCR	   step,	   rather	  than	  due	  to	  biological	  differences.	  	  The	  contribution	  of	  the	  variability	  of	  the	  assay	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for	   each	   can	   then	  be	   identified.	   	   The	   results	   are	   shown	  below	   for	   the	  1000µM	  sample,	   which	   is	   representative	   of	   the	   results	   at	   each	   dose	   level	   and	   used	   for	  illustration	  of	  assay	  variability	  (figure	  3.6)	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and	   intra-­‐qPCR	  variation	   is	  reduced	  by	  using	  an	  on-­‐plate	  standards	  and	  an	  on-­‐plate	  untreated	  sample).	  	  The	  same	  sample	  (IP	  1-­‐3)	  is	  also	  run	  on	  3	  sequential	  qPCR	  quantifications	  (qPCR	  1	  to	  3).	  	  For	  each	  IP	  sample,	  the	  IP/IN	  ratios	  are	  higher	  on	  the	  third	  qPCR	  compared	   to	   the	   first	   –	   with	   almost	   a	   2-­‐fold	   increase	   in	   IP	   sample	   1.	   	   This	  indicates	   high	   between-­‐plate	   variability	   exists	  with	   the	   qPCR	   quantification	   of	  the	   DIP-­‐chip	   assay	   and	   is	   also	   a	   source	   of	   variability	   in	   the	   DIP	   assay	   result.	  	  	  Both	  the	  immunoprecipitation	  step	  and	  the	  qPCR	  step	  are	  resulting	  in	  technical	  variation	   that	   would	   result	   in	   more	   consistent	   DIP	   output	   if	   the	   variability	   is	  decreased.	  
	  
 Modifications	  to	  the	  experimental	  protocol	  	  3.4
3.4.1 Adjustment	  to	  tissue	  culture	  and	  oxaliplatin	  treatment	  conditions	  	   	  The	   above	   experiment	   demonstrates	   that	   the	   experimental	   protocol	  requires	   significant	   modifications	   with	   several	   goals	   in	   mind.	   	   Firstly,	  modifications	  are	  required	  to	  increase	  the	  ability	  of	  the	  immunoprecipitation	  to	  discriminate	  between	  treatment	  doses	  by	  enhancing	  the	   IP/IN	  ratio,	   increasing	  the	  mean	  enrichment	  compared	  to	  the	  experimental	  error.	  	  This	  can	  be	  achieved	  by	   a	   second	   modification	   to	   improve	   the	   biological	   relevance	   of	   the	   assay	   by	  using	   a	   more	   biologically	   and	   pharmacokinetically	   representative	   treatment	  schedule,	   reflecting	   that	   the	  dose	  of	  oxaliplatin	   in	  patients	   remains	   constant	   in	  ultra-­‐filterable	  plasma	  for	  24	  hours	  after	  treatment	  and	  that	  oxaliplatin-­‐DNA	  di-­‐adducts	  may	  take	  many	  hours	  to	  from	  the	  initial	  mono-­‐adducts	  induced	  (chapter	  1,	   section	  1.2.5),	  making	   the	   changes	  detected	  with	  a	   short	  duration	   treatment	  and	  immediate	  DNA	  extraction	  problematic.	  	  Thirdly,	  with	  a	  longer	  incubation	  time	  the	  protocol	  requires	  modification	  to	   add	   appropriate	   media	   supplements	   of	   serum	   and	   antibiotics.	   	   Serum	  starvation,	   even	   over	   a	   short	   period,	   results	   in	   changes	   to	   gene	   expression,	  metabolism,	   and	   induction	   of	   autophagy	   of	   non-­‐essential	   cellular	   components	  (Chen	  et	  al.	  2014;	  Golpour	  et	  al.	  2014).	   	  Consistent	  use	  of	  supplemented	  media	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reduces	  the	  potential	  confounding	  effects	  from	  the	  use	  of	  serum-­‐free	  media	  and	  possible	  effects	  of	  serum	  starvation	  on	  the	  PBMC	  population.	  	  	  	  
3.4.2 Changes	  to	  oxaliplatin	  dose	  and	  incubation	  time	  
	   To	   predict	   for	   a	   response	   to	   treatment	   in	   DIP-­‐chip	   clinical	   samples	   it	  could	   be	   argued	   that	   the	   ex	   vivo	   treatment	   schedule	   should	   reflect	   as	   far	   as	  possible	  the	  exposure	  that	  the	  tumour	  and	  normal	  tissues	  will	  be	  exposed	  to	   in	  
vivo.	  	  During	  chemotherapy	  treatment,	  the	  pharmacokinetic	  studies	  discussed	  in	  chapter	  1,	  section	  1.2.2	  show	  the	  that	  the	  dose	  of	  oxaliplatin	  given	  to	  a	  patient	  in	  free	  filterable	  plasma	  is	  in	  the	  order	  of	  3µM	  to	  5µM,	  and	  this	  level	  remains	  for	  24	  hours.	   In	  order	  to	  mimic	  more	  closely	  the	  treatment	  schedule	  of	  patients,	  and	  to	  make	   any	   results	   generated	  more	   accurate,	   a	  modified	   treatment	   regimen	  was	  adopted.	   Once	   collected	   by	   density	   gradient	   centrifugation,	   PBMC	   were	  incubated	  in	  RPMI-­‐1640	  with	  the	  addition	  of	  10%	  foetal	  calf	  serum,	  l-­‐glutamine	  and	  penicillin/streptomycin	  for	  30	  minutes	  at	  37°C	  and	  at	  5%	  CO2,	  prior	  to	  the	  addition	  of	  cytotoxic	  agents.	  	  Samples	  were	  either	  untreated,	  or	  treated	  with	  the	  addition	  of	  different	  doses	  of	  cisplatin	  or	  oxaliplatin.	   	  After	  24	  hours	  incubation	  the	  drug	  was	   removed,	   the	  cells	  washed	   twice	   in	  PBS,	   and	  DNA	  was	  extracted.	  	  Using	  this	  approach	  any	  information	  derived	  from	  the	  experiment	  should	  more	  accurately	  reflect	  the	  conditions	  for	  treating	  patients.	  Using	  this	  new	  treatment	  schedule	  and	  unchanged	  extraction,	  sonication,	  immunoprecipitation,	   purification	   and	   qPCR	   downstream	  processing	   the	   IP/IN	  result	   generated	   from	   these	   samples,	   referenced	   to	   an	   untreated	   sample	   are	  shown	  in	  figure	  3.7.	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Figure	  3.7:	  Demonstrating	  the	  effect	  of	  changes	  to	  oxaliplatin	  dose	  and	  incubation	  time.	  PBMC	  harvested	  from	  the	  same	  blood	  sample	  are	  treated	  with	  differing	  doses	  of	  oxaliplatin	  in	  RPMI-­‐1640	  with	  or	  without	  the	  addition	  of	  serum	  supplements,	  and	  for	  4	  hours	  duration	  compared	  to	  24	  hours.	  	  The	  IP/IN	  ratio	  in	  each	  sample	  is	  normalised	  to	  an	  untreated	  sample	  and	  the	  mean	  and	  SEM	  of	  three	  independent	  experiments	  are	  shown.	  	  	  	  	   This	   result	   demonstrates	   that	   the	   detectable	   adduct	   levels	   (the	   relative	  increase	   in	   IP/IN	   ratio	   as	   a	   measure	   of	   the	   increase	   in	   immunoprecipitated	  fragments	   compared	   to	   the	   baseline	   IN	   sample,	   normalised	   to	   an	   untreated	  sample)	   are	   significantly	   increased	   compared	   to	   the	   original	   4	   hour	   drug	  exposure	   in	   media	   without	   serum,	   improving	   the	   ability	   of	   the	   assay	   to	  discriminate	  between	  dose	  levels	  following	  treatment.	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biologically	  relevant	  if	  the	  experimental	  process	  results	   in	  significant	  metabolic	  effects	  or	  high	  levels	  of	  cell	  death.	  	  The	  addition	  of	  propidum	  iodide	  (PI)	  to	  a	  cell	  population	  fluorescently	  labels	  non-­‐viable	  cells,	  as	  viable	  cells	  are	  impermeable	  to	   the	  molecule.	   	   The	   cell	   population	   can	  be	   sorted	   in	  PI	  positive	   and	  negative	  populations	  using	  flow	  cytometer	  (in	  this	  instance	  an	  Accuri	  C6	  flow	  cytometer	  was	  used),	  giving	  an	  accurate	  indication	  of	  cell	  survival	  in	  the	  PBMC	  population.	  	  Using	   the	   treatment	   schedule	   outlined	   in	   section	   3.4.2,	   including	   the	   24-­‐hour	  oxaliplatin	   incubation	   period,	   the	   following	   cell	   survival	   results	  were	   obtained	  (Figure	  3.8)	  and	  the	  combined	  results	  of	  three	  repeated	  experiments	  are	  shown	  below	  (Figure	  3.9).	  	  
	  









	   127	  
	  
Figure	  3.9:	  The	  survival	  of	  PBMC	  populations	  treated	  with	  oxaliplatin	  in	  cell	  culture.	  The	   survival	   of	   PBMC	   populations	   treated	  with	   oxaliplatin	   in	   cell	   culture	   for	   24	   hours	   as	  assessed	   by	   flow	   cytometry	   (Figure	   3.8)	   is	   shown	   relative	   to	   the	   untreated	   sample.	   	   The	  mean	  and	  SEM	  of	  three	  repeats	  is	  displayed.	  	  	  	   These	   results	   demonstrate	   that	   about	   80%	   of	   the	   cells	   are	   viable	  following	  processing	   in	  both	   the	  untreated	  sample	  and	  at	   the	  10µM	  oxaliplatin	  dose.	  	  Therefore,	  the	  plasma	  concentration	  of	  3-­‐5µM	  oxaliplatin	  found	  in	  patients	  during	   chemotherapy	   treatment	   is	   unlikely	   to	   result	   in	   increased	   rates	   of	  circulating	  PBMC	  in	  vivo.	  Increasing	  the	  oxaliplatin	  exposure	  to	  100µM	  and	  1000µM	  increases	  the	  rate	  of	  cell	  death	  in	  the	  PBMC	  population	  compared	  to	  the	  untreated	  and	  10µM	  (and	   hence	   compared	   to	   the	   in	   vivo	   clinical	   dose).	   	   Although	   this	   introduces	  potential	  differences	   in	   the	  biological	  behaviour	  of	  our	  ex	  vivo	  assay	  PBMC	  and	  the	  in	  vivo	  patient	  situation,	  the	  higher	  doses	  are	  required	  to	  generate	  sufficient	  oxaliplatin-­‐DNA	   adducts	   to	   enable	   differences	   between	   the	   dose	   points	   to	   be	  reproducibly	  detected	  by	   immunoprecipitation	  (figure	  3.7).	   	  As	  these	  doses	  are	  requires,	   the	   effect	   is	   unavoidable;	   the	   discrepancy	   is	   noted,	   and	   the	   effect	   of	  higher	  rates	  of	  cell	  death	  at	  the	  high	  dose	  levels	  will	  be	  considered	  as	  a	  potential	  confounding	   factor	   throughout	   the	   on-­‐going	   experiments	   to	   optimise	   the	   DIP-­‐chip	  assay	  for	  clinical	  applications.	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3.4.4 Standardising	  supply	  and	  storage	  of	  oxaliplatin	  and	  cisplatin	  	  To	  maximise	  reproducibility	  of	  the	  assay	  prior	  to	  use	  on	  clinical	  samples,	  the	   treatment	   with	   oxaliplatin	   and	   cisplatin	   must	   be	   standardised.	   	   	   Initial	  experiments	   were	   conducted	   on	   donations	   of	   oxaliplatin	   from	   the	   local	  chemotherapy	  pharmacy,	  each	  of	  varying	  age	  and	  shelf	  life.	  	  These	  samples	  were	  stored	   at	   4°C,	   and	   have	   been	   used	   for	   several	   months	   for	   initial	   validation	  experiments	   and	   development	   studies.	   	   	   To	   ensure	   consistency	   of	   supply,	  oxaliplatin	   and	   cisplatin	   were	   commercially	   obtained	   (Abcam),	   stored	   as	   a	  powder	  at	  4°C,	  and	  suspended	  in	  DMSO	  immediately	  prior	  to	  use,	  as	  suggested	  in	  the	  accompanying	  product	  information.	  	   To	   confirm	   the	   reproducibility,	   reliability	   and	   comparability	   to	  previous	  results	   obtained	   with	   the	   pharmacy	   supplied	   reagents,	   the	   level	   of	   adducts	  detectable	   by	   treatment	  with	   cisplatin	   and	   oxaliplatin	   in	   both	   the	   legacy	   stock	  (cisplatin	  stored	  for	  6	  months	  at	  4°C)	  and	  the	  fresh	  supply	  of	  powdered	  drugs	  in	  DMSO	  (0.4%	  final	  concentration)	  were	  assessed	  on	  a	  sample	  of	  PBMC	  obtained	  from	  the	  Welsh	  Blood	  Service	  from	  a	  single	  donor.	  	  The	  results	  are	  shown	  below	  (Figure	  3.10).	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The	   result	   of	   this	   experiment	   demonstrates	   the	   expected	  pattern	   of	   2-­‐3	  fold	   increase	   in	   adducts	   with	   fresh	   cisplatin	   compared	   to	   fresh	   samples	   of	  oxaliplatin,	   and	   comparable	   adduct	   generation	   between	   the	   two	   fresh	  formulations	  of	   oxaliplatin.	   	  The	  older	   stock	  of	   cisplatin	   generates	   significantly	  fewer	  adducts,	  highlighting	  the	  issue	  of	  inconsistent	  drug	  batches	  and	  an	  effect	  of	  drug	   storage	   on	   the	   potential	   variability	   of	   assay	   results,	   unless	   fresh	   drug	   is	  made	  and	  stored	  appropriately	  before	  each	  experiment.	  	  In	  the	  pharmacy,	  a	  fresh	  vial	  of	  platinum	  stock	  is	  used	  for	  each	  patient	  and	  then	  discarded.	   	   In	  our	  case,	  although	  all	  stock	  was	  used	  within	  the	  documented	  shelf	  life	  of	  the	  vial,	  as	  only	  microliter	   volumes	   were	   required	   for	   each	   experiment	   a	   single	   vial	   was	   used	  multiple	   times	   over	   the	   course	   of	   several	   months.	   	   One	   each	   occasion	   sterile	  technique	  was	  maintained,	  but	  the	  potential	  for	  contamination	  of	  the	  vial	  cannot	  be	  discounted.	  	  Each	  time	  a	  sterile	  needle	  was	  used	  to	  pierce	  the	  vial	  seal	  to	  gain	  access	  to	  the	  drug,	  so	  an	  alternative	  explanation	  is	  the	  possible	  breakdown	  of	  the	  seal	   with	   multiple	   needle	   tracks,	   resulting	   in	   a	   portal	   for	   the	   entry	   of	   air,	  moisture	  and	  contaminants	  that	  could	  affect	  the	  quality	  of	  the	  drug	  over	  time.	  	  
3.4.5 Optimising	  DNA	  extraction,	  condition	  and	  sample	  purity	  
	   Downstream	   applications	   of	   DIP-­‐qPCR	   and	   DIP-­‐chip	   require	   significant	  amounts	  of	  DNA	  at	  high	  purity,	  free	  from	  protein	  and	  RNA	  contamination;	  over	  95%	  of	   intra-­‐cellular	  platinum	  is	  bound	  to	  macromolecules	  other	   than	  DNA,	  so	  contamination	   is	   potentially	   a	   cause	   of	   significant	   confounding	   and	   assay	  variability.	   	   The	   benefit	   of	   improving	   the	   DNA	   yield	   from	   limited	   volumes	   of	  whole	   blood	   are	   obvious,	   and	   are	   especially	   relevant	   in	   a	   clinical	   assay	   -­‐	  maximising	   the	   number	   of	   experimental	   conditions	   that	   can	   be	   studied,	  minimising	  patient	  inconvenience	  and	  allowing	  repeat	  experiments	  if	  a	  technical	  failure	  occurs.	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3.4.5.1 Assessment	  of	  DNA	  yield	  and	  quality	  	  The	   experiments	   described	   to	   data	   use	   the	   same	   PBMC	   amount	   per	  treatment	  condition	  (~5	  million	  PBMC).	  	  At	  higher	  doses	  of	  oxaliplatin	  exposure	  of	  1mM	  for	  24	  hours	  cell	  survival	  falls	  to	  50%	  -­‐	  with	  a	  fixed	  amount	  of	  cells	  prior	  to	  treatment	  this	  could	  result	  in	  a	  reduction	  in	  DNA	  yield	  with	  increasing	  doses	  of	  platinum	  drugs.	  	  Using	  the	  treatment	  conditions	  outlined	  above,	  PBMC	  from	  a	  single	   donor	   were	   exposed	   in	   three	   replicate	   experiments	   to	   oxaliplatin.	   	   The	  DNA	  yield	  at	  the	  end	  of	  the	  DNA	  extraction	  step	  was	  quantified	  with	  a	  Nanodrop-­‐1000	  spectrophotometer	  and	  is	  shown	  below	  (Figure	  3.11)	  and	  the	  DNA	  quality	  was	  assessed	  by	  gel	  electrophoresis	  (Figure	  3.12).	  	  
	  
Figure	  3.11:	  Quantifying	  DNA	  yield	  following	  sample	  processing	  and	  DNA	  extraction.	  PBMC	  from	  a	  single	  donor	  were	  treated	  with	  oxaliplatin	  at	  varying	  doses	  for	  24	  hours	  in	  cell	  culture	   prior	   to	   DNA	   extraction.	   	   The	   DNA	   amount	   is	   quantified	   by	   Nanodrop-­‐1000	  spectrophotometer	  and	  adjusted	  to	  DNA	  yield	  per	  107	  PBMC	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Figure	  3.12:	  Assessing	  the	  quality	  of	  the	  extracted	  DNA.	  	  The	  DNA	   extracted	   from	  PBMC	   treated	  with	   varying	   doses	   of	   oxaliplatin	   is	   run	   on	   a	   0.8%	  TAE	  gel.	  	  	  These	   experiments	   reveal	   that	   the	   lower	   survival	   of	   PBMC	   with	   1mM	  oxaliplatin	  is	  associated	  with	  a	  decrease	  in	  extractable	  DNA	  following	  treatment	  and	  that	  the	  DNA	  extracted	  is	  degraded	  and	  of	  poor	  quality	  compared	  to	  lower-­‐dose	   samples.	   	   As	   apoptosis	   is	   the	   primary	  mechanism	   of	   cell	   death	   following	  platinum-­‐DNA	   adduct	   formation	   (see	   chapter	   1	   section	   1.3)	   it	   is	   the	   likely	  explanation	  for	  the	  shearing	  of	  genomic	  DNA	  seen	  in	  this	  result.	  	  The	  degradation	  of	  the	  extracted	  DNA	  at	  increased	  oxaliplatin	  doses	  could	  have	  an	  impact	  on	  the	  reliability	  of	  the	  DIP	  assay	  and	  suggests	  that	  increasing	  the	  dose	  of	  drug	  further	  could	  have	  an	  adverse	  impact	  on	  assay	  performance.	  	  
3.4.5.2 Optimising	  DNA	  extraction	  conditions	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splitting	   the	   cells	   into	   increasing	   fractions	   for	   processing	   and	   performing	   a	  second	  elution	  step,	  changes	  in	  obtainable	  DNA	  yield	  are	  shown	  in	  figure	  3.13.	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Figure	  3.14:	  Measuring	  the	  effect	  on	  DNA	  yield	  of	  optimising	  the	  DNA	  extraction	  process.	  The	   DNA	   yield	   per	   5	  million	   PBMC	   following	   the	   DNA	   extraction	   protocol	   of	   splitting	   cell	  pools	  50/50	  prior	   to	  extraction	  and	  eluting	   the	  resulting	  DNA	  twice	  with	  a	  second	  volume	  of	  100µL.	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purified	  using	  PureLink	  PCR	  Purification	  Kit	  (Invitrogen)	  prior	  to	  reanalysis	  for	  purity.	  	  The	  results	  are	  shown	  in	  figure	  3.15.	  	  
	  
Figure	  3.15:	  Improving	  DNA	  quality	  prior	  to	  immunoprecipitation.	  30	   treated	  PBMC	   cultures	   of	   5	  million	   cells	  were	   treated	   and	  DNA	  was	   extracted	  with	   the	  Qiagen	  DNeasy	  Blood	  and	  Tissue	  Kit.	  	  Protein	  and	  RNA	  contamination	  was	  measured	  with	  a	  Nanodrop-­‐1000	  spectrophotometer.	  	  A	  260/280	  ratio	  of	  1.8	  and	  260/230	  ranges	  of	  2	  to	  2.2	  are	  considered	  pure	  DNA.	  	  	  
	   In	   the	   pre-­‐purification	   samples	   significant	   contamination	   can	   be	   seen,	  shown	  by	  the	  wide	  ranges	  of	  260/280	  and	  260/230	  ratios	  displayed.	  	  Following	  purification	  with	  Pure	  Link	  PCR	  DNA	  Purification	  kit	  (Invitrogen)	  the	  ratios	  are	  highly	  homogenous,	  indicating	  that	  the	  DNA	  for	  downstream	  processes	  is	  free	  of	  protein	  and	  RNA	  contamination.	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amount	  compared	  to	  the	  starting	  sample	  to	  calculate	  the	  amount	  of	  DNA	  lost	  per	  procedure.	   	   The	   relative	   change	   in	   yield	   of	   DNA	   due	   to	   purification	   is	   shown	  below	  in	  figure	  3.16.	  	  	  	  
	  
Figure	  3.16:	  Quantifying	  the	  effect	  of	  purification	  on	  DNA	  yield.	  The	  loss	  of	  DNA	  if	  purification	  is	  added	  to	  the	  protocol	  pre	  or	  post	  sonication	  is	  shown.	  14	  samples	   are	   analysed	   pre-­‐sonication	   and	   21	   samples	   purified	   post-­‐sonication.	   	   The	  mean,	  IQR	  and	  outliers	  are	  shown.	  	  	  	  	   Clearly,	  the	  addition	  of	  a	  purification	  step	  post	  sonication	  results	  in	  pure	  DNA	  with	   improved	   yield.	   	   These	  modifications	   result	   in	   a	   good	   yield	   (Figure	  3.14)	   of	   high	  quality	  DNA	   compared	   to	   the	   initial	   protocol	   used	   at	   the	   start	   of	  these	  experiments.	  	  High	  quality	  DNA	  is	  then	  available	  for	  sonication	  and	  use	  in	  the	  immunoprecipitation	  reaction.	  	  
3.4.6 Optimisation	  of	  sonication	  conditions	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(Liu	  et	   al.	   2007).	   	  Evidently,	   to	  minimise	   systematic	  variability	   in	  both	   the	  DIP	  and	   the	   DIP-­‐chip	   assay	   between	   sample	   replicates	   and	   between	   different	  treatment	   conditions	   the	   sonication	   phase	   has	   to	   be	   carefully	   controlled	   and	  highly	  reproducible	  between	  all	  samples.	  During	   the	  DIP-­‐chip	   assay	  development	  work	  a	  protocol	  was	  developed	  for	   sonication	   of	   naked	   human	   DNA	   using	   a	   Diagenode	   Bioruptor	   Sonicator	  system	  for	  30	  seconds	  on/30	  seconds	  off,	  with	  a	  starting	  DNA	  amount	  of	  200µl	  total	   volume	  and	   a	   concentration	  of	   100ng/µl.	   	   The	   samples	   are	   cooled	   to	  4°C	  and	  with	  4	  samples	  per	  carousel	  for	  each	  sonication	  experiment.	  	  This	  results	  in	  an	  average	  fragment	  length	  of	  200bp	  (Powell	  2014).	  	  	  There	  are	  several	  issues	  with	  the	  translation	  of	  this	  phase	  of	  the	  protocol	  for	   use	   in	   these	   clinical	   samples.	   Optimisation	   of	   the	   yield	   of	   DNA	   extraction	  results	   in	   a	   final	   volume	   of	   300µl,	   rather	   than	   200µL.	   	   The	   extra	   50%	  volume	  may	  have	  an	  effect	  on	  the	  efficiency	  and	  consistency	  of	  sonication.	  	  The	  extracted	  DNA	   concentration	   can	   also	   vary	  widely	   in	   clinical	   samples,	   in	   contrast	   to	   the	  high	   concentrations	   available	   from	   batching	   of	   large	   numbers	   of	   cell	   culture	  experiments.	   	  A	  concentration	  of	  between	  100ng/µL	  and	  30ng/µL	  is	  typical	   for	  the	   PBMC	   extraction	   experiments	   described	   so	   far,	   reflecting	   the	   variability	   in	  yield	  as	  a	  consequence	  of	  treatment	  effect	  (Figure	  3.11)	  and	  purification	  (Figure	  3.15).	   	   This	   variation	   in	   DNA	   concentration	   could	   also	   have	   an	   impact	   on	   the	  consistency	  of	  sonication.	  	  Additionally,	  in	  the	  interests	  of	  efficiency,	  with	  many	  samples	  processed	  in	  parallel	  to	  reduce	  error,	  it	  is	  optimal	  to	  use	  6	  tubes	  rather	  than	  4	  per	  cycle,	  maximising	  workflow.	  	  The	  impact	  of	  these	  factors	  is	  uncertain	  and	  may	  result	  in	  unequal	  or	  variable	  fragment	  length	  following	  sonication.	  To	  measure	  the	  effect	  of	  these	  variables	  on	  sonication	  reproducibility	  and	  fragment	  length	  distribution,	  an	  experiment	  was	  conducted	  using	  70	  samples	  of	  DNA	   extracted	   using	   the	   modification	   discussed	   in	   the	   above	   experiments,	  resulting	  in	  varying	  DNA	  concentration	  between	  33	  ng/µL	  and	  100	  ng/µL.	  	  The	  samples	   are	   untreated,	   treated	  with	   oxaliplatin,	   or	   treated	  with	   cisplatin.	   	   The	  number	  of	  sonication	  cycles,	  number	  of	  tubes	  per	  sonication,	  DNA	  concentration	  was	   varied	   to	   measure	   the	   effects	   on	   sonication	   consistency.	   	   Following	  sonication	   the	   samples	   were	   analysed	   using	   a	   TapeStation	   2200	   (Agilent	  Technologies)	  a	  tool	  for	  simultaneous	  gel	  electrophoresis	  of	  multiple	  samples	  to	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measure	   and	   quantify	   the	   fragment	   distribution.	   	   Data	   was	   recorded	   for	   the	  shortest	   5%,	   followed	   by	   the	   25%,	   50%,	   75%	   and	   95%	   fragment	   lengths,	  quantifying	   the	   distribution	   of	   DNA	   in	   each	   sample	   with	   increasing	   cycles	   of	  sonication.	   	  The	   results	   are	  analysed	   to	  demonstrate	   the	  effect	  of	   varying	  DNA	  concentration,	  adduct	  type,	  cycle	  number	  and	  tubes	  per	  reaction	  in	  the	  following	  figures	  (Figure	  3.17	  to	  3.19)	  	  
	  
Figure	   3.17:	   Determining	   the	   effect	   of	   variation	   in	   sonication	   parameters	   on	   the	  
consistency	  of	  DNA	  fragmentation.	  A	   demonstration	   of	   several	   DNA	   fragment	   profiles	   following	   sonication	  with	   a	   Diagenode	  Bioruptor	  Sonicator,	  30	  seconds	  on/30	  seconds	  off,	  at	  4°C.	  	  The	  mean	  fragment	  length,	  25%	  and	   75%	   are	   shown	   in	   the	   central	   box	   and	   the	   distribution	   of	   the	   5%	   and	   95%	   longest	  fragments	   is	   shown	   by	   the	   whiskers.	   	   The	   increasing	   number	   of	   cycles	   of	   20,	   25	   and	   30	  results	   in	   a	   tighter	   distribution	   of	   fragment	   levels,	  with	   the	   central	   50%	  of	   the	   fragments	  between	   300	   bp	   and	   500	   bp	   in	   most	   samples	   and	   90%	   of	   the	   fragments	   (5%	   to	   95%)	  between	   100	   and	   900	   bp	   after	   30	   cycles.	   	   The	   distribution	   is	   more	   variable	   with	   fewer	  cycles.	   	   There	   is	   no	   effect	   of	   DNA	   concentration	   on	   sonication	   performance	   as	   fragment	  distribution	  profiles	  do	  not	  change	  with	  DNA	  concentration	  (33ng/µl	  -­‐	  light	  grey,	  66ng/µl	  –	  grey,	  100ng/µl	  –	  dark	  grey)	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Figure	   3.18:	   Determining	   the	   effect	   of	   variation	   in	   sonication	   parameters	   on	   the	  
consistency	  of	  DNA	  fragmentation.	  A	   demonstration	   of	   several	   DNA	   fragment	   profiles	   following	   sonication	  with	   a	   Diagenode	  Bioruptor	  Sonicator,	  30	  seconds	  on/30	  seconds	  off,	  at	  4°C.	  	  The	  mean	  fragment	  length,	  25%	  and	   75%	   are	   shown	   in	   the	   central	   box	   and	   the	   distribution	   of	   the	   5%	   and	   95%	   longest	  fragments	   is	   shown	   by	   the	   whiskers.	   	   The	   increasing	   number	   of	   cycles	   of	   20,	   25	   and	   30	  results	  in	  a	  tighter	  distribution	  of	  fragment	  length,	  with	  the	  central	  50%	  of	  the	  fragments	  by	  amount	   concentrated	   between	   300	   bp	   and	   500bp	   in	   most	   samples	   and	   90%	   of	   the	  fragments	  (5%	  to	  95%)	  between	  100	  and	  900	  bp	  after	  30	  cycles.	   	  The	  distribution	   is	  more	  variable	  with	  fewer	  cycles.	   	  There	   is	  no	  effect	  of	  adduct	  type	  on	  sonication	  performance	  as	  fragment	   distribution	   profiles	   do	   not	   change	   with	   adduct	   type	   (cisplatin	   –	   light	   grey,	  oxaliplatin	  –	  grey,	  untreated	  –	  dark	  grey)	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Figure	   3.19:	   Determining	   the	   effect	   of	   variation	   in	   sonication	   parameters	   on	   the	  
consistency	  of	  DNA	  fragmentation.	  A	   demonstration	   of	   several	   DNA	   fragment	   profiles	   following	   sonication	  with	   a	   Diagenode	  Bioruptor	  Sonicator,	  30	  seconds	  on/30	  seconds	  off,	  at	  4°C.	  	  The	  mean	  fragment	  length,	  25%	  and	   75%	   are	   shown	   in	   the	   central	   box	   and	   the	   distribution	   of	   the	   5%	   and	   95%	   longest	  fragments	   is	   shown	   by	   the	   whiskers.	   	   The	   increasing	   number	   of	   cycles	   of	   20,	   25	   and	   30	  results	   in	  a	  tighter	  distribution	  of	   fragment	   lengths,	  with	  the	  central	  50%	  of	  the	  fragments	  by	   amount	   concentrated	   between	   300	   bp	   and	   500bp	   in	   most	   samples	   and	   90%	   of	   the	  fragments	  (5%	  to	  95%)	  between	  100	  and	  900	  bp	  after	  30	  cycles.	   	  The	  distribution	   is	  more	  variable	  with	  fewer	  cycles.	  	  There	  is	  no	  effect	  of	  the	  number	  of	  tubes	  per	  sonication	  (4	  vs.	  6)	  on	  sonication	  performance	  as	   fragment	  distribution	  profiles	  do	  not	  change	  at	  30	  cycles,	  or	  with	  DNA	  concentration	  (33ng/µl	  -­‐	  light	  grey,	  66ng/µl	  –	  grey,	  100ng/µl	  –	  dark	  grey)	  	  
	   	  These	   data,	   displayed	   in	   Figures	   3.17	   to	   3.19	   demonstrate	   that	   there	   is	  high	  variability	  in	  the	  effect	  of	  sonication	  at	  20	  and	  25	  cycles.	  	  However,	  with	  an	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increasing	  number	  of	  sonication	  cycles	  to	  30	  the	  distribution	  fragments	  becomes	  highly	  consistent.	  	  The	  median	  fragment	  length	  is	  400bp	  and	  the	  central	  50%	  of	  the	  fragments	  are	  within	  +/-­‐200bp,	  and	  90%	  of	  the	  fragments	  between	  150	  and	  900	  base	  pairs.	  Furthermore,	  the	  sonication	  is	  consistent	  and	  unaffected	  by	  DNA	  concentration	  (Figure	  3.17)	  adduct	  type	  (Figure	  3.18)	  or	  using	  4	  or	  6	  tubes	  per	  sonication	  (Figure	  3.19).	  	   The	  protocol	  used	  in	  cell	  cultures	  needs	  to	  be	  modified	  to	  30	  cycles	  from	  24,	   as	   in	   these	   experiments	   25	   cycles	   results	   in	   significant	   heterogeneity	   in	  fragment	   distribution.	   	   This	   is	   likely	   to	   be	   a	   consequence	   of	   increasing	   the	  sample	  volume	  prior	  to	  sonication,	  as	  necessary	  to	  optimise	  the	  DNA	  yield	  from	  precious	   clinical	   samples	   compared	   to	   unlimited	   availability	   in	   cell	   culture	  models.	  	  
3.4.7 Optimisation	  of	  immunoprecipitation	  consistency	  
3.4.7.1 Calculation	  of	  DNA	  amounts	  for	  immunoprecipitation	  	   The	  amount	  of	  DNA	  typically	  used	  for	  a	  DIP	  experiment	  for	  detecting	  DNA	  damage	   is	   6µg,	   as	   determined	   from	   the	   experiments	   used	   in	   the	   assay	  development	   (Powell	   2014;	   Teng	   et	   al.	   2010).	   	   This	   amount	   of	   DNA	   in	   the	  immunoprecipitation	   reaction	   results	   in	   adequate	   amounts	   of	   precipitated	  template	   DNA	   being	   available	   post-­‐immunoprecipitation	   for	   downstream	  applications	  during	  the	  DIP-­‐chip	  process.	  	  If	  possible,	  using	  less	  DNA	  per	  reaction	  would	   increase	   the	  number	   of	   experiments	   that	   could	  be	   conducted	  with	   each	  clinical	   sample.	   	  However,	  using	   less	  DNA	  could	   influence	   the	  variability	  of	   the	  assay,	   and	   potentially	   could	   have	   a	   significant	   impact	   on	   reproducibility	   if	   it	  reduces	   the	   available	   template	   for	   DNA	   amplification,	   required	   to	   generate	  adequate	  material	   for	  microarray	  analysis	  during	   the	  chip	  experiment	  –	   it	  may	  then	   require	   further	   cycles	   of	   PCR	   with	   increases	   in	   the	   inherent	   bias	   of	   this	  process.	  	  To	  explore	  these	  effects,	  an	  experiment	  was	  conducted	  to	  assess	  the	  effect	  of	  reducing	  the	  amount	  of	  DNA	  in	  an	  immunoprecipitation	  reaction.	  	  The	  use	  of	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1µg	  of	  DNA	  was	   chosen	   to	   compare	  with	   the	   standard	  6µg	  and	   the	   results	   are	  shown	  below	  (Figure	  3.20).	  	  
	  
Figure	  3.20:	  Calculation	  of	  amount	  of	  DNA	  for	  reproducible	  DNA	  immunoprecipitation.	  Immunoprecipitation	   experiments	   with	   a	   different	   starting	   DNA	   amount	   on	   the	   same	  sample	   of	   oxaliplatin	   treated	   PBMC	   DNA,	   repeated	   on	   three	   independent	   occasions.	   	   The	  mean	  and	  SEM	  are	  shown.	  	  In	  each	  experiment	  either	  1µg	  or	  6µg	  of	  DNA	  is	  used,	  with	  other	  conditions	  identical.	  	  	  	  Figure	  3.20	  demonstrates	  that	  it	  is	  possible	  to	  reduce	  the	  amount	  of	  DNA	  in	  the	  immunoprecipitation	  step	  of	  the	  DIP	  assay	  with	  no	  significant	  effect	  on	  the	  result,	   indicating	   that	   the	   range	   of	   DNA	   used	   in	   this	   experiment	   is	   within	   the	  dynamic	  range	  of	  the	  immunoprecipitation	  assay.	  	  If	  the	  Dip-­‐qPCR	  assay	  is	  used	  as	  a	  stand-­‐alone	  measure	  of	  DNA	  damage	  and	  repair,	  lower	  amounts	  of	  DNA	  can	  be	  used,	  increasing	  the	  number	  of	  conditions	  that	  can	  be	  studied	  or	  reducing	  the	  amount	   of	   sample	   that	   is	   required.	   	   As	   1	   ml	   of	   blood	   produced	   0.8-­‐3	   million	  PBMC	   ((Njai	   et	   al.	   2011),	   Figure	   3.4),	   and	   5	   million	   PBMC	   produces	  approximately	  20µg	  DNA	  with	  the	  protocol	  amendments	  discussed	  (Figure	  3.14)	  a	   few	   millilitres	   of	   blood	   may	   be	   enough	   to	   generate	   data	   for	   several	  experimental	   conditions	   per	   patient.	   	  However,	   the	   effect	   of	   reducing	   the	  DNA	  output	   from	  the	   immunoprecipitation	  on	  downstream	  amplification	  and	  on	   the	  reproducibility	  of	  microarray	  is	  yet	  to	  be	  determined	  and	  may	  be	  significant.	  	  




































































A) Improving in PBMC extraction technique to
improve DNA yield per aliquot of blood/cells
B) Modification of standard affinity capture
technique o utilise lower DNA yi ld obtainable
from PBMC demonstrating no significant
deteriortion in enrichment using 1ug DNA
compared to 5ug.   Usual laboratory techniques
using cell lines or yeast work require a minumum
of 6ug DNA (average of 2 repeats shown)
C) Enrichments at 28S in PBMC from 3 blood
samples from volunteers, repeated twice.
Samples were treated with ox liplatin 1mM for 4
hours before harvesting or recovery in drug free
media for 24-48 hours.  IP was performed using
CP19/9 anti-platinum antibody and 1uG
sonicated genomic DNA
	   142	  
3.4.7.2 Optimising	  CP9/19	  antibody	  for	  immunoprecipitation	  
	   The	   initial	   developmental	   work	   using	   human	   dermal	   fibroblast	   in	   cell	  culture	  employed	  a	  CP9/19	  antibody	  amount	  of	  1.5µg	  per	  6µg	  of	  DNA	  for	  each	  immunoprecipitation	   experiment	   (Powell	   2014).	   	   To	   confirm	   that	   this	   is	  applicable	   to	   the	   PBMC	   clinical	   samples,	   and	   to	   show	   that	   changes	   to	   the	  antibody	   concentration	   have	   minimal	   impact	   on	   the	   variability,	   an	   antibody	  titration	  was	   conducted	   using	   6µg	  DNA	   for	   immunoprecipitation	   at	   a	   range	   of	  antibody	  concentrations,	  as	  shown	  below	  (Figure	  3.21)	  
	  
	  
Figure	  3.21:	  CP9/19	  antibody	  titration.	  An	   antibody	   titration	   experiment	   using	   6µg	   DNA	   per	   immunoprecipitation	   and	   variable	  amounts	  of	  CP9/19	  anti	  platinum	  antibody.	  	  The	  IP/IN	  ratio	  is	  normalised	  to	  a	  no-­‐antibody	  sample	  and	  a	  single	  result	  or	  the	  mean	  of	  two	  repeats	  is	  shown.	  	  These	  results	  are	  identical	  to	  those	  in	  the	  assay	  development	  work	  (Powell	  2014)	  showing	  a	  plateau	  of	  antibody	  effect	  with	  no	  improvement	  above	  0.5µg	  of	  antibody	  per	  reaction.	  	   These	   results	   confirm	   that	   the	   previously	   identified	   antibody	  concentration	  is	  appropriate	  for	  this	  series	  of	  experiments,	  and	  the	  amount	  used	  is	   saturating,	   indicating	   that	   variability	   seen	   in	   the	   experiment	   is	   not	   a	  consequence	   of	   limiting	   amounts	   of	   antibody.	   As	   the	   titration	   experiment	  indicates	  that	  a	  66%	  dilution	  or	  400%	  increase	   in	  antibody	  used	  would	  yield	  a	  similar	  IP/IN	  ratio,	  the	  antibody	  concentration	  is	  not	  contributing	  to	  variability	  in	  the	  DIP	  assay.	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3.4.7.3 Effect	  of	  DNA	  concentration	  on	  immunoprecipitation	  consistency	  	   DNA	  extraction	  results	   in	  varying	  concentrations	  of	  DNA	  being	  obtained	  prior	  to	  immunoprecipitation.	  	  This	  is	  a	  consequence	  of	  using	  a	  standard	  amount	  of	  PBMC	  for	  cell	  culture,	  drug	  treatment,	   the	  effect	  of	   the	  drug	  on	  reducing	  the	  survival	   of	   cells	   and	   the	   subsequent	   extractable	   DNA	   amount	   and	   quality	   at	  higher	  doses,	  as	  described	  in	  this	  chapter.	  	  At	  the	  higher	  dose	  of	  1mM	  oxaliplatin	  treatment	   the	   amount	   of	   material	   available	   following	   extraction	   and	   DNA	  purification	  can	  be	  50%	  lower	  than	  samples	  that	  are	  untreated	  or	  treated	  with	  a	  lower	  dose	  of	  drug.	  The	  amount	  of	  DNA	  is	  adequate	  for	  immunoprecipitation	  (1µg	  is	  as	  good	  as	  6µg),	  but	  the	  DNA	  concentration	  varies,	  typically	  between	  as	  high	  as	  100ng/µl	  and	  as	   low	  as	  33ng/µl.	   	  This	  has	  no	  effect	  on	   the	   reproducibility	  of	   sonication.	  	  However,	   when	   used	   in	   the	   immunoprecipitation	   stage	   the	   different	  concentration	   of	   DNA	   results	   in	   a	   three	   fold	   difference	   in	   buffer	   used	   in	   the	  reaction.	  	  This	  is	  a	  potential	  cause	  of	  variability	  in	  the	  assay.	  	  This	  potential	  effect	  was	  investigated	  using	  a	  pool	  of	  DNA	  extracted	  from	  a	   single	   donor	   pool	   of	   PBMC	   supplied	  by	   the	  Welsh	  Blood	   Service	   and	   treated	  with	   oxaliplatin	   and	   cisplatin	   using	   the	   standard	   protocol.	   The	   extracted	   DNA	  from	   several	   samples	   were	   pooled	   and	   adjusted	   to	   a	   final	   concentration	   of	  100ng/µl.	   	   Serial	   samples	   from	   this	   batch	   of	   DNA	   were	   diluted	   in	   extraction	  buffer	   either	   to	   a	   final	   concentration	   of	   66ng/µl,	   or	   to	   33ng/µl.	   	   The	   resulting	  buffer	   mix	   during	   the	   immunoprecipitation	   was	   therefore	   either	   a	   standard	  100ng/µl	  DNA	  with	  approximately	  75%	  PBS	  and	  25%	  AE	  (DNA	  extraction	  buffer	  from	   the	  Quiagen	  DNeasy	  Blood	  and	  Tissue	  Kit),	   or	   in	   the	  most	  dilute	   samples	  was	   approximately	   90%	  AE	   and	   10%	  PBS.	   	   The	   result	   on	   the	   IP/IN	   ratio	   (the	  mean	  -­‐	  error	  bars	  show	  SEM)	  of	  3	   independent	  experiments	   is	  shown	  in	   figure	  3.22.	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Figure	  3.22:	  The	  effect	  of	  DNA	  concentration	  and	  buffer	  variation	  of	  IP	  consistency.	  A	   pooled	   sample	   of	   DNA	   extracted	   from	   PBMC	   from	   a	   single	   donor	   treated	   ex	   vivo	   with	  oxaliplatin	   and	   cisplatin	   is	   subject	   to	   immunoprecipitation	   at	   varying	   initial	   starting	  concentration.	   	   The	   mean	   IP/IN	   ratio	   normalised	   to	   an	   untreated	   sample	   from	   three	  independent	  repeat	  experiments	  (the	  error	  bars	  show	  SEM).	  	  	   This	   results	   show	   that	   the	   outcome	   of	   the	   immunoprecipitation,	   as	  measured	  by	  the	  relative	  enrichment	  between	  the	  untreated	  and	  treated	  samples	  is	   consistent	   despite	   the	   significant	   difference	   in	   buffer	   composition	   in	   the	  reaction	  mix,	  dependant	  on	  the	  initial	  DNA	  starting	  concentration.	  This	  confirms	  that	  the	  DNA	  concentration	  and	  resulting	  composition	  of	  buffers	  in	  the	  reaction	  has	  no	  effect	  on	  the	  outcome	  of	  immunoprecipitation,	  and	  samples	  can	  be	  used	  as	  prepared	  from	  the	  DNA	  extraction	  and	  sonication	  without	  concerns	  that	  this	  step	  is	  introducing	  variability	  into	  the	  final	  result.	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3.4.8 Reducing	  qPCR	  variability	  	   For	  the	  assay	  to	  be	  used	  reliably,	  the	  results	  of	  the	  immunoprecipitation	  measured	  by	  qPCR	  and	  must	  be	  reproducible.	  	  When	  used	  for	  calculation	  of	  the	  coefficient	  of	  variance	  and	  for	  identification	  of	  sources	  of	  variability	  (in	  sections	  3.3.3	  and	  3.3.4)	  it	  is	  clear	  that	  the	  qPCR	  step	  is	  a	  significant	  source	  of	  assay	  error,	  and	   that	   results	   of	   PCR	   quantification	   of	   identical	   DNA	   on	   different	   occasions	  introduces	  considerable	  run-­‐to-­‐run	  variation,	  leading	  to	  variability	  in	  the	  results	  obtained	  from	  the	  assay.	  	  	  The	   qPCR	   step	   can	   be	   used	   only	   as	   a	   qualitative	   confirmation	   of	  immunoprecipitation	  success,	  if	  the	  DNA	  is	  later	  to	  be	  analysed	  by	  microarray	  to	  generate	   the	   DIP-­‐chip	   result	   rather	   than	   as	   a	   stand	   alone	   measure	   of	   adduct	  damage	  and	  repair	   in	  a	  DIP-­‐qPCR	  assay,	   reducing	   the	  significance	  of	   this	  assay	  variability.	  	  However,	  even	  in	  this	  circumstance,	  the	  qPCR	  is	  used	  to	  estimate	  the	  amount	   of	   DNA	   to	   be	   amplified	   on	   the	   microarray,	   so	   ideally	   it	   should	   be	   as	  consistent	  as	  possible	  to	  reduce	  the	  potential	  for	  downstream	  error	  and	  bias.	  Concerns	   regarding	   qPCR	   variability	   when	   comparing	   between	  experiments	  have	  been	  previously	  identified	  in	  the	  scientific	  literature	  (Burns	  et	  al.	   2005;	   Rutledge	   2004).	   	   The	   widespread	   use	   of	   multi-­‐step	   protocols	   with	  subtle	  variations	  at	  each	  step	  introduces	  inconsistency	  into	  qPCR	  data,	  and	  leads	  to	  in	  difficulties	  in	  reproducing	  and	  comparing	  studies	  in	  which	  the	  conclusions	  are	   based	   on	   qPCR	   analysis	   (Bustin	   2010).	   	   In	   an	   effort	   to	   standardise	   the	  reporting	  of	  qPCR	  data	  a	  set	  of	  guidelines	  to	  allow	  reproduction	  and	  comparison	  between	   experiments	   have	   been	   published	   (Bustin	   et	   al.	   2009).	   	   These	  guidelines,	   the	  Minimum	  Information	   for	  Publication	  of	  Quantitative	  Real-­‐Time	  PCR	  Experiments,	  “MIQE”	  guidelines,	  have	  been	  cited	  in	  the	  scientific	   literature	  over	  2450	   times	  by	   July	  2014.	   	  The	   issue	  of	   run-­‐to-­‐run	  variability	   is	  discussed	  and	   comparable	   samples	   on	   each	   plate	   are	   suggested	   for	   use	   as	   ‘inter-­‐run	  calibrators’.	  	  	  To	   determine	   the	   magnitude	   of	   run-­‐to-­‐run	   variability	   and	   to	   develop	  inter-­‐run	   calibrators	   to	   allow	  accurate	   comparisons	   to	  be	  made	  between	  qPCR	  results,	   an	   experiment	   was	   conducted	   to	   develop	   a	   set	   of	   common	   ‘master	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standards’	   to	   compared	   between	   qPCR	   runs.	   	   These	   standards	  were	   produced	  from	   several	   pooled	   input	   samples	   from	   untreated	   PBMC	   DNA	   that	   had	   been	  subject	   to	  all	  of	   the	  processes	   involved	   in	  the	  DIP	  assay.	   	   Initially,	   to	  assess	  the	  reproducibility	  of	  the	  qPCR	  and	  the	  validity	  of	  this	  approach	  the	  same	  standards	  were	   run	   on	   10	   sequential	   qPCR	   assays,	   using	   primers	   of	   varying	   batch	   and	  several	   different	   batches	   of	   SYBR	   green	   reagent,	   to	   mimic	   the	   conditions	   that	  would	  be	  used	  in	  the	  clinical	  use	  of	  the	  DIP-­‐chip	  assay.	  	  	  	  Initial	  analysis	  of	  the	  variability	  in	  the	  threshold	  cycles	  of	  the	  standards	  is	  shown	   below	   (Figure	   3.23	   A	   and	   B),	   demonstrating	   that	   the	   quantification	   of	  identical	  DNA	  samples	  is	  variable	  between	  repeated	  experiments,	  at	  first	  glance	  indicating	   that	   the	   qPCR	   process	   of	   this	   assay	   is	   subject	   to	   considerable	  variability.	   	   Each	   sample	   crosses	   the	   threshold	   for	   quantification	   with	   a	   95%	  confidence	   interval	   of	   (approximately)	   +/-­‐	   2	   PCR	   cycles,	  meaning	   that	   there	   is	  occasionally	  a	  4-­‐cycle	  difference	  in	  par	  conditions	  with	  identical	  DNA.	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Figure	  3.23:	  Determination	  of	  qPCR	  variability.	  10	   consecutive	   qPCR	   experimental	   quantifications	   of	   identical	   DNA	   standards	   was	  performed	   using	   varied	   batches	   of	   28S	   primers	   and	   SYBR	   green	   reagent.	   	   The	   threshold	  cycle	   of	   each	   standard	   as	   calculated	   by	   the	   automatic	   software	   (Bio-­‐Rad-­‐CFX	   connect)	   is	  shown	  in	  (A)	  and	  the	  mean	  and	  95%	  confidence	  interval	  of	  these	  repeats	  in	  (B).	  	  	  	   This	  inherent	  variability	  in	  DNA	  quantification	  of	  identical	  DNA	  standards	  potentially	   occurs	   as	   a	   consequence	  of	   automatic	   variable	   threshold	   setting	  by	  the	  qPCR	  analysis	  software	  (Bio-­‐Rad	  CFX	  Connect),	  during	  which	  the	  threshold	  for	   DNA	   quantification	   is	   set	   automatically	   at	   a	   value	   which	   is	   10	   times	   the	  baseline	  florescence	  detected	  during	  the	  run.	  To	   remove	   this	   variability	   an	   arbitrary	   figure	   of	   500	   RFU	   was	   used	   to	  manually	  set	  a	  fluorescence	  threshold.	   	  In	  this	  circumstance	  each	  experiment	  is	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subject	   to	   the	   same	   criteria	   for	   successful	   amplification	   and	   subsequent	   DNA	  quantification.	  	  In	  each	  of	  the	  10	  runs	  in	  this	  analysis	  this	  arbitrary	  threshold	  is	  higher	  than	  the	  automated	  generated	  threshold,	  and	  is	  in	  the	  logarithmic	  phase	  of	   fluorescence	   increase	   for	  all	  of	   the	  standards	  -­‐	   it	   is	   therefore	  an	  appropriate	  measure	  to	  use	  for	  manual	  threshold	  setting.	  	  Using	  a	  common	  threshold	  of	  500	  RFU	   the	   result	   of	   the	   10	   repeats	   of	   the	   5	   standards	   were	   re-­‐analysed	   and	   is	  shown	  in	  figure	  3.24	  A	  and	  B.	  	  	  	  
	  
Figure	  3.24:	  The	  effect	  of	  manual	  threshold	  setting	  on	  qPCR	  variability	  10	   consecutive	   qPCR	   experimental	   quantifications	   of	   identical	   DNA	   standards	   were	  performed	  using	  varied	  batches	  of	  28S	  primers	  and	  SYBR	  green	  reagent.	   	  The	  threshold	  for	  each	  experiment	  was	  manually	  adjusted	  to	  500	  RFU	  and	  the	  threshold	  cycle	  for	  each	  repeat	  is	  shown	  in	  (A)	  and	  the	  mean	  and	  95%	  confidence	  interval	  of	  these	  repeats	  in	  (B).	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By	  plotting	  the	  mean	  and	  95%	  confidence	  interval	  for	  the	  threshold	  cycle	  for	   each	   standard	   in	   the	  10	   repeats	  before	   and	  after	  manual	   threshold	   setting,	  the	  effect	  of	  automatic	  versus	  manual	   threshold	  setting	  can	  be	  observed.	   	  With	  this	   adjustment	   it	   can	   be	   demonstrated	   that	   even	   with	   different	   runs,	   primer	  batches	   and	   SYBR	   green	   reagents	   the	   50	   standards	   are	   quantified	   highly	  consistently.	   	   Using	   this	   approach	   the	   variability	   (95%	   CI)	   is	   reduced	   to	   a	  fraction	  of	  a	  cycle	  for	  standards	  1	  to	  4,	  indicating	  that	  the	  same	  amount	  of	  DNA	  is	  quantified	  with	  high	  precision	  between	  runs	  and	  that	  cross-­‐run	  comparisons	  of	  unknown	  experimental	  samples	  would	  be	  valid	  	  This	   experiment	   demonstrates	   that	   by	   using	   common	   qPCR	   standards	  and	  manually	   setting	  a	  arbitrary	   threshold	   the	  qPCR	  quantification	  step	  of	   this	  assay	   can	   be	   made	   highly	   consistent	   and	   allow	   accurate	   comparison	   between	  samples	   between	   runs	   –	   essential	   if	   this	   assay	   is	   to	   be	   used	   clinically.	   	   As	   the	  acceptable	  range	  of	  standards	  is	  defined,	  they	  can	  also	  be	  used	  to	  reassure	  that	  the	  qPCR	  has	  progressed	  satisfactorily	  and	  as	  a	  marker	  of	  success	  or	  failure.	  	  This	  experiment	   highlights	   the	   importance	   of	   standardising	   qPCR	   protocols	   and	  analysis	   for	   between	   experimental	   comparisons,	   both	   in	   this	   assay	   and	   for	   the	  published	  qPCR	   literature	   in	   general.	   If	   subtle	  differences,	   such	  as	   the	  variable	  automatic	   threshold	   set	   by	   the	   analysis	   software,	   can	   introduce	   noise	   into	   an	  experiment,	  this	  emphasises	  the	  need	  for	  the	  MIQE	  guideline	  approach	  to	  ensure	  all	   parameters	   are	   published	   to	   allow	   reproduction	   of	   important	   experimental	  findings	  	  To	   demonstrate	   the	   effect	   of	  manual	   vs.	   automatic	   threshold	   setting	   on	  the	   result	   of	   the	   DIP-­‐qPCR,	   rather	   than	   on	   the	   quantification	   of	   the	   qPCR	  standards,	  a	  sample	  of	  DNA	  from	  immunoprecipitation	  of	  PBMC	  extracted	  DNA	  was	   quantified	   on	   4	   consecutive	   occasions	   using	   the	   master	   standards	   and	  variable	  compared	  to	  arbitrary	  500	  RFU	  threshold	  setting	  (Figure	  3.25).	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Figure	   3.25:	   Demonstrating	   the	   effect	   of	   manual	   threshold	   setting	   on	   DIP-­‐qPCR	   assay	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 Confirmation	  of	  the	  reduction	  in	  assay	  variability	  with	  protocol	  3.5
amendments	  	   Initial	   attempts	   at	   using	   the	   DIP-­‐qPCR	   assay	   to	   measure	   induced	  oxaliplatin-­‐DNA	  adducts	  in	  multiple	  independent	  repeat	  experiments	  on	  donated	  blood	   samples	   from	   human	   volunteers	   revealed	   considerable	   heterogeneity	   in	  the	   results,	  with	   a	   CV	   calculated	   as	   between	  78%	  and	  143%	   for	   5	   repeat	  DIP-­‐qPCR	  samples	  from	  patient	  B	  (section	  3.3.3).	  	  The	  heterogeneity	  shown	  in	  initial	  use	  of	  the	  protocol	  rendered	  the	  experiment	  unsuitable	  for	  use	  in	  a	  clinical	  study	  with	   single	   attempts	   at	   obtaining	   samples	   for	   analysis,	   especially	   if	   the	   clinical	  study	  is	  then	  used	  to	  predict	  the	  requirement	  or	  necessity	  of	  chemotherapy.	  	  As	  a	  consequence,	   the	   effect	   of	   several	   modifications	   to	   the	   assay	   protocol	   were	  investigated	  and	  implemented.	  To	   measure	   the	   effect	   of	   the	   modified	   protocol,	   3	   independent	  experiments	  were	   repeated	  with	  PBMC	   from	  patient	  B.	   	  They	  were	   retested	   to	  measure	   induced	   adduct	   levels	   at	   a	   1mM	   oxaliplatin	   dose,	   comparable	   to	   the	  experiment	  in	  the	  initial	  CV	  calculations.	  	  A	  further	  experiment	  using	  a	  sample	  of	  oxaliplatin	  treated	  PBMC	  from	  a	  single	  donor,	  treated	  at	  the	  same	  time	  with	  the	  DNA	  samples	  extracted	  and	  stored	  in	  parallel,	  was	  also	  processed	  in	  parallel	  in	  a	  series	  of	  replicates,	  and	  repeated	  on	  3	  independent	  occasions.	  	  These	  two	  sets	  of	  samples	  were	  used	  to	  recalculate	  the	  assay	  CV	  obtained	  with	  the	  amended	  assay	  protocol	  (Figure	  3.26	  and	  Figure	  3.27)	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Figure	  3.26:	  The	  effect	  of	  DIP	  assay	  protocol	  amendments	  on	  assay	  variability.	  	  PBMC	   from	   a	   single	   donor	  were	   treated	  with	   100µM	  oxaliplatin	   in	   parallel,	   and	  DNA	  was	  extracted.	   	   Samples	   were	   processed	   in	   separate	   experimental	   replicates	   on	   three	  independent	  occasions.	  	  The	  IP/IN	  ratio,	  normalised	  to	  an	  untreated	  sample,	  was	  calculated	  by	  qPCR.	  	  Overall	  the	  CV	  is	  42%	  with	  all	  results,	  and	  between	  26%	  and	  68%	  with	  a	  series	  of	  replicates	  run	  during	  the	  same	  immunoprecipitation.	  	  
	  
Figure	   3.27:	  A	   comparison	   the	   effect	   of	   old	   and	  new	  DIP-­‐qPCR	   assay	  protocols	   on	   assay	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These	  result	  show	  that	  the	  DIP-­‐qPCR	  with	  the	  modified	  human	  DIP	  PBMC	  protocol	  is	  much	  more	  reproducible	  for	  single	  use	  in	  clinical	  samples,	  with	  a	  CV	  of	  17.7%	  to	  42%,	  compared	  to	  78.4%	  to	  143%	  in	  several	  experiments	  with	  the	  initial	   protocol.	   	   The	   direct	   comparison	   between	   experiments	   (Figure	   3.27)	   is	  only	  available	  for	  patient	  B,	  as	  insufficient	  data	  is	  available	  to	  calculate	  the	  CV	  for	  a	  comparable	  dose	  point	  for	  patient	  A	  due	  to	  technical	  failure	  –	  see	  section	  3.3.3.	  	  This	   result	   confirms	   the	  value	  of	   the	  experiments	  and	  modifications	  developed	  as	   reported	   in	   this	   chapter.	   	   These	   changes	   significantly	   reduce	   the	   variability	  seen	  in	  the	  measurement	  of	  induced	  oxaliplatin-­‐DNA	  adducts	  in	  clinical	  samples	  used	  in	  this	  study,	  as	  demonstrated	  by	  a	  significant	  reduction	  in	  the	  coefficient	  of	  variance	  of	  the	  assay	  in	  these	  experiments.	  
	  
 Summary	  of	  the	  DIP-­‐chip	  protocol	  amendments	  determined	  in	  the	  3.6
experiments	  described	  in	  this	  chapter	  
	  
	   In	  summary,	  several	  changes	  to	  the	  DIP-­‐chip	  experimental	  protocol	  have	  been	  examined	  and	  collectively	  result	   in	  an	  improvement	  in	  the	  reproducibility	  of	   the	   DIP	   phase	   of	   the	   assay	   from	   a	   CV	   of	   78.4%	   to	   a	   CV	   of	   17.7%.	   	   The	  amendments	  required	  to	  the	  DIP-­‐chip	  protocol	  are	   listed	  below,	  and	  have	  been	  used	  for	  the	  human	  PBMC	  DIP-­‐chip	  protocol	  described	  in	  the	  methods	  chapter	  2,	  section	  2.1.	  
	  
• A	  protocol	  for	  the	  separation	  of	  PBMC	  has	  been	  developed	  (section	  3.3.1)	  	  
• Modification	  of	  the	  oxaliplatin	  dose	  and	  exposure	  time	  is	  required.	   	  This	  results	   in	   higher	   immunoprecipitation	   efficiency	   and	   better	  discrimination	  between	  dose	  levels	  (section	  3.4.2)	  	  
• The	  need	  for	  careful	  storage	  and	  making	  fresh	  drug	  with	  each	  experiment	  was	  determined	  (section	  3.4.4)	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• The	  requirement	  to	  split	  PBMC	  samples	  into	  two	  equal	  aliquots	  for	  DNA	  extraction	  was	   demonstrated.	   	   Eluting	   extracted	  DNA	   twice	   in	   a	   second	  volume	   of	   100µL	   was	   also	   beneficial	   to	   increase	   DNA	   yield	   (section	  3.4.5.2)	  	  
• 30	   cycles	   of	   sonication	   rather	   than	  24	   is	   necessary	   as	   a	   consequence	  of	  the	  increase	  in	  extracted	  DNA	  sample	  volume	  (section	  3.4.6)	  	  
• The	   requirement	   for	   a	   second	  purification	   step	   for	  DNA	  post-­‐sonication	  was	  confirmed	  (sections	  3.4.5.3	  and	  3.4.5.4)	  	  
• Each	   qPCR	   requires	   the	   use	   of	   a	   set	   of	   master	   standards	   and	   manual	  threshold	   setting	   at	   500RFU	   to	   ensure	   run-­‐to-­‐run	   comparability	   and	  consistency	  
	  
	  
 Discussion	  	  3.7	  	   The	  formation	  of	  platinum-­‐DNA	  adducts	  and	  removal	  of	  adducts	  by	  DNA	  repair,	   particularly	   nucleotide	   excision	   repair	   (NER)	   are	   the	   key	   events	  governing	   the	   response	   and	   toxicity	   in	   patients	   of	   the	   platinum	   family	   of	  chemotherapy	  agents	  (Bowden	  2014).	   	  As	  such,	  many	  studies	  have	  investigated	  the	   link	   between	   induced	   platinum-­‐DNA	   adduct	   levels,	   adduct	   repair,	   and	   the	  clinical	  response	  from	  treatment,	  as	  discussed	  in	  several	  sections	  of	  this	  thesis.	  	  A	   large	   retrospective	   study	   demonstrating	   a	   correlation	   between	   response	   to	  platinum	   chemotherapy	   and	   germline	  DNA	   repair	   capacity	   in	   peripheral	   blood	  cells	   in	  patients	  with	  non-­‐small	  cell	   lung	  cancer	   is	   the	  strongest	   indication	  that	  these	  approaches	  could	  be	   successful	   (Olaussen	  et	  al.	  2012;	  Wang	  et	  al.	  2011).	  	  So	  far,	  however,	  the	  results	  of	  many	  of	  these	  types	  of	  studies	  are	  contradictory,	  conflicting	   or	   underpowered	   to	   demonstrate	   a	   significant	   correlation	   between	  these	  factors.	  	  A	  single	  measure	  of	  a	  NER	  factor	  (either	  protein	  or	  mRNA	  levels),	  overall	   platinum-­‐DNA	   adduct	   level,	   or	   a	   single	  measure	   of	   adduct	   repair	   lacks	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specificity	   and	   sensitivity,	   limiting	   the	   clinical	   utility	   of	   these	   types	   of	   assay	  (Bowden	   2014;	   Olaussen	   et	   al.	   2012;	   Wang	   et	   al.	   2011).	   	   The	   DIP-­‐chip	   assay	  offers	  scope	  through	  analysis	  of	  platinum-­‐DNA	  adduct	  levels	  and	  patterns	  at	  high	  resolution	  in	  sections	  of	  the	  genome	  to	  improve	  on	  the	  predictive	  power	  of	  these	  techniques.	  	   The	   DIP-­‐chip	   assay	   can	   be	   considered	   in	   two	   phases	   –	   DNA	  immunoprecipitation	  (DIP),	  confirmed	  by	  qPCR	  analysis	  of	  platinum-­‐DNA	  adduct	  levels,	  followed	  by	  genome-­‐resolution	  analysis	  with	  microarrays	  (chip).	  	  It	  is	  the	  former	   that	   is	   the	   main	   concern	   of	   this	   chapter,	   although	   the	   validity	   of	   the	  microarray	   analysis	   is	   based	   on	   the	   assumption	   that	   the	   DIP	   stage	   is	   robust,	  reliable	  and	  reproducible.	  	   The	   experiments	   described	   in	   this	   chapter	   demonstrate	   that,	   with	   the	  protocol	  modifications	  described,	  it	  is	  possible	  to	  treat	  PBMC	  with	  oxaliplatin	  ex	  
vivo	  and	  obtain	  high	  quality	  DNA	  in	  sufficient	  amounts	  for	  immunoprecipitation	  and	   downstream	   applications.	   	   Given	   the	   limitations	   on	   clinical	   samples	   from	  patients	  undergoing	  chemotherapy	  that	  this	  assay	  is	  intended	  for	  use	  with,	  these	  modifications	  and	  amendments	  to	  the	  DNA	  extraction	  protocol	  are	  an	  important	  improvement	  on	  this	  initial	  DIP-­‐chip	  protocol.	  This	  study	  also	  demonstrates	  that	  the	  DIP	  protocol,	  as	  initially	  developed	  in	  human	  cell	  culture	  models,	  results	  in	  a	  high	  variability	  when	  used	  repeatedly	  on	   the	   same	  human	  clinical	  PBMC	  samples.	   	  The	  experiments	  discussed	   in	   this	  chapter	   describe	   and	   document	   the	   process	   through	   which	   the	   DIP	   assay	   is	  deconstructed	  into	  its	  component	  parts,	  and	  how	  each	  stage	  can	  be	  assessed	  and	  amended	  to	  reduce	  the	  overall	  variation	  in	  final	  result.	  	  A	  reduction	  in	  coefficient	  of	   variance,	   a	  well-­‐used	   laboratory	  marker	   of	   assay	  quality,	   from	  78%	   to	  17%	  with	   the	   protocol	   modifications	   described	   demonstrates	   the	   benefits	   of	   this	  stepwise	   approach.	   	   This	   improvement	   confirms	   the	  DIP	   phase	   of	   the	   assay	   is	  producing	   relatively	   reproducible	   pools	   of	   DNA	   fragments	   in	   the	   IP	   and	   IN	  samples	  following	  immunoprecipitation	  and	  processing.	  For	  use	  as	  a	  single	  locus	  platinum-­‐DNA	  adduct	  level	  assay	  ideally	  a	  CV	  of	  <10%	   would	   be	   achieved	   before	   a	   form	   of	   DIP-­‐qPCR	   assay	   could	   be	   used	   on	  patient	  samples.	  	  This,	  however,	  is	  not	  the	  intended	  use	  of	  these	  DIP	  samples,	  as	  they	   will	   be	   applied	   to	   microarrays	   for	   genome-­‐scale	   platinum-­‐DNA	   adduct	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analysis.	   	   The	   large	   datasets	   generated	   through	   this	   approach	   can	   be	   used	   to	  identify	   and	   remove	   the	   effect	   of	   variability	   in	   the	   assay	   due	   to	   experimental	  noise,	  potentially	  making	  further	  improvements	  in	  consistency	  in	  the	  DIP	  phase	  of	  the	  assay	  unnecessary	  –	  this	  concept	  will	  be	  explored	  further	  in	  chapter	  5.	  	  
 Conclusions	  3.8	   Using	  the	  experiments	  outlined	  in	  this	  chapter,	  the	  DIP	  assay	  protocol	  has	  been	   thoroughly	   examined,	   amended	   and	   optimised	   for	   use	   in	   human	   clinical	  blood	   samples,	   with	   a	   significant	   improvement	   in	   the	   validity	   of	   the	   results	  generated	   by	   this	   technique.	   	   Although	   further	   improvements	   are	   desirable	   to	  further	  reduce	  the	  variability	  if	  used	  as	  a	  stand-­‐alone	  DIP-­‐qPCR	  based	  assay,	  this	  is	  not	  the	  intention	  of	  this	  project.	   	  It	  is	  unlikely	  that	  a	  single	  genetic	  locus	  DIP-­‐qPCR	   approach	  would	   offer	  much	   benefit	   above	   the	   ‘platinum-­‐adduct	   per	   unit	  DNA’	  approach	  used	  in	  many	  of	  the	  clinical	  studies	  already	  conducted.	  	  	  	  In	  view	  of	  this,	  the	  additional	  strength	  of	  the	  experiments	  outlined	  in	  this	  chapter	  are	  that	  by	  reducing	  the	  DIP	  variability	  they	  improve	  the	  validity	  of	  the	  high-­‐sensitivity	   platinum-­‐DNA	   adduct	   patterns	   generated	   when	   the	   improved	  DIP	  protocol	  is	  coupled	  with	  microarray	  based	  genome-­‐scale	  techniques.	  	  These	  experiments	  will	  be	  the	  focus	  of	  the	  following	  chapters.	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Chapter	  4 Microarray	  analysis	  of	  DIP-­‐chip	  samples	  
 Introduction	  4.1
	  	   The	  modified	  DNA	  immunoprecipitation	  (DIP)	  assay,	  discussed	  in	  chapter	  3,	   results	   in	   reproducible	   production	   of	   samples	   of	   fragmented	   DNA,	   when	  extracted	   from	   clinical	   samples	   -­‐	   in	   this	   case	   ex	   vivo	   treated	   peripheral	   blood	  mononuclear	   cells	   (PBMC).	   	   These	   fragments	   contain	   a	   reasonably	   consistent	  level	   of	   oxaliplatin	   induced	   DNA	   adducts	   in	   samples	   that	   are	   treated	  with	   the	  same	  dose	  of	  oxaliplatin,	  as	  measured	  by	  qPCR	  at	  the	  28S	  loci	  and	  compared	  to	  a	  non-­‐immunoprecipitated	  ‘input’	  reference	  and	  an	  untreated	  sample.	  	  	  In	   itself,	   this	   DIP-­‐qPCR	   assay	   could	   be	   a	   useful	   tool	   to	   study	   levels	   of	  induced	   platinum-­‐DNA	   adducts.	   	   It	   could	   potentially	   be	   used	   as	   an	   assay	   to	  predict	   response	   or	   toxicity	   to	   platinum	   drugs,	   in	   a	   similar	   approach	   to	   the	  technique	   used	   by	   Wang	   (2011),	   when	   measuring	   the	   germline	   DNA	   repair	  capacity	   of	   peripheral	   blood	   mononuclear	   cells	   of	   non-­‐small	   cell	   lung	   cancer	  patients	   undergoing	   cisplatin	   chemotherapy	   (Wang	   et	   al.	   2011),	   as	   the	   output	  resulting	   from	   the	   DIP-­‐qPCR	   analysis	   is	   a	   quantification	   of	   induced	   platinum-­‐DNA	  adducts	   at	   a	   single,	   or	   limited	  number	  of	   genetic	   loci.	   	   It	   is	   also	   a	   similar	  quantification	  to	  the	  ‘platinum-­‐DNA	  adducts	  per	  unit	  of	  DNA’	  result	  produced	  by	  several	  other	  assays	  that	  have	  been	  used	  to	  measure	  platinum-­‐DNA	  damage,	  as	  discussed	   in	   the	   introductory	   discussion	   in	   the	   previous	   chapter,	   section	   3.1.	  	  Unfortunately,	   these	  assays	  are	  of	  not	  powerful	  enough	  for	  clinical	  use,	  as	   they	  lack	   sensitivity	   and	   specificity,	   resulting	   in	   a	   limited	   capability	   to	   discriminate	  between	  different	  clinical	  outcomes	  (Bowden	  2014).	  	  	   One	  reason	  for	  the	  lack	  of	  predictive	  power	  of	  ‘platinum-­‐DNA	  adducts	  per	  unit	  of	  DNA’	  assays	  may	  be	  variation	  in	  the	  presence	  of	  platinum-­‐DNA	  adducts	  at	  different	  regions	  of	   the	  genome.	   	  A	  variable	   level	  of	   induction	  of	  platinum-­‐DNA	  adducts	   in	  vivo	  has	  been	  demonstrated	   in	  human	  cell	   culture	  models	  using	  our	  DIP-­‐chip	   technique	   (Powell	  2014).	   	  Additionally,	   in	  different	   tissues	  nucleotide	  excision	   repair	   (NER)	   operates	   at	   variable	   rates	   at	   distinct	   sections	   of	   the	  genome	   (Furuta	   et	   al.	   2002;	   Nouspikel	   2009).	   	   As	   a	   consequence	   of	   variable	  platinum-­‐DNA	   damage	   induction,	   combined	   with	   differences	   in	   NER	   rate,	   the	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level	   of	   platinum-­‐DNA	   adducts	   potentially	   varies	   significantly	   throughout	   the	  genome	  during	  and	  in	  the	  period	  after	  chemotherapy	  treatment.	  Crude	  assays	  of	  ‘platinum-­‐DNA	  adducts	   per	   unit’	   are	   an	   average	  measure	   of	   adduct	   levels,	   and	  are	  unable	   to	  detect	  differences	   in	   induced	  adduct	  patterns	  and	  repair	   rates	  at	  specific	   regions.	   	   In	   this	   context,	   patterns	   of	   platinum-­‐DNA	   adducts	   and	  platinum-­‐DNA	   adduct	   repair	   at	   key	   genomic	   regions	   (for	   example,	   the	   genes	  which	   are	   most	   actively	   transcribed)	   may	   be	   a	   more	   sensitive	   and	   specific	  marker	  for	  platinum	  drug	  response	  or	  toxicity	  than	  the	  single	  measure	  of	  overall	  genomic	  platinum-­‐DNA	  adducts	  currently	  available.	  There	   is,	   therefore,	   the	  possibility	  that	  an	  approach	  to	  measure	  patterns	  of	  platinum-­‐DNA	  adducts	  at	  high-­‐resolution	   throughout	   the	  genome	  could	  be	  a	  significant	   improvement	   in	  patient	  stratification	  technology	  compared	  to	  single	  locus	   or	   single	  measure	   assays.	   	  With	   the	  modified	  human	  PBMC	  DIP	  protocol	  developed	   in	   chapter	   3	   coupled	   to	   microarray	   chip	   analysis	   techniques,	   high-­‐resolution	  genomic-­‐scale	  information	  for	  DNA	  damage	  patterns	  can	  be	  obtained.	  	  By	   analysing	   the	   immunoprecipitated	   (IP)	   and	   input	   (IN)	   control	   sample	  generated	  by	  the	  DIP	  assay	  with	  microarray	  technology	  it	  is	  possible	  to	  compare	  the	  relative	  amounts	  of	  DNA	  fragments	  in	  paired	  IP	  and	  IN	  samples	  at	  thousands	  of	   genetic	   loci	   simultaneously,	   resulting	   in	   a	   genomic	   pattern	   of	   the	   levels	   of	  platinum-­‐DNA	  adducts	  (for	  an	  example	  see	  figure	  4.2).	  	  	   The	   experiments	   discussed	   in	   this	   chapter	   used	   custom	   designed	   DNA	  microarrays	   to	  measure	   the	   relative	   fragment	   frequency	   at	   44,000	   loci	   over	   a	  5Mb	  region	  of	  chromosome	  17.	  	  These	  parameters	  are	  chosen	  as	  they	  have	  been	  established	   as	   the	   standard	   human	   microarray	   parameters	   used	   in	   our	  laboratory.	   	  The	  assay	  characteristics	  and	  performance	  has	  been	  determined	  in	  previous	   experiments	   using	   the	   DIP-­‐chip	   technique	   to	   measure	   cisplatin	   and	  oxaliplatin	  damage	  in	  cell	  culture	  models	  (Powell	  2014),	  and	  demonstrate	  high-­‐resolution	  DNA	  damage	  patterns.	  	   The	   techniques,	   results	   and	   discussions	   presented	   both	   in	   this	   chapter	  and	  the	  next	  chapter	  (chapter	  5)	  can	  be	  considered	  as	  one	  section	  of	  this	  thesis,	  although	   each	   chapter	   has	   a	   different	   emphasis.	   	   As	   discussed	   extensively	   in	  chapter	  3,	   the	   translation	  of	   a	   cell	   culture	   tool	   into	  an	  assay	   to	  analyse	  human	  clinical	   samples	   requires	   in-­‐depth	   investigation,	   optimisation	   and	  modification	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of	   the	   laboratory	   workflow	   and	   chip	   protocol	   to	  maximise	   the	   reproducibility	  and	  reliability	  of	  the	  technique	  for	  these	  types	  of	  human	  tissues.	  	  Central	  to	  this	  are	   experiments	   to	   determine	   the	   ability	   the	   DIP-­‐chip	   assay	   to	   generate	  reproducible	   and	   accurate	   platinum-­‐DNA	   adduct	   patterns	   in	   repeated	   samples	  taken	   from	   the	   same	   individual,	   when	   treated	   under	   the	   same	   experimental	  conditions	  –	  an	  issue	  of	  minimising	  variability	  in	  the	  assay.	  	  This	  will	  be	  the	  main	  focus	  of	  the	  experiments	  described	  in	  this	  chapter.	  	  	  Once	  accurate	  and	  reproducible	  adduct	  patterns	  have	  been	  produced	  by	  the	  DIP-­‐chip	  assay,	  the	  next	  issue	  will	  be	  the	  detection	  of	  a	  biological	  signal	  –	  the	  differences	  in	  platinum-­‐DNA	  adduct	  patterns	  that	  occur	  between	  samples	  taken	  from	   different	   individuals,	   when	   treated	   under	   the	   same	   experimental	  conditions.	   	  This	  is	  the	  ultimate	  role	  of	  the	  DIP-­‐chip	  assay	  in	  the	  context	  of	  this	  thesis	   and	   for	   use	   in	   future	   clinical	   studies.	   	   Determining	   the	   capability	   of	   the	  DIP-­‐chip	   assay	   to	   detect	   inter-­‐individual	   differences	   in	   platinum-­‐induced	   DNA	  adduct	   patterns	   requires	   the	   development	   of	   new	   analytical	   and	   bioinformatic	  tools	  to	  detect	  and	  report	  characteristics	  of	  biological	  signals.	  	  Additionally,	  this	  effort	  requires	  experimental	  evidence,	  described	  in	  this	  chapter,	  to	  quantify	  and	  minimise	   noise	   in	   the	   assay.	   	   Along	   with	   bioinformatic	   tools	   developed	   to	  improve	  the	  analysis	  of	  DIP-­‐chip	  assay	  development	  experiments	  and	  for	  quality	  control	  purposes,	  the	  bioinformatic	  methods	  for	  the	  detection	  of	  inter-­‐individual	  differences	  will	  be	  presented	  in	  the	  final	  section	  of	  the	  following	  chapter.	  	  
4.1.1 Microarray	  technology	  	  
	  
	   Microarrays	   have	   been	   used	   as	   a	   widely	   accepted	   research	   tool	   to	  generate	  genomic	  data	  from	  ChIP-­‐chip	  experiments	  for	  over	  a	  decade	  (Ren	  et	  al.	  2000).	   	  As	  discussed	   in	   chapter	  3,	   section	  3.1.9,	   examples	  of	   this	   include	  many	  types	  of	  related	  experimental	  approaches	  to	  measure	  protein-­‐DNA	  binding	  (Iyer	  et	   al.	   2001),	   histone	   modifications	   (Kurdistani	   et	   al.	   2002),	   and	   to	   detect	   the	  genomic	  location	  of	  methylated	  DNA	  (Weber	  et	  al.	  2007).	  	  Microarrays	  have	  also	  been	  widely	  used	  in	  other	  research	  techniques,	  including	  use	  for	  gene	  expression	  profiling	  experiments,	  for	  the	  detection	  of	  alternative	  RNA	  splicing,	  the	  study	  of	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microRNA,	  and	  for	  comparative	  genomic	  hybridisation	  and	  genotyping.	  	  A	  review	  published	   in	   2006	   provides	   a	   broad	   summary	   of	   the	   range	   of	   applications	   to	  which	  this	  technology	  has	  been	  applied	  (Hoheisel	  2006).	  	  	   Next-­‐generation	  DNA	  sequencing	  technologies	  are	  increasingly	  providing	  an	   alternative	   platform	   to	   microarray-­‐based	   analysis,	   including	   for	   ChIP-­‐chip	  (Furey	   2012;	   Ho	   et	   al.	   2011).	   	   However,	   the	   well-­‐established	   laboratory	  workflow,	  available	  bioinformatic	   techniques	   for	  data	  processing	  and	   the	  more	  manageable	  size	  of	  the	  genomic-­‐scale	  data	  generated	  make	  microarrays	  an	  ideal	  platform	   for	   development	   studies	   and	   in	   this	   effort	   to	   translate	   the	   DIP-­‐chip	  assay	  for	  use	  on	  clinical	  samples.	  	  Once	  any	  issues	  surrounding	  the	  translation	  of	  the	  DIP-­‐chip	  assay	  for	  clinical	  use	  are	  addressed	  and	  a	  stable	  and	  reliable	  assay	  pipeline	   has	   been	   developed,	   the	   data	   generated	   by	   the	   DIP-­‐chip	   assay	   can	  provide	  a	  baseline	  and	  a	  model	  for	  the	  future	  development	  of	  DIP-­‐sequencing	  in	  this	   context,	   especially	   in	   light	   of	   the	   rapid	   and	   continuing	   advances	   in	   DNA	  sequencing	  that	  are	  currently	  occurring	  (Bahassi	  and	  Stambrook	  2014).	  	  	  	  
4.1.2 Microarray	  structure	  and	  layout	  	   In	   simple	   terms,	   a	   DNA	   microarray	   consists	   of	   thousands	   of	   unique	  oligonucleotide	   probes	   lithographically	   printed	   onto	   a	   glass	   slide.	   	   Groups	   of	  identical	  oligonucleotides	  are	  adjacently	  situated	  to	  form	  ‘features’,	  so	  called	  as	  these	  groups	  of	  probes,	  when	  hybridised	  to	  a	  fluorescently	  labelled	  DNA	  sample,	  can	  be	  scanned	  and	  detected	  as	  an	  individual	  genomic	   ‘feature’	   for	  analysis.	   	   In	  the	   experiments	   discussed	   in	   this	   thesis	   the	   microarrays	   used	   are	   custom	  designed	   ‘4	   x	   44K’	   feature	   arrays	   obtained	   from	   Agilent	   Technologies	   Inc.	   	   As	  such,	   they	  are	  made	  up	  of	  4	  microarrays	  per	  slide,	  each	  with	  45,219	   individual	  features,	   the	   majority	   of	   which	   are	   available	   to	   generate	   experimental	   data	  (Technologies	   2008).	   	   The	   remaining	   features	   are	   present	   as	   controls	   and	   for	  localisation	  and	  identification	  during	  scanning	  (Figure	  4.1).	  The	  application	  of	  two	  pools	  of	  DNA	  to	  the	  microarray	  slide,	  each	  with	  a	  different	  fluorescent	  label,	  under	  appropriate	  conditions	  results	  in	  hybridisation	  between	   complementary	   fragments	   to	   the	   corresponding	   feature(s).	   	   The	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relative	  hybridisation	  between	  fragments	  from	  each	  DNA	  sample	  can	  be	  detected	  using	  a	  fluorescent	  laser	  scanner	  to	  excite,	  and	  subsequently	  detect,	  the	  relative	  fluorescence	  present	  after	  hybridisation	  at	  each	  microarray	  feature.	  	  Information	  on	  the	  spatial	  location	  and	  the	  fluorescence	  intensity	  can	  then	  be	  linked	  back	  to	  the	   feature’s	   genomic	   location	  and	   to	   the	  known	  probe	   sequence.	   	   In	   this	  way,	  the	   relative	   proportions	   of	   fragments	   in	   the	   two	   DNA	   samples	   applied	   can	   be	  mapped	   back	   to	   the	   sequence	   of	   the	   DNA	   region	   of	   interest,	   identifying	   the	  amounts	  of	  material	  in	  each	  pooled	  sample	  at	  multiple	  loci	  along	  the	  genome.	  	  	  In	  this	  DIP-­‐chip	  assay,	  the	  two	  samples	  applied	  to	  the	  microarray	  are	  the	  paired	   IP	   and	   IN	   sample	   from	   one	   experimental	   condition	   per	   microarray.	  	  	  Microarray	  interrogation	  consequently	  generates	  a	  numerical	  value	  for	  the	  IP/IN	  ratio.	   	   As	   previously	   discussed,	   the	   IP/IN	   ratio	   is	   a	   measure	   of	   the	  immunoprecipitation	  efficiency,	  and	  is	  a	  method	  of	  quantifying,	  normalising	  and	  comparing	   platinum-­‐DNA	   adduct	   levels	   at	   different	   loci.	   	   At	   each	   feature	  analysed,	  a	  higher	   IP/IN	  value	   indicates	   that	  a	  greater	  proportion	  of	   fragments	  are	   immunoprecipitated	  during	   the	  DIP	  relative	   to	   the	   input	  control,	   indicating	  that	   there	   is	   a	  higher	   level	  of	  platinum-­‐DNA	  adducts	  at	   this	   location.	   	  Mapping	  the	  IP/IN	  ratio	  at	  each	  genomic	  location	  of	  every	  feature	  allows	  the	  generation	  of	  a	  high-­‐resolution	  platinum-­‐DNA	  adduct	  patterns	  along	  the	  genome	  (Figure	  4.2)	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Figure	  4.1:	  The	  layout	  of	  an	  Agilent	  4x	  44k	  microarray.	  The	   layout	   of	   an	   Agilent	   4x	   44k	   microarray	   (Agilent	   Technologies	   Inc.	   2007)	  	  (http://www.chem.agilent.com/Library/technicaloverviews/Public/G450290001_MicroarrayFormat.pdf)	  	  
	  
Figure	  4.2:	  An	  example	  of	  a	  oxaliplatin-­‐DNA	  adduct	  pattern	  plot.	  The	  log2	  IP/IN	  ratio	  is	  plotted	  on	  the	  y-­‐axis	  against	  the	  location	  of	  each	  probe	  along	  the	  x-­‐axis.	  The	  genomic	  location	  of	  each	  probe	  is	  shown	  on	  the	  lower	  x-­‐axis	  as	  a	  grey	  dot,	  and	  the	  position	  along	  chromosome	  17	  is	  displayed	  on	  the	  upper	  x-­‐axis.	   	  Peaks	  and	  troughs	  can	  be	  seen	   corresponding	   to	   putative	   areas	   of	   increased	   and	   decreased	   oxaliplatin-­‐DNA	   adduct	  formation.	  	  	  The	  use	  of	  the	  log2	  of	  the	  IP/IN	  ratio	  for	  the	  y-­‐axis	  allows	  easier	  visualisation	  when	  there	  is	  a	   large	   difference	   between	   the	   IP	   and	   IN	   fluorescence	   values,	   and	   allows	   equal	  representation	   of	   reciprocal	   ratios	   (i.e.	  when	   the	   probe	   IP	   value	   is	   twice	   or	   half	   of	   the	   IN	  value	  the	  distance	  from	  the	  centre	  of	  the	  data	  will	  be	  equal,	  but	  with	  opposing	  direction).	  A	  log2	  binding	  level	  of	  0	  equates	  to	  an	  IP/IN	  ratio	  of	  1,	  as	  20=1.	  	  	  	  
CHAPTER 2. TECHNICAL OVERVIEW
Figure 2.1: Agilent 4 x 44k microarray format: Layout and dimensions of
the Agilent 4 x 44k microarray (Agilent Technologies Inc., 2007)
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4.1.3 Overview	  of	  the	  ‘chip’	  experiment	  
	  	   The	  experimental	  workflow	  of	  the	  DIP-­‐chip	  assay	  can	  be	  conceptualised	  in	  two	   distinct	   phases;	   an	   initial	   DNA	   immunoprecipitation	   (DIP),	   followed	   by	  genomic	   scale	   analysis	   using	   microarray	   technology	   (chip).	   	   The	   initial	   DNA	  immunoprecipitation	   was	   extensively	   discussed	   in	   chapter	   3.	   	   For	   each	  experimental	   condition	   the	   DIP	   results	   in	   two	   pools	   of	   DNA	   fragments,	   the	  immunoprecipitated	   (IP)	   sample	   and	   the	   control	   input	   (IN)	   sample.	   	   The	   IN	  sample	   is	   taken	   from	   the	   pre-­‐immunoprecipitated	   pool	   of	   purified,	   sonicated	  DNA	   and	   represents	   the	   background	   variation	   in	   DNA	   quality	   and	   initial	  fragment	  frequency.	  	  As	  it	  is	  processed	  in	  parallel	  to	  the	  IP	  sample	  (except	  for	  the	  immunoprecipitation	  stage)	  it	  also	  acts	  as	  an	  internal	  control	  for	  non-­‐biological	  variability	   in	   the	   assay	   technique,	   especially	   in	   sample	  handling,	  DNA	   labelling	  and	  in	  PCR	  amplification	  steps.	  	  	   In	  the	  chip	  aspect	  of	  the	  assay	  there	  are	  four	  main	  laboratory	  preparation	  phases	   (figure	   4.3):	   DNA	   amplification,	   sample	   labelling,	   microarray	  hybridisation,	   and	   scanning	   and	   data	   extraction.	   	   There	   is	   a	   fifth	   step	   -­‐	   the	  extracted	  data	   then	  require	  bioinformatic	  processing	   to	  generate	  and	   interpret	  platinum-­‐DNA	  adduct	  patterns.	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Figure	  4.3:	  The	  chip	  phase	  of	  the	  DIP-­‐chip	  assay	  experimental	  pathway.	  Following	  the	  immunoprecipitation	  purification	  the	  immunoprecipitated	  (IP)	  sample	  and	  an	  input	  (IN)	  control	  sample	  are	  amplified,	   fluorescently	   labelled,	  and	  hybridised	  to	  a	  custom	  microarray	   prior	   to	   data	   extraction	   and	   bioinformatic	   processing	   to	   generate	   a	   high	  resolution	  genome	  scale	  damage	  pattern	  trace	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and	  parameters	  on	  both	  the	  IP	  and	  the	  diluted	  IN	  samples.	  	  In	  this	  way	  the	  IP	  and	  IN	   samples	   have,	   as	  much	   as	   is	   possible,	   been	   processed	   in	   the	   same	   fashion,	  with	  the	  intention	  of	  maintaining	  the	  IN	  as	  an	  internal	  control.	  	   Several	   methods	   of	   amplification	   have	   been	   used	   for	   this	   purpose	   in	  published	   ChIP-­‐chip	   experiments.	   	   The	   two	   typical	  ways	   of	   amplifying	   DNA	   in	  this	   context	   are	   though	   ligation-­‐mediated	   PCR	   	   (LM-­‐PCR),	   as	   described	   by	  (Mueller	   and	  Wold	   1989)	   or	   through	  whole	   genome	   (WGA-­‐PCR)	   amplification	  (O'Geen	  et	  al.	  2006).	  	  	   As	   used	   extensively	   in	   our	   laboratory,	   LM-­‐PCR	   requires	   initial	   DNA	  manipulation	   to	   ensure	   all	   DNA	   fragments	   have	   a	   blunt	   end,	   using	   T4	   DNA	  polymerase	   (NEB)	   to	   act	   as	   a	   3’	   to	   5’	   endonuclease	   and	   to	   end-­‐fill	   3’	   recessed	  nucleotides.	   	   Purified	   fragments	   are	   then	   incubated	  with	  T4	  DNA	   ligase	   (NEB)	  and	   a	   common	   linker	   DNA	   sequence.	   	   Ligation	   to	   the	   DNA	   fragments	   of	   the	  common	   linker	   subsequently	   allows	   PCR	   amplification	   using	   primers	   to	   the	  common	  sequence.	  	  This	  process	  is	  effective	  to	  adequately	  amplify	  the	  DNA,	  and	  variations	   of	   LM-­‐PCR	   have	   been	   widely	   used	   in	   many	   ChIP-­‐chip	   experiments	  (O'Geen	  et	  al.	  2006).	  	   Whole	   genome	   amplification	   (WGA-­‐PCR)	   is	   also	   widely	   used	   to	   amplify	  DNA	  prior	  to	  microarray	  (O'Geen	  et	  al.	  2006).	  	  In	  the	  WGA	  process	  typically	  used	  in	   our	   laboratory	   the	   PCR	   based	   amplification	  method	   uses	   a	   random	  priming	  approach	  –	  a	  primer	  with	  a	  random	  3’	  sequence	  and	  defined	  5’	  sequence	  of	  DNA	  is	  annealed	  randomly	   to	   the	  DNA	   in	   the	  mixed	  pool	  of	  DNA	   fragments.	   	  This	   is	  followed	  by	  a	  PCR	  amplification	  using	  primers	  to	  the	  defined	  5’	  random	  primer	  sequence.	  	  The	  WGA-­‐PCR	  kit	  used	  in	  these	  experiments	  and	  in	  the	  DIP-­‐chip	  assay	  development	  is	  the	  WGA2	  kit	  (Sigma	  UK).	   	  The	  WGA2	  kit	  a	  two	  stage	  PCR,	  with	  proprietary	   universal	   primers	   in	   an	   initial	   brief	   PCR	   reaction	  with	   the	   pool	   of	  fragmented	  DNA,	  resulting	  in	  PCR-­‐amplifiable	  DNA	  library	  fragments	  flanked	  by	  universal	   priming	   sites.	   	   Primers	   to	   the	   universal	   flanking	   sequence	   are	   then	  used	  in	  a	  second,	  more	  extensive	  PCR	  amplification	  (Sigma).	  	   WGA-­‐PCR	   has	   been	   compared	   directly	   to	   LM-­‐PCR	   when	   used	   to	   amplify	  ChIP-­‐chip	  DNA	  prior	  to	  microarray,	   in	  an	  experiment	  investigating	  the	  genomic	  location	   Oct4	   protein-­‐DNA	   binding	   sites	   in	   the	   human	   genome	   (O'Geen	   et	   al.	  2006).	  	  A	  comparison	  of	  the	  technologies	  in	  this	  circumstance	  showed	  that	  WGA-­‐
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PCR	  produced	  superior	  signal	   to	  noise	  ratios	   following	  hybridisation	  compared	  to	  LM-­‐PCR.	  	   Of	   particular	   importance,	   when	   translating	   this	   technique	   for	   use	   in	  detecting	   subtle	   differences	   between	   experimental	   conditions	   and	   between	  individuals	   as	   in	   this	   thesis,	   is	   that	   PCR-­‐based	   DNA	   amplification	   for	   library	  preparation	   for	   sequencing	   or	  microarray	   analysis	   is	   known	   to	   be	   a	   potential	  source	  of	  significant	  experimental	  bias	  (Dabney	  and	  Meyer	  2012;	  Hasmats	  et	  al.	  2014;	  Quail	   et	   al.	   2012;	   van	  Dijk	   et	   al.	   2014),	   and	  WGA-­‐PCR	  amplification	  bias	  due	   to	   preferential	   annealing	   of	   universal	   or	   random	   primers	   with	   DNA	  fragments	  of	  differing	  characteristics	  is	  a	  complication	  that	  can	  have	  statistically	  significant	  effects	  on	  experimental	  results	  (Pinard	  et	  al.	  2006).	  	  	  For	  example,	  in	  one	  study	  of	  WGA-­‐PCR	  based	  amplification	  bias,	  copy	  number	  at	  individual	   loci	  following	  amplification	  varied	  between	  100-­‐10,000	   fold	   (Dean	  et	  al.	  2002)	  and	  during	   WGA-­‐PCR	   based	   amplification	   of	   heterozygous	   alleles	   for	   pre-­‐implantation	  genetic	  diagnosis,	  preferential	  WGA-­‐PCR	  amplification	  of	  one	  allele	  compared	   to	   the	  other	  has	  been	  described	   (Paunio	  et	  al.	  1996).	   	  Evidently,	   the	  risk	  of	  amplification	  biases	  in	  the	  experiments	  discussed	  in	  this	  chapter	  must	  be	  addressed.	  	  
4.1.3.2 DNA	  labelling	  	  	   Once	   sufficient	   DNA	   has	   been	   amplified	   and	   purified	   the	   samples	   are	  quantified	   by	   spectrophotometry	   using	   a	   Nanodrop-­‐1000	   spectrophotometer.	  	  After	  adjustment	  to	  identical	  DNA	  amounts	  in	  the	  paired	  IP	  and	  IN	  samples	  each	  is	  labelled	  with	  a	  fluorescent	  marker.	  	  In	  our	  DIP-­‐chip	  assay	  this	  is	  done	  using	  the	  BioPrime	   Total	   Genomic	   DNA	   Labelling	   System	   (Invitrogen)	   following	   the	  manufacturers	  protocol.	   	  Typically,	  Alexa-­‐Fluor	  5	   is	  used	   for	   the	   IP	  sample	  and	  Alexa-­‐Fluor	   3	   for	   the	   IN	   sample.	   	   The	   labelled	   IN	   sample	   then	   produces	   green	  fluorescence	   at	   555nm	  excitation	   and	  565	  nm	  emission,	   and	   the	  Alexa-­‐Fluor	  5	  labelled	   IP	   sample	  produces	   red	   fluorescence	   at	   650nm/670nm	  excitation	   and	  emission	   respectively.	   	   Again,	   labelling	   requires	   a	   DNA	   amplification	   reaction,	  using	  the	  Exo-­‐Klenow	  fragment	  (the	  N-­‐terminal	  fragment	  of	  DNA	  polymerase	  I)	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to	   incorporate	   the	   labelled	  nucleotides	   into	  newly	   synthesized	  DNA	   fragments,	  resulting	   in	   an	   eight-­‐fold	   increase	   in	   DNA	   quantity	   during	   the	   reaction	  (Invitrogen	   2014).	   Following	   labelling,	   both	   samples	   are	   purified	   and	   the	  labelling	  efficiency	  and	  quantity	  of	  labelled	  DNA	  in	  each	  sample	  can	  be	  quantified	  using	  the	  Nanodrop-­‐1000	  spectrophotometer.	  	  
4.1.3.3 Microarray	  hybridisation	  
	  	   Prior	  to	  hybridisation	  the	  IN	  and	  IP	  samples	  are	  combined	  and	  precipitated	  into	  a	  single	  DNA	  pellet,	  before	  re-­‐suspension	  in	  purified	  water.	   	  The	  sample	   is	  mixed	  with	  appropriate	  buffers,	  denatured,	  cooled	  to	  37°C	  and	  then	  applied	  to	  a	  microarray	  chamber.	   	  The	  oligonucleotide	  covered	  glass	  slide	   forms	  the	  roof	  of	  the	   small	   chamber.	   	   Each	   individual	   microarray	   is	   sealed	   and	   the	   chamber	   is	  gently	  rotated	  for	  24	  hours	  at	  65°C	  to	  allow	  free	  circulation	  of	  the	  sample	  over	  the	   slide	   surface,	   giving	   maximum	   opportunity	   for	   hybridisation	   to	  complementary	   probes.	   	   At	   the	   end	   of	   the	   hybridisation	   period	   the	   slide	   is	  washed	   to	   remove	   non-­‐specific	   and	  weakly	   bound	  DNA	   fragments,	   the	   slide	   is	  gently	  dried,	  kept	  clean	  and	  covered	  from	  light	  in	  the	  period	  prior	  to	  scanning.	  	  
4.1.3.4 Microarray	  scanning	  and	  processing	  	   The	   microarray	   slide	   is	   then	   scanned,	   using	   an	   Agilent	   Microarray	  Scanner	  (model	  G2505B).	  	  Laser	  light	  of	  the	  desired	  wavelength	  is	  used	  to	  excite	  the	   relevant	   fluorophore	   and	   any	   emitted	   light	   is	   measured	   to	   a	   5-­‐micron	  resolution.	   	   Increasing	   hybridisation	   of	   greater	   amounts	   of	   one	   fluorophore	  labelled	  DNA	  compared	  to	  the	  paired	  sample	  gives	  a	  brighter	  fluorescence	  of	  that	  colour.	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4.1.3.5 Initial	  data	  extraction	  and	  processing	  	   The	   TIFF	   file	   output	   from	   the	   microarray	   scanner,	   giving	   the	   relative	  colour	   and	   spatial	   location	   of	   each	   feature,	   is	   analysed	   using	   Agilent’s	   Feature	  Extraction	   (FE)	   software.	   	   In	   basic	   terms,	   each	   feature	   is	   identified	   by	  comparison	  of	  the	  spatial	  location	  of	  the	  feature	  with	  respect	  to	  a	  grid	  aligned	  to	  the	  position	  of	  reference	  features	  printed	  on	  the	  array.	  	  The	  relative	  fluorescence	  is	   calculated,	   giving	   a	   conversion	   of	   the	   fluorescence	   intensity	   at	   each	   feature	  into	   a	   numerical	   value,	   linked	   to	   the	   location,	   feature	   position	   and	   sequence	  information.	  	  An	  additional	  computation	  is	  made	  by	  the	  FE	  software	  to	  calculate	  each	  feature	   intensity	  value	  subtracted	  for	  the	  background	  intensity	  emanating	  from	  the	  fluorescence	  of	  surrounding	  features.	  	  The	  background	  corrected	  IP	  and	  IN	   values	   are	   used	   for	   the	   experiments	   described	   in	   this	   thesis.	   	   This	   dataset	  forms	  the	  FE	  software	  output	  in	  the	  format	  of	  a	  tab	  delimited	  text	  file,	  containing	  the	  vital	  feature	  identification	  and	  location	  information,	  feature	  intensity	  values,	  and	  background	  subtracted	  feature	   intensity	  data,	   in	  addition	  to	  multiple	   fields	  of	  technical	  information.	  A	  second	  bioinformatic	  package,	  Sandcastle,	   is	  used	  to	   interpret	   the	  text	  file	  containing	  the	  data	  generated	  by	  the	  FE	  software.	   	  Sandcastle	  (Software	  for	  the	  Analysis	  and	  Normalisation	  of	  Data	   from	  ChIP-­‐chip	  AssayS	  of	  Two	  or	  more	  Linked	  Experiments)	  is	  a	  package	  of	  tools	  developed	  in	  our	  laboratory	  (Bennett	  2013),	   designed	   for	   use	   in	   R,	   the	   programming	   environment	   (R	   Development	  Core	  Team	  2014).	  	  Functions	  in	  the	  Sandcastle	  package	  can	  be	  used	  to	  import	  the	  relevant	   information	   from	  the	   text	   file	   into	  R	  and	   to	  ensure	   the	  data	  generated	  from	   the	  microarray	  meets	   quality	   standards.	   	   The	   data	   can	   be	   normalised	   (if	  possible	   and	   applicable)	   between	   replicate	   data	   sets,	   and	   the	   package	   can	   be	  used	  to	  generate	  plots	  to	  visualise	  patterns	  of	  data	  and	  to	  calculate	  relationships	  between	  microarray	  datasets.	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4.1.3.6 Sandcastle	  outputs	  for	  DIP-­‐chip	  microarray	  data	  analysis	  	  Three	   analysis	   tools	   and	   data	   outputs	   from	   Sandcastle	   in	   particular	   are	  relevant	  to	  the	  DIP-­‐chip	  experiments	  conducted	  in	  this	  thesis.	  	  	  	  
4.1.3.6.1 Adduct	  pattern	  plots	  	   The	  pattern	  of	  platinum-­‐DNA	  adducts	  along	  the	  genome	  can	  be	  plotted	  in	  what	  will	  be	  referred	  to	  as	  an	  adduct	  pattern	  plot.	  	  An	  example	  is	  shown	  below	  in	  figure	   4.4.	   	   On	   the	   x-­‐axis	   the	   genomic	   location	   is	   identified	   above,	   and	   the	  location	  of	  the	  individual	  probe	  position	  to	  which	  the	  IP/IN	  ratio	  corresponds	  is	  identified	  below	  by	  a	  grey	  circle.	  	  	  The	  adduct	  pattern	  is	  generated	  by	  plotting	  the	  log2	  ratio	  of	   the	  background	  corrected	  IP/IN	  ratio	  at	  each	  probe	  position	  along	  the	  section	  of	  the	  genome	  examined.	  	  	  On	  the	  y-­‐axis	  the	  use	  of	  the	  log2	  for	  the	  IP/IN	  ratio	  allows	  visualisation	  of	  probe	   IP/IN	   values	  when	   there	   are	   large	   differences	   between	  probe	   IP	   and	   IN	  values,	   as	   a	   consequence	   of	   large	   differences	   between	   the	   IP	   and	   IN	   sample	  probe	  hybridisation	  and	  fluorescence.	  	  In	  addition,	  the	  use	  of	  a	  log2	  scale	  allows	  equal	  visual	  representation	  of	  reciprocal	  ratios	  -­‐	  for	  example,	  ratios	  generated	  if	  the	  IP	  value	  is	  either	  double	  or	  half	  of	  the	  IN	  value	  (i.e.	  if	  considering	  two	  probes,	  at	  one	  the	  IP	  value	  =	  a*IN	  value,	  and	  at	  the	  other	  probe	  the	  IN	  value	  =	  (1/a)*IP	  value,	  the	  distance	  of	  each	  plotted	  point	  from	  the	  central	  point	  of	  the	  pattern	  plot	  data	  will	  be	  the	  same,	  although	  in	  opposing	  direction.	   	  For	  reference,	  as	  20=1,	  a	  log2	  binding	   level	   of	  0	   equates	   to	   equal	  probe	   IP	   and	   IN	   fluorescence	   intensity	  values,	  resulting	  in	  an	  IP/IN	  ratio	  of	  1.	  	  This	  corresponds	  to	  approximately	  equal	  fragments	  in	  the	  IP	  and	  IN	  samples	  at	  that	  probe	  region.	  An	  equal	  amount	  of	  fragments	  in	  the	  IP	  and	  IN	  samples	  is	  not	  present	  in	  the	  pre-­‐amplification	  DIP	  samples,	  because	  much	  more	  DNA	  is	  present	  in	  the	  IN	  sample	   than	   the	   IP	   sample	   -­‐	   only	   ~1%	   of	   fragments	   are	   immunoprecipitated	  	  (discussed	  later	  in	  section	  4.4.5	  and	  table	  4.1).	  	  Only	  after	  DNA	  amplification	  and	  labelling	   is	   the	   total	   DNA	   content	   of	   the	   IP	   and	   IN	   samples	   equal,	   allowing	  determination	  with	   the	  microarray	   of	   the	   relative	   hybridisation	   at	   each	  probe.	  	  
	   170	  
By	  amplifying	  all	  IP	  samples	  and	  adjusting	  to	  the	  same	  final	  DNA	  concentration	  pre-­‐hybridisation,	   information	   on	   the	   relative	   immunoprecipitation	   efficiency	  between	  IP	  samples,	  previously	  acquired	   in	  the	  qPCR	  stage	  of	   the	  DIP	  phase	  of	  the	  assay	  and	  dependent	  on	   the	  overall	   level	  of	   induced	  adducts,	   is	   lost.	   	  What	  remains	   is	   the	   relationship	   between	   fragments	   in	   the	   IP	   and	   IN	   sample	   –	   the	  pattern	  of	   peaks	   and	   troughs	   –	   that	   can	  be	   compared	  between	   repeat	   samples	  from	   the	   same	   individual	   (an	   issue	   of	   assay	   noise)	   and	   between	   samples	  different	  individuals	  treated	  under	  the	  same	  conditions	  (an	  issue	  of	  assay	  signal).	  	  
	  
Figure	  4.4:	  Example	  oxaliplatin-­‐DNA	  adduct	  pattern	  plots.	  Oxaliplatin-­‐DNA	  adduct	  pattern	  plots	   from	   four	  experimentally	  generated	  microarray	  DIP-­‐chip	  datasets	  over	  a	  short	  section	  of	  chromosome	  17	  are	  shown.	   	  Datasets	  1	   (black)	  and	  2	  (red)	   are	   compared	   in	   the	   upper	   panel	   (A)	   and	   datasets	   3	   (blue)	   and	   4	   (purple)	   are	  compared	  in	  the	  lower	  panel	  (B).	  	  This	  figure	  demonstrates	  how	  the	  adduct	  pattern	  profiles	  can	   be	   visualised	   with	   a	   adduct	   pattern	   plot.	   	   It	   is	   obvious	   in	   this	   extreme	   example	   to	  identify	  the	  two	  matching	  oxaliplatin-­‐DNA	  adduct	  pattern	  datasets	  (1	  and	  2	  in	  panel	  A)	  and	  two	  poorly	  matching	  datasets	  (3	  and	  4	  in	  panel	  B).	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4.1.3.6.2 Spearman’s	  correlation	  coefficient	  	   The	  second	  metric	  available	  in	  R,	  and	  used	  extensively	  in	  this	  thesis,	  is	  the	  Spearman’s	   correlation	   coefficient,	   a	   non-­‐parametric	   measure	   of	   statistical	  dependence	  between	  two	  (microarray)	  datasets.	  	  The	  non-­‐parametric	  statistic	  is	  considered	   more	   statistically	   robust	   and	   used	   in	   preference	   to	   the	   related	  Pearson’s	  correlation,	  a	  parametric	  statistic,	  as	  the	  distribution	  and	  parameters	  of	   the	   experimental	   datasets	   and	   are	   not	   normally	   distributed	   and	   cannot	   be	  assumed.	   	   In	   most	   instances,	   however,	   the	   Spearman’s	   and	   Pearson’s	  correlations	  are	  very	  similar	  for	  the	  DIP-­‐chip	  datasets	  used	  in	  this	  thesis	   	  (data	  not	  shown).	  In	   the	   context	  used	   in	   this	   thesis,	   the	   Spearman’s	   correlation	   is	   a	   single	  quantification	   of	   how	   closely	   two	   independent	   microarray	   adduct	   pattern	  datasets	  match	  one-­‐another.	   	   In	  each	  dataset	  the	  probes	  are	  ranked	  in	  order	  of	  (log2)	   IP/IN	   ratio	   value.	   	   The	   correlation	   between	   probe	   rankings	   are	   then	  compared,	  with	  a	  Spearman’s	  correlation	  of	  1	  if,	  in	  both	  datasets,	  the	  rank	  orders	  are	  identical,	  -­‐1	  if	  the	  rankings	  are	  exactly	  inverse,	  and	  0	  if	  there	  is	  no	  association	  between	  rank	  orders	  (and	  hence	  adduct	  patterns)	  between	  datasets.	  	  Spearman’s	  correlation	  values	  are,	   in	  many	   instances	   in	   the	   following	  discussion,	  displayed	  in	  a	  matrix	  of	  correlation	  values	  between	  several	  experimental	  conditions	  with	  colour	   coding	   to	   give	   a	   broad	  overview	  of	   the	   strength	  of	   association	  between	  several	  different	  samples.	  	  	  An	   example	   of	   the	   relationship	   between	   the	   adduct	   pattern	   plot	   and	  Spearman’s	   correlation	   in	   this	   context	   can	   be	   demonstrated	   using	   4	  experimentally	   generated	   oxaliplatin-­‐DNA	   adduct	   pattern	   datasets	   (arbitrarily	  labelled	   1	   to	   4).	   	   An	   oxaliplatin-­‐DNA	   adduct	   pattern	   plot	   of	   two	   of	   the	  experimentally	   generated	   datasets,	   1	   and	   2,	   with	   patterns	   that	   match	   well	   is	  displayed	  above	  in	  figure	  4.4	  (A),	  and	  two	  poorly	  matching	  datasets,	  3	  and	  4,	  in	  figure	  4.4	  (B).	  	  In	  figure	  4.5	  the	  probe	  log2	  IP/IN	  values	  from	  each	  pair	  of	  experimental	  microarray	   datasets	   are	   plotted	   against	   one	   another	   in	   a	   density	   scatter	   plot,	  with	   darker	   blue	   colour	   representing	   a	   higher	   density	   of	   data-­‐points	   from	   the	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~44,000	   features	   represented	   in	   each	  dataset.	   	   In	  4.5	   (A)	   the	   closely	  matching	  adduct	  pattern,	  datasets	  1	  and	  2,	  are	  plotted,	  and	  in	  4.5	  (B)	  data	  from	  the	  poorly	  matching	  datasets	  3	  and	  4	   is	  displayed.	   	   In	   figure	  4.5	   (A),	  where	   there	   is	   close	  matching	  of	   the	  underlying	  oxaliplatin-­‐DNA	  adduct	  patterns,	   the	  data	  points	   lie	  predominantly	   on	   the	   line	   y=x,	   i.e.	   at	   each	   probe	   in	   dataset	   1	   the	   IP/IN	   value	  closely	  matches	  that	  in	  dataset	  2.	  	  The	  close	  match	  of	  the	  data	  is	  summarised	  by	  the	  Spearman’s	  correlation	  of	  0.93.	  Compare	  this	  with	  figure	  4.5	  (B),	  in	  which	  the	  IP/IN	  values	  at	  each	  probe	  from	   the	  poorly	  matching	  oxaliplatin-­‐DNA	  adduct	  pattern	  datasets	  3	  and	  4	  are	  plotted.	   	   	  There	   is	  a	  poor	  relationship	  between	   the	   IP/IN	  values	  at	  each	  probe,	  and	  the	  data	  shows	  no	  obvious	  relationship	  along	  the	  line	  y=x.	  	  This	  information	  -­‐	   the	   lack	  of	   relationship	  between	   IP/IN	  values	  at	   each	  probe	   in	  each	  dataset	   -­‐	  can	  be	  condensed	  into	  the	  single	  Spearman’s	  correlation	  value	  of	  0.07.	  	  
	  
Figure	  4.5:	  Example	  density	  scatter	  plots.	  The	   four	   experimentally	   generated	   oxaliplatin-­‐DNA	   adduct	   pattern	   microarray	   datasets	  used	   in	   figure	  5.4	  are	  compared	   in	  density	  scatter	  plots	   in	   this	   figure.	   	   In	  A,	   the	   log2	  IP/IN	  value	   at	   each	   probe	   is	   plotted	   in	   two	   closely	   matching	   datasets	   (1	   and	   2,	   also	   shown	   in	  figure	  5.4A).	  	  Panel	  B	  shows	  a	  plot	  of	  the	  IP/IN	  values	  of	  datasets	  3	  and	  4	  (corresponding	  to	  poorly	  matching	  patterns	  and	  the	  datasets	  in	  figure	  5.4	  B).	  	  The	  closely	  matching	  datasets	  1	  and	  2	  (in	  plot	  A)	  cluster	  along	  the	  line	  y=x,	  and	  have	  a	  Spearman’s	  correlation	  of	  0.93.	  	  The	  poorly	   matching	   datasets	   3	   and	   4	   in	   panel	   B	   demonstrate	   no	   obvious	   relationship,	   in	  agreement	   with	   Spearman’s	   correlation	   value	   of	   0.07	   and	   the	   poorly	   matching	   adduct	  patterns	  in	  figure	  5.4B	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4.1.3.6.3 Mathematically	  generated	  predicted	  adduct	  profiles	  	   A	   third	  Sandcastle	   tool,	  used	  extensively	   in	   the	   following	  sections,	   is	   the	  ability	  to	  generate	  a	  theoretical	  dataset	  representing	  a	  predicted	  platinum-­‐DNA	  adduct	   pattern.	   	   As	   discussed	   in	   chapter	   1,	   section	   1.2.6,	   both	   cisplatin	   and	  oxaliplatin	   form	   platinum-­‐DNA	   intrastrand	   adducts	   at	   the	   same	   ratio	   between	  different	  combinations	  of	  dinucleotides	  –	  65%	  between	  adjacent	  guanines	  (GpG),	  25%	   between	   adjacent	   adenine-­‐guanine	   dinucleotides	   (ApG),	   and	   5-­‐10%	  between	   two	   guanines	   separated	   by	   an	   unspecified	   third	   nucleotide	   (GpNpG)	  (Kozelka	  2009).	  	  Using	  this	  information	  it	  is	  possible	  to	  mathematically	  estimate	  the	  relative	  probability	  of	  adduct	  formation	  at	  each	  probe	  location,	  based	  on	  the	  predicted	   affinity	   of	   platinum-­‐DNA	   adduct	   for	   the	   sequence	   of	   each	   probe	   and	  the	  adjacent	  DNA	  sequence.	  Notably,	   the	  Sandcastle	  platinum	  predicted	  profile	   is	  based	  only	  on	  DNA	  sequence	  information.	  	  The	  studies	  that	  elucidated	  the	  dinucleotide	  specificity	  of	  cisplatin	  were	  based	  on	  studies	  in	  naked,	  purified	  DNA	  and	  may	  not	  fully	  reflect	  the	  adduct	  profile	  that	  occurs	  in	  vivo	  (chapter	  1	  section	  1.2.6).	  	  For	  example,	  the	  model	  does	  not	  take	  account	  of	  the	  effect	  of	  higher	  order	  chromatin	  structure	  on	  adduct	  formation,	  or	  the	  preference	  for	  the	  formation	  of	  adducts	  at	  nucleosome	  linker	   regions	   compared	   to	   the	  nucleosome	  core	   (see	   chapter	  1,	   section	  1.2.8).	  	  As	  such,	  the	  model	  is	  an	  approximation	  of	  a	  true	  platinum-­‐DNA	  adduct	  pattern.	  	  	  Even	   with	   these	   caveats,	   the	   Sandcastle	   platinum	   prediction	   profile	  appears	   to	   correlate	   positively	   with	   platinum	   adduct	   patterns	   experimentally	  generated	   with	   in	   vivo	   cell	   culture	   models,	   with	   a	   Spearman’s	   correlation	  coefficient	  of	  0.76	  between	  predicted	  and	  experimental	  microarray	  data	  (figure	  4.6	  (Powell	  2014)).	   	   In	   the	  context	  of	   this	   thesis,	   the	  mathematically	  generated	  platinum	  predicted	  profile	  dataset	  will	  be	  compared	  to	  experimentally	  generated	  microarray	   datasets	   in	   the	   adduct	   pattern	   plot	   and	   by	   using	   the	   Spearman’s	  correlation	   to	   give	   an	   single	   metric	   of	   how	   experimental	   data	   matches	   this	  independent	  reference	  data.	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Figure	  4.6:	  An	  example	  cisplatin-­‐DNA	  adduct	  pattern	  plot	  and	  predicted	  adduct	  profile.	  An	   adduct	   pattern	   plot	   showing	   an	   experimentally	   generated	   cisplatin	   adduct	   profile	  (black)	   over	   a	   short	   section	   of	   chromosome	   17.	   	   The	   theoretical	   ‘platinum	   predication	  profile’,	  mathematically	   generated	   to	   reflect	   the	  preference	   for	   the	   formation	  of	  platinum-­‐DNA	   adducts	   at	   specific	   dinucleotide	   sequences	   is	   also	   displayed	   (red).	   	   The	   Spearman’s	  correlation	  between	  experimental	  and	  theoretic	  datasets	   is	  0.76	  in	  this	  section,	  confirming	  that	  the	  patterns	  match	  closely	  (Data	  from	  (Powell	  2014)).	  	  	  
 Aims	  of	  this	  chapter	  4.2
	   The	  DNA	  damage	  microarray	  technique	  developed	  in	  our	   laboratory	  has	  been	   translated,	   initially	   from	  a	   research	   tool	   to	   investigate	   protein	   binding	   in	  yeast,	   into	   a	   DIP-­‐chip	   method	   of	   detecting	   DNA	   damage	   at	   high	   resolution	  through	  sections	  of	  the	  genome	  from	  UV	  irradiation	  in	  yeast	  (Teng	  et	  al.	  2010).	  	  More	  recent	  work	  has	  adapted	  the	  technique	  into	  a	  method	  that	  can	  be	  used	  for	  detecting	  platinum-­‐DNA	  adducts	  in	  cultured	  human	  cells	  (Powell	  2014).	  The	  experiments	  described	   in	   the	  previous	  chapter	  demonstrate	  several	  steps	  that	  were	  required	  to	  translate	  the	  DNA	  immunoprecipitation	  stage	  of	  the	  DIP-­‐chip	  assay	  into	  a	  tool	  capable	  of	  reliably	  measuring	  oxaliplatin-­‐DNA	  adducts	  in	  ex	  vivo	  oxaliplatin	  treated	  clinical	  samples	  at	  a	  limited	  number	  of	  28S	  loci	  by	  qPCR.	  	  This	  chapter	  concerns	  the	  next	  step	  in	  this	  process	  -­‐	  the	  translation	  of	  the	  full	  DIP-­‐chip	  technique	  into	  a	  single-­‐use	  assay	  for	  the	  generation	  and	  analysis	  of	  patterns	   of	   platinum-­‐DNA	   adducts	   in	   the	   same	   human	   clinical	   samples.	   	   This	  requires	  a	  thorough	  study	  of	  the	  performance	  of	  the	  assay	  in	  this	  new	  tissue,	  and	  the	  modification	  and	  optimisation	  of	  the	  assay	  to	  generate	  platinum-­‐DNA	  adduct	  profiles	   in	   a	   reliable	   and	   reproducible	   output,	   a	   critical	   step	   in	   adapting	   this	  technology	  for	  use	  in	  future	  clinical	  studies.	  
 
Figure 4.12 - DNA microarray data for normal dermal fibroblast DNA treated in vitro with 
2.5mM cisplatin or oxaliplatin. Scatter plots demonstrate the association between iological repeat 
microarray datasets. Log2 IP/IN values are presented and these plots are displayed as ‘heat plots’ 
whereby the darker blue regions represent the greater density of data. These datasets demonstrate a 
linear relationship, with the majority of values congregated along or near the line of x = y. 4.12(a) 
displays the values at each microarray feature for two biological repeats of cisplatin treated DNA 
(Pearson's product moment correlation coefficient (r) = 0.89) and 4.12(b) for two biological repeats of 
oxaliplatin treated DNA (r = 0.6). 4.12(c) and (d) show genome plots where log2 IP/IN ratios are 
plotted for a section of chromosome 17 showing the genomic distribution of platinum-induced DNA 
damage (black profile) and the predi ted distribution for damage (red profil ) in this region. 4.12(c) 
shows the mean of 3 repeat experiments for cisplatin-treated DNA (Pearson’s correlation with the 
predicted trace is 0.76 for the region plotted, 0.73 for the whole genome), 4.12(d) shows the mean of 
the 2 repeat experiments for oxaliplatin-treated DNA presented in (b) (correlation with the predicted 
trace is 0.55 f r region plotted and 0.42 for the whole genome). The yellow boxes sh w ORF positions 
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   The	   distinction	   between	   two	   specific	   applications	   of	   the	   DIP-­‐chip	   assay	  during	  development	  and	  validation	  studies	  is	  central	  to	  this	  and	  the	  next	  chapter.	  	  Firstly,	   experiments	   are	   required	   to	   assess	   the	   ability	   of	   the	  DIP-­‐chip	   assay	   to	  reproducibly	   generate	   oxaliplatin-­‐DNA	   adduct	   patterns	   from	   clinical	   samples	  taken	  repeatedly	  from	  the	  same	  individual	  and	  treated	  in	  the	  same	  experimental	  conditions	   –	   an	   issue	   of	   assay	   ‘noise’.	   	   This	   differs	   from	   developing	   and	  determining	   the	   capability	   of	   the	   assay,	   and	   associated	   bioinformatic	   analysis	  tools,	  to	  detect	  ‘signals’	  by	  comparing	  oxaliplatin-­‐DNA	  adduct	  patterns	  generated	  between	   two	   different	   individuals	   under	   the	   same	   experimental	   conditions.	  	  Detection	  of	  biological	  signals	  with	  the	  DIP-­‐chip	  assay	  is	  the	  ultimate	  aim	  of	  this	  thesis,	  and	  is	  essential	  for	  future	  clinical	  studies.	  The	  ability	  to	  reliably	  detect	  a	  biological	  signal	  -­‐	  to	  discriminate	  between	  adduct	  patterns	  from	  different	  individuals	  -­‐	  is	  partially	  dependent	  on	  the	  noise	  in	  the	   assay.	   	   The	   assay	  must	   reproducibly	   generate	   adduct	   patterns	   in	   repeated	  samples	   from	   the	   same	   individual	   (i.e.	   have	   a	   low	   noise	   profile)	   before	  comparisons	   between	   different	   individuals	   can	   be	   trusted	   and	   used	   to	   guide	  treatment	  decisions.	  	  The	  concept	  of	  the	  relationship	  between	  signal	  and	  noise	  in	  the	   DIP-­‐chip	   assay	   –	   the	   signal	   to	   noise	   ratio	   –	   is	   central	   to	   this	   and	   the	   next	  chapter.	  The	  specific	  aims	  of	  this	  chapter	  are	  to	  translate	  the	  chip	  assay	  for	  use	  in	  analysing	  clinical	  samples,	  and	  to	  explore	  the	  experimental	  and	  laboratory	  issues	  that	   arise	   from	   this	   transition	   from	   a	   cultured	   cell	   model,	   particularly	   when	  repeatedly	  generating	  oxaliplatin-­‐DNA	  adduct	  patterns	  from	  the	  same	  individual.	  	  As	  will	  be	  shown,	  the	  transfer	  of	  this	  technology	  into	  clinical	  samples	  results	  in	  significant	  variability	  between	  adduct	  patterns	  from	  the	  same	  individual,	  leading	  to	   experimental	   and	   technical	   challenges	   that	   need	   to	   be	   overcome	   before	   the	  technique	  can	  be	  used	  reliably	  in	  the	  clinical	  setting.	  The	  experiments	  and	  results	  described	  in	  this	  chapter	  are	  also	  extensively	  referred	  to	  on	  many	  occasions	  in	  chapter	  5	  for	  two	  main	  reasons.	  	  Firstly,	  during	  the	   laboratory	  phase	  of	   the	  translation	  of	   this	   technique	   it	  will	  become	  evident	  that	  new	  bioinformatic	  tools	  are	  required	  to	  analyse	  the	  data	  in	  more	  depth	  than	  are	   currently	   available	   in	   the	   standard	   laboratory	   ChIP/DIP-­‐chip	   Sandcastle	  analysis	   package.	   	   In	   combination	   with	   experimental	   approaches	   used	   below,	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   The	  methods	  and	   laboratory	  protocols	  used	   for	   the	  microarray	  phase	  of	  the	  DIP-­‐chip	   assay	   are	  described	   in	   chapter	  2,	   section	  2.2.	   	  When	  applicable,	   a	  brief	  overview	  will	  follow	  at	  stages	  in	  the	  subsequent	  discussion.	  	  	  
4.2.2 Overview	  of	  ‘chip’	  assay	  laboratory	  workflow	  	  	   The	  experiments	  conducted	   in	   this	  chapter	  continue	   to	  use	   the	  methods	  and	   techniques	   used	   extensively	   in	   chapter	   3	   to	   generate	   DIP	  immunoprecipitated	   DNA.	   	   Further	   processing	   of	   the	   post-­‐qPCR	   IP	   and	   IN	  samples	   for	   amplification,	   DNA	   labelling,	   microarray	   hybridisation	   and	   data	  analysis	  are	  the	  main	  focus	  of	  this	  chapter.	  Briefly,	  the	  following	  experimental	  approach	  was	  used.	  	  Peripheral	  blood	  mononuclear	   cells	   (PBMC)	   samples	   used	   in	   these	   experiments	  were	   harvested	  from	  blood	  samples	  donated	  by	  two	  volunteers	  (Patient	  A	  and	  B)	  or	  from	  blood	  samples	   obtained	   from	   the	   Welsh	   Blood	   Service	   after	   appropriate	   ethical	  permissions	   were	   obtained	   (reference	   WBS	   Ad-­‐Hoc-­‐008-­‐12).	   	   Following	  venesection,	  PBMC	  were	  harvested,	  washed,	  counted	  and	  subsequently	  5	  million	  cells	  per	  experimental	  condition	  were	  cultured	  at	  37°C,	  5%	  CO2	  for	  30	  minutes	  in	  RPMI	  1640	  media	  containing	  serum,	  L-­‐glutamine	  and	  antibiotic,	  before	  exposure	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to	  oxaliplatin	  for	  24	  hours	  by	  the	  addition	  of	  small	  volumes	  of	  concentrated	  drug	  to	   the	   culture	   medium.	   	   The	   doses	   of	   oxaliplatin	   used	   were	   chosen	   following	  detailed	  review	  in	  the	  experiments	  in	  the	  previous	  chapter,	  and	  covered	  a	  dose	  range	  of	   10µM	   	   (considered	  a	   ‘physiological’	   dose	  point),	   100µM	  and	  1000µM,	  acknowledging	  the	  potential	  for	  an	  increased	  rate	  of	  adduct	  formation,	  cell	  death	  and	  DNA	  degradation	   previously	   demonstrated	   at	   these	   doses,	   as	   described	   in	  the	   previous	   chapter,	   section	   3.4.5.	   	   After	   24	   hours	   incubation	   the	   cells	   were	  harvested,	  washed	  twice	  in	  PBS	  and	  re-­‐suspended	  in	  200uL	  of	  PBS	  prior	  to	  DNA	  extraction	  using	  DNeasy	  Blood	  and	  Tissue	  Kit	  (Quiagen)	  using	  the	  manufacturers	  protocol.	   	   Extracted	   DNA	   samples	   were	   processed	   by	   sonication,	  immunoprecipitation,	   purification	   and	   quantification	   by	   qPCR,	   with	   the	  conditions	   as	   outlined	   in	   the	   previous	   chapter,	   and	   described	   in	   the	   methods	  chapter	  2,	  section	  2.1.	  	  Independent	  repeat	  experiments	  were	  performed	  twice	  for	  the	  untreated	  and	   10µM	   oxaliplatin	   treated	   samples.	   	   The	   treated	   samples	   at	   100µM	   and	  1000µM	   dose	   of	   oxaliplatin	   were	   performed	   three	   times	   as	   fully	   independent	  repeat	  experiments.	  	  The	   microarray	   aspect	   of	   the	   DIP-­‐chip	   assay	   requires	   four	   stages	   of	  laboratory	   processing	   of	   the	   paired	   immunoprecipitated	   samples	   (IP)	   and	   the	  input	   control	   sample	   (IN).	   	   Firstly,	   amplification	   to	   (at	   least)	   the	  DNA	   amount	  required	   for	   downstream	   processing	   using	   whole	   genome	   amplification	   PCR	  (WGA-­‐PCR)	   based	   amplification	   using	   the	   WGA2	   Kit	   (Sigma)	   and	   associated	  protocol	   (Sigma	   2014).	   	   Secondly,	   the	   amplified	   DNA	   was	   labelled	   using	   the	  BioPrime	   Total	   Genome	   Labelling	   Kit	   (Invitrogen),	   using	   the	   manufacturers	  protocol.	   	  In	  the	  third	  and	  fourth	  stages	  the	  labelled	  DNA	  was	  hybridised	  to	  the	  microarray	  slide	  using	  the	  Agilent	  aCGH	  kit	  and	  associated	  microarray	  protocol	  (Technologies	  2008),	  and	  the	  slide	  was	  scanned	  for	  data	  extraction.	  	  	  Finally,	  all	  data	  was	  processed	  following	  the	  procedure	  explained	  above	  in	  section	  4.1.3.5.	  In	  addition	  to	  each	  experiment	  being	  repeated	  as	  complete	   independent	  biological	   repeats,	   at	   different	   stages	  of	   the	   assay	   several	   samples	  were	   run	   in	  parallel	   as	   ‘technical	   replicates’	   allowing	   further	   detailed	   investigation	   and	  distinction	  between	   the	  biological	   and	   technical	  variability	  at	   each	   stage	  of	   the	  chip	  phase	  of	  the	  DIP-­‐chip	  assay.	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 Results	  4.3
4.3.1 Initial	  analysis	  of	  oxaliplatin	  PBMC	  microarrays	  	  At	   each	   dose	   point	   (untreated,	   10µM,	   100µM	   and	   1000µM),	   and	   for	  patients	   A	   and	   B,	   several	   independent	   repeat	   DIP-­‐chip	   experiments	   were	  conducted.	   	   Microarrays	   were	   processed	   and	   data	   was	   analysed	   as	   discussed	  above.	  	  Oxaliplatin-­‐DNA	  adduct	  pattern	  plots	  (Figure	  5.7	  and	  5.8)	  and	  a	  matrix	  of	  Spearman’s	  correlations	  between	  each	  sample	  was	  generated	  (Figure	  5.9).	  	  
	  
Figure	  4.7:	  A	  series	  of	  oxaliplatin-­‐DNA	  adduct	  pattern	  plots	  of	  several	  oxaliplatin	  treated	  
PBMC	  independent	  biological	  repeat	  samples	  from	  patient	  A.	  	  	  The	  top	  section	  shows	  the	  IP/IN	  ratio	  patterns	  generated	  in	  the	  untreated	  samples	  (purple).	  	  The	  100µM	  (middle	  -­‐	  blue),	  and	  1000µM	  (bottom	  -­‐	  orange)	  samples	  are	  also	  presented.	  	  The	  ‘trace’	   generated	   from	   each	   independent	   repeat	   experiment	   is	   shown	   separately	   in	   each	  panel,	  as	  described	  in	  the	  legend.	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Figure	  4.8:	  A	  series	  of	  oxaliplatin-­‐DNA	  adduct	  pattern	  plots	  of	  several	  oxaliplatin	  treated	  
PBMC	  independent	  biological	  repeat	  samples	  from	  patient	  B.	  	  The	   top	   section	   displays	   the	   IP/IN	   ratio	   patterns	   generated	   in	   the	   untreated	   samples	  (purple).	   	   In	   each	   lower	   panel	   the	   10µM	   (pink),	   100µM	   (blue),	   and	   1000µM	   (orange)	  samples	   are	   shown	   respectively.	   	   The	   trace	   generated	   from	   each	   independent	   repeat	  experiment	  is	  shown	  in	  each	  panel,	  as	  described	  in	  the	  legend.	  	  
	   	  The	  oxaliplatin-­‐DNA	  adduct	  pattern	  plots	  presented	  in	  figure	  4.7	  and	  4.8,	  generated	   from	   the	   DIP-­‐chip	   experiment,	   reveal	   underlying	   variability	   in	   the	  patterns	  generated	  by	  the	  assay	  when	  experiments	  are	  repeated	  in	  what	  should	  be	   identical	   samples	   and	   conditions.	   	   This	   is	   not	   unexpected	  when	   translating	  this	  technology	  from	  carefully	  controlled	  cell	  culture	  models	  into	  human	  clinical	  samples	   for	   the	   first	   time.	   	   In	   all	   of	   the	   oxaliplatin-­‐DNA	   adduct	   pattern	   plots	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(Figures	  4.7	  and	  4.8)	  the	  pattern	  varies	  over	  the	  area	  of	  the	  genome	  plotted,	  with	  variation	  in	  profile	  at	  each	  dose	  level	  and	  in	  both	  individuals.	  Notably,	  a	  pattern	  can	  be	  detected	  in	  the	  untreated	  sample,	  reflecting	  the	  fact	  that	  some	  DNA	  is	  immunoprecipitated	  by	  the	  CP9/19	  antibody	  and	  has	  been	  amplified	   sufficiently	   by	   WGA-­‐PCR	   to	   allow	   labelling	   and	   application	   to	   the	  microarray.	  	  Note	  that	  the	  centre	  of	  the	  data	  meets	  the	  y-­‐axis	  at	  approximately	  -­‐4,	  as	  opposed	  to	  0	  in	  the	  treated	  samples.	  	  When	  considering	  the	  adduct	  pattern	  troughs,	  a	  value	  of	  log2	  -­‐8	  correspond	  to	  an	  IP/IN	  ratio	  of	  0.004,	  so	  at	  this	  probe	  the	  relative	  fluorescence	  intensity	  of	  the	  IP	  to	  the	  IN	  sample	  is	  ~0.4%,	  indicating	  that	  minimal	  DNA	  is	  present	  at	  this	  probe	  in	  the	  IP	  sample.	  	  The	  midpoint	  of	  the	  probe	  values	  is	  approximately	  -­‐4	  on	  a	  log2	  scale,	  corresponding	  to	  an	  IP/IN	  ratio	  of	   0.06	   and	   only	   occasionally	   is	   the	   fluorescence	   intensity	   in	   the	   IP	   and	   IN	  samples	   equal,	   resulting	   in	   a	   log2	   binding	   level	   of	   0.	   	   This	   indicates	   that	   even	  though	  a	  pattern	  can	  be	  seen,	  very	  little	  DNA	  corresponding	  to	  this	  5Mb	  section	  of	   the	   genome	   is	   present	   in	   the	   IP	   sample	   and	   almost	   the	   entire	   pool	   of	   DNA	  fragments	  hybridised	  to	  each	  probe	  is	  from	  the	  IN	  sample.	  In	   the	   treated	   10µM,	   100µM	   and	   1000µM	   samples	   the	  midpoint	   of	   the	  plot	   is	   approximately	   set	   at	   0	   on	   the	   y-­‐axis,	   indicating	   equal	   fluorescence	  intensity	   at	   these	   probes	   in	   the	   IP	   and	   IN	   sample.	   	   With	   these	   experimental	  conditions,	   the	   comparison	   is	   then	   between	   the	   pattern	   of	   peaks	   and	   troughs,	  indicating	  areas	  of	  the	  genome	  where	  oxaliplatin-­‐DNA	  adducts	  are	  more,	  or	  less	  prevalent	  in	  the	  treated	  DNA	  samples.	  	  The	   presence	   of	   variability	   between	   adduct	   patterns	   from	   the	   same	  individual	   during	   independent	   repeat	   experiments,	   and	   at	   each	   experimental	  condition,	  is	  confirmed	  by	  reviewing	  the	  matrix	  of	  Spearman’s	  correlation	  values	  (figure	   4.9).	   	   This	   format	   allows	   a	   visual	   comparison	   of	   all	   of	   the	   processed	  clinical	  samples,	  at	  all	  of	  the	  different	  dose	  levels	  in	  both	  volunteers,	  and	  for	  each	  repeat.	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Individual B B A A A A B B B A A A B B B A A A
Condition U U U U 10 10 100 100 100 100 100 100 1000 1000 1000 1000 1000 1000
IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN
Individual Condition 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Condition Individual
B U IP/IN 1 0.47 0.60 0.36 0.42 0.23 0.21 0.03 0.30 0.25 0.31 0.24 0.27 0.22 0.21 0.30 0.25 0.29 1 IP/IN U B
B U IP/IN 2 0.47 0.50 0.29 0.34 0.20 0.17 M0.01 0.27 0.19 0.23 0.21 0.20 0.15 0.16 0.20 0.18 0.24 2 IP/IN U B
A U IP/IN 3 0.60 0.50 0.38 0.43 0.23 0.20 M0.02 0.32 0.23 0.30 0.24 0.25 0.20 0.20 0.27 0.23 0.29 3 IP/IN U A
A U IP/IN 4 0.36 0.29 0.38 0.26 0.16 0.15 0.02 0.21 0.16 0.20 0.17 0.16 0.15 0.15 0.17 0.15 0.20 4 IP/IN U A
A 10 IP/IN 5 0.42 0.34 0.43 0.26 0.21 0.30 0.03 0.37 0.31 0.35 0.27 0.30 0.25 0.26 0.31 0.34 0.31 5 IP/IN 10 A
A 10 IP/IN 6 0.23 0.20 0.23 0.16 0.21 0.20 0.03 0.23 0.20 0.21 0.18 0.16 0.15 0.15 0.18 0.19 0.19 6 IP/IN 10 A
B 100 IP/IN 7 0.21 0.17 0.20 0.15 0.30 0.20 0.07 0.48 0.59 0.50 0.37 0.37 0.24 0.25 0.47 0.45 0.30 7 IP/IN 100 B
B 100 IP/IN 8 0.03 M0.01 M0.02 0.02 0.03 0.03 0.07 0.06 0.09 0.10 0.03 0.10 0.18 0.11 0.10 0.17 0.10 8 IP/IN 100 B
B 100 IP/IN 9 0.30 0.27 0.32 0.21 0.37 0.23 0.48 0.06 0.49 0.51 0.40 0.32 0.26 0.29 0.40 0.44 0.36 9 IP/IN 100 B
A 100 IP/IN 10 0.25 0.19 0.23 0.16 0.31 0.20 0.59 0.09 0.49 0.57 0.37 0.39 0.23 0.25 0.53 0.48 0.31 10 IP/IN 100 A
A 100 IP/IN 11 0.31 0.23 0.30 0.20 0.35 0.21 0.50 0.10 0.51 0.57 0.40 0.33 0.26 0.26 0.45 0.51 0.34 11 IP/IN 100 A
A 100 IP/IN 12 0.24 0.21 0.24 0.17 0.27 0.18 0.37 0.03 0.40 0.37 0.40 0.24 0.19 0.21 0.30 0.32 0.28 12 IP/IN 100 A
B 1000 IP/IN 13 0.27 0.20 0.25 0.16 0.30 0.16 0.37 0.10 0.32 0.39 0.33 0.24 0.36 0.35 0.45 0.38 0.35 13 IP/IN 1000 B
B 1000 IP/IN 14 0.22 0.15 0.20 0.15 0.25 0.15 0.24 0.18 0.26 0.23 0.26 0.19 0.36 0.38 0.35 0.37 0.37 14 IP/IN 1000 B
B 1000 IP/IN 15 0.21 0.16 0.20 0.15 0.26 0.15 0.25 0.11 0.29 0.25 0.26 0.21 0.35 0.38 0.33 0.35 0.36 15 IP/IN 1000 B
A 1000 IP/IN 16 0.30 0.20 0.27 0.17 0.31 0.18 0.47 0.10 0.40 0.53 0.45 0.30 0.45 0.35 0.33 0.45 0.37 16 IP/IN 1000 A
A 1000 IP/IN 17 0.25 0.18 0.23 0.15 0.34 0.19 0.45 0.17 0.44 0.48 0.51 0.32 0.38 0.37 0.35 0.45 0.41 17 IP/IN 1000 A
A 1000 IP/IN 18 0.29 0.24 0.29 0.20 0.31 0.19 0.30 0.10 0.36 0.31 0.34 0.28 0.35 0.37 0.36 0.37 0.41 18 IP/IN 1000 A
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN
U U U U 10 10 100 100 100 100 100 100 1000 1000 1000 1000 1000 1000
B B A A A A B B B A A A B B B A A A
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
vs.)Platinum)Precition 0.27 0.21 0.28 0.14 0.30 0.16 0.35 M0.26 0.42 0.42 0.42 0.28 0.29 0.09 0.20 0.36 0.28 0.25
Scale 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0
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bottom	  right	  section	  contains	  the	  correlation	  values	  between	  microarray	  adduct	  patterns	   generated	   in	   treated	   samples,	   which	   have	   higher	   correlation	   values	  between	   one-­‐another	   (e.g.	   Spearman’s	   correlation	   values	   of	   0.45-­‐0.6	   between	  100µM	   samples	   and	   0.4-­‐0.5	   between	   100µM	   and	   1000µM	   samples)	   than	  with	  the	   untreated	   samples	   (values	   of	   0.1	   to	   0.3).	   	   This	   suggests	   that	   the	   DIP-­‐chip	  technique	   is	   able	   to	   detect	   a	   difference	   in	   the	   patterns	   generated	   between	   the	  higher	  dose	  oxaliplatin	  treated	  samples	  and	  the	  low	  dose	  or	  untreated	  samples.	  The	  matrix	   format	  also	  allows	  rapid	   identification	  of	  array	  datasets	   that	  may	   have	   developed	   technical	   problems.	   In	   this	   instance,	   a	   single	   experiment	  appears	   to	  have	   failed,	   the	   sample	   indicated	  by	   the	   red	  star	   (Patient	  B,	  100µM	  oxaliplatin,	  repeat	  2).	   In	  this	  sample	  the	  adduct	  pattern	  does	  not	  correlate	  well	  with	   any	   other	   samples	   (0.0-­‐0.2).	   	   Also	   of	   note,	   the	   100µM	   samples	   correlate	  with	  each	  other	   (0.4-­‐0.6)	  and	  with	   the	  predicted	  profile	   (~0.4)	  better	   than	   the	  highest	  dose	  1000µM	  samples	   (0.3-­‐0.4).	   	   This	  may	   reflect	   the	  degradation	   and	  poor	  DNA	  quality	  of	   the	   initial	  DNA,	  as	  demonstrated	   in	  experiments	  shown	   in	  chapter	  3,	  section	  3.4.5.1.	  The	   correlation	  between	   the	  oxaliplatin-­‐DNA	  adduct	  patterns	   generated	  in	  the	  experimental	  datasets	  with	  the	  mathematically	  generated	  platinum	  adduct	  predicted	  profile	  (described	  in	  section	  4.1.3.6.3)	  is	  shown	  in	  the	  lower	  bar,	  with	  higher	   correlation	   values	   appearing	   darker	   yellow	   in	   colour.	   	   The	   highest	  correlation	   value	   achieved	   is	   with	   several	   of	   the	   100uM	   samples,	   and	   lower	  correlation	   occurs	   with	   the	   untreated	   and	   very	   highly	   treated	   samples,	   again	  potentially	  reflecting	  the	  poor	  quality	  of	  the	  DNA	  used	  in	  the	  supra-­‐physiological	  doses	  1000µM	  oxaliplatin	  samples.	  	  Several	   initial	   conclusions	   and	   hypotheses	   can	   be	   drawn	   from	   this	   first	  analysis	   of	   human	   PBMC	   data.	   	   The	   higher	   correlation	   at	   100µM	   between	  independent	   repeats	   and	   with	   the	   predicted	   profile	   suggests	   that	   there	   is	   an	  oxaliplatin-­‐DNA	  adduct	  treatment	  ‘signal’	  that	  can	  be	  detected	  with	  the	  DIP-­‐chip	  experiment,	  as	  would	  be	  expected.	  	  There	  is,	  however,	  significant	  noise	  resulting	  in	  relatively	  high	  variability	  between	  patterns	  generated	  in	  the	  same	  individual	  in	  this	  series	  of	  independent	  biological	  repeats	  (Figures	  4.7	  and	  4.8).	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It	  appears	  that	  this	  technique	  can	  detect	  an	  oxaliplatin-­‐DNA	  pattern	  in	  the	  blood	  from	  an	  individual	  patient,	  with	  the	  potential	  that	  this	  signal	  could	  be	  used	  in	   to	   attempt	   to	   predict	   clinical	   outcome.	   	   It	   may	   be	   possible	   to	   improve	   the	  chances	   of	   reliably	   detecting	   the	   DNA	   damage	   signal	   if	   the	   assay	   could	   be	  improved	  to	  reduce	  the	  ‘noise’	  and	  improve	  the	  reproducibility.	  	  A	  higher	  ‘signal-­‐to-­‐noise’	  ratio	  would	  be	  beneficial	  if	  the	  assay	  is	  to	  be	  used	  as	  a	  single-­‐stop	  assay	  to	  generate	  an	  accurate	  platinum-­‐DNA	  adduct	  pattern	  that	  could	  be	  analysed	  as	  a	  predictive	  marker	  of	  biological	  effect	  and	  response	  or	  toxicity	  to	  chemotherapy	  agents.	  	  
4.3.2 Using	  mean	  adduct	  pattern	  datasets	  as	  a	  method	  to	  reduce	  
variability	  	   Significant	  variability	  in	  the	  oxaliplatin-­‐DNA	  patterns	  generated	  occurs	  in	  repeat	   samples	   from	   the	   same	   individual.	   	   It	  may	  be	   that	   calculating	   the	  mean	  IP/IN	   value	   at	   each	   probe	   position	   from	   several	   independent	   biological	   repeat	  datasets	  can	  reduce	  background	  noise	  present	  in	  the	  assay,	  and	  could	  potentially	  improve	   the	   correlation	   of	   the	   experimental	   patterns	   generated	   with	   the	  platinum	   predicted	   profile	   and	   with	   other	   clinical	   samples.	   	   To	   test	   this	  hypothesis,	   the	  mean	   IP/IN	   value	   at	   each	   probe	   location	   from	   each	   treatment	  condition	   in	   for	   each	   individual	  was	   calculated	   to	   produce	   a	  mean	   oxaliplatin-­‐DNA	   adduct	   pattern	   at	   each	   dose	   level,	   with	   the	   standard	   error	   of	   the	   repeat	  samples	  also	  calculated,	  displayed	  in	  figure	  4.10.	  	  The	  mean	  adduct	  pattern	  only	  is	  plotted	  in	  figure	  4.11.	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Figure	   4.10:	   	   The	  mean	   adduct	   pattern	   and	   standard	   error	   of	   several	   independent	  DIP-­‐
chip	  experiments	  The	   mean	   oxaliplatin-­‐DNA	   adduct	   pattern	   (solid	   line)	   and	   standard	   error	   (shaded	   area)	  from	   a	   series	   of	   oxaliplatin-­‐DNA	   adduct	   pattern	   plots	   of	   several	   oxaliplatin	   treated	   PBMC	  independent	   biological	   repeat	   samples	   from	  patient	   A	   and	  B	   is	   shown.	   	   This	   plot	   displays	  the	   log2	   IP/IN	   ratio	   patterns	   generated	   in	   the	   untreated	   samples	   in	   the	   top	   plot,	   in	   the	  middle	   plot	   the	   100µM	   (blue)	   samples,	   and	   the	   lower	   plot	   shows	   the	   1000µM	   (orange)	  samples.	  	  	   As	   can	   be	   seen,	   the	   standard	   error	   of	   all	   of	   the	   comparisons	   between	  patients	   A	   and	   B	   overlaps	   in	   the	   central	   distribution	   of	   each	   trace.	   	   It	   is	   not	  possible	   to	   differentiate	   the	   pattern	   between	   patient	   A	   and	   B	   under	   these	  conditions.	  	  However	  the	  mean	  trace,	  a	  similar	  pattern	  in	  between	  individuals	  is	  more	  apparent	  and	  is	  demonstrated	  in	  figure	  4.11.	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Figure	  4.11:	  Adduct	  pattern	  plots	  with	  mean	  datasets:	  	  The	  mean	   oxaliplatin-­‐DNA	   adduct	   pattern	   (solid	   line)	   from	   a	   series	   of	   oxaliplatin	   treated	  PBMC	   independent	   biological	   repeat	   samples	   from	   patient	   A	   and	   B	   is	   shown.	   	   The	   top	  section	  displays	   the	  mean	   IP/IN	  ratio	  patterns	  generated	   in	   the	  untreated	  samples.	   	   In	   the	  middle	   panels	   10µM	   (pink)	   100µM	   (blue),	   and	   1000µM	   (orange)	   oxaliplatin	   treated	  samples	  are	  shown	  respectively.	  	  A	   correlation	  matrix	   generated	  using	   the	  mean	  probe	   value	   data,	   figure	  4.12,	  reveals	  that	  the	  mean	  of	  the	  independent	  samples	  follow	  a	  similar	  overall	  relationship	   as	   previously	   demonstrated	   in	   the	   correlation	   matrix	   from	  individual	   repeats	   in	   figure	   4.9,	   in	   this	   instance	   with	   untreated	   samples	  correlating	  better	   together	  (0.63)	   than	  with	   the	   treated	  samples	   (a	  Spearman’s	  correlation	  of	  0.3-­‐0.4).	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Figure	  4.12:	  Correlations	  between	  mean	  probe	  value	  datasets.	  A	   matrix	   of	   Spearman’s	   correlation	   values	   comparing	   oxaliplatin-­‐DNA	   adduct	   patterns	  generated	  from	  mean	  probe	  IP/IN	  values	  from	  independent	  biological	  repeats	  at	  each	  dose	  level	   of	   oxaliplatin	   treated	   PBMC	   samples	   from	   individuals	   A	   and	   B.	   	   The	   correlation	  between	  the	  mean	  damage	  pattern	  and	  the	  platinum	  predicted	  profile	   is	  also	  shown	  in	   the	  lowest	  bar.	  	  	  	   Using	  this	  ‘mean	  dataset’	  approach	  the	  similarities	  between	  patterns	  from	  DIP-­‐chip	   samples	   treated	   under	   the	   same	   experimental	   conditions	   between	  individuals	   are	   greater,	   and	   the	   discrimination	   between	   treated	   and	   untreated	  adduct	   patterns	   is	   also	   better.	   	   For	   example,	   untreated	   patterns	   between	  individuals	  match	  0.63	   (as	  opposed	   to	  0.3-­‐0.6	  with	   individual	   samples	  –	   figure	  4.9)	   and	  100µM	  sample	   correlate	  0.69	  between	  patient	  A	  and	  B	  as	  opposed	   to	  0.37-­‐0.59	  with	  individual	  samples	  (figure	  4.9).	  	  In	  the	  top	  right	  section	  the	  mean	  treated	   datasets	   compared	   to	   the	   mean	   untreated	   datasets	   correlate	   0.3-­‐0.4,	  indicating	  the	  difference	  between	  untreated	  and	  treated	  patterns	  is	  more	  robust	  and	  more	  consistent	  than	  with	  individual	  samples.	  	  Additionally,	  the	  correlation	  values	   between	  mean	   treated	   samples	   and	   the	   platinum	  predicted	   profiles	   are	  higher	   than	  with	   individual	   samples	   (a	   range	   of	   0.26	   to	   0.46	   (figure	   4.12)	   vs.	  0.25-­‐0.42	  (figure	  4.9)).	  	  	  	  
Means U U 10 100 100 1000 1000
B A A B A B A
IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN
1 2 3 4 5 6 7
U B IP/IN 1 0.63 0.44 0.33 0.35 0.31 0.37 1 IP/IN B U
U A IP/IN 2 0.63 0.42 0.32 0.33 0.31 0.35 2 IP/IN A U
10 A IP/IN 3 0.44 0.42 0.40 0.40 0.35 0.40 3 IP/IN A 10
100 B IP/IN 4 0.33 0.32 0.40 0.68 0.44 0.58 4 IP/IN B 100
100 A IP/IN 5 0.35 0.33 0.40 0.68 0.43 0.59 5 IP/IN A 100
1000 B IP/IN 6 0.31 0.31 0.35 0.44 0.43 0.61 6 IP/IN B 1000
1000 A IP/IN 7 0.37 0.35 0.40 0.58 0.59 0.61 7 IP/IN A 1000
1 2 3 5 6 7 8
IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN IP/IN
B A A B A B A
U U 10 100 100 1000 1000
Prediction;Profile 1 2 3 4 5 6 7
Platinum;Damage 0.28 0.27 0.29 0.44 0.46 0.26 0.36
Scale 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0
	   187	  
With	   independent	   repeat	   samples	   the	   pattern	   from	   any	   one	   sample	  overlaps	  with	  patterns	  from	  repeat	  samples	  (figure	  4.10)	  indicating	  the	  presence	  of	   high	   assay	   noise,	   resulting	   in	   inability	   to	   discriminate	   pattern	   ‘signals’	  between	   individuals.	   	   However,	  when	   the	  mean	   probe	   values	   only	   are	   plotted	  (figure	   4.11)	   these	   patterns	   demonstrate	  more	   consistent	   correlation	   between	  individual	   A	   and	   B	   at	   each	   dose	   level.	   	   These	   results	   indicate	   that	   when	  developing	  tools	  to	  identify	  pattern	  difference	  signals	  between	  patients	  A	  and	  B,	  using	  a	  mean	  dataset	  approach	  will	  be	  more	  reliable	  and	  less	  influenced	  by	  assay	  noise	  than	  comparing	  single	  DIP-­‐chip	  assay	  datasets.	  	  	  In	   the	   present	   form,	   if	   the	   variability	   in	   patterns	   between	   the	   same	  individual	   remains,	   the	   assay	   would	   generate	   inconsistent	   single	   experiment	  patterns	   when	   used,	   unless	   repeated	   sampling	   from	   patients	   was	   employed.	  	  This	   would	   be	   impractical,	   especially	   if	   the	   assay	   is	   to	   be	   used	   in	   future	   to	  analyse	  other	  clinical	  tissues	  such	  as	  biopsy	  samples.	  To	  refine	  the	  assay	  it	  may	  be	  possible	  to	  further	  optimise	  the	   laboratory	  protocols.	   	  The	  effect	  of	  protocol	  modifications	   and	   of	   experimental	   methods	   to	   reduce	   the	   noise	   further	   by	  improving	   the	   technical	   performance	   of	   the	   assay	   will	   be	   examined	   in	   the	  remaining	  experiments	  presented	  in	  this	  chapter.	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4.3.3 Determining	  the	  assay	  stages	  contributing	  to	  DIP-­‐chip	  experimental	  
variability	  	   In	   the	  multi-­‐step	  DIP-­‐chip	  assay	   there	  are	  several	  stages	  of	   the	  protocol	  that	   could	   be	   responsible	   for	   introducing	   the	   variability,	   demonstrated	   above,	  into	  the	  experimentally	  generated	  microarray	  results.	  	  As	  shown	  in	  many	  of	  the	  experiments	  described	   in	   chapter	  3,	   the	  variability	  of	   the	   immunoprecipitation	  phase	   of	   the	   assay	   can	   be	   minimised	   by	   careful	   handling	   and	   processing	   of	  samples	  within	   experimentally	  well-­‐defined	   parameters,	   resulting	   in	   improved	  consistency	   in	   IP/IN	   ratio	   compared	   to	   the	   IP/IN	   ratio	   in	   untreated	   samples,	  albeit	  at	  limited	  genetic	  loci	  as	  described.	  	  Because	  of	  the	  consistent	  results	  seen	  with	  the	  improved	  DIP	  protocol	  the	  variability	  seen	  in	  the	  microarray	  datasets	  is	  likely	   to	  be	  produced	  predominantly	  during	   the	  processing	  downstream	  of	   the	  immunoprecipitation	   sample	   and	   input	   control	   sample	   during	   the	   microarray	  preparation	  stages.	  To	  estimate	  the	  noise	  generated	  at	  each	  stage	  of	  the	  assay	  an	  experiment	  using	  a	   series	  of	   technical	   replicates	  was	   conducted.	   	  These	   samples	   consist	   of	  aliquots	  of	  PBMC-­‐extracted	  DNA	  immunoprecipitated	   in	  parallel	  before	  pooling	  and	  dividing	  into	  equal	  identical	  samples	  prior	  to	  processing	  at	  sequential	  stages	  during	   the	   microarray	   preparation.	   	   As	   each	   stage	   in	   the	   experiment	   has	   the	  potential	  to	  add	  noise	  to	  the	  final	  result,	  the	  microarray	  datasets	  generated	  from	  this	  experiment	  are	  analysed	   from	   the	  microarray	  stage	   in	   reverse,	   to	  quantify	  increases	   in	   variability	   between	   identical	   technical	   repeats	   with	   increasing	  number	  of	  assay	  stages.	   	  This	  approach	   identifies	  and	  quantifies	   the	  variability	  introduced	  at	  each	  stage	  of	  the	  assay.	  	  	  Four	   sets	   of	   paired	   technical	   replicates	   were	   used	   either	   pre-­‐immunoprecipitation,	   pre-­‐amplification,	   pre-­‐labelling,	   pre-­‐hybridisation,	   and	  identical	  replicates	  were	  run	  on	  the	  same	  and	  different	  arrays	  to	  quantify	  intra-­‐	  and	  inter-­‐array	  variability.	  	  A	  comparison	  of	  the	  oxaliplatin-­‐DNA	  adduct	  patterns	  at	  each	  stage	  of	  the	  assay	  and	  Spearman’s	  correlation	  values	  between	  technical	  replicates	  are	  shown	  in	  figure	  4.13.	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Figure	   4.13:	   A	   comparison	   of	   pairs	   of	   oxaliplatin-­‐DNA	   adduct	   patterns	   generated	   from	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majority	  of	  the	  variability	  introduced	  into	  this	  microarray	  phase	  of	  the	  assay	  is	  a	  consequence	   of	   the	   whole-­‐genome	   PCR	   (WGA-­‐PCR)	   amplification	   process	  required	  to	  ensure	  adequate	  DNA	  is	  available	  for	  labelling	  and	  hybridisation.	  	  	  The	   biological	   signal	   present	   in	   the	   assay	   is	   transmitted	   through	  differences	   in	   the	   proportion	   of	   DNA	   fragments	   between	   experimental	  conditions	   resulting	   from	   the	  affinity	  of	   the	  DIP	  antibody	   for	   the	   target,	   in	   this	  case	  platinum-­‐DNA	  adducts.	  	  	  It	  follows	  then,	  that	  a	  fundamental	  requirement	  of	  the	   DIP-­‐chip	   assay	   is	   to	   faithfully	   maintain	   the	   relationship	   between	   DNA	  fragment	   amounts	   and	   distribution	   in	   each	   IP	   and	   IN	   sample	   throughout	   the	  multi-­‐step	   assay	   process.	   Otherwise,	   the	   specific	   biological	   information	   that	  potentially	   exists	   between	   samples	   (i.e.	   that	   should	   result	   in	   specific	   inter-­‐patient	   platinum-­‐DNA	   adduct	   patterns)	   could	   be	   masked	   by	   experimentally	  generated	  differences	  in	  fragment	  pools,	  resulting	  in	  noise	  or	  systematic	  bias.	  	  As	  discussed	   above	   in	   section	   4.1.3.1,	   it	   is	   well	   recognised	   that	   PCR	   based	  amplification	   techniques	   have	   significant	   potential	   to	   introduce	   noise	   and	   bias	  during	   library	  preparation	  by	  differential	  amplification	  of	   fragments	  depending	  on	   subtle	   differences	   in	   random	   or	   universal	   primer	   annealing	   and	   by	   the	  preferential	   amplification	   of	   different	   fragments	   due	   to	   small	   differences	  physical	   or	   chemical	   properties	   between	   fragments	   (including	   GC	   content,	  fragment	  length	  and	  annealing	  and	  denaturing	  temperature).	   	  Small	  differences	  in	   fragment	   amplification	   characteristics	  ultimately	  have	  a	   large	   impact	  during	  the	   exponential	   amplification	   process.	   	   The	   result	   of	   this	   experiment	   (figure	  4.13)	   indicates	   that	   this	  well-­‐recognised	   phenomenon	   is	   an	   important	   issue	   in	  the	  DIP-­‐chip	  assay	  used	  here.	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4.3.4 Experimental	  measures	  to	  improve	  DIP-­‐chip	  assay	  reproducibly	  
	   As	  discussed,	  the	  issue	  of	  PCR-­‐based	  amplification	  noise	  and	  bias	  is	  well	  recognised	   and	   a	   significant	   issue	   for	   immunoprecipitation	   microarray	   or	  sequencing	  based	  experiments,	  in	  which	  the	  proportion	  of	  fragments	  generated	  by	   immunoprecipitation	   (and	   in	   the	   IN	   sample	   for	   correct	   data	   normalisation)	  must	  be	  maintained	  during	  all	  stages	  of	  the	  assay,	  and	  are	  especially	  vulnerable	  to	   bias	   if	   subtle	   variation	   exist	   between	   fragments	   are	  multiplied	   through	   the	  exponential	  kinetics	  of	  PCR	  amplification.	  	  Several	  factors	  affecting	  the	  fidelity	  of	  PCR	   reactions,	   and	   hence	   the	   reproducibility	   of	   WGA-­‐PCR,	   have	   been	  documented,	  and	  include	  the	  polymerase	  enzyme	  used	  in	  the	  reaction,	  the	  initial	  DNA	  template	  amount,	  the	  number	  of	  PCR	  cycles	  used	  during	  amplification,	  the	  temperature	   ramp	   rate	   of	   the	   thermo	   cycler,	   the	   GC	   content	   of	   the	   fragments	  amplified	  and	  the	  fragment	  length	  (Aird	  et	  al.	  2011;	  Han	  et	  al.	  2012;	  Hasmats	  et	  al.	  2014;	  Pinard	  et	  al.	  2006;	  Quail	  et	  al.	  2012;	  van	  Dijk	  et	  al.	  2014).	  	  Notably,	  the	  DIP-­‐chip	  assay	  was	  developed	  in	  S.	  cerevisiae	  and	  human	  cell	  culture	   models	   where	   these	   technical	   issues	   were	   less	   significant	   in	   these	  systems,	  and	  the	  technical	  reproducibility	  of	  DNA	  damage	  patterns	  produced	  by	  the	  assay	  was	  high,	  especially	  when	  used	  to	  investigate	  the	  genomic	  location	  of	  protein	   binding.	   	   In	   this	   situation,	   the	   vast	   majority	   of	   fragments	   are	  immunoprecipitated	  at	  discrete	  sites	  with	  very	  little	  DNA	  immunoprecipitated	  at	  other	  locations	  in	  the	  rest	  of	  the	  genome	  –	  for	  example	  at	  some	  protein	  binding	  sites	   there	   can	   be	   a	   >30,000	   fold	   difference	   in	   IP/IN	   ratio	   compared	   to	   non-­‐protein	   binding	   regions	   of	   the	   genome	   (Teng	   et	   al.	   2010).	   	   In	   these	  circumstances,	   noise	   generated	   by	   small	   differences	   in	   relative	   fragment	  amplification	  when	  the	  immunoprecipitated	  fragments	  are	  exclusively	  at	  binding	  sites	  (at	  a	  ratio	  of	  30,000	  to	  1)	  would	  not	  result	  in	  loss	  of	  such	  a	  strong	  biological	  signal	   in	   the	   assay.	   	   The	   high	   signal-­‐to-­‐noise	   ratio	   results	   in	   good	   assay	  reproducibility	   metrics.	   	   Conversely	   in	   the	   human	   platinum-­‐adduct	   DIP-­‐chip	  experiments	  the	  peak-­‐to-­‐trough	  difference	  in	  the	  treated	  samples	  is	  in	  the	  order	  of	   2	   to	   4	   fold	   for	   oxaliplatin	   and	   cisplatin	   (e.g.	   figures	   4.7	   for	   oxaliplatin	   and	  figure	   4.6	   for	   cisplatin)	   presumably	   reflecting	   the	   widespread	   induction	   of	  platinum-­‐DNA	  adducts	   throughout	   the	   genome.	   	  Under	   these	   conditions	   subtle	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differences	  in	  fragment	  WGA-­‐PCR	  amplification	  characteristics	  would	  result	  in	  a	  much	  higher	  noise	  to	  signal	  ratio,	  with	  the	  consequences	  outlined	  in	  the	  results	  so	  far	  in	  this	  chapter.	  It	   is	   only	   through	   the	   experiments	   discussed	   here,	   of	   the	   translation	   of	  this	  technique	  into	  human	  clinical	  samples,	  that	  issues	  of	  reproducibility,	  unique	  to	   this	   context,	   have	   become	   apparent.	   	   In	   the	   following	   section,	   the	   effect	   of	  WGA-­‐PCR	   related	   variables	   on	   the	   reproducibility	   of	   human	   DIP-­‐chip	   PBMC	  experiments	  will	  be	  explored,	  with	  the	  intention	  of	  minimising	  the	  noise	  and	  bias	  introduced	  into	  the	  assay	  during	  DNA	  amplification.	  	  	  	  
4.3.5 Measuring	  the	  effect	  of	  DNA	  template	  on	  WGA-­‐PCR	  amplification	  
noise	  and	  bias	  	  	   During	   the	   DIP-­‐chip	   experiment	   the	   IN	   and	   IP	   sample	   are	   amplified	   in	  parallel.	   	   Because	   immunoprecipitation	   is	   by	   nature	   selective	   for	   the	   DNA	  fragments	  of	  interest,	  only	  a	  fraction	  of	  the	  original	  DNA	  fragments	  are	  retained	  in	   the	  PBMC	  post-­‐immunoprecipitation	   sample	   (typically	   0.1-­‐0.2%	   -­‐	   table	   4.1).	  Following	   immunoprecipitation,	   purification	   and	   qPCR,	   differing	   absolute	  amounts	  of	  DNA	  template	  is	  therefore	  available	  for	  amplification	  in	  each	  sample,	  and	  can	  be	  calculated	  following	  sample	  quantification	  by	  qPCR	  (table	  4.1).	  	  	  If	  the	  difference	   in	   template	   concentration	   has	   a	   significant	   effect	   on	   the	  reproducibility	   of	   the	   WGA-­‐PCR	   stage,	   it	   may	   be	   possible	   to	   demonstrate	  amplification	   differences	   experimentally	   in	   these	   samples.	   	   The	   absolute	  amounts	   of	   DNA	   in	   each	   sample	   can	   also	   be	   calculated	   and	   compared	   to	   the	  human	  cell	  culture	  development	  experiments	  conducted	  to	  ascertain	  whether	  in	  template	  variability	  resulting	  in	  PCR	  noise	  is	  specific	  to	  the	  PBMC	  context.	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Table	  4.1:	  The	  relative	  amounts	  of	  DNA	  in	  paired	  IP	  and	  IN	  samples	  processed	  through	  the	  
DIP	  reaction	  and	  quantified	  by	  qPCR.	  	  	  In	   three	   independent	   experiments	   the	   amount	   of	   DNA	   in	   the	   IP	   samples	   is	   shown	   as	   a	  percentage	  of	  the	  IN	  sample.	   	  The	  relative	  dilution	  of	  the	  IN	  sample	  that	  would	  be	  required	  to	  match	  the	  concentration	  in	  the	  IP	  sample	  is	  displayed	  below	  each	  percentage	  figure.	  	  The	  volumes	   of	   each	   sample	   are	   the	   same	  post	   immunoprecipitation.	   	   Results	   from	  oxaliplatin	  treated	   PBMC	   and	   dermal	   fibroblast	   cell	   cultures	   (treated	   with	   2500µM	   oxaliplatin)	   are	  shown	  in	  the	  lower	  section.	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possible	   –	   a	   dose	   point	   of	   1000	   times	   that	   seen	   in	   patients	   used	   during	   assay	  development	   was	   rejected	   on	   these	   grounds.	   	   Notably,	   at	   similar	   oxaliplatin	  doses	  and	  treatment	  schedule	  (4	  hours	  in	  serum	  free	  media)	  in	  human	  PBMC	  cell	  the	   IP/IN	   ratio	   obtained	  was	   relatively	   low	   (chapter	   3,	   section	   3.4.2)	   and	   at	   a	  1mM	  dose	  50%	  cell	  death	  (chapter	  3,	  figure	  3.8)	  and	  DNA	  degradation	  occurred	  (chapter	   3,	   figure	   3.11)	  making	   this	   an	   unviable	   treatment	   schedule	   in	   human	  clinical	  samples.	  	  	  	  The	   effect	   of	   template	   quantity	   on	   the	   quality	   of	   the	   WGA-­‐PCR	  amplification	   output	   can	   be	   demonstrated	   by	   comparison	   of	   DNA	   fragment	  profiles	   by	   gel	   electrophoresis	   using	   the	   Agilent	   TapeStation	   2200	   to	   perform	  electrophoresis	  and	  fragment	  distribution	  analysis	  on	  post-­‐immunoprecipitation	  IP	  and	   IN	  samples	  of	  DNA	   fragments	  between	  50	  and	  1200bp	   in	   length	   (figure	  4.14)	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and	  C)	  and	  post-­‐	  WGA-­‐PCR	  (D	  and	  E)	  it	   is	  possible	  to	  demonstrate	  a	  significant	  change	   in	   fragment	   distribution	   caused	   by	   the	   WGA-­‐PCR	   process	   in	   the	   IN	  sample.	   	   It	   is	   clear	   that	   longer	   fragments	  have	  been	  amplified	   in	  preference	   to	  shorter	  fragments,	  skewing	  the	  distribution	  profile	  to	  the	  right	  (E).	  	  This	  has	  not	  occurred	  in	  the	  IP	  sample	  (D)	  compared	  to	  the	  pre-­‐immunoprecipitation	  sample	  (A),	   although	   because	   no	   fragments	   can	   be	   detected	   at	   the	   lower	   limit	   of	  detection	  in	  the	  pre-­‐WGA-­‐PCR	  IP	  sample	  (B)	  it	  is	  not	  possible	  to	  confirm	  whether	  the	   distribution	   post-­‐WGA	   is	   due	   to	   the	   immunoprecipitation	   or	   the	  amplification	  process.	  To	  determine	   if	   these	   findings	  are	  due	   to	   template	   concentration	  by	  gel	  electrophoresis,	  an	  experiment	  was	  conducted	  taking	  a	  single	  pre-­‐amplification	  IN	   sample	  and	  diluting	   this	   sample	   in	   serial	  10	   fold	  dilutions.	   	   In	   this	  way,	   the	  diluted	   IN	   sample	   concentration	   includes	   the	   typical	   concentration	   of	   IPs	  samples	  usually	  a	  100-­‐1000	  fold	  lower	  concentration.	  	  Each	  diluted	  sample	  was	  amplified	   through	   the	  WGA-­‐PCR	   and	   for	   visualisation	   run	   on	   a	   0.8%	   TAE	   gel	  (figure	   4.15).	   	   The	   typical	   IN	   and	   IP	   pre-­‐WGA-­‐PCR	   sample	   concentrations	   are	  indicated	  below	  by	  a	  green	  and	  red	  star	  respectively.	  	  	  	  
	  
Figure	   4.15:	   Determining	   the	   effect	   of	   sample	   concentration	   on	   fragment	   profile	   post	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   Figure	   4.15	   demonstrates	   that	   the	   template	   concentration	   has	   a	  significant	   effect	   on	   the	   resulting	   fragment	   profile	   following	   WGA-­‐PCR	  amplification,	   presumably	   by	   influencing	   which	   fragments	   are	   preferentially	  amplified.	   	   With	   each	   sequential	   10-­‐fold	   dilution	   the	   profile	   of	   fragments	  changes,	   with	   a	   progressive	   reduction	   of	   the	   median	   and	   range	   of	   fragments	  visible	  on	  the	  electrophoresis	  gel.	  	  This	  implies	  that	  the	  IN	  and	  IP	  samples	  in	  the	  PBMC	   samples	   are	   subject	   to	  differential	   amplification,	   as	   the	   staring	   template	  DNA	   concentrations	   in	   these	   samples	   are	   several	   fold	   different.	   	   As	   the	   IN	   is	  intended	   to	   be	   a	   faithful	   reflection	  of	   the	   relative	   amounts	   of	   fragments	   in	   the	  initial	   starting	   sample,	   and	   the	   difference	   in	   the	   IP	   and	   IN	   samples	   at	   the	  microarray	   stage	   are	   presumably	   due	   only	   to	   the	   fragment-­‐selective	  immunoprecipitation	   step,	   there	   appears	   to	   be	   a	   significant	   concern	   that	  template-­‐dependent	  amplification	  bias	  may	  introduce	  variability	   into	  the	  assay.	  	  The	   effect	   of	   this	   potential	   source	   of	   bias	   on	   the	   microarray	   output	   will	   be	  examined	  in	  the	  next	  section.	  	  
4.3.6 Examining	  the	  effect	  of	  WGA	  template	  concentration	  of	  IN	  samples	  
on	  array	  correlation	  values	  	   The	  above	  experiments	   	  (Figures	  4.13-­‐4.15)	  demonstrate	  that	  variability	  in	   DIP-­‐chip	   generated	   oxaliplatin-­‐DNA	   adduct	   patterns,	   present	   in	   the	   repeat	  analysis	  of	  oxaliplatin	   treated	  PBMC	  samples,	   is	  primarily	  due	   to	   the	  WGA-­‐PCR	  process.	   	   This	   variability	   could	   potentially	   be	   generated	   through	   noise	  introduced	   in	  either,	  or	  both,	  of	   the	   IN	  and	   IP	  samples,	  as	  during	  data	  analysis	  they	   are	   combined	   to	   give	   the	   IP/IN	   ratio	   at	   each	   probe	   used	   to	   generate	   the	  adduct	  pattern.	  As	   demonstrated	   above	   (Figure	   4.15),	   the	   WGA-­‐PCR	   template	  concentration	  has	  a	  significant	  impact	  on	  the	  distribution	  of	  fragments	  generated	  by	  amplification,	  although	  it	  is	  yet	  to	  be	  shown	  if	  these	  changes	  have	  a	  significant	  impact	  on	  the	  microarray	  variability.	  	  Intuitively	  this	  would	  be	  expected	  to	  have	  an	   effect,	   as	   the	   IN	   fragment	   profile	   and	   distribution	   is	   generated	   and	   used	  specifically	   to	   normalise	   variability	   in	   the	   IP	   probe	   values	   due	   to	   underlying	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variation	   in	   DNA	   fragment	   frequency	   in	   the	   initial	   pre-­‐immunoprecipitation	  sample	  and	  to	  correct	  for	  experimental	  variability.	  	  Inadvertently	  experimentally	  altering	  the	  distribution	  of	  DNA	  fragments	  in	  either	  the	  IN	  or	  IP	  samples	  would	  presumably	   have	   a	   differential	   effect	   on	   the	   IP/IN	   value	   at	   each	   probe	   in	  different	  samples,	  particularly	  if	  the	  background	  frequency	  and	  distribution	  of	  IN	  fragments	  at	   each	  probe	  has	  been	  altered	  compared	   to	   the	   IP	   (as	   the	   template	  differential	  is	  in	  the	  order	  of	  100-­‐1000	  fold).	  	  Another	  uncertainty	  is	  differential	  amplification	   of	   IP	   fragments	   dependant	   on	   the	   treatment	   condition	   and	  resulting	   immunoprecipitation	   efficiency,	   as	   the	   IP/IN	   ratio	   in	   10µM	   samples	  and	   1mM	   samples	   is	   roughly	   10	   fold	   different	   (Chapter	   3	   figure	   3.6)	   –	   a	  difference	   in	   template	   large	  enough	   to	  result	   in	  differential	  amplification	  and	  a	  different	  pool	  of	   fragments	  produced	  by	   the	  WGA-­‐PCR	  process	   in	   these	   two	   IP	  samples	  (Figure	  4.15)	  	  To	  reduce	  unintentionally	   introduced	  template-­‐concentration	  dependent	  amplification	  bias,	  it	  follows	  that	  the	  template	  concentration	  must	  be	  the	  same	  in	  both	  IP	  and	  IN	  samples	  prior	  to	  amplification.	  	  If	  an	  IP	  sample	  with	  much	  higher	  concentration	   could	   be	   generated,	   sufficient	   to	   match	   the	   IN	   sample	  concentration,	  this	  would	  be	  optimal.	  	  It	  may	  be	  possible	  for	  the	  IP	  concentration	  to	   be	   increased,	   possibly	   by	   increasing	   the	   drug	   concentration	   of	   the	   DNA	  damaging	   agent,	   by	   improving	   the	   antibody	   affinity	   for	   damaged	   DNA,	   or	   by	  using	  cells	  that	  are	  more	  sensitive	  to	  platinum	  drugs	  as	  a	  surrogate	  tissue.	  	  The	  degraded	  DNA	  seen	  in	  1000µM	  samples	  compared	  to	  100µM	  samples	  (chapter	  3,	  figure	  3.11)	  suggests	  that	  in	  PBMC	  increasing	  the	  drug	  dose,	  the	  simplest	  option,	  may	  not	  be	  viable.	  	  	  Another	  possible	  option	  to	  equalise	  any	  amplification	  bias	  between	  IP	  and	  IN	  samples	   is	   to	  decrease	   the	   IN	  sample	   template	  concentration	  prior	   to	  WGA-­‐PCR	  to	  ensure	  any	  template	  dependent	  amplification	  bias	  is	  matched	  between	  IN	  and	   IP	   samples,	   and	   therefore	   normalised	   by	   the	   IP/IN	   ratio	   used	   in	   adduct	  pattern	  generation.	  	   To	   see	   if	   using	   the	   same	   concentration	   of	   template	   in	   the	   WGA-­‐PCR	  reaction	  would	  eliminate	   this	  potential	   source	  of	  bias,	  microarray	  experiments	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were	   conducted	   using	   several	   parallel	   immunoprecipitated	   IP	   samples	   which	  were	  combined	  and	  equally	  divided	  prior	  to	  amplification,	  with	  the	  intention	  of	  producing	   identical	   technical	   IP	   replicate	   samples	   prior	   to	   WGA-­‐PCR.	   An	   IN	  sample	  was	  diluted	  either	  10	  fold	  (the	  typical	  dilution	  used)	  or	  diluted	  500	  fold	  to	  match	  the	  IP	  template	  concentration	  as	  calculated	  by	  qPCR	  in	  these	  samples.	  	  Following	   WGA-­‐PCR	   amplification	   these	   technical	   replicate	   samples	   were	  analysed	   by	   gel	   electrophoresis	   and	   using	   the	   TapeStation	   2200	   (Agilent	  Technologies)	  prior	  to	  the	  labelling	  step	  of	  the	  assay	  (figure	  4.16).	  	  	  	  	  
	  
Figure	   4.16:	   Determining	   the	   effect	   of	   sample	   concentration	   on	   fragment	   profile	   post	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amplification	   (our	   standard	   DIP-­‐chip	   protocol)	   has	   a	   significantly	   longer	  fragment	  median	  and	  range.	  	  These	  results	  again	  confirm	  that	  different	  pools	  of	  DNA	   fragments	   are	   produced	   by	   WGA-­‐PCR	   amplification	   depending	   on	   the	  concentration	   of	   starting	   material,	   a	   potential	   source	   of	   system	   noise	   and	  systematic	  bias.	  As	   all	   the	   IP	   samples	   are	   identical	   replicates,	   and	   the	   IN	   samples	   differ	  only	  by	   the	  amplification-­‐dependent	   change	   in	   fragment	  profiles,	   the	  paired	   IP	  and	  IN	  samples	  were	  labelled,	  hybridised	  and	  analysed	  on	  standard	  microarray	  protocols.	   	   The	   oxaliplatin-­‐DNA	   adduct	   patterns	   generated	   in	   three	   pairs	   of	  samples	  (2	  IP/IN	  pairs	  with	  500X	  dilution	  and	  1	  IP/IN	  sample	  pair	  with	  a	  10X	  IN	  dilution)	   are	   compared	   in	   figure	   4.17.	   	   The	   Spearman’s	   correlation	   value	  between	  the	  patterns	  is	  included	  in	  the	  legend.	  	  
	  
Figure	  4.17:	  Determining	   the	  effect	  of	   sample	  concentration	  pre-­‐WGA	  on	  adduct	  pattern	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On	   reviewing	   the	  Spearman’s	   correlation	   coefficients	   in	   this	   figure	  4.17,	  between	  the	  oxaliplatin-­‐DNA	  adduct	  patterns	  generated	  when	  the	  samples	  with	  variable	   IN	   amplification	   are	   run	   on	   microarrays,	   the	   patterns	   generated	   are	  highly	  variable	  and	  fail	  to	  correlate	  well	  with	  one	  another	  (Correlations	  values	  of	  ~0.3).	   	   This	   does	   not	   improve	   when	   the	   IN	   sample	   template	   concentration	   is	  decreased	  to	  match	  the	  IP	  concentration	  (middle	  and	  lower	  panels	  compared	  to	  upper	  panel).	  	  This	  indicates	  that	  changing	  the	  IN	  concentration	  to	  match	  the	  IP	  template	  concentration	  does	  not	   improve	   the	  reproducibility	  of	   the	  microarray	  by	  normalising	  any	  bias	  introduced	  by	  template	  dependent	  amplification.	  	  It	  may	  be,	  however,	  that	  this	  potentially	  bias-­‐reducing	  effect	  is	  masked	  by	  other	  sources	  of	   noise	   in	   the	  microarray	   data,	   specifically	  within	   the	   IP	   channel	   rather	   than	  within	   just	  the	  IN	  channel.	   	   	  With	  the	  currently	  available	  bioinformatic	  analysis	  techniques	  it	  is	  impossible	  to	  identify	  where,	  or	  why,	  this	  problem	  is	  occurring,	  signalling	  the	  need	  for	  further	  analysis	  tools	  to	  inspect	  the	  data	  in	  greater	  depth	  to	  resolve	  this	  issue,	  rather	  than	  to	  perform	  further	  experimental	  permutations	  to	  explore	  this	  problem	  further.	  	  
4.3.7 Modification	  of	  IP	  template	  amount	  and	  adjustment	  of	  PCR	  cycles	  	  	   A	   reduction	   in	   the	   IN	   template	   concentration	   prior	   to	   WGA-­‐PCR	  amplification	   results	   in	   a	   better	   match	   of	   fragment	   distribution	   with	   the	   IP	  sample	   (figure	   4.16)	   and,	   more	   importantly,	   with	   the	   original	   pre-­‐immunoprecipitation	   DNA	   sample	   (figure	   4.14),	   but	   still	   results	   in	   a	   low	  correlation	  between	  identical	  technical	  replicates	  run	  through	  the	  later	  stages	  of	  the	  DIP-­‐chip	  assay	  (figure	  4.17).	  	  The	  solution	  may	  be	  to	  increase	  the	  template	  of	  the	   IP	   sample	   prior	   to	   amplification,	   leading	   to	   more	   reproducible	   damage	  patterns	  than	  reducing	  the	  IN	  concentration.	  With	  this	  in	  mind,	  an	  experiment	  was	  conducted	  to	  modify	  the	  amount	  of	  DNA	  template	   for	  WGA-­‐PCR	   in	   the	   IP	  sample	  by	   increasing	   the	  amount	  of	  DNA	  used	   in	   the	   immunoprecipitation	   reaction,	   and	   combining	   immunoprecipitated	  samples	   prior	   to	   amplification.	   	   This	   approach	   was	   used	   to	   enhance	   the	   IP	  sample	  DNA	  concentration	  rather	  than	  increasing	  the	  drug	  exposure	  of	  the	  PBMC	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in	  culture	  because	  as	  previously	  demonstrated,	  increasing	  the	  dose	  of	  drug	  (from	  100µM	  to	  1000µM)	  does	   increase	  adduct	   levels	  and	  improve	  IP/IN	  enrichment	  at	  qPCR	  (chapter	  3	  figure	  3.6),	  but	  results	   in	  higher	  cell	  death	  and	  poor	  quality	  degraded	   DNA	   (chapter	   3,	   figures	   3.7	   and	   3.11),	   and	   is	   associated	   with	   a	  reduction	  in	  damage	  pattern	  reproducibility	  (figure	  4.11).	  	  The	  use	  of	  drug	  doses	  of	   increasing	   orders	   of	   magnitude	   higher	   than	   used	   in	   patients	   undergoing	  chemotherapy	   (typically	   3-­‐5µM)	   also	   further	   reduces	   the	   potential	   biological	  relevance	  of	  the	  output	  of	  the	  assay.	   	  To	  measure	  the	  effect	  of	  increasing	  IP	  template	  concentration,	  allowing	  a	  reduction	   in	   PCR	   cycles	   to	   generate	   adequate	  WGA-­‐PCR	  DNA	   for	   labelling	   and	  microarray	   hybridisation,	   a	   single	   post-­‐immunoprecipitation	   IN	   sample	   was	  diluted	  into	  several	  identical	  aliquots	  at	  a	  concentration	  of	  to	  10	  ng/µL	  prior	  to	  WGA-­‐PCR	   were	   used	   for	   the	   IN	   channel.	   	   IP	   samples	   were	   generated	   by	  immunoprecipitation	   with	   either	   3µg	   or	   6µg	   of	   sonicated	   DNA,	   aiming	   to	  increase	   the	   absolute	  DNA	  yield	  of	   the	   IP	  procedure,	   or	  with	   two	  pooled	  post-­‐immunoprecipitation	   6µg	   samples	   for	   the	   highest	   template	   concentration.	  Fidelity	  of	  PCR	  amplification	  is	  known	  to	  decrease	  with	  increasing	  cycle	  numbers	  (van	  Dijk	  et	  al.	  2014),	  so	  with	  each	  2-­‐fold	  increase	  in	  template	  amount	  the	  cycle	  number	   was	   able	   to	   be	   decreased,	   whilst	   still	   generating	   enough	   DNA	   for	  downstream	  processing,	  further	  reducing	  the	  potential	  for	  bias.	  	  Oxaliplatin-­‐DNA	  adduct	   pattern	   plots	   and	   the	   corresponding	   Spearman’s	   correlation	   coefficient	  demonstrating	  the	  reproducibility	  between	  paired	  technical	  replicate	  IP	  samples	  at	  each	  template	  level	  are	  displayed	  in	  figure	  4.18.	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Figure	   4.18:	   The	   effect	   of	   PCR	   conditions	   and	   template	   concentration	   on	   DIP-­‐chip	  
reproducibility.	  An	   oxaliplatin-­‐DNA	   adduct	   pattern	   plot	   comparison	   of	   oxaliplatin-­‐DNA	   adduct	   patterns	  generated	   from	  100µM	  oxaliplatin	   treated	  PBMC	  samples	  with	   identical	   IN	  samples	  and	   IP	  samples	   of	   increasing	   concentration	   prior	   to	   WGA-­‐PCR.	   	   	   With	   each	   lower	   panel	   the	   IP	  template	   available	   for	  WGA-­‐PCR	   is	   increased	   and	   the	   PCR	   cycles	   are	   decreased	   (see	   each	  panel	  legend).	  	  The	  Spearman’s	  correlation	  between	  replicate	  samples	  is	  shown	  on	  the	  right	  with	  an	  increasing	  change	  from	  red	  to	  green	  to	  highlight	  increasing	  value	  (arbitrary	  scale).	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not	   possible	   to	   reduce	   PCR	   cycles	   further	   in	   lower	   template	   samples	   without	  correspondingly	  requiring	  a	  doubling	   in	  the	   initial	   template	  DNA	  amount.	  Even	  using	  pooled	  samples	  and	  6µg	  of	  DNA	  in	  the	  original	  immunoprecipitation	  stage	  of	   the	  experiment	   (bottom	  panel	   figure	  4.18),	   significant	  variability	   still	   occurs	  between	  what	   should	   be	   identical	   samples,	   and	   is	   still	   well	   short	   of	   the	   95%-­‐100%	   reproducibility	   seen	   between	   technical	   replicates	   when	   run	   post	   WGA-­‐PCR	  (figure	  4.13).	  	  Somewhat	  limiting	  the	  use	  of	  the	  approach	  of	  further	  boosting	  the	  DNA	  in	  the	   IP	   sample	   to	   further	   improve	   assay	   reproducibility	   is	   that	   12µg	   of	   DNA	   is	  close	   to,	   or	   in	   some	   instances	   greater,	   than	   the	   maximum	   amount	   of	   DNA	  extracted	   from	  each	  PBMC	  clinical	   sample	   in	   the	   initial	  DIP	  phase	  of	   the	   assay	  (chapter	  3,	  figure	  3.13).	  	  Whilst	  this	  experiment	  highlights	  the	  role	  of	  enhancing	  the	  IP	  sample	  in	  improving	  assay	  reproducibility,	  it	  is	  not	  a	  complete	  solution	  to	  this	  problem,	  both	  because	  12µg	  of	  DNA	  for	  immunoprecipitation	  still	  results	  in	  significant	   assay	   variability	   between	   what	   should	   be	   identical	   post-­‐immunoprecipitation	   DNA,	   and	   also	   because	   of	   the	   physical	   limits	   to	   the	   DNA	  available	  for	  the	  assay	  from	  PBMC	  samples.	  	  This	   result,	   however,	   confirms	   that	   measures	   to	   improve	   the	   technical	  performance	  of	   the	  WGA-­‐PCR	  amplification	  of	   the	   IP	  sample	  may	  be	  the	  key	  to	  resolving	   the	   issue	   of	   poor	   reproducibility	   of	   the	   assay	   in	   this	   context.	   	   In	  combination	  with	   this	  approach,	   it	  may	  be	  also	  possible	   to	  apply	  bioinformatic	  tools	   to	   the	   large	   datasets	   generated	   by	   the	  DIP-­‐chip	   to	  minimise	   the	   effect	   of	  noise	  introduced	  during	  the	  processing	  of	  the	  assay	  and	  improve	  that	  capacity	  of	  the	  assay	  to	  detect	  oxaliplatin-­‐induced	  adduct	  signals	  between	  individuals.	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 Summary	  4.4
	  
	   The	  key	  results	  described	  in	  this	  chapter	  are	  summarised	  as	  follows:	  	  
• Using	  the	  DIP-­‐chip	  assay	   it	   is	  possible	  to	  detect	  differences	   in	  generated	  patterns	   between	   untreated	   and	   oxaliplatin	   treated	   PBMC	   samples	  (Figures	  4.7-­‐4.9)	  	  
• Significant	   variability	   occurs	   between	   oxaliplatin	   treated	   single	   PBMC	  samples	  from	  the	  same	  individual	  (Figure	  4.10)	  	  
• Mean	  adduct	  pattern	  data	  may	  be	  more	  accurate	  than	  single	  samples	  for	  later	   use	   in	   developing	   tools	   to	   detect	   biological	   signals	   (Figures	   4.11-­‐4.12)	  	  
• The	  single	  sample	  variability	  is	  primarily	  due	  to	  noise	  introduced	  during	  WGA-­‐PCR	  (Figure	  4.13)	  	  
• A	   large	   difference	   in	   the	   DNA	   template	   available	   for	   WGA-­‐PCR	   occurs	  between	   the	   IP	   and	   IN	   sample,	   due	   to	   the	   nature	   of	   the	  immunoprecipitation	   process.	   	   This	   difference	   is	   greater	   in	   the	   PBMC	  samples	  than	  in	  fibroblast	  cell	  culture	  models	  (table	  4.1)	  	  
• Over	  the	  range	  of	  DNA	  concentrations	  present	  in	  the	  pre-­‐amplification	  IP	  and	  IN	  samples,	  a	  different	  profile	  of	  fragments	  is	  produced	  by	  WGA-­‐PCR	  amplification	  (Figures	  4.14-­‐4.16)	  	  
• Reducing	   the	   IN	   sample	   concentration	   to	   match	   the	   IP	   sample	  concentration	   to	   equalise	   this	   potential	   bias	   does	   not	   improve	  correlations	  between	  replicate	  samples	  (Figure	  4.17)	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• Increasing	  the	  IP	  sample	  template	  concentration	  for	  WGA-­‐PCR	  (closer	  to	  that	   in	   the	   IN	   sample),	   and	   reducing	   the	   PCR	   cycles	   for	  WGA-­‐PCR	   does	  improve	  correlation	  between	  replicate	  DIP-­‐chip	  samples.	  	  	   	  In	   summary,	   the	   experimental	   techniques	   and	   bioinformatic	   analysis	  conducted,	  using	   the	   tools	  available	  and	  demonstrated	   in	   this	   chapter,	   indicate	  that	   the	  WGA-­‐PCR	   amplification	   stage	   can	   introduce	   significant	   variability	   into	  the	  output	  of	   the	  DIP-­‐chip	   assay	   (figure	  4.13),	   if	   not	   carefully	   controlled.	   	   This	  effect	  appears	  to	  be	  dependent	  on	  the	  PCR	  template	  concentration	  (figures	  4.14-­‐4.16),	   and	   is	   a	   particularly	   important	   issue	   in	   the	   context	   of	   the	   low	   adduct	  amounts	   and	   resulting	   post-­‐immunoprecipitation	   DNA	   yield	   seen	   with	   human	  PBMC	  samples	  (see	  table	  4.1).	  The	  effect	  of	  WGA-­‐PCR	  template-­‐dependent	  changes	  in	  the	  distribution	  of	  DNA	  fragments	  in	  the	  IN	  sample	  compared	  to	  the	  pre-­‐amplification	  and	  starting	  material	  (figure	  4.14)	  is	  a	  concern,	  given	  the	  fundamental	  role	  of	  this	  sample	  in	  normalising,	   at	  every	  probe,	   the	   IP	  value	   in	   the	  processed	   immunoprecipitated	  sample.	  	  This	  could	  be	  a	  significant	  source	  of	  the	  noise	  introduced	  into	  the	  DIP-­‐chip	   assay	   patterns.	   	   Two	   approaches	   have	   been	   taken	   to	   ameliorate	   this	  potential	   source	   of	   variability.	   	   First,	   in	   the	   most	   experimentally	   simple	  approach,	   the	   IN	   sample	   is	   diluted	   to	   match	   the	   IP	   sample	   concentration.	  	  However,	   this	  does	  not	   improve	   the	  correlation	  between	  patterns	  produced	  by	  replicate	   samples	   (figure	   4.17).	   	   The	   alternative	   is	   to	   boost	   the	   DNA	   in	   the	   IP	  sample,	  which,	   in	   combination	  with	   reducing	   the	  PCR	  cycles,	  does	   improve	   the	  correlation	  between	  replicate	  samples	  (figure	  4.18).	   	  The	  effect	  of	  reducing	  the	  PCR	   cycles	   without	   increasing	   the	   IP	   sample	   template	   concentration	   is	  impossible	  to	  independently	  determine,	  as	  without	  template	  improvements	  this	  modification	  results	  in	  insufficient	  DNA	  for	  microarray	  hybridisation.	  The	   results	   of	   the	   experiments	   presented	   in	   this	   chapter	   indicate	   that	  measures	  to	  improve	  the	  technical	  performance	  of	  the	  DIP	  assay	  and	  WGA-­‐PCR	  amplification,	   specifically	   to	   focused	   on	   the	   IP	   sample,	   are	   the	   main	   areas	   of	  assay	   development	   that	   should	   improve	   the	   reproducibility	   of	   adduct	   patterns	  generated	  by	  the	  DIP-­‐chip	  assay,	  as	  can	  be	  determined	  by	  assessing	  variability	  in	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patterns	  from	  repeated	  samples	  obtained	  from	  the	  same	  individual.	  	  There	  could	  also	   be	   an	   alternative	   to	   this	   purely	   laboratory-­‐based	   approach.	   	   It	   may	   be	  possible	  to	  apply	  bioinformatic	  tools	  to	  the	  large	  datasets	  generated	  by	  the	  DIP-­‐chip	  to	  address	  and	  reduce	  the	  contribution	  of	  noise	  to	  the	  overall	  signal	  to	  noise	  ratio,	   and	   in	   this	   way	   improve	   the	   capacity	   of	   the	   assay	   to	   detect	   oxaliplatin-­‐induced	  adduct	  signals	  between	   individuals.	   	  A	  combination	  of	  both	   laboratory	  and	  bioinformatic	  approaches	  is	  more	  likely	  to	  be	  successful.	  	  	  One	   drawback	   with	   the	   current	   experimental	   approach	   to	   assay	  improvement	   is	   that	   the	   analysis	   tools	   available	   are	   not	   able	   to	   give	   a	   clear	  picture	  of	  the	  independent	  contribution	  of	  the	  separate	  IN	  and	  IP	  channels	  in	  the	  generation	  of	   variability	   in	   the	  assay,	  primarily	  because	   the	  only	  bioinformatic	  metric	   available	   is	   the	  measure	  of	   the	   IP/IN	   ratio	   and	   the	   correlation	  between	  IP/IN	   value	   patterns.	   	   As	   an	   further	   example	   of	   the	   limitations	   of	   the	   tools	  available	   for	   DIP-­‐chip	   analysis,	   in	   the	   18	   repeat	   oxaliplatin	   treated	   PBMC	  samples	   displayed	   in	   figure	   4.9,	   a	   sample	   from	   patient	   B,	   100µM	   repeat	   2	   -­‐	  indicated	  by	  a	  red	  star,	  fails	  to	  match	  any	  of	  the	  other	  samples.	  	  With	  the	  current	  Sandcastle	  tools	  for	  the	  analysis	  for	  DIP-­‐chip	  datasets	  it	  is	  possible	  to	  detect	  that	  this	  experiment	  failed,	  but	  it	  is	  not	  possible	  to	  determine	  in	  which	  of	  the	  IP	  or	  IN	  samples	  (or	  both)	  the	  technical	  problem	  has	  arose,	  or	  at	  which	  stage	  of	  the	  assay	  failure	   occurred.	   	   These	   are	   fundamental	   questions	   that	   require	   appropriate	  tools	   to	   answer,	   as	   this	   type	   of	   experimental	   failure	   could	   provide	   useful	  information	   for	   assay	   modification	   and	   optimisation.	   	   This	   highlights	   the	  limitations	  of	  the	  current	  microarray	  analysis	  techniques	  available.	  Inherent	   in	   the	   goal	   of	   this	   project	   is	   the	   development	   a	   model	  experimental	   pathway	   to	   allow	   the	   translation,	   optimisation	   and	   validation	   of	  this	  DIP-­‐chip	  assay	  into	  other	  clinical	  tissues,	  such	  as	  tumour	  or	  biopsy	  samples.	  	  It	  is	  likely	  that	  during	  future	  projects	  similar	  issue	  with	  DIP-­‐chip	  assay	  variability	  in	  different	  tissue	  types	  will	  manifest.	  	  The	  experimental	  approach	  outlined	  here,	  and	  in	  the	  previous	  chapter,	  can	  be	  used	  as	  a	  model	  pathway	  for	  determining	  the	  relative	   contribution	   of	   different	   stages	   of	   the	   multi-­‐step	   assay	   and	   for	  optimising	  the	  assay	  for	  different	  situations.	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One	   bottleneck,	   evident	   in	   this	   discussion,	   is	   therefore	   developing	  appropriate	  bioinformatic	  analysis	  tools	  to	  further	  assess,	  optimise	  and	  validate	  the	  DIP-­‐chip	  assay.	  With	  this	  in	  mind,	  of	  critical	  importance	  is	  the	  development	  of	   novel	   tools	   capable	   of	   accurately	   measuring	   the	   independent	   effects	   of	  experimental	  modifications	  made	  to	  the	  IN	  and	  IP	  samples.	  	  These	  developments	  will	  be	  one	  of	  the	  two	  main	  aspects	  of	  the	  following	  chapter.	  Finally,	   it	   has	   been	   demonstrated	   in	   this	   chapter	   that	   mean	   adduct	  pattern	   datasets	   generated	   as	   an	   average	   pattern	   from	   repeat	   DIP-­‐chip	  experiments	   are	   more	   reproducible	   than	   single	   samples.	   	   With	   on-­‐going	  developments	   in	   assay	   technique	   both	   single	   sample	   and	   average	   adduct	  patterns	   should	   become	   even	   more	   accurate.	   	   As	   the	   mean	   adduct	   patterns	  generated	   between	   PBMC	   samples	   from	   two	   different	   individuals	   match	  relatively	  well	  already	  (correlations	  of	  0.68	  –	  figure	  4.12),	  rather	  than	  to	  improve	  the	   correlation	   between	   these	   patterns	   further,	   it	   is	   appropriate	   to	   use	   these	  datasets	   to	   develop	   tools	   to	   detect	   and	   determine	   the	   significance	   of	   adduct	  pattern	   differences	   between	   individuals	   –	   to	   detect	   biological	   signal	   -­‐	   the	  ultimate	   aim	   of	   this	   project.	   	   The	   development	   of	   tools	   for	   this	   analysis	   will	  finally	  enable	  the	  use	  of	  the	  DIP-­‐chip	  assay	  in	  clinical	  studies.	  This	  phase	  of	  the	  project	  will	  be	  discussed	  in	  the	  second	  section	  of	  the	  following	  chapter.	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Chapter	  5 The	  development	  of	  bioinformatic	  tools	  for	  the	  in-­‐depth	  
analysis	  of	  DIP-­‐chip	  microarray	  data	  
	   The	   results	   and	   discussion	   of	   the	   previous	   chapter	   reveal	   that	   the	  optimisation	   of	   the	   DIP-­‐chip	   technology	   to	   generate	   oxaliplatin-­‐DNA	   damage	  patterns	   from	   human	   clinical	   samples	   poses	   significant	   experimental	   and	  analytical	   challenges,	   and	   demonstrates	   the	   advances	   made	   in	   these	   areas	   to	  date.	   	   Further	   efforts	   to	   optimise	   and	   enhance	   the	   reproducibility	   of	   the	  technique	   could	   improve	   the	   assay.	   	   The	   initial	   analysis	   indicates	   that	   the	  problem	   with	   relatively	   low	   reproducibility	   of	   microarray	   adduct	   profiles	  evaluated	   over	   multiple	   independent	   repeat	   experiments	   (Figures	   4.7	   to	   4.9)	  appears	   to	   be	   primarily	   a	   consequence	   of	  WGA-­‐PCR	   generated	   noise	   and	   bias	  introduced	   during	   the	   PCR-­‐based	   amplification	   process	   (Figure	   4.13).	   	   This	   is	  shown	  to	  be	  a	  consequence	  of	  the	  lower	  template	  in	  the	  IP	  sample	  than	  in	  the	  IN	  sample	   (Table	   4.1	   and	   figures	   4.15-­‐4.16),	   because	   the	   poor	   reproducibility	  between	  identical	  technical	  replicate	  samples	  is	  partially	  corrected	  by	  improving	  the	  template	  amount	  for	  WGA-­‐PCR	  in	  the	  IP	  sample	  (Figure	  4.18).	  The	  results	  of	  the	  experiments	  described	  in	  chapters	  3	  and	  4	  indicate	  that	  the	   lower	   reproducibility	   of	   the	   PBMC	   oxaliplatin-­‐DNA	   adduct	   patterns	  generated	  (a	  correlation	  value,	  at	  best,	  of	  0.4-­‐0.6)	  compares	  poorly	   to	  DIP-­‐chip	  microarrays	   from	   pairs	   of	   repeat	   samples	   of	   dermal	   fibroblasts	   treated	   as	  cultured	  cells	  with	  a	  dose	  of	  2500µM	  oxaliplatin	  during	  the	  assay	  development	  (with	  a	  correlation	  between	  two	  repeat	  samples	  of	  up	  to	  0.74	  (Powell	  2014)).	  	  In	  view	   of	   the	   problem	   associated	   with	   the	   template-­‐dependent	   PCR	   issue,	   this	  difference	   in	   reproducibility	   could	   be	   related	   to	   the	   relatively	   low	   amount	   of	  DNA	   present	   in	   the	   PBMC	   IP	   samples	   (~0.2%	   of	   the	   IN	   sample	   DNA	   amount)	  compared	  to	  the	  IP	  samples	  from	  dermal	  fibroblast	  experiments	  (~5%	  of	  the	  IN	  sample	   DNA	   amount)	   prior	   to	   the	   WGA-­‐PCR	   amplification	   (Table	   4.1).	  	  Significantly,	   the	   IN	   samples	   contain	   similar	   amounts	   of	   DNA	   in	   the	   dermal	  fibroblast	  and	  PBMC	  assays.	  	  	  	  This	   highlights	   a	   central	   issue	   in	   the	   translation	   of	   the	   DIP-­‐chip	   assay	  from	  one	  cell	  type	  to	  another.	  	  Unlike	  the	  dermal	  fibroblasts,	  PBMC	  samples	  have	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a	  relatively	  low	  IP/IN	  ratio	  with	  an	  equivalent	  treatment	  schedule	  to	  that	  used	  in	  dermal	   fibroblast	   cell	   culture	  work	   (Chapter	   3,	   figure	   3.6,	   and	   (Powell	   2014))	  and	   the	   sensitivity	   of	   PBMC	   to	   platinum	   drugs	   appears	   to	   limit	   the	   dose	   of	  oxaliplatin	  to	  which	  the	  cells	  can	  be	  exposed.	  	  This	  is	  demonstrated	  by	  high	  rates	  of	   cell	   death	   (chapter	   3	   Figures	   3.7-­‐3.8)	   and	   deterioration	   the	   quality	   of	  extracted	   DNA	   at	   a	   1mM	   oxaliplatin	   dose	   level	   (Chapter	   3,	   figure	   3.11).	  	  Additionally,	   the	   highest	   doses	   of	   oxaliplatin	   result	   in	   a	   worse	   correlation	  between	  adduct	  patterns	  (at	  1mM	  a	  Spearman’s	  correlation	  of	  0.4-­‐0.5	  between	  repeats)	  compared	  to	  100µM	  dose	  levels	  (a	  correlation	  value	  of	  0.5-­‐0.6	  between	  repeats)	   (Figure	   4.9).	   	   In	   an	   assay	   developed	   to	   predict	   clinical	   response	   by	  treating	   surrogate	   tissue	   in	   clinically	   relevant	   conditions	   in	   order	   to	   generate	  meaningful	  results,	  a	  dose	  of	  100µM	  is	  still	  roughly	  30	  fold	  higher	  than	  the	  level	  used	   in	   patients	   (Chapter	   1,	   section	   1.2.1),	   compared	   to	   300	   times	   the	   patient	  dose	  with	  1000µM	  and	  1000	  times	  the	  dose	  used	  to	  treat	  patients	  at	  2500µM.	  	  At	  very	  high	  doses	   the	  biological	   relevance	  and	   the	  applicability	  of	   any	  generated	  platinum-­‐DNA	  adduct	  patterns	  to	  the	  clinical	  setting	  may	  be	  less	  relevant.	  In	   the	   context	   of	   this	   information,	   it	   is	   not	   feasible	   to	  modify	   the	  PBMC	  DIP-­‐chip	   assay	   by	   increasing	   the	   oxaliplatin	   dose	   further	   to	   raise	   the	   level	   of	  adducts	   generated	   per	   DNA	   fragment,	   with	   the	   intention	   to	   improve	   the	  proportion	   of	   DNA	   in	   the	   IP	   sample	   following	   immunoprecipitation.	   	   Instead,	  technical	  improvements	  in	  the	  assay	  are	  required	  to	  improve	  the	  reproducibility,	  using	   the	   adduct	   levels	   and	   samples	   generated	   at	   the	   current	   oxaliplatin	   dose	  levels.	   	   For	   future	   translational	   projects,	   a	   useful	   application	   of	   the	   DIP-­‐chip	  assay	  would	  be	  to	  use	  blood	  samples	  taken	  from	  patients	  during,	  or	  in	  the	  period	  after,	  chemotherapy	  –	  a	  true	  in	  vivo	  measure	  of	  oxaliplatin-­‐DNA	  damage.	  	  For	  this	  type	  of	  application	  of	  the	  assay,	  or	  in	  the	  translation	  of	  the	  assay	  to	  other	  clinical	  tissues,	   technical	   improvements	   are	   also	   desirable	   to	   further	   develop	   the	  capacity	  of	  the	  reliable	  detection	  of	  DNA	  adduct	  patterns	  at	  even	  lower	  levels	  of	  drug	  exposure,	  or	  in	  tissues	  that	  are	  more	  sensitive,	  or	  more	  platinum	  resistant,	  than	  the	  PBMC	  samples	  used	  here.	  It	   is	   also	   apparent	   that	   the	   analysis	   tools	   currently	   available	   for	   the	  interpretation	   of	   platinum-­‐DNA	   adduct	   patterns	   (a	   visual	   inspection	   of	   adduct	  patterns	   and	   a	   single	  metric	   of	   a	   Spearman’s	   correlation	   between	  probe	   IP/IN	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ratios)	   are	   inadequate	   to	   permit	   a	   thorough	   understanding	   of	   the	   technical	  issues	   faced	   in	   the	   transfer	   of	   this	   technology.	   	   It	   is,	   therefore,	   necessary	   to	  develop	   more	   sophisticated	   analysis	   tools	   to	   interpret	   the	   available	  experimentally	  generated	  datasets	  in	  more	  detail.	  	  	  A	  more	  sophisticated	  DIP-­‐chip	  data	  analysis	  tool	  may	  also	  be	  useful	  as	  a	  quality	  control	  measure	  and	  to	  examine	  at	  which	  stage,	  and	  in	  which	  of	  the	  IP	  or	  IN	   samples,	   experimental	   failures	   occur,	   notably	   in	   the	   sample	   that	   failed	   in	  Figure	   4.9	   (Patient	   B,	   100µM	   oxaliplatin	   treatment,	   repeat	   2).	   	   This	   particular	  oxaliplatin-­‐DNA	   adduct	   pattern	   fails	   to	   correlate	  with	   any	   of	   the	   other	   adduct	  patterns.	  	  The	  currently	  available	  analysis	  tools	  are	  unable	  to	  determine	  whether	  the	   issue	   lies	   with	   the	   IP	   or	   IN	   channel	   in	   the	   experiment,	   or	   possibly	   with	   a	  combination	   of	   both	   of	   these.	   	   The	   ability	   to	   compare	   platinum-­‐DNA	   adduct	  pattern	  correlations	  at	  different	  sections	  of	  the	  same	  paired	  microarrays	  would	  also	  allow	  the	  determination	  of	  the	  impact	  of	  other	  factors	  on	  assay	  variability,	  importantly	  in	  the	  context	  of	  PCR	  noise	  such	  as	  the	  GC	  content	  of	  sections	  of	  the	  genome,	  which	  are	  well	  known	  to	  have	  an	  impact	  on	  PCR	  reproducibility.	  	  	  So	   far	   the	   experiments	   in	   this	   thesis	   have	   focussed	   on	   reducing	   system	  ‘noise’	   by	   reducing	   the	   differences	   between	   datasets	   generated	   by	   DIP-­‐chip	   in	  repeated	  sampling	  of	   the	  same	  patients.	   	   In	  potential	   future	  applications	  of	   the	  DIP-­‐chip	   assay,	   for	   example	   examining	   differences	   in	   adduct	   patterns	   between	  ‘responder’	   and	   ‘non-­‐responder’	   cohorts	   of	   patients,	   a	   method	   of	   rapidly	   and	  accurately	   identifying	   the	   signal,	   the	   inter-­‐individual	   differences	   between	   DIP-­‐chip	  microarray	  datasets,	  is	  required.	  	  	  The	  tools	  to	  facilitate	  these	  types	  of	  detailed	  DIP-­‐chip	  data	  analysis	  will	  be	  developed	   in	   this	   chapter	   and	   used	   to	   analyse	   the	   experimental	   DIP-­‐chip	  platinum-­‐DNA	  adduct	  datasets	  presented	  in	  the	  previous	  section.	  
	  
 The	  examination	  of	  microarray	  datasets	  to	  enable	  a	  ‘single	  channel	  5.1
analysis’	  of	  IP	  and	  IN	  samples	  
	   The	   current	   version	   of	   Sandcastle	   (version	   1.0),	   the	   microarray	   data	  analysis	   software	   developed	   in	   our	   laboratory	   (Bennett	   2013),	   allows	   the	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calculation	   of,	   and	   graphical	   plotting	   of,	   the	   IP	   value	   corrected	   for	   the	  background	  fragment	  levels	  via	  the	  IN	  sample	  at	  each	  probe.	  	  This	  corrects	  each	  IP	   probe	   value	   for	   the	   relative	   level	   of	   DNA	   fragments	   present	   in	   the	   starting	  material,	   and,	   to	   a	   degree,	   for	   experimental	   variability	   as	   the	  paired	   IP	   and	   IN	  samples	  are	  processed	  throughout	  the	  assay	  in	  parallel.	  	  As	  the	  IP/IN	  ratio	  value	  is	  the	  proportion	  of	  fragments	  in	  the	  IP	  sample	  relative	  to	  the	  background,	  it	  is	  a	  measure	   of	   the	   relative	   immunoprecipitation	   efficiency	   between	   probes,	   and	  hence	  the	  relative	  amount	  of	  adducts	  at	  each	  loci.	  	  It	  is	  by	  plotting	  the	  (log2)	  ratio	  of	  the	  IP	  to	  IN	  probe	  values	  at	  each	  probe	  location	  that	  the	  platinum-­‐DNA	  adduct	  pattern	  is	  generated.	  	   Sandcastle	   imports	   data	   to	   the	   R	   statistical	   package	   from	   the	   text	   file	  dataset	  generated	  by	  the	  Agilent	  Feature	  Extraction	  Software	  during	  the	  analysis	  of	  scanned	  microarray	  slides	  (see	  section	  4.1.3.4	  for	  a	  detailed	  description	  of	  this	  process).	  	  The	  data	  imported	  at	  each	  probe	  location	  is	  the	  fluorescence	  intensity	  at	   each	   feature/probe	   location	   of	   the	   background	   subtracted	   red	   and	   green	  channels,	  corresponding	  to	  the	  IP	  and	  IN	  values	  at	  each	  probe	  respectively.	  	  This	  data	   on	   the	   fluorescence	   intensity	   has	   been	   adjusted	   by	   the	   feature	   extraction	  software	   to	   account	   for	  background	  and	  adjacent	  probe	   fluorescence	   intensity,	  giving	  an	  accurate	  reading	  for	  each	   individual	  probe	  by	  removing	  the	   influence	  of	   adjacent	   probe	   fluorescence.	   	   During	   the	   import	   process,	   from	   the	   feature	  extraction	  output	   file	   to	  R	  by	  Sandcastle,	   the	  (log2)	  ratio	  of	   the	  BGredsubsignal	  (the	   background	   adjusted	   IP	   values)	   and	   BGgreensubsignal	   (the	   background	  adjusted	  IN	  values)	  are	  calculated	  and	  retained	  in	  R	  as	  the	  log2	  IP/IN	  ratio.	  	  	   It	   is,	   therefore,	   possible	   to	  manipulate	   the	   data	   by	  manually	   editing	   the	  feature	   extraction	   generated	   text	   file	   datasets	   to	   adjust	   each	   probe	  ‘BGgreensubsignal’	   value	   to	   a	   new	   value	   of	   1.	   	   Once	   this	   modified	   dataset	   is	  imported	  by	  Sandcastle	  to	  R,	  the	  ‘ratios’	  value,	  used	  in	  the	  subsequent	  Sandcastle	  functions,	   becomes	  BGredsubsignal/1,	   altering	   the	   ratios	   value	   to	   the	   initial	   IP	  probe	  value.	  	  Correspondingly,	  by	  modifying	  each	  BGredsubsignal	  to	  a	  value	  of	  1	  the	  ratios	  values	   for	   the	   imported	  R	  data	  become	  1/BGgreensubsignal,	  or	  1/IN	  probe	  value.	   	  By	  further	  modifying	  the	  BGgreensubsignal	  to	  its	  reciprocal	  value	  in	  the	  initial	  data	  file,	  once	  imported	  the	  ratios	  value	  and	  associated	  sandcastle	  plotting	  and	  analysis	  tools	  give	  the	  probe	  values	  for	  the	  IN	  channel	  only.	  	  Three	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microarray	   datasets	   of	   fluorescence	   intensity	   values	   are	   generated	   from	   the	  initial	  data,	   at	   each	  probe	  position	  –	   the	   initial	  data	  of	   the	   IP/IN	  values,	   the	   IP	  intensity	  values	  only,	  and	  the	  IN	  intensity	  values	  only	  respectively.	  	  	  Following	   this	   modification	   these	   three	   datasets	   can	   be	   plotted	  simultaneously	   (figure	   5.1).	   	   The	   platinum-­‐DNA	   adduct	   profile	   (black)	   can	   be	  plotted,	   as	   in	   all	   previous	   adduct	   pattern	   plots,	   but	   now	   along	  with	   the	   probe	  intensity	   values	   for	   the	   IN	   (green)	   and	   IP	   (red)	   single	   channels	   (Figure	   5.1	   -­‐	  upper	   plot).	   	   Once	   the	   BGgreensubsignal	   is	   corrected	   by	   modification	   the	  reciprocal	   value,	   the	   IP	   and	   IN	   probe	   values	   are	   juxtaposed,	   allowing	   a	   visual	  comparison	  of	  the	  two	  probe	  value	  patterns	  along	  the	  datasets	  (figure	  5.1	  -­‐	  lower	  plot)	   These	  modifications	   to	   the	   procedure	   for	   loading	   the	   data	   allow	   a	   new	  analysis	  of	  the	  data	  –	  referred	  to	  from	  this	  point	  as	  a	  ‘single	  channel	  analysis’,	  or	  SCA.	   	   This	   can	   identify	   the	   separate	   influence	   of	   the	   IN	   and	   IP	   values	   in	   the	  experiment,	   more	   clearly	   demonstrating	   why	   some	   experimentally	   generated	  datasets	   fail	   to	   correlate	  with	   one-­‐another,	   and	  why	   some	  of	   the	   experimental	  protocol	  modifications	  discussed	  in	  the	  section	  above	  failed	  to	  improve	  the	  assay	  reliability	  (e.g.	  diluting	  the	  IN	  sample	  to	  match	  the	  IP	  sample	  pre-­‐amplification	  -­‐	  section	  4.4.6).	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Figure	  5.1:	  An	  example	  single	  channel	  analysis	  (SCA)	  plot.	  An	  example	   single	   channel	   analysis	   (SCA)	  plot	   of	  modified	  microarray	  data	   from	  a	  100μM	  oxaliplatin	  treated	  PBMC	  sample.	   	   In	  the	  top	  panel	  the	   initial	  modification	  is	  demonstrated	  with	  the	  oxaliplatin-­‐DNA	  adduct	  pattern	  present	  (black),	  the	  single	  IN	  channel	  data	  (green)	  and	  the	  single	  IP	  channel	  (red)	  displayed.	   	  This	  demonstrates	  the	  relationship	  between	  the	  three	  datasets	  after	  initial	  data	  modification.	  	  The	  lower	  panel	  displays	  the	  same	  result	  after	  the	  IN	  data	  is	  further	  adjusted	  to	  modify	  the	  BGgreensubsignal	  value	  to	  the	  reciprocal	  of	  the	  BGgreensubsignal	  value,	  allowing	  easier	  comparison	  of	  the	  IN	  and	  IP	  patterns.	  
	  
5.1.1 An	  example	  of	  the	  benefit	  of	  Single	  Channel	  Analysis	  	  	   	  During	   the	   generation	   of	   DIP-­‐chip	   data	   from	   oxaliplatin-­‐treated	   PBMC	  from	   individuals	  A	  and	  B	   (Section	  4.4.1)	  one	  of	   the	   independent	   repeats	  of	   the	  PBMC	  microarrays	  of	  patient	  B	   	  (repeat	  2	  at	  the	  100µM	  dose	  level)	  displays	  an	  obviously	   different	   pattern	   to	   repeat	   1	   and	   3,	  with	   a	   correlation	   value	   of	   0.07	  between	  repeat	  2	  and	  either	  of	   repeat	  1	  or	  3.	   	   	  The	  generated	  adduct	  patterns	  from	   repeats	   1	   and	   3	   appear	   typical	   for	   this	   experiment,	   with	   a	   Spearman’s	  correlation	   value	   of	   0.48	   between	   repeats	   1	   and	   3	   and	   0.5-­‐0.6	   between	   other	  100µM	  samples	  (Figures	  4.9	  and	  again	  in	  figure	  5.2),	  indicating	  that	  the	  problem	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lies	  with	  repeat	  sample	  2.	  	  Using	  the	  standard	  Sandcastle	  analysis	  tools	  it	  is	  not	  possible	  to	  identify	  at	  which	  stage,	  or	  in	  which	  ‘channel’,	  the	  second	  experiment	  failed,	   only	   that	   the	   patterns	   do	   not	   match	   well.	   	   The	   oxaliplatin-­‐DNA	   adduct	  patterns	   and	   corresponding	   correlation	   values	   are	   calculated	   using	   standard	  Sandcastle	  tools	  for	  figure	  5.2.	  	   	  	  
	  
Figure	   5.2:	   Oxaliplatin-­‐DNA	   adduct	   pattern	   plots	   from	   three	   independent	   repeat	  
experiments.	  Oxaliplatin-­‐DNA	   adduct	   pattern	   plots	   have	   been	   generated	   from	   three	   independent	  biological	   repeats	   of	   100µM	   oxaliplatin	   treated	   PBMC	   from	   individual	   B,	   and	   all	   three	  patterns	  are	  shown	  in	  the	  top	  panel.	   	  The	  three	  lower	  panels	  show	  sequential	  comparisons	  between	   pairs	   of	   the	   repeat	   datasets	   and	   the	   Spearman’s	   correlation	   value	   between	   the	  patterns.	  	  Repeat	  2	  has	  a	  correlation	  with	  repeat	  1	  of	  0.07	  and	  with	  repeat	  3	  of	  0.05	  (Second	  top	   and	   lowest	   panel).	   	   In	   the	   third	   panel	   (labelled	   repeat	   1	   vs.	   repeat	   3)	   the	   adduct	  patterns	  generated	  in	  repeats	  1	  and	  3	  match	  more	  closely	  (a	  correlation	  of	  0.48).	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The	   result	   displayed	   in	   figure	   5.2	   demonstrates	   that	   adduct	   patterns	   in	  repeats	   1	   and	   3	   (the	   plot	   in	   the	   third	   panel	   labelled	   Repeat	   1	   vs.	   Repeat	   3)	  correlate	   most	   closely,	   as	   shown	   by	   the	   Spearman’s	   correlation	   coefficient	   of	  0.48,	  and	  the	  visually	  similar	  appearing	  traces	  on	  the	  adduct	  pattern	  plot,	  whilst	  repeat	  2	  fails	  to	  match	  the	  patterns	  on	  the	  two	  subsequent	  pairwise	  plots	  (panels	  2	  and	  4)	  and	  has	  a	  very	  low	  Spearman’s	  correlation	  value	  (0.07	  and	  0.05).	  	  This	  identifies	   a	   discrepancy	   with	   this	   particular	   experiment,	   but	   does	   not	  demonstrate	  at	  which	  stage	  or	  in	  which	  of	  the	  IP	  or	  IN	  samples	  the	  problem	  has	  occurred.	  After	  modifying	   the	   three	  100µM	  oxaliplatin	   repeat	  microarray	  datasets	  with	  the	  data	  alterations	  as	  described	  above	  to	  allow	  single	  channel	  analysis	  it	  is	  then	   possible	   to	   plot	   and	   calculate	   the	   Spearman’s	   correlation	   values	   between	  the	  separate	  IN	  and	  IP	  single	  channels.	   	  These	  single	  channel	  IN	  (green)	  and	  IP	  (red)	  patterns	  are	  plotted	  in	  figure	  5.3	  for	  the	  same	  data.	  	  
	  
Figure	  5.3:	  SCA	  plot	  of	  three	  repeat	  experiments.	  A	  single	  channel	  analysis	  plot	  of	   the	   IN	  and	  IP	  single	  channel	  patterns	   from	  3	   independent	  repeats	   of	   100uM	   oxaliplatin	   treated	   PBMC	   from	   individual	   B.	   	   The	   IN	   channels	   of	   the	   3	  repeats	  are	  shown	  in	  the	  upper	  panel	  (green)	  and	  the	  IP	  channels	  in	  the	  lower	  panel	  (red).	  	  	  The	  correlation	  values	  between	  each	  repeat	   in	  each	  group	  of	   IN	  or	  IP	  channels	   is	  shown	  in	  the	  legend.	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Using	  the	  single	  channel	  analysis	  approach	  it	  is	  clear	  in	  figure	  5.3	  that	  the	  IN	  samples	  (green)	  have	  a	  very	  high	  degree	  of	  reproducibility,	  demonstrated	  by	  a	  high	  correlation	  value	  (Spearman’s	  correlation	  between	  patterns	  of	  >0.94),	  and	  with	   no	   visible	   difference	   evident	   between	   the	   patterns	   generated	   and	  plotted	  from	  the	  data.	  	  This	  is	  a	  high	  degree	  of	  consistency,	  considering	  that	  44,000	  data	  points	   are	   involved	   and	   the	   samples	   were	   processed	   independently	   over	   the	  course	  of	  a	  six-­‐week	  period.	   	  The	  IP	  channel	  (bottom	  panel,	  red)	  shows	  a	  more	  variable	  pattern	   in	   the	   second	   sample,	   compared	   to	   the	   first	   and	   third	   repeats	  which	   match	   one-­‐another	   better,	   in	   keeping	   with	   the	   Spearman’s	   correlation	  values	  displayed	  of	  0.87	  between	  repeat	  1	  and	  3	  and	  0.72	  between	  either	  pattern	  1	  or	  3	  when	  compared	  to	  pattern	  2.	  Additionally,	   a	   ‘single	   channel	   analysis’	   matrix	   (an	   SCA	   matrix)	   of	  Spearman’s	  correlation	  values	  between	  the	  IP/IN	  patterns	  (the	  oxaliplatin-­‐DNA	  adduct	  pattern)	  and	  between	  single	  IP	  and	  IN	  channels	  can	  been	  generated,	  and	  is	  displayed	  in	  figure	  5.4.	   	  The	  oxaliplatin-­‐DNA	  adduct	  patterns	  (the	  IP/IN	  ratio	  patterns)	  are	  shown	  the	  left	  top	  box	  (yellow),	  the	  IN	  single	  channel	  patterns	  are	  in	  the	  central	  box	  (green),	  and	  the	  correlation	  between	  IP	  channels	  are	  displayed	  in	  the	  right	  lower	  box	  (red).	  
	  
Figure	  5.4:	  A	  SCA	  matrix	  of	  three	  independent	  repeat	  experiments.	  A	   single	   channel	   analysis	   (SCA)	   matrix	   of	   Spearman’s	   correlation	   values	   between	  oxaliplatin-­‐DNA	  adduct	   (IP/IN)	  patterns	   (yellow),	   single	   IN	  channels	   (green)	  and	  single	   IP	  channels	   (red)	   from	   3	   independent	   repeats	   of	   100uM	   oxaliplatin	   treated	   PBMC	   from	  individual	  B.	  	  The	  higher	  the	  correlation	  value	  the	  darker	  the	  box	  colour,	  as	  indicated	  in	  the	  key	  below	  the	  main	  plot.	  	  	  
Rpt 1 2 3 1 2 3 1 2 3 Rpt
Rpt Type IP/IN IP/IN IP/IN IN IN IN IP IP IP Type Rpt
Patient.B.100uM.Oxaliplatin 1 IP/IN 0.07 0.48 IP/IN 1
Patient.B.100uM.Oxaliplatin 2 IP/IN 0.07 0.06 IP/IN 2
Patient.B.100uM.Oxaliplatin 3 IP/IN 0.48 0.06 IP/IN 3
Patient.B.100uM.Oxaliplatin 1 IN 0.94 0.94 IN 1
Patient.B.100uM.Oxaliplatin 2 IN 0.94 0.97 IN 2
Patient.B.100uM.Oxaliplatin 3 IN 0.94 0.97 IN 3
Patient.B.100uM.Oxaliplatin 1 IP 0.72 0.87 IP 1
Patient.B.100uM.Oxaliplatin 2 IP 0.72 0.72 IP 2
Patient.B.100uM.Oxaliplatin 3 IP 0.87 0.72 IP 3
Scale IP/IN vs. IP/IN 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0
IN vs. IN 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0
IP vs. IP 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0
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This	  matrix	   approach	   allows	   a	   visual	   overview	   of	   all	   of	   the	   correlation	  values	  between	   samples,	   a	  useful	   approach	  when	  many	   samples	  are	   compared	  simultaneously	   and	   the	   relative	   colour	   intensity	   allows	   a	   rapid	   appreciation	  of	  the	  numerical	  similarities	  and	  differences	  between	  pairs	  and	  groups	  of	  samples.	  The	   SCA	   matrix	   demonstrates	   that	   patterns	   generated	   from	   the	   single	  channel	   IN	   data	  match	   very	  well,	   as	   shown	   by	   correlation	   values	   of	   0.94-­‐0.97.	  This	  indicates	  that	  IN	  samples	  are	  highly	  reproducible	  in	  these	  experiments.	  	  The	  IP	  patterns	  match	  less	  well	  (correlation	  values	  of	  0.72	  to	  0.87),	  and	  significantly	  lower	   in	   pairwise	   comparisons	   involving	   sample	   2	   (correlations	   of	   0.72)	   than	  between	   samples	   1	   and	   3	   (correlation	   0.87).	   	   The	   decrease	   in	   correlation	  between	   IP	   sample	   2	   compared	   to	   between	   1	   and	   3	   is	   therefore	   likely	   to	   be	  responsible	  for	  the	  failure	  of	  the	  IP/IN	  adduct	  pattern	  to	  match	  the	  other	  repeat	  samples	   (correlations	   of	   0.05	   and	   0.07),	   and	   indicates	   that	   there	   has	   been	  problems	  with	  the	  IP	  experiment	  in	  sample	  2,	  whereas	  the	  IN	  sample	  appears	  to	  have	   been	   purified,	   amplified,	   labelled	   and	   hybridised	   appropriately.	   	   A	   small	  reduction	  in	  IP	  channel	  reproducibility,	  when	  subsequently	  used	  to	  calculate	  the	  IP/IN	  ratio,	  results	  in	  a	  small	  difference	  that	  is	  multiplied	  when	  the	  data	  is	  used	  at	  44,000	  data	  points	  to	  generate	  an	  IP/IN	  pattern.	  	  As	  the	  IN	  channels	  are	  highly	  reproducibly,	   it	   must	   be	   this	   small	   variation	   in	   IP	   channel	   consistency	   that	   is	  sufficient,	  through	  the	  introduction	  of	  subtle	  variability	  at	  each	  of	  44,000	  values,	  to	   introduce	   significant	   noise	   into	   the	   IP/IN	   adduct	   pattern	   to	   result	   in	   a	  dramatic	  fall	  in	  correlation	  between	  IP/IN	  adduct	  patterns.	  	  This	  example	  demonstrates	  the	  use	  of	  SCA	  for	  data	  interpretation	  and	  for	  quality	   control	   assessment	   of	   DIP-­‐chip	   data.	   	   Prior	   to	   this	   development	   it	  was	  possible	  only	  to	  identify	  a	  failed	  DIP-­‐chip	  assay.	  	  It	  is	  now	  possible	  to	  identify	  in	  which	  sample	  the	  issue	  occurred	  using	  SCA,	  information	  that	  can	  be	  compared	  to	  laboratory	   records	   to	   identify	   assay	   failings.	   	   As	   SCA	   can	   identify	   subtle	  differences	  in	  single	  samples,	  it	  is	  potentially	  a	  useful	  tool	  in	  assay	  development	  and	  validation	  experiments,	  as	  will	  be	  shown	  in	  subsequent	  sections.	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5.1.2 Extracting	  latent	  information	  from	  microarrays:	  The	  development	  of	  
a	  custom	  R	  functions	  for	  single	  channel	  analysis	  to	  produce	  SCA	  plots	  
and	  SCA	  correlation	  matrices	  	   The	   above	   example	   of	   single	   channel	   analysis	   (SCA)	   demonstrates	   the	  power	   of	   this	   approach	   to	   allow	   a	   more	   detailed	   interpretation	   of	   DIP-­‐chip	  microarray	  data,	  specifically	  in	  determining	  the	  influence	  of	  changes	  in	  IN	  and	  IP	  samples	  on	   the	  ultimate	  platinum-­‐DNA	  adduct	  pattern.	   	  Application	  of	   the	  SCA	  approach	   to	   microarray	   data	   analysis	   will	   be	   applied	   to	   the	   experimental	  attempts	   to	   improve	   the	   DIP-­‐chip	   reproducibility,	   conducted	   and	   described	   in	  the	  previous	  chapter,	  in	  order	  to	  accurately	  determine	  the	  effect	  of	  experimental	  and	  analytical	  changes	  on	  either,	  or	  both,	  of	  the	  single	  IP	  and	  IN	  channels.	  	  This	  approach	   may	   shed	   new	   light	   on	   why	   the	   experimental	   changes	   intended	   to	  improve	   assay	   reproducibility	   met	   with	   only	   limited	   success,	   as	   described	   in	  chapter	  4.	  In	  order	   to	  perform	  this	  more	  detailed	  analysis,	   and	   to	  develop	   the	  SCA	  process	   as	   a	   tool	   for	   future	   studies,	   the	   SCA	   technique	  was	   automated	   by	   the	  development	  of	  a	  series	  of	  R	  functions	  capable	  of	  taking	  initial	  standard	  DIP-­‐chip	  microarray	  datasets	  and	  to	  rapidly	  generate	  two	  graphical	  outputs	  -­‐	  SCA	  pattern	  plots	  of	  single	  channel	  data	  (as	  in	  Figure	  5.3)	  and	  SCA	  correlation	  matrices	  (as	  in	  figure	   5.4)	   -­‐	   allowing	   visualisation	   and	   comparisons	   between	   adduct	   patterns	  (IP/IN	  ratios),	  IN	  and	  IP	  single	  channels	  simultaneously.	  	  	  In	  the	  discussion	  and	  description	  of	  the	  R	  functions	  below,	  the	  following	  terminology	  is	  used:	  	  
Function:	   An	   R	   function	   is	   a	   discrete	   package	   of	   R	   script	   that	   takes	   a	  series	  of	  inputs	  (in	  the	  form	  of	  arguments),	  and	  returns	  an	  output.	  	  The	  output	  is	  typically	   derived	   from	   a	   series	   of	   calculations	   and	   sub-­‐functions,	   such	   as	  graphical	  plot	  commands,	  specified	  in	  the	  body	  of	  the	  function.	  	  In	  essence,	  an	  R	  function	  binds	  together	  a	  series	  of	  R	  programming	  steps,	  simplifying	  potentially	  lengthy	   analysis	   and	   graphical	   operations	   into	   a	   consistent	   single	   integrated	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procedure.	  	  In	  the	  discussion	  below	  the	  names	  of	  individual	  functions	  are	  noted	  in	  bold	  font.	  	  
Argument:	   	   An	   argument	   provides	   information	   as	   an	   input	   into	   an	   R	  function,	  and	   is	   required	   to	  generate	   the	  output	   from	  the	   function.	   	  Arguments	  can	  be	  essential	  for	  the	  generation	  of	  function	  output	  (i.e.	  which	  datasets	  to	  use	  for	  the	  analysis)	  or	  can	  be	  optional	  (i.e.	  specifying	  the	  text	  size	  of	  the	  graphical	  output).	   	   Arguments	   can	   be	   pre-­‐set	   to	   a	   default	   value	   if	   optional.	   	   In	   the	  description	  below	  arguments	  when	  named	  are	  in	  italic	  font.	  	  
Vector:	   	   In	  the	  context	  used	  below,	  a	  vector	  is	  an	  object	  that	  can	  contain	  information	  in	  the	  R	  environment.	  	  In	  the	  description	  below	  vectors	  when	  named	  are	  underlined.	  	  For	   each	   of	   the	   five	   functions	   described	   below,	   the	   full	   R	   script	   code	   is	  included	   in	   appendices	   2	   to	   4,	   and	   an	   electronic	   version	   is	   included	   in	   the	  electronic	  appendix.	  	  	  	  
5.1.2.1 SCA	  ancillary	  functions	  
	  	   The	  goal	  of	   the	  work	  as	  described	  here	   is	   the	  development	  of	   custom	  R	  functions	   that	  will	   allow	  automated	  data	  entry,	   analysis	   and	  graphical	  outputs,	  generating	   a	   single	   channel	   analysis	   correlation	  matrix	   and	  plot	   from	  DIP-­‐chip	  microarray	   datasets.	   	   This	   allows	   the	   procedure	   to	   be	   consistently	   and	   easily	  performed	  by	  any	  member	  of	  the	  laboratory	  team,	  using	  a	  simple	  line	  of	  R	  code	  to	   call	   the	   function	   and	   to	   specify	   the	   arguments	   specifically	   required	   for	   each	  analysis.	  	   Firstly,	  the	  data	  must	  be	  entered	  in	  the	  correct	  format	  for	  SCA,	  and	  is	  then	  analysed	  to	  generate	  correlation	  matrices,	  which	  can	  subsequently	  be	  plotted	  as	  SCA	   adduct-­‐pattern	   plots	   or	   as	   correlation	   tables.	   	   This	   process	   is	   conducted	  through	   a	   set	   of	   three	   SCA	   ancillary	   functions,	   named	   SCAdataload,	   corsCalc	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and	  corsPredCalc.	  	  These	  three	  SCA	  ancillary	  functions	  are	  available	  in	  appendix	  2,	  which	  lists	  the	  source	  code	  required	  for	  these	  preparatory	  functions.	  	  	  	  The	   function	   SCAdataLoad	   is	   run	   first.	   	   This	   function	   uses	   pre-­‐set	  procedures	  available	  in	  Sandcastle	  (version	  1.0)	  to	  extract	  data	  from	  the	  text	  file	  output	   from	  Agilent’s	   feature	  extraction	  software,	   generated	   from	   the	   required	  microarray	  datasets	   in	   the	  working	  directory.	   	  The	   function	  stores	   information	  from	  these	  datasets	  to	  the	  vector	  SCAdata,	  in	  the	  order	  of:	  1)	  adduct	  pattern	  data	  (for	   all	   datasets	   present	   sequentially)	   followed	   by	   2)	   the	   probe	   IN	   values,	  followed	  by	  3)	  the	  probe	  IP	  values.	  	  For	  example,	  for	  three	  microarray	  datasets	  A,	  B	   and	   C	   the	   data	   is	   stored	   in	   the	   order	   A-­‐IP/IN	   ratios,	   B-­‐IP/IN	   ratios,	   C-­‐IP/IN	  ratios,	  A-­‐IN	  values,	  B-­‐IN	  values	  C-­‐IN	  values,	  A-­‐IP	  value,	  B	  IP	  values,	  C	  IP	  values.	  	  	  The	   function	   SCAdataLoad	   can	   be	   modified	   by	   specifying	   the	   optional	  argument	   ‘all=FALSE’,	   allowing	   the	   specification	   of	   individual	   microarray	   data	  files	  to	  load	  for	  analysis	  and	  resulting	  in	  the	  generation	  of	  an	  on-­‐screen	  request	  for	   the	  selection	  of	   the	   files	   to	  be	   loaded	  by	   identification	  of	   the	  dataset	  by	  the	  order	  they	  appear	  in	  the	  working	  directory	  (i.e.	  only	  the	  1st,	  3rd	  and	  7th	  datasets	  can	   be	   used	   for	   SCA	   analysis	   by	   entering	   these	   numeric	   identifiers	   when	  requested).	  	  	  	  	   The	   ancillary	   functions	   corsCalc	   and	   corsPredCalc	   are	   then	   used	   to	  calculate	  the	  Spearman’s	  correlation	  between	  the	  datasets	  that	  have	  been	  loaded	  by	  SCAdataLoad.	   	  The	  corsCalc	   function	  calculates	  the	  correlation	  between	  all	  datasets	  and	  between	  each	  single	  channel,	  and	  the	  output	  must	  be	  stored	  in	  the	  vector	   ‘cors’.	   	   For	   the	   prediction	   to	   be	   accurately	   generated,	   the	   prediction	  profiles	  are	  required	  to	  be	  loaded	  to	  R	  with	  Sandcastle	  in	  the	  vector	  predPlat	  for	  the	  platinum	  profile	  and	  the	  vector	  predUV	  for	  the	  UV	  prediction	  profile,	  if	  these	  are	   required	   for	   the	   analysis.	   	   The	   function	   corsPredCalc	   can	   then	   be	   run	   to	  calculate	   the	   correlation	   between	   predicted	   profiles	   and	   microarray	   single	  channel	  data.	  	  The	  output	  must	  be	  stored	  to	  the	  vector	  ‘corspred’.	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5.1.2.2 SCA	  plot	  and	  correlation	  matrix	  functions	  	  	   Once	   the	   ancillary	   functions	   have	   been	   run	   the	   data	   can	   be	   used	   to	  generate	  a	   SCA	  plot	   (using	   the	   function	  SCAplot)	  or	   an	  SCA	  correlation	  matrix	  (with	  the	  function	  corsPlot)	  (full	  scripts	  for	  these	  two	  functions	  are	  available	  in	  appendix	  3	  and	  4).	  	  	  To	  plot	  a	  SCA	  plot	  (as	  in	  figure	  5.3	  and	  figure	  5.5)	  the	  function	  SCAplot	  is	  used.	   	   This	   function	   uses	   the	   data	   loaded	   with	   preparatory	   function	  
SCAdataLoad	  to	  plot	  the	  platinum-­‐DNA	  adduct	  patterns	  from	  each	  dataset	  in	  the	  upper	  plot,	  the	  IN	  values	  in	  the	  middle	  plot	  (patterns	  displayed	  in	  green)	  and	  the	  IP	  values	  in	  the	  lower	  plot	  (patterns	  displayed	  in	  red).	  	  	  The	   default	   region	   plotted	   is	   chromosome	   17,	   nucleotides	   10050000	   to	  10075000,	   and	   can	   be	   adjusted	   with	   the	   optional	   arguments	   ‘start’	   and	   ‘end’.	  	  The	  arguments	  legends,	  labels,	  highlight	  and	  datatohighlight	  can	  also	  be	  used.	  	  If	  the	   argument	   legends=FALSE	   is	   used	   this	   will	   remove	   the	   data	   legends.	   	   If	  
labels=TRUE	   is	   used	   the	   name	   of	   each	   dataset	   will	   be	   prompted	   for,	   and	  subsequently	  displayed	  alongside	  the	  plot.	   	  To	  highlight	  a	  dataset	  the	  argument	  
highlights	   can	   be	   set	   highlights=TRUE	   and	   a	   numerical	   value	   (n)	   used	   for	  
datatohighlight=n	   to	   identify	   which	   dataset	   to	   highlight.	   (see	   figure	   5.5	   for	   an	  example)	  	  	   The	   function	   corPlot	   is	   used	   to	   generate	   and	   label	   an	   SCA	   correlation	  matrix	   of	   Spearman’s	   correlation	   values	   in	   the	   format	   used	   in	   figure	   5.4	   and	  figure	  5.6	  A	  and	  B.	  	  This	  standardised	  format	  will	  be	  used	  for	  all	  SCA	  correlation	  matrices.	  	  For	  a	  breakdown	  of	  the	  format	  see	  figure	  5.6B.	  	  	  The	   IP/IN	   (the	   adduct	   pattern)	   correlations	   are	   presented	   in	   the	   upper	  left	   (the	   analysis	   labelled	   A	   in	   figure	   5.6B),	   the	   correlation	   between	   IN	   single	  channels	   in	   the	   central	   green	   box	   (the	   analysis	   labelled	   B	   in	   figure	   5.6B),	   and	  correlation	   between	   IP	   single	   channel	   in	   the	   left-­‐lower	   red	   box	   (the	   analysis	  labelled	  C	  in	  figure	  5.6B).	  	  Correlations	  between	  IN	  and	  IP	  single	  channels	  can	  be	  seen	  in	  the	  central	  lower	  box	  (the	  analysis	  labelled	  X	  in	  figure	  5.6B)	  and	  between	  IP/IN	  ratios	  and	  IN	  and	  IP	  single	  channels	  in	  the	  left	  hand	  middle	  and	  lower	  box	  respectively	   (the	   analysis	   labelled	   Y	   and	   Z	   in	   figure	   5.6B).	   	   In	   all	   cases	   the	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strength	  of	  the	  correlation	  is	  graded	  by	  increasing	  darkness	  of	  colour	  as	  shown	  by	   the	  key	   to	   the	   right	  hand	  of	   the	  plot.	   	  The	  colour	   scale	  used	   for	  each	  key	   is	  adjusted	   to	   reflect	   the	   typical	   range	   of	   values	   seen	   with	   the	   SCA	   correlation	  matrix.	   	  The	   single	   IN	  and	   IP	   channel	   correlations	   are	   typically	   in	   the	   range	  of	  0.85-­‐1.	  	  The	  IP/IN	  patterns	  are	  derived	  from	  the	  IN	  and	  IP	  single	  channels,	  and	  as	  such	  the	  error	  in	  this	  channel	  is	  due	  to	  a	  combination	  of	  the	  error	  in	  each	  single	  channel,	   resulting	   in	   a	   greater	   variability	   in	   correlation	   values	   in	   the	   IP/IN	  pattern	   compared	   to	   the	   single	   channels,	   and	   this	   is	   reflected	   in	   differences	   in	  the	  key	  scales.	   	  For	  example,	  a	  colour	  gradient	  begins	  at	  above	  a	  correlation	  of	  0.5	  is	  used	  in	  the	  IP/IN	  region,	  but	  in	  the	  single	  channel	  IN	  or	  IP	  section	  a	  colour	  scale	   above	   values	   of	   0.85	   is	   used.	   	   The	   correlation	   between	   experimentally	  generated	  samples	  and	  the	  mathematically	  generated	  predicted	  profiles,	  if	  used,	  are	  shown	  below	  the	  main	  matrix	  with	  the	  colour	  gradient	  key	  as	  applied.	  	   The	   optional	   arguments	   prediction=TRUE	   can	   be	   used	   to	   add	   the	  correlation	   values	   of	   the	   experimentally	   generated	   data	   to	   the	  mathematically	  generated	   prediction	   profile	   (using	   the	   arguments	   UV=TRUE	   and/or	  
platinum=TRUE	  to	  select	  the	  prediction	  profile	  to	  use).	   	  The	  arguments	  ‘boxtext’	  and	   ‘FigSize’	   can	  be	  numerically	   set	   to	   scale	   the	  correlation	  value	   text	   size	  and	  the	   figure	   size	   respectively,	   useful	   for	   visualisation	  purposes	   (the	  default	   is	  1).	  	  The	  argument	   labels=TRUE	  will	  result	   in	  a	  call	   for	  defined	  label	  names	  for	  each	  sample.	   	   For	   ease	   of	   display	   the	   key	   can	   be	   removed	   using	   the	   argument	  
key=FALSE.	  An	   example	   of	   the	   output	   plots	   generated	   by	   this	  SCAplot	   and	   corPlot	  functions	  are	  shown	  in	  figure	  5.5	  and	  5.6	  respectively,	  and	  are	  created	  with	  the	  DIP-­‐chip	   datasets	   used	   for	   the	   example	   single	   channel	   analysis	   from	   in	   the	  previous	  section	  5.1.1.	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Figure	  5.5:	  An	  example	  plot	  generated	  by	  the	  SCAplot	  R	  function.	  An	   example	   plot	   generated	   by	   the	   SCAplot	   R	   function	   developed	   to	   allow	   efficient	   single	  channel	  analysis	  of	  DIP-­‐chip	  microarray	  datasets.	   	  Three	  repeats	  of	  oxaliplatin-­‐DNA	  adduct	  pattern	   microarray	   datasets	   from	   100µM	   oxaliplatin	   treated	   PBMC	   from	   patient	   B	   are	  shown.	  	  The	  top	  plot	  is	  of	  three	  platinum-­‐DNA	  adduct	  patterns,	  the	  middle	  plot	  is	  the	  single	  IN	   channels	   (green)	   and	   the	  bottom	  plot	   is	   the	   single	   channel	   IP	  patterns	   (red)	   generated	  from	  the	  three	  datasets.	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Figure	  5.6:	  (A)	  An	  example	  of	  the	  SCA	  matrix	  produced	  by	  the	  corPlot	  function.	  An	  example	  of	   the	  SCA	  matrix	  produced	  by	   the	  corPlot	   function	  developed	   to	  enable	  rapid	  single	  channel	  analysis	  of	  DIP-­‐chip	  microarray	  datasets.	  	  This	  figure	  is	  a	  recreation	  of	  figure	  5.4,	   using	   three	   repeat	   100µM	   oxaliplatin	   treated	   PBMC	   sample	   datasets	   to	   compare	   the	  IP/IN	   ratios	   (upper	   left	   box	   –	   darker	   yellow	  with	   increasing	   Spearman’s	   correlation),	   the	  single	  channel	   IN	  samples	   (central	  box	  –	  darker	  green	   for	  higher	  Spearman’s	  correlations)	  and	  lower	  left	  box	  for	  the	  single	  channel	  IP	  relationships	  (darker	  red	  for	  higher	  Spearman’s	  correlations).	   	  The	  correlation	  between	  patterns	  generated	  between	   IP	  and	   IN	  can	  be	  seen	  in	  the	  central	  lower	  box,	  and	  between	  IP/IN	  ratios	  and	  the	  single	  channel	  II	  or	  IP	  patterns	  in	  the	  left	  centre	  and	  lower	  boxes	  respectively	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Figure	  5.6	  (B):	  An	  example	  of	  the	  SCA	  matrix	  produced	  by	  the	  corPlot	  function	  
	  	  	  This	   figure	  shows	  the	  relationship	  between	  the	  SCAplot	  (right)	  and	  SCA	  correlation	  matrix	  (left)	  generated	  by	  the	  SCAplot	  and	  corPlot	  functions	  and	  presented	  in	  figures	  5.5	  and	  5.6A	  above.	  	  	  The	  three	  key	  relationships	  are	  demonstrated	  and	  are	  between:	  A)	   IP/IN	   adduct	   patterns	   in	   the	   top	   of	   the	   SCAplot	   (black)	   and	   the	   correlations	   between	  these	  patterns	  (analysis	  A)	  presented	  in	  the	  top	  left	  of	  the	  correlation	  matrix.	  	  	  B)	   The	   relationship	   between	   IN	   single	   channels	   (green)	   as	   plotted	   in	   the	   SCAplot	   central	  plot	  is	  shown	  in	  analysis	  B	  and	  presented	  in	  the	  central	  box	  of	  the	  correlation	  matrix.	  	  	  C)	  The	  relationship	  between	  single	  channels	  is	  shown	  in	  red	  in	  the	  lower	  plot	  of	  the	  SCAplot	  and	  the	  lower	  right	  box	  of	  the	  correlation	  matrix.	  	  	  Three	  further	  relationships	  are	  also	  shown	  here:	  	  	  X)	  Analysis	  X	  shows	  the	  relationship	  between	  single	  IP	  and	  IN	  channels,	  and	  is	  displayed	  in	  the	  central	  lower	  box	  of	  the	  correlation	  matrix.	  	  	  Y)	  The	  relationship	  between	   the	   IP	  single	  channels	  and	   the	   IP/IN	  adduct	  pattern	   is	   shown	  by	  Y	  and	  is	  displayed	  in	  the	  lower	  left	  box.	  	  	  Z)	   	   The	   relationship	   between	   IN	   single	   channel	   patterns	   and	   the	   IP/IN	   adduct	   pattern	   is	  shown	  by	  Z	  and	  displayed	  in	  the	  left	  central	  box.	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 Single	  channel	  analysis	  of	  oxaliplatin-­‐PBMC	  microarray	  datasets	  5.2	  	   In	   this	   section	   the	   SCA	  method	  will	   be	   used	   to	   re-­‐analyse	   the	   DIP-­‐chip	  microarray	   datasets	   generated	   in	   the	   experiments	   described	   in	   the	   previous	  chapter.	   	  Firstly,	   in	  section	  5.2.1,	  this	  analysis	  will	  be	  conducted	  to	  examine	  the	  relationship	   between	   single	   IN	   and	   IP	   channels	   in	   human	   PBMC	   experimental	  repeat	   samples	   to	   determine	   the	   reason	   for	   low	   reproducibility	   between	  biological	  repeat	  samples.	  	  In	  sections	  5.2.2	  to	  section	  5.2.4	  the	  SCA	  method	  will	  then	  be	  applied	  to	  technical	  replicate	  experiments	  to	  further	  identify	  the	  cause	  of	  poor	   reproducibility	   and	   to	   demonstrate	   in	   which	   channel	   experimental	  modifications	   to	   improve	   the	   protocol	   are	   acting.	   	   Finally,	   in	   section	   5.2.5,	   the	  SCA	   method	   will	   be	   applied	   to	   dermal	   fibroblast	   datasets	   generated	   in	   cell	  culture	   conditions	   during	   the	   DIP-­‐chip	   assay	   development.	   	   This	   analysis	   will	  determine	  the	  level	  of	  single	  channel	  reproducibility	  that	  is	  required	  to	  generate	  reproducible	  DIP-­‐chip	  datasets	  in	  clinical	  samples.	  
	  
5.2.1 A	  single	  channel	  analysis	  of	  oxaliplatin-­‐treated	  PBMC	  DIP-­‐chip	  
datasets	  	   In	  section	  4.3.1,	  DIP-­‐chip	  assays	  to	  generate	  18	  microarray	  datasets	  were	  performed.	   	  The	  DIP-­‐chip	  experiments	  discussed	  were	  conducted	  on	  oxaliplatin	  treated	  PBMC	  from	  patients	  A	  and	  B	  at	  4	  dose	   levels	  (untreated,	  10µM,	  100µM	  and	   1000µM),	   with	   correlations	   between	   the	   resulting	   microarray	   data	   and	  oxaliplatin-­‐DNA	  adduct	  patterns	  at	  best	  of	  0.6	  between	  repeated	  experiments	  in	  the	   same	   experimental	   condition	   (inter-­‐sample	   correlations	   are	   displayed	   in	  figure	  4.9).	  	  	  In	  the	  following	  SCA	  analysis	  it	  is	  intended	  to	  explore	  in	  more	  detail	  the	  correlations	  and	  patterns	  evident	  between	  the	  oxaliplatin-­‐DNA	  adduct	  patterns	  and	  the	  single	  IN	  and	  IP	  channels,	  with	  the	  intent	  of	  identifying	  in	  which	  channel	  and	  in	  which	  samples	  noise	  is	  being	  introduced	  into	  the	  assay.	   	  SCA	  results	  in	  a	  large	   matrix	   of	   correlation	   values	   (figure	   5.7),	   a	   format	   that	   is	   less	   useful	   for	  visualising	   the	   individual	   correlation	   between	   samples,	   but	   more	   useful	   for	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obtaining	   an	   overview	   of	   the	   relationships	   between	   the	   various	   samples	   and	  channels.	   	   To	   allow	   this	   to	   be	   viewed	   adequately,	   the	   data	   is	   included	   in	   the	  electronic	   appendix	   so	  more	   information	   or	   a	   higher	   resolution	   image	   can	   be	  viewed.	   	  The	  correlation	  matrix	  has	  been	  transferred	  from	  the	  R	  function	  to	  an	  excel	  output	  in	  this	  instance	  solely	  to	  allow	  presentation	  of	  this	  large	  dataset	  and	  matrix	  in	  the	  format	  required	  for	  this	  thesis.	  
	  
Figure	   5.7:	   An	   SCA	   matrix	   of	   Spearman’s	   correlations	   values	   between	   18	   DIP-­‐chip	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are	   used	   to	   give	   an	   overview	   of	   the	   relationships	   between	   IP/IN	   adduct	   patterns	   (upper	  right)	   and	   patterns	   of	   single	   channel	   IN	   samples	   (green)	   and	   IP	   channels	   (red).	   	   	   The	   left	  upper	  box	  displays	  the	  correlation	  between	  IP/IN	  adduct	  patterns	  (all	  between	  0.0	  and	  0.6)	  and	   previously	   documented	   in	   figure	   4.9.	   	   The	   central	   green	   box	   shows	   the	   relationships	  between	   the	   IN	   single	   channels,	   and	   all	   correlations	   are	   >0.9.	   	   The	   right	   lower	   red	   box	  displays	   the	   relationships	  between	   the	  patterns	   in	   the	   IP	   channels	   for	  each	  of	  18	   samples.	  	  The	  correlation	  between	  samples	  increases	  with	  increasing	  oxaliplatin	  dose.	  The	  left	  central	  and	  lower	  boxes	  show	  the	  correlation	  between	  IP/IN	  adduct	  pattern	  and	  single	  channel	  IN	  and	  IP	  respectively	  (correlations	  typically	  0.0-­‐0.4	  IN/IP	  vs.	  IN	  and	  0.0-­‐0.6	  IP/IN	  vs.	  IP).	  	  The	  central	  lower	  box	  shows	  a	  high	  correlation	  ~0.9	  between	  IP	  and	  IN	  single	  channel	  patterns	  in	  samples	  treated	  with	  a	  higher	  dose.	  	  	  	   In	  each	  small	  box	  in	  the	  matrix	  is	  the	  Spearman’s	  correlation	  co-­‐efficient	  between	   the	  pattern	   generated	   in	   the	   samples	   and	   channels	   labelled	   along	   the	  columns	   and	   rows.	   	   In	   each	   column	   the	   sample	   data	   is	   arranged	   in	   the	   order	  IP/IN	  ratio	  (i.e.	  the	  IP/IN	  pattern	  representing	  the	  platinum-­‐DNA	  adduct	  pattern	  (coloured	  yellow)),	  IN	  single	  channel	  for	  each	  sample	  (coloured	  green)	  then	  the	  IP	   single	   channel	   for	   each	   sample	   (coloured	   red),	   arranged	   sequentially	   by	  individual	   PBMC	   donor	   then	   by	   increasing	   oxaliplatin	   dose	   for	   each	   sample	  followed	  by	  experiment	  repeat	  number.	  	  Several	  overall	  patterns	  can	  be	   inferred	  from	  visualising	  the	  data	   in	   this	  fashion	   by	   breaking	   the	   matrix	   into	   four	   sections	   to	   analyse:	   the	   yellow	   box	  showing	   the	   correlations	   between	   IP/IN	   patterns,	   the	   green	   central	   box	  displaying	  correlations	  between	  IN	  single	  channel	  patterns,	  the	  red	  lower	  left	  IP	  single	  channel	  pattern	  correlation	  box,	  and	  finally	  the	  boxes	  comparing	  between	  channels	   and	   adduct	   patterns	   in	   the	   left	   central,	   left	   lower	   and	   central	   lower	  boxes.	  	  	  In	   the	   top	   left	  box	   is	   the	   IP/IN	  relationships	   (i.e.	  between	   the	  platinum-­‐DNA	  adduct	  patterns)	  between	  all	  18	  samples,	  with	  clear	  boxes	  below	  a	  cut-­‐off	  of	  a	  correlation	  value	  of	  0.7	  and	  yellow	  boxes	  showing	  values	  closer	  to	  1,	  a	  ‘perfect’	  match	  between	  patterns.	  	  As	  no	  boxes	  are	  coloured,	  the	  correlation	  between	  any	  of	  the	  samples	  is	  <0.7,	  as	  previously	  shown	  for	  this	  data	  in	  chapter	  4,	  figure	  4.9.	  The	   central	   large	   IN	   channel	   box	   (dark	   green)	   shows	   the	   correlation	  values	  between	  IN	  channels	  for	  each	  of	  the	  18	  datasets,	  with	  values	  less	  than	  0.7	  in	  clear	  boxes	  and	  with	  the	  samples	  darker	  in	  green	  colour	  the	  closer	  the	  value	  to	  1.	   	   It	   is	   clear	   from	   the	  homogenous	  dark	   green	  box	   that	   all	   of	   the	   IN	   channels	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correlate	  with	  one	   another	  highly,	   i.e.	   they	  have	   a	   very	   similar	  pattern	   in	   each	  experiment,	  with	  correlation	  values	  between	  each	  sample	  of	  0.93-­‐0.99.	  	   The	   right	   lower	   IP	   channel	   large	   box	   (red)	   shows	   the	   inter-­‐IP	   channel	  correlations,	  with	  values	  below	  0.7	  in	  colourless	  boxes,	  and	  increasing	  colour	  red	  boxes	  as	  the	  values	  increase	  from	  0.7	  to	  1.	  	  The	  lower	  right	  aspect	  of	  the	  IP	  box	  demonstrates	  improving	  correlation	  between	  the	  IP	  channels	  for	  these	  samples,	  corresponding	  to	  an	  increase	  in	  oxaliplatin	  dose,	  with	  the	  highest	  (darkest	  red)	  correlations	   between	  100uM	   samples.	   	   The	  untreated	   and	  10uM	   samples	   have	  correlation	   values	   of	   0.5-­‐0.7,	   lower	   than	   the	   100uM	   and	   1000uM	   samples,	  corresponding	  to	  more	  variability	  between	  patterns	  at	  these	  doses.	  	  	   This	   analysis	   confirms	   the	   hypothesis,	   outlined	   in	   the	   final	   discussion	  section	  of	  chapter	  4,	  that	  the	  failure	  of	  the	  patient	  A	  and	  patient	  B	  PBMC	  repeat	  DIP-­‐chip	   adduct	   profiles	   to	  match	  well	   between	   individual	   repeat	   experiments	  under	   the	   same	   conditions	   is	   due	   to	   a	   failure	   of	   the	   IP	   channel	   to	   be	   reliably	  reproduced.	   	  The	  IN	  channels	  all	  correlate	  highly	  (values	  >0.92),	  indicating	  that	  the	   purification,	   amplification,	   labelling	   and	   array	   hybridisation	   are,	   in	   these	  samples,	  highly	  reproducible.	   	   In	  the	  IP	  channel	  there	  are	  clear	  increases	  in	  the	  assay	  reproducibility	  with	  increasing	  doses	  of	  drug,	  until	  at	  the	  highest	  1000µM	  dose	   there	   is	   a	   slight	   decrease	   in	   reproducibility	   (0.85-­‐0.9)	   in	   the	   IP	   sample	  compared	   to	   the	   100uM	   dose	   level	   (>0.9).	   	   This	  may	   be	   accounted	   for	   by	   the	  decrease	   in	   DNA	   quality	   demonstrated	   by	   the	   degraded	   and	   smeared	   DNA	  samples	  extracted	   from	  these	  samples	  and	  shown	  by	  gel	  electrophoresis	   in	   the	  chapter	  3,	  figure	  3.11.	  	   This	   analysis	   indicates	   that	   there	   is	   potential	   for	   increasing	   the	  reproducibility	  of	  the	  datasets,	  by	  modification	  and	  optimisation	  of	  the	  workflow	  to	   increase	   the	   reproducibility	   of	   the	   IP	   sample.	   This	   step	   is	   important	   to	  improve	  the	  reproducibility	  of	  adduct	  patterns	  in	  these	  types	  of	  clinical	  samples.	  	  Because	  of	  the	  drop	  in	  reproducibility	  at	  1000µM	  compared	  to	  100µM	  doses	  (a	  fall	  in	  correlation	  of	  adduct	  patterns	  from	  0.5-­‐0.6	  to	  0.4-­‐0.5	  and	  IP	  patterns	  from	  >0.9	   to	   0.85-­‐0.9)	   it	   appears	   that	   an	   improvement	   in	   reproducibility	   cannot	  simply	  be	  achieved	  by	  increasing	  the	  dose	  of	  drug,	  as	  this	  results	  in	  degradation	  of	   the	  DNA,	   increased	  apoptosis	  of	  cells	  during	  ex	  vivo	   treatment,	  and	  arguably	  
	   230	  
reduces	   the	   biological	   relevance	   of	   any	   subsequent	   findings.	   	   As	   previously	  discussed,	   central	   to	   improving	   the	   reproducibility	   is	   improving	   the	   technical	  performance	  of	  the	  assay,	  now	  demonstrated	  to	  be	  failing	  because	  of	  variability	  in	  the	  IP	  channel.	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5.2.2 Examining	  IP	  amplification	  fidelity	  using	  single	  channel	  analysis	  
	   In	   this	   section,	   SCA	   analysis	   will	   be	   conducted	   on	   microarray	   datasets	  generated	   in	   the	   previous	   chapter	   to	   determine	   the	   effect	   of	   protocol	   changes	  with	  a	  focus	  on	  the	  reproducibility	  of	  the	  single	  IP	  channel.	  	  	   Previous	   analysis	   in	   the	   experimental	   results	   documented	   in	   the	   last	  chapter,	  section	  4.3.6,	  demonstrated	  that	  reducing	  the	  IN	  concentration	  prior	  to	  amplification	   to	  match	   the	   concentration	  of	   the	   IP	   template	  prior	   to	  WGA-­‐PCR	  reduces	   the	   reproducibility	   of	   the	   damage	   profile	   (figure	   4.17).	   Further	  experiments	  (section	  4.3.7)	  indicate	  that	  increasing	  the	  IP	  template	  amount,	  with	  a	   corresponding	   reduction	   in	   PCR	   cycles,	   improves	   the	   reproducibility	   of	   the	  assay	  (figure	  4.18).	  	  In	  this	  section	  these	  datasets	  will	  be	  re-­‐analysed	  using	  single	  channel	   analysis	   to	   attempt	   to	   demonstrate	   exactly	   how	   these	   changes	   cause	  variability	   in	   the	   resulting	   adduct	   profiles,	   and	   to	   attempt	   to	   confirm	   the	  hypothesis	  that	  poor	  reproducibility	  is	  a	  result	  of	  failure	  of	  the	  IP	  channel	  only.	  In	  the	  experiment	  in	  section	  4.3.3,	  identical	  technical	  replicates	  were	  run	  in	   parallel,	   and	   divided	   into	   either	   pre-­‐amplification,	   pre-­‐labelling	   or	   pre-­‐hybridisation,	   and	   on	   the	   same	   or	   different	   arrays	   to	   measure	   the	   inter-­‐	   and	  intra-­‐array	   reproducibility,	   demonstrating	   poor	   reproducibility	   in	   identical	   IP	  and	   IN	   samples	   divided	   pre-­‐amplification	   (correlation	   of	   0.43	   between	   adduct	  pattern)	   compared	   to	   post-­‐WGA-­‐PCR	   amplification	   (correlation	   between	   all	  other	   technical	   replicates	   of	   >0.93)	   (Figure	   4.13).	   	   For	   this	   single	   channel	   re-­‐analysis,	   an	   SCA	   matrix	   and	   SCA	   plot	   of	   the	   experimental	   data	   previously	  presented	  in	  section	  4.3.3	  is	  shown	  below	  in	  figure	  5.8	  and	  5.9.	  	  For	  clarity,	  only	  the	   three	   key	   boxes	   of	   the	   IP/IN	   pattern	   correlation	   (upper	   left),	   single	   IN	  channel	   correlations	   (central)	   and	   single	   IP	   channels	   (lower	   right)	   are	   shown.	  	  The	  full	  matrix	  is	  available	  in	  the	  electronic	  appendix	  and	  in	  higher	  resolution.	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Figure	   5.8:	   AN	   SCA	  matrix	   from	   4	   pairs	   of	   technical	   replicates	   at	   different	   stages	   of	   the	  
assay.	  An	   SCA	   matrix	   showing	   correlation	   values	   between	   IP/IN	   ratios	   (platinum-­‐DNA	   adduct	  patterns)	  (top	  left	  yellow	  box),	  single	  IN	  channels	  (central	  green	  box)	  and	  IP	  single	  channels	  (lower	   right	   red	   box).	   	   Samples	   are	   from	   4	   pairs	   of	   technical	   replicate	   oxaliplatin	   treated	  PBMC	   samples	   divided	   immediately	   pre–amplification,	   pre-­‐labelling,	   or	   between	  microarrays	   on	   the	   same	   slide	   (intra-­‐array)	   and	   between	   microarrays	   on	   separate	   slides	  (inter-­‐array).	   	   The	   smaller	   individual	   boxes	   indicate	   the	   individual	   correlations	   between	  replicate	  pairs.	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The	  top-­‐left	  large	  box	  of	  figure	  5.8	  displays	  the	  correlation	  between	  IP/IN	  adduct	   profile	   correlations,	   as	   previously	   discussed	   in	   section	  4.3.3,	   showing	   a	  relatively	  poor	  correlation	  (0.43)	  between	  technical	  replicates	   if	  run	   in	  parallel	  pre-­‐amplification,	   and	   a	   high	   correlation	   between	   replicates	   if	   run	   post-­‐amplification	  (a	  correlation	  between	  paired	  replicate	  samples	  of	  >0.93).	  	  In	   the	   single	   channel	   boxes	   (green	   and	   red)	   the	   reason	   for	   this	   can	   be	  immediately	   discerned.	   	   The	   IN	   channel,	   shown	   in	   the	   centre	   box,	  with	  darker	  green	   being	   boxes	   with	   values	   closer	   to	   1	   and	   below	   0.7	   as	   colourless	   boxes,	  demonstrates	  that	  the	  stage	  of	  the	  assay	  at	  which	  the	  replicates	  are	  divided	  has	  no	  effect	  on	  the	  IN	  correlation	  values,	  all	  of	  which	  are	  above	  0.94.	  	  	  However,	  the	  IP	  values	  (shown	  in	  the	  right	  bottom	  box	  with	  a	  scale	  of	  below	  0.7	  as	  colourless,	  increasing	   to	  1	  as	  darker	   red)	  demonstrate	   that	   replicates	   run	   in	  parallel	   from	  pre-­‐amplification	  have	  a	   lower	  correlation	  of	  0.87,	  where	  as	  pairs	  of	   replicates	  run	   pre-­‐labelling,	   or	   when	   investigating	   inter-­‐	   and	   intra-­‐array	   hybridisation,	  show	  high	  correlation	  between	  samples	  (>0.94),	  confirming	  that	  the	  noise	  in	  the	  damage	  profile	  repeats	  is	  generated	  through	  the	  amplification	  of	  the	  IP	  sample.	  	  	  These	  findings	  also	  can	  be	  demonstrated	  by	  using	  an	  SCA	  plot	  to	  show	  the	  profiles	   as	   seen	   in	   figure	   5.9,	   with	   the	   top	   panel	   showing	   the	   oxaliplatin-­‐DNA	  adduct	  pattern	  of	  three	  of	  the	  samples	  –	  a	  pre-­‐amplification	  sample	  (blue),	  intra-­‐array	   sample	   (orange)	   and	   inter-­‐array	   sample	   (brown).	   	   The	   IN	   and	   IP	   single	  channel	  plots	   for	  each	  of	   these	   three	   samples	  are	   shown	   in	   the	  panel	  below	   in	  green	   (IN)	   and	   red	   (IP).	   	   The	   most	   variable	   sample	   is	   the	   pre-­‐amplification	  pattern	   (blue),	   one	   of	   the	   replicates	   which	   has	   been	   split	   pre-­‐amplification	   is	  dotted	  whereas	  the	  other	  two	  samples	  (which	  correlate	  well)	  are	  the	  solid	  lines	  in	  each	  plot.	  	  It	  is	  clear	  that	  the	  pattern	  variation	  as	  shown	  by	  the	  correlation	  co-­‐efficient	  corresponds	   to	   the	  pattern	  changes	   in	   the	  pre-­‐amplification	  compared	  to	   the	  post-­‐amplification	  samples,	  and	  again	  demonstrates	   that	   the	   IN	   is	  highly	  reproducible	  in	  all	  of	  these	  conditions,	  and	  that	  it	  is	  the	  IP	  that	  varies	  dependent	  on	  the	  amplification	  process,	  resulting	  in	  a	  very	  different	  damage	  profiles	  in	  the	  pre-­‐amplification	  replicates	  despite	  identical	  samples	  being	  used.	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Figure	  5.9:	  A	  single	  channel	  analysis	  plot	  of	   technical	   replicate	  samples	   from	  oxaliplatin	  
treated	  PBMC	  DNA.	  	  	  Samples	   are	   run	   in	   parallel	   pre-­‐amplification	   (dotted	   lines)	   or	   post-­‐amplification	   (solid	  lines).	   	  The	  upper	  panel	  shows	  three	  damage	  patterns,	  with	  a	  pre-­‐amplification	  replicate	  in	  blue,	   a	   pre-­‐labelling	   replicate	   in	   orange	   and	   a	   pre-­‐hybridisation	   replicate	   in	   brown.	   	   The	  middle	  and	  lower	  panel	  shows	  the	  single	  channel	  IN	  (green)	  and	  IP	  (red).	  	  	  	  
5.2.3 Single	  channel	  analysis	  of	  DIP-­‐chip	  data	  generated	  during	  changes	  to	  
IP	  template	  amount	  and	  WGA-­‐PCR	  cycle	  number	  	   Using	   the	   same	   SCA	   approach,	   re-­‐analysis	   of	   the	   effect	   on	   microarray	  reproducibility	  of	  changes	  made	  to	  IP	  WGA-­‐PCR	  template	  concentrations	  and	  to	  PCR	  cycle	  number	  (discussed	  in	  section	  4.3.7	  and	  figure	  4.18)	  can	  be	  performed	  to	   show	   the	   power	   of	   SCA	   for	   use	   in	   assay	   development	   experiments.	   	   A	   SCA	  correlation	  matrix	   showing	   the	   IP/IN	   analysis,	   IN	   single	   channel	   and	   IP	   single	  channel	  correlation	  is	  displayed,	  in	  the	  format	  previously	  used,	  in	  figure	  5.10.	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Figure	  5.10:	  An	  SCA	  matrix	  demonstrating	  the	  effect	  of	  changing	  PCR	  conditions	  on	  IP,	  IN	  
and	  IP/IN	  sample	  correlations.	  	  An	  SCA	  matrix	  of	  correlation	  values	  between	  platinum-­‐DNA	  adduct	  patterns	  (IP/IN	  ratios)	  (top	   left	  yellow	  box),	   single	   IN	  channels	   (central	  green	  box)	  and	   IP	   single	   channels	   (lower	  right	   red	   box).	   	   Samples	   are	   from	   4	   pairs	   of	   technical	   replicate	   oxaliplatin	   treated	   PBMC	  samples.	   	   Each	   pair	   of	   replicates	   was	   amplified	   with	   a	   different	   template	   of	   DNA	   pre-­‐immunoprecipitation	   and	  with	   varied	   number	   of	   PCR	   cycles,	   indicated	   by	   the	   labels.	   	   The	  correlation	   values	   between	   replicate	   pairs	   are	   highlighted	   by	   the	   thicker	   outline	   between	  paired	  samples	  and	  coloured	  according	  to	  the	  key	  on	  the	  right	  of	  the	  plot.	  	  	   This	   result	   confirms	   that	   the	   changes	   to	   IP	  DNA	   concentration	   and	  PCR	  cycles	   improves	   the	   correlation	   between	   technical	   replicates,	   as	   demonstrated	  by	  the	  change	  in	  paired	  IP	  channel	  correlations	  (lower	  right	  red	  box)	  from	  0.87	  with	  3µg	  template/17	  cycles	  WGA-­‐PCR,	  sequentially	  through	  0.89,	  0.93	  and	  0.95	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between	  replicates	  amplified	  with	  12µg	   IP	   template	  and	  14	  PCR	  cycles.	  The	   IN	  correlation	  values	  are	  unaffected	  by	  these	  changes,	  as	  the	  central	  green	  IN	  box	  is	  homogenously	  green	  with	  all	  sample	  patterns	  matching	  with	  a	  correlation	  >0.95.	  	  This	   suggests	   that	   the	   improvements	   in	   IP	   pattern	   correlations	   results	   in	   the	  improvements	   in	  oxaliplatin-­‐DNA	  adduct	  patterns	   in	   the	  upper	   left	  yellow	  box,	  with	  improvements	  in	  replicate	  correlations	  from	  0.43	  to	  0.7	  with	  the	  increase	  in	  IP	  template	  and	  decrease	  in	  WGA-­‐PCR	  cycle	  number.	  	  
5.2.4 SCA	  re-­‐analysis	  of	  microarray	  experiments	  determining	  effect	  of	  
decreased	  IN	  template	  concentration	  	   In	   section	   4.3.6	   and	   figure	   4.17	   the	   effect	   of	   diluting	   the	   IN	   samples	   to	  match	  the	  IP	  template	  concentration	  was	  experimentally	  determined.	   	  Previous	  experiments	   had	   demonstrated	   that	   the	   fragment	   pool	   produced	   by	  WGA-­‐PCR	  was	   different	   at	   the	   concentrations	   of	   template	   DNA	   used	   in	   the	   IN	   and	   IP	  samples	   (figure	   4.15).	   	   The	   intention	   of	   this	   experiment	   was	   to	   use	   the	   same	  template	   concentration	   in	   both	   IP	   and	   IN	   sample	   to	   remove	   any	   bias	   by	  correcting	  WGA-­‐PCR	   induced	   fragment	   changes	   later	   in	   the	   analysis.	   	   Because	  the	   adduct	   pattern	   is	   generated	   from	   the	   ratio	   of	   IP	   to	   IN	   feature	   intensity,	  proportional	  to	  the	  fragment	  distribution,	  if	  both	  pools	  of	  fragments	  are	  equally	  biased	  by	  the	  WGA-­‐PCR	  process	  the	  ratio	  calculation	  would	  potentially	  remove	  this	   effect	   from	   the	   final	   calculated	   adduct	   pattern.	   	   To	   examine	   the	   effect	   of	  these	   experimental	   changes	   on	   the	   IP	   and	   IN	   samples	   a	   SCA	   was	   performed	  (figure	  5.11).	   	  Only	  the	  IP/IN,	  single	  IP	  and	  IN	  channels	  are	  shown.	  	  For	  the	  full	  matrix	  see	  the	  electronic	  appendix.	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Figure	   5.11:	   An	   SCA	  matrix	   demonstrating	   the	   effect	   of	   changing	   sample	   concentration	  
pre-­‐amplification	  on	  between	  IP,	  IN	  and	  IP/IN	  sample	  correlations.	  An	  SCA	  matrix	  of	  correlation	  values	  between	  platinum-­‐DNA	  adduct	  patterns	  (top	  left	  yellow	  box),	   single	   IN	   channels	   (central	   green	   box)	   and	   IP	   single	   channels	   (lower	   right	   red	   box).	  	  Samples	   are	   from	  4	   technical	   replicate	   oxaliplatin	   treated	   PBMC	   samples.	   	   In	   each	   sample	  the	   IP	   is	   identical	   –	   4	   aliquots	   of	   6ug	   DIP-­‐chip	   samples	   were	   pooled	   post-­‐immunoprecipitation	   then	  divided	   into	  4	   equal	   samples	   for	  WGA-­‐PCR.	   	  A	   single	   IN	   sample	  was	   used	   for	   the	   IN	   replicates,	   either	   diluted	   10x	   for	   two	   of	   the	   samples	   or	   500X	   for	   the	  other	  two	  samples.	  	  DNA	  was	  amplified	  and	  all	  pairs	  of	  IP	  and	  IN	  samples	  were	  labelled	  and	  hybridised	  and	  processed	  on	  the	  same	  microarray	  during	  the	  same	  experiment.	  	  	  	   	  Despite	   dilution	   of	   the	   IN	   concentration	   to	   reflect	   the	   IP	   template	  concentration,	   resulting	   in	   a	   better	   match	   of	   pre-­‐amplification	   IN	   and	   post-­‐amplification	  fragment	  profile	  (the	  experiment	  shown	  in	  chapter	  4,	  figure	  4.16),	  dilution	  of	  the	  IN	  template	  to	  match	  the	  IP	  concentration	  results	  in	  more	  variable	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IN	   samples	   than	   seen	  previously	   (shown	   in	   the	   central	   green	   IN	   channel	   large	  box	  of	  figure	  5.11),	  demonstrating	  a	  fall	  in	  IN	  correlation	  to	  0.93	  with	  a	  500-­‐fold	  template	  dilution	  pre-­‐WGA-­‐PCR,	  compared	  to	  0.99	  with	  a	  standard	  10X	  dilution,	  and	  resulting	  in	  more	  variable	  adduct	  patterns	  (upper	  left	  box).	  	  Also,	  using	  the	  SCA	  technique	   it	   is	  clear	   in	   this	  example	  sample	  4	   failed	   in	   the	   IN	  channel,	  and	  this	   is	   detected	   by	   a	   significant	   fall	   in	   the	   4th	   IN	   sample	   correlation	   with	   the	  corresponding	  IN	  samples.	  	  
5.2.5 The	  identification	  of	  optimal	  target	  single	  IP	  channel	  correlation	  
values	  	   The	   dermal	   fibroblast	   platinum-­‐DNA	   adduct	   pattern	   datasets	   generated	  during	  assay	  development	   (Powell	  2014)	  can	  be	  re-­‐analysed	  by	  SCA	   to	  give	  an	  indication	   of	   the	   target	   single	   IP	   channel	   reproducibility	   required	   to	   generate	  less	   variable	  oxaliplatin-­‐DNA	  adduct	  patterns	   in	  PBMC	   samples.	   	   	   The	  datasets	  used	   are	   of	   two	   oxaliplatin	   adduct	   DIP-­‐chip	   experiments	   with	   two	   paired	  biological	  replicates	  in	  each	  experiment.	  	  	  	   The	   resulting	   oxaliplatin	   adduct	   pattern	   profiles	   from	   the	   fibroblast	  experiments	   are	   more	   reproducible	   than	   the	   PBMC	   datasets,	   with	   correlation	  values	  of	  0.75	  between	  biological	   replicates	   (Powell	  2014),	   significantly	  higher	  than	  the	  best	  value	  of	  0.6	  with	  PBMC	  experiments.	  	  Using	  single	  channel	  analysis	  of	   the	   successful	   fibroblast	   experiment	   datasets	   may	   give	   an	   indication	   of	   to	  what	   extent	   an	   IP	   sample	   must	   be	   amplified	   to	   give	   greater	   adduct	   pattern	  reproducibility.	   	   The	   single	   channel	   analysis	   matrix	   is	   shown	   below	   in	   figure	  5.12.	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Figure	  5.12:	  A	  SCA	  correlation	  matrix	  comparing	  4	  experimentally	  generated	  oxaliplatin-­‐
DNA	  DIP-­‐chip	  datasets	  generated	  in	  dermal	  fibroblasts	  A	   SCA	   correlation	  matrix	   comparing	   4	   experimentally	   generated	   oxaliplatin-­‐DNA	  DIP-­‐chip	  datasets	   generated	   in	   dermal	   fibroblasts	   (data	   from	   Powell	   2014).	   	   The	   left	   upper	   box	  shows	   the	   correlation	  between	   IP/IN	   -­‐	   adduct	   patterns	   -­‐	   in	   the	   four	   samples.	   	   The	   central	  green	   box	   shows	   the	   correlation	   between	   IN	   single	   channels	   and	   the	   lower	   right	   red	   box	  shows	  the	  correlation	  between	  IP	  single	  channels.	   	  The	  strength	  of	  correlation	   is	   indicated	  by	  the	  box	  colour,	  as	  per	  the	  right	  hand	  key.	  	  	  	  Once	  again,	   the	  amplification	  of	   the	   IN	  sample	   is	  highly	  reproducible,	  as	  shown	  by	  the	  consistently	  dark	  green	  colour	  of	  the	  central	  large	  box.	  	  Notably	  the	  IP	   box	   in	   the	   bottom	   right	   (as	   before,	   darker	   red	   indicates	   higher	   correlation	  values)	   shows	   values	   of	   0.95	   -­‐	   0.98.	   	   The	   combination	   of	   these	   two	   highly	  reproducible	   channels	   evidently	   results	   from	   the	   better	   correlation	   of	   the	  corresponding	   adduct	   patterns	   (upper	   left	   box	   –	   correlations	   between	   paired	  experimental	  repeats	  of	  0.75	  and	  0.82).	  	  	  As	  a	  marker	  for	  the	  PBMC	  experiments,	  this	   level	   of	   single	   channel	   IP	   reproducibility	   is	   therefore	   required	   to	   match	  adduct	  patterns	  at	  this	  level	  of	  correlation.	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5.2.6 Summary	  of	  SCA	  analysis	  	  
	   In	  summary,	  the	  single	  channel	  analysis	  method	  developed	  here	  appears	  to	   be	   a	   very	   useful	   tool	   when	   applied	   to	   the	   analysis	   of	   platinum	   DIP-­‐chip	  microarray	   datasets.	   	   It	   gives	   more	   information	   than	   the	   previously	   available	  adduct	  pattern	  plot	  and	  adduct	  pattern	  correlation	  value.	  	  Using	  SCA	  to	  perform	  a	   detailed	   analysis	   of	   experimentally	   generated	   platinum	   DIP-­‐chip	   microarray	  datasets	   confirms	   that	   the	   poor	   reproducibility	   of	   the	   platinum-­‐DNA	   adduct	  patterns	   obtained	   from	   oxaliplatin	   treated	   PBMC	   biological	   repeats	   is	   a	  consequence	  of	  a	  decrease	  in	  reproducibility	  of	  the	  IP	  channel,	  due	  to	  an	  increase	  in	   amplification	   dependent	   noise	   generated	   at	   the	   low	   template	   levels	   seen	   in	  PBMCs	  treated	  with	  oxaliplatin.	  This	  is	  demonstrated	  by	  the	  greater	  variability	  of	  the	   IP	   channel	   compared	   to	   the	   IN	   channel.	   	   Analysis	   of	   previously	   successful	  datasets	   from	   dermal	   fibroblast	   cell	   culture	  models	   suggests	   that	   to	   achieve	   a	  reproducible	   damage	  profile	   in	   the	  PBMC	   samples	   IP	   correlations	   of	   >0.95	   are	  required.	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 Examination	  of	  DNA	  GC	  content	  and	  the	  effect	  on	  DIP-­‐chip	  microarray	  5.3
reproducibility	  
	   It	  is	  well	  established	  that	  one	  of	  the	  key	  variables	  governing	  the	  success,	  fidelity	  and	  relative	  yield	  of	  PCR	  amplification	  is	  the	  GC	  content	  of	  the	  fragment	  to	   be	   amplified	   (Dabney	   and	  Meyer	   2012;	   Hasmats	   et	   al.	   2014;	   van	  Dijk	   et	   al.	  2014).	  	  	  	  In	  the	  5Mb	  region	  of	  chromosome	  17	  used	  to	  generate	  the	  platinum	  DIP-­‐chip	  adduct	  patterns	  in	  this	  thesis	  the	  average	  GC	  content	  of	  the	  fragments	  to	  be	  amplified	   varies	   from	   as	   low	   as	   36%	   or	   as	   high	   as	   46%	   when	   looked	   at	   in	  windows	  of	  100,000	  bases	  (figure	  5.13).	  	  	  	  
	  
Figure	   5.13:	   The	   average	   GC	   content	   of	   100,000	   base	   pair	   windows	   along	   the	   5Mb	   of	  
chromosome	  17	  used	  in	  this	  series	  of	  DIP-­‐chip	  experiments.	  	  	  Data	   calculated	   using	   R	   package	   BSgenome	   	   with	   genome	   reference	   sequence	   hg19.	  (http://www.bioconductor.org/packages/release/bioc/html/BSgenome.html)	  	  	  The	  yield	  of	  PCR	  reactions	  with	  DNA	  polymerases	  commonly	  used	  for	  this	  type	  of	   experiment	  are	  all	  highly	  dependent	  on	  GC	  content	   (figure	  5.14).	   	   	  The	  data	   for	   the	  GC-­‐dependent	  PCR	  yield	   for	   the	  proprietary	  DNA	  polymerase	  used	  for	  the	  WGA2	  Kit	  (Sigma)	  is	  unknown.	  	  	  	  
(%
)$
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Figure	  5.14:	  	  PCR	  DNA	  yield	  by	  GC	  content	  and	  enzyme.	  The	   relative	   yield	   of	   PCR	   product	   is	   dependent	   on	   the	   DNA	   polymerase	   used	   and	   the	   GC	  content	  of	   the	  DNA	  template	   for	  many	  commercially	  available	  DNA	  polymerases.	   	  For	  each	  template	  GC	  value	  different	  polymerases	  result	   in	  different	  DNA	  yields	  (shown	  by	  the	  area	  of	  the	  accompanying	  circle).	  	  (http://www.neb.uk.com/product_overview/Q5.asp)	  	   	  The	   DIP-­‐chip	   assay	   is	   dependent	   on	   the	   faithful	   amplification	   of	   the	  relative	   proportion	   of	   DNA	   fragments	   which	   are	   generated	   by	  immunoprecipitation,	  and	  this	  information	  is	  corrected	  during	  analysis	  by	  the	  IN	  sample,	   also	   representing	   a	   faithful	   copy	   of	   the	   relative	   proportions	   of	   DNA	  fragments	  in	  the	  pre-­‐immunoprecipitation	  sample.	  	  If	  the	  relative	  amount	  of	  DNA	  fragments	   generated	   through	  WGA-­‐PCR	   of	   each	   fragment	   varies	   dependent	   on	  the	   fragment	   GC	   content	   this	   could	   have	   a	   significant	   bearing	   on	   the	   ultimate	  platinum-­‐DNA	  adduct	  pattern	  produced,	  as	   the	  DIP-­‐chip	  assay	   is	  dependent	  on	  the	   maintenance	   of	   the	   fragment	   relationship	   and	   the	   accurate	   detection	   of	  subtle	   (at	  most	  ~4	   fold)	  differences	   in	   the	   relative	  proportion	  of	  200bp-­‐600bp	  DNA	   fragments	   along	   a	   5MB	   stretch	   of	   chromosome	   17	   in	   two	   samples,	  processed	  over	  a	  ten-­‐day	  laboratory	  protocol.	  	  If	   the	   variation	   in	   PCR	   amplification,	   dependent	   on	   GC	   content	   as	  illustrated	   in	   figure	  5.14,	  occurs	  with	  the	  polymerase	  used	   in	  this	  assay,	   it	  may	  contribute	  considerably	   to	  variability	   in	   the	   final	  adduct	  pattern	  generated.	   	  At	  the	  extreme,	  it	  could	  result	  in	  IP/IN	  patterns	  based	  on	  the	  characteristics	  of	  the	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DNA	  polymerase	  used,	  rather	  than	  based	  on	  the	  subtle	  biological	  signal	  the	  assay	  is	  intended	  to	  detect.	  	  	  	  Additionally,	   as	   platinum	   adducts	   form	   at	   the	   highest	   proportion	   at	  adjacent	   GG	   adducts	   (~65%	   of	   adducts)	   (Kozelka	   2009),	   the	   proportion	   of	  damaged	   fragments	   in	   the	   post-­‐immunoprecipitated	   sample	   could	   be	   over	  represented	  in	  high	  GC	  (and	  hence	  GG	  rich)	  fragments,	  resulting	  a	  combination	  of	  both	  differential	   template	   concentration	  and	  GC	  content–related	  polymerase	  bias.	   	   Although	   the	   IN	   sample	   may	   be	   expected	   to	   correct	   for	   some	   of	   this	  potential	  bias,	   the	   fragment	  profile	  will	  not	  be	  GC	  dependent	   in	   the	   IN	  sample,	  but	  will	  differ	  depending	  on	  GC	  content	  in	  the	  IP	  sample,	  because	  of	  the	  bias	  for	  immunoprecipitation	  of	  GC	  rich	   fragments.	   	   In	   this	  way	   the	  GC	  content	  has	   the	  potential	  to	  affect	  multiple	  aspects	  of	  the	  functioning	  of	  this	  assay	  when	  used	  to	  detect	   platinum-­‐DNA	   adducts.	   	   It	   may	   be	   possible	   to	   measure	   the	   relative	  magnitude	  of	   these	  effects,	   if	  present,	  by	  comparing	  any	  GC/GG	  content	  effects	  between	   platinum	   and	   UV	   (i.e.	   a	   non-­‐GG	   immunoprecipitation	   dependent)	  adduct	  samples.	  	  
5.3.1 The	  development	  of	  a	  custom	  R	  function	  for	  the	  ‘Along	  Genome	  
Correlation	  ‘of	  paired	  DIP-­‐chip	  microarray	  datasets	  	  	   To	  enable	  to	  study	  the	  effects	  of	  GC	  and	  GG	  content	  on	  the	  reproducibility	  of	   the	  oxaliplatin	  treated	  PBMC	  sample	  data,	  and	  on	  oxaliplatin	  and	  UV	  treated	  fibroblast	  cell	  culture	  sample	  data,	  it	  was	  necessary	  to	  develop	  an	  analysis	  tool	  to	  examine	   the	   reproducibility	   of	   datasets	   along	   the	   5Mb	   of	   chromosome	   17,	  allowing	  the	  comparison	  of	  variability	  between	  datasets	  with	  changes	  in	  GG	  and	  GC	  content.	  	  	  To	  perform	  this	  analysis	  a	  custom	  set	  of	  two	  R	  functions	  were	  developed	  –	  the	  along	  genome	  correlation	  ‘AGC’	  functions	  AGCcalc	  and	  AGCplot.	  	  For	  the	  R	  script	   and	   source	   code	   see	   appendix	   5	   and	   6	   respectively).	   	   The	   AGCcalc	   R	  function	  generates	  a	  matrix	  of	  comparisons	  of	  paired	  DIP-­‐chip	  array	  datasets	  at	  matched	  coordinates	  along	  the	  chromosome.	  	  This	  is	  achieved	  by	  specifying	  the	  start	  probe	  coordinate	  (s),	  end	  probe	  coordinate	  (e)	  and	  the	  number	  of	  sections	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in	   which	   the	   data	   is	   to	   be	   analysed	   (n),	   and	   dividing	   the	   data	   into	   (e-­‐s)/n	  windows.	   	   In	   each	   window	   the	   Spearman’s	   correlation	   coefficient	   between	  paired	  datasets	  is	  compared	  by	  calculation	  of	  the	  correlation	  between	  the	  IP/IN	  values	   at	   each	   probe	   in	   both	   datasets	   in	   the	   specific	  window.	   	   Additionally,	   at	  each	   window	   the	   DNA	   sequence	   is	   obtained	   (based	   on	   genome	   reference	  sequence	  hg19)	  between	  the	  start	  and	  end	  coordinate	  for	  each	  window,	  and	  the	  percentage	  GC	  or	  GG	  content	  for	  each	  window	  is	  calculated	  and	  stored.	  Using	   the	   second	   function,	   AGCplot,	   the	   between	   dataset	   window	  correlation	   values	   can	   then	  be	  plotted	   for	   each	  window	  along	   chromosome	  17	  from	  co-­‐ordinate	  s	  to	  co-­‐ordinate	  e	  at	  n	  data-­‐points,	  referenced	  to	  the	  left	  hand	  y-­‐axis.	  	  Specifying	  the	  argument	  GC=TRUE	  (the	  default)	  results	  in	  each	  window	  GC	  content	   being	   plotted	   in	   the	   lower	   section	   of	   the	   graph	   and	   referenced	   to	   the	  right	  hand	  y-­‐axis.	  	  	  The	  function	  prompts	  for	  the	  title	  and	  legend	  details,	  and	  the	  final	  plot	  is	  customisable	  using	  several	  arguments	  to	  modify	  the	  look	  of	  the	  final	  plot	  (see	  appendix	  6).	  	  	  
5.3.2 Analysis	  of	  oxaliplatin-­‐treated	  PBMC	  DIP-­‐chip	  datasets	  with	  the	  AGC	  
function	  	  	   An	   AGC	   plot	   is	   shown	   in	   figure	   5.15	   for	   the	   along	   genome	   comparison	  (AGC)	   of	   mean	   probe	   value	   datasets	   experimentally	   generated	   from	   100µM	  oxaliplatin	   treated	   PBMC	   from	   patients	   A	   and	   B.	   	   At	   each	   of	   50	   windows	   the	  probe	   IP/IN	   values	   are	   compared	   using	   the	   Spearman’s	   correlation,	   and	   are	  plotted	  for	  that	  specific	  window.	  	  The	  mean	  correlation	  between	  whole	  datasets	  is	  plotted	  by	  a	  single	  horizontal	  line.	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Figure	  5.15:	  An	  example	  Along	  Genome	  Correlation	  (AGC)	  plot.	  This	   plot	   is	   showing	   the	   correlation	   between	   two	   experimentally	   generated	   microarray	  datasets	   at	   50	   windows	   along	   5Mb	   of	   chromosome	   17.	   	   The	   panel	   shows	   the	   correlation	  between	  datasets	   (calculated	   from	   the	  mean	  probe	  values	  of	   three	   independent	   repeats	  of	  100uM	  oxaliplatin	  treated	  PBMC	  samples)	  from	  individual	  A	  compared	  to	  individual	  B.	  	  This	  data	   is	   displayed	   by	   the	   connecting	   line	   and	   solid	   points	   for	   each	   window.	   	   The	   average	  correlation	  value	  between	  the	  whole	  microarray	  data	  from	  both	  datasets	  is	  displayed	  by	  the	  horizontal	  dotted	  line.	  	  	  In	  figure	  5.15	  the	  correlation	  values	  between	  paired	  DIP-­‐chip	  microarray	  datasets	   along	   the	   genome	  are	  plotted,	   and	   the	  mean	   correlation	   value	   for	   the	  whole	  microarray	  datasets	  are	  also	  demonstrated	  by	  the	  horizontal	  line.	  	  Clearly,	  the	  correlation	  values	  vary	  along	  the	  chromosome,	  with	  some	  windows	  showing	  the	   adduct	   patterns	   at	   this	   region	   are	   more	   closely	   matched	   than	   at	   other	  sections,	  as	   indicated	  by	   the	  higher	  window	  correlation	  value.	   	  The	  GC	  content	  for	  each	  window	   is	  plotted	  below	  (purple),	  and	   is	   referenced	   to	   the	  right	  hand	  scale.	   	   To	   aid	   visualisation,	   in	   the	   window	   correlation	   trace	   open	   and	   closed	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points	   are	   used	   to	   display	  whether	   in	   each	  window	   if	   the	  GC	   content	   is	   above	  average	  (closed	  point)	  or	  below	  average	  (open	  point)	  for	  the	  whole	  dataset.	  A	  second	  Spearman’s	  correlation	  value	  and	  plot	  can	  then	  be	  generated	  to	  examine	   the	   relationship	  between	   the	   ‘primary’	  window	  correlation	  value	   (the	  Spearman’s	   correlation	  between	   the	   two	  microarray	  datasets	   at	   each	  window)	  and	  the	  GC	  content	  of	  the	  window	  GG	  (figure	  5.16).	  	  	  	  
	  
Figure	  5.16:	  An	  example	  secondary	  AGC	  correlation	  plot.	  	  	  This	   panel	   shows	   the	   secondary	   correlation	   between	   the	   window	   between	   dataset	  correlation	   values	   and	   the	   window	   GC	   content.	   	   The	   window	   microarray	   correlation	   is	  plotted	  against	  the	  window	  GC	  content.	   	  The	  mean	  value	  for	  each	  variable	  is	  plotted	  by	  the	  vertical	   and	   horizontal	   lines	   respectively.	   	   Open	   points	   are	   used	   in	   windows	   with	   below	  average	  GC	  content	  and	  closed	  points	  for	  windows	  with	  above	  average	  GC	  content.	  	   Of	   the	   50	  windows	   analysed	   along	   the	   5Mb	   of	   chromosome	   17	   used	   in	  this	  analysis	  there	  is	  a	  positive	  relationship	  between	  higher	  window	  GC	  content	  and	  improved	  correlation	  between	  microarray	  datasets.	  	  In	  the	  22	  windows	  with	  GC	   content	   above	   average	   the	   correlation	   between	   the	   two	   array	   datasets	   is	  above	   average	   in	   18	   (78%)	   compared	   to	   the	   28	   windows	   with	   a	   GC	   content	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below	   average,	   in	   which	   19/28	   correlation	   values	   between	   repeats	   are	   below	  average	   (68%)	   (figure	  5.15).	   	  The	   secondary	   correlation	  of	   the	  GC	  content	  and	  array	  window	  reproducibility	  is	  0.42,	  indicating	  that	  GC	  content	  is	  an	  important	  component	  in	  the	  reproducibility	  between	  the	  datasets.	  As	  an	  additional	  way	  of	  displaying	  this	  data,	  in	  the	  secondary	  plot	  (figure	  5.16)	  all	  of	  the	  closed	  points	  show	  the	  windows	  with	  above	  average	  GC	  content.	  	  18/23	   (78%)	   of	   these	   points	   are	   in	   the	   upper	   right	   quadrant,	   indicating	   that	  these	   are	   the	   windows	   with	   above	   average	   reproducibility,	   compared	   to	   only	  5/23	   closed	   points	   (22%)	   are	   in	   the	   upper	   left	   quadrant.	   	   This	   indicates	   that	  there	   is	   a	   tendency	   towards	   more	   reproducible	   microarray	   data	   in	   higher	   GC	  content	  fragments.	  	   This	  relationship	  could	  be	  due	  to	  less	  reproducible	  WGA-­‐PCR	  in	  lower	  GC	  content	  DNA	  fragments.	  	  Alternatively,	  it	  could	  occur	  because	  higher	  GC	  content	  regions	   of	   the	   genome	   contain	   higher	   amounts	   of	   platinum	   adducts	   (as	  previously	   discussed	   65%	   of	   platinum	   adducts	   form	   at	   adjacent	   guanine	  nucleotides	   (Kozelka	   2009).	   DNA	   fragments	   with	   platinum	   adducts	   are	  preferentially	   immunoprecipitated,	  as	   the	  epitope	  of	   the	  CP9/19	  antibody	  used	  is	   the	   platinum-­‐GG	   DNA	   adduct	   (Meczes	   et	   al.	   2005),	   resulting	   in	   higher	  proportion	   of	   high	   GG	   DNA	   fragments	   in	   the	   pre-­‐amplification	   sample,	   and	  therefore	  greater	  template	  amounts	  available	  for	  amplification	  by	  WGA-­‐PCR.	   	  It	  has	   been	   established	   in	   the	   previous	   section	   that	   higher	   DNA	   template	  concentration	  for	  WGA-­‐PCR	  results	  in	  a	  less	  variable	  DNA	  fragment	  distribution	  post-­‐amplification,	  and	  better	  correlation	  between	  microarray	  datasets.	  	  	  Mathematically,	  the	  guanine	  content	  of	  the	  human	  genome	  is	  21%,	  so	  the	  percentage	  of	  adjacent	  GG	  dinucleotides	  should	  be	  ~4.4%	  (i.e.	  the	  probability	  of	  a	  pair	  of	  dinucleotides	  being	  adjacent	  GGs	  is	  0.21*0.21).	  	  The	  window	  GC	  content	  should	  be	  an	  accurate	  reflection	  of	   the	  window	  GG	  content	  unless	   there	   is	  bias	  away	   from	   GG	   dinucleotides	   in	   the	   windows	   used	   over	   the	   5Mb	   section	   of	  chromosome	   17	   in	   this	   analysis.	   	   For	   example,	   the	   sequences	   GCGCGCGCGCGC	  and	  GGCCGGCCGGCC	  have	  the	  same	  GC	  100%	  content,	  but	  the	  GG	  content	  is	  0%	  in	  the	  first	  and	  50%	  in	  the	  second.	  	  To	  confirm	  that	  the	  GC	  and	  GG	  content	  of	  this	  section	   of	   the	   human	   genome	   are	   directly	   correlated,	   window	   GC	   and	   GG	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contents	  were	  calculated	  and	  plotted	  at	  50	  windows	  over	  5Mb	  of	  chromosome	  17	  (figure	  5.17).	  	  
	  
Figure	  5.17:	  A	  comparison	  of	  window	  GC	  and	  GG	  content.	  The	   left-­‐hand	  plot	   shows	   the	  window	  GC	   content	   (above)	   and	  GG	   content	   (below)	   along	  5	  Mb	   of	   chromosome	   17	   (nucleotides	   10,000,000	   to	   15,000,000),	   divided	   into	   50	  windows.	  	  The	  pattern	  of	  higher	  and	   lower	  than	  average	  GC	  content	  matches	  the	  window	  GG	  content,	  in	  a	  ratio	  of	  ~10:1.	  	  The	  correlation	  between	  each	  pattern	  is	  shown	  in	  the	  right	  hand	  panel,	  with	  a	  correlation	  between	  window	  GG	  and	  GC	  content	  of	  0.96.	  	  	   The	  result	   indicates	  that	  window	  GC	  and	  GG	  content	  are	  proportional	   in	  this	   region	  of	   the	  genome,	   suggesting	   that	  higher	  GC	  content	   fragments	  will	  be	  over	  represented	  in	  platinum	  treated	  DIP	  samples	  because	  of	  the	  preference	  for	  platinum-­‐DNA	   adduct	   formation	   at	   GG	   dinucleotides.	   	   As	   demonstrated	  extensively	   in	   this	   previous	   section,	   higher	   DNA	   template	   concentrations	   for	  WGA-­‐PCR	   result	   in	   more	   reproducible	   microarray	   data,	   particularly	   in	   the	   IP	  single	   channel	   –	   suggesting	   this	   could	   be	   the	   mechanism	   between	   better	  microarray	  correlation	  at	  high	  GC	  content	  regions	  of	  the	  genome.	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5.3.3 Comparison	  of	  AGC	  plots	  from	  platinum-­‐DNA	  adduct	  DIP-­‐chip	  
samples	  and	  UV-­‐DNA	  adduct	  DIP-­‐chip	  samples	  	  Figures	   5.15	   and	   5.16	   demonstrate	   that	   the	   PBMC	  DIP-­‐chip	  microarray	  datasets	  are	  more	  reproducible	  at	  regions	  of	  the	  genome	  with	  an	  above	  average	  GC	   content.	   	   This	   mechanism	   behind	   this	   observation	   could	   be	   a	   relationship	  solely	   between	   GC	   content	   and	   PCR	   reproducibility,	   or	   could	   potentially	   be	  through	   an	   effect	   of	   changes	   in	   WGA-­‐PCR	   template	   concentration	   affecting	  microarray	  reproducibility.	   	  As	  the	  epitope	  for	  the	  anti-­‐platinum	  antibody	  used	  in	   the	   DIP-­‐chip	   is	   GG	   di-­‐adducts,	   higher	   GC	   content	   fragments	   are	   likely	   to	   be	  immunoprecipitated	  compared	  to	  DNA	  fragments	  with	  a	  low	  GC	  content.	  	  	  The	   relative	   contribution	   of	   these	   two	   effects	   on	   microarray	  reproducibility	   can	   be	   assessed	   by	   comparing	   the	   ‘along	   genome	   correlation’	  window	  values	  between	  paired	  platinum	  treated	  and	  paired	  UV	  treated	  datasets.	  	  The	  UV	   treated	  microarray	  datasets	   in	   this	  analysis	  were	  generated	  during	   the	  DIP-­‐chip	   assay	   development	   study	   (Powell	   2014).	   	   Dermal	   fibroblasts	   were	  treated	   with	   UV	   as	   a	   source	   of	   DNA	   adducts,	   forming	   cyclobutane-­‐pyrimidine	  (CPD)	  dimers	   in	  DNA,	  as	   immunoprecipitated	  as	   the	  DNA-­‐adduct	   target	   for	   the	  DIP-­‐chip	   assay.	   	   Approximately	   68%	   of	   CPDs	   occur	   at	   adjacent	   thymidine	  nucleotides	  and	  the	  antibody	  used	  in	  this	  form	  of	  the	  DIP-­‐chip	  assay	  was	  for	  this	  CPD	   subtype	   (the	   same	   antibody	   was	   used	   in	   chapter	   6,	   section	   6.6.1	   for	  immuno-­‐slotblot	   detection	   of	   UV	   damage).	   	   The	   chip	   stage	   of	   the	   assay	  (amplification,	  labelling,	  hybridisation,	  scanning	  and	  data	  analysis)	  are	  identical	  to	  that	  used	  with	  this	  platinum-­‐DNA	  adduct	  DIP-­‐chip,	  including	  the	  same	  WGA-­‐PCR	   amplification	   and	   PCR	   conditions.	   	   As	   any	   fragment	   bias	   from	  immunoprecipitation	  should	  be	  for	  thymidine	  rich	  fragments	  in	  UV	  induced	  DNA	  adduct,	   as	   opposed	   to	   guanine	   rich	   fragments	   with	   platinum-­‐DNA	   adduct	  immunoprecipitation,	   if	   the	   improvement	   in	   window	   array	   reproducibility	  demonstrated	   at	   regions	   of	   higher	   GC	   content	   is	   due	   to	   a	   PCR-­‐template	   effect,	  because	  of	  an	  increase	  in	  adducts	  for	  immunoprecipitation	  at	  GC	  rich	  fragments,	  this	   should	   occur	   in	   an	   inverse	   relationship	   between	   paired	   platinum-­‐DNA	  adduct	   samples	  and	  paired	  UV	   treated	  DNA	  samples.	   	   If	   the	  effect	   is	  due	   to	  GC	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effect	   on	   PCR	   reproducibility	   it	   should	   be	   similar	   in	   both	   UV	   and	   platinum	  microarray	  paired	  datasets.	  	  To	   examine	   for	   this	   effect,	   the	   100µM	   oxaliplatin	   PBMC	   datasets	  generated	   from	   the	   mean	   probe	   values	   from	   three	   independent	   repeats	   was	  compared	   between	   individuals	  A	   and	  B.	   	   Two	  UV	  damage	  microarray	   datasets	  were	  also	  compared	  by	  AGC	   in	   the	  same	  way.	   	  Both	  AGC	  plots	  were	  aligned	   to	  show	   the	   similarities	   and	   differences	   between	   window	   reproducibility,	   and	  compared	  to	  window	  GC	  content.	  	  The	  result	  is	  shown	  in	  figure	  5.18	  A	  and	  B.	  
	  
Figure	   5.18	   (A):	   A	   50	   window	   AGC	   plot	   of	   dermal	   fibroblast	   cell	   lines	   treated	   with	   UV	  
irradiation	  compared	  to	  PBMC	  samples	  treated	  with	  oxaliplatin.	  A	   50	   window	   AGC	   plot	   of	   dermal	   fibroblast	   cell	   lines	   treated	   with	   UV	   irradiation	   and	  immunoprecipitated	   by	   the	   DIP-­‐chip	   assay	   with	   an	   anti-­‐TT	   CPD	   antibody	   (lilac	   points)	   is	  compared	   to	   an	   along	   genome	   correlation	   plot	   of	   oxaliplatin-­‐DNA	   adduct	   microarray	  datasets	   (black	   points)	   generated	   from	   the	   mean	   values	   from	   three	   independent	   repeat	  experiments	   in	  two	  individuals.	   	  The	  GC	  content	  of	  each	  of	  50	  windows	  is	  presented	  in	  the	  lower	   section	   of	   the	   plot	   and	   referenced	   to	   the	   right	   hand	   y-­‐axis.	   	   The	  UV	   and	   oxaliplatin	  microarray	  window	  correlation	  values	  are	  plotted	  with	  solid	  points	   in	  higher	  than	  average	  GC	  content	  windows	  and	  open	  points	  in	  lower	  than	  average	  GC	  content	  windows.	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Figure	  5.18	  (B):	  	  The	  window	  correlations	  between	  the	  paired	  UV	  (purple)	  and	  oxaliplatin	  
(black)	  DIP-­‐chip	  microarray	  datasets	  are	  plotted	  against	  one	  another.	  	  	  The	  average	  correlation	  of	  all	  probe	  values	  of	  between	  each	  pair	  of	  datasets	  is	  shown	  by	  the	  horizontal	   purple	   line	   (UV	   datasets)	   and	   black	   vertical	   line	   (oxaliplatin	   datasets).	   	   The	  window	  GC	   content	   is	   shown	   by	   the	   closed	   points	   if	  window	  GC	   content	   is	   above	   average	  and	  open	  points	  if	  the	  window	  GC	  content	  is	  below	  average	  	  	   Both	   the	  UV	  adduct	  DIP-­‐chip	  datasets	  (lilac)	  and	  oxaliplatin	  adduct	  DIP-­‐chip	   datasets	   (black)	   show	   a	   better	   correlation	   between	   paired	   datasets	   in	  windows	   with	   higher	   than	   average	   GC	   content	   (Figure	   5.18A	   and	   5.18B).	   	   In	  5.18B	  the	  distribution	  of	  window	  correlation	  vales	  for	  each	  dataset	  comparison	  is	   plotted	   and	   compared.	   	   All	   of	   the	  windows	  with	   an	   above	   average	  window	  correlation	   in	   both	  dataset	   comparisons	  have	   an	   above	   average	  GC	   content,	   as	  shown	  by	  the	  exclusive	  presence	  of	  closed	  points	  in	  the	  upper	  right	  corner	  of	  this	  plot,	   indicating	   that	   high	   GC	   content	   is	   associated	   with	   less	   variability	   in	   the	  adduct	  patterns	  produced	  from	  the	  DIP-­‐chip	  assay.	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  This	  result	  indicates	  the	  GC	  effect	  on	  DIP-­‐chip	  sample	  reproducibility	  is	  a	  consequence	   of	   more	   reproducible	   amplification	   in	   GC	   rich	   regions.	   If	   these	  differences	  were	  due	   to	   a	  PCR-­‐template	   effect	   on	   reproducibility	   as	   a	   result	   of	  preferential	  immunoprecipitation	  of	  GC	  rich	  fragments	  in	  the	  platinum	  DIP-­‐chip	  and	  TT	  rich	  i.e.	  low	  GC	  fragments	  in	  the	  UV	  DIP-­‐chip	  inverse	  patterns	  should	  be	  seen	  between	  AGC	  plots	  of	  paired	  UV	  DIP-­‐chip	  and	  platinum	  DIP-­‐chip	  samples.	  	  As	   the	   pattern	   of	   GC	   related	   amplification	   fidelity	   occurs	   similarly	   in	   both	   UV	  DIP-­‐chip	  and	  platinum	  DIP-­‐chip	  samples	  this	  is	  not	  the	  predominant	  cause	  of	  this	  result.	  	  
5.3.4 Summary	  of	  AGC	  analysis	  	  The	   potential	   explanation	   for	   these	   results	   presented	   above,	   following	  along	   genome	   correlation	   (AGC)	   analysis	   of	   paired	  microarray	  datasets,	   is	   that	  increased	   ‘noise’	   introduced	   by	   the	   WGA-­‐PCR	   amplification	   process	   occurs	   at	  regions	   with	   lower	   GC	   content,	   contributing	   to	   a	   reduction	   in	   array	  reproducibility	   when	   compared	   to	   higher	   GC	   content	   sections	   along	   the	  chromosome.	   	  This	   is	  demonstrated	  in	  both	  the	  UV	  DIP-­‐chip	  and	  platinum	  DIP-­‐chip	  samples.	  	  As	  this	  effect	  occurs	  in	  both	  UV	  and	  platinum	  damaged	  datasets	  it	  is	  a	   function	  of	   the	  WGA-­‐PCR	  process,	   rather	   than	  a	   template	  dependent	  effect	  resulting	  from	  differences	  in	  DNA	  concentration	  as	  a	  consequence	  of	  the	  profile	  of	  adducts	  immunoprecipitated.	  This	  evidence	   leads	   to	  potential	  methods	   to	   improve	   the	  reproducibility	  of	  PBMC	  DIP-­‐chip	  microarray	  datasets.	  	  One	  method	  is	  through	  modification	  and	  optimisation	  of	  WGA-­‐PCR	  conditions	   to	   improve	   the	   fidelity	  of	   amplification	  of	  low	   GC	   content	   regions,	   resulting	   in	   an	   overall	   increase	   in	   reproducibility.	  	  Further	  experiments	  to	  examine	  the	  effects	  of	  PCR	  modifications	  is	  outside	  of	  the	  scope	  of	  the	  work	  presented	  in	  this	  thesis,	  but	  could	  be	  conducted	  during	  future	  projects	  involving	  DIP-­‐chip	  assay	  development.	  Alternatively,	   if	  AGC	  analysis	  is	  used	  to	  identify	  area	  of	  the	  genome	  with	  characteristics	   that	   result	   in	   poor	   reproducibility	   of	   the	   DIP-­‐chip	   assay	   as	   a	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consequence	   of	   WGA-­‐PCR,	   then	   these	   regions	   could	   legitimately	   be	   excluded	  from	   downstream	   analysis,	   specifically	  when	   determining	   differences	   between	  adduct-­‐DNA	   patterns	   from	   clinical	   samples.	   	   This	   could	   be	   justified	   by	   the	  analysis	  presented	  above,	  as	  higher	  rates	  of	  adduct-­‐DNA	  pattern	  variation	  due	  to	  technical	  factors	  may	  reduce	  the	  reliability	  of	  any	  pattern	  differences	  detected	  in	  these	  high	  variability	  genomic	  regions	  during	  downstream	  analysis.	  	  
 Determining	  the	  effect	  of	  DNA	  polymerases	  on	  adduct	  patterns	  5.4
produced	  by	  the	  DIP-­‐chip	  assay	  	  
	   As	   outlined	   above	   the	   reproducibility	   of	   the	   DIP-­‐chip	   assay	   generated	  platinum-­‐DNA	   adduct	   patterns	   is	   critically	   dependent	   on	   the	   WGA-­‐PCR	  amplification	  step	  of	  the	  assay.	   	   	  Both	  the	  amount	  of	  DNA	  template	  available	   in	  the	   sample	   for	   amplification	   and	   the	  GC	   content	  of	   the	   regions	   amplified	   are	   a	  significant	  factor	  in	  introducing	  noise	  into	  the	  assay.	   	  An	  additional	  factor	  to	  be	  considered	  is	  the	  role	  of	  the	  particular	  DNA	  polymerase	  used	  for	  the	  PCR,	  in	  light	  of	   the	   evidence	   that	  many	   DNA	   polymerases	   produce	   a	   DNA	   yield	   that	   varies	  depending	   on	   the	   characteristics	   of	   the	   template,	   especially	   the	   GC	   content	  (Figure	  5.14).	  The	  DNA	  polymerase	  available	  with	  the	  WGA2	  kit	  (Sigma)	  is	  a	  proprietary	  polymerase.	   	  Several	  variations	  to	  the	  WGA2	  kit	  are	  available.	   	  One	  version,	  the	  WGA1	  kit	  is	  identical	  except	  no	  polymerase	  comes	  with	  the	  product,	  allowing	  the	  use	   of	   alternative	   DNA	   polymerases	   whilst	   maintaining	   the	   universal	   priming	  system	  and	  maintaining	  the	  use	  of	  proprietary	  amplification	  buffers.	  	  	  A	   WGA4	   variant	   is	   also	   available.	   	   This	   differs	   in	   the	   fragmentation	  protocol	   (not	   used	   as	   our	   DNA	   is	   pre-­‐fragmented)	   and	   is	   suggested	   for	  amplification	  of	  genomic	  DNA	  from	  a	  single	  cell	  for	  use	  on	  picogram	  quantities	  of	  DNA.	  	  The	  main	  difference	  in	  the	  WGA2	  kit	  and	  WGA4	  kit	  protocol	  is	  the	  use	  of	  25	  cycle	  of	  PCR	  with	  WGA4	  rather	  than	  14	  to	  17	  cycles	  with	  WGA	  1	  and	  2.	  	  As	  the	  template	  DNA	  in	  the	  IP	  sample	  is	  low,	  the	  WGA4	  kit	  potentially	  could	  be	  used	  to	  improve	   the	   IP	   sample	   amplification	   fidelity,	   however,	   the	   downside	   of	   the	  WGA4	  kit	  is	  a	  documented	  allelic	  dropout	  rate	  of	  30%	  -­‐	  because	  of	  the	  low	  DNA	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template	  ~30%	  of	  the	  DNA	  does	  not	  amplify	  correctly,	  making	  it	   less	  useful	  for	  the	  DIP-­‐chip	  assay.	  To	   consider	   the	   effect	   of	   changes	   to	   the	   DNA	   polymerase	   on	   adduct	  patterns	   generated	   by	   DIP-­‐chip,	   three	   identical	   IP	   samples	   were	   used	   and	  amplified	  with	  the	  standard	  WGA2	  protocol.	   	  One	  post-­‐DIP	  IN	  sample	  was	  used	  to	  generate	  4	  WGA-­‐PCR	  IN	  samples.	  	  In	  one	  sample	  the	  IN	  was	  used	  unamplified.	  	  A	   further	   3	   aliquots	   of	   1µL	   of	   the	   IN	   sample	  were	   diluted	   10	   fold	   to	   produce	  three	  identical	  IN	  samples	  for	  amplification.	  	  One	  of	  these	  samples	  was	  amplified	  with	  the	  standard	  WGA2	  kit,	  and	  one	  with	  the	  WGA1	  kit	  with	  the	  addition	  of	  Q5	  high	   fidelity	   DNA	   polymerase	   (NEB).	   	   Additionally,	   a	   further	   IN	   sample	   was	  processed	  with	  the	  WGA2	  kit	  with	  a	  paired	  IP	  sample	  amplified	  with	  the	  WGA4	  kit.	  	  	   This	   experiment	   allows	   a	   comparison	   on	   single	   IN	   channel	   patterns	  produced	  in	  the	  unamplified	  sample	  compared	  to	  the	  WGA2	  polymerase	  and	  Q5	  polymerase.	   Following	   amplification	   each	   IN	   sample	   was	   paired	   with	   an	   IP	  sample	   and	   processed	   to	   generate	   the	   platinum-­‐DNA	   adduct	   pattern	   dataset,	  which	  was	  subsequently	  analysed	  by	  single	  channel	  analysis	  (Figure	  5.19).	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Figure	  5.19:	  A	  single	  channel	  analysis	  plot	  of	  DNA	  produced	  by	  a	  DIP	  experiment	  using	  a	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from	   the	   patterns	   in	   the	   sample	   when	   amplified	   by	   WGA	   polymerase	   or	   Q5	  (correlation	   0.66-­‐0.77).	   	   This	   is	   evidence	   that	   the	   pattern	   generated	   by	   the	  amplification	   is	   different	   to	   the	   underlying	   pattern	   of	   fragments	   in	   the	   pre-­‐amplification	   sample.	   	   The	   amplified	   samples	   are	  more	   closely	  matched	   (0.93-­‐0.94)	   between	   WGA2	   amplified	   IN	   DNA	   and	   Q5	   IN	   DNA.	   	   A	   fall	   in	   single	   IN	  channel	   correlations	   to	  0.93	   is	  enough	   to	   result	   in	  high	  variability	   in	   the	   IP/IN	  generated	   adduct	   pattern	   (as	   shown	   by	   differences	   in	   the	   previous	   figure	   5.8-­‐5.10),	   and	   by	   the	   fact	   that	   correlation	   of	   single	   channel	   IN	   patterns	   of	   0.99	   is	  needed	   to	   generate	   reproducible	   adduct	   patterns	   in	   the	   dermal	   fibroblast	   cell	  culture	  system	  (e.g.	  figure	  5.12).	  	  The	  WGA2	  patterns	  generated	  by	  the	  two	  pools	  of	   DNA	   amplified	   by	   WGA2	   polymerase	   correlate	   0.98,	   as	   previously	  demonstrated,	   but	   the	   patterns	   of	   probe	   values	   in	   these	   samples	   are	   both	  different	  to	  the	  unamplified	  sample.	  The	   three	   identical	   IP	   sample	   patterns	   from	   DNA	   amplified	   with	   the	  WGA2	   kit	   all	   correlate	   with	   each	   other	   reasonably	   well	   (~0.90)	   and	   slightly	  better	  with	  each	  other	   than	  with	   the	  WGA4	  amplified	  DNA	  (~0.88),	   suggesting	  that	  this	  variant	  of	  WGA-­‐PCR	  may	  potentially	  have	  a	  use	  in	  amplification	  of	  low	  amounts	  of	  DNA,	  but	  that	  this	  needs	  to	  be	  optimised	  and	  assessed	  with	  further	  experiments.	  The	  variability	  generated	  by	  the	  differences	   in	  IN	  single	  channels	  and	  IP	  single	  channels	  results	  in	  low	  correlations	  between	  the	  adduct	  patterns	  derived	  from	  these	  paired	  single	  channel	  patterns	  (IP/IN	  box,	   top	  right,	  all	  correlations	  <0.3).	   	  	   This	   result	   is	   evidence	   that	   the	   WGA-­‐PCR	   amplification	   process	   is	  producing	  amplified	  DNA	  that	  is	  different	  to	  the	  pre-­‐amplified	  sample	  (compare	  the	  unamplified	  to	  amplified	  IN	  single	  channels	  –	  correlations	  of	  ~0.8)	  and	  that	  the	  enzyme	  used	   in	   the	  amplification	  results	   in	  a	  different	  pattern	  of	  amplified	  DNA	  (compare	  single	  channel	  IN	  correlations	  between	  Q5	  and	  WGA	  Polymerase	  –	  correlations	  of	  ~0.93).	   	  This	   is	   further	  evidence	  of	   the	  role	  of	  WGA-­‐PCR	  DNA	  amplification	   in	   the	  generation	  variable	  and	  of	  PCR-­‐dependent	  adduct	  patterns	  by	   the	  DIP-­‐chip	   assay.	   	   In	   future,	   it	  may	   be	   that	   using	   unamplified	   IN	   samples	  recues	  the	  potential	  for	  PCR	  induced	  bias	  in	  the	  assay	  and	  improves	  the	  overall	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microarray	  dataset	   reproducibility.	   	  Experiments	   to	  determine	   if	   this	   approach	  offers	  benefits	  above	  the	  current	  amplification	  of	  the	  IN	  sample	  are	  beyond	  the	  scope	   of	   this	   thesis	   but	   may	   be	   investigated	   in	   future	   assay	   development	  projects.	  	  	  
 Summary	  5.5
	  
	   The	   analytical	   tools	   developed	   in	   the	   section	   above	   in	   this	   chapter	   are	  methods	  of	  extracting	   latent	   information	   from	  microarray	  datasets.	   	  The	  single	  channel	  analysis	  (SCA)	  and	  along	  genome	  correlation	  (AGC)	  approaches	  can	  be	  used	   as	   quality	   control	   steps,	   to	   confirm	   the	   DIP-­‐chip	   experiment	   has	   been	  successfully	  conducted.	  	  Additionally,	  these	  tools	  have	  demonstrated	  in	  the	  work	  presented	   so	   far	   in	   this	   chapter	   that	   they	  are	  valuable	  analytical	   tools	   for	  DIP-­‐chip	   assay	   development	   work.	   	   The	   application	   of	   these	   techniques	   to	   the	  microarray	   datasets	   generated	   in	   the	   previous	   chapter	   have	   clearly	  demonstrated	   issue	  with	   the	   introduction	  of	  variability	   into	   the	  DIP-­‐chip	  assay	  through	   the	   WGA-­‐PCR	   step,	   and	   have	   highlighted	   potential	   areas	   for	   further	  experimental	  projects	  to	  improve	  the	  assay	  further,	  including	  by	  optimising	  the	  PCR	   to	   maximise	   the	   IP	   single	   channel	   reproducibility	   between	   experimental	  repeats,	  and	  to	  optimise	  the	  PCR	  reaction	  to	  improve	  the	  fidelity	  of	  amplification	  at	  low	  GC	  content	  regions.	  	   The	   AGC	   analysis	   also	   highlights	   that	   microarray	   datasets	   derived	   at	  specific	  regions	  of	  the	  genome	  have	  higher	  variability	  than	  other	  regions,	  and,	  in	  the	  absence	  of	  experimental	  measures	  to	  reduce	  this	  variability,	  to	  improve	  the	  validity	  of	   the	  data	   it	  may	  be	  prudent	  to	  exclude	  these	  areas	   from	  downstream	  analysis.	  	   Finally,	   the	   use	   of	   unamplified	   and	   amplified	   IN	   samples	   demonstrates	  that	   the	   WGA-­‐PCR	   process	   does,	   to	   a	   degree,	   alter	   the	   pattern	   of	   fragments	  produced	  during	  amplification,	  and	  this	  does	  have	  an	  impact	  on	  the	  adduct-­‐DNA	  pattern	  produced.	  	  This	  is	  one	  rationale	  for	  the	  use	  of	  the	  IN	  sample	  to	  normalise	  these	  effects	  in	  the	  IP	  sample	  during	  the	  generation	  of	  the	  adduct	  pattern.	   	  The	  benefit	   and	   implication	   of	   using	   unamplified	   IN	   samples	   to	   generate	   the	   final	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IP/IN	   adduct	  pattern	  has	   yet	   to	  be	   explored	   and	   is	   outside	  of	   the	   scope	  of	   the	  experiments	  presented	  in	  this	  thesis.	  	  	  	   All	  of	  the	  experiments	  and	  tools	  developed	  to	  this	  point	  focus	  on	  reducing	  noise	   in	   the	   DIP-­‐chip	   assay,	   reducing	   variation	   between	   adduct-­‐DNA	   patterns	  when	  the	  same	  sample	  is	  run	  repeatedly,	  with	  the	  intent	  to	  increase	  the	  validity	  of	   inter-­‐individual	   differences	   in	   adduct	   patterns	   detected	   in	   downstream	  analysis.	  	  In	  the	  final	  section	  of	  this	  chapter	  we	  will	  now	  turn	  to	  the	  development	  of	  tools	  to	  allow	  the	  detected	  of	  inter-­‐individual	  difference	  in	  DIP-­‐chip	  platinum-­‐DNA	  adduct	  patterns	  –	  the	  ultimate	  goal	  of	  this	  project.	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 The	  development	  of	  an	  R	  function	  to	  detect,	  display	  and	  compare	  5.6
regions	  of	  difference	  between	  DIP-­‐chip	  generated	  adduct	  patterns	  
derived	  from	  different	  individuals.	  	   The	   DIP-­‐chip	   microarray	   datasets	   used	   in	   these	   analyses	   each	   contain	  approximately	  30,000	  to	  40,000	  data	  points.	   	  So	   far	   the	   focus	  of	   this	   thesis	  has	  been	  on	  improving	  the	  signal–to-­‐noise	  ratio	  in	  the	  DIP-­‐chip	  assay	  by	  decreasing	  the	   background	   noise.	   	   This	   has	   been	   achieved	   by	   modifying	   the	   protocol	   to	  reduce	   the	  differences	  between	  DIP-­‐chip	  generated	  adduct	  datasets	   in	   samples	  of	  identical	  DNA,	  as	  demonstrated	  with	  the	  new	  bioinformatic	  tools	  developed	  in	  this	  chapter.	  	  In	  the	  final	  section	  of	  this	  chapter	  the	  effort	  will	  be	  on	  detecting	  the	  signal	   -­‐	   differences	   between	   adduct	   patterns	   between	   individuals	   -­‐	   by	   the	  development	  of	  a	  new	  analysis	  tool	  to	  be	  used	  with	  the	  DIP-­‐chip	  assay.	  The	  goal	  of	  the	  DIP-­‐chip	  assay	  is	  to	  detect	  biological	  differences	  in	  adduct	  patterns	   between	   individuals,	   as	   a	   potential	   marker	   of	   how	   an	   individual’s	  phenotypic	   response	   to	   the	   drug	   may	   differ	   as	   a	   consequence	   of	   this	   signal.	  	  	  Therefore,	   the	   development	   of	   a	   function	   to	   identify	   biological	   differences	  between	   adduct	   patterns	   generated	   between	   individuals	   will	   be	   necessary	   for	  the	  DIP-­‐chip	  assay	  to	  work	  in	  this	  context.	  	   When	   two	   experimental	   conditions	   are	   compared	   over	   several	  independent	  repeat	  experiments	  the	  mean	  of	  several	  repeats	  is	  similar	  in	  adduct	  patterns.	   	   However,	   the	   IP/IN	   value	   at	   each	   data	   point	   varies	   considerably	  (Chapter	  4	  section	  4.3.1-­‐4.3.2).	  	  With	  40,000	  data	  points,	  variation	  in	  probe	  value	  can	   be	   influenced	   and	   introduced	   by	   the	   experimental	   technique,	   by	   true	  biological	   signal,	   and	   by	   differences	   between	   probe	   values	   occurring	   due	   to	  chance	   variation.	   	   The	   true	   biological	   signal	   needs	   to	   be	   identified	   from	  differences	   in	   the	   datasets	   due	   to	   background	   experimental	   and	   chance	  variation.	  	  	   Two	   issues	   require	   consideration	   in	   the	   development	   of	   a	   tool	   for	  identifying	   and	   concisely	   displaying	   regions	   of	   putative	   biological	   significance.	  	  Firstly,	  a	  statistically	  robust	  method	  of	  identifying	  biological	  differences	  between	  datasets	   and	   generating	   the	   information	   in	   a	   set	   of	   genomic	   location	   and	  magnitude	  values	  identifying	  where	  this	  variation	  occurs	  is	  required.	  	  Secondly,	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this	   list	   of	   locations	   of	   interest	   and	  magnitude	   of	   difference	   between	   datasets	  needs	  to	  be	  utilised	  and	  plotted,	  alongside	  supporting	  information	  with	  respect	  to	  the	  statistical	  validity	  of	  the	  approach.	  
	  
5.6.1 Statistical	  considerations	  	  	   There	  are	  several	  potential	  methods	  of	  identifying	  statistically	  significant	  differences	  between	  datasets.	   	  During	   the	  development	  of	   the	  analysis	   function	  described	  below,	  an	  outlier	  detection	  method	  is	  employed	  to	  identify	  regions	  of	  the	  genome	  with	   the	   largest	  differences	  between	  probe	  values	  paired	  between	  datasets.	   	   This	   may	   be	   a	   valid	   approach	   if	   the	   key	   differences	   between	   drug	  response	  between	  individuals	  are	  determined	  by	  the	  probes	  that	  vary	  the	  most	  widely	  between	  two	   individuals.	   	  Additionally,	  much	  of	   the	  noise	   in	   the	  system	  (the	   smaller	   magnitude	   variation	   between	   datasets)	   is	   filtered	   out	   by	  concentrating	  on	  the	  data	  points	  with	  the	  largest	  variation	  between	  individuals.	  	  	  Whilst	  useful	  in	  the	  development	  of	  this	  R	  function,	  an	  outlier	  approach	  to	  identifying	  differences	  between	  datasets	  has	   limitations,	   including	   that	   ranking	  each	   paired	   probe	   independently	   of	   genomic	   position	   results	   in	   the	   loss	   of	  information	   from	   the	   genomic	   context,	   local	   relationships	   and	   patterns	   of	   the	  surrounding	   probes.	   	   This	   approach	   is	   also	   has	   the	   limitation	   inherent	   in	  identifying	   a	   set	   of	   probes	   with	   the	   largest	   difference	   between	   datasets	   -­‐	  potentially	   it	   also	   identifies	   probes	   at	  which	   high	   variation	   between	   probes	   is	  due	   to	   experimental	   failure	   at	   this	   location	   (and	   resulting	   in	   larger	  differences	  between	   datasets),	   rather	   than	   through	   the	   presence	   of	   true	   biological	  difference.	  A	   potential	   alternative	   approach	   is	   to	   use	   t-­‐tests	   on	   probes	   paired	  between	  groups	  of	  datasets	  to	  identify	  a	  list	  of	  probes	  with	  value	  differences	  of	  significance	  determined	  by	  a	  pre-­‐set	  statistically	  cut-­‐off,	  rather	  than	  identifying	  the	   most	   extreme	   differences	   between	   pairs	   of	   probes.	   	   This	   approach	   is	   in	  development	   in	  our	   laboratory,	  however	   further	  refinement	  of	   the	  technique	   is	  currently	  limited	  by	  the	  necessity	  to	  have	  several	  relevant	  datasets	  available	  to	  optimise	  the	  method.	  	  This	  shortcoming	  will	  be	  addressed	  through	  a	  pilot	  study	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currently	   in	   progress	   to	   obtain	   the	   microarray	   data	   required	   to	   optimise	   this	  approach	  (as	  discussed	  in	  chapter	  7,	  section	  7.2).	  A	  modification	  of	  the	  t-­‐test	  approach	  utilises	  a	  ‘sliding	  window’	  method	  to	  perform	   a	   t-­‐test	   to	   identify	   statistically	   significant	   differences	   between	   probe	  values	   in	   two	   groups	   of	   datasets	   at	   different	   sections	   along	   the	   genome,	  combining	   the	   statistical	   rigour	   of	   a	   t-­‐test	   and	   preserving	   the	   information	  available	   from	   the	   influence	  of	  genomic	  position	  and	   local	  probe	  context.	   	  This	  approach	   to	   identifying	   statistically	   significant	   differences	   between	  microarray	  datasets	   at	   different	   windows	   along	   the	   genome	   has	   been	   developed	   in	   our	  laboratory	  and	  validated	  for	  ChIP-­‐chip	  microarray	  datasets	  (Bennett	  2013)	  and	  has	  recently	  been	  peer-­‐reviewed	  and	  accepted	  for	  publication.	  	  This	  method	  can	  be	   adapted	   for	   the	   analysis	   of	   DIP-­‐chip	   datasets	   and	   is	   under	   development.	  	  Again	   further	   preliminary	   data	   is	   needed	   to	   refine	   this	   approach,	   but	   once	  optimised	  this	  has	  the	  potential	   to	  be	  a	  statistically	  rigorous	  way	  of	   identifying	  patterns	  of	  differences	  between	  DIP-­‐chip	  microarray	  datasets.	  In	   the	   R	   data	   analysis	   function	   developed	   in	   this	   section	   the	   main	  emphasis	  is	  on	  visually	  displaying	  and	  streamlining	  the	  process	  for	  analysing	  the	  output	  of	  probes	  identified	  as	  having	  biological	  significance,	  and	  can	  be	  modified	  to	  use	  any	  of	  these	  statistical	  methods	  to	  generate	  a	  list	  of	  probes	  of	  interest.	  	  To	  summarise,	   the	   optimal	   approach	   to	   generate	   the	   list	   of	   probes	   of	   difference	  between	   datasets	   is	   a	   matter	   of	   current	   debate,	   requires	   further	   microarray	  datasets	   to	   refine,	   and	   is	   subject	   to	   on-­‐going	   work	   along	   the	   lines	   discussed	  above	  by	  the	  laboratory	  bioinformatic	  and	  statistical	  team.	  	  
5.6.2 Outlier	  Detection	  	   In	   this	   section,	   one	   of	   several	   potential	   methods	   of	   generating	   a	   list	   of	  probes	  of	  possible	  significance	  is	  demonstrated,	  and	  is	  used	  as	  the	  basis	  for	  the	  development	  of	  the	  R	  functions	  required	  –	  essential	  for	  streamlining	  the	  analysis	  and	  visualisation	  process.	  	  For	  this	  example,	  probes	  of	  interest	  are	  identified	  by	  examining	  the	  data	  for	  probes	  with	  the	  greatest	  magnitude	  of	  difference	  between	  datasets.	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   As	   an	   example	   of	   this	   approach,	   two	   100µM	   oxaliplatin	   treated	   PBMC	  microarray	  datasets	   generated	  and	  used	   throughout	   this	   series	  of	   experiments	  between	   patient	   A	   and	   B	   will	   be	   compared	   to	   detect	   probes	   with	   the	   largest	  value	  difference	  between	  datasets,	  either	  positive	  or	  negative.	  	  If	  the	  IP/IN	  ratio	  value	   used	   to	   generate	   the	   adduct	   pattern	   at	   each	   probe	   is	   subtracted	   in	   one	  dataset	   from	   the	   other	   the	   spread	   of	   the	   ‘subtracted	   values’	   approximates	   a	  normal	   distribution	   (Figure	   5.37).	   	   The	   tails	   of	   the	   plot	   of	   subtracted	   values	  indicates	  a	  potential	  population	  of	  ‘outlier’	  probes,	  locations	  at	  which	  the	  probe	  values	  have	  a	  larger	  difference	  (either	  positive	  or	  negative)	  between	  datasets.	  	  A	  key	  requirement	  of	  the	  DIP-­‐chip	  analysis	  is	  to	  identify	  which	  of	  the	  probes	  with	  the	  greatest	  difference	  between	  datasets	  vary	  because	  of	  the	  tail	  of	  the	  normally	  distributed	   experimental	   noise,	   and	  which	   probes	   in	   this	   pool	   vary	   because	   of	  biological	  differences	  between	  datasets.	  	   	  	  
	  
Figure	  5.20:	  Plotting	  the	  distribution	  of	  subtracted	  probe	  values.	  The	   IP/IN	  probe	  values	   from	  one	  100µM	  oxaliplatin	   treated	  PBMC	  dataset	  generated	   from	  patient	  B	  is	  subtracted	  from	  a	  similar	  dataset	  from	  patient	  A.	  	  The	  difference	  between	  probe	  values	   (A-­‐B)	   approximates	   a	   normal	   distribution.	   	   The	   tail	   of	   the	   distribution	   indicates	  where	   the	   probe	   values	   (and	   hence	   adduct	   patterns)	   have	   a	   greater	   difference	   between	  individuals.	   	   Arbitrary	   purple	   and	   pink	   dotted	   horizontal	   lines	   are	   added	   to	   indicate	  potential	  outlier	  probes.	  	  	  	  	   The	  identification	  of	  the	  particular	  outlier	  probes	  in	  this	  population	  -­‐	  the	  probes	   with	   the	   most	   different	   values	   between	   datasets	   –	   is	   then	   an	   issue	   of	  statistical	   interpretation	   of	   the	   significance	   of	   different	   IP/IN	   values	   at	   probes	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within	  this	  population.	  	  Outliers	  in	  large	  datasets	  can,	  somewhat	  subjectively,	  be	  defined	   as	   “an	   observation	   (or	   subset	   of	   observations)	   that	   appears	   to	   be	  inconsistent	  with	  the	  remainder	  of	  that	  set	  of	  data”	  (Barnett	  and	  Lewis	  1994)	  	  As	   discussed	   above,	   a	   method	   is	   required	   to	   identify	   a	   population	   of	  probes	  with	  values	  in	  this	  population	  that	  differ	  between	  datasets	  due	  to	  normal	  variation	  in	  the	  assay,	  and	  a	  population	  of	  probes	  that	  have	  significantly	  different	  values	   between	   datasets	   due	   to	   a	   potential	   biological	   signal.	   	   The	   techniques	  used	   in	   our	   laboratory	   include	   t-­‐tests	   and	  R	   statistical	   functions	   and	   packages	  used	  to	  identify	  outlier	  populations.	  	  A	  t-­‐test	  approach	  was	  initially	  performed	  to	  analyse	   outliers	   between	   the	   datasets	   generated	   from	   individual	   A	   and	   B,	   but	  was	   not	   able	   to	   detect	   statistically	   significant	   outliers	   between	   these	   two	  datasets.	  	  For	  this	  thesis,	  and	  for	  the	  critical	  development	  of	  custom	  R	  functions	  to	  automate	  data	  analysis	  and	  processes	  for	  the	  visualisation	  of	  the	  result	  of	  DIP-­‐chip	  comparative	  analysis,	  an	  outlier	  detection	  methodology	  used	  previously	   in	  our	  laboratory	  (Bennett	  2013;	  Powell	  2014)	  –	  the	  R	  extremevalues	  package	  -­‐	  will	  be	  employed.	  For	  a	  detailed	  description	  of	   the	  statistical	  methods	  behind	  this	  package	  see	   an	   associated	   reference	   (Loo	   2010).	   	   As	   explained	   by	   the	   author	   in	   the	  summary	   “the	   extreme	   values	   package	   estimates	   the	   underlying	   data	  distribution	   by	   regression	   of	   the	   observed	   values	   on	   their	   estimated	   QQ	   plot	  position	   using	   a	   model	   cumulative	   distribution	   function…	   Having	   obtained	   a	  description	  of	  the	  bulk	  distribution…	  we	  determine	  the	  values	  above	  which	  less	  than	  a	   certain	  number	  of	  observations	  are	  expected,	   given	   the	   total	  number	  of	  observations	  and	  the	  fitted	  distribution.”	  	   In	   essence,	   normally	  distributed	  data	   forms	  a	   straight	   line	  on	  a	  QQ	  plot	  when	  the	  observed	  data	  is	  compared	  to	  a	  theoretical	  predicted	  (and	  in	  this	  case	  normally	  distributed)	  dataset.	  	  The	  greater	  the	  variation	  of	  subtracted	  value	  data	  points	  to	  this	  line,	  the	  more	  likely	  the	  difference	  in	  value	  between	  probe	  between	  two	   datasets	   is	   due	   to	   biological	   signal	   rather	   than	   normally	   distributed	  experimental	  error.	   	  The	  extremevalues	  package	  assesses	   the	  data	  under	   these	  assumptions	  and	  generates	  a	  QQplot,	  identifying	  likely	  outlier	  probes	  as	  probes	  as	  those	  that	  vary	  most	  from	  this	  distribution,	  shown	  in	  red	  at	  the	  left	  and	  right	  extremes	   of	   a	  QQ	  plot	   (Figure	   5.21).	   	   The	   software	   package	   generates	   a	   list	   of	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these	  probes	  that	  are	  likely	  to	  be	  outliers	  identified	  by	  this	  method.	  	  	  By	  manually	  searching	  the	  outlier	  probe	  list	  generated	  these	  can	  be	  linked	  back	  to	  the	  original	  Sandcastle	  adduct	  pattern	  plots.	  	  The	  limitations	  inherent	  in	  this	  approach	  have	  been	  discussed	  in	  section	  5.6.1.	  
	  	   	  
Figure	  5.21:	  A	  QQ	  plot	  output	  form	  the	  extremevalues	  R	  package,	  used	  to	  compare	  two	  sets	  
of	  experimentally	  generated	  oxaliplatin	  treated	  PBMC	  microarray	  datasets.	  The	   variation	   in	   probe	   values	   between	   the	   two	   datasets	   approximates	   a	   normal	  distribution,	   resulting	   in	   close	  approximation	  of	   the	  data	   to	  a	   straight	   line	  on	   the	  QQ	  plot,	  when	   the	   observed	   dataset	   is	   compared	   to	   a	   predicted	   dataset	   if	   the	   data	   is	   normally	  distributed.	   	  At	   the	   left	   and	   right	  extremes	  of	   the	  plot	  probes	   that	  do	  not	  approximate	   the	  normal	   distribution	   above	   a	   threshold	   determined	   by	   the	   underlying	   spread	   of	   the	   data	  (shown	  by	  the	  purple	  and	  pink	  lines)	  are	  identified	  in	  red.	  	  
5.6.3 The	  development	  of	  the	  outlierDataPlot	  R	  function	  
	  
	   For	  analysis	  of	  DIP-­‐chip	  data	  a	  function	  is	  required	  to	  identify	  significant	  outlier	   probes	   between	   experimentally	   generated	   datasets	   and	   to	   plot	   these	  outlier	   regions	   for	   comparisons	   between	   experimental	   conditions	   or	   between	  individuals.	   	   This	   is	   functionality	   is	   unavailable	   in	   Sandcastle.	   	   The	   function	  
outlierDataPlot	  was	  developed	  to	  perform	  this	  analysis	  (appendix	  7),	  and	  at	  its	  core	  uses	  the	  extremevalues	  R	  package	  to	  generate	  lists	  of	  probes	  that	  are	  likely	  to	   be	   different	   between	   datasets	   because	   of	   biological	   signal	   rather	   than	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underlying	  noise	  in	  the	  assay,	  before	  displaying	  these	  in	  an	  variety	  of	  plots	  to	  aid	  interpretation	  and	  providing	  a	  list	  of	  outlier	  probes	  for	  further	  analysis.	  Other	   methods	   of	   identifying	   statistically	   significant	   outlier	   probes	  between	  platinum	  adduct	  DIP-­‐chip	  datasets	  are	  available	  and	   the	  development	  of	   these	   is	  underway	   in	  our	   laboratory,	   including	  using	   t-­‐tests	  (Dr	  M	  Bennett	  –	  unpublished	  work).	   	  The	  extremevalues	  package	  is	  used	  in	  this	  instance	  for	  the	  reasons	   outlined	   above,	   but	   the	   outlierDataPlot	   R	   function	   can	   be	   modified	  easily	  to	  use	  alternative	  methods	  of	  generating	  outlier	  probe	  lists.	  	  	  One	  initiated,	  the	  outlierDataPlot	   function	  requires	  the	  identification	  of	  the	  numerical	  location	  of	  the	  datasets	  to	  be	  compared	  from	  the	  vector	  data.	  	  The	  first	  two	  arguments	  are	  reserved	  for	  these	  identifiers.	  	  	  	  An	  example	  plot	  generated	  from	  the	  analysis	  of	  100µM	  oxaliplatin	  treated	  PBMC	   samples	   from	   individual	   A	   compared	   to	   individual	   B	   is	   shown	   below	  (figure	  5.22).	   	  Once	   run,	   the	   function	  generates	   the	  outlier	  probe	   list	   and	  plots	  three	  graphics.	  	  Firstly,	  in	  the	  top	  left	  the	  QQ	  plot	  and	  outlier	  probe	  distribution	  is	  plotted.	  	  Secondly,	  in	  the	  top	  right	  the	  distribution	  of	  the	  subtracted	  dataset	  is	  displayed	  to	  give	  an	  overview	  of	  the	  spread	  and	  distribution	  of	  the	  data	  over	  the	  ~44,000	  data	  points.	  	  	  	  	   The	   third	   plot,	   the	   lower	   plot,	   shows	   the	   position	   of	   the	   outlier	   probes	  along	   the	   section	   of	   the	   genome	   analysed,	   and	   with	   a	   colour	   scale	   for	   the	  magnitude	  of	  the	  difference	  between	  the	  two	  datasets	  compared	  indicated	  by	  the	  colour	  key.	   	  The	  outlier	  can	  be	  negative	  or	  positive	  (i.e.	   the	  difference	  between	  the	   two	   adduct	   patterns	   is	   either	   significantly	   higher	   in	   one	   than	   the	  other,	   or	  significantly	  lower).	  	  The	  central	  data,	  between	  the	  purple	  and	  pink	  dotted	  lines	  –	  not	  shown,	  would	  contain	  the	  remaining	  non-­‐outlier	  data	  points,	  with	  normally	  distributed	   differences	   between	   datasets	   of	   low	   magnitude	   and	   likely	   due	   to	  experimental	   variation	   rather	   than	   biological	   differences.	   	   	   A	   list	   of	   outlier	  probes,	  subtracted	  probe	  values	  and	  the	  genomic	  location	  can	  be	  obtained	  from	  the	  outlierDataPlot	  function	  using	  the	  argument	  csv=TRUE.	  	   	  This	  tool	  can	  now	  be	  used	  to	  rapidly	  assess	  for	  variations	  between	  clinical	  samples	   from	   patients	   in	   the	   DIP-­‐chip	   profiles	   generated	   and,	   additionally,	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removes	  much	  of	  the	  normally	  distributed	  variation	  between	  samples	  presumed	  to	  be	  due	  to	  experimentally	  generated	  noise.	  	  In	  this	  example	  the	  outlier	  probes	  are	  well	  spread	  over	  the	  section	  of	  the	  genome	  studied	  (figure	  5.22),	  however	  on	  visual	  inspection	  there	  appears	  to	  be	  a	  group	  of	  outlier	  probes	  at	  approximately	  10,500,000,	   possibly	   indicating	   an	   area	   of	   greater	   inter-­‐individual	   variability	  between	   adduct	   patterns	   in	   this	   region	   that	   could	   be	   examined	   in	  more	   detail	  and	  at	  greater	  resolution.	  	  
	  
Figure	  5.22:	  A	  plot	  generated	  by	  the	  outlierDataPlot	  R	  function.	  	  	  Two	   experimentally	   generated	   oxaliplatin	   treated	   PBMC	  DIP-­‐chip	  microarray	   datasets	   are	  compared	   to	   identify	   significant	   outlying	   probes	   in	   this	   example.	   	   The	   top	   left	   plot	   shows	  the	   QQ	   plot	   between	   samples,	  with	   the	  majority	   of	   data	   points	   approximating	   the	   normal	  distribution	  and	  a	  tail	  of	  outlying	  points	  at	  the	  left	  and	  right	  extremes	  identified	  as	  outliers	  by	   the	   increase	   distance	   between	   these	   points	   and	   the	   normal	   line.	   	   The	   right	   upper	   plot	  shows	   the	  spread	  of	  probe	   IP/IN	  value	  when	  one	  dataset	   is	   subtracted	   from	  the	  other	  and	  the	   two	   tails	  where	   significant	   outliers	   are	   likely	   to	   be	   found	   (the	   pink	   and	  purple	   cut-­‐off	  lines)	   correspond	   to	   the	  QQ	   plot	   and	   have	   been	   generated	   by	   the	   extremevalues	   package.	  	  The	   lower	  plot	   shows	   the	  genomic	   location	  of	   identified	  outlier	  probes	  and	   the	  magnitude	  of	  the	  difference	  between	  the	  two	  datasets	  of	  the	  value	  of	  the	  outlier	  probe	  (corresponding	  to	  the	  right	  hand	  key).	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5.6.4 Development	  of	  the	  outlierDataMultiPlot	  R	  function	  	  	   To	   compare	   between	   multiple	   datasets	   the	   outlierDataMultiPlot	  function	   was	   developed	   (for	   the	   full	   script	   see	   appendix	   8).	   	   This	   allows	   the	  simultaneous	  generation	  of	  lists	  and	  plots	  of	  outlier	  probes,	  calculated	  again	  by	  the	  extremevalues	  package	  and	  modifiable	  for	  alternative	  statistical	  approaches	  if	  desired.	  	  The	  number	  of	  datasets	  to	  compare	  is	  specified	  in	  the	  first	  argument	  and	   subsequent	   to	   this	   the	  programme	  will	   prompt	   the	  numerical	   identifier	   of	  the	  datasets	  to	  compare	  from	  the	  vector	  ‘data’.	  	   The	  genomic	  locations	  and	  magnitude	  of	  subtracted	  values	  at	  each	  outlier	  probe	   for	   each	   dataset	   can	   be	   overlaid	   on	   the	   same	   plot	   using	   the	   argument	  
plotsame=TRUE,	  or	  in	  separate	  plots	  using	  the	  argument	  plotsame=FALSE.	   	  Tiles	  for	  each	  plot	  will	  be	  requested	  by	  the	  function	  if	  the	  argument	  title=TRUE	  is	  used,	  and	   again	   a	   csv	   file	   of	   all	   of	   the	   outlying	  probes	   and	   genomic	   locations	   can	  be	  generated	   and	   labelled	   by	   using	   the	   arguments	   csv=TRUE	   and	   specifying	   a	   file	  name	  with	  the	  argument	  CSVtitle.	  	  	   An	  example	  of	   the	  potential	  use	  of	   the	  outlierDataMultiPlot	   function	   is	  for	   the	   comparisons	   of	   100µM	   oxaliplatin	   treated	   PBMC	   DIP-­‐chip	   datasets	  between	  patient	  A	  and	  B.	  	  As	  previously	  discussed,	  (chapter	  4	  section	  4.3.2)	  the	  mean	   datasets	   between	   three	   repeats	  matching	  well	   (correlation	   0.69)	   but	   for	  any	   one	   for	   any	   two	   of	   the	   repeats	   the	   adduct	   patterns	   are	   more	   variable	  (correlation	  0.4-­‐0.6).	  	  	  The	   question	   to	   be	   answered	   in	   this	   example	   analysis	   is	   whether	   the	  outliers	   between	   repeats	   experiments	   are	   at	   the	   same	   probe	   location	   when	  comparing	   the	   independent	   repeat	   patterns	   from	   one	   individual	   against	   the	  mean	  of	  the	  other	  individual	  as	  a	  reference	  pattern.	  	  In	  this	  way,	  the	  mean	  of	  the	  repeats	   from	   individual	  A	   is	  used	  as	  a	   reference	   to	   compared	   the	  variability	   in	  detected	   outlier	   position	   in	   each	   individual	   dataset	   for	   patient	   B.	   	   The	  
outlerDataMultiPlot	   produces	   three	   genomic	   plots	   showing	   the	   location	   of	  outliers	  for	  each	  of	  these	  three	  comparisons	  (figure	  5.23)	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Figure	  5.23:	  An	  outlierDataMultiPlot	  output.	  An	   outlierDataMultiPlot	   output	   showing	   the	   genomic	   location	   of	   outlier	   probes	   in	   the	  comparison	   of	   Dip-­‐chip	  microarray	   datasets	   between	   a	   reference	   sample	   (in	   this	   case	   the	  mean	   of	   three	   repeats	   of	   oxaliplatin	   treated	   PBMC	   from	   patient	   A)	   and	   three	   biological	  repeat	  experimental	  generated	  data	  from	  individual	  B.	  	  	  	  In	  this	  example,	  outliers	  appear	  to	  be	  relatively	  evenly	  distributed	  along	  the	   genome.	   	   This	   function	   can	   be	   used	   to	   compare	   multiple	   outlier	   plots	  simultaneously,	   allowing	   easier	   visual	   identification	   in	   patterns	   within	   and	  between	  microarray	  datasets.	  	  In	  samples	  with	  higher	  signal	  and	  lower	  noise	  this	  should	  be	  a	  valuable	  analysis	  tool.	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5.6.5 Summary	  
	  
	   The	   functions	   presented	   in	   this	   section	   (5.5)	   are	   capable	   of	   detecting,	  plotting	   and	   listing	   individual	   probes,	   from	  DIP-­‐chip	  microarray	   datasets,	   that	  differ	  between	   individuals,	  with	  the	  level	  of	  significance	  determined	  by	  either	  t-­‐tests	   or	   with	   outlier	   detection	   package.	   	   As	   discussed,	   the	   optimal	   statistical	  method	  used	   to	   identify	   probes	  with	   differences	   between	  datasets	   due	   to	   true	  biological	   signal	   is	   yet	   to	   be	   determined,	   and	   is	   a	   current	   area	   of	   on-­‐going	  research	   by	   our	   laboratory	   bioinformatics	   team.	   	   Potential	   limitations	   of	   the	  outlier	  detection	  approach	  used	  above	  include	  that	  by	  the	  process	  of	  identifying	  probes	  with	   the	   greatest	  magnitude	   of	   difference	   between	   datasets,	   regions	   of	  potential	  experimental	  failure	  may	  be	  additionally	  be	  detected	  (as	  failure	  in	  one	  experiment	  may	  result	  in	  large	  differences	  between	  these	  failed	  and	  a	  non-­‐failed	  paired	  dataset).	   	  Additionally,	  this	  technique	  may	  result	  in	  a	  loss	  of	  information	  from	   the	   genomic	   and	   local	   probe	   context	   by	   identifying	   probes	   only	   by	   the	  greatest	   difference	   between	   datasets.	   	   As	   discussed	   in	   section	   5.6.2	   a	   ‘sliding	  window’	  based	  t-­‐test	  approach	  may	  offer	  a	  robust	  statistical	  approach	  and	  retain	  the	  genomic	  and	  local	  probe	  context	  during	  analysis.	  	  At	  the	  time	  of	  writing	  these	  bioinformatic	   developments	   are	   incomplete,	   and	   a	   detailed	   discussion	   of	   the	  current	   debate	   as	   to	   the	   relative	   merits	   of	   different	   statistical	   approaches	   to	  identify	  differences	  between	  the	  datasets	  are	  beyond	  the	  scope	  and	  limitations	  of	  this	  thesis.	  However,	   despite	   these	   limitations,	   this	   capability	   is	   now	   sufficiently	  developed	  with	  the	  tools	  described	  here,	  using	  the	  currently	  available	  t-­‐tests	  or	  extreme	  outlier	  approaches	  (and	  more	  refined	  approaches	  as	  they	  are	  developed	  in	   future),	   to	   allow	   the	   assay	   to	   be	   applied	   to	   clinical	   samples	   from	   cohorts	   of	  patients	   with	   a	   different	   response	   or	   toxicity	   from	   platinum	   based	  chemotherapy,	   in	   order	   to	   identify	   patterns	   and	   probes	   that	   differ	   between	  individuals	   and	   cohorts.	   	   Using	   the	   assay	   on	   cohorts	   of	   patients	   with	   valid	  phenotypic	   differences	   will,	   in	   addition,	   allow	   the	   further	   refinement	   and	  validation	  of	  several	  candidate	  statistical	  approaches	  to	  more	  precisely	   identify	  differences	  between	  microarray	  datasets.	  	  In	  this	  way,	  the	  PBMC	  DIP-­‐chip	  assay	  and	  analytical	  tools	  developed	  here	  can	  now	  be	  used	  as	  a	  clinical	  assay.	  	  
	   270	  
 Discussion	  and	  Conclusions	  5.7
	   The	  aim	  of	  this	  project	  is	  to	  continue	  the	  translation	  of	  a	  cell	  culture	  based	  laboratory	  assay,	  with	  limited	  data	  analysis	  tools,	  into	  a	  single-­‐use	  clinical	  assay,	  utilising	   the	  DIP-­‐chip	   technique	   to	  generate	  platinum-­‐DNA	  adduct	  profiles	   that	  can	  be	  used	  to	  predict	  for	  clinical	  outcome	  from	  platinum	  treatment.	  	  As	  a	  clinical	  assay,	  the	  DIP-­‐chip	  assay	  would	  be	  run	  prior	  to	  first	  exposure	  to	  chemotherapy,	  through	   a	   single	   blood	   test	   that	   could	   rapidly	   and	   accurately	   be	   analysed	   to	  generate	   an	   idiosyncratic	   adduct	   pattern.	   	   The	   adduct	   pattern,	   or	   patterns	   of	  outlier	  probes	  with	  validated	  predictive	  significance,	   could	   then	  be	  analysed	   to	  estimate	   the	   chances	   of	   clinical	   outcome	   of	   interest,	   and	   be	   used	   to	   guide	   the	  treatment	  choices.	  One	  limitation	  of	  the	  DIP-­‐chip	  assay	  for	  this	  clinical	  application	  is	  the	  use	  of	   PBMC	   as	   a	   surrogate	   tissue,	   reflecting	   aspects	   of	   cell	   specific	   and	   germline	  DNA	  damage	  and	  repair	  capacity	  rather	  than	  that	  the	  specific	  DNA	  damage	  and	  repair	  profile	  of	  tumour	  tissue.	  	  However,	  as	  discussed	  in	  section	  3.1.7,	  repeated	  biopsies	  to	  obtain	  tumour	  tissue	  are	  impractical	  and	  hazardous,	  and	  despite	  the	  limitations	  PBMC	  are	  commonly	  used	  as	  an	  easily	  accessible	  surrogate	  tissue	  in	  similar	   DNA	   damage	   and	   repair	   based	   clinical	   assays	   of	   tumour	   response	   and	  toxicity,	   as	   extensively	   discussed	   in	   the	   introductory	   sections	   to	   chapters	   3,	   4	  and	   5.	   	   To	   determine	   the	   impact	   of	   this	   effect	   it	   may	   be	   possible	   in	   future	   to	  compare	  platinum-­‐induced	  adduct	  patterns	  in	  paired	  PBMC	  and	  tumour	  tissue.	  	   The	   experiments	   conducted	   in	   human	   PBMC	   cells	   in	   this,	   and	   the	   two	  proceeding	  chapters,	  and	  the	  results	  of	  the	  analysis	  conducted	  in	  these	  chapters,	  are	   the	   first	   time	   this	   technique	   has	   been	   used	   in	   clinical	   samples.	   	   The	  work	  conducted	   and	   described	   highlights	   the	   significant	   experimental	   and	  bioinformatic	   challenges	   involved	   in	   this	   process	   and	   represents	   several	  important	  steps	  in	  adapting	  the	  DIP-­‐chip	  technology	  towards	  our	  goal.	  The	  methods	   and	   experiments	   outlined	   in	   chapter	  3,	   demonstrating	   the	  adaptation	  of	   the	  DIP-­‐chip	   technique	   to	  PBMC	  samples,	   as	   analysed	  at	   a	   single	  genetic	  locus,	  has	  identified	  that	  with	  protocol	  modifications	  and	  amendments	  it	  is	   possible	   to	   generate	   reproducible	   immunoprecipitated	   samples.	   	   The	  experiments	   subsequently	   conducted	   in	   chapter	  4	   focused	  on	   the	  development	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and	  optimisation	  of	  the	  high-­‐resolution	  genomic	  scale	  application	  of	  the	  DIP-­‐chip	  assay.	  	  Several	  experiments	  were	  conducted	  to	  enhance	  the	  reproducibility	  of	  the	  assay	   following	   identification	   of	  WGA-­‐PCR	   as	   a	   step	   that	   introduces	   variability	  into	   the	   final	   platinum-­‐DNA	   adduct	   pattern	   generated	   by	   the	   technique.	   	   High	  levels	   of	   variability	   potentially	   limit	   the	   clinical	   utility	   of	   the	   assay,	   which	   is	  required	   to	   generate	   reproducible	   patterns	   of	   induced	   DNA	   damage	   when	  repeated	   on	   the	   same	   individual	   -­‐	   an	   essential	   output	   to	   allow	   reliable	  comparisons	  between	  individuals.	  Several	  protocol	   amendments	  described	  have	   resulted	   in	   improvements	  in	  adduct	  pattern	  reproducibility,	   for	  example	  by	  increasing	  the	  IP	  sample	  DNA	  concentration	  or	  decreasing	  the	  PCR	  cycles	  (Chapter	  4,	  section	  4.3.7).	  	  However,	  to	   assess	   the	   effects	   of	   small	   changes	   in	   DIP-­‐chip	   assay	   protocol	   is	   a	   slow	  process,	   as	   each	  assay	   takes	   almost	   two	  weeks	   to	  perform,	   limiting	   the	   rate	  of	  experimental	   effort	   to	   measure	   the	   effect	   of	   subtle	   protocol	   amendments	   in	  multiple	   repeat	   experiments.	   	   Additionally,	   given	   the	   limited	   information	  available	  from	  the	  available	  analysis	  tools	  applicable	  to	  DIP-­‐chip	  assay,	  it	  was	  not	  possible	  to	  make	  rapid	  or	  further	  significant	  progress	  on	  this	  front.	  	   The	  bioinformatic	   techniques	   for	  use	  with	   the	  DIP-­‐chip	  assay	  developed	  and	   demonstrated	   in	   this	   chapter	   are	   a	   significant	   step	   forward	   for	   the	   data	  interpretation,	  assay	  development	  and	  quality	  control	  of	  DIP-­‐chip	  experiments.	  	  	  The	   development	   of	   the	   single	   channel	   analysis	   functionality	   (SCA	   -­‐	  section	  5.2)	  allows	   the	   in-­‐depth	   interpretation	  of	  DIP-­‐chip	  microarray	  datasets	  to	  identify	  the	  effects	  of	  subtle	  protocol	  amendments	  during	  optimisation	  work,	  for	   example	   by	   demonstrating	   the	   effect	   on	   the	   IP	   sample	   of	   PCR	   template	  changes	   (figure	   5.10).	   	   SCA	   is	   also	   a	   useful	   quality	   control	   metric	   to	   confirm	  successful	   completion	  of	   the	  DIP-­‐chip	  assay,	  by	   the	  demonstration	  appropriate	  IN	  and	  IP	  sample	  correlations	  (e.g.	  identifying	  an	  IP	  correlation	  of	  >0.95,	  section	  5.2.5)	   and	   to	   identify	   the	   presence	   and	   stages	   at	   which	   any	   technical	   failures	  have	  occurred	  (for	  example	  see	  figure	  5.	  6).	  	  The	   along	   genome	   correlation	   functionality	   (AGC,	   section	   5.3)	   gives	   the	  ability	   to	   interpret	  DIP-­‐chip	   datasets	   in	   different	  windows	   along	   the	   data,	   and	  has	   proved	   useful	   in	   identifying	   low	  DNA	  GC	   content	   as	   a	   source	   of	  WGA-­‐PCR	  introduced	   noise	   into	   the	   assay.	   	   Previous	   studies	   have	   demonstrated	   that	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additives	  to	  PCR	  samples	  and	  modification	  of	  reaction	  conditions	  can	  reduce	  GC	  content	  related	  differences	  in	  PCR	  efficiency	  (Aird	  et	  al.	  2011).	  	  The	  AGC	  function	  will	  be	  of	  benefit	  for	  this	  type	  of	  DIP-­‐chip	  development	  work.	  	  For	  example,	  with	  this	   new	   tool	   it	   is	   now	   be	   possible	   to	   test	   and	   demonstrate	   the	   effect	   of	   the	  addition	   of	   PCR	   additives	   or	   modification	   of	   PCR	   conditions	   to	   improve	   the	  amplification	  of	  low	  GC	  regions.	  	  The	  experiments	  and	  developments	  discussed	  so	  far	  have	  focussed	  on	  the	  reduction	  of	  noise	  to	  improve	  the	  signal-­‐to-­‐noise	  ratio	  in	  the	  DIP-­‐chip	  assay.	  	  The	  final	   group	   of	   tools	   developed	   in	   this	   chapter	   are	   tools	   to	   identify	   biological	  signals	   amongst	   the	   large	   microarray	   datasets	   generated	   by	   this	   technique.	  	  Within	  the	  limitations	  of	  the	  statistical	  approaches	  currently	  available	  to	  identify	  differences	   between	   datasets,	   as	   extensively	   discussed,	   the	   outlierDataPlot	  functions	  developed	  in	  this	  chapter	  streamline	  what	  was	  previously	  a	  multistep	  process	   requiring	   the	   use	   of	   several	   R	   functions	   to	   generate	   a	   list	   of	   potential	  outlier	  probes.	  	  The	  outlierDataPlot	  functions	  provide	  several	  graphical	  outputs	  for	   quality	   control	   (the	   QQplot	   and	   histogram	   of	   subtracted	   data)	   and	   several	  metrics	  for	  outlier	  probe	  analysis,	  including	  overlaid	  and	  separate	  plots	  showing	  the	   genomic	   position	   of	   outlier	   probes	   and	   magnitude	   of	   difference	   between	  datasets,	   and	   with	   the	   outlierDataMulitPlot	   function	   provides	   the	   ability	   to	  simultaneously	  visually	  compare	  multiple	  outlier	  probes	  generated	  from	  several	  paired	  DIP-­‐chip	  datasets	  and	  provides	  lists	  of	  data	  for	  further	  analyses.	  	  	  There	   are	   significant	   limitations	   to	   the	   statistical	   approaches	   applied	   to	  identify	   difference	   between	   datasets,	   including	   the	   loss	   of	   genomic	   and	   local	  probe	   context	   if	   whole	   array	   or	   outlier	   approaches	   to	   identify	   differences	  between	  datasets	  are	  employed.	   	  By	   focussing	  on	  maximal	  differences	  between	  microarray	   datasets	   the	   outlier	   detection	   methodology	   used	   also	   identifies	  potential	  regions	  of	  experimental	   failure,	  rather	  than	   just	   true	  biological	  signal.	  	  We	  are	  in	  the	  process	  of	  modifying	  an	  accepted	  method	  of	  ChIP-­‐chip	  analysis	  to	  develop	   a	   t-­‐test	   based	   approach	   used	   on	   sections	   of	   the	   datasets	   to	   retain	   the	  local	  probe	  context,	  an	  approach	  that	  should	   lead	  to	  a	  more	  statistically	  robust	  method	   of	   identifying	   regions	   of	   difference	   between	   two	   microarray	   DIP-­‐chip	  datasets.	   	   The	   refinement	   of	   these	   approaches	   requires	   the	   availability	   of	  DIP-­‐chip	   datasets	   with	   underlying	   biological	   differences,	   which	   will	   be	   obtained	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through	  a	  small-­‐scale	  clinical	  studies,	  the	  details	  of	  which	  are	  discussed	  further	  in	  chapter	  7.	  	  	  In	  summary,	  the	  experiments	  and	  developments	  described	  in	  this,	  and	  the	  proceeding	  two	  chapters,	  are	  an	  important	  component	  of	  the	  on-­‐going	  efforts	  to	  develop	  the	  DIP-­‐chip	  assay	  into	  a	  clinically	  useful	  tool.	  	  The	  work	  presented	  here	  is	   critical	   experimental	   evidence	   to	   support	   the	   protocol	   modifications	   that	  reduce	   the	  noise	   in	   the	  DIP	  assay	   (chapter	  3)	   and	   the	   chip	   aspect	  of	   the	   assay	  (chapter	   4),	   improving	   the	   signal-­‐to-­‐noise	   ratio	   and	   potential	   clinical	  applicability	  of	  the	  assay.	  	  The	  bioinformatic	  tools	  developed	  and	  documented	  in	  this	   chapter	   have	   demonstrated	   their	   worth	   in	   the	   re-­‐analysis	   of	   DIP-­‐chip	  microarray	  datasets,	  and	  provide	  vital	  additional	  analytical	  capabilities,	  essential	  for	  the	  translation	  of	  this	  DIP-­‐chip	  assay	  for	  patient	  clinical	  samples.	  	  	  To	   date,	   the	   assay	   has	   been	   used	   on	   healthy	   volunteers,	   potentially	  exaggerating	   the	  effect	  of	  noise	  on	   the	  signal-­‐to-­‐noise	  ratio	  of	   the	  assay,	  as	   the	  biological	  signal	  from	  healthy	  volunteers	  is	  likely	  to	  be	  low.	  	  Alongside	  on-­‐going	  efforts	   to	   improve	   the	   reproducibility	   of	   the	   assay	   through	   protocol	  modifications,	   particularly	   of	   the	   WGA-­‐PCR,	   one	   of	   the	   critical	   phases	   of	   the	  development	  of	  this	  assay	  is	  to	  test	  the	  system	  in	  situations	  where	  any	  biological	  signal	  is	  likely	  to	  be	  strongly	  present,	  either	  through	  the	  development	  of	  model	  systems,	  as	  described	  in	  the	  next	  chapter,	  or	  through	  clinical	  studies	  in	  cohorts	  of	  patients	  with,	   or	  without,	   the	   outcome	   of	   interest.	   	   Only	   in	   this	  way	  will	   it	   be	  possible	  to	  refine	  the	  statistical	  approaches	  to	  identify	  the	  underlying	  biological	  signal,	   and	   to	  determine	   the	   influence	  of	   signal	   strength	  on	   the	   signal-­‐to-­‐noise	  ratio	  and	  on	  the	  clinical	  performance	  of	  the	  DIP-­‐chip	  assay.	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Chapter	  6 The	  development	  of	  S.	  cerevisiae	  models	  to	  examine	  the	  
functional	  impact	  of	  single	  nucleotide	  polymorphisms	  associated	  with	  
oxaliplatin	  induced	  peripheral	  neuropathy	  in	  colorectal	  cancer	  
patients.	  	  
 Introduction	  6.1	   Oxaliplatin	  chemotherapy,	  a	  treatment	  used	  to	  significantly	  improve	  cure	  rates	   in	   patients	   with	   colorectal	   cancer,	   often	   results	   in	   oxaliplatin	   induced	  peripheral	   neuropathy	   (OIPN).	   In	   some	   patients	   this	   can	   be	   a	   permanent	   and	  disabling	   side	   effect.	   	   At	   present	   there	   is	   no	  way	   to	   stratify	   patients	   to	  predict	  those	  who	  will	   benefit	   from	   treatment	   or	   to	   reduce	   the	   risk	   of	   this	   potentially	  devastating	  complication.	  	  	  There	   may	   be	   a	   role	   for	   the	   DIP-­‐chip	   assay	   technology	   in	   stratifying	  patients	   for	   the	   risk	   of	   developing	   OIPN.	   	   This	   condition	   has	   been	   linked	   to	  defects	   in	   DNA	   repair	   capacity,	   particularly	   in	   the	   nucleotide	   excision	   repair	  (NER)	   pathway,	   through	   genome	   wide	   association	   mechanistic	   and	   functional	  studies	   (see	   (Cavaletti	   et	   al.	   2011;	   Dzagnidze	   et	   al.	   2007;	   Ta	   et	   al.	   2006)	  respectively).	   	  The	  conclusions	  from	  many	  of	  these	  studies	  are	  compatible	  with	  the	   underlying	   hypothesis	   of	   this	   thesis	   -­‐	   that	   as	   DNA	   repair	   pathways	   are	  responsible	   for	   the	   removal	   of	   adducts	   formed	   by	   the	   interaction	   of	   platinum	  agents	  with	  DNA,	   through	  understanding	  variations	   in	   the	   functioning	  of	   these	  pathways	   in	   individual	   patients	   it	   may	   be	   possible	   to	   stratify	   patients	   for	  response	  and	  toxicity	  from	  these	  agents,	  and	  for	  the	  risk	  of	  OIPN	  in	  particular.	  	  Novel	   single	   nucleotide	   polymorphisms	   (SNPs)	   have	   been	   recently	  identified	  at	  Cardiff	  University	   from	  a	   cohort	  of	   colorectal	   cancer	  patients	  who	  developed	  OIPN	  during	  treatment	  (West	  2013).	  	  These	  polymorphisms	  are	  in	  the	  gene	   XPF,	   involved	   in	   both	   the	   NER	   and	   interstrand	   crosslink	   (ICL)	   repair	  pathways,	  and	  may	  have	  a	  mechanistic	  effect	  on	  DNA	  repair	  and	  consequently	  on	  the	  risk	  of	  developing	  OIPN	  
	   275	  
The	  main	   focus	  of	   this	   chapter	   is	  on	   the	  development	  of	  genetic	  models	  that	   will	   be	   used	   to	   determine	   whether	   these	   SNPs	   have	   an	   impact	   on	   DNA	  repair,	   through	   assessment	   of	   UV	   damage	   as	   a	   paradigm	   for	   NER,	   and	   on	   the	  result	  of	  oxaliplatin	  sensitivity	  assays.	  	  This	  study	  will	  use	  cloning	  techniques	  to	  genetically	  manipulate	  S.	  cerevisiae	  to	  model	  analogous	  SNPs	  in	  the	  homologous	  yeast	   NER	   gene	   RAD1,	   and	   will	   attempt	   to	   demonstrate	   the	   effect	   of	   these	  polymorphisms	   on	   oxaliplatin	   toxicity	   in	   this	   classical	   genetic	   and	   functional	  model	  system.	  	  If	  a	  link	  between	  subtle	  perturbations	  in	  DNA-­‐repair	  capacity	  and	  OIPN	  can	  be	  demonstrated	  this	  will	  provide	  further	  evidence	  to	  support	  the	  use	  of	   the	   DIP-­‐chip	   assay	   in	   future	   clinical	   studies	   in	   this	   context.	   	   A	   robust	  laboratory	  model	  of	  OIPN	  would	  also	  be	  an	  invaluable	  tool	  for	  the	  development	  of	  our	  DNA	  repair	  based	  assays	  for	  patient	  stratification	  in	  this	  condition.	  
	  
6.1.1 Current	  biomarkers	  of	  response	  and	  toxicity	  to	  platinum	  agents	  	   The	  platinum	  family	  of	  chemotherapy	  drugs	  are	  an	  essential	  component	  of	   the	   majority	   of	   chemotherapy	   regimes,	   but	   come	   with	   significant	  complications	   and	   adverse	   effects,	   and	   can	   occasionally	   be	   fatal	   in	   a	   patient	  otherwise	  cured	  of	   their	   initial	  malignant	  disease	  (Reed	  2006).	   	   In	   light	  of	   this,	  biomarker	  studies	  with	  the	  aim	  of	  finding	  a	  mechanism	  to	  predict	  response	  and	  toxicity	  to	  these	  drugs	  have	  been	  a	  research	  priority,	  especially	  in	  tumour	  types	  in	  which	  platinum	  agents	   form	   the	  main	   line	   of	   effective	   treatment,	   notably	   in	  lung	  cancer	  (Bowden	  2014).	  There	  are	  a	  multitude	  of	  potential	  biomarkers	  that	  are	  candidates	  to	  have	  a	   role	   in	   stratification	   for	   response	   and	   toxicity	   to	   platinum	   drugs.	   	   Of	   those	  proposed,	   many	   are	   at	   early	   stages	   of	   development	   -­‐	   typically	   in	   preclinical	  stages	  of	  identification	  and	  validation.	  	  A	  few	  have	  progressed	  through	  to	  large-­‐scale	   clinical	   trials	   to	  attempt	   to	  demonstrate	  evidence	  of	   clinically	  meaningful	  predictive	  or	  prognostic	  power.	  	  In	  general,	  however,	  very	  few	  have	  progressed	  to	  this	  stage,	  and	  in	  the	  main	  the	  clinical	  results,	  usually	  of	  retrospective	  studies	  and	  analyses,	  have	  been	  inconsistent	  (Besse	  et	  al.	  2013;	  Bowden	  2014).	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As	  discussed	  in	  chapter	  1,	  section	  1.4.1.6,	  there	  is	  significant	  evidence	  that	  platinum-­‐DNA	   adducts	   are	   the	   lethal	   damage	   caused	   by	   exposure	   to	   platinum	  agents	   (Martin	   et	   al.	   2008)	   and,	   as	   such,	   the	   repair	   pathways	   are	   leading	  candidates	   in	   the	   search	   for	   clinically	  meaningful	   biomarkers.	   	   An	   example	   of	  this,	  and	  a	  leading	  candidate	  that	  has	  progressed	  through	  to	  validation	  through	  large	  scale	   in	  clinical	   trials,	   is	   tumour	  ERCC1	  status	   (Bowden	  2014;	  Cobo	  et	  al.	  2007).	  The	   ERCC1	   protein	   has	   an	   important	   role	   in	   NER,	   acting	   in	   a	  heterodimeric	   endonuclease	   complex	  with	   XPF	   to	   excise	   5’	   of	   the	   pre-­‐incision	  complex	   (see	   chapter	   1	   section	   1.4	   and	   (Marteijn	   et	   al.	   2014)).	   	   High	   levels	   of	  ERCC1	  protein	  expression	  have	  been	  demonstrated	   to	  be	  a	  positive	  prognostic	  factor	   in	   untreated	   surgically	   resected	   NSCLC	   (Simon	   et	   al.	   2007)	   and	   ERCC1	  expression,	  obtained	  by	  measuring	  protein	  or	  mRNA	  levels,	  has	  been	  implicated	  in	  resistance	  to	  platinum	  agents	  in	  lung,	  ovarian	  and	  gastric	  malignancies	  (Li	  et	  al.	  2010;	  Tiseo	  et	  al.	  2013).	  	  The	  most	  common	  method	  of	  assessment	  of	  ERCC1	  status	   is	   through	   the	   measurement	   of	   relative	   protein	   levels	   measured	   by	  immunohistochemistry,	   for	  example	  used	   in	  the	  clinical	   trial	  by	  Cobo	  et	  al.	  as	  a	  marker	  for	  the	  response	  to	  platinum	  agents	  in	  non-­‐small	  cell	  lung	  cancer	  (Cobo	  et	  al.	  2007).	  	  ERCC1	  status	  is	  currently	  being	  assessed	  as	  a	  predictive	  biomarker	  for	   cisplatin	   response	   in	   several	   lung	   cancer	   treatment	   clinical	   trials	   (Bowden	  2014).	  Although	   several	   studies	   have	   revealed	   a	   possible	   relationship	   between	  changes	   in	   DNA	   repair	   capacity	   and	   the	   response	   of	   patients	   to	   platinum	  chemotherapy,	   especially	   in	   the	   treatment	   of	   lung	   cancer,	   it	   is	   so	   far	   unclear	  whether	   the	  best	  biological	  markers	  are	  at	   the	   level	  of	  genetic	  polymorphisms,	  mRNA	   levels	   or	   immunohistochemistry	   for	   protein	   expression	   (Peters	   et	   al.	  2014).	  	  	  One	  recent	  publication	  regarding	  this	  issue	  describes	  a	  lack	  of	  specificity	  of	   the	   antibodies	   commonly	   used	   in	   immunohistochemical	   analysis	   of	   ERCC1	  levels	   for	  specific	   isoforms	  of	  the	  protein	  (Friboulet	  et	  al.	  2013).	   	   In	  the	  case	  of	  ERCC1,	  five	  isoforms	  exist,	  and	  the	  protein	  level	  of	  only	  one	  of	  the	  possible	  five	  isoforms	  correlates	  with	  cisplatin	  response.	  	  Because	  of	  strong	  homology	  among	  the	   five	   isoforms,	   the	   commonly	   available	   and	   frequently	   used	   antibodies	   for	  
	   277	  
immunohistochemical	  detection	  of	  this	  protein	  are	  non-­‐isoform	  specific	  and,	  as	  a	  consequence,	   both	   functional	   and	   non-­‐functional	   isoforms	   are	   detected	   by	  immunohistochemistry.	   	   In	   some	   circumstances	   a	   tumour	   may	   selectively	  overexpress	   non-­‐functional	   isoforms	   of	   ERCC1	   and	   be	   characterised	   by	  immunohistochemistry	   as	   ERCC1	   positive,	   but	   have	   no	   increase	   in	   functional	  NER	   capacity,	   reducing	   the	   association	   between	   immunohistochemical	  determined	   ERCC1	   level	   and	   the	   outcome	   from	   treatment.	   	   Additionally	   this	  study	   discovered	   evidence	   that	   the	   epitope	   for	   the	  most	   commonly	   used	   anti-­‐ERCC1	  antibody	  (8F1)	  may	  have	  changed	  over	  the	  period	  these	  antibodies	  have	  been	   regularly	   used	   for	   clinical	   studies,	  with	   discordance	   in	   detectable	   ERCC1	  expression	  between	  the	  same	  samples	  re-­‐tested	  over	  a	  5-­‐year	  period	  (Friboulet	  et	   al.	   2013).	   	   This	   could	   introduce	   unexpected	   variability	   in	   staining	   between	  pre-­‐clinical	  and	  related	  clinical	  validation	  studies.	  As	   an	   alternative	   approach,	   several	   groups	   have	   attempted	   to	   identify	  predicative	  biomarkers	  at	  the	  genetic	  level.	  	  Many	  studies,	  usually	  genome	  wide	  association	   studies	   (GWAS),	   have	   identified	   single	   nucleotide	   polymorphisms	  that	   are	   statistically	   associated	   both	   with	   response	   and	   toxicity	   to	   platinum	  agents	  (Wheeler	  et	  al.	  2011)	  especially	  in	  lung	  cancer	  (examples	  include(Ren	  et	  al.	  2012;	  Shiraishi	  et	  al.	  2010;	  Tan	  et	  al.	  2011),	  gastric	  cancer	  (Park	  et	  al.	  2011)	  and	  pancreatic	  cancer	  (Okazaki	  et	  al.	  2008).	  	  As	  an	  indication	  of	  the	  importance	  of	   the	   DNA	   repair	   pathways	   in	   this	   area,	   these	   studies	   highlight	   the	   potential	  biomarker	   role	   of	  DNA	   repair	   associated	   genes,	   particularly	   of	   SNPs	   in	  ERCC1,	  XPD,	  XRCC1	  and	  XRCC3,	   as	  predictive	  markers	  of	  patient	  outcome	   (Tiseo	  et	   al.	  2013).	  	  Despite	   these	   advances,	   progress	   to	   a	   clinically	   applicable	   marker	   of	  platinum	   response	   or	   toxicity	   is	   hindered	   by	   the	   fact	   that	   the	   results	   in	   the	  literature	   are	   not	   consistent,	   mainly	   relate	   to	   cisplatin,	   and	   typically	   are	   from	  retrospective	   single-­‐arm	   studies	   (Tiseo	   et	   al.	   2013).	   	   To-­‐date,	   none	   of	   these	  putative	  associations	  has	  been	  translated	  into	  a	  tool	  that	  has	  made	  an	  impact	  in	  the	  clinic,	  and	  the	  optimal	  pathway	  for	  the	  rapid	  translation	  of	  this	  type	  of	  pre-­‐treatment	   genetic	   screening	   assay	   into	   the	   clinic	   is	   uncertain	   (Houtsma	   et	   al.	  2010).	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6.1.2 Oxaliplatin	  Induced	  Peripheral	  Neuropathy	  -­‐	  OIPN	  	   	  The	   natural	   history	   and	   molecular	   mechanism	   of	   the	   development	   of	  OIPN	  is	  extensively	  discussed	  in	  chapter	  1,	  section	  1.4.4.	  	  The	  serious	  long	  term	  impact	  of	  OIPN	  and	  the	  lack	  of	  available	  diagnostic	  tools	  and	  treatments	  makes	  OIPN	  an	  ideal	  area	  for	  the	  development	  of	  predicative	  biomarkers	  enabling	  the	  stratification	  of	  treatment	  and	  risk	  reduction	  of	  this	  adverse	  event	  (Travis	  et	  al.	  2014).	  	  
	  
6.1.3 Proposed	  biomarkers	  of	  OIPN	  	   Several	   studies	   have	   focussed	   on	   polymorphisms	   in	   DNA	   repair	   and	  platinum-­‐drug	  detoxification	  pathways	  that	  could	  be	  used	  to	  predict	  oxaliplatin	  response	  and	  OIPN	  toxicity	  (Boige	  et	  al.	  2010;	  Custodio	  et	  al.	  2014;	  Inada	  et	  al.	  2010;	  Kanai	  et	  al.	  2010).	  Examples	   include	  studies	  examining	  SNPs	  in	  a	  host	  of	  genes	  related	   to	  oxaliplatin	   response	  and	   toxicity,	   including	  GSTP1	  and	  GSTT1,	  members	   of	   the	   glutathione	   S-­‐transferase	   pathway	   that	   sequester	   platinum	  agents	  in	  the	  cytoplasm	  (Cortejoso	  et	  al.	  2013;	  Goekkurt	  et	  al.	  2009b;	  Inada	  et	  al.	  2010).	  	  	  SNPs	   in	   several	   DNA	   repair	   genes	   involved	   in	   platinum-­‐DNA	   adduct	  repair	   (see	   chapter	   1,	   section	   1.4)	   have	   been	   studied,	   including	   the	  polymorphism	  Asn118Asn	  in	  ERCC1,	  correlated	  to	  protein	  expression	  level	  and	  toxicity	  from	  oxaliplatin	  in	  colorectal	  cancer	  patients	  (Zhou	  et	  al.	  2010),	  as	  have	  SNPs	   in	  ERCC2	  and	  XRCC1	  (Boige	  et	  al.	  2010).	   	   In	  a	  study	  by	  Cortejoso	  (2013),	  SNPs	   in	   ERCC1	   have	   also	   been	   associated	   with	   reduced	   risk	   of	   toxicity	   from	  treatment	   (Cortejoso	   et	   al.	   2013).	   	   Other	   genetic	   studies	   have	   shown	  contradictory	   results	   from	   investigating	   the	   same	   SNPs,	   particularly	   in	   ERCC1	  (reviewed	  in	  (Henriette	  Tanja	  et	  al.	  2009))	  and	  different	  groups	  have	  not	  found	  a	  strong	  link	  with	  ERCC1	  and	  OIPN	  (Chua	  et	  al.	  2009;	  Cortejoso	  et	  al.	  2013{Inada,	  2010	  #2474),	  for	  several	  reasons,	  as	  will	  be	  discussed	  below.	  	   In	  the	  multitude	  of	  published	  GWAS	  and	  genetic	  studies	  of	  chemotherapy-­‐induced	   neuropathy	   (extensively	   reviewed	   in(Cavaletti	   et	   al.	   2011))	   many	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candidate	  genetic	  polymorphisms	  have	  been	  proposed	  as	  potentially	  having	  an	  impact	   on	   toxicity	   and	   response,	   particularly	   to	   oxaliplatin.	   	   These	   studies	   are	  typically	  single	  centre	  studies	   investigating	  statistical	  associations	   in	  a	  selected	  handful	   of	   genes	   considered	   to	   be	   potentially	   correlated	   to	   outcome.	   	   The	  currently	  available	  data	  is	  conflicting,	  inconclusive,	  and	  insufficient	  to	  justify	  the	  use	   of	   these	  markers	   in	   clinical	   practice	   (Cavaletti	   et	   al.	   2011;	   Custodio	   et	   al.	  2014).	   	   In	   addition	   to	   the	   conflicting	   data	   from	   many	   of	   the	   statistically	  significant	   GWAS	   and	   genetic	   studies,	   very	   few	   groups	   provide	   any	   functional	  experimental	  evidence	  to	  support	  their	  genetic	  findings.	  	  One	   example	   of	   an	   alternative	   functional	   approach	   to	   OIPN	   biomarker	  detection	  is	  a	  study	  by	  Pieck	  (Pieck	  et	  al.	  2008).	  	  The	  kinetics	  of	  oxaliplatin-­‐DNA	  adduct	  formation	  and	  repair	  was	  investigated	  in	  peripheral	  blood	  cells	  from	  27	  patients	   undergoing	   chemotherapy	   with	   oxaliplatin	   for	   a	   variety	   of	   solid	  tumours.	   	  Oxaliplatin-­‐DNA	  adducts	  were	  measured	  by	  using	  atomic	  absorption	  spectroscopy	   to	   detect	   platinum	   molecules	   bound	   to	   extracted	   genomic	   DNA,	  giving	   a	   platinum-­‐per	   unit	   of	   DNA	   measurement	   for	   samples	   from	   peripheral	  blood	   mononuclear	   cells	   (PBMC)	   taken	   from	   patients	   after	   treatment.	   	   In	   the	  small	  number	  of	  patients	  tested	  (with	  a	  heterogeneous	  treatment	  schedule	  and	  in	   a	   wide	   variety	   of	   solid	   tumours)	   a	   trend	   towards	   higher	   oxaliplatin-­‐DNA	  adduct	   levels	   in	   patients	   with	   more	   OIPN	   was	   described,	   but	   perhaps	   not	  surprisingly	  given	  the	  small	  sample	  size	  and	  the	  relatively	  crude	  assay	  this	  was	  not	  statistically	  significant	  (Pieck	  et	  al.	  2008).	  	  
	   Attempts	  have	  also	  been	  made	  to	  develop	  clinical	  predictive	  risk	  markers	  for	  OIPN	  (Argyriou	  et	  al.	  2013;	  Renn	  et	  al.	  2011;	  Velasco	  et	  al.	  2014)	  but	  have	  been	  hampered	  by	  a	  lack	  of	  agreement	  on	  a	  consistent	  grading	  system	  for	  OIPN.	  	  One	  of	  several	  grading	  systems	  is	  commonly	  used	  for	  clinical	  trials	  (Cavaletti	  et	  al.	  2013),	  making	  comparisons	  between	  studies	  using	  different	  scales	  difficult	  to	  interpret,	   and	   to-­‐date	   no	   consistent	   tool	   for	   neuropathy	   grading	   has	   been	  adopted	  in	  routine	  practice	  (Argyriou	  et	  al.	  2014).	  	  To-­‐date	   no	   biomarker	   or	   risk	   stratification	   tool	   has	   been	   developed	   to	  accurately	   stratify	   patients	   for	   the	   risk	   of	   OIPN.	   	   A	   recent	   study,	   lead	   by	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Professor.	  J.	  Cheadle	  at	  Cardiff	  University,	  has	  identified	  new	  candidate	  SNPs	  in	  DNA	   repair	   genes	   that	   could	   be	   associated	   with	   the	   risk	   of	   developing	   OIPN	  (West	   2013).	   	   Given	   the	   conflicting	   results	   and	   the	   lack	   of	   supporting	  mechanistic	  work	  in	  the	  publications	  discussed	  above,	  our	  approach,	  outlined	  in	  the	  experiments	  described	  in	  this	  chapter,	  is	  to	  develop	  additional	  functional	  and	  mechanistic	   experimental	   evidence	   to	   support	   the	   statistically	   significant	  findings	  described	  below.	  	  	  
	  
 Candidate	  biomarkers	  of	  OIPN	  recently	  discovered	  in	  the	  COIN	  trial:	  6.2
OIPN	  associated	  SNPs	  in	  XPF	  	  	   Recently,	   the	   laboratory	  of	  Professor	   J.	  Cheadle	  at	  Cardiff	  University	  has	  used	   an	   enriched	   population	   of	   patients	   with	   OIPN	   to	   find	   candidate	   genetic	  markers	   that	   may	   predict	   for	   the	   development	   of	   this	   adverse	   effect.	   	   A	   brief	  outline	   of	   the	  protocol	   used	  by	   the	  Cheadle	   laboratory	   to	   generate	   this	   data	   is	  discussed	  below.	  	  
	  
6.2.1 Methods	  
	   Genomic	  DNA	  was	  obtained	   from	  stored	  blood	  samples	   from	  the	  Cardiff	  University-­‐based,	  UK	  national	  2445	  patient	  COIN	  trial	  investigating	  the	  benefit	  of	  continuous	  compared	  to	  intermittent	  oxaliplatin	  and	  fluoropyrimidine	  palliative	  chemotherapy	   for	   advanced	   colorectal	   cancer	   and	   the	   effect	   of	   the	   addition	   of	  anti-­‐EGFR	  cetuximab	  to	  standard	  chemotherapy	  (Adams	  et	  al.	  2011;	  Maughan	  et	  al.	   2011).	   	   All	   patients	   received	  oxaliplatin	   and	   fluoropyrimidine	   treatment	   for	  the	   first	  12	  weeks,	  with	  a	  randomisation	   for	   the	  addition	  of	  cetuximab	  therapy	  (Figure	  6.1).	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Figure	  6.1:	  The	  UK	  COIN	  trial	  design	  (from	  (Adams	  et	  al.	  2011))	  	   During	   an	   initial	   phase	   of	   the	   this	   study	   DNA	   from	   the	   10	   patients	  identified	  as	  developing	  the	  most	  severe	  OIPN	  (at	  least	  CTC	  grade	  3	  or	  4)	  (figure	  6.2)	  during	  the	  first	  12	  weeks	  of	  treatment	  was	  exome	  re-­‐sequenced.	  	  	  
	  
Figure	  6.2:	  NCI-­‐CTC	  Common	  Toxicity	  Criteria	  for	  Adverse	  Advents	  Version	  3:	  	  Sensory	  Neuropathy	  Criteria	  (http://ctep.cancer.gov)	  (ADL-­‐	  activities	  of	  daily	  living)	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 Grade 
Adverse Event Short Name 1 2 3 4 5 
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Neuropathy: cranial  
– Select 
Asymptomatic, detected 
on exam/testing only 
– CN I  Smell 
– CN II  Vision 
– CN III  Pupil, upper eyelid, extra ocular movements 
– CN IV  Downward, inward movement of eye 
– CN V  Motor-jaw muscles; Sensory-facial 
– CN VI  Lateral deviation of eye 
– CN VII Motor-face; Sensory-taste 
– CN VIII Hearing and balance 
– CN IX Motor-pharynx; Sensory-ear, pharynx, tongue 
– CN X Motor-palate; pharynx, larynx 
– CN XI Motor-sternomastoid and trapezius 
– CN XII Motor-tongue 
Symptomatic, not 
interfering with ADL 
Symptomatic, interfering 
with ADL 
Life-threatening; disabling Death 
Neuropathy: 
motor  
Neuropathy-motor Asymptomatic, weakness 
on exam/testing only 
Symptomatic weakness 
interfering with function, 
but not interfering with 
ADL 
Weakness interfering with 
ADL; bracing or 
assistance to walk (e.g., 
cane or walker) indicated 
Life-threatening; disabling 
(e.g., paralysis)  
Death 
REMARK: Cranial nerve motor neuropathy is graded as Neuropathy: cranial – Select. 
ALSO CONSIDER: Laryngeal nerve dysfunction; Phrenic nerve dysfunction.  
Neuropathy: 
sensory 
Neuropathy-sensory Asymptomatic; loss of 
deep tendon reflexes or 
paresthesia (including 
tingling) but not 
interfering with function 
Sensory alteration or 
paresthesia (including 
tingling), interfering with 
function, but not 
interfering with ADL 
Sensory alteration or 
paresthesia interfering 
with ADL  
Disabling  Death 
REMARK: Cranial nerve sensory neuropathy is graded as Neuropathy: cranial – Select. 
Personality/behavioral Personality Change, but not 
adversely affecting 
patient or family 
Ch nge, adversely 
affecting patient or family  
Mental health in ervention 
indicated 
Change harmful to others 
or self; hospitalization 
indicated 
Death 
Phrenic nerve dysfunction  Phrenic nerve Asymptomatic weakness 
on exam/testing only 
Symptomatic but not 
interfering with ADL; 












Psychosis — Transient episode Interfering with ADL; 
medication, supervision 
Harmful to others or self; 
life-threatening 
Death 
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genes	   involved	   in	   drug	   influx	   (n=4),	   oxaliplatin	   trafficking	   (n=3),	   drug	  detoxification	   (n=7),	   oxalate	   metabolism	   (n=2),	   sequestration	   (n=3),	   and	   drug	  efflux	  (n=7).	   	  Although	  patients	  with	  a	  history	  of	  pre-­‐existing	  neuropathy	  were	  excluded	  from	  the	  COIN	  trial,	  the	  main	  genetic	  causes	  of	  peripheral	  neuropathy	  were	   excluded	   in	   all	   10	   patients	   in	   this	   sub-­‐study	   by	   sequencing	   the	   28	   genes	  associated	   with	   rare	   hereditary	   neuropathies	   in	   each	   patient.	   No	   causative	  mutations,	  polymorphisms	  or	   truncating	   indels	   in	   this	  selection	  of	  neuropathy-­‐associated	  genes	  was	  identified.	  	  
6.2.2 Study	  results	  
	   A	   single	   patient	   with	   severe	   OIPN	   carried	   a	   novel	   stop	   gain	   (a	  polymorphism	  resulting	  in	  the	  change	  of	  a	  codon	  to	  a	  stop-­‐codon)	  -­‐	  Ser613X	  in	  exon	  9	  of	  XPF.	   	   Sanger	   sequencing	  of	   an	   independent	  PCR	  product	  verified	   the	  presence	  of	  the	  novel	  SNP	  and	  mutation	  in	  the	  second	  XPF	  allele	  was	  excluded	  by	  direct	  sequence	  analysis	  of	   the	  entire	  open	  reading	  frame	  and	  flanking	  intronic	  sequences.	   	  This	  patient	  had	  no	  past	  medical	  history	  of	   skin	  cancers	  or	   related	  diseases,	  and	  no	  history	  of	  ataxia,	  memory	  loss	  or	  muscle	  weakness.	  	  The	  patient	  did	  not	  clinically	  have	  XP	  and	  was	  a	  carrier	  of	  a	  single	  mutant	  XPF	  allele.	   	  This	  raises	  the	  possibility	  that	  haploinsufficiency	  for	  a	  mutant	  XPF	  allele	  is	  sufficient	  to	  induce	  OIPN	  upon	  exposure	  to	  oxaliplatin.	  	   To	   explore	   further	   the	   potential	   role	   of	   SNPs	   in	   XPF	   as	   a	   biomarker	   of	  OIPN,	   the	   open	   reading	   frame	   and	   flanking	   sequences	   of	   the	   gene	   were	  sequenced	   in	  an	  additional	  54	  patients	   in	   the	  COIN	  cohort	  who	  developed	  CTC	  grade	  3	  or	  4	  OIPN	  during	  treatment.	  	  	  Using	   this	   approach,	   5	   non-­‐synonymous	   variants	   were	   identified	   and	  referenced	   against	   known	   SNPs	   using	   the	   dbSNP	   database	   -­‐http://www.ncbi.nlm.nih.gov/SNP/.	   	   The	   variant	   Pro379Ser	   was	   found	   in	   3	  patients	   with	   OIPN	   and	   was	   previously	   documented	   in	   dbSNP	   (rs1799802).	  Arg415Gln	  was	   found	   in	  9	  patients	   and	   in	  dbSNP	   (rs1800067),	  His466Gln	   in	   a	  single	   patient	   and	   not	   in	   dbSNP,	   Arg576Thr	   was	   present	   in	   1	   patient	   and	   in	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dbSNP	   (rs1800068)	   and	   Glu875Gly	  was	   identified	   in	   4	   patients	   and	   in	   dbSNP	  (rs1800124).	  An	  in	  silico	  analysis	  of	  the	  potential	  of	  these	  variants	  to	  affect	  XPF	  protein	  function	   was	   conducted	   using	   the	   online	   tool	   Align-­‐GVDG	  (http://agvgd.iarc.fr/agvgd_input.php,	   (Tavtigian	   et	   al.	   2006)).	   The	   variants	  Pro379Ser,	  Arg576Thr	  and	  Glu875Gly	  were	  predicted	  to	  interfere	  with	  function,	  whilst	  the	  variant	  Arg415Gln	  was	  not.	  	  	  To	   examine	   the	   prevalence	   of	   these	   variants	   in	   the	   COIN	   population	   all	  2186	   available	   sample	   from	   individual	   patients	   in	   the	   COIN	   study	   were	  genotyped	   for	   the	  4	  XPF	  gene	  variants	  previously	   listed	   in	  dbSNP	   	   (Pro379Ser,	  Arg415Gln,	  Arg576Thr	  and	  Glu875Gly)	  with	  an	  overall	  genotyping	  success	  rate	  of	   98.1%.	   	   The	   frequencies	   of	   individual	   variants,	   grouped	   by	   the	   putative	  functional	   effects,	   in	   patients	   with,	   and	   without,	   OIPN	   were	   compared	   (Table	  6.1).	  	  Each	  ‘functional’	  variant	  was	  found	  more	  frequently	  in	  cases	  with	  OIPN	  as	  compared	  to	  those	  without,	  however,	  none	  were	  individually	  significantly	  over-­‐represented.	   	   In	   combination	   more	   patients	   with	   OIPN	   carried	   a	   potentially	  functionally	   impaired	   variant	   (7/63,	   11.11%)	   compared	   to	   patients	   without	  OIPN	  (90/1762,	  5.1%).	  	  This	  gives	  an	  overall	  odds	  ratio	  for	  the	  presence	  of	  one	  of	  the	  functionally	   impaired	  variants	   in	  a	  COIN	  study	  OIPN	  case,	  compared	  to	  a	  non-­‐OIPN	   case,	   of	   2.32	   [95%	   CI	   1.02-­‐5.24].	   	   Considering	   the	   presence	   of	   a	  function	   variant	   in	   an	  OIPN	   case,	   compared	   to	   a	   non-­‐OIPN	   case,	   the	   statistical	  significance	  was	  assessed	  using	  Chi	  square	  (and	  Fishers	  exact	  test	  for	  cells	  with	  a	  value	  of	  <5),	  giving	  a	  X2	  of	  4.36	  and	  a	  P	  value	  of	  0.037.	   	   In	  contrast	  the	  variant,	  Arg415Gln,	  which	  was	  predicted	  as	  unlikely	  to	  interfere	  with	  function,	  was	  found	  in	  a	  similar	  proportion	  of	  patients	  with	  and	  without	  OIPN	  (Table	  6.1).	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Table	  6.1:	  Variants	  in	  XPF	  identified	  in	  the	  study	  by	  Cheadle	  (West	  2013).	  	  	  The	   frequency	   of	   each	   SNP	   in	   OIPN	   cases	   and	   controls,	   and	   the	   statistical	   significance	   is	  displayed.	   	   The	   four	   variants	   with	   a	   likely	   functional	   role	   (defined	   using	   align-­‐GVGD)	   when	  combined	  are	   significantly	  more	   likely	   to	  occur	   in	  OIPN	  cases	   compared	   to	   controls	   (OR	  2.32).	  	  The	  non-­‐functional	  Arg415Gln	  is	  equally	  represented	  in	  cases	  and	  controls.	  	  The	  Chi-­‐square	  (X2)	  test	  was	  used	  to	  test	  significance	  (or	  Fishers	  exact	  test	  was	  used	  if	  cell	  value	  was	  below	  5).	  	  The	  significance	   is	   shown	  by	   the	   respective	  P	   value	   (P),	   given	   along	  with	   the	   odds	   ratio	   (OR)	  with	  95%	  confidence	  intervals.	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  Potential	  mechanism	  of	  OIPN	  susceptibility	  as	  a	  result	  of	  XPF	  SNPs	  -­‐6.3
The	  use	  of	  the	  budding	  yeast	  S.	  cerevisiae	  as	  a	  genetic	  model	  
 	   The	  budding	  yeast	  S.	  cerevisiae	  has	  been	  a	  widely	  used	  model	  organism	  in	  genetic	   research	   for	   several	   decades	   and	   has	   been	   described	   as	   the	   ‘premier	  model	   for	   eukaryotic	   cell	   biology’	   (Botstein	   and	  Fink	  2011).	   	   This	   is	   especially	  true	  in	  the	  field	  of	  NER	  research,	  in	  which	  the	  proteins	  and	  pathways	  of	  NER	  in	  S.	  
cerevisiae	  and	  humans	  are	  highly	  conserved	  (Reed	  2011),	  and	  for	  gene-­‐protein-­‐function	  association	  experiments	  (Botstein	  and	  Fink	  2011;	  Dunham	  and	  Fowler	  2013).	   	  In	  an	  era	  with	  a	  wealth	  of	  genetic	  sequencing	  information	  derived	  from	  human	  tissues	  and	  tumours,	  defining	  which	  genetic	  variants	  result	  in	  significant	  changes	   to	  phenotype	   is	  often	  a	   rate-­‐limiting	  step	   (Dunham	  and	  Fowler	  2013).	  	  To	  overcome	  this,	  S.	  cerevisiae	  has	  long	  been	  extensively	  used	  in	  many	  studies	  to	  recreate	   genetic	   variants	   in	   homologous	   genes,	   including	   experiments	  identifying	  the	  association	  of	  colorectal	  cancer	  risk	  with	  the	  alleles	  of	  the	  MMR	  gene	  MSH2	  (Gammie	  et	  al.	  2007)	  and	  the	  relationship	  between	  variants	  in	  MTO1,	  detected	  by	  high	  throughput	  sequencing,	  and	  the	  cardiac	  condition	  hypertrophic	  cardiomyopathy	  (Ghezzi	  et	  al.	  2012).	  Yeast	   models	   have	   several	   advantages	   over	   their	   mammalian	  counterparts.	   	   The	   doubling	   time	   of	   yeast	   is	   approximately	   90	   minutes,	  compared	  to	  several	  days	  for	  most	  human	  cell	  cultures,	  allowing	  for	  more	  rapid	  cell	  production	  and	  experimental	   throughput,	  and	  the	  small,	  well-­‐characterised	  genome	   is	   a	  manageable	   12MB,	  with	  many	   tried-­‐and-­‐tested	   tools	   available	   for	  accurate	   genetic	   manipulation.	   	   The	   key	   advantage	   is	   gene	   targeting	   due	   to	  extraordinary	  homologous	  recombination	  efficiency	  (Dunham	  and	  Fowler	  2013).	  	   To	   simplify	   this	   study,	   two	   of	   the	   SNPs	   identified	   by	   the	   Cheadle	  laboratory	  will	  be	  taken	  forward	  into	  our	  S.	  cerevisiae	  genetic	  model.	   	  Ser613X,	  the	   stop-­‐gain	  mutation,	   will	   be	  modelled,	   as	   it	   is	   novel,	   likely	   to	   have	   a	  more	  pronounced	  phenotype	  and	  is	  potentially	  easier	  to	  detect.	  	  Of	  the	  five	  other	  non-­‐synonymous	  mutations	  identified	  Pro379Ser	  occurs	  at	  a	  highly	  conserved	  region	  of	   the	   yeast	   XPF	   homolog	   RAD1	   and	   will	   be	   used	   to	   model	   the	   effect	   of	   the	  variants	  on	  cell	  survival	  and	  DNA	  repair.	  
	   286	  
6.3.1 An	  introduction	  to	  S.	  cerevisiae	  RAD1	  and	  RAD10,	  and	  the	  
mammalian	  homologs	  XPF	  and	  ERCC1	  	   Initially,	   the	   details	   of	   much	   of	   the	   mechanisms	   of	   human	   DNA	   repair	  were	   elucidated	   in	   genetic	   studies	   using	   S.	   cerevisiae,	   an	   approach	   possible	  because	  of	  the	  high	  degree	  of	  conservation	  between	  these	  systems	  in	  eukaryotes.	  	  Early	   experiments	  demonstrated	   that	   induced	  mutations	   leading	   to	  deletion	  of	  one	   or	   more	   of	   a	   group	   several	   genes	   result	   in	   extreme	   sensitivity	   to	   UV	  radiation.	   	  This	  group	  of	  genes,	  named	  RAD	  for	  ‘radiation	  sensitive’,	   include	  the	  regions	  subsequently	  identified	  as	  RAD1	  and	  RAD10,	  indicating	  an	  important	  role	  for	  these	  genes	  in	  repair	  of	  UV	  damage.	  	  Subsequent	  screening	  of	  yeast	  genomic	  libraries	  for	  the	  complementation	  of	  UV	  radiation	  sensitivity	  of	  RAD1	  and	  RAD10	  mutants	   identified	   the	   sequence	   of	   the	   genes	   concerned.	   	   These	   were	   later	  identified	  to	  be	  highly	  homologous	  to	  the	  mammalian	  orthologs	  XPF	  and	  ERCC1	  (reviewed	  in	  (Friedberg	  2005)).	  	  	  With	   in	   vitro	   yeast	   two-­‐hybrid	   experiments	   it	   was	   subsequently	  demonstrated	   that,	   in	   the	   absence	   of	   damaged	   DNA,	   Rad1	   and	   Rad10	   protein	  form	  a	  stable	  heterodimeric	  complex	  with	  high	  affinity	  and	  a	  long	  half-­‐life	  of	  >15	  hours	  (Bailly	  et	  al.	  1992;	  Bardwell	  et	  al.	  1992).	  	  	  	  In	  a	  purified	  protein	  system	  the	  endonuclease	   activity	   of	   Rad1	   and	   Rad10	   requires	   the	   combination	   of	   both	  proteins;	  when	  applied	  individually	  no	  activity	  can	  be	  detected	  (Sung	  et	  al.	  1993;	  Tomkinson	   et	   al.	   1993).	   	   The	   Rad1-­‐Rad10	   complex	   has	   significant	   affinity	   for	  junctions	   between	   double	   stranded	   DNA	   and	   single	   stranded	   DNA	   tails	   with	  3’ends	  (Bardwell	  et	  al.	  1994),	  which	  indicates	  its	  role	  in	  NER	  as	  the	  equivalent	  to	  ERCC1-­‐XPF,	   cleaving	   5’	   of	   the	   pre-­‐incision	   complex	   at	   the	   junction	   of	   single	  stranded	  and	  double	  stranded	  DNA	  (Marteijn	  et	  al.	  2014),	  making	   it	  one	  of	   the	  two	   junction	   specific	   endonucleases	   involved	   in	   excision	   of	   the	   damage	  containing	  oligonucleotide	  during	  NER.	  The	  protein	  structures	  of	  Rad1	  and	  Rad10	  are	  shown	  below	  (Figure	  6.3).	  	  The	   Rad1	   protein	   includes	   a	   Rad10	   protein-­‐binding	   domain	   between	   amino	  acids	  809	  and	  997,	  and	  conversely	  the	  Rad1	  binding	  domain	  of	  Rad10	  is	  located	  between	   amino	   acids	   90	   and	  210	   (Bardwell	   et	   al.	   1993;	   Bardwell	   et	   al.	   1992).	  	  These	  interaction	  domains	  are	  hydrophobic	  and	  the	  strength	  of	  the	  complex	  can	  
	   287	  
be	   increased	  at	  a	  higher	   ionic	   strength	   (Bardwell	  et	  al.	  1993).	   	  The	  association	  between	  proteins	  is	  mediated	  by	  a	  leucine-­‐isolucine	  zipper	  motif	  between	  amino	  acids	  931	  and	  966	   in	  the	  Rad10	  binding	  domain	  of	  Rad1	  (Prakash	  et	  al.	  1993),	  and	   a	   helix-­‐turn-­‐helix	   motif	   typical	   of	   protein-­‐protein	   interactions	   have	   been	  demonstrated	   in	   the	  Rad1	  binding	  domain	  of	  Rad10	  (Reynolds	  et	  al.	  1985;	  van	  Duin	  et	  al.	  1986).	  	  	  
	  
Figure	  6.3:	  The	  interaction	  domains	  of	  the	  Rad1	  and	  Rad10	  proteins.	  The	  regions	  (orange)	  between	  amino	  acids	  90	  and	  210	  of	  Rad10	  and	  809	  and	  997	  of	  Rad1	  are	   necessary	   for	   the	   heterodimerisation	   and	   interaction	   of	   these	   proteins	   (Adapted	   from	  (Friedberg	  2005))	  
	  
6.3.1.1 The	  XPF	  gene	  and	  XPF	  protein	  –the	  RAD1	  human	  homolog	  	  	  	  The	  human	  orthologs	  of	   the	  S.	  cerevisiae	  RAD1	   gene	  specifically	  corrects	  phenotypes	   in	   cells	   from	   patents	   of	   XP	   complementation	   group	   F	   and	   was	  identified	  from	  its	  homology	  with	  the	  yeast	  RAD1	  gene	  (Sijbers	  et	  al.	  1996).	  	  All	  patients	   in	  XP	  complementation	  group	  F	  have	  been	  shown	  to	  have	  mutation	   in	  the	   XPF	  gene	   (Matsumura	   et	   al.	   1998;	   Sijbers	   et	   al.	   1996).	   	   The	   open	   reading	  frame	  of	  XPF	  encodes	  a	  916	  amino	  acid	  polypeptide	  of	  molecular	  weight	  104	  kDa	  orthologous	  to	  Rad1	  protein	  of	  S.	  cerevisiae	  (Brookman	  et	  al.	  1996).	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heterodimeric	  complex	  with	  XPF.	  In	  the	  absence	  of	  XPF,	  the	  human	  ERCC1	  gene	  does	   not	   compliment	   XP	   cell	   lines	   that	   are	   defective	   in	   NER	   (van	   Duin	   et	   al.	  1989).	  	  
6.3.1.3 ERCC1-­‐XPF	  also	  form	  a	  functional	  heterodimeric	  complex	  The	   initial	   suggestion	   that	   the	   ERCC1	   and	   XPF	   proteins	   form	   a	  heterodimer	   complex	   was	   evidenced	   by	   the	   lack	   of	   complementation	   when	  mutant	   cell	   extracts	   are	  mixed	   in	   vitro	   (Biggerstaff	   et	   al.	   1993;	   Reardon	   et	   al.	  1993;	   van	  Vuuren	   et	   al.	   1993)	   and	  were	   subsequently	   shown	   to	  be	   active	   in	   a	  heterodimeric	  complex	  (Brookman	  et	  al.	  1996;	  Sijbers	  et	  al.	  1996).	   	  ERCC1	  and	  XFP	  are	  unstable	  in	  the	  absence	  of	  the	  other	  protein,	  as	  can	  be	  demonstrated	  by	  low	   levels	   present	   of	   ERCC1	   protein	   in	   XPF	   mutant	   cells	   in	   the	   presence	   of	  normal	  ERCC1	  mRNA	  levels	  (Biggerstaff	  et	  al.	  1993;	  Yagi	  et	  al.	  1997),	  indicating	  breakdown	  of	  the	  protein	  after	  synthesis.	  Analogous	   to	   Rad1-­‐Rad10,	   ERCC1-­‐XPF	   is	   a	   structure	   specific	  endonuclease	  and	  can	  cut	  at	  junctions	  between	  double	  and	  single	  stranded	  DNA	  where	   the	   single	   strand	  moves	   5’	   to	   3’	   away	   from	   the	   junction	   (de	   Laat	   et	   al.	  1998;	   Sijbers	   et	   al.	   1996),	   allowing	   the	   protein	   to	   act	   as	   a	   site	   specific	  endonuclease	   5’	   of	   unwound	  DNA	  during	  NER	   (Bardwell	   et	   al.	   1994;	  Mu	   et	   al.	  1996;	  Sijbers	  et	  al.	  1996).	  The	  XPF-­‐ERCC1	  heterodimer	  and	  is	  crucially	  involved	  in	  NER,	  but	  also	  in	  a	  number	  of	   other	  DNA	   repair	  pathways	  with	  a	  possible	   role	   in	  platinum-­‐DNA	  repair.	   	   Its	  other	   functions	  are	   in	   ICL	  repair	  and	   in	  double	  strand	  break	  repair,	  especially	   in	   the	   function	   of	   replication	   dependent	   ICL	   repair	   (Kirschner	   and	  Melton	  2010).	  	  
6.3.1.4 Protein	  domain	  structure	  of	  the	  ERCC1-­‐XPF	  heterodimer	  	   The	   ERCC1-­‐XPF	   protein	   family	   (including	   Rad1	   and	   Rad10)	   are	   highly	  conserved	   in	   eukaryotes.	   	   Neither	   protein	   has	   orthologs	   in	   E.	   coli	   or	   other	  eubacteria.	  	  Instead,	  XPF	  appears	  to	  be	  related	  to	  archeal	  helicases	  (Aravind	  et	  al.	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1999;	  Sgouros	  et	  al.	  1999).	  In	  archaeobacteria	  the	  protein	  equivalent	  of	  XPF	  only	  is	  present	  and	  functions	  as	  a	  homodimer	  (Aravind	  et	  al.	  1999;	  Gaillard	  and	  Wood	  2001),	   indicating	  that	  ERCC1	   is	   likely	   to	  have	  evolved	   from	  gene	  duplication	  of	  XPF	  in	  the	  eukaryotic	  lineage	  (Gaillard	  and	  Wood	  2001).	  	  An	  overview	  of	  the	  protein	  domains	  of	  XPF	  and	  ERCC1	  are	  shown	  below	  (Figure	  6.4)	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consistent	  with	  the	  function	  of	  XPF	  as	  an	  ATP-­‐independent	  nuclease	  rather	  than	  an	  ATP-­‐dependent	  helicase	  -­‐	  the	  similarities	  between	  XPF	  and	  helicase	  structure	  may	   reflect	   the	   necessity	   to	   bind	   DNA	   as	   many	   helicase	   enzymes	   bind	   to	   the	  junction	  between	  dsDNA	  and	  RNA	  tail	  with	  a	  3’end,	  similar	  to	  the	  function	  of	  XPF	  to	  bind	  the	  double	  strand-­‐single	  strand	  DNA	  junction	  in	  a	  5’	  to	  3’	  direction	  prior	  to	  cleavage	  at	  double	  strand/	  single	  strand	  junctions	  (de	  Laat	  et	  al.	  1998;	  Yao	  et	  al.	  1997).	  The	  nuclease	  region	  667	  to	  824,	  contains	  approximately	  90	  amino	  acids	  from	  670-­‐740	  that	  are	  highly	  conserved	  in	  the	  XPF	  and	  archeal	  enzyme	  families,	  and	   is	  not	  present	   in	  ERCC1.	   	  Using	  an	  affinity	  cleavage	  assay	   the	  active	  site	  of	  nuclease	  catalysis	  by	  ERCC1-­‐XPF	  was	  located	  to	  residues	  670-­‐740	  of	  XPF	  (Enzlin	  and	  Scharer	  2002).	  	  	  Mutation	  of	  several	  specific	  residues,	  including	  Asp	  687,	  Asp	  715,	  Lys	  727	  and	  Asp731	  have	  identified	  amino	  acids	  in	  the	  this	  region	  that	  are	  key	  to	  the	  nuclease	  function	  of	  XPF	  (McNeil	  and	  Melton	  2012).	  	  The	   ERCC1	   protein	   differs	   from	   XPF.	   	   Aside	   from	   the	   C-­‐terminal	   HhH2	  domain,	  it	  consists	  of	  a	  catalytically	  inactive	  central	  domain	  responsible	  for	  DNA	  binding,	  and	  unlike	  XPF	  has	  no	  helicase	  domain	  (Figure	  6.4).	  	  	  
6.3.1.5 Specific	  function	  of	  XPF	  and	  ERCC1	  subunits	  	  In	   mammalian	   ERCC1-­‐XPF	   the	   XPF	   sub-­‐unit	   contributes	   the	   nuclease	  activity	  whilst	   the	   helicase	   related	  N-­‐terminal	   domain	   probably	   contributes	   to	  DNA	  binding.	  	  ERCC1	  has	  no	  active	  nuclease	  site	  but	  retains	  the	  HhH	  domain	  for	  active	  binding	  of	  XPF	  and	  to	  DNA.	  	  As	  ERCC1	  is	  catalytically	  inactive,	  its	  role	  is	  in	  mediating	  DNA	  and	  XPA	   interactions	   through	  a	   v-­‐shaped	  groove	   in	   the	   central	  domain.	  	  This	  region	  binds	  to	  single	  stranded	  DNA	  with	  a	  strong	  preference	  for	  5’	  overhangs,	   resulting	   in	   a	   degree	   of	   structural	   specificity	   of	   the	   ERCC1-­‐XPF	  complex	  (McNeil	  and	  Melton	  2012).	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6.3.1.6 The	  role	  of	  ERCC1-­‐XPF	  in	  NER	  	   As	   discussed	   previously	   (Chapter	   1	   section	   1.4)	   NER	   involves	   the	  sequential	   action	   of	   approximately	   30	   proteins	   in	   a	   series	   of	   stepwise	   and	  complex	   interactions	   (See	   chapter	   1,	   section	   1.4,	   Figure	   1.12).	   	   The	   role	   of	  ERCC1-­‐XPF	  was	  initially	  elucidated	  by	  in	  vitro	  studies	  that	  demonstrated	  that	  the	  incision	   step	   requires	   6	   proteins	   to	   be	   present	   in	   vitro,	   namely	   XPC/RAD23B,	  XPA,	  RPA,	  TFIIH,	  XPG	  and	  XPF-­‐ERCC1	  (Aboussekhra	  et	  al.	  1995)	  and	  the	  protein-­‐protein	   interaction	  of	   these	   individual	  pathway	  components	   is	   fundamental	   for	  NER	   to	   proceed	   (Park	   and	   Choi	   2006).	   	   Once	   DNA	   damage	   is	   recognised	   by	  stalled	   RNA	   polymerase	   II	   at	   transcription	   forks	   (TC-­‐NER	   sub-­‐pathway)	   or	  through	   XPC-­‐RAD23B	   at	   structurally	   distorted	   DNA	   (via	   the	   GG-­‐NER	   sub-­‐pathway)	   the	   common	   phase	   of	   the	   repair	   mechanism	   occurs,	   consisting	   of	  recruitment	  of	  TFIIH,	  comprising	  key	  subunits	  XPB	  and	  XPD	  directional	  helicases	  which	  unwind	  DNA	  through	  an	  ATP-­‐dependent	  helicase	  activity	  (Park	  and	  Choi	  2006).	  	  Recruitment	  of	  XPA	  and	  RPA	  proceed	  to	  stabilise	  the	  unwound	  complex	  and	   recruit	   the	   structure	   specific	   endonucleases	   XPG	   and	   ERCC1-­‐XPF	   to	   incise	  the	  damaged	  strand	  either	  side	  of	  the	  damage.	  	  XPA	  recognises	  the	  helical	  kink	  at	  the	  unwinding	  of	  DNA	  duplex	  and	  acts	  as	  the	  framework	  for	  the	  binding	  of	  TFIIH,	  RPA	  and	  ERCC1-­‐XPF.	  	  	  The	  function	  of	  the	  ERCC1-­‐XPF	  heterodimer	  is	  thought	  to	  be	  mediated	  by	  ERCC1-­‐XPA	   interaction	   and	   XPF-­‐RPA	   interaction,	   resulting	   in	   excision	   of	   the	  single	  strand	  at	  the	  double-­‐single	  strand	  5’	  unwinding	  junction	  (Friedberg	  2005;	  Marteijn	  et	  al.	  2014;	  McNeil	  and	  Melton	  2012).	  	  
6.3.1.7 ERCC1-­‐XPF	  in	  DSB	  repair	  	   Double	  strand	  breaks	  are	  induced	  by	  ionizing	  radiation,	  free	  radicals	  and	  chemotherapy	  agents	  and	  can	  be	  repaired	  by	  either	  homologous	  recombination	  (HR)	   or	   by	   non-­‐homologous	   end	   joining	   (NHEJ).	   	   Rad1	   and	   Rad10,	   the	  orthologues	   of	   ERCC1	   and	   XPF,	   were	   used	   initially	   to	   demonstrate	   the	  importance	  of	  this	  complex	  in	  DSB	  repair	  (Schiestl	  and	  Prakash	  1990).	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ERCC1-­‐XPF	  mutant	  mammalian	  cells	  are	  sensitive	  to	  DSBs	  (Ahmad	  2008)	  (Ahmad	  et	  al.	  2008)	  and	  the	  NHEJ	  pathways	  for	  DSB	  repair	  are	  attenuated	  (Al-­‐Minawi	   et	   al.	   2009;	   Niedernhofer	   et	   al.	   2001;	   Sargent	   et	   al.	   1997).	   	   The	  main	  function	  appears	  the	  be	  the	  role	  of	  ERCC1-­‐XPF	  in	  removing	  non-­‐homologous	  3’	  single	  stranded	  flaps	  at	  the	  broken	  end	  of	  double	  strand	  breaks	  before	  they	  are	  repaired	  (Ahmad	  et	  al.	  2008)	  in	  single	  strand	  annealing	  (SSA)	  sub	  pathway	  of	  HR	  and	   in	   micro-­‐homology	   mediated	   end	   joining	   (MMEJ)	   sub	   pathway	   of	   NHEJ	  (Ahmad	  et	  al.	  2008;	  Ma	  et	  al.	  2003;	  McVey	  and	  Lee	  2008).	  	  
6.3.1.8 ERCC1-­‐XPF	  in	  ICL	  repair	  	   Removal	  of	   inter-­‐stand	  cross-­‐links	  (ICLs)	   is	  essential	  to	  cellular	  survival.	  	  Crosslinks	   can	   be	   formed	   through	   several	   mechanisms,	   including	   through	   the	  action	   of	   the	   platinum	   agents,	   as	   well	   as	   other	   chemotherapy	   drugs	   including	  mitomycin	   C,	   and	   agents	   such	   as	   psoralens	   (Wood	   2010).	   	   	   As	   discussed	  previously	   (Chapter	   1,	   section	   1.4.2.1),	   the	   linking	   of	   opposite	   strands	   of	   DNA	  prevents	   essential	   cellular	   functions	   of	   transcription	   and	   DNA	   replication.	  	  Evidence	  for	  the	  importance	  of	  this	  pathway	  is	  that	  mammalian	  NER	  mutants	  are	  sensitive	   to	   cross-­‐linking	   agents	   and	   XPF-­‐ERCC1	   mutants	   are	   particularly	  sensitive,	   indicating	   an	   especially	   important	   role	   of	   the	   heterodimer	   in	   this	  pathway	  (Wood	  2010).	  Although	   the	   full	   and	   precise	   mechanism	   of	   ICL	   repair	   is	   not	   fully	  elucidated,	   (see	   chapter	   1,	   section	  1.4.2.1)	   XPF-­‐ERCC1	   features	   in	   a	   dependent	  step	   and	   has	   been	   shown	   to	   be	   required	   for	   both	   S-­‐phase	   dependent	   and	  independent	  ICL	  repair	  (Bhagwat	  et	  al.	  2009;	  Niedernhofer	  et	  al.	  2004).	  	  
6.3.1.9 Non-­‐repair	  roles	  of	  ERCC1-­‐XPF	  	   The	   ERCC1-­‐XPF	   heterodimer	   is	   also	   involved	   in	   telomere	   maintenance	  and	   interacts	   with	   TRF2,	   a	   telomere	   associated	   protein.	   	   It	   has	   also	   has	   been	  shown	   to	  have	  a	   role	   in	  mitotic	  progression	   (McNeil	   and	  Melton	  2012).	   	  Given	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the	   mechanism	   of	   platinum	   damage	   and	   mechanism	   of	   OIPN,	   these	   non-­‐DNA	  repair	  interactions	  are	  unlikely	  to	  be	  related	  to	  this	  condition.	  XPF	  has	  also	  been	  shown	  to	  participate	  in	  the	  modification	  to	  chromatin	  structure	  during	  transcription,	  in	  a	  role	  independent	  of	  its	  function	  in	  the	  repair	  of	  DNA	  damage	  (Le	  May	  et	  al.	  2012).	  	  
6.3.2 Summary	  –	  the	  potential	  effects	  of	  SNPs	  on	  XPF	  protein	  structure	  
and	  function	  	  
	  
	   The	   variants	   identified	   in	   the	   genetic	   study	   discussed	   above	   and	   taken	  forward	  into	  this	  investigation,	  Ser613X	  and	  Pro379Ser,	  both	  potentially	  have	  an	  effect	  on	  the	  structure	  and	  function	  of	  XPF.	  	  As	  described	  in	  the	  previous	  section	  ERCC1-­‐XPF	  is	  involved	  in	  several	  molecular	  pathways,	  primarily	  DNA	  repair,	  but	  with	  several	  additional	  roles	  in	  other	  non-­‐repair	  pathways.	  	  Using	  a	  yeast	  model	  system	   it	   is	   possible	   to	   examine	   the	   effect	   of	   mutations	   on	   many	   of	   these	  pathways,	  including	  NER,	  DSB	  repair	  and	  ICL	  repair.	  	  As	  RAD1,	  and	  subsequently	  XPF,	  were	  discovered	  through	  the	  profound	  effect	  of	  their	  absence	  on	  NER,	  it	  is	  likely	   that	   the	   central	   role	   these	   proteins	   play	   in	   this	   pathway	   will	   give	   the	  highest	  chances	  of	  determining	   if	   functional	  effects	  result	   from	  the	  presence	  of	  these	  variants.	  	  For	  this	  reason,	  the	  effect	  of	  the	  Pro379Ser	  and	  Ser613X	  variants	  will	  primarily	  be	  assessed	   thought	   the	   impact	  of	   these	  mutations	  on	  NER,	  with	  the	  opportunity	  for	  future	  studies	  (beyond	  the	  scope	  and	  time	  constraints	  of	  this	  project)	  to	  examine	  the	  impact	  of	  these	  changes	  on	  other	  DNA	  repair,	  and	  non-­‐repair,	  molecular	  pathways.	  	  	  	  	   	  	  	  
	  
	   	  
	   294	  
 	  Aims	  of	  this	  chapter	  6.4
	   This	   chapter	   will	   investigate	   whether	   it	   is	   possible	   to	   demonstrate	   a	  functional	   role	   of	   single	   nucleotide	   polymorphisms	   recently	   identified	   from	   a	  cohort	  of	  colorectal	  cancer	  patients	  who	  developed	  OIPN	  during	  chemotherapy.	  	  These	  polymorphisms	  are	  located	  in	  the	  NER	  gene	  XPF,	  involved	  in	  both	  the	  NER	  and	   interstrand	   crosslink	   repair	   (ICL)	   pathways,	   and	   may	   have	   a	   functional	  impact	  on	  NER,	  and	  consequently	  on	  the	  risk	  of	  developing	  OIPN.	  	  	  The	   functional	   effects	   of	   the	   recently	   identified	   XPF	   SNPs	   will	   be	  investigated	  in	  an	  S.	  cerevisiae	  model	  system.	  	  The	  appropriate	  mutations	  will	  be	  introduced	  into	  the	  XPF	  homolog	  RAD1	  and	  their	  effect	  will	  be	  assessed	  on	  UV-­‐induced	  DNA	  damage	  and	  repair	   (as	  a	  marker	  of	  NER	  capacity)	  and	  oxaliplatin	  sensitivity.	  	  This	   study	  will	   be	   conducted	   in	   the	   following	   stages.	   	   Firstly,	   a	  plasmid	  containing	   a	   selectable	  marker	   and	  wild	   type	   (WT)	  RAD1	  will	   be	   constructed.	  	  After	  demonstrating	  appropriate	  function	  by	  complementation	  of	  UV	  resistance	  in	   a	   rad1Δ	   strain,	   mutations	   in	   pRAD1	   will	   be	   introduced	   into	   the	   plasmid	  construct	   and	   transformed	   into	   rad1Δ	   strains.	   	   These	   models	   will	   then	   be	  assessed	   for	   UV	   and	   oxaliplatin	   sensitivity	   compared	   to	   control	   strains	   to	  determine	  if	  there	  is	  a	  functional	  effect	  in	  these	  OIPN-­‐associated	  variants.	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6.5.1 Strain	  Tables	  	  Strain	   (haploid)	   	   Genotype	   	   	   	   	   Source	  	  SX46a	  Wild-­‐Type	   	   Mat	  a,	  ade2,	  his3-­‐372,	  trp	  289,	  ura3-­‐52	   	   EUROSCARF	  SX46a	  rad1Δ	   	   	   Mat	  a,	  rad1::URA3,	  	   	   	   	   EUROSCARF	   	   	   	   ade2,	  his3-­‐372,	  trp-­‐289,	  ura3-­‐52	  	  SX46a	  rad1Δ	  pRS313-­‐RAD1	   	   	   	   	   	   	   This	  Study	  SX46a	  rad1Δ	  pRS313-­‐RAD1-­‐P469S	   	   	   	   	   	   This	  Study	  SX46a	  rad1Δ	  pRS313-­‐RAD1-­‐S747X	   	   	   	   	   	   This	  Study	  
	  
Table	  6.2:	   	  The	  S.	  cerevisiae	  strain	  identifier,	  genotype	  and	  origin	  of	  the	  five	  strains	  used	  
for	  this	  study	  
	  
6.5.2 Conservation	  of	  amino	  acid	  sequence	  between	  XPF	  and	  RAD1	  	  
	  	   The	   site	   of	   mutations	   to	   be	   inserted	   into	   the	   RAD1	   gene	   to	   enable	  modelling	  of	  the	  XPF	  SNPs	  was	  identified	  by	  an	  alignment	  comparison	  between	  the	   amino	   acid	   sequence	   of	   the	   homologs	  XPF	   and	  RAD1	  using	   the	   online	   tool	  Clustal	   Omega	   (http://www.ebi.ac.uk/Tools/msa/clustalo/)	   with	   protein	  sequences	   obtained	   from	   NCBI	   (http://www.ncbi.nlm.nih.gov/protein).	   	   To	  increase	   the	   validity	   of	   the	   alignment,	   the	   XPF	   homolog	   Rad16	   from	   the	   yeast	  
Saccharomyces	   Pombe	   was	   also	   aligned	   with	   both	   XPF	   and	   Rad1	   protein	  sequences.	  	  The	  alignment	  is	  shown	  below	  (figure	  6.5)	  with	  the	  Rad1	  amino	  acid	  sequence	  also	  displayed	  for	  reference	  (figure	  6.6).	  	  The	  alignment	  demonstrates	  the	  conservation	  of	  sequence	  around	  position	  379	  in	  XPF,	  with	  a	  proline	  residue	  present	  at	  XPF	  position	  379,	  as	  shown	  by	  the	  green	  star,	  corresponding	  to	  Rad1	  position	   469	   (figure	   6.6).	   	   The	   XPF	   Ser613	   alignment	   demonstrates	   serine	  conserved	  at	  XPF	  position	  613,	  indicated	  by	  the	  pink	  star,	  and	  corresponding	  to	  Rad1	  position	  747	  (figure	  6.6).	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Figure	  6.5:	  Alignment	  of	  residues	   in	  XPF	  (Homo	  Sapiens),	  Rad	  16	  (S.	  pombe)	  and	  Rad1	  (S.	  
cerevisiae)	  associated	  with	  OIPN	  in	  the	  COIN	  trial	  patient	  cohort.	  Pro379	  and	  alignment	  with	  XPF	  and	  Rad1	  is	  shown	  by	  the	  green	  band	  and	  green	  star.	   	  The	  alignment	  of	  Ser613	  in	  XPF	  with	  Rad1	  in	  S.	  cerevisiae	  	  is	  shown	  by	  the	  green	  band	  and	  pink	  star.	  	  
	  




XPF Pro379 and Arg399 
 
Homo sapiens - NP_005227.1         EGEETKKELVLESNPKWEALTEVLKEIEAENKE--SEALGGPGQVLICASDDRTCSQLRD 
S.pombe - NP_587855.2              -GPNMDAIPILEEQPKWSVLQDVLNEVCHETMLADTDAETSNNSIMIMCADERTCLQLRD 
S.cerevisiae - NP_015303.1         -------EYTLEENPKWEQLIHILHDISHERMTNH-----LQGPTLVACSDNLTCLELAK 




Homo sapiens - NP_005227.1         FGILKEPLT-IIHPLLGCSDPYALTRVLHEVEPRYVVLYDAELTFVRQLEIYRASRPGKP 
S.pombe - NP_587855.2              FEVIDDFNSIYIYSYNGE----RDELVLNNLRPRYVIMFDSDPNFIRRVEVYKATYPKRS 
S.cerevisiae - NP_015303.1         YEYVDRQDEILISTFK----SLNDNCSLQEMMPSYIIMFEPDISFIRQIEVYKAIVKDLQ 




Homo sapiens - NP_005227.1         LRVYFLIYGGSTEEQRYLTALRKEKEAFEKLIREKASMVVPEEREGR--DETN--LDLVR 
S.pombe - NP_587855.2              LRVYFMYYGGSIEEQKYLFSVRREKDSFSRLIKERSNMAIVLTADSERFESQE--SKFLR 
S.cerevisiae - NP_015303.1         PKVYFMYYGESIEEQSHLTAIKREKDAFTKLIRENANLSHHFETNEDLSHYKNLAERKLK 




Homo sapiens - NP_005227.1         AATALAITADSETLP-------ESEKYNPGPQDFLLKMPGVNAKNCRSLMH-HVKNIAEL 
S.pombe - NP_587855.2              PASAASIGLEA-GQD-------STNTYNQAPLDLLMGLPYITMKNYRNVFYGGVKDIQEA 
S.cerevisiae - NP_015303.1         PSNAVILGTNKVRSDFNSTAKGLKDGDNESKFKRLLNVPGVSKIDYFNLRK-KIKSFNKL 
                                    :.*  :  :             .:  * .  . *: :* :.  :  .:    :*.: :  
 
Figure 6.5 – Alignment of residues implicated in PNAO in XPF (Homo sapiens), Rad16 (S.pombe) and Rad1 (S.cerevisiae). 
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Figure 6.5 – Alignment of residues implicated in PNAO in XPF (Homo sapiens), Rad16 (S.pombe) and Rad1 (S.cerevisiae). 
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   To	   model	   the	   two	   mutations	   XPF	   of	   Pro379Ser	   and	   Ser613X	   in	   the	  homologous	   RAD1	   gene,	   strains	   with	   the	   analogous	   mutations	   in	   the	   RAD1	  protein	   of	   Pro469Ser	   and	   Ser747X	   must	   be	   constructed.	   	   Accounting	   for	   the	  altered	   codon	   composition	  between	   species,	   the	   simplest	  mutation	   required	   to	  model	   the	   changes	   in	   the	   human	   context	   is	   the	   substitution	   of	   proline	   (codon	  TCC)	   to	   serine	   (codon	  TTC)	  with	   the	  RAD1	  gene	  mutation	  C1406T	   (figure	   6.7)	  and	  modification	  serine	  (codon	  AGT)	  to	  a	  stop	  codon	  (TGA)	  at	  positions	  A2240T	  and	   T2242A	   (figure	   6.8),	   resulting	   in	   the	   desired	   amino	   acid	   and	   protein	  sequence	  substitutions	  	  	  
	  
Figure	  6.7:	  The	  DNA	  sequence	  changes	  required	  that	  result	  in	  the	  Pro469Ser	  Rad1	  variant.	  	  	  The	  proline	  amino	  acid	  at	  469	   (green	  box)	   is	   changed	   to	  a	   serine	  by	   the	  conversion	  of	   the	  cytosine	  at	  DNA	  position	  1406	  to	  a	  thymine.	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6.5.3 Overview	  of	  strain	  construction	  –	  cloning	  strategy	  	  To	  investigate	  the	  functional	  effects	  of	  the	  recently	  identified	  XPF	  SNPs	  in	  an	  S.	  cerevisiae	  model	  the	  appropriate	  mutations	  need	  to	  be	  introduced	  into	  the	  homolog	  RAD1.	  	  The	  initial	  step	  is	  constructing	  plasmids	  containing	  a	  selectable	  marker	   (in	   this	   instance	   histidine)	   and	  wild	   type	   (WT)	  RAD1	   that	   can	   then	   be	  introduced	  into	  rad1Δ	  strains.	  	  	  
6.5.3.1 Preparation	  of	  RAD1	  DNA	  with	  modified	  restriction	  sites	  for	  
cloning	  
	   A	  4058bp	  product	  containing	  RAD1	  and	  500	  nucleotide	  promoter	  region	  was	   amplified	   from	   BY4742	   genomic	   DNA	   template	   by	   PCR	   using	   a	   30-­‐mer	  upstream	  primer,	  modified	   to	   introduce	  a	  proximal	  BamH1	  restriction	  site	  500	  nucleotides	  3’	  of	  the	  ORF,	  and	  36-­‐nucleotide	  primer	  modified	  to	  introduce	  a	  Sal1	  restriction	   site	   5’	   of	   the	   stop	   codon.	   	   The	   primers	   used	   and	   the	   nucleotides	  altered	  to	  introduce	  the	  required	  restriction	  sites	  are	  highlighted	  and	  underlined	  in	  orange	  (BamH1)	  for	  the	  forward	  RAD1-­‐BAMH1-­‐U	  primer	  and	  purple	  (Sal1)	  for	  the	  RAD1-­‐Sal1-­‐L	  reverse	  primer.	  	  PCR	   amplification	   was	   conducted	   using	   the	   high	   fidelity	   Phusion	   DNA	  polymerase	  (NEB)	  and	  PTJ2000	  thermocycler	  using	  the	  following	  programme:	  	   1)	  95°C	   2	  minutes	  2)	  95°C	  	   30	  seconds	  3)	  55°C	   30seconds	  4)	  70°C	   60	  seconds	  5)	  Go	  to	  2	   15	  times	  6)	  70°C	  	   5	  minutes	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The	   resulting	   4085-­‐nucleotide	   PCR	   product	   was	   confirmed	   by	   gel	  electrophoresis	  following	  purification	  with	  PureLink	  PCR	  column	  purification	  kit	  (Invitrogen)	  (figure	  6.9).	  	  
	  
Figure	  6.9:	  Introduction	  of	  restriction	  enzyme	  sites	  into	  RAD1	  The	  4058	  kb	   region	  of	   genomic	  BY4742	  DNA	   is	   indicated	  by	   the	  diagram	   in	  grey,	  with	   the	  forward	   RAD1-­‐BAMH1-­‐U	   primer	   position	   and	   reverse	   RAD1-­‐Sal1-­‐L	   primer	   position	   and	  sequence	   as	   indicated.	   	   The	   nucleotides	   modified	   from	   the	   initial	   RAD1	   sequence	   are	  indicated	   in	   orange	   to	   introduce	   a	   BamH1	   restriction	   site	   proximal	   to	   500bp	   of	   RAD1	   to	  include	   the	  promoter	  region.	   	  The	  reverse	  RAD1-­‐Sal1-­‐L	  primer	   is	  modified	   from	  the	   initial	  
RAD1	  with	   the	  nucleotides	  highlighted	   in	  purple	   to	   introduce	   a	  distal	   Sal1	   restriction	   site,	  approximately	  100bp	  3’	  of	   the	  RAD1	  gene	  (purple	  box).	   	  Following	  PCR	  a	  4058	  bp	  product	  can	  be	  identified	  on	  a	  1%	  TAE	  gel.	  	  	  



















	   300	  
	  
Figure	  6.10:	  Blunt	  end	  ligation	  of	  RAD1	  into	  plasmid	  pJET1.2.	  The	   4058	   bp	   RAD1	   product	   is	   blunt-­‐end	   ligated	   to	   2974	   bp	   pJET1.2	   vector.	   Following	  ligation,	   digestion	  with	   a	   single	   BamH1	   restriction	   enzyme	   results	   in	   a	   7kb	   product	  when	  run	   on	   a	   1%	   TAE	   gel,	   and	   digestion	   with	   both	   BamH1	   and	   Sal1	   returns	   the	   4058	   bp	  fragment	  and	  the	  2974	  bp	  pJET1.2	  vector,	  a	  demonstrated	  by	  the	  gel	  image.	  (pJET1.2	  image	  obtained	  from	  http://www.snapgene.com/resources/plasmid_files/basic_cloning_vectors/pJET1.2/)	  
	  
6.5.3.3 Ligation	  into	  pRS313	  plasmid	  vector	  
	   The	   PCR	   product	   from	   restriction	   digestion	  with	   BamH1	   and	   Sal1	   from	  the	   pJet1.2-­‐RAD1	   plasmid	   was	   isolated	   and	   purified	   by	   gel	   purification.	   	   The	  purified	   product	   was	   subsequently	   ligated	   to	   plasmid	   pRS313	   and	   correct	  ligation	   was	   confirmed	   by	   restriction	   enzyme	   digestion,	   resulting	   in	   two	  products	  of	  the	  appropriate	  size	  (figure	  6.11).	  For	   further	   details	   of	   the	   plasmid	   pRS313	   genes	   and	   sequence	   see	  www.snapgene.com/resources/plasmid_files/yeast_plasmids/pRS313/	  
	  
Blunt(end(liga=on(into(pJET1.2(vector(
(Map and Features of pJET1.2/blunt Cloning Vector
Available with the CloneJET™ PCR Cloning Kit (#K1231, #K1232)
Enzymes produced by Fermentas are shown in orange.







































Genetic elements of the pJET1.2/blunt cloning vector
Element Function Position, bp
rep (pMB1)
Replicon (rep) from the pMBI plasmid is responsible 
for the replication of pJET1.2
1762-1148
Replication start Initiation of the replication 1162 +1 
bla (ApR)
ß-lactamase gene conferring resistance to ampicillin. 








Modifi ed Plac promoter for expression of the eco47IR 
gene at a level suffi cient to provide positive selection
892-769
T7 promoter
T7 RNA polymerase promoter for in vitro transcription 
of the cloned insert
305-324
Multiple cloning site (MCS) Mapping, screening and excision of the cloned insert 422-328
Insertion site Blunt DNA ends for ligation with insert 371-372
Primer binding sites:
pJET1.2 forward sequencing Sequencing of insert, colony PCR 310-332
pJET1.2 reverse sequencing Sequencing of insert, colony PCR 428-405
Enzymes that do not cut pJET1.2/blunt DNA 
AarI, Acc65I, AjiI, AjuI, AlfI, ApaI, BamHI, BclI, BcuI, 
BoxI, BplI, Bpu1102I, BseJI, BshTI, Bsp68I, Bsp119I, 
Bsp120I, Bsp1407I, BspTI, Bst1107I, BstXI, Cfr9I, 
Cfr42I, CpoI, Ecl136II, Eco24I, Eco32I, Eco47III, 
Eco72I, Eco81I, Eco91I, Eco105I, Eco147I, EcoO109I, 
EcoRI, EheI, FspAI, HincII, KpnI, KspAI, MlsI, MluI, 
Mph1103I, NdeI, NheI, OliI, PaeI, PasI, PauI, PdiI, 
Pfl 23II, PfoI, Ppu21I, Psp5II, PsyI, SacI, SalI, SdaI, 
Sfi I, SgfI, SgsI, SmaI, TstI, Van91I, XagI, XcmI, XmaJI.
Primer sequences
Primer Sequence
pJET1.2 Forward Sequencing Primer, 23-mer 5’-CGACTCACTATAGGGAGAGCGGC-3’
pJET1.2 Reverse Sequencing Primer, 24-mer 5’-AAGAACATCGATTTTCCATGGCAG-3’
DNA sequence of MCS region
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Figure	  6.11:	  Insertion	  of	  RAD1	  into	  vector	  pRS313.	  The	  4058	  bp	   fragment	   is	   ligated	   into	   the	  4967	  bp	  plasmid	  pRS313	  at	   the	  BamH1	  and	  Sal1	  restriction	   sites.	   	   To	   confirm	   ligation,	   the	   plasmid	   and	   insert	   can	   be	   identified	   as	   a	   single	  band	  after	  single	  restriction	  enzyme	  digestion	  and	  gel	  electrophoresis	  of	  pRS313-­‐RAD1,	  or	  a	  double	  band	  of	  the	  correct	  sizes	  after	  digestion	  with	  BamH1	  and	  Sal1.	  	  	  (pRS313	  image	  from	  https://www.snapgene.com/resources/plasmid_files/yeast_plasmids/pRS313)	  
	  
6.5.3.4 E.	  coli	  transformation	  by	  pRS313-­‐RAD1	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6.5.3.5 Transformation	  of	  SX46a	  rad1Δby	  pRS313-­‐RAD1	  
	   SX46a	   rad1Δ	   strain	   was	   transformed	   by	   the	   pRS313-­‐RAD1	   plasmid	  following	   the	   TRAFO	   protocol	   ((Gietz	   and	   Woods	   2002)	   and	  http://home.cc.umanitoba.ca/~gietz/method.html).	   	   As	   the	   pRS313	   plasmid	  contains	   a	   selectable	   histidine	   genetic	   marker	   successful	   transformants	   were	  selected	  by	  the	  ability	  of	  colonies	  to	  grow	  on	  histidine	  deficient	  (His-­‐)	  plates	  and	  in	  His-­‐	  growth	  media.	  To	   confirm	   successful	   transformation,	   the	   presence	   of	   RAD1	   DNA	   in	   a	  genomic	   BY4742	   DNA	   control,	   the	   SX46a	   rad1Δ	   pRS313-­‐RAD1	   strain	   and	   the	  absence	  of	  RAD1	  DNA	  in	  the	  SX46a	  rad1Δ	  strain	  is	  demonstrated	  by	  colony	  PCR	  of	  a	  1500	  nucleotide	  product	  of	  the	  central	  section	  of	  RAD1	  in	  Figure	  6.12,	  using	  the	  colony	  PCR	  method	  outlined	  in	  chapter	  2,	  section	  2.3.10	  to	  extract	  DNA,	  and	  the	  primers	  Check-­‐F	  and	  Check-­‐R	  listed	  below	  	  	  Check-­‐F	   	   5’-­‐TCAGGTCAATTGACTCGGTGATGG-­‐3’	  Check-­‐R	   	   5’-­‐GGCTAATCTGTTATTCTGTAATGACCCA-­‐3’	  	  
	  
Figure	  6.12:	  Identification	  of	  the	  presence	  of	  RAD1	  DNA	  using	  colony	  PCR.	  The	   presence	   of	   a	   1500	   base	   pair	   section	   of	   RAD1	   sequence	   can	   be	   identified	   by	   PCR	   of	  BY4742	   genomic	   DNA	   control	   and	   in	   DNA	   from	   the	   newly	   created	   SX46a	   rad1Δ	   pRS313-­‐
RAD1	   strain,	   using	   the	   PCR	   conditions	   described	   in	   chapter	   2,	   section	   2.3.10	   and	   the	  primers	  Check-­‐F	  and	  Check-­‐R	  (see	  appendix	  9).	  	  No	  PCR	  product	  is	  identifiable	  in	  the	  SX46a	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6.5.3.6 Complementation	  of	  UV	  resistance	  of	  rad1Δ 	  strain	  transformed	  by	  
pRS313-­‐RAD1	  	  	   To	   demonstrate	   that	   the	   pRS313-­‐RAD1	   plasmid	   is	   effective	   in	   restoring	  UV	  resistance	  of	   the	  SX46a	  rad1Δ	   strain	   to	  wild-­‐type	   levels,	   these	   three	  strains	  were	  assessed	  using	  a	  UV	  sensitivity	  assay	  (Figure	  6.13).	  	  
The	   UV	   sensitivity	   of	   SX46a	  wildtype	   (WT)	   (black),	   SX46a	   rad1Δ	   (grey)	   and	   SX46a	   rad1Δ	  pRS313-­‐RAD1	  (orange)	  is	  shown	  in	  this	  figure.	  	  Colonies	  of	  WT	  and	  the	  plasmid	  strain	  show	  similar	  UV	  resistance	  whilst	  the	  rad1Δ	  strain	  is	  highly	  UV	  sensitive.	  	  	  
	   As	   can	   be	   seen	   the	   SX46a	   rad1Δ	   pRS313-­‐RAD1	   strain	   UV	   resistance	   is	  complemented	  to	  near	  wildtype	  levels	  by	  the	  transformation	  of	  mutant	  strain	  by	  the	   plasmid	   containing	   RAD1	   sequence	   and	   it’s	   promoters,	   in	   contrast	   to	   the	  extreme	  sensitivity	  of	  the	  SX46a	  rad1Δ	  strain.	  	  	   	  








SX46a rad1D pRS313-RAD1 WT
SX46a rad1D
















Figure	  6.13:	  UV	  sensitivity	  analysis	  of	  yeast	  strains.	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6.5.4 Site	  directed	  mutagenesis	  of	  pRS313-­‐RAD1	  to	  create	  the	  variants	  
Pro469S	  and	  Ser747X	  	  Mutation	  P469S	   (C1406T	   in	  RAD1)	  and	  S747X:	   (A2240T	  and	  T2242A	   in	  
RAD1)	  of	   the	  pRS313-­‐RAD1	  plasmid,	   the	  homologous	  mutations	   in	  RAD1	  to	   the	  P379S	   and	   S613X	   mutations	   in	   XPF,	   was	   introduced	   using	   QuikChange	  Lightening	   Site	   Directed	   Mutagenesis	   Kit,	   using	   the	   manufacturers	   protocol	  (Revision	  B)	  and	  the	  following	  mutagenic	  primers,	  with	  the	  position	  of	  mutated	  bases	  indicated	  in	  red.	  	  P469S-­‐Forward	  	   5’-­‐TTTAGAAGAAAATTCAAAATGGGAACAA-3’	  P469S-­‐Reverse	   5’-­‐TTGTTCCCATTTTGAATTTTCTTCTAAA-3’	  	  S747X	  Forward	   5’-­‐ATGTACTACGGTGAATGAATTGAAGAGCAAAGTCA-3’	  S747X	  Reverse	   5’-­‐TGACTTTGCTCTTCAATTCATTCACCGTAGTACAT-3’	  	  
6.5.4.1 Confirmation	  of	  successful	  RAD1	  mutation	  by	  sequencing	  	   The	   initial	   construct	   pRS313-­‐RAD1,	   and	   the	   two	   variants	   generated	   by	  site	   directed	   mutagenesis	   were	   sequenced	   using	   BigDye	   Terminator	   3.1	  Sequencing	   Kit	   (LifeTechnologies).	   	   Sequencing	   reactions	   were	   conducted	  through	  Cardiff	  University	  School	  of	  Medicine	  Central	  Biotechnology	  Service.	  	  	  In	   addition,	   to	   exclude	   the	   generation	   of	   inadvertent	   mutations	   in	   the	  plasmid	   RAD1	   and	   promoter	   sequence	   through	   site	   directed	   mutagenesis,	  sequential	   primers	   were	   used	   to	   generate	   700bp	   fragments	   to	   fully	   cover	   the	  cloned	   gene,	   promoters	   and	   downstream	   regions.	   The	   sequence,	   priming	   site	  and	  orientation	  of	  each	  primer	  used	  in	  the	  experiment	  are	  listed	  in	  appendix	  9.	  Sequencing	   information	   was	   viewed	   using	   4Peaks	  (http://4peaks.en.softonic.com/mac)	  and	  multiple	  sequences	   from	  each	  primer	  were	   assembled	   using	   DNA	   Baser	   V	   3.5.3	   (http://www.dnabaser.com),	  confirming	  only	  the	  desired	  mutations	  had	  been	  introduced.	  	  The	  data	  from	  this	  sequencing	  experiment	  and	  assembly	  is	  included	  in	  the	  electronic	  appendix	  9.	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6.5.4.2 Transformation	  of	  E.	  coli,	  plasmid	  amplification,	  extraction	  and	  
purification	  
	   	  DH5α	   E.	   coli	   (Invitrogen)	   were	   transformed	   with	   the	   pRS313-­‐RAD1-­‐P469S	  and	  pRS313-­‐RAD1-­‐S747X	  plasmids	  following	  the	  manufacturers	  standard	  protocol,	  and	  grown	  overnight	  at	  37°C	  in	  a	  rotatory	  incubator	  at	  180	  rpm	  prior	  to	   plasmid	   extraction	   using	   PureLink	   Quick	   Plasmid	  MiniPrep	   Kit	   (Invitrogen)	  plasmid	  using	  the	  manufacturers	  standard	  protocol.	  	  
6.5.4.3 Transformation	  of	  SX46a	  rad1Δ 	  by	  mutant	  pRS313-­‐RAD1	  plasmids	  	  
	   Following	   confirmation	   of	   appropriate	   mutation	   through	   sequencing	   of	  the	   entire	   promoter	   and	   RAD1	   gene,	   the	   yeast	   strain	   SX46a	   Δrad1	   was	  transformed	  with	  both	  mutated	  plasmids	   in	   two	  experiments	  using	   the	  TRAFO	  protocol	   ((Gietz	   and	   Woods	   2002)	   and	  http://home.cc.umanitoba.ca/~gietz/method.html).	   	   Selective	   His-­‐	   media	   and	  plates	  were	  used	   for	   selection	  of	   transformed	  colonies.	   	  Again,	   the	  presence	  of	  
RAD1	  was	  confirmed	  by	  colony	  PCR	  using	  CHECK-­‐F	  and	  CHECK-­‐R	  primers	  (see	  6.5.3.6),	   and	   by	   sequencing	   of	   the	   colony	   PCR	   product	   to	   ensure	   the	   desired	  mutation	  was	  in	  situ	  and	  in	  the	  correctly	  labelled	  strain.	  
	  
	  
6.5.4.3.1 Confirmation	  of	  transformation	  and	  of	  appropriate	  pRS313-­‐RAD1	  
plasmid	  copy	  number	  	  Successfully	   grown	   colonies	   were	   grown	   in	   His-­‐	   media,	   and	   DNA	   was	  subsequently	   extracted	   using	   a	   phenol/chloroform	   extraction	   protocol	   (see	  Chapter	  2,	   Section	  2.3.11).	   	   PCR	  of	  DNA	   from	  each	   strain	  was	   conducted	  using	  primers	   for	   RAD1	   and	   primers	   for	   RAD16	   as	   a	   control	   to	   examine	   for	   the	  presence	  of	  RAD1	  DNA,	  using	   the	  protocol	  and	  primers	  described	   in	  chapter	  2,	  section	  2.3.10.	   	  The	  PCR	  products	  were	   resolved	  by	  gel	   electrophoresis	   (figure	  6.14).	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   The	   pRS313	   series	   of	   plasmid	   vectors	   are	   centromeric,	   and	   should	   be	  maintained	   at	   a	   single	   copy	   number	   per	   cell	   following	   transformation	   (Clarke	  and	   Carbon	   1980;	   Sikorski	   and	  Hieter	   1989).	   	   	   To	   confirm	   this	   and	   ensure	   no	  differential	  in	  RAD1	  gene	  dosing	  is	  present	  that	  could	  affect	  subsequent	  results,	  the	  relative	  amount	  of	  RAD1	  DNA	  per	  strain	  was	  quantified	  using	  qPCR	  following	  the	  protocol	   in	  chapter	  2,	  section	  2.3.12,	  and	  normalised	  to	  the	  actin	  gene	  DNA	  content	  in	  each	  sample.	  	  The	  results	  are	  shown	  in	  figure	  6.15.	  	  The	  primers	  used	  were	  as	  follows:	  	  RAD1	  Forward	   5’-­‐AAATGCCGCAAACGATTCAA-­‐3’	  RAD1	  Reverse	   5’-­‐CAAATCCTTCACTATGGCCTTA-­‐3’	  ACT1	  Forward             5’-­‐GTTTGGAATCTGCCGGTATT-­‐3’	  ACT1	  Reverse	  	   5’-­‐TACCACCGGACATAACGATG-­‐3’	  	  
	  
Figure	  6.15:	  The	  relative	  amount	  of	  RAD1	  DNA	  quantified	  by	  qPCR	  in	  each	  strain	  used	  in	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These	  results	  conform	  the	  successful	  transformation	  of	  the	  SX46a	  rad1Δ	  strain	   by	   each	   plasmid	   (the	  wildtype	  RAD1	  and	   both	  mutated	  RAD1	  plasmids)	  and	   the	   retention	   of	   a	   single	   copy	   of	   each	   plasmid	   per	   cell.	   	   The	   data	   also	  confirms	   that	   RAD1	   is	   undetectable	   in	   the	   pre-­‐transformation	   SX46a	   rad1Δ	  strain.	  	  	  	  
6.5.4.4 Determining	  the	  effect	  of	  RAD1	  mutations	  and	  plasmid	  
transformation	  on	  cell	  growth	  	  To	  determine	  the	  effect	  of	  the	  addition	  of	  the	  plasmid	  with	  a	  wild	  type	  or	  mutated	  RAD1	  gene	  on	  the	  growth	  of	  cells	  in	  media,	  the	  average	  growth	  rate	  of	  the	   strains	  was	  measured	   by	   spectrometry.	   	   To	  maintain	   selective	   pressure	   to	  ensure	   the	   continued	   presence	   of	   the	   pRS313-­‐RAD1	  plasmid	   the	   transformed	  strains	   are	   required	   to	   be	   grown	   in	   selective	   dropout	   media.	   	   This	   contains	  containing	   all	   of	   the	   necessary	   nutrients	   and	   amino	   acids	   required	   for	   cell	  growth	   except	   histidine.	   	   The	   SX46a	   wildtype	   and	   SX46a	   rad1Δ	   strains	   are	  unable	  to	  grow	  in	  histidine	  deficient	  selective	  growth	  media	  so	  are	  not	  directly	  compared	  with	  the	  plasmid	  containing	  strains	  in	  this	  experiment.	  Briefly,	  the	  growth	  rate	  was	  calculated	  by	  growing	  cells	  to	  log	  phase	  and	  diluting	   to	   an	   OD600	   of	   0.5,	   calculated	   using	   a	   spectrophotometer	   (Thermo	  Scientific	  Evolution	  600	  UV-­‐Vis	  Spectrophotometer).	  	  Subsequent	  hourly	  changes	  in	   OD600	   were	   measured	   over	   the	   following	   6	   hours	   in	   three	   independent	  experiments	  and	  the	  mean	  change	  in	  OD600	  is	  shown	  below	  (Figure	  6.16).	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Figure	  6.16:	  The	  growth	  rate	  of	  each	  strain	  containing	  a	  histidine	  selectable	  plasmid	  and	  
grown	  in	  his-­‐	  selective	  media.	  	  	  	  The	   OD600	   is	   calculated	   hourly	   and	   the	   data	   adjusted	   to	   show	   an	   increase	   in	   OD	   from	   a	  staring	   value.	   	   The	   mean	   and	   95%	   confidence	   intervals	   calculated	   from	   4	   independent	  repeat	   experiments	   are	   shown.	   	   In	   the	   right	   lower	   inset	   box	   the	  mean	   hourly	   increase	   in	  OD600	   is	  displayed	  with	   the	  95%	  confidence	   intervals	   (CI)	   for	  each	  strain,	  as	   indicated	  by	  colour	  with	  reference	  to	  the	  legend.	  	  
	   As	  can	  be	  seen,	  the	  growth	  rate	  is	  identical	  in	  all	  three	  strains,	  indicating	  the	   presence	   of	   the	   plasmid,	   and	   the	   additional	   RAD1	   mutations,	   has	   no	  significant	  effect	  on	  the	  health	  of	  these	  strains	  in	  standard	  growth	  conditions.	  
	  
6.5.4.5 Summary	  of	  experiments	  to	  validate	  the	  pRS313-­‐RAD1	  model	  	  	  To	   complete	   the	   validation	   of	   the	   model	   system	   constructed	   in	   these	  experiments,	  ideally	  protein	  levels	  of	  each	  plasmid	  strain	  would	  be	  confirmed	  by	  western	   blotting.	   	  However,	   no	   specific	   antibody	   to	  RAD1	   is	   available	   to	   allow	  this	   quantification	   –	   only	   non-­‐specific	   products	   are	   seen	   with	   the	   two	  commercially	   available	   S.	   cerevisiae	  RAD1	  antibodies	   (data	  not	   shown).	   	   In	   the	  absence	  of	  data	  on	  RAD1	  protein	   levels,	   the	  sequencing	  and	  qPCR	  experiments	  described	   above	   demonstrate	   that	   the	   RAD1	   gene	   and	   promoters	   are	   present	  with	  the	  same	  sequence	  and	  with	  one	  copy	  of	  promoter	  and	  RAD1	  gene	  per	  cell	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in	   each	   strain.	   	   Crucially,	   the	   transformation	   of	   SX46a	   rad1Δ	   strain	   with	   the	  pRS313-­‐RAD1	  plasmid	  results	  in	  complementation	  of	  UV	  resistance	  to	  near	  wild-­‐type	   levels,	   which	   is	   strong	   evidence	   that	   the	   plasmid	   model	   system,	   as	  constructed,	   is	   robust.	   	   The	   only	   difference	   identified	   in	   these	   experiments	  between	   each	   of	   the	   three	   strains	   containing	   the	   pRS313-­‐RAD1	   plasmid	   is	   a	  single	   nucleotide	   in	   the	   P469S	   variant	   and	   two	   nucleotides	   in	   the	   Ser747X	  variant.	  	  Experiments	  to	  determine	  the	  functional	  effect	  of	  these	  point	  mutations	  will	  be	  the	  focus	  of	  the	  following	  section.	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 Determination	  of	  UV	  phenotype	  of	  newly	  created	  RAD1	  yeast	  strains	  6.6
	   Exposure	   of	   cells	   to	   ultraviolet	   irradiation	   results	   in	   the	   formation	   of	  cyclobutane-­‐pyrimidine	   dimers	   (CPDs)	   in	   DNA,	   which	   are	   repaired	   by	   NER.	  	  Hence,	  assessment	  of	  colony	  survival	  following	  DNA	  damage	  induction	  with	  UV	  radiation	  can	  serve	  as	  a	  marker	  of	  the	  strains	  ability	  to	  repair	  DNA	  damage,	  and	  so	  act	  as	  a	  measure	  of	  NER	  efficiency.	  The	   UV	   sensitivity	   of	   the	   five	   strains	   was	   assessed	   using	   the	   method	  outlined	  in	  chapter	  2,	  section	  2.4.1.	  	  Briefly,	  a	  fixed	  number	  of	  cells	  were	  spread	  evenly	  on	  agar	  plates	  prior	  to	  being	  irradiated	  with	  UV-­‐C	  radiation	  at	  a	  dose	  of	  between	  1	  and	  160	  J/m2.	   	  After	  incubation	  at	  30°C	  in	  the	  dark	  for	  72	  hours	  the	  visible	   colonies	   formed	  on	  each	  plate	  were	   counted.	   	   In	   an	  untreated	  plate	   the	  plating	  efficiency	  is	  typically	  100%	  with	  this	  type	  of	  experiment	  in	  S.	  cerevisiae,	  but	   to	  account	   for	  any	  variation	   in	  cell	   counts	   in	  biological	   repeat	  experiments	  the	  results	  were	  normalised	  against	   the	  average	  number	  of	  colonies	   formed	  on	  the	  untreated	  plate.	  	  Each	  experiment	  was	  conducted	  in	  triplicate	  and	  the	  mean	  result	  was	  used,	  and	  experiments	  were	  repeated	  on	  three	  independent	  biological	  repeats	  (figure	  6.17).	  	  	  
	  
	  
Figure	  6.17:	  The	  results	  of	  UV	  irradiation	  colony	  survival	  assay.	  	  	  The	  average	  number	  of	  visible	  colonies	  formed	  72	  hours	  after	  UV	  irradiation	  of	  a	  standard	  number	   of	   cells	   per	   plate,	   normalised	   to	   the	   average	   of	   the	   untreated	   plate	   is	   shown.	   	   All	  experiments	  were	   conducted	   in	   triplicate	   and	   in	   four	   independent	  biological	   repeats.	   	  The	  mean	  and	  SEM	  is	  displayed	  by	  the	  error	  bars.	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   The	  results	  of	  this	  UV	  survival	  assay	  demonstrate	  slightly	  lower	  levels,	  of	  survival	  for	  each	  dose	  of	  UV	  irradiation	  in	  the	  mutant	  RAD1	  strain	  SX46a	  rad1Δ	  pRS313-­‐RAD1-­‐P469S	   compared	   to	   the	   RAD1	   wildtype	   strain	   SX46a	   rad1Δ	  pRS313-­‐RAD1.	  This	  demonstrates	  that	  the	  mutation	  results	  in	  an	  increase	  in	  UV	  sensitivity,	  possibly	  due	  to	  impaired	  NER	  capacity	  in	  this	  point	  mutant	  strain.	  The	  stopgain	  mutant	  Ser747X	  demonstrates	  extreme	  UV	  sensitivity,	  with	  identical	  levels	  of	  colony	  formation	  following	  UV	  irradiation	  to	  the	  SX46a	  rad1Δ	  strain,	   indicating	   that	   NER	   is	   not	   functional	   in	   this	   mutant	   strain,	   despite	   the	  presence	  of	  the	  gene	  and	  promoters	  as	  previously	  demonstrated	  by	  sequencing,	  colony	  PCR	  and	  qPCR.	  	  This	  result	  is	  consistent	  with	  the	  hypothesis	  that	  the	  stop-­‐gain	  mutant	  should	  produce	  a	  non-­‐functional	  RAD1	  protein,	  and	  is	  as	  sensitive,	  and	  hence	  as	  deficient	  in	  NER,	  as	  a	  strain	  completely	  lacking	  the	  RAD1	  gene.	  
	  
6.6.1 Measurement	  of	  UV	  induced	  DNA	  damage	  and	  repair	  capacity	  using	  
an	  immuno-­‐slotblot	  assay	  	   To	   demonstrate	   if	   a	   difference	   in	   UV	   induced	   CPD	   damage	   and	   repair	  occurs	   in	   strains	   an	   experiment	   was	   conducted	   using	   an	   immuno-­‐slotblot	  method	  to	  measure	  CPD	  damage	  and	  repair	  rates.	  	  For	  details	  of	  the	  method	  see	  chapter	   2,	   section	   2.4.2-­‐2.4.3.	   	   Briefly,	   cells	   were	   grown	   to	   log	   phase	   and	  centrifuged	  and	  re-­‐suspended	  in	  PBS.	  	  The	  suspension	  was	  irradiated	  with	  UV	  at	  a	  dose	  of	  50J/m2,,	  chosen	  as	  this	  was	  the	  UV	  radiation	  dose	  which	  resulted	  in	  the	  greatest	   difference	   in	   survival	   between	   the	  wildtype	   and	   P469S	  mutant	   in	   the	  previous	  study	  (figure	  6.17)	  .	  	  Following	  irradiation	  cells	  were	  suspended	  in	  YPD	  medium	  and	  either	  harvested	   immediately	  or	  allowed	   to	   repair	   for	  one	  or	   two	  hours,	  before	  cells	  were	  chilled	  to	  4°C	  to	  prevent	  further	  enzymatic	  activity	  and	  DNA	  was	  subsequently	  extracted.	  For	   each	   experimental	   condition	   DNA	  was	   transferred	   to	   a	   GeneScreen	  Plus	   Hybridisation	   transfer	   membrane	   using	   Bio-­‐Dot	   SF	   Microfiltration	  equipment.	   	   The	   level	   of	   UV	   damage	   was	   measured	   using	   an	   antibody	   raised	  against	   CPDs	   and	   probed	   using	   an	   alkaline	   phosphatase	   linked	   secondary	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antibody.	   	   The	   binding	   of	   secondary	   antibody	  was	   detected	  with	   an	   enhanced	  chemi-­‐fluorescent	   (ECF)	  dye	  and	  developed	  on	  a	  Typhoon	  TRIO	  Variable	  Mode	  imager	  (Amersham	  Biosciences).	  	  The	  relative	  band	  intensity	  is	  calculated	  using	  Image	   J	   (http://imagej.nih.gov/ij/).	   	   An	   example	   figure	   of	   the	   immuno-­‐slotblot	  output	  (figure	  6.18)	  and	  the	  results	  of	  UV	  DNA	  damage	  and	  repair	  in	  each	  strain	  from	  the	  average	  independent	  experiments	  are	  shown	  in	  figure	  6.19.	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Figure	  6.19:	  Combined	  result	  of	  several	  UV	  immuno-­‐slotblot	  experiments.	  Combined	  result	  from	  UV	  immuno-­‐slotblot	  experiments	  on	  the	  yeast	  strains	  indicated	  in	  the	  legend,	   demonstrating	   changes	   in	   CPD-­‐DNA	   adduct	   levels	   detectible	   during	   a	   120-­‐minute	  period	  after	  UV	  radiation	  exposure.	   	  Data	  points	  are	  from	  1-­‐3	  independent	  repeats	  and	  the	  mean	  and	  standard	  error	  is	  shown.	  	  The	  results	  (figure	  6.19)	  demonstrate	  a	  typical	   immuno-­‐slotblot	  readout	  from	  experiments	  on	  each	  strain	  as	  indicated.	  High	  levels	  of	  damage	  are	  present	  and	   can	   be	   detected	   immediately	   after	   UV	   exposure	   (0	   minutes).	   	   The	   band	  intensity	   decreases	   with	   increasing	   repair	   time	   in	   the	   left-­‐	   hand	   and	   central	  panels.	  	  At	  120	  minutes	  the	  band	  is	  less	  intense	  in	  the	  left-­‐hand	  panel,	  the	  SX4a	  
rad1Δ	  pRS313-­‐RAD1	  wildtype	  strain,	  compared	  to	  the	  central	  panel	  showing	  the	  SX4a	  rad1Δ	  pRS313-­‐RAD1-­‐P469S	  strain.	   	  This	   is	  evidence	   that	   the	  P469S	  point	  mutation	  reduces	  the	  NER	  capacity	  of	  the	  strain.	  	  The	  right-­‐hand	  panel	  shows	  the	  S747X	  mutant	  strain	  and	  the	  band	  intensity	  is	  similar	  at	  all	  time	  points	  post	  UV	  exposure,	  indicating	  that	  no	  CPD	  repair	  is	  occurring	  in	  this	  strain	  over	  the	  period	  studied	  in	  this	  example.	   	   	  This	  is	  evidence	  of	  a	  complete	  loss	  of	  NER	  capacity	  in	  this	  mutant	  strain.	  This	   experiment	   was	   conducted	   in	   a	   number	   of	   independent	   biological	  repeats	  (for	  raw	  datasets	  see	  the	  accompanying	  electronic	  appendix).	  	  The	  result	  of	  each	  experiment	  is	  combined	  to	  show	  the	  mean	  (and	  SEM)	  percentage	  of	  CPDs	  remaining	  at	  each	  time	  point	  for	  the	  strains	  in	  figure	  6.20,	  normalised	  to	  the	  CPD	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adducts	  present	  immediately	  after	  exposure.	   	  Clearly,	  the	  stop-­‐gain	  mutant	  fails	  to	   repair	  DNA	  damage	  over	   the	   time	  course	  of	   the	  experiment,	   and	   the	   rate	  of	  DNA	  repair	  is	  lower	  in	  the	  P469S	  mutant	  than	  the	  wildtype	  strains.	   	  The	  SX46a	  (black)	   and	   SX46a	   rad1Δ	   pRS313-­‐RAD1	  wildtype	   (grey)	   strains	   show	   identical	  levels	   of	   CPD	   repair,	  which	   is	   further	   evidence	   that	   the	  model	   plasmid	   system	  constructed	  here	  is	  valid.	  	  	   These	  results	  are	  consistent	  with	  the	  UV	  survival	  result	  (Figure	  6.17)	  and	  together	   these	   experiments	   demonstrate	   that	   the	   P469S	  mutant	   has	   impaired	  levels	   of	   NER	   compared	   the	   wild-­‐type	   RAD1	   strains,	   resulting	   in	   impaired	  survival	   after	  UV	   treatment.	   	   The	   stopgain	   S747X	  mutant	   shows	   no	   significant	  DNA	   repair	   after	   two	   hours,	   corresponding	   to	   the	   extreme	   UV	   sensitivity	  phenotype	  demonstrated	  by	  the	  survival	  assay.	  	   These	   results	   reflect	   the	   UV	   induced	   of	   NER	   capacity	   of	   the	   strains	  examined.	  	  The	  next	  phase	  of	  this	  study	  is	  to	  test	  the	  strains	  following	  oxaliplatin	  treatment	  to	  assess	  the	  effect	  of	  this	  drug	  on	  NER.	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 Determination	  of	  oxaliplatin	  phenotype	  of	  newly	  created	  RAD1	  yeast	  6.7
strains	  	   In	   the	   previous	   section,	   6.6,	   the	   UV	   treatment	   of	   yeast	   cells	   was	   easily	  accomplished	  using	  a	  brief	  exposure	  to	  UV	  light	  and	  returning	  the	  cells	  to	  growth	  media	  or	  plates	  to	  measure	  the	  effect	  on	  colony	  forming	  ability	  of	  the	  strains.	  	  A	  short	  exposure	  to	  UV	  radiation	  is	  sufficient	  to	  rapidly	  induce	  DNA	  adducts.	  	  The	  treatment	  with	  chemical	  agents	  is	  more	  complex	  for	  several	  reasons.	   	  Chemical	  agents	  are	  used	  in	  solution,	  and	  the	  effect	  of	  the	  solution	  on	  the	  cell	  phenotype	  and	  on	  the	  drug	  efficacy	  must	  be	  determined.	  	  Oxaliplatin	  also	  forms	  di-­‐adducts	  over	  many	  hours	  after	  drug	  exposure,	   so	   for	  a	  period	  after	   treatment	  both	   the	  formation	   and	   removal	   of	   adducts	   will	   be	   occurring	   simultaneously.	   	   This	  complicates	   the	  measurement	   of	   adduct	   levels,	   and	  data	   generated	  during	   this	  ill-­‐defined	  period	  is	  more	  difficult	  to	  interpret	  compared	  to	  the	  measurement	  of	  UV	  induced	  DNA	  adducts.	  In	   order	   to	   determine	   the	   conditions	   for	   treating	   yeast	  with	   oxaliplatin	  experiments	  to	  establish	  treatment	  parameters	  that	  result	  differential	  sensitivity	  of	   the	   strains	   to	   oxaliplatin	  were	   conducted.	   	   In	   the	   first	   instance,	   this	  was	   by	  measuring	   the	  effect	  of	  adding	  different	  doses	  of	  drug	   to	   the	  growth	  of	  cells	   in	  standard	   histidine	   deficient	   selective	   yeast	   culture	   media.	   	   Logarithmically	  growing	  cells	  growing	  at	   the	  same	  rate	  (a	  doubling	  time	  of	  1	  hour	  50	  minutes)	  were	  diluted	  to	  OD600	  0.8	  and	  concentrated	  oxaliplatin	  was	  added	  at	  several	  dose	  levels.	  	  The	  OD600	  was	  measured	  hourly	  in	  each	  strain	  over	  the	  following	  8	  hours.	  The	  effects	  of	  the	  addition	  of	  oxaliplatin	  to	  the	  growth	  of	  SX46a	  rad1Δ	  pRS313-­‐RAD1,	  and	  the	  P469S	  and	  S747X	  mutants	  can	  be	  seen	  in	  figure	  6.20.	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Figure	  6.20:	  The	  effect	  of	  the	  addition	  of	  oxaliplatin	  on	  yeast	  growth	  rates.	  This	  figure	  shows	  the	  effect	  of	  the	  addition	  of	  oxaliplatin	  to	  a	  final	  concentration	  of	  100µM,	  500µM	   and	   1mM	   to	   cells	   growing	   for	   90	   minutes	   in	   selective	   histidine	   deficient	   growth	  media.	   	   The	   addition	   of	   the	   drug	   indicated	   by	   a	   red	   arrow.	   	   Each	   strain	   is	   shown	   in	   a	  separate	  figure	  (A-­‐C)	  and	  all	  strains	  are	  displayed	  in	  figure	  D	  to	  allow	  comparison	  	  	  	   These	   results	   indicate	   that	   the	   doses	   of	   oxaliplatin	   used	   in	   this	  experiment	   have	   no	   effect	   on	   the	   rate	   of	   growth	   in	   the	   6	   hours	   following	  administration,	   under	   these	   treatment	   conditions.	   	   It	   may	   be	   that	   the	   media	  neutralises	   the	   oxaliplatin;	   plasma	   proteins	   bind	   oxaliplatin	   irreversibly	   when	  administered	   to	   patients	   (as	   discussed	   in	   chapter	   1,	   section	   1.2.1),	   and	   the	  protein	  rich	  media	  used	  for	  yeast	  growth	  may	  sequester	  some	  of	  the	  oxaliplatin,	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making	   the	   effective	   dose	   lower.	   	   It	   also	   may	   take	   several	   hours	   from	   the	  addition	   of	   oxaliplatin	   to	   the	   growth	  media	   for	   oxaliplatin-­‐DNA	  mono-­‐adducts	  and	   subsequent	   di-­‐adducts	   to	   form,	   and	   for	   the	   cell	   to	   mount	   a	   DNA	   damage	  response.	   	   It	   could	   also	   be	   that	   the	   doses	   used	   are	   insufficient,	   although	   the	  strains	  in	  this	  experiment	  are	  exposed	  to	  oxaliplatin	  doses	  that	  are	  30-­‐300	  fold	  more	  than	  are	  used	  during	  chemotherapy	  in	  humans.	  
	  
6.7.1 Modification	  of	  treatment	  conditions:	  Incubation	  of	  cells	  with	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Figure	  6.21:	  	  The	  effect	  of	  prior	  oxaliplatin/PBS	  incubation	  on	  yeast	  strain	  growth	  rates.	  Each	   strain	   is	   exposed	   to	   increasing	   doses	   of	   oxaliplatin	   suspended	   in	   PBS	   for	   3	   hours	  before	  washing	  and	  incubation	  in	  growth	  media.	   	  The	  increase	  in	  OD600	  over	  the	  12	  hours	  following	  drug	  exposure	  is	  displayed	  in	  each	  panel	  (A	  to	  C),	  normalised	  to	  the	  initial	  staring	  OD600	  and	  adjusted	  to	  0	  at	   t=0.	  The	  mean	  of	   three	   independent	  biological	  repeats	  and	  the	  standard	  error	  is	  shown.	  	   Figure	  6.21	  shows	  the	  effect	  of	  oxaliplatin	  on	  each	  of	   the	  three	  plasmid-­‐containing	  strains.	  	  As	  can	  be	  seen	  in	  the	  results,	  each	  untreated	  strain	  grows	  at	  a	  constant	   rate	   of	   0.28	   OD600	   per	   hour	   (a	   doubling	   time	   of	   1	   hour	   50	  minutes),	  indicating	  that	  the	  incubation	  for	  three	  hours	  in	  PBS	  has	  had	  no	  adverse	  effect	  on	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growth	  characteristics.	   	   In	  each	  of	   the	   three	  strains	   the	  effect	  on	  growth	  of	   the	  addition	  of	  increasing	  doses	  of	  oxaliplatin	  can	  be	  seen.	  	  A	  sequential	  decrease	  in	  growth	  rate	  with	  increasing	  exposure	  to	  oxaliplatin	  occurs	  and	  is	  more	  marked	  in	  the	  S747X	  mutant	  than	  the	  wildtype	  and	  P493S	  mutant.	  To	  allow	  and	  easier	  visual	  comparison	  of	  the	  effect	  of	  oxaliplatin	  exposure	  between	   the	   three	   strains	   the	   same	   result	   is	  displayed	  plotted	  by	  dose	   (Figure	  6.22).	  	  	  
	  
Figure	  6.22:	  The	  results	  from	  figure	  6.21	  displayed	  by	  dose	  rather	  than	  by	  strain.	  This	  is	  to	  allow	  comparison	  of	  the	  effect	  of	  the	  addition	  of	  oxaliplatin	  between	  strains.	  	  Each	  panel	   (A	   to	  D)	   displayed	   the	   effect	   on	   subsequent	   growth	  of	   an	   increased	   exposure	   of	   the	  strains	  to	  oxaliplatin.	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At	  each	  dose	  level	  (A	  to	  D)	  the	  relative	  effect	  of	  oxaliplatin	  on	  the	  growth	  between	  each	  strain	  is	  evident.	  	  In	  the	  untreated	  samples	  (A)	  the	  growth	  rate	  is	  identical	  at	  a	  0.28	  increase	  in	  OD600	  per	  hour,	  corresponding	  to	  a	  doubling	  time	  of	  1	  hour	  50	  minutes.	   	  This	   indicates	   that	  a	  3-­‐hour	   incubation	   in	  PBS	  does	  not	  have	  a	  detrimental	  effect	  on	  cell	   growth	   rate	  –	  when	  retuned	   to	  growth	  media	  the	   cells	   immediately	   begin	   to	   grow	   at	   the	   rate	   at	   which	   they	   were	   growing	  before	  the	  PBS	  incubation.	  	  	  With	  exposure	   to	   increasing	  doses	  of	  oxaliplatin	   the	   inhibition	  of	   future	  cell	   growth	   is	   identical	   between	   the	   wildtype	   and	   P469S	   mutant	   plasmid	  containing	  strains,	  although	  at	  the	  5mM	  dose	  level	  a	  slight	  trend	  towards	  a	  lower	  growth	  rate	  is	  seen	  in	  the	  P469S	  mutant	  strain.	   	  The	  effect	  of	  oxaliplatin	  on	  the	  stopgain	  S747X	  mutant	  at	  each	  dose	  level	  is	  much	  greater,	  with	  no	  evidence	  of	  an	  increase	  in	  cell	  growth	  at	  5mM	  in	  the	  12	  hours	  following	  oxaliplatin	  exposure.	  	  This	  result,	  using	  these	  specific	  oxaliplatin	  treatment	  parameters,	  clearly	  demonstrates	  an	  effect	  of	  oxaliplatin	  exposure	  on	   the	   three	  plasmid-­‐containing	  strains,	  and	  that	  this	  effect	   is	  greater	  in	  the	  S747X	  variant	  than	  the	  wildtype	  or	  P469S	  variant.	   	   It	   is,	  however,	  not	   clear	   from	   this	   result	   exactly	  what	   this	  data	  represents.	   	   The	   assay	  measures	   the	   change	   in	   optical	   density	   of	   1ml	   volume	  sample	   of	   yeast	   cells,	   a	   robust	   and	  widely	   used	   proxy	   for	   the	   number	   of	   cells	  present	  in	  the	  sample	  (Myers	  et	  al.	  2013).	   	  Over	  time	  after	  oxaliplatin	  exposure	  the	  optical	  density	  increases,	  and	  increases	  at	  a	  slower	  rate	  with	  higher	  doses	  of	  drug.	   	  This	  could	  reflect	  the	  action	  of	  oxaliplatin	  on	  all	  of	  the	  cells	  in	  the	  media,	  for	  example	  an	  inhibitory	  effect	  on	  cell	  division	  following	  platinum-­‐DNA	  adduct	  formation.	  	  It	  could	  also	  reflect	  the	  survival	  of	  a	  specific	  proportion	  of	  cells	  after	  drug	  exposure,	  and	  this	  population	  goes	  on	  to	  result	  in	  the	  detected	  increases	  in	  optical	  density	  following	  oxaliplatin	  exposure.	  	  
	  
	   The	   treatment	   parameters	   established	   here	   result	   in	   detectible	  differences	   between	   strain	   phenotypes	   and	   will	   therefore	   be	   used	   in	   an	  alternative	  assay	  to	  measure	  cell	  survival	  following	  oxaliplatin	  exposure.	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6.7.2 Measuring	  survival	  following	  exposure	  of	  plasmid-­‐containing	  yeast	  
strains	  to	  oxaliplatin	  
	   An	  alternative	  survival	  assay	  was	  conducted	  using	  a	  similar	  method	  to	  the	  UV	   survival	   assay	   outlined	   above	   (6.5.1)	   and	   using	   the	   method	   described	   in	  chapter	   2,	   section	   2.4.6.	   	   Briefly,	   cells	   growing	   in	   log	   phase	  were	  washed,	   and	  subsequently	   incubated	   in	   PBS	   containing	   increasing	   doses	   of	   oxaliplatin	   for	   3	  hours	  at	  30°C	  with	  rotation	  at	  180	  rpm.	  	  Following	  treatment,	  cells	  were	  washed	  twice	   and	   re-­‐suspended	   in	   PBS,	   and	   serially	   diluted.	   	   200	   cells	   per	   plate	  were	  plated	   in	   triplicate	   onto	   agar	   plates	   and	  were	   incubated	   for	   72	   hours	   at	   30°C.	  	  The	  number	  of	  visible	  colonies	  on	  each	  plate	  was	  counted	  and	  normalised	  to	  the	  average	  number	  of	  cells	  on	  the	  untreated	  plates.	  	  The	  experiment	  was	  conducted	  on	  3	  independent	  occasions	  and	  the	  results	  are	  shown	  below	  (Figure	  6.23).	  	  
	  
Figure	  6.23:	  An	  oxaliplatin	  survival	  assay.	  	  Colonies	   formed	  72	  hours	   following	   oxaliplatin	   exposure	  were	   counted	   and	  normalised	   to	  the	  average	  of	  the	  untreated	  plate.	  	  Experiments	  were	  conducted	  in	  triplicate	  and	  on	  3	  or	  4	  independent	  occasions.	  	  The	  mean	  and	  SEM	  is	  shown.	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   The	  results	  of	  this	  experiment	  in	  figure	  6.24	  demonstrate	  a	  difference	  in	  survival	   following	   oxaliplatin	   exposure	   in	   all	   3	   plasmid-­‐containing	   strains.	  	  Firstly,	   the	   survival	   in	   the	   SX46a	   wildtype	   and	   SX46a	   rad1Δ	   pRS313-­‐RAD1	  wildtype	  is	  the	  same,	  again	  supporting	  the	  validity	  of	  the	  model.	  	   Following	  exposure	   to	  oxaliplatin	   the	  P469S	  point	  mutation	   results	   in	   a	  decrease	   in	   survival	   compared	   to	  wildtype,	   and	   the	   S747X	   variant	   results	   in	   a	  much	  lower	  survival,	  similar	  to	  the	  SX46a	  rad1Δ	  strain	  with	  complete	  absence	  of	  the	  RAD1	  gene.	  	  	  	  
 Discussion	  and	  Conclusions	  6.8	   Oxaliplatin	   induced	   peripheral	   neuropathy	   is	   a	   severe	   side	   effect	   of	  oxaliplatin	  chemotherapy	  treatment	  that	  can	  result	   in	   long-­‐term	  numbness	  and	  painful	   paraesthesia	   in	   patients	   often	   cured	   of	   their	   malignant	   disease.	   	   At	  moderate	  doses	  the	  development	  of	  OIPN	  is	  idiosyncratic,	  and	  to-­‐date	  there	  is	  no	  way	   of	   stratifying	   patients	   for	   the	   risk	   of	   developing	   this	   toxicity.	   	   It	   is	   made	  more	  of	  an	  issue	  by	  the	  lack	  of	  any	  effective	  treatment	  and	  by	  the	  persistence	  or,	  at	   best,	   slow	   resolution	   of	   symptoms	   over	  many	   years	   (Argyriou	   et	   al.	   2014).	  	  When	  oxaliplatin	  is	  used	  in	  the	  adjuvant	  setting,	  in	  over	  10,000,	  patients	  per	  year	  in	  the	  UK,	  the	  benefit	  is	  in	  the	  order	  of	  5%	  to	  10%	  improvement	  in	  cure	  rate	  (i.e.	  a	  number-­‐needed-­‐to-­‐treat	  of	  10	  to	  20)	  so	  the	  majority	  of	  patients	  at	  risk	  of	  OIPN	  gain	   no	   benefit	   from	   the	   addition	   of	   oxaliplatin	   treatment	   to	   surgery	   and	  fluoropyrimidine	  adjuvant	  chemotherapy	  (Andre	  et	  al.	  2009).	  The	  need	   to	   find	   accurate	  biomarkers	   to	   stratify	  patients	   for	   the	   risk	  of	  OIPN	   is	   urgent.	   	   So	   far,	   many	   genomic	   studies	   have	   identified	   statistically	  significant	  potential	  genetic	  markers	  of	  risk,	  but	  these	  studies	  are	  hampered	  by	  inconsistent	   and	   conflicting	   results,	   and	   a	   lack	   of	   mechanistic	   or	   functional	  evidence	  to	  support	  their	  conclusions	  (Cavaletti	  et	  al.	  2011;	  Custodio	  et	  al.	  2014).	  	  A	  recent	  study	  by	  Professor	  J	  Cheadle	  at	  Cardiff	  University	  using	  patient	  samples	   from	   the	   UK	   national	   COIN	   trial	   (Maughan	   et	   al.	   2011)	   has	   identified	  several	   potential	   biomarkers	   markers	   of	   OIPN	   risk	   by	   studying	   DNA	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polymorphisms	  in	  the	  DNA	  repair	  gene	  XPF.	  	  The	  aim	  of	  this	  study	  is	  to	  provide	  supporting	  functional	  and	  mechanistic	  information	  in	  a	  robust	  model	  system	  to	  support	  these	  findings.	  	  	  	  The	   results	   of	   the	   experiments	   conducted	   and	  described	   in	   this	   chapter	  outline	   the	   steps	   taken	   to	   develop	   a	  S.	   cerevisiae	  model	   to	   determine	  whether	  two	   of	   the	   SNPs	   found	   in	   the	   XPF	  gene	  of	   patients	   who	   have	   developed	   OIPN	  could	   be	   mimicked	   and	   have	   a	   mechanistic	   effect	   on	   DNA	   repair	   and	   on	  sensitivity	  to	  oxaliplatin	  DNA	  damage.	  The	  evidence	  presented	  demonstrates	  the	  effect	  of	  these	  genetic	  variants	  on	   DNA	   repair	   and	   survival	   following	   DNA	   damage.	   	   The	   sequencing	  confirmation	  after	  site-­‐directed	  mutagenesis,	  demonstration	  of	  appropriate	  copy	  number	   of	   plasmids,	   and	   the	   identical	   growth	   rate	   of	   the	   constructed	   strains	  indicate	   that,	   as	   a	   baseline,	   these	   strains	   have	   similar	   characteristics	   and	  phenotype	  with	  respect	  to	  these	  parameters.	  After	  UV	   treatment	   the	  model	  demonstrates	   that	   the	  mutations	   in	  RAD1	  do	   result	   in	   a	   functional	   defect	   in	   NER	   through	   the	   survival	   assay	   results	   and	  immuno-­‐slotblot	  assessment	  of	  NER	  capacity.	  	  	  The	  RAD1	  stopgain	  variant	  Ser747X	  results	   in	  complete	   failure	   to	  repair	  	  (UV	   induced)	   CPD	   or	   photo	   products,	   resulting	   in	   an	   extreme	   UV	   sensitive	  phenotype.	  	  When	  exposed	  to	  oxaliplatin	  this	  strain	  also	  shows	  a	  highly	  sensitive	  phenotype,	   manifested	   in	   significantly	   reduced	   colony	   survival	   and	   highly	  impaired	  growth	  in	  the	  12	  hours	  after	  drug	  exposure.	  The	   stain	   SX46a	   rad1Δ	   pRS313-­‐RAD1-­‐P469S	   also	   demonstrates	   a	  significant	   difference	   when	   compared	   to	   the	   SX46a	   wildtype	   and	   the	   SX46a	  
rad1Δ	  pRS313-­‐RAD1	  complemented	  strain.	   	  The	  UV	  sensitivity	  shown	  in	  the	  UV	  survival	   assay	   is	   increased,	   although	   this	   effect	   is	   subtle.	   	   The	   reduction	   in	  survival	  after	  UV	  exposure	  is	  demonstrated	  to	  be	  due	  to	  the	  lower	  rate	  of	  repair	  of	  UV	  induced	  CPD	  adducts	  when	  compared	  to	  the	  wildtype	  strains.	  	  	  The	   sensitivity	   to	   oxaliplatin	   of	   this	   strain	   compared	   to	   the	  wildtype	   is	  statistically	   significant,	   but	   subtle.	   	   When	   the	   effect	   of	   the	   mutation	   on	   the	  growth	  rate	  following	  oxaliplatin	  exposure	  is	  evaluated	  there	  is	   little	  difference	  at	   lower	  doses	  when	  compared	   to	   the	  wildtype	  strains	  although	  at	  a	  high	  dose	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there	  appears	   to	  be	  a	   trend	  towards	  slower	  growth	  rates	   in	   the	  P469S	  mutant.	  When	   exposed	   to	   increasing	   doses	   of	   oxaliplatin	   the	   P469S	   mutant	   strain	  displays	  a	  significant	  but	  small	  decrease	  in	  survival,	  consistent	  with	  the	  effect	  of	  impairment	  in	  DNA	  repair	  previously	  demonstrated.	  	  The	   findings	   of	   these	   experiments	   indicate	   that	   modelling	   the	   XPF	  variants	  leads	  to	  a	  functional	  defect	  in	  cell	  growth	  and	  repair	  after	  DNA	  damage.	  	  In	  theory,	  a	  stopgain	  variant	  S613X	  in	  XPF	  should	  result	  in	  the	  complete	  loss	  of	  function	   of	   the	   protein	   from	   this	   allele,	   with	   translation	   of	   mRNA	   terminated	  prematurely	   and	   resulting	   in	   a	   truncated	   protein	   missing	   the	   C-­‐terminal	  nuclease	   and	   ERCC1	   binding	   domains.	   	   A	   complete	   loss	   of	   function	   is	  demonstrated	   in	   our	   study	   by	   showing	   a	   phenotype	   similar	   to	   that	   of	   a	   total	  
RAD1	  deletion	  strain.	   	   In	  a	  patient	  with	   this	  mutation	  the	  effect	  on	  XPF	  protein	  level	  may	  not	   translate	   to	  an	  XP	  phenotype	   if	   the	  heterozygous	  allele	  produces	  adequate	  XPF	  protein	  to	  maintain	  a	  certain	  NER	  capacity.	  	  In	  keeping	  with	  XP	  as	  an	  autosomal	  recessive	  disease,	  in	  a	  series	  of	  patients	  with	  XP	  due	  to	  mutations	  in	  XPF	  described	  by	   (Ahmad	  et	  al.	  2010)	  none	  of	   the	  patients	  with	   the	  disease	  had	  a	  wildtype	  XPF	  allele	  –	  all	  had	  mutations	  in	  both	  alleles.	  	  The	  father	  of	  one	  of	  the	  patients,	  a	  carrier	  with	  one	  wildtype	  allele	  and	  one	  with	  a	  variant	  (R799W),	  showed	   no	   clinical	   evidence	   of	   XP,	   normal	   functioning	   unscheduled	   DNA	  synthesis	  and	  no	  evidence	  of	  an	  increase	  in	  UV	  sensitivity.	  	  Contrary	  to	  this,	  the	  fact	  that	  no	  mutation	  could	  be	  found	  on	  the	  other	  XPF	  allele	  in	  our	  patient	  with	  the	   S613X	   variant	   indicates	   that	   this	   is	   a	   potential	   example	   of	   haplo-­‐insufficiency.	   	   However,	   the	   patient	   did	   not	   clinically	   have	   XP.	   	   In	   the	   diploid	  heterozygous	  context	  it	  may	  be	  that	  the	  S613X	  mutation	  results	  in	  lower	  levels	  of	  XPF	   protein,	   only	   manifesting	   the	   OIPN	   phenotype	   under	   the	   severe	   DNA	  damage	   induced	   by	   chemotherapy.	   	   However,	   only	   a	   limited	   number	   of	   104	  genes	  were	  examined	  for	  the	  presence	  of	  genetic	  variants	  (see	  section	  6.2.1)	  and	  an	   alternative	   explanation	   is	   the	   presence	   of	   mutations	   elsewhere	   in	   the	  chromosome	   or	   genome	   that	   contribute	   to	   this	   patient’s	   phenotype,	   but	   that	  have	   been	   filtered	   out,	   and	   hence	   not	   detected,	   by	   the	   type	   of	   pathway-­‐based	  approach	  used	  in	  this	  investigation.	  
	   326	  
The	  variant	  P379S	  has	  been	  documented	  in	  patients	  with	  mild	  XP	  (Ahmad	  et	  al.	  2010;	  Berneburg	  et	  al.	  2000)	  and	  has	  been	  hypothesised	  to	  result	  in	  protein	  misfolding	  and	   loss	  of	  nuclear	   localisation	   signalling	   (Ahmad	  et	  al.	  2010).	   	  The	  consequence	   appear	   to	   be	   changes	   to	   the	   cellular	   allocation	   of	   XPF,	   with	   a	  reduction	  in	  nuclear	  localisation	  of	  XPF	  from	  93%	  in	  controls	  to	  73%	  in	  a	  patient	  with	   single	   allele	   mutated	   to	   P379S,	   and	   a	   resulting	   increase	   in	   non-­‐nuclear	  localisation	  (using	   immunofluorescence)	   from	  7%	  to	  27%	  (Ahmad	  et	  al.	  2010).	  	  A	   reduction	   in	   availability	   in	   the	   nucleus	   of	   essential	   NER	   factors	   could	  potentially	  be	  detected	  in	  our	  model	  as	  a	  reduction	  in	  NER	  activity,	  although	  this	  would	   likely	   be	   subtle	   in	   the	   P379S	   strain	   than	   in	   the	   stop-­‐gain	  mutant.	   	   The	  subtle	  decrease	  in	  NER	  capacity	  demonstrated	  in	  our	  haploid	  S.	  cerevisiae	  model	  may	   be	   absent	   in	   the	   heterozygote	   diploid	   human	   context,	   but	   again	   may	   be	  enough	   to	  result	   in	  OIPN	  when	  exposed	   to	  chemotherapy.	  Unfortunately,	  as	  no	  effective	  RAD1	  antibody	  is	  available,	  it	  is	  not	  possible	  to	  probe	  for	  differences	  in	  RAD1	  cellular	  location	  in	  our	  S.	  cerevisiae	  model.	  A	  limitation	  of	  the	  work	  as	  described	  is	  the	  inability	  to	  demonstrate	  that	  functional	   RAD1	   is	   produced	   in	   each	   strain	   in	   similar	   amounts,	   as	   it	   is	   not	  technically	  possible	  with	   the	   commercially	   available	  RAD1	  antibodies	   to	  probe	  for	  this	  protein.	  	  The	  DNA	  quantification	  qPCR	  experiment	  suggests	  strongly	  that	  only	  a	  single	  copy	  of	  each	  plasmid	  is	  present	  per	  cell,	  and	  as	  the	  promoters	  and	  expression	   of	   the	   protein	   in	   the	   plasmids	   used	   in	   the	   SX46a	   rad1Δ	   strain	  transformation	  are	  identical	  (as	  confirmed	  by	  sequencing)	  it	  is	  likely	  that	  there	  is	  no	  difference	  between	  strains.	  In	   conclusion,	   the	   experiments	   outlined	   in	   this	   chapter	   demonstrate	  robust	  evidence	  of	  a	   functional	   link	  between	  the	  presence	  of	  SNPs	   identified	   in	  the	  XPF	  gene	  of	  patients	  who	  have	  developed	  severe	  OIPN	  and	  NER	  capacity,	  and	  on	   the	   sensitivity	   to	   oxaliplatin.	   	   These	   results	   indicate	   that	   these	   SNPs	   are	  functionally	   linked	   to	   the	   development	   of	   OIPN	   and	   may	   be	   good	   candidate	  biomarkers	  for	  future	  genetic	  pre-­‐chemotherapy	  screening.	  	  This	  work	  also	  lends	  further	   weight	   to	   the	   hypothesis	   that	   functional	  measurements	   of	   DNA	   repair	  capacity	  are	  a	  useful	  tool	  that	  could	  potentially	  be	  used	  to	  stratify	  patients	  for	  the	  response	  and	  toxicity	  to	  platinum	  chemotherapy	  agents;	  an	  idea	  explored	  in	  all	  of	  the	  chapters	  of	  this	  thesis.	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Chapter	  7 Discussion,	  future	  directions	  and	  thesis	  conclusion	  
 Thesis	  summary	  7.1
	   In	  summary,	  the	  key	  findings	  and	  developments	  outlined	  in	  this	  thesis	  are	  as	  follows:	  	  
• The	  translation	  of	  a	  DIP-­‐chip	  assay	  from	  use	  in	  cell	  culture	  into	  an	  assay	  capable	   of	   detecting	   platinum-­‐DNA	   adduct	   patterns	   in	   clinical	   samples,	  requiring	  the	  following	  steps:	  	  
o The	  development	  of	  standardised	  and	  robust	  treatment	  protocols	  for	  the	  ex	  vivo	  treatment	  of	  PBMC	  from	  clinical	  samples.	   	  
o The	   optimisation	   of	   assay	   experimental	   protocols	   to	   ensure	   and	  demonstrate	  reproducible	  DNA	  immunoprecipitation.	  
o The	   optimisation	   of	   protocols	   for	   the	   production	   of	   reproducible	  genome	   scale	   microarray	   chip	   platinum-­‐DNA	   patterns	   from	   DIP	  samples.	  	  
• The	  development	  of	  enhanced	  DIP-­‐chip	  bioinformatic	  analysis	  tools	  for:	  	  	  
o The	   extraction	   of	   latent	   information	   from	   DIP-­‐chip	   microarrays:	  used	  as	   a	   tool	   for	   enhanced	  QC	  of	  DIP-­‐chip	  data	   and	   for	  detailed	  analysis	  and	  interpretation	  of	  assay-­‐development	  experiments.	  
o For	   determining	   reproducibly	   of	   microarray	   data	   along	   the	  genome	   –	   used	   to	   determine	   the	   effect	   of	   assay	   protocol	  modifications	   and	   for	   the	   identification	   of	   regions	   of	   DIP-­‐chip	  microarray	  data	  that	  is	  highly	  variable,	  and	  which	  can	  be	  excluded	  from	  inter-­‐individual	  analysis	  
o Determining,	  plotting	  and	  listing	  regions	  of	  significant	  differences	  between	  inter-­‐individual	  DIP-­‐chip	  platinum-­‐DNA	  adduct	  patterns.	  	  
	   328	  
• An	  experimental	  study	  confirming	  and	  supporting	  the	   importance	  of	   the	  link	   between	   germline	   DNA	   repair	   gene	   polymorphisms	   and	   platinum	  toxicity	  experienced	  by	  patients	  during	  platinum-­‐based	  chemotherapy.	  
	  
 Discussion	  	  7.2	   This	  thesis	  primarily	  concerns	  the	  development	  of	  methods	  and	  tools	  that	  can	  be	  used	   for	  stratification	  of	  patients	   for	   response	  and	   toxicity	   to	  platinum-­‐based	   chemotherapy,	   with	   an	   emphasis	   on	   oxaliplatin	   induced	   peripheral	  neuropathy	  in	  the	  context	  of	  the	  treatment	  of	  colorectal	  cancer.	  	  	  As	  discussed	  extensively	  in	  the	  introductory	  section	  of	  chapters	  3,	  4	  and	  6,	  robust	  evidence	  exists	  that	  several	  measurable	  aspects	  of	  DNA	  repair	  capacity	  are	  important	  determinants	  of	  the	  response	  and	  toxicity	  that	  occurs	  in	  patients	  treated	   with	   platinum	   agents.	   	   Many	   studies	   that	   have	   been	   conducted	   to	  examine	   this	   relationship	   have	   been	   cited	   in	   these	   chapter	   introductions,	   and	  several	  of	  these	  studies	  have	  determined	  a	  correlation	  between	  these	  factors.	  	  As	  described	  in	  chapter	  3,	  these	  studies	  can	  be	  grouped	  by	  the	  different	  approaches	  taken	   to	   investigate	   this	   concept,	   including	   grouping	   into	   ‘genetic	   studies’	   -­‐	  studies	   examining	   for	   the	   presence	   or	   absence	   of	   single	   nucleotide	  polymorphisms	  in	  repair	  genes,	  into	  studies	  that	  use	  measurements	  of	  germline	  DNA	  repair	  capacity,	  studies	  examining	  levels	  of	  expressed	  DNA	  repair	  proteins,	  and	   studies	   measuring	   the	   levels	   of	   DNA	   adducts	   in	   samples	   from	   patients	  previously	  treated	  with	  platinum	  agents.	  On	  the	  strength	  of	  these	  results,	  the	  concept	  of	  measuring	  features	  of	  the	  DNA	   repair	   pathway	   as	   a	   potential	   determinant	   of	   platinum	   response	   and	  toxicity	  has	  been	  adopted	  by	  the	  clinical	  community,	  and	  has	  progressed	  to	  use	  in	  large-­‐scale	  clinical	  studies	  to	  stratify	  patients	  for	  the	  response	  and	  toxicity	  of	  platinum	  agents	  (for	  reviews	  see	  (Cavaletti	  et	  al.	  2011)	  and	  (Bowden	  2014)).	  	  As	  discussed,	  the	  currently	  available	  approaches	  to	  measure	  platinum-­‐DNA	  adducts	  when	   applied	   to	   clinical	   studies	   can	   be	   characterised,	   in	   general,	   as	   studies	  utilising	  a	  single	  measurement	  of	  a	  single	  feature	  of	  DNA	  repair	  capacity,	  either	  at	   the	  genetic	   level	  by	  assessing	   the	  presence	  or	  absence	  of	  polymorphisms,	  at	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the	  protein	  levels	  by	  measuring	  the	  presence	  or	  absence	  of	  a	  single	  DNA	  repair	  protein	  (such	  as	  ERCC1),	  or	  at	  the	  functional	  level	  by	  determining	  the	  total	  level	  of	   platinum-­‐DNA	   adducts	   per	   unit	   of	   DNA.	   	   To	   date,	   however,	   the	  widespread	  adoption	   of	   these	   types	   of	   stratification	   tools	   has	   been	   limited	   by	   the	   lack	   of	  predictive	   power	   that	   has	   been	   demonstrated	   in	   clinical	   studies	   using	   these	  approaches	  (Bowden	  2014).	   	  However,	  the	  general	  concept	  of	  these	  pre-­‐clinical	  and	   clinical	   studies	   is	   support	   for	   the	   rationale	   of	   the	   experiments	   and	  approaches	  explored	  and	  described	  this	  thesis.	  	  	  	  Whilst	  there	  are	  several	  limitations	  to	  the	  current	  technique	  and	  aspects	  of	   the	   DIP-­‐chip	   assay	   to	   be	   improved,	   once	   optimised	   and	   refined	   it	   is	   our	  contention	   that	   the	  DIP-­‐chip	   assay,	   as	   used	   extensively	   throughout	   this	   thesis,	  has	   three	   key	   advantages	   compared	   to	   the	   currently	   available	   approaches	   to	  measure	  platinum-­‐DNA	  adducts	  described	  above.	  Firstly,	   a	   DIP-­‐chip	   assay	   is	   a	   functional	   assay,	   and	   measures	   platinum-­‐DNA	  adducts	  directly,	   rather	   than	  measuring	   surrogate	  markers	   (such	  a	   repair	  gene	  SNPs)	  or	  measuring	  markers	  several	  steps	  removed	  from	  the	  final	  common	  endpoint	  of	  DNA	  damage,	   such	  as	  protein	  expression	   levels.	   	  As	  platinum-­‐DNA	  adducts	  are	  the	  direct	  insult	  leading	  to	  the	  DNA	  damage	  response,	  apoptosis	  or	  necrosis,	   and	   ultimately	   govern	   the	   response	   and	   toxicity	   of	   these	   agents,	  measurement	  directly	  of	  adducts	  rather	  than	  ‘upstream’	  and	  surrogate	  markers	  is	  less	  subject	  to	  potential	  bias	  and	  confounding,	  and	  is	  therefore	  more	  likely	  to	  be	  a	  reliable	  marker	  for	  determining	  platinum	  response	  and	  toxicity.	  	  	  One	  significant	  limitation	  of	  the	  assay	  is	  the	  requirement	  to	  use	  surrogate	  tissue	  of	  PBMC	  instead	  of	  tumour	  tissue.	   	  A	  PBMC-­‐based	  assay	  may	  be	  accurate	  in	  the	  assessment	  of	  germline	  DNA	  damage	  and	  repair	  as	  a	  measure	  of	  toxicity	  of	  chemotherapy	  on	  normal	  tissues,	  rather	  than	  when	  assessing	  the	  heterogeneous	  tumour	   repair	   profile	   for	   tumour	   response,	   and	   may	   also	   have	   a	   use	   in	   the	  assessment	   of	   response	   of	   normal	   tissue	   with	   similar	   post-­‐differentiated	   DNA	  repair	  patterns	  such	  as	  neuronal	  tissue	  in	  the	  assessment	  of	  OIPN.	   	  Despite	  the	  limitations,	  PBMC	  are	  commonly	  used	  for	  this	  type	  of	  assay	  (see	  section	  3.1.7)	  as	  a	   surrogate	   tissue	   and	   reduce	   the	   need	   for	   potential	   hazardous	   biopsies	   in	   a	  research	   study.	   	   It	  may	   be	   possible	   to	   determine	   the	   effect	   of	   similarities	   and	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differences	  between	  platinum-­‐induced	  DNA	  adduct	  profiles	  in	  PBMC	  and	  paired	  tumour	  tissue	  in	  future	  research	  projects	  using	  the	  DIP-­‐chip	  assay.	  A	  second	  strength	  of	  the	  DIP-­‐	  chip	  assay	  is	  the	  ability	  to	  measure	  the	  level	  of	   induced	   DNA	   adducts	   at	   multiple	   genetic	   loci	   simultaneously.	   	   As	  demonstrated	   previously	   in	   our	   laboratory	   in	   fibroblast	   cell	   culture	   models	  (Powell	  2014)	  and	  in	  many	  occasions	   in	  the	  experiments	  and	  results	  described	  in	   chapter	   4	   and	   5,	   platinum-­‐DNA	   adducts	   form	   at	   different	   levels	   at	   different	  regions	  of	  the	  genome.	  	  Rather	  than	  the	  single	  average	  measures	  of	  DNA	  damage	  or	  repair	  used	  in	  previous	  clinical	  studies	  (Bowden	  2014;	  Wang	  et	  al.	  2011),	  the	  ability	  to	  determine	  the	  level	  of	  platinum-­‐DNA	  adducts	  at	  high	  resolution	  and	  a	  genomic	  scale	  gives	  in	  the	  DIP-­‐chip	  assay	  an	  important	  advantage	  for	  detecting	  and	  measuring	   the	  distribution	  of	  platinum-­‐DNA	  adducts.	   	  Additionally,	   as	   it	   is	  recognised	  that	  NER	  occurs	  at	  different	  rates	  in	  different	  section	  of	  the	  genome	  in	  different	   tissues,	   especially	  neuronal	   tissue,	   a	  key	  determinant	  of	  peripheral	  neuropathy,	   and	   in	   PBMC,	   the	   surrogate	   tissue	   used	   in	   these	   experiments	  (Nouspikel	  2009),	  the	  DIP-­‐chip	  assay	  is	  particularly	  appropriate	  for	  investigating	  oxaliplatin	  induced	  peripheral	  neuropathy.	  A	  third	  key	  strength	  of	  the	  DIP-­‐chip	  assay	  is	  the	  genomic-­‐scale	  approach	  and	  genomic-­‐scale	  datasets	  generated	  by	   this	   technology,	   in	   comparison	   to	   the	  data	   generated	   from	   a	   single	  measure	   assay.	   	   Rather	   than	   a	   single	   output	   (for	  example	  high	  or	   low	  ERCC1	  protein	  expression,	  or	  high	  or	   low	  average	  adduct	  levels	   per	   unit	   of	   DNA)	   the	   genomic	   approach	   allows	   a	   non-­‐biased	   and	   un-­‐filtered	   ability	   to	  determine	  differences	   in	  patterns	   through	   the	   representative	  section	   of	   the	   genome	   examined.	   	   Single	   or	   limited	  measure	   approaches	   filter	  information	  by	  concentrating	  on	  one	  particular	  marker	  and	  ignoring	  information	  in	  other	   genetic	   regions	  or	   in	  other	  proteins,	   reducing	   the	  power,	   applicability	  and	  predictive	  ability	  of	  these	  types	  of	  assay.	  	  	  There	   are	   significant	   limitations	   of	   the	  DIP-­‐chip	   assay	   to	   overcome.	   	   As	  discussed	  above,	   the	  use	  of	  PBMC	  as	  a	  surrogate	   tissue	   is	  a	  potential	   source	  of	  inaccuracy.	   	  The	  use	  of	  PBMC	   is	  a	   common	  approach	   in	   this	   type	  of	  assay,	   and	  reduces	  the	  need	  for	  repeat	  tissue	  biopsy,	  especially	  during	  assay	  development	  (see	  section	  3.1.7).	  	  One	  future	  project	  under	  consideration	  is	  to	  induce	  platinum	  DNA	   damage	   in	   paired	   tumour	   and	   PBMC	   tissue	   from	   the	   same	   individuals	   to	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compare	   the	   DIP-­‐chip	   patterns	   generated	   to	   determine	   similarities	   and	  differences	  between	  the	  induced	  DNA	  damage	  patterns	  in	  these	  different	  tissue	  types.	  	  This	  may	  resolve	  or	  quantify	  the	  impact	  of	  this	  potential	  limitation	  of	  the	  PBMC	  DIP-­‐chip	  assay.	  The	  accuracy	  and	  applicability	  of	  the	  DIP-­‐chip	  assay	  is	  also	  limited	  by	  the	  poor	   reproducibility	   of	   the	   assay,	   and	   the	   resolution	   of	   this	   issue	   is	   a	   primary	  focus	  of	  chapters	  3,	  4	  and	  5.	  	  To	  reliably	  compare	  inter-­‐individual	  differences	  the	  assay	   must	   be	   capable	   of	   generating	   relatively	   reproducible	   DNA	   damage	  patterns	  in	  repeated	  samples	  from	  the	  same	  individual.	   	  This	  has	  partially	  been	  addressed	  through	  modifying	  the	  DIP-­‐chip	  protocol,	  and	  by	  using	  this	  approach	  the	   experimental	   variability	   has	   been	   demonstrably	   reduced.	   	   Additionally,	   by	  filtering	  the	  datasets	  to	  identify	  only	  statistically	  significant	  differences	  between	  datasets,	  primarily	  by	  using	  the	  bioinformatic	  tools	  developed	  in	  chapter	  5,	   the	  impact	  of	  this	  variability	  can	  also	  potentially	  be	  reduced.	  	  The	  choice	  of	  statistical	  method	   to	   achieve	   this	   filtering	   requires	   refinement,	   and	   the	   outlier	   detection	  technique	  used	   in	  chapter	  5	  has	  several	   limitations,	   including	  the	   identification	  of	   outliers	   which	   may	   result	   from	   experimental	   error	   rather	   than	   biological	  signal	  and	  the	  loss	  of	  genomic	  and	  local	  probe	  context	  by	  focusing	  on	  individual	  probes	   comparisons	   between	   datasets.	   	   Further	   developments	   in	   the	  bioinformatic	  analysis	  of	  datasets	  discussed	  in	  section	  5.6.2,	  particularly	  the	  use	  of	  a	  sliding	  window	  t-­‐test,	  may	  resolve	  some	  of	  these	  issues.	  	  	  If	  the	  limitations	  of	  the	  assay	  can	  be	  overcome,	  by	  combining	  a	  functional	  measure	   of	   platinum-­‐DNA	   damage	   with	   a	   genome-­‐scale,	   un-­‐biased	   and	   non-­‐filtered	   approach	   to	   measuring	   patterns	   of	   adduct	   levels,	   and	   using	   genomic	  scale	   data	   and	   bioinformatic	   tools	   to	   reveal	   differences	   in	   patterns	   between	  individuals,	   the	  DIP-­‐chip	  assay	  has	  many	  potential	  advantages	  compared	  to	  the	  previously	  available	  technology	  used	  in	  this	  field	  of	  research.	  	  In	   this	   context,	   the	   key	   developments	   described	   in	   this	   thesis	   is	   the	  translation	   of	   cell	   culture	   model	   analysis	   DNA	   immunoprecipitation	   and	  microarray	   (DIP-­‐chip)	   techniques	   into	   a	   robust	   method	   for	   measuring	   the	  distribution	   of	   induced	   oxaliplatin-­‐DNA	   adducts	   at	   high	   resolution	   and	   at	   a	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genomic	   scale	   in	   human	   clinical	   samples.	   	   This	   thesis	   also	   includes	   the	  development	  of	  the	  necessary	  bioinformatic	  analysis	  tools	  for	  the	  quality	  control	  and	  the	  analysis	  of	   inter-­‐individual	  differences	  in	  DIP-­‐chip	  generated	  platinum-­‐DNA	   adduct	   patterns.	   	   This	   was	   attained	   over	   the	   course	   of	   experiments	   and	  developments	  outlined	  and	  described	  over	  three	  chapters.	  	  Chapter	  3	  described	  the	   experimental	   development	   and	   optimisation	   of	   DNA	   immunoprecipitation,	  the	  first	  stage	  of	  the	  DIP	  chip	  assay,	  for	  use	  in	  human	  clinical	  samples.	  	  Chapter	  4	  dealt	  with	  issues	  that	  arise	  from	  the	  translation	  of	  thus	  technique	  into	  the	  ‘chip’	  genomic	  scale	  analysis	  phase	  of	  the	  assay.	  	  For	  the	  assay	  to	  function	  properly,	  for	  further	   development	   work,	   for	   quality	   control,	   and	   to	   ultimately	   detect	  differences	  in	  platinum-­‐DNA	  adduct	  signatures	  the	  bioinformatic	  tools	  required	  were	  developed	  in	  chapter	  5.	  Additionally,	  this	  thesis	  includes	  a	  functional	  study	  that	  demonstrates	  the	  influence	   that	   subtle	   perturbations	   in	   DNA	   repair	   capacity	   can	   have	   on	   the	  outcome	  of	  chemotherapy	  treatment	  in	  colorectal	  cancer	  patients.	  	  This	  aspect	  of	  the	  study	  provides	  functional	  evidence	  to	  support	  the	  initial	  genetic	  evidence	  –	  a	  study	  that	   identified	  a	  statistical	   link	  between	  DNA	  repair	  gene	  polymorphisms	  and	  oxaliplatin	  toxicity	  (West	  2013).	  	  The	  findings	  of	  this	  chapter	  are	  support	  for	  the	   central	  hypothesis	  of	   this	   thesis;	   that	  by	  measuring	   changes	   in	  DNA	   repair	  capacity,	   and	   specifically	   in	   the	   level	   and	   patterns	   of	   induced	   platinum-­‐DNA	  adducts,	  it	  may	  be	  possible	  to	  stratify	  patients	  for	  the	  response	  and	  toxicity	  that	  occurs	   during	   treatment	   with	   platinum	   based	   chemotherapy.	   	   The	   three	   S.	  
cerevisiae	  models	   developed	   during	   this	   study	   are	   of	   a	   normal,	   moderate	   and	  extreme	  oxaliplatin-­‐induced	  peripheral	  neuropathy	  (OIPN)	  phenotype,	  and	  will	  have	   an	   important	   role	   in	   the	   further	   development	   and	   validation	   of	   DIP-­‐chip	  based	  assays	  of	  OIPN	  in	  future	  projects	  in	  our	  laboratory.	  	  
 Pathway	  for	  clinical	  development	  7.3 	  The	  DIP-­‐chip	  assay	  protocols	  and	  bioinformatic	  analysis	   tools	  presented	  here,	   despite	   the	   limitations	   and	   need	   for	   refinements	   discussed	   above,	  represent	  a	  clinically	  usable	  assay,	  from	  initial	  venesection	  of	  10-­‐20mls	  of	  fresh	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blood	   to	   the	   generation	   and	   analysis	   of	   the	   pattern	   of	   induced	   platinum-­‐DNA	  adducts	  at	  high	  resolution	  over	  a	  5Mb	  section	  of	  the	  genome.	  	  The	  analysis	  tools	  developed	   here,	   within	   the	   limitations	   discussed,	   allow	   the	   determination	   of	  differences	   between	   patterns	   generated	   in	   different	   individuals	   and	   between	  cohorts	  with	  different	  responses	  and	  toxicities	  to	  platinum-­‐based	  chemotherapy	  treatment.	  There	   are	  many	   steps	   still	   required	   to	   reliable	   use	   the	   assay	   in	   clinical	  studies	  and	  to	  validate	  the	  assay	  for	  use	  in	  these	  contexts.	  	  A	  three	  stage	  process	  of	  biomarker	  development,	  as	  suggested	  by	  Hall,	  would	  be	  a	  valuable	  model	   to	  follow	   to	   develop	   and	   validate	   the	   assay	   towards	   these	   goals,	   and	   will	   be	  described	  below	  (Hall	  et	  al.	  2007).	  Following	   the	   pre-­‐clinic	   development	   described	   in	   this	   thesis	   the	   first	  phase	  of	  clinical	  use	  must	  be	  a	  feasibility	  and	  small-­‐scale	  pilot	  study.	  	  	  The	  assay	  needs	  to	  be	  tested	  in	  the	  clinical	  environment	  to	  assess	  the	  practicality	  of	  using	  the	   technique	  with	   the	  current	  protocol,	  and	   to	  understand	   the	  difficulties	   that	  may	  occur	  when	   taking	   samples	   in	   the	   clinical	   setting.	   	   For	  example,	  one	   issue	  may	  be	  optimising	  the	  timing	  and	  transport	  of	  venesection	  samples	  –	  issues	  that	  do	  not	  arise	  in	  the	  laboratory-­‐based	  development	  phase.	  	  	  In	  such	  a	  pilot	  study	  it	  would	  be	  prudent	  to	  use	  two	  groups	  of	  patients	  of	  known	  extreme	  phenotypic	  response	  to	  platinum	  agents	  to	  increase	  the	  chance	  of	   detecting	   differences	   between	   cohorts.	   	   For	   example,	   platinum-­‐based	  chemotherapy	  for	  stage	  IV	   lung	  cancer	  has	  approximately	  a	  50%	  response	  rate	  (Cobo	  et	  al.	  2007).	   	  Taking	  a	  cohort	  of	  10	  patient	  who	  responded	   to	   treatment	  and	   10	   who	   progressed	   on	   treatment	   would	   assess	   the	   feasibility	   of	   taking	  clinical	   samples,	   and	   potentially	   allow	   the	   initial	   identification	   of	   putative	  patterns	   of	   adducts	   that	   are	   different	   between	   the	   two	   cohorts.	   	   This	   type	   of	  exploratory	  study	  would	  be	  hypothesis	  generating;	  producing	  putative	  genomic	  signatures	  of	  chemotherapy	  response,	  and	  would	  allow	  the	  further	  refinement	  of	  the	  assay	  and	  the	  process	  by	  which	  blood	  samples	  are	  taken,	  transported	  to	  the	  laboratory,	   and	   the	   development	   and	   refinement	   of	   the	   statistical	   approaches	  needed	   to	   robustly	   analyse	   the	   microarray	   data	   generated.	   	   As	   discussed	   in	  chapter	  5,	  the	  identification	  of	  characteristic	  patterns	  and	  the	  refinement	  of	  the	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statistical	  approaches	  and	  cut-­‐offs	  required	  to	  detect	  this	  putative	  difference	  are	  critical	  to	  the	  future	  development	  of	  this	  assay	  in	  this	  context.	  The	  putative	  genomic	  signature	  identified	  in	  the	  exploratory	  study	  would	  then	  require	  confirmation	  in	  a	  larger	  and	  statistically	  robust	  second	  phase	  study.	  	  The	   magnitude	   of	   differences	   between	   the	   datasets	   identified	   as	   a	   candidate	  genomic	  signature	  in	  the	  pilot	  project	  would	  allow	  power	  calculation	  of	  sample	  sizes	   to	   allow	   rigorous	   independent	   statistical	   validation	   of	   the	   hypothesised	  patterns.	  	  This	  type	  of	  study	  would	  require	  the	  relationship	  to	  be	  investigated	  in	  a	   similar	   population	   and	   context	   as	   used	   in	   the	   initial	   pilot	   project.	   	   With	  adequate	  samples	  numbers.	  It	  may	  be	  that	  an	  iterative	  process	  is	  required	  between	  the	  two	  phases	  of	  clinical	   projects,	   with	   a	   small	   hypothesis	   generating	   study	   and	   a	   larger	  ‘confirmation	  of	  relationship’	  study	  required	  over	  several	  iterations	  to	  refine	  the	  signature	  under	  consideration	  and	  a	  the	  magnitude	  of	  differences	  detected.	  	  The	  requirement	  for	  obtaining	  genomic	  scale	  data	  may	  be	  reduced	  if	  the	  region	  of	  the	  genome	   is	   identified	   as	   containing	   a	   putative	   signature	   exists	   over	   a	   small	  number	  of	  genetic	   loci.	   	   In	   this	  circumstance	   it	  may	  be	  possible	   to	  detect	   these	  differences	   between	   samples	   at	   a	   small	   number	   of	   loci	   using	   only	   DIP-­‐qPCR,	  dramatically	  reducing	  the	  complexity	  and	  cost	  of	  the	  assay.	  If	   a	   hypothesised	   signature	   can	   be	   confirmed	   in	   a	   larger,	   statistically	  robust	   second-­‐phase	   study	   the	   next	   stage	   would	   be	   to	   estimate	   the	   clinical	  relevance	   of	   the	   assay,	   principally	   by	   testing	   in	   a	   prospective	   fashion	   that	   the	  marker	  improves	  patient	  or	  treatment	  selection	  compared	  to	  currently	  available	  approaches.	   	   This	   could	   be	   conducted	   in	   a	   similar	   manner	   to	   the	   testing	   of	  putative	   ERCC1	   biomarker	   in	   a	   2007	   lung	   cancer	   trial	   (Cobo	   et	   al.	   2007)	   or	  similar	  to	  the	  on-­‐going	  UK	  FOCUS	  4	  trial	  assessing	  the	  impact	  of	  several	  different	  biomarkers	   in	   predicting	   the	   outcome	  of	   treatment	   for	   colorectal	   cancer	   (MRC	  2015).	  	  	  This	  type	  of	  large	  prospective	  study	  would	  be	  required	  to	  provide	  robust	  evidence	  for	  the	  use	  of	  a	  predictive	  biomarker	   in	  the	  selection	  of	   treatment	   for	  routine	  use	  in	  clinical	  patients.	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 Potential	  clinical	  applications	  7.4	  	   The	  evidence	  presented	  in	  this	  thesis	  demonstrates	  that	  the	  technique	  is	  ready	   for	   testing	   and	   refinement	   through	   clinical	   application,	   following	   the	  pathway	  discussed	  in	  the	  previous	  section	  and	  the	  refinement	  and	  resolution	  of	  the	  limitations	  described.	  	  The	  context	  and	  potential	  uses	  of	  the	  assay	  in	  clinical	  studies	   requires	   careful	   consideration,	   as	   the	   development	   pathway	   outlined	  above	  is	  context	  specific	  and	  would	  require	  the	  ultimate	  clinical	  application	  to	  be	  in	   mind	   at	   the	   outset;	   validation	   and	   development	   of	   putative	   genomic	  signatures	  needs	  to	  be	  conducted	  with	  the	  ultimate	  use	  of	  the	  assay	  in	  mind.	  	  In	  view	   of	   this,	   several	   example	   clinical	   scenarios	   where	   a	   validated	   and	  prospectively	   tested	   predictive	   biomarker	   assay	   for	   platinum	   response	   or	  toxicity	  could	  be	  employed	  are	  discussed	  below.	  	  One	   example	   of	   a	   potential	   clinical	   application	   is	   to	   examine	   for	  differences	   in	   induced	  oxaliplatin-­‐DNA	  adduct	  patterns	   in	   cohorts	  of	   colorectal	  cancer	  patients	  previously	  treated	  with	  adjuvant	  oxaliplatin-­‐base	  chemotherapy,	  comparing	   the	   induced	   patterns	   in	   a	   cohort	   with	   and	   without	   OIPN	   during	  treatment.	   	   Evidence	  presented	   in	   the	   functional	   study	  described	   in	   this	   thesis	  suggests	   some	   patients	   who	   develop	   severe	   OIPN	   may	   have	   defects	   in	   DNA	  repair	   capacity,	   supporting	   this	   approach.	   	   If	   a	   signature	   of	   platinum-­‐DNA	  adducts	   identifies	   patients	   at	   higher	   risk	   of	   severe	   OIPN,	   this	   would	   give	   the	  treating	  clinician	  several	  advantages,	  including	  to	  allow	  identification	  of	  patients	  who	   would	   benefit	   from	   closer	   monitoring	   for	   the	   development	   of	   OIPN,	  modification	   of	   the	   chemotherapy	   drugs	   used	   to	   a	   less	   neurotoxic	   equivalent,	  and	  more	  effective	  testing	  of	  preventative	  measures	  in	  a	  high	  risk	  cohort.	  	  	   An	  alternative	  potential	  clinical	  study	  is	  to	  examine	  platinum-­‐DNA	  adduct	  patterns	   in	   patients	   treated	  with	   cisplatin	   for	  metastatic	   or	   surgically	   resected	  non-­‐small	  cell	  lung	  cancer	  (NSCLC).	  	  Cisplatin	  in	  NSCLC	  has	  approximately	  a	  40%	  response	  rate	  (Cobo	  et	  al.	  2007).	   	  A	  20ml	  blood	  sample	  prior	   to	  chemotherapy	  could	   be	   taken	   and	   platinum-­‐DNA	   adduct	   patterns	   generated.	   	   The	   tools	  developed	  in	  this	  thesis	  could	  be	  used	  to	  compare	  the	  adduct	  patterns	  generated	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between	  responders	  and	  non-­‐responders,	  potentially	   identifying	  platinum-­‐DNA	  adducts	   at	   different	   regions	   of	   the	   genome	   that	   correlate	   more	   closely	   with	  response	  and	  toxicity	  than	  the	  ‘average’	  platinum-­‐DNA	  adduct	  levels,	  or	  average	  levels	   of	   DNA	   repair	   that	   have	   previously	   demonstrated	   significant,	   albeit	  limited,	  predictive	  potential	  in	  this	  context	  (Hutchinson	  2011;	  Wang	  et	  al.	  2011)	  	  	  Other	   clinical	   tumour	   sites	   and	   treatments	   that	   could	   benefit	   from	   this	  approach	   to	   patient	   stratification	   include	   the	   treatment	   of	  malignancies	   of	   the	  head	  and	  neck.	  	  For	  example,	  many	  patients	  are	  treated	  with	  curative	  intent	  with	  a	  combination	  of	  chemotherapy	  and	  radiotherapy,	  with	  the	  addition	  of	  cisplatin	  chemotherapy	  during	  radiotherapy	  offering	  a	  5-­‐10%	  additional	  survival	  benefit,	  depending	   on	   tumour	   type,	   stage	   and	   patient	   age	   (Pignon	   et	   al.	   2009).	   	   The	  addition	   of	   cisplatin	   significantly	   increases	   the	   side	   effect	   profile	   of	   treatment	  (Bernier	  et	  al.	  2004;	  Cooper	  et	  al.	  2004),	  although	  an	  alternative	  treatment	  with	  monoclonal	   antibody	   treatment	   cetuximab	   offers	   a	   less	   toxic,	   but	   much	   more	  expensive	  alternative	  (Bonner	  et	  al.	  2006),	  which	  currently	  can	  only	  be	  used	   if	  cisplatin	  is	  contraindicated	  (NICE	  2008).	  	  The	  DIP-­‐chip	  assay	  could	  be	  applied	  to	  pre-­‐treatment	   blood	   samples	   and	   generated	   platinum-­‐DNA	   adduct	   patterns	  compared	   between	   responders	   and	   non-­‐responders,	   or	   between	   patients	   who	  developed	   severe	   toxicities.	   	   If	   a	   characteristic	   signature	   of	   platinum	   non-­‐response	   or	   platinum-­‐related	   severe	   toxicity	   could	   be	   identified,	   it	   could	  potentially	   be	   used	   pre-­‐treatment	   to	   determine	   if	   patients	   should	   receive	  concomitant	   chemotherapy	   with	   cisplatin	   or	   cetuximab	   during	   curative	  radiotherapy	  treatment.	  	   Alternative	  lines	  of	  clinically	  relevant	  experiments	  could	  also	  be	  pursued.	  	  One	   example	   is	   study	   to	   compare	   the	   generation	   of	   platinum-­‐DNA	   adduct	  patterns	  in	  surrogate	  tissues	  (such	  as	  PBMC	  or	  buccal	  cells)	  compared	  to	  tumour	  samples.	  	  This	  could	  be	  done	  in	  the	  context	  of	  oxaliplatin	  use	  as	  a	  treatment	  prior	  to	   the	   resection	  of	   liver	  or	   lung	  metastasis,	   or	   in	   lung	   cancer	   comparing	   tissue	  taken	  during	  curative	  surgery	  of	  primary	  lung	  tumours,	  comparing	  the	  germline	  DNA	  and	  tumour	  DNA	  platinum	  adduct	  patterns,	  and	  compared	  to	  the	  response	  and	  toxicity	  from	  adjuvant	  cisplatin	  chemotherapy.	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   These	  are	  just	  a	  few	  examples	  of	  the	  important	  clinical	  role	  for	  which	  an	  accurate	   method	   of	   identifying	   patients	   at	   high	   risk	   of	   toxicity	   or	   low	   risk	   of	  response	  would	  be	  a	  valuable	  clinical	  tool.	  	  
 Other	  potential	  applications	  of	  the	  DIP-­‐chip	  assay	  7.5 	  The	  DNA-­‐damage	  adduct	  patterns	  generated	  by	  this	  technique	  have	  many	  applications	  for	  basic	  scientific	  research	  purposes.	   	  One	  example	  is	  in	  the	  study	  of	   causes	   of	   mutation	   spectra	   recently	   identified	   during	   next-­‐generation	  sequencing	  of	  tumour	  and	  germline	  DNA	  (Alexandrov	  et	  al.	  2013a;	  Alexandrov	  et	  al.	   2013b;	   Nik-­‐Zainal	   et	   al.	   2012).	   	   Patterns	   of	  mutations	   have	   been	   identified	  which	   characterise	   a	   specific	   underlying	   mutational	   processes	   -­‐	   for	   example	  smokers	   have	   a	   particular	   spectrum	   of	   mutation,	   as	   do	   patients	   previously	  treated	  for	  cancer	  with	  temozolomide	  or	  patient	  heavily	  exposed	  to	  UV	  damage	  who	   develop	   melanoma.	   	   Of	   the	   characteristic	   mutation	   spectra	   identified,	   in	  several	  examples	  the	  specific	  underlying	  cause	  remains	  undetermined.	  One	   potential	   application	   of	   the	   DIP-­‐chip	   assay	   technology	   is	   the	  generation	   of	   induced	   DNA	   damage	   patterns,	   comparing	   the	   sites	   of	   elevated	  DNA-­‐adduct	  formation	  with	  the	  mutation	  spectra	  that	  occur.	  	  This	  could	  be	  used	  in	  patients	  previously	  exposed	  to	  platinum-­‐treatment.	  	  For	  example,	  many	  young	  patients	  with	  testicular	  cancer	  are	  treated	  curatively	  with	  cisplatin,	  but	  adducts	  can	  be	  identified	  decades	  after	  treatment	  completed	  (Gietema	  et	  al.	  2000),	  and,	  by	   some	   estimates,	   there	   is	   a	   40%	   increased	   risk	   of	   second	  malignancy	   in	   the	  decades	  following	  chemotherapy	  treatment	  for	  this	  condition	  (Fung	  et	  al.	  2013).	  	  Comparison	   of	   DIP-­‐chip	   cisplatin-­‐DNA	   adduct	   patterns	   with	   the	   spectrum	   of	  mutations	  present	   in	   germline	   and	   tumour	  DNA	   in	   this	   cohort	  of	  patients	  may	  shed	  light	  on	  this	  process,	  and	  could	  again	  be	  potentially	  used	  as	  a	  stratification	  tool	   to	   identify	   patients	   at	   increased	   risk	   of	   second	   malignancy	   following	  curative	  chemotherapy.	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Additional	   applications	   of	   the	  work	   presented	   in	   this	   thesis	   include	   the	  use	  of	  the	  bioinformatic	  tools	  developed	  in	  other	  similar	  experimental	  systems,	  and	   these	   tools	   are	   applied	   in	   the	   laboratory	   for	   a	  quality	   control	  measure	   for	  DNA	   micro-­‐arrays,	   to	   assess	   whether	   the	   IN	   and	   IP	   samples	   have	   correctly	  amplified	   and	  processed	   compared	   to	  other	   experimental	   samples,	   not	   just	   for	  platinum-­‐DIP	   chip	   samples,	   but	   in	   a	   variety	   of	   different	   contexts	   including	  protein-­‐binding	  analysis	  and	  histone	  acetylation	  DIP-­‐chip	  studies.	  	  Finally,	   inherent	   in	   the	   goal	   of	   this	   project	   is	   the	   development	   a	  model	  experimental	   pathway	   to	   allow	   the	   translation,	   optimisation	   and	   validation	   of	  this	  DIP-­‐chip	  assay	  into	  other	  clinical	  tissues,	  such	  as	  tumour	  or	  biopsy	  samples.	  	  It	  is	  likely	  that	  during	  future	  projects	  similar	  issues	  surrounding	  DIP-­‐chip	  assay	  variability	   in	   different	   tissue	   types	   will	   manifest.	   	   The	   experimental	   approach	  outlined	   in	   this	   thesis	   can	   be	   used	   as	   a	   model	   pathway	   for	   determining	   the	  relative	   contribution	   of	   different	   stages	   of	   the	   multi-­‐step	   assay	   and	   for	  optimising	   the	   DIP-­‐chip	   assay	   for	   different	   situations	   and	   different	   clinical	  material.	  
	  
 Conclusions	  7.6
	  Subtle	   differences	   in	   DNA	   repair	   gene	   function	   are	   associated	   with	  outcome	  from	  chemotherapy,	  for	  example	  in	  the	  form	  of	  OIPN	  as	  demonstrated	  in	   the	   functional	   study	  presented	   in	   this	   thesis.	   	  This	  work	   lends	  weight	   to	   the	  hypothesis	  that	  functional	  measurements	  of	  DNA	  repair	  are	  potentially	  a	  useful	  tool	   that	   could	   be	   used	   to	   stratify	   patients	   for	   the	   response	   and	   toxicity	   to	  platinum	   chemotherapy	   agents;	   an	   idea	   explored	   in	   all	   of	   the	   chapters	   of	   this	  thesis.	  	  Evidence	  from	  ‘single	  measure’	  adduct	  studies,	  as	  described	  above,	  have	  demonstrated	  that	  stratification	  of	  patients	  for	  response	  and	  toxicity	  to	  platinum	  agents	   by	   measuring	   features	   of	   germline	   DNA	   repair	   capacity	   is	   possible,	  although	  with	  a	  limited	  predictive	  power.	  By	  measuring	  induced	  platinum-­‐DNA	  adduct	  levels	  at	  high	  resolution	  and	  at	   a	   genomic-­‐scale,	   and	   by	   developing	   and	   applying	   unbiased	   genomic	   scale	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analysis	   techniques,	  we	  have	  developed	  a	   technology	  with	  robust	  experimental	  protocols	   and	   analysis	   pipelines,	   with	   the	   potential	   to	   overcome	   these	  technological	  limitations.	  	  This	  thesis	  documents	  and	  describes	  the	  development	  of	   this	   technology	   for	   use	   in	   human	   clinical	   samples	   and	   includes	   robust	  protocols	   to	   perform	   the	   assay	   and	   analyse	   the	   result,	   as	   well	   as	   providing	   a	  pathway	   for	   the	  refinement	  and	   future	  validation	  of	   the	   technique	   if	  applied	   to	  other	  clinical	  tissues.	   	  The	  DIP-­‐chip	  assay,	   in	  the	  form	  and	  context	  as	  described	  here,	  has	  opened	  the	  door	  to	  many	  clinical	  and	  research	  applications,	  and	  several	  potential	  studies	  that	  will	  be	  conducted	  in	  our	  laboratory	  in	  the	  coming	  months	  and	  years.	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Chapter	  8 Appendicies	  
 Appendix	  1:	  Media	  and	  Solutions	  8.1
8.1.1 Yeast	  Media	   	  
YPD	  (400	  ml)	  4	  g	  Bacto	  Yeast	  Extract	  8	  g	  Bacto	  Peptone	  8	  g	  Glucose	  Made	  up	  to	  400	  ml	  with	  H2O	  YPD	  plates	  were	  obtained	  by	  supplementing	  above	  medium	  with	  8	  g	  Bacto	  Agar	  	  
Minimal	  Media	  (400	  ml)	  2.68	  g	  Yeast	  Nitrogen	  Base	  w/o	  Amino	  Acids	  8	  g	  Glucose	  Made	  up	  to	  400	  ml	  with	  H2O	  For	  plates	  supplement	  with	  2%	  Bacto	  Agar	  	  Dosage	  of	  Amino	  Acids	  added:	  Adenine	  	  	  	  	  	  	  	  	  	  40	  μg/ml	  Leucine	  	  	  	  	  	  	  	  	  	  	  60	  μg/ml	  Uracil	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  20	  μg/ml	  Tryptophan	  	  	  40	  μg/ml	  Lysine	  	   	  	  	  	  	  40	  μg/ml	  Histidine	   40	  μg/ml	  	  
8.1.2 Solutions	  
	  
0.5	  M	  EDTA	  (pH	  8.0)	  EDTA	  .	  Na2	  .	  2H2O	   	   186.1g	  H2O	   	   	   	   	   800ml	  Stir	  on	  a	  magnetic	  stirrer.	  	  Adjust	  the	  pH	  to	  8.0	  with	  NaOH	  (~22	  g	  of	  NaOH	  pellets).	  Add	  H2O	  to	  make	  1	  L	  and	  sterilise	  by	  autoclaving.	  
	  
1	  M	  Tris	  Tris	  base	  	   	   	   	   121.1	  g	  H2O	   	   	   	   	   800	  ml	  Adjust	  the	  pH	  to	  the	  desired	  value	  by	  adding	  concentrated	  HCl.	  	  Add	  H2O	  to	  make	  1	  L.	  
	  
10	  x	  TE	  Buffer	  (400	  ml)	  40	  ml	  1	  M	  Tris-­‐HCl,	  pH	  7.5	  	  8	  ml	  0.5	  M	  EDTA,	  pH	  8.0	  352	  ml	  of	  H2O	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3	  M	  Sodium	  acetate	  (pH	  5.2)	  (400	  ml)	  Sodium	  acetate	  -­‐	  3H2O	  	   163.24	  g	  H2O	  	   	   	   	   	   300	  ml	  Adjust	  the	  pH	  to	  5.2	  with	  acetic	  acid.	  Adjust	  the	  volume	  to	  400	  ml	  with	  H2O.	  	  Filter	  to	  sterilise.	  
	  
	  
5M	  NaCL	  (400	  ml)	  Dissolve	  116.9	  g	  of	  NaCl	  in	  350	  ml	  of	  H2O	  Adjust	  the	  volume	  to	  400	  ml	  with	  H2O.	  	  Sterilise	  by	  autoclaving.	  
	  
	  
10%	  SDS	  (Sodium	  dodecyl	  sulfate)	  (1	  L)	  Dissolve	  100g	  of	  SDS	  in	  800	  ml	  of	  distilled	  H2O.	  	  Add	  distilled	  H2O	  to	  make	  a	  total	  volume	  of	  1	  L.	  
	  
	  
20%	  SDS	  (Sodium	  dodecyl	  sulfate)	  (500	  ml)	  Dissolve	  100	  g	  of	  SDS	  in	  350	  ml	  of	  distilled	  H2O.	  	  Add	  distilled	  H2O	  to	  make	  a	  total	  volume	  of	  500	  ml.	  
	  
	  
PBS	  (1	  L)	  NaCL	  	   	   	   8g	  KCl	   	   	   	   0.2g	  Na2HPO4	  	   	   	   1.44	  g	  	  KH2PO4	   	   	   0.24g	  H2O	  	   	   	   	   800ml	  Adjust	  the	  pH	  to	  7.4.	  	  Add	  H2O	  to	  1	  L.	  	  Sterilise	  by	  autoclaving.	  	  	  
Sorbitol	  TE	  (1L)	  (Kept	  in	  cold	  room	  at	  4°C)	  Sorbitol	   	   	   165g	  Tris	  .	  HCl	  (pH8.0)	   100ml	  EDTA	   	   	   200ml	   	  Add	  500	  ml	  H2O	  to	  dissolve	  the	  sorbitol.	  	  Adjust	  the	  final	  volume	  to	  1L.	  
	  
DNA	  Lysis	  Buffer	  (1	  L)	  Urea	  	   	   	   240g	  NaCl	   	   	   	   11.69g	  CDTA	   	   	   5g	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SDS	   	   	   	   5g	  1	  M	  Tris-­‐HCl	  (pH	  8.0)	  100ml	  Add	  700	  ml	  of	  H2O	  to	  dissolve	  the	  chemicals	  Adjust	  the	  final	  volume	  to	  1L.	  	  	  
1	  M	  DTT	  (Dithiothreitol)	  DTT	  3.09	  g	  Dissolved	  in	  20	  ml	  of	  0.01	  M	  sodium	  acetate	  (pH	  5.2)	  Sterilise	  by	  filtration.	  Do	  not	  autoclave	  solutions	  containing	  DTT.	  	  
	  
8.1.3 Solutions	  for	  electrophoresis	  
	  
50	  x	  TAE	  (Tris-­‐acetate)	  (1	  L)	  Tris	  base	   	   	   	   242g	  Sodium	  Acetate	  .3	  H2O	   136g	  0.5	  M	  EDTA	   	   	   200ml	  	  Adjust	  to	  pH	  7.2	  with	  acetic	  acid.	  	  Add	  H2O	  to	  make	  1	  L.	  
	  
	  
10	  x	  TBE	  (1	  L)	  Tris	  base	   	   	   	   106g	  Boric	  acid	   	   	   	   55g	  	  EDTA	   	   	   	   8.3g	   	  Add	  H2O	  to	  1	  L.	  
	  
	  
8.1.4 Solutions	  for	  ChIP	  
FA/SDS	  Buffer	  HEPES	  KOH	  pH	  7.5	   	   50mM	  NaCl	   	   	   	   	   150mM	  EDTA	   	   	   	   1mM	  Triton	  X	  100	   	   	   1%	  Deoxycholate	  Na	   	   0.1%	  SDS	   	   	   	   	   0.1%	  PMSF	  *	   	   	   	   1mM	  	  *Add	  just	  before	  use	  as	  the	  activity	  decreases	  in	  H20	  solution	  The	  NaCl	  concentration	  can	  be	  adjusted	  to	  500mM.	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5	  x	  Pronase	  Buffer	  (100	  ml)	  1	  M	  Tris	  pH7.5	   	   	   12.5mM	  0.5	  M	  EDTA	   	   	   5ml	  10%	  SDS	   	   	   	   25ml	  Add	  H2O	  to	  make	  100	  ml.	  	  	  
LiCl	  Buffer	  (500	  ml)	  1	  M	  Tris	  pH	  8.0	   	   	   5ml	  5	  M	  LiCl	   	   	   	   25ml	  0.5	  M	  EDTA	   	   	   1ml	  NP40	   	   	   	   2.5ml	  Deoxycholate	  Na	   	   25ml	  Add	  H20	  to	  make	  500	  ml.	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1)	   SCAdataload	  function	  	  Version	  2.0	  11/09/14	  Role:	  Loads	  data	  for	  SCA	  plot	  and	  corPlot	  functions	  	  Requirements:	  Sandcastle	  1.0	  	   	   	   Output	  to	  vector	  SCAdata	  
 
Example	  SCAdata<-­‐SCAdataLoad	  SCAdata<-­‐SCAdataLoad	  	  
 
SCAdataLoad<-function(all=TRUE){ 
  dataratio<-loadArrayFiles(chromosomeIDs=c(1:22,"X","Y")) 
  dataIN<-loadArrayFiles(chromosomeIDs=c(1:22,"X","Y"), 
 redValues=NULL) 
  dataIP<-loadArrayFiles(chromosomeIDs=c(1:22,"X","Y"), 
 greenValues=NULL) 
   
if(all){ 
    SCAdata<-c(dataratio,dataIN,dataIP)} 
 
else{ 
     z<-readline("How many array files to load for SCA analysis?") 
     z<-as.numeric(z) 
     mat<-matrix(nrow=2,ncol=z) 
     for (n in 1:z) mat[1,n]<-n 
     print("Enter datasets in order to load") 
     for (n in 1:z) { 
 
 print(n) 
     mat[2,n]<-as.numeric(readline("Enter dataset..."))} 
    for (n in 1:z) for (m in 1:2) mat[m,n]<-as.numeric(mat[m,n]) 
     SCAdata<-dataratio[,(mat[2,1])] 
     for (n in 1:(z-1)) SCAdata<-c(SCAdata,dataratio[,(mat[2,(n 
  +1)])]) 
     for (n in 1:z) SCAdata<-c(SCAdata,dataIN[,(mat[2,n])]) 
     for (n in 1:z) SCAdata<-c(SCAdata,dataIP[,(mat[2,n])]) 
    return(SCAdata)} 
}#end function 
 	  	  	  
2)	   corsCalc	  function	  
	  Version	  1.0	  11/06/14	  Role:	  	   	   Calculates	  correlation	  matrix	  table	  from	  SCAdata	  to	  use	  in	  SCAplot	  	   	   and	  corsPlot	  	  Requirements:	  	  Vector	  SCAdata	  from	  SCAdataload	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  cors<-matrix(ncol=(ncol(SCAdata)), nrow=(ncol(SCAdata))) 
  for (n in 1:ncol(SCAdata)) for (m in 1:ncol(SCAdata)) cors[m,n]<- 
cor.test(SCAdata[,n]$ratios,SCAdata[,m]$ratios, method="spearman") 
$estimate 









  r=2 
  corspred<-matrix(ncol=(ncol(SCAdata)), nrow=r) 
  for (n in 1:ncol(SCAdata)) corspred[1,n]<-cor.test(SCAdata[,n] 
$ratios,predPlat$ratios, method="spearman")$estimate 
  for (n in 1:ncol(SCAdata)) corspred[r,n]<-cor.test(SCAdata[,n] 
$ratios,predUV$ratios, method="spearman")$estimate 
  return(corspred)} 	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 Appendix	  3:	  SCAplot	  function	  	  8.3	  Version	  1.1,	  110614	  Role:	  Plots	  data	  in	  vector	  SCAdata,	  separated	  by	  channels	  	  Requirements:	  	   Sandcastle	  package.	  Human	  genome	  annotation	  to	  vector	  anno.human	  	  SCA	  ancillary	  function	  SCAdataload	  to	  vector	  SCAdata	   	  	  
Examples:	  	  SCAplot()	  SCAplot(end=10080000,legends=FALSE)	  SCAplot(11000000,10060000)	  SCAplot(highlight=T,	  labels=T,	  datatohighlight=5)	  	  
 
SCAplot<-function(start=10050000,end=10075000, legends=TRUE, 
labels=FALSE, highlight=FALSE, datatohighlight=FALSE){ 
   
 if ((end-start)>50000) stop(" Resolution too low >50000 
 nucleotides") 
if ((start>end)) stop("End position must be after start 
position") 





#add text for labels if needed 
if(labels){ 
mat<-matrix(nrow=1,ncol=a) 
print("Enter dataset labels in order of use") 





   
if(!highlight){ 
    genomePlot(SCAdata[,c((1:a),((a+1):(2*a)),(((2*a)+1):(3*a)))], 
               anno.human,chr=17,ylim.constant=FALSE, 
               multi=TRUE,toPlot=x, lwd=2, 
               cols=list(rep(1,a),rep(3,a),rep(2,a)), 
               ltys=list(seq(1:a))) 
     
if (legends){ 
       
if (!labels){ 
    legend(cex=0.8,x="topright",box.lwd=1, box.lty=1, box.col=1, 
 bg="lightgoldenrod", 
     ncol=1,title="IP/IN Pattern", 
     legend=seq(1:a), 
     col=rep(1,a), 
 lty=seq(1:a)) 
         
legend(cex=0.8,x="right",box.lwd=1, box.lty=1, box.col=1, 
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 bg="lightgoldenrod", 
     ncol=1,title="IN Pattern", 
     legend=seq(1:a), 
     col=rep(3,a), 
     lty=seq(1:a)) 
 
legend(cex=0.8,x="bottomright",box.lwd=1, box.lty=1, 
 box.col=1, bg="lightgoldenrod", 
    ncol=1,title="IP Pattern", 
    legend=seq(1:a), 
     col=rep(2,a), 
     lty=seq(1:a))} 
       
if(labels){ 
         
legend(cex=0.8,x="topright",box.lwd=1, box.lty=1, box.col=1, 
 bg="lightgoldenrod", 
     ncol=1,title="IP/IN Pattern", 
     legend=mat[1,], 
     col=rep(1,a), 
     lty=seq(1:a)) 
      
legend(cex=0.8,x="right",box.lwd=1, box.lty=1, box.col=1, 
 bg="lightgoldenrod", 
     ncol=1,title="IN Pattern", 
     legend=mat[1,], 
     col=rep(3,a), 
     lty=seq(1:a)) 
 
legend(cex=0.8,x="bottomright",box.lwd=1, box.lty=1, 
 box.col=1, bg="lightgoldenrod", 
     ncol=1,title="IP Pattern", 
     legend=mat[1,], 
     col=rep(2,a), 
     lty=seq(1:a))}}} 
   
if(highlight){ 
    genomePlot(SCAdata[,c((1:a),((a+1):(2*a)),(((2*a)+1):(3*a)))], 
      anno.human,chr=17,ylim.constant=FALSE, 
          multi=TRUE,toPlot=x, lwd=2, 
          cols=list(c(rep(1,(dth-1)),dthcol,rep(1,(a-
dth))),c(rep(3,(dth-1)),dthcol,rep(3,(a-dth))),c(rep(2, 
(dth-1)),dthcol,rep(2,(a-dth)))), 
         ltys=list(seq(1:a))) 
     
if (legends){ 
       
if(!labels){ 
 
legend(cex=0.8,x="topright",box.lwd=1, box.lty=1, box.col=1, 
  bg="lightgoldenrod", 
          ncol=1,title="IP/IN Pattern", 
          legend=seq(1:a), 
          col=c(rep(1,(dth-1)),dthcol,rep(1,(a-dth))), 
          lty=seq(1:a)) 
         
legend(cex=0.8,x="right",box.lwd=1, box.lty=1, box.col=1, 
  bg="lightgoldenrod", 
          ncol=1,title="IN Pattern", 
          legend=seq(1:a), 
          col=c(rep(3,(dth-1)),dthcol,rep(3,(a-dth))), 
          lty=seq(1:a)) 
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legend(cex=0.8,x="bottomright",box.lwd=1, 
 box.lty=1,box.col=1,bg="lightgoldenrod", 
     ncol=1,title="IP Pattern", 
     legend=seq(1:a), 
     col=c(rep(2,(dth-1)),dthcol,rep(2,(a-dth))), 
     lty=seq(1:a))}} 
     
if(labels){ 
 
legend(cex=0.8,x="topright",box.lwd=1, box.lty=1, box.col=1, 
 bg="lightgoldenrod", 
     ncol=1,title="IP/IN Pattern", 
     legend=mat[1,], 
    col=c(rep(1,(dth-1)),dthcol,rep(1,(a-dth))), 
     lty=seq(1:a)) 
      
legend(cex=0.8,x="right",box.lwd=1, box.lty=1, box.col=1, 
 bg="lightgoldenrod", 
     ncol=1,title="IN Pattern", 
    legend=mat[1,], 
    col=c(rep(3,(dth-1)),dthcol,rep(3,(a-dth))), 
     lty=seq(1:a)) 
      
legend(cex=0.8,x="bottomright",box.lwd=1, box.lty=1,box.col=1,  
 bg="lightgoldenrod", 
    ncol=1,title="IP Pattern", 
    legend=mat[1,], 
    col=c(rep(2,(dth-1)),dthcol,rep(2,(a-dth))), 
     lty=seq(1:a))}} 
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 Appendix	  4:	  	  The	  corPlot	  Function	  8.4	  Version	  1.2	  11/09/14	  Role:	  Plots	  SCA	  matrix	  Requirements:	  	   Data	  in	  vector	  SCAdata	  from	  SCAdataLoad	  function	  	   	   	   Correlations	  calculated	  by	  corsCalc	  in	  vector	  cors	  	   	   If	  prediction	  profile	  required	  the	  prediction	  correlations	  in	  vector	  	   	   corspred	  from	  function	  corsPredCalc	   	  	  
	  





corPlot<-function(boxtext=TRUE, prediction=FALSE, UV=FALSE, 
platinum=FALSE, labels=FALSE, FigSize=1, key=TRUE){ 
 
#check if prediction required then has been specified and logical 
arguments are correct   
if (!is.logical(boxtext) |!is.logical(prediction) | !is.logical(UV) | 
!is.logical(platinum)) stop ("Invalid TRUE/FALSEargument present") 
if ((prediction) & ((!UV)&(!platinum))) stop ("Prediction pattern is 
selected.  Choose either/both UV or platinum as TRUE and ensure 
correct matrix from CorsPredCal() is complete") 
   
#set up numbers 
s<-(ncol(cors)/3)       #need to use to remove data from cor table 
for individual colour boxes 
  boxtextsize<-((1-(0.07*s))*FigSize) 
  axistextsize<-((1.2-(0.05*s))*FigSize) 
 
#add text for labels if needed 
    if(labels){ 
     same<-readline("Use same labels for IP/IN, IN and IP? - Enter 1 
if yes or 2 if no") 
    if ((same!=1)&(same!=2)) stop ("Must be 1 or 2") 
    if (same==1){ 
     mat<-matrix(nrow=2,ncol=s) 
     for (n in 1:s) mat[1,n]<-n 
     print("Enter dataset labels in order of use") 
     
for (n in 1:s) { 
      print(n) 
      mat[2,n]<-readline("Enter label...")}} 
 
if (same==2){ 
      mat<-matrix(nrow=2,ncol=(3*s)) 
      for (n in 1:(3*s)) mat[1,n]<-n 
      print("Enter dataset labels in order of use") 
      for (n in 1:(3*s)) { 
 print(n) 
         mat[2,n]<-readline("Enter label...")}} 
    } 
 
#set up color palettes 




















#calculate plot specific correlation values and rotate for image 
corst<-t(cors)[,nrow(cors):1] 
 
#calculate individual value sets to use for overlying plots 




#remove 1vs1 for later tables 
corst[corst>0.999]<-NA 




















#plot individual sections, overlying each other on same grid 
#set plot area and adjust from center by figure size 






 #plot 1s only as grey 
image(x=seq(dim(corst1only)[2]),y=seq(dim(corst1only)[1]),z=corst1onl
y, axes=FALSE,xlab="",ylab="",useRaster=TRUE, col="grey90") 
  
#plot IP/IN  
par(new=TRUE) 
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image(x=seq(dim(corstIPIN)[2]),y=seq(dim(corstIPIN)[1]),z=corstIPIN, 








































#if no labels needed 
















line=linewd, tck=0, lty=0)} 
 
#add option to label individual lanes 
  else {linewd=1.5 
    if(same==1){ 
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   #if same label for IP/IN, IN or IP needed 
     for (n in 1:s) { 
       axis(1, at=c(n,(s+n),(2*s+n)), 
 lab=c(mat[2,n],mat[2,n],mat[2,n]), las=2, 
cex.axis=axistextsize, 
 line=linewd, lty=0) 
      axis(2, at=c((3*s+1-n),(2*s+1-n),(s+1-n)), 
 lab=c(mat[2,n],mat[2,n],mat[2,n]),las=1, cex.axis=axistextsize, 
 line=linewd, lty=0) 
       axis(3, at=c(n,(s+n),(2*s+n)), 
 lab=c(mat[2,n],mat[2,n],mat[2,n]),las=2, cex.axis=axistextsize, 
 line=linewd, lty=0) 
       axis(4, at=c((3*s+1-n),(2*s+1-n),(s+1-n)), 
 lab=c(mat[2,n],mat[2,n],mat[2,n]),las=1, cex.axis=axistextsize, 
 line=linewd, lty=0) 
 }} 
     
else{ 
      #if individual labels for IP/IN, IN and IPs needed 
      for (n in 1:s) { 
        axis(1, at=c(n,(s+n),(2*s+n)), lab=c(mat[2,n],mat[2,(s 
+n)],mat[2,(n+2*s)]), las=2, cex.axis=axistextsize, line=linewd, 
lty=0) 
        axis(2, at=c((3*s+1-n),(2*s+1-n),(s+1-n)), 
lab=c(mat[2,n],mat[2,(s+n)],mat[2,(2*s+n)]),las=1, 
cex.axis=axistextsize, line=linewd, lty=0) 
        axis(3, at=c(n,(s+n),(2*s+n)), lab=c(mat[2,n],mat[2,(s 
+n)],mat[2,(n+2*s)]),las=2, cex.axis=axistextsize, line=linewd, 
lty=0) 
        axis(4, at=c((3*s+1-n),(2*s+1-n),(s+1-n)), 
lab=c(mat[2,n],mat[2,s+n],mat[2,n+2*s]),las=1, 
cex.axis=axistextsize, line=linewd, lty=0) 
}}} 
  #add IP/IN, IN and IP inner coloured labels to plot 
  linewd<-(-0.5) 
  if (s<11) { 
    for (n in 1:s) 
    {axis(1, at=n, lab=("IP/IN"), col.axis="goldenrod3", 
line=linewd, las=2, lty=0, cex.axis=axistextsize) 
     axis(1, at=s+n, lab=("IN"), col.axis="darkgreen", line=linewd, 
tck=0, las=2, lty=0, cex.axis=axistextsize) 
     axis(1, at=(2*s+n), lab=("IP"), col.axis="darkred", 
line=linewd, tck=0, las=2, lty=0, cex.axis=axistextsize) 
     axis(2, at=2*s+n, lab=("IP/IN"), col.axis="goldenrod3", 
line=linewd, tck=0, las=2, lty=0, cex.axis=axistextsize) 
     axis(2, at=s+n, lab=("IN"), col.axis="darkgreen", line=linewd, 
tck=0, las=1, lty=0, cex.axis=axistextsize) 
     axis(2, at=n, lab=("IP"), col.axis="darkred", line=linewd, 
tck=0, las=1, lty=0, cex.axis=axistextsize) 
     axis(3, at=n, lab=("IP/IN"), col.axis="goldenrod3", 
line=linewd, tck=0, las=2, lty=0, cex.axis=axistextsize) 
     axis(3, at=s+n, lab=("IN"), col.axis="darkgreen", line=linewd, 
tck=0, las=2, lty=0, cex.axis=axistextsize) 
     axis(3, at=(2*s+n), lab=("IP"), col.axis="darkred", 
line=linewd, tck=0, las=2, lty=0, cex.axis=axistextsize) 
     axis(4, at=2*s+n, lab=("IP/IN"), col.axis="goldenrod3", 
line=linewd, tck=0, las=2, lty=0, cex.axis=axistextsize) 
     axis(4, at=s+n, lab=("IN"), col.axis="darkgreen", line=linewd, 
tck=0, las=1, lty=0, cex.axis=axistextsize) 
     axis(4, at=n, lab=("IP"), col.axis="darkred", line=linewd, 
tck=0, las=1, lty=0, cex.axis=axistextsize)}} 
  else { 
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    #just add one IP/IN IN and IP label if too many datasets to avoid 
crowding 
    axis(1, at=(s/2), lab=("IP/IN"), col.axis="goldenrod3", 
line=linewd, tck=0, las=2, lty=0, cex.axis=axistextsize) 
    axis(1, at=1.5*s, lab=("IN"), col.axis="darkgreen", line=linewd, 
tck=0, las=2, lty=0, cex.axis=axistextsize) 
    axis(1, at=2.5*s, lab=("IP"), col.axis="darkred", line=linewd, 
tck=0, las=2, lty=0, cex.axis=axistextsize) 
    axis(2, at=2.5*s, lab=("IP/IN"), col.axis="goldenrod3", 
line=linewd, tck=0, las=2, lty=0, cex.axis=axistextsize) 
    axis(2, at=1.5*s, lab=("IN"), col.axis="darkgreen", line=linewd, 
tck=0, las=1, lty=0, cex.axis=axistextsize) 
    axis(2, at=(s/2), lab=("IP"), col.axis="darkred", line=linewd, 
tck=0, las=1, lty=0, cex.axis=axistextsize) 
    axis(3, at=(s/2), lab=("IP/IN"), col.axis="goldenrod3", 
line=linewd, tck=0, las=2, lty=0, cex.axis=axistextsize) 
    axis(3, at=1.5*s, lab=("IN"), col.axis="darkgreen", line=linewd, 
tck=0, las=2, lty=0, cex.axis=axistextsize) 
    axis(3, at=2.5*s, lab=("IP"), col.axis="darkred", line=linewd, 
tck=0, las=2, lty=0, cex.axis=axistextsize) 
    axis(4, at=2.5*s, lab=("IP/IN"), col.axis="goldenrod3", 
line=linewd, tck=0, las=2, lty=0, cex.axis=axistextsize) 
    axis(4, at=1.5*s, lab=("IN"), col.axis="darkgreen", line=linewd, 
tck=0, las=1, lty=0, cex.axis=axistextsize) 
    axis(4, at=(s/2), lab=("IP"), col.axis="darkred", line=linewd, 
tck=0, las=1, lty=0, cex.axis=axistextsize) 
} 
  #fill in lines around specific boxes 
  box() 
  segments((s+0.5),(s+0.5),(s+0.5),(3*s+0.5), lwd=3) 
  segments(0,(2*s+0.5),(2*s+0.5),(2*s+0.5), lwd=3) 
  segments(0.52,(2*s+0.5),0.52,(3*s+0.5), lwd=3) 
  segments(0.5,(3*s+0.48),(s+0.5),(3*s+0.48), lwd=3) 
  segments((s+0.5),(s+0.5),(3*s+0.5),(s+0.5), lwd=3) 
  segments((2*s+0.5),0,(2*s+0.5),(2*s+0.5), lwd=3) 
  segments((2*s+0.5),0.52,(3*s+0.5),0.52, lwd=3) 
  segments((3*s+0.48),0.5,(3*s+0.48),(s+0.5), lwd=3) 
  segments((s+0.5),(s+0.5),(s+0.5),0, lwd=2) 
  segments(0.5,(s+0.5),(s+0.5),(s+0.5), lwd=2) 
  abline(h=2*s+0.5, lty=2) 
  abline(v=2*s+0.5, lty=2) 
  for (n in 1:s){ 
    abline (h=(n+0.5), v=(n+0.5),lty=2) 
    segments((s+n+0.5),(2*s+0.5),(s+n+0.5),0, lty=2) 
    segments((2*s+n+0.5),(s+0.5),(2*s+n+0.5),0, lty=2) 
    segments(0,(s+n+0.5),(2*s+0.5),(s+n+0.5), lty=2) 
    segments(0,(2*s+n+0.5),(s+0.5),(2*s+n+0.5), lty=2) 
} 
  #draw prediction profiles under main figure 
  if (prediction){ 
    #If both needed 
    if((platinum)&(UV)){ 
      corstpred<-t(corspred)[,nrow(corspred):1] 
      nrow(corstpred)->r 
      if (FigSize==1) par(fig=c(0.05,0.8,0.05,0.3),new=TRUE) else 
par(fig=c((0.4-(0.34*FigSize)),(0.4+(0.4*FigSize)),0.05,0.3), 
new=TRUE) 
      image(x=seq(1,(nrow(corstpred)),1),y=seq(1,2,1),z=corstpred, 
ylab="", xlab="",col=palrest, breaks=breaksrest, axes=FALSE) 
      text(expand.grid(x=seq(1,(nrow(corstpred)), 
1),y=seq(1,2,1)),labels=round(c(corstpred),2), cex=0.5) 
      box(lwd=2) 
      abline(h=1.5, lty=2) 
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      for (n in 1:2) abline(v=(n*(r/3)+0.5), lwd=2) 
      for (n in 1:r) abline(v=n+0.5, lty=2) 
      mtext(1, line=2, text="Correlation with Predicted Profiles", 
cex=0.75) 
      axis(4, at=c(1,2), lab=c("vs. \nUV", "vs.\nPlatinum"), las=2, 
tck=0, cex.axis=0.75) 
    } 
    #if only platinum 
    if((platinum)&(!UV)){ 
      corstpred<-t(corspred)[,nrow(corspred):1] 
      nrow(corstpred)->r 
      corstpred[,1]<-NA 
      if (FigSize==1) par(fig=c(0.05,0.8,0.01,0.25),new=TRUE) else 
par(fig=c((0.4-(0.34*FigSize)),(0.4+(0.4*FigSize)),0.01,0.25), 
new=TRUE) 
      image(x=seq(1,(nrow(corstpred)),1),y=seq(1,2,1),z=corstpred, 
ylab="", xlab="",col=palrest, breaks=breaksrest, axes=FALSE) 
      text(expand.grid(x=seq(1,(nrow(corstpred)), 
1),y=seq(1,2,1)),labels=round(c(corstpred),2), cex=0.5) 
      abline(h=1.5, lwd=2) 
      abline(h=2.48,lwd=2) 
      segments(0.52,1.5,0.52,2.5,lwd=2) 
      for (n in 1:4) segments((((n-1)*s)+0.5),1.5,(((n-1)*s)+0.5), 
2.5, lwd=2) 
      for (n in 1:r) segments((n+0.5),1.5,(n+0.5),2.5, lty=2) 
      mtext(1, line=1, text="Correlation with Platinum Predicted 
Profile", cex=0.75) 
      axis(4, at=2, lab=c("vs.\nPlatinum"), las=2, tck=0, 
cex.axis=0.75) 
    } 
    #if only UV 
    if((!platinum)&(UV)){ 
      corstpred<-t(corspred)[,nrow(corspred):1] 
      nrow(corstpred)->r 
      corstpred[,2]<-NA 
      if (FigSize==1) par(fig=c(0.05,0.8,0.05,0.3),new=TRUE) else 
par(fig=c((0.4-(0.34*FigSize)),(0.4+(0.4*FigSize)),0.05,0.3), 
new=TRUE) 
      image(x=seq(1,r,1),y=seq(1,2,1),z=corstpred, ylab="", 
xlab="",col=palrest, breaks=breaksrest, axes=FALSE) 
      text(expand.grid(x=seq(1,(nrow(corstpred)), 
1),y=seq(1,2,1)),labels=round(c(corstpred),2), cex=0.5) 
      abline(h=0.5, lwd=2) 
      abline(h=1.5,lwd=2) 
      segments(0.52,0.5,0.52,1.5,lwd=2) 
      for (n in 1:4) segments((((n-1)*s)+0.5),0.5,(((n-1)*s)+0.5), 
1.5, lwd=2) 
      for (n in 1:r) segments((n+0.5),0.5,(n+0.5),1.5, lty=2) 
      mtext(1, line=3, text="Correlation with UV Predicted Profile", 
cex=0.75) 
      axis(4, at=1, lab=c("vs.\nUV "), las=2, tck=0, cex.axis=0.75) 
}} 
  #draw key 
   if (key){ 
  # set up key specific breaks guide 
  brkINIP=c(seq(0,50,length=10),seq(51,75,length=40), 
(seq(75,100,length=150))) 
  brkIN=c(seq(0,50,length=5),seq(51,75,length=10), 
(seq(75,100,length=185))) 
  brkIP=c(seq(0,50,length=5),seq(51,75,length=10), 
(seq(75,100,length=185))) 
  brkrest=c(seq(0,10,length=20),seq(10,90,length=160), 
(seq(90,100,length=20))) 
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  #set up matrix for key plots 
  z=matrix(1:100,nrow=1) 
  x=1 
  y=seq(0,1,length=101) 
  p=matrix(1:100,nrow=1) 
  q=1 
  s=seq(-1,1,length=101) 
  #draw scale forIP/IN 
  par(fig=c(0.8,0.95,0.65,1), new=TRUE) 
  image(x,y,z,col=palINIP,breaks=brkINIP,axes=FALSE,ylab="",xlab="") 
  mtext("IP/IN vs. IP/IN Correlation Key",2,line=0.5, cex=0.8) 
  axis(4, at=c(seq(0.0,1.0,0.1)), lab=c(seq(0.0,1.0,0.1)), las=2, 
cex.axis=0.75, tck=-0.5) 
  box() 
  #draw scale for IN 
  par(fig=c(0.8,0.95,0.45,0.8), new=TRUE) 
  image(x,y,z,col=palIN,breaks=brkIN,axes=FALSE, ylab="", xlab="") 
  mtext("IN vs. IN Correlation Key",2,line=0.5, cex=0.8) 
  axis(4, at=c(seq(0.0,1.0,0.1)), lab=c(seq(0.0,1.0,0.1)), las=2, 
cex.axis=0.75,tck=-0.5) 
  box() 
  #draw scale for IP 
  par(fig=c(0.8,0.95,0.25,0.6), new=TRUE) 
  image(x,y,z,col=palIP,breaks=brkIP,axes=FALSE,ylab="",xlab="") 
  mtext("IP vs. IP Correlation Key",2,line=0.5, cex=0.8) 
  axis(4, at=c(seq(0.0,1.0,0.1)), lab=c(seq(0.0,1.0,0.1)), las=2, 
cex.axis=0.75,tck=-0.5) 
  box() 
  #draw scale for rest of correlations 
  if(!prediction){ 
  par(fig=c(0.8,0.95,0,0.4), new=TRUE) 
  image(q,s,p,col=palrest, 
breaks=brkrest,axes=FALSE,ylab="",xlab="") 
  mtext("IP/IN vs. IN. vs IP Correlation Key",2,line=0.5, cex=0.8) 
  axis(4, at=c(seq(-1,1.0,0.2)), lab=c(seq(-1,1.0,0.2)), las=2, 
cex.axis=0.75,tck=-0.5) 
box()} else { 
  par(fig=c(0.8,0.95,0,0.4), new=TRUE) 
  image(q,s,p,col=palrest, 
breaks=brkrest,axes=FALSE,ylab="",xlab="") 
  mtext("IP/IN vs. IN. vs IP vs. Prediction\n Correlation Key", 
2,line=0.5, cex=0.8) 
  axis(4, at=c(seq(-1,1.0,0.2)), lab=c(seq(-1,1.0,0.2)), las=2, 
cex.axis=0.75,tck=-0.5) 
box()} } 
}#End of function 
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 Appendix	  5:	  	  The	  AGCcalc	  function	  8.5	  Version	  1.1	  Role:	  Generates	  correlation	  between	  datasets	  at	  specified	  windows.	  	  Calculates	  window	  GC	  content.	  Requirements:	   DIP-­‐chip	  microarray	  data	  in	  vector	  dataAGC	  	   	   	   Output	  stored	  to	  vector	  AGCmatrix	  	  






#choose which datasets in dataAGC to compare 
     tocompare<-matrix(ncol=3,nrow=comparisons) 
     for (n in 1:comparisons) tocompare[n,1]<-n 
     print("Enter datasets to copmare in order of desired comparisons 
  i.e. 1a vs 1b, 2a vs 2b...") 
     for (n in 1:comparisons){ 
    print("For comparison") 
 print(n) 
     tocompare[n,2]<-as.numeric(readline("Enter dataset 
 ‘a' (identified using numerical order in vector 'dataAGC')...")) 
    tocompare[n,3]<-as.numeric(readline("Enter dataset 
 'b' (identified using numerical order in vector 'dataAGC')...")) 
    } 
     
#caluclate GC content at each window 
    #check necessary packages and obtain if absent 
    require(Biostrings) #load package if required 
    require(BSgenome) #load package if required 
    require(BSgenome.Hsapiens.UCSC.hg19) 
 
#set up matrix for to contain window data 
    AGCmatrix<-matrix(nrow=comparisons+1,ncol=segments) 
    winsize=((end-start)/segments) 
 
#calculate GC content of window and add to matrix seqmat 
 
for (n in 1:segments){ 
    winstart=start+((n-1)*winsize) 
     winend=start+n*(winsize) 
     chr17s<-getSeq(Hsapiens,"chr17",start=winstart,end=winend-1) 
     L<-length(chr17s) 
     p1<-"G" 
     p2<-"C" 
     G<-countPattern(p1,chr17s) 
     C<-countPattern(p2,chr17s) 
     AGCmatrix[(comparisons+1),n]<-(G+C)/L} 
 
#calculate correlation between datasets at each window 
 
for (m in 1:segments) for (n in 1:comparisons) AGCmatrix[n,m]<- 
cor.test(dataAGC[,(tocompare[n,2])][dataAGC[,(tocompare[n,2])] 
$coordinates[,1]==17 & dataAGC[,(tocompare[n,2])]$coordinates[, 
2]>=((start-((end-start)/segments))+(m*((end-start)/segments))) & 
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dataAGC[,(tocompare[n,2])]$coordinates[,3]<=(start+(m*((end-start)/ 
segments))),1]$ratios,dataAGC[,(tocompare[n,3])][dataAGC[, 
(tocompare[n,3])]$coordinates[,1]==17 & dataAGC[,(tocompare[n,3])] 
$coordinates[,2]>=((start-((end-start)/segments))+(m*((end-start)/ 
segments))) & dataAGC[,(tocompare[n,3])]$coordinates[,3]<=(start+ 
(m*((end-start)/segments))),1]$ratios, method="spearman")$estimate 
    return(AGCmatrix) 
}#end of function 
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 Appendix	  6:	  	  The	  AGCplot	  function	  8.6	  Version	  1.1	  15/09/14	  Role:	  Plots	  AGC	  plots	  Requirements:	  	   Data	  in	  vector	  AGCmatrix	  generated	  by	  AGCcalc	  function	  Arguments	  start,	  end,	  segments	  and	  comparisons	  must	  be	  the	  same	  as	  used	  to	  generate	  data	  with	  the	  AGCcalc	  function	  
 














#plot comparions 1a vs 1b as inital plot 
 
par(mar=c(4,4,4,4)) 
  plot(as.numeric(AGCmatrix[1,]), 
     ,type="o",lty=1, lwd=1, 
     ylab="",xlab="", 
     ylim=c(0,1), 





for (n in 1:comparisons) 
abline(h=mean(AGCmatrix[n,]),lty=3,col=n,lwd=1) 
 
#overlie plots from additional comparisons 
if (comparisons>1) {for (n in 1:(comparisons-1)) points(corseq[(n 




if (comparisons>1) {for (n in 1:(comparisons-1)) lines(corseq[(n 
 +1),], lty=1, col=(n+1))} 
 






mtext("Chromosome 17 Position", side=1, line=3) 
 
#add left y axis 
axis(2, at=c(0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,1), las=2) 
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mtext("Spearman's rank correlation", side=2, line=3, col="black") 
 
#add GC content if argument GC=TRUE is used 
legcex=1){  if(GC){ 
    par(new=TRUE) #set par to overlay previous plot 
    #plot window GC content 
    plot(as.numeric(AGCmatrix[(comparisons+1),]), 
 type="l",col="darkorchid4",lty=1,lwd=2,ylim=c((0.2+reposition 
 GC),(0.7+repositionGC)),ylab="",xlab="",axes=FALSE) 
   
for (n in 1:(segments-1)) polygon(c(n,n,(n+1),(n 
+1)),c(0.3,AGCmatrix[(comparisons+1),n],AGCmatrix[(comparisons+1),(n 
+1)],0.3), col="grey", border=NA) 
  
#add average line 
    abline(h=mean(AGCmatrix[comparisons+1,]), col="grey",lty=3) 
    #add axis - right Y axis 
    axis(4, col="darkorchid4", col.axis="darkorchid4", 
 at=c(0.3,0.4,0.5), las=2, lwd=2) 
     mtext("GC Content", side=4, line=3, col="darkorchid4", adj=(0.4- 
 repositionGC), lwd=2)} 
  
#add user defined title if argument title=TRUE is used, and for 
titlelines number of lines 
   
if(title){ 
    for (n in 1:titlelines){ 
      print(c("For line",n)) 
      usertitle<-readline("Please enter plot title .....") 
      title(main=usertitle,line=(titlelines-n)) 
}} 
 
#add legend if argument legend=TRUE is used 
  if(legend){ 
    legmatrix<-matrix(nrow=2*comparisons,ncol=1) 
    legmatrixpoints<-matrix(nrow=2*comparisons,ncol=4) 
    for(n in 1:comparisons){ 
      print(c("Add legend details for comparison",n)) 
      legmatrix[(2*n-1),1]<-readline("Please enter comparison 
  details ...") 
      legmatrix[(2*n),1]<-paste(legmatrix[(2*n-1),1],"- Mean Dataset 
  Correlation") 
      legmatrix[(2*n-1),1]<-paste(legmatrix[(2*n-1),1],"- Window 
  Correlation Value") 




    legmatrixpoints[(2*n-1),3]<-1 
    legmatrixpoints[(2*n),3]<-3 
     legmatrixpoints[c((2*n-1),2*n),4]<-2 
 
legGCmatrix<-matrix(nrow=2, ncol=1) 
      legGCmatrixpoints<-matrix(nrow=2,ncol=4) 
      legGCmatrix[1,]<-"Window GC Content" 
      legGCmatrix[2,]<-"Mean GC Content" 
      legGCmatrixpoints[1,]<-c(8,NA,1,4) 
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          legend=(legmatrix[,1]), 
          col=(legmatrixpoints[,1]), 
          pch=(legmatrixpoints[,2]), 
          lty=(legmatrixpoints[,3]), 
          lwd=(legmatrixpoints[,4]))}} 
 
}#end of function 
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 Appendix	  7:	  	  The	  outlierDataPlot	  function	  8.7	  Version	  1.1:	  11/06/14	  Role:	  Plots	  outlier	  probes	  locations	  between	  two	  DIP-­‐chip	  datasets	  and	  QC	  plots	  Requirements:	   Datasets	  in	  vector	  data	  	  	  





sameaxis=FALSE, csv=FALSE, CSVtitle="outlierprobes.csv"){ 
   
#remove arguments if inconsistent 
if(!dataset1) stop ("Need identifying value for dataset1 for 
comparison") 
if(!dataset2) stop ("Need identifying value for dataset2 for 
comparison") 
if(!is.logical(sameaxis)) stop ("Waterfall plot must be either on 
same axis (sameaxis=TRUE) or separate axis (sameaxis=FALSE)") 
if(!is.logical(csv)) stop ("Specify whether to produce csv file of 
outlier probes cvs=TRUE or csv=FALSE") 
   
#subtract dataset2 from dataset1 to give difference of IP/IN ratio 
#values at each probe 
subvalues<-data[,dataset1]-data[,dataset2] 
 




#get extreme values package, run to generate list of outliers, and 
#programme calculated upper and lower limits 
  require(extremevalues) 
  outliers<-
getOutliers(sv$ratios[,1],method="I",distribution="normal") 
  outlierlist<-c(outliers$iRight,outliers$iLeft) 
  limits<-matrix(as.numeric(outliers$limit)) 
 
#calculations for rainfall plot 
#calculating for if both postive and negative subtracted values to 
#be displayed on same axis with all values negative 
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proberanktable_all[,3]<-(proberanktable_all[,3]- 





#top left - qqplot with outliers 
par(fig=c(0.01,0.4975,0.505,0.99 
outlierPlot(sv$ratios[,1],outliers,mode="qq")       
abline(h=limits[1,1], col="purple4", lty=2, lwd=2)           
abline(h=limits[2,1], col="maroon3", lty=2, lwd=2)     
box(which="figure")      
 
                                     
# top right - hstogram with upper and lower limits 
par(fig=c(0.5025,0.99,0.505,0.99), new=TRUE)                 
hist(sv, col="skyblue", breaks=100, 
       main=title(" Distribution of Probe Values"), 
       xlab="Probe Values after Subtraction") 
  abline(v=limits[1,1], lty=2, col="purple4", lwd=2)           
  abline(v=limits[2,1], lty=2, col="maroon3", lwd=2 
  box(which="figure) 
 
#draw lower box for plot and key 
par(fig=c(0.01,0.99,0.01,0.5), new=TRUE)              
box(which="figure")                                          
#make either single waterfall or split by pos/neg outliers 
#if on same axis (argument sameaxis=TRUE) 
#bottom row - rainfall plot 
   
if(sameaxis){ 
    par(fig=c(0.01,0.85,0.01,0.5), new=TRUE) 
    plot(proberanktable_all[,2],proberanktable_all[,3], pch=16, 
 cex=0.5, 
    col=rainbow(1.1*(nrow(outlierprobematrix))), 
    xlab="Probe Position", ylab="Difference in IN/IP ratio 
 values", 
    main=title("Array position and Difference in IP/IN ratio of 
 outlying probes \n (Probe values calculated as distance from \n 
 mean of all subtracted probe values)", 
     cex.main=1, font.main=1), 






         las=2,cex.axis=0.8) 
 
#set up matrix for key plots 
    z=matrix(100:1,nrow=1) 
    x=1 
    y=seq(0,1,length=101) 
    #draw key 
    par(fig=c(0.8,0.98,0,0.5), new=TRUE) 
image(x,y,z,col=rainbow(dim(outlierprobematrix)),axes=FALSE,ylab="", 
xlab="", ylim=c(0.1,1)) 
axis(1, at=1,lab="Maximum", cex.axis=0.8,tck=0,line=-1) 
axis(3,at=1,lab="Minimum",cex.axis=0.8,tck=0,line=-1) 
mtext("Difference in IP/IN ratio values \n of outlying probes", 
2,line=0.5, cex=0.8) 
box() 
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} 
 
#if all data plotted above and below central data 
  if (!sameaxis){ 
    #bottom row - rainfall up and down pos and neg 
    par(fig=c(0.01,0.85,0.01,0.5), new=TRUE) 
    plot(proberanktable_posandneg[,2],proberanktable_posandneg[,3], 
 pch=16, cex=0.5, 
     col=rainbow(1.1*(nrow(proberanktable_posandneg))), 
     xlab="Probe Position", ylab="Difference in IN/IP ratio 
 values",main=title("Array position and Difference in IP/IN ratio 
of 
 outlying probes"), 
 axes=FALSE, 
    ylim=c((ceiling(min(proberanktable_posandneg[,3]))-1), 
 (ceiling(max(proberanktable_posandneg[,3]))))) 
     segments(10000000,limits[2,1],15000000,limits[2,1], lty=2, 
 lwd=2, col="maroon3") 
     segments(10000000,limits[1,1],15000000,limits[1,1], lty=2, 
 lwd=2, col="purple4") 
     axissize<-max(proberanktable_posandneg[,3])- 
 min(proberanktable_posandneg[,3]) 
 
if(axissize>10) steps=2 else steps=1 
     axis(1, at=c(seq(10000000,15000000,1000000))) 
     axis(2, at=c(seq((ceiling(min(proberanktable_posandneg[,3]))-1), 
 (ceiling(max(proberanktable_posandneg[,3]))),steps)), 
     ,las=2, cex.axis=0.8, 
     lab=c(seq((ceiling(min(proberanktable_posandneg[,3]))-1), 
 (ceiling(max(proberanktable_posandneg[,3]))),steps))) 
 
#set up matrix for key plots 
    z=matrix(100:1,nrow=1) 
    x=1 
    y=seq(0,1,length=101) 
    #draw key 
    par(fig=c(0.8,0.98,0,0.5), new=TRUE) 
image(x,y,z,col=rainbow(dim(outlierprobematrix)),axes=FALSE,ylab="", 
xlab="", ylim=c(0.1,1)) 
    axis(1, at=1,lab="Most Negative", cex.axis=0.8,tck=0,line=-1) 
    axis(3,at=1,lab="Most Positive",cex.axis=0.8,tck=0,line=-1) 
    mtext("Difference in IP/IN ratio values \n of outlying probes", 
2,line=0.5, cex=0.8) 
    box()} 
  if(csv){ 
    write.csv(proberanktable_posandneg, file=CSVtitle)} 
  } #end function 	   	  
	   364	  
 Appendix	  8:	  	  The	  outlierDataMultiPlot	  function	  8.8	  Version	  1.0	  14/09/14	  Role:	  Compare	  outlier	  probe	  positions	  between	  datasets	  
 




title=FALSE, csv=FALSE, CSVtitle="outlierprobes.csv"){ 
   
require(extremevalues) 
options(scipen=999) 
#choose which datasets in data to compare 
 
tocompare<-matrix(ncol=5,nrow=comparisons) 
  for (n in 1:comparisons) tocompare[n,1]<-n 
  print("Enter datasets to copmare in order of desired comparisons 
 i.e. 1a vs 1b, 2a vs 2b...") 
  for (n in 1:comparisons){ 
  print("For comparison") 
  print(n) 
    tocompare[n,2]<-as.numeric(readline("Enter dataset 
'a' (identified using numerical order in vector 'data')...")) 
    tocompare[n,3]<-as.numeric(readline("Enter dataset 
'b' (identified using numerical order in vector 'data')...")) 
 
    tmpsv<-data[,(tocompare[n,2])]-data[,(tocompare[n,3])] 
    tmpsvna<-tmpsv[!is.na(tmpsv$ratios[,1]),] 
    tmpoutliers<-getOutliers(tmpsvna$ratios[,1],method="I", 
 distribution="normal") 
    tmpoutlierlist<-c(tmpoutliers$iRight,tmpoutliers$iLeft) 
    tolm<-matrix(unlist(tmpoutlierlist)) 
    tocompare[n,5]<-nrow(tolm) 
} 
     
#make large matrix of 1)outlier probe, 2) midpoint 3)subtracted 
€probe value for each comparison 
    proberanktable<-matrix(ncol=3,nrow=(max(tocompare[,5]))) 
    masterproberanktable<-matrix(ncol=3,nrow=(max(tocompare[,5]))) 
    for (n in 1:comparisons){ 
      tmpsv<-data[,(tocompare[n,2])]-data[,(tocompare[n,3])] 
      tmpsvna<-tmpsv[!is.na(tmpsv$ratios[,1]),] 
      tmpoutliers<-getOutliers(tmpsvna$ratios[,1],method="I", 
  distribution="normal") 
      tmpoutlierlist<-c(tmpoutliers$iRight,tmpoutliers$iLeft) 
      tolm<-matrix(unlist(tmpoutlierlist)) 
      proberanktable[(1:(nrow(tolm))),1]<-tolm 
      proberanktable[(1:(nrow(tolm))),2]<-((tmpsvna[tmpoutlierlist, 
 1]$coordinates[,2]+tmpsvna[tmpoutlierlist,1]$coordinates[,3])/2) 
      proberanktable[(1:(nrow(tolm))),3]<-tmpsvna[tmpoutlierlist, 
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  if(plotsame){ 
par(fig=c(0,0.9,0,1),new=FALSE) 
plot(masterproberanktable[,2],masterproberanktable[,3], pch=16, 
  cex=0.5, 
         #ylim=c(min(masterproberanktable[,c(3*(seq(1,n, 
  1)))]),max(masterproberanktable[,c(3*(seq(1,n,1)))])), 
         xlab="Probe Position", ylab="Difference in IN/IP ratio 
  values") 
 
for (n in 1:(comparisons-1)){ 
    par(new=TRUE) 
    plot(masterproberanktable[,(3*n+2)],masterproberanktable[,3*n 
  +3], 
         #ylim=c(min(masterproberanktable[,c(3*(seq(1,n, 
  1)))]),max(masterproberanktable[,c(3*(seq(1,n,1)))])), 
         pch=16, cex=0.5, col=n+1, axes=FALSE, xlab="", ylab="") 
      }} 
   
if(!plotsame){ 
    titlemat<-matrix(nrow=comparisons,ncol=1) 
    if(title){ 
        for (n in 1:comparisons){ 
          print("For plot") 
          print(n) 
          titlemat[n,]<-readline("Enter title....") 
}} 
    maxmat<-matrix(apply(masterproberanktable,2,max,na.rm=TRUE)) 
    minmat<-matrix(apply(masterproberanktable,2,min,na.rm=TRUE)) 
  
par(fig=c(0,0.9,(1-1/comparisons),1),new=FALSE) 
     plot(masterproberanktable[,2],masterproberanktable[,3], pch=16, 
 cex=0.5, 
     axes=FALSE,xlab="",ylab="", 
 main=title(titlemat[1,])) 
 axis(1) 
     axis(2,at=c((maxmat[3,1]/1.3),(minmat[3,1]/ 
 1.3)),lab=c("higher","lower")) 
     mtext("Chromosome 17 Position", side=1, line=3) 
     mtext("Difference in IN/IP ratio values",side=2, line=2) 
     box(which="figure") 
 
for (n in 1:(comparisons-1)){ 
 par(fig=c(0,0.9,(1-((n+1)*(1/comparisons))),(1-(n*(1/ 
 comparisons)))),new=TRUE) 
      
 plot(masterproberanktable[,(3*n+2)],masterproberanktable[,3*n 
  +3], 
         axes=FALSE,xlab="",ylab="", 
         pch=16, cex=0.5, col=n+1, 




mtext("Chromosome 17 Position", side=1, line=3) 
mtext("Difference in IN/IP ratio values",side=2, line=2) 
box(which="figure") 
}} 
  if(csv){ 
    write.csv(masterproberanktable, file=CSVtitle)} 
} #end function 
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 Appendix	  9:	  	  RAD1	  Primers	  8.9	  
RAD1	  position	  	  	  	  	  	  	  Strand	   	  	  	  Name	   	   	  	  	  	  Sequence	  (5’	  to	  3’)	   	  	  	  
-544 to -514   (US) BamH1  CCATAGGATCCCCAAGTAACCGTGATAAACA 
 
97 to 118  (US) n69-US  AAATGAAGATGAACCCGACGAC 
 
119 to 98  (LS) n69-LS  GTCGTCGGGTTCATCTTCATTT 
  
673 to 694  (US) n672-US  CTTATCCGGCATTGTTCACCCA 
 
1118 to 1142  (US) Check-F  TCAGGTCAATTGACTCGGTGATGG 
  
1150 to 1171  (US)   Rad1-F  AACTGGCACCGAATTTCTTATGAA 
 
1393 to 1420  (US) rad1(P379S)-F TTTAGAAGAAAATTCAAAATGGGAACAA 
 
1420 to 1393   (LS) rad1(P379S)-R TTGTTCCCATTTTGAATTTTCTTCTAAA 
 
1870 to 1879  (US) Rad1(S613X)-Seq AAATGCCGCAAACGATTCAA 
 
1879 to 1870      (LS)     Rad1(P379S)-Seq       TTGAATCGTTTGCGGCATTT 
 
2185 to 2206  (US) n2184 US  TAAGGCCATAGTGAAGGATTTG 
 
2206 to 2185  (LS) n2184 LS  CAAATCCTTCACTATGGCCTTA 
 
2224 to 2259  (US)    rad1(S613X)-F  ATGTACTACGGTGAATGAATTGAAGAGCAAAGTCA 
 
2259 to 2224      (LS)    rad1(S613X)-R       TGACTTTGCTCTTCAATTCATTCACCGTAGTACAT 
 
2562 to 2538  (LS)  Rad1-R  TAATCGCCGACTGTCAACATACAA 
 
2641 to 2614  (LS) Check-R  GGCTAATCTGTTATTCTGTAATGACCCA 
 
2783 to 2801  (US) n2781-US  TCAAGCAAGTTATCCCAGGATG 
 
3560 to 3515      (LS) Rad1-Sal1-L            GGTCATGTCGACTGCTAAAAAGTGGAAGATGAATTG 	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 Appendix	  10:	  	  Content	  of	  the	  Electronic	  Appendix	  8.10	  	  	  Chapter	  3	  	  	   A	   folder	   labelled	   Chapter	   3,	   containing	   an	   Excel	   spread	   sheet	  with	   raw	  data	  for	  each	  figure,	  separated	  by	  workbook.	  	  Chapter	  4	  	  	   A	  folder	  labelled	  Chapter	  4,	  containing	  Sandcastle	  version	  1.0	  R	  package,	  and	  microarray	  datasets	  separated	  for	  each	  relevant	  figure	  	  Chapter	  5	  	  	   A	   folder	   labelled	   Chapter	   5	   containing	   relevant	   microarray	   datasets	  separated	   for	   each	   figure	   and	   a	   sub-­‐folder	   containing	   custom	   R	   scripts	   as	  described	   in	   the	   chapter	   and	   the	   above	   appendices.	   	   An	   additional	   subfolder	  contains	  several	  chapter	  5	  figures	  in	  higher	  resolution.	  	  Chapter	  6	  	  	   A	   folder	   labelled	   Chapter	   6,	   contain	   an	   Excel	   spread	   sheet	  with	   all	   raw	  data	   for	   the	  relevant	   figures,	  separated	  by	  workbook.	   	  Additionally,	  sequencing	  data	   for	   the	   entirety	   of	   each	   plasmid	   is	   included	   in	   the	   sub-­‐folder	   labelled	  sequencing	  data.	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